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Abstract
The European Commission asked EFSA for a scientiﬁc evaluation on the risks to human health related
to the presence of perﬂuorooctane sulfonic acid (PFOS) and perﬂuorooctanoic acid (PFOA) in food.
Regarding PFOS and PFOA occurrence, the ﬁnal data set available for dietary exposure assessment
contained a total of 20,019 analytical results (PFOS n = 10,191 and PFOA n = 9,828). There were
large differences between upper and lower bound exposure due to analytical methods with insufﬁcient
sensitivity. The CONTAM Panel considered the lower bound estimates to be closer to true exposure
levels. Important contributors to the lower bound mean chronic exposure were ‘Fish and other
seafood’, ‘Meat and meat products’ and ‘Eggs and egg products’, for PFOS, and ‘Milk and dairy
products’, ‘Drinking water’ and ‘Fish and other seafood’ for PFOA. PFOS and PFOA are readily absorbed
in the gastrointestinal tract, excreted in urine and faeces, and do not undergo metabolism. Estimated
human half-lives for PFOS and PFOA are about 5 years and 2–4 years, respectively. The derivation of a
health-based guidance value was based on human epidemiological studies. For PFOS, the increase in
serum total cholesterol in adults, and the decrease in antibody response at vaccination in children were
identiﬁed as the critical effects. For PFOA, the increase in serum total cholesterol was the critical
effect. Also reduced birth weight (for both compounds) and increased prevalence of high serum levels
of the liver enzyme alanine aminotransferase (ALT) (for PFOA) were considered. After benchmark
modelling of serum levels of PFOS and PFOA, and estimating the corresponding daily intakes, the
CONTAM Panel established a tolerable weekly intake (TWI) of 13 ng/kg body weight (bw) per week for
PFOS and 6 ng/kg bw per week for PFOA. For both compounds, exposure of a considerable proportion
of the population exceeds the proposed TWIs.
© 2018 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Explanatory note: Due to the nature of the scientiﬁc uncertainties described in this opinion and in
the minutes of the expert meeting of 24 September 2018 (EFSA/CONTAM/3503) (https://www.efsa.
europa.eu/sites/default/ﬁles/news/efsa-contam-3503.pdf), and the possible application of the
forthcoming Scientiﬁc Committee guidance on combined exposure to multiple chemicals, the
conclusions of this assessment will be reviewed in parallel with the ﬁnalisation of the EFSA scientiﬁc
opinion on The risks to human health related to the presence in food of perﬂuoroalkylated substances
other than PFOS and PFOA (EFSA-Q-2017-00549). The indicative timeline for this is December 2019.
Until such time, the conclusions and derived tolerable weekly intakes shall be considered provisional.
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Summary
In a request from the European Commission, the EFSA Panel on Contaminants in the Food Chain
(CONTAM Panel) was asked to assess the risk to human health related to the presence of
perﬂuorooctane sulfonic acid (PFOS) and perﬂuorooctanoic acid (PFOA) in food, considering existing
hazard assessments and available occurrence data.
PFOS and PFOA belong to the group of per- and polyﬂuoroalkyl substances (PFASs). This group of
substances consists of a hydrophobic alkyl chain of varying length (typically C4–C16) and a hydrophilic
end-group. PFOS belongs to the perﬂuoroalkyl sulfonic acids (PFSAs), whereas PFOA belongs to the
perﬂuoroalkyl carboxylic acids (PFCAs). Linear, branched or linear/branched mixtures of PFOS and
PFOA are produced and are found in human and environmental samples. Liquid chromatography
coupled to quadrupole tandem mass spectrometry (LC–MS/MS) is commonly used to determine PFOS
and PFOA in both food and biological samples. Two major processes exist for production of PFOS and
PFOA, Simons electrochemical ﬂuorination and telomerisation. The telomerisation process generates
almost exclusively linear PFOS and PFOA, whereas the electrochemical process produces a mixture of
branched and linear isomers. Since the 1940s, PFASs have been produced and used in numerous
commercial and industrial applications, including textile, carpet and leather treatment (water and dirt
prooﬁng), surfactants, ﬁreﬁghting foams, metal plating and paper grease-prooﬁng treatments. The
widespread use of PFOS, PFOA and their precursors, together with their persistency, has resulted in
widespread environmental contamination. Contamination of food with PFOS and PFOA is thought to
occur mainly through two different processes (i) from bioaccumulation in aquatic and terrestrial food
chains and (ii) as a result of transfer of PFOS, PFOA and their precursors from contact materials used
in food processing and packaging. Contamination can also arise when food-producing animals are
exposed to sources of pollution such as wild boars feeding at dumpsites.
An initial number of 21,411 results for food samples analysed for PFOS (n = 10,889) and PFOA
(n = 10,522) from 16 European countries were available for the assessment. The data set was
characterised by a high proportion of left-censored data (results below limit of detection (LOD)/limit of
quantiﬁcation (LOQ)) with 74% of left-censored data for PFOS and 91% of left-censored data for
PFOA. A total of 20,019 analytical results for PFOS (n = 10,191) and PFOA (n = 9,828) fulﬁlled the
quality criteria applied and have been considered in the assessment. The highest mean concentrations
of PFOS and PFOA were recorded in the food category ‘Meat and meat products’. This was affected by
high mean concentrations in the liver from game mammals (lower bound/upper bound (LB/UB)
mean = 215/215 lg/kg for PFOS and LB/UB mean = 5.46/8.11 lg/kg for PFOA). Excluding offal, the
mean concentration in the category ‘meat and meat products’ was LB/UB = 0.55/0.75 lg/kg for PFOS
and LB/UB = 0.10/0.34 lg/kg for PFOA. In edible offal from farmed animals, the concentration was for
PFOS (LB/UB mean) 0.66/2.12 lg/kg and for PFOA (LB/UB mean) 0.05/1.39 lg/kg. High levels were
also observed in ‘Fish and other seafood’ (LB/UB mean = 2.08/2.59 lg/kg for PFOS and LB/UB
mean = 0.18/0.90 lg/kg for PFOA.
For PFOS, the LB mean dietary exposure ranges from 1.26 (adolescents) to 20.86 (other children)
ng/kg body weight (bw) per week, across age groups and surveys. The high (95th percentile) LB
exposure ranges from 3.5 (adolescents) to 165.9 (other children) ng/kg bw per week. For PFOA, the
mean LB dietary exposure estimates range from 1.47 ng/kg bw per week (elderly and very elderly) up
to 18.27 ng/kg bw per week (toddlers). The high LB (95th percentile) exposures range from 3.43
(very elderly) to 37.59 (toddlers) ng/kg bw per week. The most important contributors to the LB mean
chronic exposure to PFOS, were ‘Fish and other seafood’ (contributing up to 86% in adults), especially
‘Fish meat’, followed by ‘Meat and meat products’ and ‘Eggs and egg products’. Regarding PFOA, ‘Milk
and dairy products’ (contributing up to 86% in toddlers, but based on only a few samples with
detectable levels for cow milk and gouda cheese), ‘Drinking water’ and ‘Fish and other seafood’ made
the largest contribution to the LB mean chronic exposure.
PFOS and PFOA are readily absorbed in the gastrointestinal tract in mammals, including humans,
and distribute predominantly to the plasma and liver. They are not metabolised and are excreted in
both urine and faeces. Differences in biological half-lives between species for both PFOS and PFOA are
mainly due to differences in renal clearance. Signiﬁcant gender differences in the elimination of PFOA
are observed in some, but not all species; gender differences in renal clearance have not been
reported in humans. The half-lives of the branched chain PFOS and PFOA isomers are generally shorter
than those for the linear molecules, with the exception of 1 m-PFOS. For both PFOS and PFOA,
maternal transfer occurs prenatally to the fetus through the placenta transfer and postnatally through
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breastfeeding. The estimated half-life for PFOS in humans is approximately 5 years, whereas for PFOA,
several studies estimated a half-life between 2 and 4 years.
With regard to information on human biomonitoring, PFOS and PFOA were detected in blood samples
of almost all individuals assessed, demonstrating ubiquitous exposure. For PFOS, the median of the
values reported as median concentrations in a number of studies was higher in adults (7.7 ng/mL)
compared to children (3.2 ng/mL), while the opposite was seen for PFOA, where the median of the
values reported as median concentrations was 1.9 and 3.3 ng/mL for adults and children, respectively.
The breast milk concentrations were usually around 0.9–2% and 1.8–9% of the maternal serum/plasma
concentrations for PFOS and PFOA, respectively. Concentrations observed in European populations were
comparable to those observed in general populations’ worldwide.
In experimental animal toxicity studies, the liver was a target organ in rodents. For PFOS, increases in
relative liver weight were noted from 0.15 mg/kg bw per day and for PFOA, increased absolute and
relative liver weight and hepatic peroxisomal b-oxidation were noted at 0.64 mg/kg bw per day. From
long-term/carcinogenicity studies, PFOS was found to cause tumours in the liver of rats. PFOA induced
Leydig cell tumours in Sprague–Dawley rats. Both PFOS and PFOA have developmental neurotoxicity
potential and widespread effects on the expression of genes relevant for signal transmission in the brain.
From rodent studies, male offspring are more sensitive than females, and the most frequent behavioural
outcome reported after PFOS exposure is decreased spontaneous activity, which on the contrary is
increased by PFOA. Exposure of rodents to PFOS and PFOA during pregnancy affects both mothers and
the development of the offspring. For PFOS, the most sensitive effects were on maternal liver weight
(0.3 mg/kg bw per day), placental physiology (0.5 mg/kg bw per day) and on glucose homoeostasis
(0.3 mg/kg bw per day). Pathological alterations, following PFOA exposure, included increased liver
weight in pups and mothers following exposure at doses of 0.1 and 0.6 mg/kg bw per day, respectively.
Male reproductive organs and male sex hormone levels were affected at 0.3 mg/kg bw per day. Low-
dose effects (delay of mammary gland development and changes of levels of metabolic parameters)
were noted at 0.01 mg/kg bw per day. No health risks can be deduced from these latter biological
response data. PFOS affects various structural and functional parameters in the immune system in
rodents. The most sensitive parameter affected by PFOS is the T-cell-dependent antibody response to
immunisation. The effects of PFOA are similar with both structural and functional parameters inﬂuenced.
The no-observed-adverse-effect-level (NOAEL) for immunotoxicity of PFOS and PFOA was 1.66 lg/kg bw
per day and 1 mg/kg bw per day, respectively, based on suppression of anti-SRBC IgM titres. From
in vitro and in vivo genotoxicity studies, there is no evidence for a direct genotoxic mode of action for
both PFOS and PFOA, however, genotoxicity cannot be excluded. There is some evidence for oxidative
stress induced by both PFOA and PFOS.
Human epidemiological studies provide some evidence for a causal association between prenatal
exposures to PFOS and PFOA and birth weight. Despite relatively consistent ﬁndings, the role of
confounding by glomerular ﬁltration rate during pregnancy cannot be excluded. Moreover, there is some
uncertainty on the clinical relevance of these ﬁndings, as associations with low birth weight (deﬁned as
< 2,500 g) have not been reported. Epidemiological studies conducted provide insufﬁcient evidence for a
causal association between prenatal exposures to PFOS and PFOA and increased prevalence of birth
defects or stillbirths, subfecundity, risk of miscarriage or pregnancy hypertension. Human epidemiological
studies provide insufﬁcient support for causal associations between prenatal or perinatal exposure to
PFOS/PFOA and neurodevelopment, growth in infancy or childhood, timing of puberty, semen quality or
metabolic outcomes. For neurotoxicity outcomes, human epidemiological studies provide insufﬁcient
support for causal associations between exposure to PFOS/PFOA and neurobehavioural, neuropsychiatric
or cognitive outcomes in childhood or adulthood. For immune outcomes, human epidemiological studies
suggest that exposure to PFOS, and possibly PFOA, adversely affect serum antibody response following
vaccination in children, and it is concluded that this association is likely to be causal. There are some
suggestions from epidemiological studies that prenatal exposures to PFOS and PFOA may lead to
increased propensity of infection. With regard to asthma and allergies in children and adults,
epidemiological studies provide insufﬁcient support for causal associations between exposures to PFOS
and PFOA. For endocrine outcomes, human epidemiological studies provide insufﬁcient support for
causal associations between exposure to PFOS/PFOA and timing of puberty, menopause, menstrual cycle
changes, endometriosis, duration of breastfeeding, semen quality, levels of sex hormones or thyroid
function. For metabolic outcomes, human epidemiological studies provide strong support for causal
associations between exposure to PFOS and PFOA and increased serum levels of cholesterol and support
for a causal association between exposure to PFOA and increased serum levels of the liver enzyme
alanine transferase (ALT). However, there is insufﬁcient support for causal associations with diabetes,
PFOS and PFOA in food
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obesity and metabolic syndrome. Human epidemiological studies provide insufﬁcient support for causal
associations between exposure to PFOS and PFOA, and changes in kidney function or serum levels or uric
acid. For carcinogenicity outcomes, human epidemiological studies provide insufﬁcient support for
carcinogenicity of PFOS and PFOA. This conclusion applies to both studies conducted in occupationally
exposed individuals and among those exposed to background levels. For cardiovascular outcomes,
human epidemiological studies provide insufﬁcient support for causal associations between exposure to
PFOS/PFOA and increased risk of cardiovascular disease. This also applies to other outcomes, like risk of
ulcerative colitis, osteoarthritis, rheumatoid arthritis or bone mineral density.
With regard to the possible mode of action in relation to liver toxicity, PFOS and PFOA are both
ligands of the nuclear receptor peroxisome proliferator activated receptor-alpha (PPARa), and induce
liver growth, proliferation of peroxisomes and induction of peroxisomal b-oxidation in rodents. Elevated
peroxisomal b-oxidation in rodents may lead to hepatic lipid peroxidation and subsequently to cell
death and enhanced release of liver transaminases. It is presently unclear by which mechanisms PFOA
and maybe PFOS could increase serum levels of ALT in humans. With regard to the possible mode of
action in relation to blood lipid effects, unlike other PPARa agonists, PFOS and PFOA are positively
associated with blood cholesterol concentrations in humans and with triglyceride levels. In rodents,
PFOS and PFOA may impair the release of cholesterol and/or triglycerides from the liver causing
elevated intrahepatic and lowered serum cholesterol and/or triglyceride concentrations. These effects
in rodents may not be of human relevance presumably due to species-speciﬁc differences in the
function of PPARa affecting the metabolism of lipids. With regard to the possible mode of action in
relation to birth weight, in human studies, an inverse relation between PFOS and IGF-1 levels has
been shown which may be associated with a reduced growth rate. In rodents, PFOS and PFOA
reduced body weight, which is associated with loss of white adipose tissue, upregulation of uncoupling
protein-1 (UCP-1) and its association with energy expenditure and regulation of food consumption.
With regard to the possible mode of action in relation to immunotoxicity, PFOS and PFOA affect
lymphocytes, macrophages and other cells of the immune system. PFASs may modulate gene
regulation via peroxisome proliferator activated receptors (PPARs). They inﬂuence NF-jB transcription
and gene expression of apoptotic regulators, and immune functionality and activation of T-cell receptor
signalling involved in the regulation of immune responses. PFOS and PFOA share mechanisms, but
may also be different as cytokine proﬁles in lymphoid cells have shown to be differentially affected.
With regard to the possible mode of action in relation to carcinogenicity in rodent, PFOS and PFOA act
as tumour promoters in rodent liver. Transactivation of rodent PPARa but not of human PPARa appears
to mediate the carcinogenic activity of PPARa ligands. A similar mechanism may be anticipated for
PFOS and PFOA. PFOA induces Leydig cell adenomas in rat testis, caused by reduced serum
testosterone levels and compensatory release of luteotrophic hormone, which stimulates growth of
Leydig cells and tumour formation. Leydig cell tumours occur frequently in rodents but rarely in
humans. PFOA causes pancreatic hyperplasia, a prestage of tumour formation. As known from another
PPARa ligand, altered composition and output of bile acids may enhance the secretion of
cholecystokinin, which binds to acinar CKK1 receptor and stimulates growth of this cell type. This
mode of action appears to be irrelevant for humans.
For PFOS and outcomes identiﬁed in adults, the CONTAM Panel identiﬁed the increase of serum
cholesterol as the critical effect. Three studies on serum cholesterol showed very similar BMDL5 levels
expressed as plasma PFOS (21–25 ng/mL), corresponding to an estimated chronic daily intake of
1.7–2.0 (median 1.8) ng/kg bw per day based on a human physiologically based pharmacokinetic
(PBPK) model. For children the lowest BMDL5 is for antibody response after vaccination (10.5 ng/mL).
Since for children, the relation between serum concentrations of PFOS and corresponding daily intake
rates is not as straight-forward as in adults, due to the contribution from breastfeeding, the CONTAM
Panel considered it not appropriate to calculate which intake rate for children after the end of
breastfeeding would correspond to the BMDL5 serum level of PFOS in 5-year old children. Instead, the
serum PFOS levels in the pregnant mothers in the critical study were compared with serum PFOS
levels for the other potential critical effects, and serum levels in breastfed children were modelled to
illustrate how maternal serum PFOS levels and intake rates would be related to serum PFOS levels in
their 5-year old children. A maternal intake of 1.8 ng/kg per day and 6 months of exclusive
breastfeeding was estimated to result in a plasma PFOS level below 10.5 ng/mL. The BMDL5 for
reduced birth weight was about the same as for increased cholesterol. The CONTAM Panel noted that
there is still some uncertainty, both regarding causality and adversity of reduced birth weight.
However, since there is likely confounding by glomerular ﬁltration rate, an intake rate based on
increased cholesterol is protective also for reduced birth weight. With serum cholesterol, antibody
PFOS and PFOA in food
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response after vaccination and birth weight, all considered as potential critical endpoints, the CONTAM
Panel found it appropriate to weigh the overall evidence from the human observational studies when
setting an health-based guidance value (HBGV). For these endpoints, the reference points were
centred around 1.8 ng/kg bw per day with some variation depending on the outcome and study.
Therefore, the CONTAM Panel considers 1.8 ng/kg bw per day as an appropriate reference point. In
order to take into account the long half-life of PFOS, the CONTAM Panel established a tolerable weekly
intake (TWI) of 13 ng/kg bw per week. If applied for all age groups, it is protective for adverse effects
on vaccination response and reduced birth weight.
For PFOA, the CONTAM Panel considers the increase of serum cholesterol to be the critical effect.
Two studies on serum cholesterol showed very similar BMDL5 values expressed as plasma/serum PFOA
(9.2–9.4 ng/mL), corresponding to an estimated chronic intake of 0.8 ng/kg bw per day. The CONTAM
Panel considered 0.8 ng/kg bw per day to be an appropriate reference point. Based on the long half-life
of PFOA, the CONTAM Panel established a TWI of 6 ng/kg bw per week. It is protective also for increased
risk of liver damage, indicated by high serum ALT. It is protective against reduced birth weight, taking
into account the fact that there is likely to be an impact of confounding by glomerular ﬁltration rate.
For both established HBGVs, the CONTAM Panel decided not to apply any additional uncertainty
factors because the BMD modelling was based on large epidemiological studies from the general
population, including potentially sensitive subgroups. The CONTAM Panel also took into account that
the BMD modelling was performed on risk factors for disease rather than disease.
For PFOS, mean LB dietary exposure ranged from 1.3 to 20.9 ng/kg bw per week, across age
groups and surveys. The high (95th percentile) LB exposure ranged from 3.5 to 165.9 ng/kg bw per
week. Therefore, a considerable proportion of the population exceeds the TWI of 13 ng/kg bw per
week, by up to 1.6- and 13-fold, for mean LB and high LB exposure, respectively. For PFOS, at the UB,
the TWI is exceeded in all surveys at mean exposure, and the high UB (95th percentile) exposures
exceed the TWI from 1.7- to 15-fold across surveys and age groups. For PFOA, mean LB dietary
exposure estimates range from 1.5 to 18.3 ng/kg bw per week. The high (95th percentile) LB
exposures range from 3.4 to 37.6 ng/kg bw per week. Therefore, a considerable proportion of the
population exceeds the TWI of 6 ng/kg bw per week, by up to 3- and 6-fold for mean LB and high LB
exposure, respectively. For PFOA, at the mean UB, the TWI is exceeded 1.4- to 14-fold across surveys
and up to 28-fold at the high UB (95th percentile) exposure for toddlers. Therefore, it is clear that a
considerable proportion of the population exceeds the established TWIs for PFOS and PFOA. The
exceedances of the TWIs for PFOS and PFOA at LB exposure estimates are of concern.
The CONTAM Panel is aware of the fact that the present exposure assessment is highly uncertain.
Large differences between LB and UB concentrations were observed in foods, as a result of analytical
methods being used that are not sufﬁciently sensitive. This results in a large difference between
maximum UB and minimum LB chronic dietary exposure estimates for PFOS and PFOA. The CONTAM
Panel considers that the true exposure level for both PFOS and PFOA is closer to the LB than the UB
values. This assumption is based on two facts:
• Studies performed using the best analytical methods with good sensitivity and high levels of
quality control give results with fewer left censored data and conﬁrm occurrence in foods at
levels close to the lower bound estimates.
• Median LB data in this opinion are consistent with what would be expected based on median
population blood serum levels.
The CONTAM Panel recommends the development of analytical methods with higher sensitivity
which are easy to perform (sensitive methods exists, but are primarily used by research laboratories,
and are quite complex). Data obtained by more sensitive analytical methods with high levels of quality
control (to avoid matrix effects or impact of background contamination) are needed in order to
increase the proportion of quantiﬁed results and thus improve the quality of the dietary exposure
assessment. Improved reporting of data in terms of clarifying whether upper or lower bound and
clariﬁcation of whether or not data are corrected for recovery will reduce uncertainty in exposure
estimates. More studies on the effect of cooking and food processing would improve exposure
assessments given that most food is consumed after cooking/processing and the data reported in the
scientiﬁc literature are inconsistent regarding which impact this has on exposure. For many of the
outcomes reviewed, the majority of epidemiological studies were cross-sectional. More longitudinal
epidemiological studies are needed, in particular prospective vaccination studies covering more varied
types of vaccines and age groups, as well as more studies on other immune outcomes in humans.
Moreover, access to individual data in epidemiological studies would be useful in order to perform
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accurate dose–response analysis and risk characterisation. Most epidemiological studies examine
associations between health-related outcomes and single PFASs separately in spite of co-exposures.
For risk assessment, it would be useful also to report results mutually adjusted for several PFASs so
conclusions can be drawn on the independent associations of PFOS and PFOA.
PFOS and PFOA in food
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
1.1.1. Background
Following the Scientiﬁc Opinion on Perﬂuorooctane sulfonate (PFOS), perﬂuorooctanoic acid (PFOA)
and their salts,1 the European Commission recommended an EU-wide monitoring2 of perﬂuoroalkylated
substances in food. The occurrence data generated by this monitoring have been used in the Scientiﬁc
Report entitled ‘perﬂuoroalkylated substances in food: occurrence and dietary exposure’.3
1.1.2. Terms of reference
In accordance with Art 29 (1) of Regulation (EC) No 178/2002, the European Commission asks the
European Food Safety Authority to prepare an opinion on the risks to human health related to the
presence of perﬂuoroalkylated substances in food, considering existing hazard assessments and
available occurrence data.
1.2. Interpretation of the Terms of Reference
Following the agreement reached in June 2017 with the European Commission, the CONTAM
Panel decided to address the mandate in two separate opinions, one on perﬂuorooctane sulfonic acid
and perﬂuorooctanoic acid (EFSA-Q-2015-00526) and another on other perﬂuoroalkylated substances
(EFSA-Q-2017-00549).
1.3. Additional information
1.3.1. Chemistry
Perﬂuorooctane sulfonic acid (PFOS) and perﬂuorooctanoic acid (PFOA) belong to the group of per-
and polyﬂuoroalkyl substances (PFASs).
PFASs (R-X) are compounds consisting of a hydrophobic alkyl chain, of varying length (typically
C4–C16) and a hydrophilic end group. PFOS (8 perﬂuorinated carbons) and PFOA (7 perﬂuorinated
carbons) both have an anionic end group and belong to the perﬂuoroalkyl sulfonic acids (PFSAs) and
the perﬂuoroalkyl carboxylic acids (PFCAs), respectively (Table 1). PFOS and PFOA appear to be highly
persistent because of the strong covalent C–F bond.
Depending on the synthesis, linear PFOS (n-PFOS) and PFOA (n-PFOA) or a mixture of linear and
branched PFOS (br-PFOS) and PFOA (br-PFOA) are produced (see Section 1.3.3). In environmental
Table 1: Chemical characteristics of PFOS and PFOA and their uses as derived from Buck et al. (2011)
Acronym Chemical name CAS number Structural formula
Molecular
weight
Uses
PFOS Perﬂuorooctane
sulfonic acid
2795-39-3
(potassium
salt); 1763-23-
1 (acid)
F F
S
O
O
OH
FF
F F
FFF
F
F
F F
FF
F F 538.22
(potassium
salt)
500.13
(acid)
Surfactant
PFOA Perﬂuorooctanoic
acid
335-67-1 O
F
F
F
FF
F F
FF
F F
FF
F F
OH
414.07 Surfactant
1 Opinion of the Scientiﬁc Panel on Contaminants in the Food chain on Perﬂuoroctane sulfonate (PFOS) perﬂuorooctanoic acid
(PFOA) and their salts. The EFSA Journal (2008) Journal number, 653, 1–131.
2 Commission Recommendation 2010/161/EU of 17 March 2010 on the monitoring of perﬂuoroalkylated substances in food. OJ L
68, 18.3.2010, p. 22–23.
3 European Food Safety Authority, perﬂuoroalkylated substances in food: occurrence and dietary exposure. EFSA Journal 2012,
10(6) 2743.
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and human samples (De Silva and Mabury, 2006), PFOS and PFOA are found as a mixture of the linear
and branched isomers (Riddell et al., 2009). Theoretically, there are many geometric PFOS and PFOA
isomers that are branched, although only few of them have been identiﬁed in technical products, and
in samples reported in environmental and human biomonitoring studies. Figure 1 displays linear and
monomethyl-branched isomers for which m refers to a perﬂuoromethyl branch and the number
preceding it indicates the carbon position on which the branch resides (Benskin et al., 2010). Similarly,
dimethyl-substituted-branched isomers are labelled as m2 and the preceding numbers refer to the
locations of the CF3 branching points.
1.3.2. Methods of analysis
1.3.2.1. Analytical methods for PFASs
PFOS and PFOA are normally measured alongside other PFASs as part of multianalyte methods.
These do not always measure the same PFASs and some methods measure more compounds than
others. But even when only PFOS and PFOA are determined, it is important to know that these
compounds can be distinguished from other PFASs, which may co-elute and have common ion
fragments. For these reasons, analytical methods are considered for the whole group of PFASs.
It has been the advances in analytical technology over the past decade that made it possible to
measure PFASs in foods and environmental samples at the levels that are typically found. Because PFCAs
and PFSAs are not very volatile, they are not amenable to direct analysis by gas chromatography (GC),
and because there is no suitable chromophore, liquid chromatography (LC) analysis with ultraviolet
detection is also not suitable (Martin et al., 2004). It is possible to analyse using GC if PFCAs and PFSAs
are ﬁrst derivatised to form their methyl esters, and detection is possible either using electron capture
detector (Ylinen et al., 1985) or mass spectrometry (MS). Advances in LC coupled to quadrupole tandem
Figure 1: Structure of PFOS/PFOA isomers discussed in this opinion (R = CF2SO3 (PFOS) or CO2
(PFOA); R’ = SO3)
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mass spectrometry (LC–MS/MS) with electrospray ionisation (ESI) have made this by far the most
commonly used instrumental method for measuring PFSAs and PFCAs in food (Jahnke and Berger, 2009).
Due to the better separation that is achievable with GC methods, the derivatisation followed by GC–MS is
still sometimes used when a higher resolving power is needed to separate isomers that co-elute when
using LC methods, such as for neutral and volatile PFASs, including ﬂuorteleomer alcohols (FTOHs),
perﬂuoroalkane sulfonamides (FASAs), N-ethyl perﬂuoroalkane sulfonamides (EtFASAs) and N-
ethylperﬂuoroalkane sulfonamidoethanols (EtFASEs) (Jahnke and Berger, 2009). LC–MS/MS can be used
to measure neutral PFASs and to screen for a large number of non-ionic and anionic ﬂuorinated
surfactants used in food contact materials (Trier et al., 2011).
PFCAs and PFSAs are normally extracted from food using ion-pair extraction (IPE) or solid–liquid
extraction (SLE) methods. Early IPE methods used tetrabutylammonium counter ion at alkaline pH and
ethyl acetate as the extraction solvent (Ylinen et al., 1985), but most recent methods for food (Guruge
et al., 2008; Vestergren et al., 2012) use methodology ﬁrst developed for environmental applications
where methyl tert–butyl ether is used as the extraction solvent (Hansen et al., 2001). Co-extraction of
lipophilic matrix constituents can cause instrumental problems, which is perhaps the reason why this
technique is not used more widely (Powley et al., 2005; van Leeuwen et al., 2009). SLE extraction
using solvents with medium polarity such as acetonitrile or methanol is more commonly used,
especially for foods with a high fat content (Powley et al., 2005; Berger et al., 2009). Only a few of the
methods developed for PFASs and PFCAs have been optimised for the determination of ﬂuorotelomer
alcohols (FTOH), FASAs, EtFASAs, EtFASEs and n:2 polyﬂuoroalkyl phosphoric acid esters (PAPs).
Soxhlet with a 2:1 hexane:acetone mixture was the ﬁrst approach for the analysis of neutral FASAs
and EtFASAs (Tittlemier et al., 2006). FASAs, EtFASAs, EtFASEs and anionic PFSAs and PFCAs are all
neutral and can be extracted together using SLE (Ostertag et al., 2009; Lacina et al., 2011).
One of the biggest challenges using LC–MS/MS methods using ESI is ion suppression or ion
enhancement which can occur when co-eluting compounds are present in the extract (Mallet et al.,
2004). There have been a variety of approaches taken to remove these interfering compounds
including the use of carbon, ion-exchange or silica, all of which have been used with good recovery
rates (Powley et al., 2005; Taniyasu et al., 2005; Powley et al., 2008; K€arrman et al., 2009;
Ballesteros-Gomez et al., 2010; Lacina et al., 2011; Vestergren et al., 2012).
The rapid development of LC–MS/MS instrumentation and increased availability of analytical standards
has resulted in signiﬁcant advances in methodology for PFASs with many more individual PFASs being
measured and improvements in limits of detection (LODs) of up to three orders of magnitude (Hansen
et al., 2001; Ballesteros-Gomez et al., 2010; Haug et al., 2010a; Lacina et al., 2011; Sundstr€om et al.,
2011; Vestergren et al., 2012). The results of these improvements are reﬂected by overall performance
that can be seen by laboratories participating in interlaboratory comparison studies (van Leeuwen et al.,
2006; Lindstr€om et al., 2008; Longnecker et al., 2008; van Leeuwen et al., 2009; van der Veen et al.,
2012). There nevertheless remains an important need to remain vigilant in terms of quality control when
undertaking analysis of food samples for PFASs, and measures such as inclusion of procedural blanks to
check for laboratory contamination, estimates of recovery and matrix effects, and regular participation in
laboratory intercomparison studies is important to ensure data quality.
Analytical columns used for standard analysis may not be suitable to quantify branched chain
molecules and specialist columns designed for this application may be needed to ensure separation
(Miralles-Marco and Harrad, 2015). The same applies to enantiomers if these are to be measured
separately. For both situations, it is important to use appropriate analytical standards (Benskin et al.,
2010; Miralles-Marco and Harrad, 2015).
1.3.2.2. Analytical methods for determination of PFASs in biological samples
Similar to food samples, PFOS and PFOA are determined in biological samples using LC–MS/MS.
The sample preparation usually involves a combination of protein precipitation, on-line or off-line solid-
phase extraction and/or liquid–liquid extraction (Jahnke and Berger, 2009; Salihovic et al., 2013a).
Recently, also methods including l-SPE (Lashgari and Lee, 2016) and 96-well plates (Salihovic et al.,
2013b) have been applied. If an additional clean-up is required, dispersed graphitised carbon with
glacial acetic acid or clean-up by ﬁltration is commonly used (Salihovic et al., 2013a).
1.3.3. Synthesis
Most information in this Section is taken from the previous opinion of the CONTAM Panel (EFSA,
2008), which in turn was to a large extent based on information in the 3M assessment (3M Company,
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2003), the OECD hazard assessment (OECD, 2002) via the report from UK Environment Agency (Brooke
et al., 2004) and the PERFORCE report (de Voogt et al., 2006). Two major processes exist for production
of PFOS and PFOA, Simons electrochemical ﬂuorination (ECF) and telomerisation (Hekster et al., 2003).
The telomerisation process generates almost exclusively linear PFOS and PFOA, whereas the
electrochemical process produces a mixture of branched and linear isomers (see Figure 1) (Buck et al.,
2011). In the ECF process, organic feed stocks are dispersed in liquid anhydrous hydrogen ﬂuoride, and
an electric current is passed through the solution, leading to the replacement of all of the hydrogen
atoms in the molecule with ﬂuorine atoms. In the telomerisation process, tetraﬂuoroethylene is reacted
with iodine pentaﬂuoride (IF5) to produce ﬂuorinated alkyl iodide with linear, even numbered alkyl chain
lengths, so called ﬂuorotelomers. Production of ﬂuorotelomer-based products started around 1974 (van
Zelm et al., 2008), whereas production with the ECF process was initiated already in the late 1940s.
For additional information on the synthesis of PFASs dealt with in this opinion, the reader is referred
to, e.g. Buck et al. (2011), van Zelm et al. (2008), L€ofstedt Gilljam et al. (2016) and OECD (2011).
1.3.4. Production and use of the compounds
The chemical resistance, the surface tension lowering properties and the ability to create stable
foams have made PFASs extremely versatile. Since the 1940s, PFASs have been produced and used in
numerous commercial and industrial applications, including textile, carpet and leather treatment (water
and dirt prooﬁng), surfactants, ﬁreﬁghting foams, metal plating and paper grease-prooﬁng treatments
(Kissa, 2001). Eight-carbon based molecules dominated the early production of PFASs but as a result
of national and international legislations on production and use of PFOS and PFOA, and its possible
precursors, a number of other PFASs have been placed on the market. This includes compounds with
chain lengths from four to eighteen carbon atoms.
Fluorinated surfactants with ﬂuorinated hydrophobic/oleophobic chains longer than seven ﬂuorinated
carbon atoms have reduced water solubility. This means that seven or eight perﬂuorinated carbons have
optimal functionality from a surfactant perspective on low surface tension. This could indicate that
transition from production and use of molecules with seven or eight perﬂuorinated carbons could result in
higher demand and production in order to obtain comparable technical performance. The effects of such
a transition have been discussed further elsewhere (Danish EPA, 2015).
In the open literature, there are a limited number of reports on the production of PFOS and PFOA.
Paul et al. (2009) report on an inventory of global production of PFOS. The authors estimated the total
global production during 1970–2002 to have been 122,500 tonnes, whereof 26,500 tonnes was
classiﬁed as manufacturing wastes. Prevedouros et al. (2006) estimated the total global production of
PFCAs to be 4,400–8,000 tonnes, where 3,600–5,700 tonnes represent ammonium perﬂuorooctanoate
(APFO) and 800–2,300 tonnes represent ammonium perﬂuorononanoate (APFN). The same authors
also reported on the production of AFPO. The largest production sites were located in the US and
Belgium. Less extensive production was occurring in Italy and Japan. The remaining 10–20% was
manufactured from about 1975 at one site in Germany. By 2002, the principal worldwide manufacturer
of APFO by the ECF process discontinued external sales and ceased production leaving only a number
of relatively small producers in Europe and in Asia (OECD, 2004).
The 3M Company started its production of perﬂuorinated octylchemicals around 1947 (3M
Company, 1999; Kissa, 2001). Production increased in the 1960s and 1970s as a result of a generally
increased demand for PFASs where these compounds became a standard additive in aqueous
ﬁreﬁghting foams. Production continued to increase throughout the 1980s and 1990s, and it reached
its maximum in 2000 just prior to the phase-out of the perﬂuorooctyl-based production. In these days,
3M was the world’s leading producer of PFOS- and PFOA-related compounds. These related
compounds comprise the possible precursors as well as compounds/intermediates used in the
production (for PFOS perﬂuorooctane sulfonyl ﬂuoride (POSF)) but also salts, aldehydes, amides, etc.
According to the 3M Company (2003), the global production of PFOS was decreased from 3,535
tonnes in 2000 to 175 tonnes in 2001. In late 2002, 3M Company closed down its production of PFOS
and PFOA. In connection to this, their production of perﬂuorobutyl-based products increased, but more
precise production volumes have not been identiﬁed. This shift away from the perﬂuorooctyl-based
compounds is likely to be a response to national and international legislations on production and use
of PFOS and PFOA, and its possible precursors (OECD, 2006).
OECD has investigated the production of PFSAs and PFCAs and products containing these groups of
compounds (OECD, 2006). The report indicates that in 2005, 74–175 tonnes as the sum of PFOS and
PFOS-containing products were manufactured or imported, and of this up to 90 tonnes consisted of
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POSF. The corresponding ﬁgures for PFOA and PFOA-containing products were estimated to be 69–
320 tonnes.
1.3.5. Environmental fate
PFASs have both hydrophobic and oleophobic properties, surface tension lowering properties, as
well as chemical resistance. This versatility has resulted in PFASs being used in a plethora of industrial
processes as well as numerous consumer products worldwide (Kissa, 2001; Buck et al., 2011). PFOS
and PFOA are highly resistant to physical and microbiological degradation (Kissa, 2001), and are thus
extremely persistent in the environment and they therefore fulﬁl international persistent organic
pollutant (POP) criteria. In fact, there are no indications that the perﬂuorinated part of PFOS or PFOA
could be decomposed in the environment.
Many PFASs are considered to be potential precursors of PFSAs and PFCAs (see Figure 2), and these
precursors are usually not environmentally persistent, but may be transformed in the environment
among others through biodegradation. In a study by Peng et al. (2014), Japanese Medaka were exposed
to an N-ethyl perﬂuorooctanesulfonamido ethanol (FOSE)-based phosphate diester through water, and
N-ethyl perﬂuorooctane sulfonamide (EtFOSA), N-ethyl perﬂuorooctane sulfonamidoethanol (EtFOSE),
perﬂuorooctane sulfonamide (FOSA) and PFOS were measured in the samples. Polyﬂuoroalkyl
phosphates (PAPs) have been shown to biodegrade to FTOHs and PFCAs. For instance in a study by
D’Eon and Mabury (2007), Sprague–Dawley rats were exposed to 8:2 diPAPs and 8:2 mono PAPs, and
both PFOA and metabolites previously identiﬁed in 8:2 FTOH metabolism studies were observed (D’Eon
and Mabury, 2007). It should however be noted that environmental transformation of such precursors
occurs in the non-perﬂuorinated part of the molecules.
The widespread use of PFOS, PFOA and their precursors, in combination with their persistency in
the environment, has resulted in a widespread contamination of the environment. PFOS and PFOA are
ubiquitous and are found in a variety of compartments, including wildlife and humans (Giesy and
Kannan, 2001).
1.3.5.1. Release and distribution in the environment
PFOS and PFOA can be released to the environment at various stages of production, through
product use and as a result of disposal of the products at the end of their life (Ahrens and Bundschuh,
2014). It has been shown from environmental monitoring and inventory studies that a substantial
amount of the PFOS and PFOA found in the environment has been released into aquatic ecosystems,
(Prevedouros et al., 2006; Paul et al., 2009). As a result of high persistency and relatively high water
solubility, PFOS and PFOA can undergo long-range transport as aerosols but also via water currents
(Prevedouros et al., 2006; Ahrens et al., 2011). Furthermore, long-range atmospheric transport of
precursors of PFOS and PFOA (Young and Mabury, 2010; Benskin et al., 2011) as well as human
activities, as shown by, e.g. Wild et al. (2015), could contribute to the long-range transport of these
compounds. Consequently, historic and current production of PFASs has resulted in, and will for a long
time to come, lead to further distribution of PFOS and PFOA in the environment. More speciﬁcally,
environmental waterways can act as both a mode of transport and as a ﬁnal sink due to their relatively
high water solubility (> 0.5 g/L for PFOA; Kissa, 2001) and due to the low volatility of the PFASs in
Figure 2: Simpliﬁed ﬁgure illustrating biodegradation of certain groups of PFASs
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their deprotonated form (Armitage et al., 2006). Exposure of aquatic organisms can therefore be
expected, either directly via contaminated water or indirectly through the ecological food chains.
Important direct releases to aquatic ecosystems come from, for instance, municipal waste water
treatment plants, landﬁll waste sites and industrial plants (Eggen et al., 2010; Post et al., 2012; Arvaniti
and Stasinakis, 2015). Atmospheric deposition, as a secondary source is also a major contributor (Ahrens
and Bundschuh, 2014). More than 90% of investigated European rivers have shown to be contaminated
with PFASs at concentrations between 3 and 1,400 ng/L (Loos et al., 2009, 2010; M€oller et al., 2010) and
PFASs have also been found in drinking water (Loos et al., 2010; Ahrens and Bundschuh, 2014).
1.3.5.2. Bioaccumulation in aquatic and terrestrial food chains
Bioaccumulation processes for organic chemicals are generally related to octanol–water equilibrium
coefﬁcients which reﬂect how hydrophobic compounds partition into the fatty tissues of living
organisms. Unlike lipophilic persistent organic chemicals, such as polychlorinated biphenyls (PCBs) and
polybrominated diphenylethers (PBDEs), PFOS and PFOA partition to serum proteins (Han et al., 2003;
Jones et al., 2003; Conder et al., 2008; Bischel et al., 2010). Bioaccumulation and biomagniﬁcation
factors (BAFs and BMFs) determined in the laboratory and in the ﬁeld are generally consistent with the
proteinophilicity of PFASs (Martin et al., 2003a,b; Kelly et al., 2009). In a study by Gebbink et al.
(2016), ﬁeld-based sediment-water distribution coefﬁcients (logKD) of 2.7 and 2.5 were reported for
PFOS and PFOA, respectively. In the same study, log BAFs from water to Baltic Herring
(Clupea harengus) of 4.11 and 2.34 were observed for PFOS and PFOA, respectively.
For land-based food chains, the bioaccumulation processes are more complex. A study by Stahl
et al. (2009) demonstrated that PFOA and PFOS can accumulate in plants after being taken up from
soil by the roots. The fact that PFOA and PFOS can be taken up and retained in humans (Olsen et al.,
2007) and other mammals (Houde et al., 2006, 2011) suggests that bioaccumulation of PFOA and
PFOS may also be important for farm animals. Biomagniﬁcation of PFOS in an Arctic terrestrial food
chain, from lichen to caribou to wolf, has also been reported (M€ueller et al., 2011). BMFs varied greatly
with tissue type and compound, but it was concluded that PFOS and PFOA are biomagniﬁed in marine
and terrestrial food chains (Kelly et al., 2009; M€ueller et al., 2011).
1.3.5.3. Time trends
The occurrence of PFASs in biota varies with time and compound. PFOS showed a profound
increase in biota representing various trophic levels at least until the late 1990s. As an example, eggs
from guillemot (Uria aalge) sampled at the same island in the Baltic Proper between 1968 and 2003
showed a dramatic increase in the PFOS concentrations from almost zero in 1968 to more than
1,300 ng/g fresh weight in the late 1990s. Thereafter the concentrations have decreased (Holmstr€om
et al., 2005) and in 2003 the concentrations were around 550 ng/g. In a compilation by the Swedish
Environmental Protection Agency in 2012, temporal trends for PFOS and PFOA were reported from the
Baltic Sea area and the Swedish mainland and this is described in Table 2.
Table 2: Temporal trends for PFOS and PFOA in grey seal (Halichoerus grypus), otter (Lutra lutra)
and peregrine falcon (Falco peregrinus)
Compound Species Organ Period
Concentration trend over time
period, ng/g ww
Trend
PFOS Peregrine falcon Egg 1975–1994 10–90(a) Increasing
1995–2005 90–80(a) NS
Grey seal Liver 1969–1995 12–620 Increasing
1996–2008 429–451 NS
Otter Liver 1972–2011 200–2,500(a) Increasing
2002–2011 2,500–2,500(a) NS
PFOA Peregrine falcon Egg 1975–2006 < LOD NS
Grey seal Liver 1969–1998 < LOD–11 Increasing
1999–2008 2.8–0.6 Decreasing
Otter Liver 1972–2011 1–16(a) Increasing
2002–2011 5–16(a) Increasing
NS: No signiﬁcant trend; LOD: limit of detection; PFOA: perﬂuorooctanoic acid; PFOS: perﬂuorooctane sulfonic acid; ww: wet weight.
(a): Estimated from ﬁgures in selected references: Holmstr€om et al. (2010), Kratzer et al. (2011), Roos et al. (2013) and the
Swedish EPA (2012).
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1.3.5.4. Contamination of food
Contamination of food with PFOS and PFOA is thought to come via two different main processes,
these being ﬁrstly from bioaccumulation in aquatic and terrestrial food chains, and secondly, as a
result of transfer of PFOS, PFOA and their precursors from contact materials used in food processing
and packaging (for further information on migration from food contact materials, including non-stick
coatings used on cookware see Section 3.1.3.1). Contamination from packaging and processing
reﬂects current production and use of these compounds, while bioaccumulation in food chains in
general reﬂects long-term use. In order to improve the effectiveness of future measures to reduce
dietary exposure, it is important to quantify the relative contribution from both of these source groups.
Contamination can also arise when food-producing animals are exposed to sources of pollution, for
example boars feeding at dumpsites and other contaminated sites could be exposed to high levels of
PFOS and other environmental contaminants, and associated high levels of PFOS and PFOA have been
found in edible tissues from such animals (see Section 3.1.2).
1.3.6. Previous risk assessments
In 2008, EFSA published a scientiﬁc opinion on PFOS, PFOA and their salts (EFSA, 2008). For PFOS,
a tolerable daily intake (TDI) of 150 ng/kg body weight (bw) per day was established, based on a
lowest no-observed-adverse-effect-level (NOAEL) of 0.03 mg/kg bw per day derived from a subchronic
study on cynomolgus monkeys, where a decrease in serum total cholesterol and high-density
lipoproteins (HDL), increased thyroid stimulating hormone (TSH) levels and lowered triiodothyronine
(T3) concentrations were observed. An uncertainty factor (UF) of 200 was applied to the NOAEL. A UF
of 100 was used for inter- and intraspecies differences and an additional UF of 2 to compensate for
uncertainties related to the duration of the key study and the elimination kinetics of PFOS. The EFSA
CONTAM Panel concluded that the exposure to the general population was well below the derived TDI,
while highly exposed individuals might slightly exceed this level. Serum PFOS levels in general
populations were found to be in the range 200–3,000 times lower than serum levels in the cynomolgus
monkeys from which the NOAEL was derived. For PFOA, a benchmark dose for a 10% increase in
increased liver weight (BMDL10) of 0.3 mg/kg bw per day based on studies in mice and rats was used
to derive a TDI of 1.5 lg/kg bw per day, applying a UF of 200 to the BMDL10. A UF of 100 was used
for inter- and intraspecies differences and an additional UF of 2 to compensate for uncertainties
relating to the internal dose kinetics. The estimated high level dietary exposure of 6 ng/kg bw per day
was found to be well below the TDI, and serum levels in humans were around three orders of
magnitude lower than levels in rats in the studies from which the BMDL10 was derived. Based on this,
the CONTAM Panel concluded that it is unlikely that adverse effects related to the presence of PFOS
and PFOA in food are occurring in the general population. The 2012 EFSA scientiﬁc report (EFSA,
2012) on the occurrence and dietary exposure of PFASs in food conﬁrmed that dietary exposure to
PFOS and PFOA was highly unlikely to exceed the TDIs established by EFSA in 2008.
The Federal Institute for Risk Assessment in Germany (BFR) concluded in 2008 that there is no
health risk in the German population arising from dietary exposure to PFOS and PFOA at levels found
in food. BFR agreed with the respective TDIs established by EFSA in 2008 but referred to them as
provisional TDIs (BfR, 2008).
In 2012, the Swedish Environmental Protection Agency published an Environmental and Health Risk
Assessment of 23 PFASs including PFOS and PFOA. For the Swedish general population, the risk
characterisation did not indicate any cause for concern for reproductive toxicity or hepatotoxicity. In a
subpopulation that consumed contaminated ﬁsh, PFOS levels were close to being of concern. In the
general population, risk characterisation ratios (RCRs) for hepatotoxicity were highest for PFOS (0.17)
and PFOA (0.04) contributing in total with 77% to the cumulative RCRs. For reproductive toxicity, the
highest RCR was identiﬁed for PFOS (0.14), contributing with 76% to the cumulative RCR. Additionally,
for PFOS, immunotoxicity (RCR 229) and for PFOA (RCR 2.6), impaired mammary gland development,
were identiﬁed as endpoints at very low doses (Swedish EPA, 2012).
In 2014, the United States Environmental Protection Agency (US EPA) selected 0.03 lg/kg bw per
day as the reference dose (RfD) for PFOS based on developmental toxicity and increased liver weight
in rats as the most sensitive endpoints (US EPA, 2014). For PFOA, an RfD of 0.02 lg/kg bw per day
was derived based on the endpoint increased liver weight, in rats and mice (US EPA, 2014).
In 2015, the Danish Environmental Protection Agency established for PFOS a TDI of 0.03 lg/kg bw
per day based on developmental toxicity and increased liver weight in rats as the most sensitive
endpoints and for PFOA a TDI of 0.1 lg/kg bw per day based on increased liver weight in rats. For FOSA
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it was stated that no sufﬁcient data were available for derivation of a speciﬁc TDI. However, because
FOSA is the amide derivate of PFOS and a precursor of PFOS, the Danish Environmental Protection
Agency concluded that it seems justiﬁable to apply the TDI for PFOS to FOSA as well (Danish EPA, 2015).
The Agency for Toxic Substances and Disease Registry (ATSDR), the Federal public health agency of
the U.S. Department of Health and Human Services, prepared a draft Toxicological Proﬁle for 13 PFASs
including PFOS and PFOA which has been on Public comment up to the 1 December 2015. For PFOS, an
intermediate-duration oral minimum risk level of 0.03 lg/kg bw per day was established. A NOAEL for
female monkeys based on increased absolute liver weight was used as the point of departure for
establishing the minimum risk level. The minimum risk level was based on back-calculation from internal
doses (serum levels), as using external doses is problematic due to differences in half-lives. A total UF of
90 was applied due to animal to human extrapolation (3), human variability (10) and lack of
developmental and immunological data in monkeys (3). For PFOA, an intermediate-duration oral
minimum risk level of 0.02 lg/kg bw per day was established. The minimum risk level is based on a
BMDL where a 10% relative deviation in absolute liver weight for male monkeys was used as the point of
departure. A UF of 90 was applied due to animal to human extrapolation (3), human variability (10) and
lack of developmental and immunological data in monkeys (3). Back-calculation from internal doses
(serum levels) was applied to establish the minimum risk level, as external doses were problematic to use
because of differences in half-lives (ATSDR, 2015).
In 2015, the Committee for Risk Assessment (RAC), established a Derived No Effect Level (DNEL)
for PFOA of 800 ng/mL serum for the general population. This was based on developmental toxicity
studies in mice (ECHA, 2015).
In 2016, the German Human Biomonitoring (HBM) Commission decided to set HBM I values for
PFOA and PFOS in blood plasma at 2 ng/mL and 5 ng/mL, respectively. The HBM I value represents
the concentration of a substance in a body matrix at and below which, adverse health effects are not
expected (Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2016; Apel et al., 2017).
In 2016, the US EPA derived an RfD for PFOS of 0.02 lg/kg bw per day based on decreased neonatal
rat body weight from a two-generation study. A pharmacokinetic model was used to calculate a human
equivalent dose (HED) NOAEL. A UF of 30 was applied to the HED NOAEL, which included a UF of 10 for
intrahuman variability and a UF of 3 to account for toxicodynamic differences between animals and
humans. It was concluded that the weight of evidence for a carcinogenic potential of PFOS to humans
was too limited to support a quantitative cancer assessment (US EPA, 2016a). For PFOA, US EPA selected
in 2016 an RfD of 0.02 lg/kg bw per day based on reduced ossiﬁcation and accelerated puberty effects
observed in a developmental toxicity study in mice. A UF of 300 (10 for intrahuman variability, 3 to
account for toxicodynamic differences between animals and human, 10 to account for use of a lowest-
observed-adverse-effect-level (LOAEL) as the point of departure (POD)) was applied to the HED LOAEL.
The selected RfD is supported by the other candidate RfDs based on effects on the immune system in a
15-day short-term study and on the kidneys of F0 and F1 males in a two-generation study of
developmental and reproductive toxicity. It was concluded that there is ‘suggestive evidence of
carcinogenic potential’ for PFOA (US EPA, 2016b). The US EPA issued a lifetime drinking water Health
Advisory (HA) for PFOS and PFOA of each 0.07 lg/L based on the respective RfDs. US EPA
recommended to compare the sum of the concentrations of PFOS and PFOA to the HA (0.07 lg/L) when
these two chemicals co-occur at the same time and location in a drinking water source.
In 2016, the National Toxicology Program (NTP) concluded from a systematic review of
immunotoxicity associated with exposure to PFOS and PFOA that these compounds present an immune
hazard to humans. This conclusion was based on a high level of evidence that both PFOS and PFOA
suppressed the antibody response from animal studies and a moderate level of evidence from studies
in humans. Although the strongest evidence for an effect of PFOS on the immune system was for
suppression of the antibody response, there was additional, although weaker evidence that is primarily
from studies in experimental animals, that PFOS suppresses disease resistance and natural killer (NK)
cell activity. PFOA seems to affect multiple aspects of the immune system. Thereby, strongest effects
were observed for suppression of the antibody response and increased hypersensitivity. Weaker effects
exist from epidemiological studies with PFOA reducing infectious disease resistance, increased
hypersensitivity-related effects, and increased autoimmune disease (NTP, 2016).
In 2016, the RIVM has derived a health-based limit value for chronic exposure to PFOA equal to
12.5 ng/kg bw per day based on increased liver weight and hypertrophy in liver cells in rats, as the
most sensitive endpoints. Blood serum concentrations in humans that are considered safe as regards
the occurrence of liver effects and developmental effects were derived on the basis of toxicological
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data for various animal species and uncertainty factors. A blood serum concentration of 89 ng/mL
blood serum was calculated as the health-based limit value for prolonged exposure (RIVM, 2016).
In 2016, the International Agency for Research on Cancer (IARC) assessed PFOA and stated that
there is limited evidence for carcinogenicity in experimental animals and moderate evidence for
mechanisms of PFOA-associated carcinogenesis, including some evidence for these mechanisms being
operative in humans (IARC, 2016). The compound was assigned to group 2B as being possibly
carcinogenic to humans (Group 2B).
In 2017, Food Standards Australia New Zealand (FSANZ) established for PFOS a TDI of 0.02 lg/kg
bw per day, based on decreased parental and offspring body weight gains in a multigeneration
reproductive toxicity study in rats. For PFOA, a TDI of 0.16 lg/kg bw per day based on a NOAEL for
fetal toxicity in a developmental and reproductive study in mice was recommended. The TDIs were
derived by applying pharmacokinetic modelling to the serum PFOS concentrations measured in
experimental animals, to calculate HEDs. A UF of 30 was applied to the respective HEDs, which
comprised a default factor of 3 to account for interspecies differences in toxicodynamics and a default
factor of 10 for intraspecies differences in the human population (FSANZ, 2017).
1.3.7. Legislation
1.3.7.1. PFOS
Originally in the European Union (EU) Directive 2006/122/EC4 of the European Parliament and of
the Council of 12 December 2006, restrictions were laid down on the marketing and use of PFOS for
new products in the non-food area, which applied from 27 June 2008. This Directive also stated that
on-going risk assessment activities for PFOA should be kept under review.
Subsequently, by Regulation (EC) No 552/2009,5 restrictions on the marketing and use of PFOS for
new products in the non-food area were included in Annex XVII of Regulation (EC) No 1907/2006 of
the European Parliament and of the Council of 18 December 2006 concerning the Registration,
Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals
Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and
Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission
Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC.6
In 2009 PFOS, its salts and perﬂuorooctane sulfonyl ﬂuoride (PFOSF) was added to Annex B
(Restriction) to the Stockholm Convention. During the review of PFOS, the POPs Review Committee
adopted the risk management evaluation.
In accordance with Article 6 of the Stockholm Convention on environmentally sound management
of waste, the technical guidelines on the environmentally sound management of wastes containing
PFOS, its salts or PFOSF was developed and adopted by the Basel Convention.
The UNECE Convention on Long-range Transboundary Air Pollution (CLRTAP) contains a Protocol on
Persistent Organic Pollutants (POPs) established in 1998 and amended in 2009 where PFOS is
proposed to be treated in a similar way as within the Stockholm Convention. This amendment on PFOS
has however not yet come into force. The CLRTAP Protocol has so far no text on PFOA.
In 2011, Commission Regulation (EU) No 207/20117 deleted Entry 53 concerning PFOS from Annex
XVII of Regulation (EC) No 1907/2006 as PFOS became regulated under Regulation (EC) No 850/20048
by means of Commission Regulation (EU) No 757/2010 of 24 August 2010.9 Currently, the production,
placing on the market and use of PFOS, its salts and other derivatives is within the EU regulated under
4 Directive 2006/122/EC of the European Parliament and of the Council of 12 December 2006 amending for the 30th time
Council Directive 76/769/EEC on the approximation of the laws, regulations and administrative provisions of the Member States
relating to restrictions on the marketing and use of certain dangerous substances and preparations (perﬂuorooctane
sulfonates). OJ L 372, 27.12.2006, p. 32–34.
5 Commission Regulation (EC) No 552/2009 of 22 June 2009 amending Regulation (EC) No 1907/2006 of the European
Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) as regards
Annex XVII. OJ L 164, 26.6.2009, p. 7–31.
6 OJ L 396, 30.12.1996, p. 1–520.
7 Commission Regulation (EU) No 207/2011 of 2 March 2011 amending Regulation (EC) No 1907/2006 of the European
Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) as regards
Annex XVII (diphenylether, pentabromo derivative and PFOS). OJ L 58, 3.3.2011, p. 27–28.
8 Regulation (EC) No 850/2004 of the European Parliament and of the Council of 29 April 2004 on persistent organic pollutants
and amending Directive 79/117/EEC. OJ L 158, 30.4.2004, p. 7–49.
9 Commission Regulation (EU) No 757/2010 of 24 August 2010 amending Regulation (EC) No 850/2004 of the European
Parliament and of the Council on persistent organic pollutants as regards Annexes I and III. OJ L 223, 25.8.2010, p. 29–36.
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the POP Regulation. Compared to the Stockholm Convention, the numbers of exemptions are fewer in
the POP regulation, as alternatives were found to be available to many of those uses.
The derogation was given for production and placing on the market for the following uses until 26
August 2015, (a) wetting agents for use in controlled electroplating systems; (b) photoresists or
antireﬂective coatings for photolithography processes; (c) photographic coatings applied to ﬁlms,
papers or printing plates; (d) mist suppressants for non-decorative hard chromium (VI) plating in
closed loop systems; (e) hydraulic ﬂuids for aviation. Today there are no remaining exemptions.
1.3.7.2. PFOA
On 14 June 2013, the Member State Committee, referred to in Article 76(1)(e) of Regulation (EC)
No 1907/2006, identiﬁed PFOA as a persistent, bioaccumulative and toxic (PBT) substance, in
accordance with Article 57(d) of that Regulation. On 20 June 2013, PFOA was included in the
Candidate List of Substances of Very High Concern (SVHC), for possible inclusion into Annex XIV to
Regulation (EC) No 1907/2006.
By means of Commission Regulation (EU) 2017/1000,10 PFOA was included in Annex XVII to
Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the
Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) as regards PFOA, its salts
and PFOA-related substances. Within the scope of entry 68 of this Regulation, PFOA is included, its
salts, as well as ‘Any related substance (including its salts and polymers) having a linear or branched
perﬂuoroheptyl group with the formula C7F15– directly attached to another carbon atom, as one of
the structural elements’ and ‘any related substance (including its salts and polymers) having a linear or
branched perﬂuorooctyl group with the formula C8F17– as one of the structural elements’. The
following substances are excluded from this designation:
– C8F17–X, where X = F, Cl, Br.
– C8F17–C(=O)OH, C8F17–C(=O)O–X0 or C8F17–CF2–X0 (where X0 = any group, including salts)
The substances within the scope of entry 68 shall not, as of 4 July 2020, be manufactured or
placed on the market as substances on their own or be used in the production of, or placed on the
market in, another substance, as a constituent; a mixture; an article, in a concentration equal to or
above 25 ppb of PFOA including its salts, or 1,000 ppb of one or a combination of PFOA-related
substances. There are however a number of exemptions that go beyond 2020: for equipment used to
manufacture semi-conductors and latex printing inks (4 July 2022); textiles for the protection of
workers from risks to their health and safety; membranes intended for use in medical textiles and
ﬁltration in water treatment, production processes and efﬂuent treatment; plasma nano-coatings
(4 July 2023); medical devices other than implantable medical devices within the scope of Directive
93/42/EEC11 (July 2023).
2. Data and methodologies
2.1. Data
2.1.1. Occurrence in food data
2.1.1.1. Data collection and validation
Following an European Commission mandate to EFSA, a call for annual collection of chemical
contaminant occurrence data in food, including PFOS and PFOA, was issued by the former EFSA Dietary
and Chemical Monitoring Unit (now DATA Unit)12 in December 2010 with a closing date of 1 October of
each year.13 European national authorities and similar bodies, research institutions, academia, food
business operators and other stakeholders were invited to submit analytical data on PFAS in food. The
data for the present assessment were provided by national authorities from Austria, Belgium, Cyprus, the
Czech Republic, Germany, Denmark, Finland, France, Greece, Ireland, Italy, Malta, Norway, Slovenia,
Spain and the United Kingdom (UK).
10 Commission Regulation (EU) 2017/1000 of 13 June 2017 amending Annex XVII to Regulation (EC) No 1907/2006 of the
European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals
(REACH) as regards perﬂuorooctanoic acid (PFOA), its salts and PFOA-related substances. OJ L 150, 14.6.2017, p. 14–18.
11 Council Directive 93/42/EEC of 14 June 1993 concerning medical devices. OJ L 169, 12.7.1993, p. 1–43.
12 From 1 January 2014 onwards, Evidence Management Unit (DATA).
13 http://www.efsa.europa.eu/en/data/call/datex101217
PFOS and PFOA in food
www.efsa.europa.eu/efsajournal 21 EFSA Journal 2018;16(12):5194
The data submission to EFSA followed the requirements of the EFSA Guidance on Standard Sample
Description for Food and Feed (EFSA, 2010a); occurrence data were managed following the EFSA
standard operational procedures (SOPs) on ‘Data collection and validation’ and on ‘Data analysis of
food consumption and occurrence data’.
By the end of October 2016, a total of 21,411 analytical results of food and beverages on PFOS
and PFOA were available in the EFSA database. Data received after that date was not included in the
data set used for further evaluation for this opinion.
2.1.1.2. Data analysis
Following the EFSA SOP on ‘Data analysis of food consumption and occurrence data’ to guarantee
an appropriate quality of the data used in the exposure assessment, the initial data set was carefully
evaluated applying several data cleaning and validation steps. Special attention was paid to different
parameters such as ‘Sampling strategy’, ‘Sampling method’, ‘Sampling year’, ‘Sampling country’,
‘Analytical methods’, ‘Reporting unit’, ‘Limit of detection’ and the codiﬁcation of the different samples
under FoodEx classiﬁcation. The outcome of the data analysis is presented in Section 3.1.1.
In the analysis of PFOS and PFOA occurrence data, the left-censored data (results below LOD or
below limit of quantiﬁcation (LOQ)) were treated by the substitution method as recommended in the
‘Principles and Methods for the Risk Assessment of Chemicals in Food’ (WHO/IPCS, 2009). The same
method is indicated in the EFSA scientiﬁc report ‘Management of left-censored data in dietary exposure
assessment of chemical substances’ (EFSA, 2010b) as an option for the treatment of left-censored
data. The guidance suggests that the lower bound (LB) and upper bound (UB) approach should be
used for chemicals likely to be present in food (e.g. naturally occurring contaminants, nutrients and
mycotoxins). The LB is obtained by assigning a value of zero (minimum possible value) to all samples
reported as lower than the LOD (< LOD) or LOQ (< LOQ). The UB is obtained by assigning the
numerical value of the LOD to values reported as < LOD and LOQ to values reported as < LOQ
(maximum possible value), depending on whether the LOD or LOQ is reported by the laboratory.
2.1.2. Consumption data
2.1.2.1. Food consumption data
The EFSA Comprehensive European Food Consumption Database (Comprehensive Database)
provides a compilation of existing national information on food consumption at individual level. It was
ﬁrst built in 2010 (EFSA, 2011a; Huybrechts et al., 2011; Merten et al., 2011). Details on how the
Comprehensive Database is used are published in the Guidance of EFSA (EFSA, 2011a). The latest
version of the Comprehensive Database updated in 2015 contains results from a total of 51 different
dietary surveys carried out in 23 different Member States covering 94,532 individuals.
Within the dietary studies, subjects are classiﬁed in different age classes as follows:
Infants: < 12 months old
Toddlers: ≥ 12 months to < 36 months old
Other children: ≥ 36 months to < 10 years old
Adolescents: ≥ 10 years to < 18 years old
Adults: ≥ 18 years to < 65 years old
Elderly: ≥ 65 years to < 75 years old
Very elderly: ≥ 75 years old
Two additional surveys provided information on speciﬁc population groups: ‘Pregnant women’
(≥ 15 years to ≤ 45 years old; Latvia) and ‘Lactating women’ (≥ 28 years to ≤ 39 years old; Greece).
For chronic exposure assessment, food consumption data were available from 44 different dietary
surveys carried out in 19 different European countries. When for one particular country and age class two
different dietary surveys were available, only the most recent one was used. This resulted in a total of 35
dietary surveys selected to estimate chronic dietary exposure. In Appendix A, Table A.1, these dietary
surveys and the number of subjects available for the chronic exposure assessment are described.
Overall, the food consumption data gathered by EFSA in the Comprehensive Database are the most
complete and detailed data currently available in the EU. Consumption data were collected using single
or repeated 24- or 48-h dietary recalls or dietary records covering from 3 to 7 days per subject. Owing
to the differences in the methods used for data collection, direct country-to-country comparisons can
be misleading.
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2.1.2.2. Food classiﬁcation
Consumption data were classiﬁed according to the FoodEx classiﬁcation system (EFSA, 2011b).
FoodEx is a food classiﬁcation system developed by EFSA in 2009 with the objective of simplifying the
linkage between occurrence and food consumption data when assessing the exposure to hazardous
substances. It contains 20 main food categories (ﬁrst level), which are further divided into subgroups
having 140 items at the second level, 1,261 items at the third level and reaching about 1,800 end-
points (food names or generic food names) at the fourth level.
In 2011, a new version of FoodEx, named FoodEx2 has been developed and is described in the
scientiﬁc document ‘Report on the development of a Food Classiﬁcation and Description System for
exposure assessment and guidance on its implementation and use’ (EFSA, 2011c). The last release of
FoodEx2 complements the previous hierarchical classiﬁcation system of basic codes with more detailed
food levels and gives the possibility of reporting additional information through the use of facets and
facet descriptors (EFSA, 2015).
2.1.3. Toxicokinetic and toxicological data
Data were obtained from the scientiﬁc literature as described in Section 2.2.2.
2.2. Methodologies
2.2.1. Dietary exposure assessment
The CONTAM Panel considered it appropriate to estimate only chronic exposure to PFOS and PFOA
(see Section 3.4). As suggested by the EFSA Working Group on Food Consumption and Exposure
(EFSA, 2011a), dietary surveys with only 1 day per subject were not considered as they are not
adequate to assess repeated exposure. Similarly, subjects who participated only 1 day in the dietary
studies, when the protocol prescribed more reporting days per individual, were also excluded for the
chronic exposure assessment. Thus, for chronic exposure assessment, food consumption data were
used from 35 different and most recent dietary surveys carried out in 19 different European countries
present in the latest version of the Comprehensive Database (Appendix A, Table A.1). Not all countries
provided consumption information for all age groups, and in some cases the same country provided
more than one consumption survey. When for one particular country and age class two different
dietary surveys were available, only the most recent one was used.
For calculating chronic dietary exposure to PFOS and PFOA, food consumption and body weight
data at the individual level were accessed in the Comprehensive Database.
Occurrence data and consumption data were linked at the lowest (most detailed) FoodEx level
possible. In addition, the different food commodities were grouped within each food category to better
explain their contribution to the total dietary exposure to PFOS and PFOA (see Section 3.2.1).
The mean and the high (95th percentile) chronic dietary exposures were calculated by combining
PFOS and PFOA mean occurrence values for food samples collected in different countries (pooled
European occurrence data) with the average daily consumption for each food at individual level in
each dietary survey and age class. Consequently, average exposures per day and body weight were
obtained for all individuals. On the basis of distributions of individual exposures, the mean and 95th
percentile exposures were calculated per survey and per age class. Dietary exposure was assessed
using overall European LB and UB mean occurrence of PFOS and PFOA.
All analyses were performed using the SAS Statistical Software (SAS enterprise guide 5.1).
2.2.2. Literature search and appraisal of studies
EFSA outsourced an extensive literature search related to the oral toxicity of PFASs, their precursors
and potential replacements, in experimental animals and humans (contract: RC/EFSA/BIOCONTAM/
2012/02). The aim of the assignment was to identify and collect all relevant literature regarding PFASs,
including PFOS and PFOA. The search was performed in March 2013, covering the period 2008–2013,
for PFOS and PFOA. The methodology and the results are detailed in Bull et al. (2014).
The following areas were covered:
• Area 1: Data on toxicokinetics (absorption, distribution, metabolism and excretion) in in vitro
studies, experimental animals and humans.
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• Area 2: Data on toxicity in experimental animals (i.e. acute and repeat dose toxicity,
immunotoxicity, developmental and reproductive toxicity, neurotoxicity, carcinogenicity and
other effects.
• Area 3: Data on observations in humans, including epidemiology, case reports and biomarkers
of exposure and effects.
In addition to the literature search outsourced by EFSA, further literature searches were performed
in June 2016 and December 2016, for the above 3 areas, in order to cover peer-reviewed literature
published between 2013 and November 2016. Further search strategies were designed to identify
literature published after 2007, which covered additional areas, including, chemistry, analysis,
synthesis, production, use, environmental fate, food occurrence and human exposure. An overview of
the search terms is given in Appendix D (Table D.1).
Web of Science14 and PubMed15 were identiﬁed as databases appropriate for retrieving literature for
the present evaluation. The references resulting from the literature search were imported and saved
using a software package (EndNote16), which allows effective management of references and citations.
Reviews, relevant scientiﬁc evaluations and assessments by national or international bodies were
also considered for the current risk assessment. When relevant papers were identiﬁed during the risk
assessment process (e.g. from other studies or reviews), they were also considered.
The references obtained were screened using title and abstract to identify relevant literature.
The information retrieved was subsequently reviewed by the CONTAM working group (WG) on
PFASs in food, and has been used for the present assessment based on expert judgement. Selection of
the scientiﬁc papers for inclusion or exclusion was based on consideration of the extent to which the
study was relevant to the assessment and general study quality considerations.
2.2.3. Benchmark dose analysis
Benchmark dose (BMD) modelling was used for calculation of PFOS/PFOA concentrations in plasma
which could be used to derive an health-based guidance value (HBGV). The EFSA guidance on BMD
modelling of experimental animal data (EFSA Scientiﬁc Committee, 2017a) cannot be applied for
epidemiological data since there are speciﬁc challenges that need additional consideration as described
below. For BMD modelling, the CONTAM Panel identiﬁed a large set of possible models to ﬁt
concentration–response data for PFOS/PFOA and the potential critical effects. The best ﬁtting model was
selected and the BMD and BMDL were calculated for that model using a benchmark response (BMR) level
speciﬁcally deﬁned for each study. This is in line with what was done in a previous CONTAM Panel risk
assessment for lead (EFSA CONTAM Panel, 2010) based on large human epidemiological studies.
In epidemiological data, there is greater scattering of PFOS and PFOA concentrations compared
with data from controlled animal experiments. There is no group with uniform concentration and no
control group without exposure due to the ubiquitous nature of these contaminants. Furthermore, due
to data protection issues it is difﬁcult to obtain individual data points. Therefore, the human data were
analysed grouped as quantiles as presented in the papers or provided by the authors. The main
consequences are loss of information (data are grouped at a concentration equal to the median values
of each quantile), and increased uncertainty. In some papers (Steenland et al., 2009; Nelson et al.,
2010; Eriksen et al., 2013), concentrations in each quantile and/or mean responses were not reported
numerically, quantitative values were depicted from published graphs after magniﬁcation and numerical
digitisation. Modelling was performed using the author’s results adjusted for potential confounders.
Curve ﬁtting was performed using commercial curve-ﬁtting software (TableCurve2D). This
commercial software allows over 100 different monotonic models to be tested (including simple models
such as linear, exponential, logarithmic models and more complicated models including logistic (Hill),
Gompertz model, Lorentzian model or cumulative (log) normal) and compared using different statistical
parameters (for goodness of ﬁt- r2, DOF r2, standard error and F statistic and for curve ﬁtting, Lorentzian
minimization, least square minimization and Pearson minimization) for obtaining the best ﬁtting curve. As
the benchmark calculations are dependent on the choice of the dose–effect function (Budtz-Jørgensen
et al., 2001), in the absence of clear guidelines for the modelling of human data, this large possibility of
14 Web of Science (WoS), formerly ISI Web of Knowledge, Thomson Reuters. Available at: http://thomsonreuters.com/thomson-
reuters-web-of-science/
15 PubMed, Entrez Global Query Cross-Database Search System, National Center for Biotechnology Information (NCBI), National
Library of Medicine (NLM), Department of the National Institutes of Health (NIH), United States Department of Health and
Human Services. Available at: http://www.ncbi.nlm.nih.gov/pubmed/
16 EndNote X5, Thomson Reuters. Available at: http://endnote.com/
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choice in either models or statistical parameters allows a better estimate of the BMD and BMDL in
epidemiological data. In addition to the examination of the statistical parameters, also a visual inspection
was used to identify the best-ﬁtting model.
As unexposed individuals rarely exist in observational settings and given the fact that data were
aggregated in quantiles, the BMR was considered as an increase relative to the lowest quantile (see
Appendix B) which is in line with some results already published on benchmark dose modelling on
epidemiological data (Grandjean and Budtz-Jørgensen, 2013). However, as shown in Section 3.4.2.1, the
BMD modelling of a 5% increase of serum cholesterol vs serum PFOA (median in the lowest decile) in the
C8 cohort (Steenland et al., 2009) had an overall increase slightly less than 5% (Appendix B, model #6).
In this cohort, the participants had much higher levels (mean 80, median 27 ng/mL) than the general
populations in the US and Europe. The serum PFOA level was also relatively high in the lowest decile
(median 5.5 ng/mL). A serum PFOA concentration of 1 ng/mL (half of the median of the medians in
European studies, Section 3.3.2.3, Table 8) was used, as a proxy for the ‘low’ serum PFOA concentrations
in European populations.
The BMDL was calculated as the lower limit of the 95% conﬁdence interval of the BMD. In this
software, the conﬁdence interval is given and calculated as below:
Y^+/ t (MSE)1/2 (1’(X’X)1 1)1/2
Y^ : predicted value
t : student’s t for conﬁdence level and Degree of Freedom (DOF)
1 : coefﬁcient partial derivative vector evaluated at xi
(X’X)1 : inverse of design matrix
MSE : Mean Square Error = SSE/ DOF
SSE : Sum of square due to error = Σ wi (yi – y^i)
2 for i = 1 to n
with wi : weight
yi : y data value
y^i : predicted y value
n : number of data points
The weights were based on the inverse square of the SD.
2.2.4. Physiologically based pharmacokinetic modelling
Physiologically based pharmacokinetic (PBPK) modelling was performed in order to estimate the
relationships between serum concentrations of PFOA and PFOS and dietary intakes. The resultant
BMDLs expressed as PFOS and PFOA levels in plasma, were converted into dietary exposure values,
corresponding to life-time continuous exposure (daily ingested dose). See Appendix C for details on
the methodology used.
2.2.5. Methodology applied for risk assessment
The CONTAM Panel applied the general principles of the risk assessment process for chemicals in
food as described by WHO/IPCS (2009), which include hazard identiﬁcation and characterisation,
exposure assessment and risk characterisation. In addition to the principles described by WHO/IPCS
(2009), any EFSA guidance pertaining to risk assessment and relevant for the present assessment has
been duly considered (see Appendix E).
3. Assessment
3.1. Occurrence data
3.1.1. Current occurrence data in food
An initial number of 21,411 results from food samples analysed for PFOS and PFOA from 16
European countries were available for the assessment. The major contributor of PFOS and PFOA data
was Germany which reported 62% of the data, followed by Norway and France. Data were reported
for samples collected between the years 2000 and 2015, with the majority of the data collected after
2007. For PFOS, 10,889 analytical results were obtained, while 10,522 analytical results were available
for PFOA (Table 3). For the majority of results, PFOS data (n = 10,531) were reported without
information on the isomers analysed; linear, sum of branched or both types. Only a limited number of
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results were reported either as linear PFOS or sum of branched PFOS (n = 179 for each). The current
data were not systematically checked for possible duplicate occurrence with the data reported in
Section 3.1.2. This might have resulted in a partial overlap between the data reported in the scientiﬁc
literature and the data reported to EFSA and used in the current exposure assessment.
As described in Section 2.1.1, the occurrence data were carefully evaluated and a list of validation
steps was applied before being used to estimate dietary exposure.
Outdated results may not reﬂect the current contamination. Therefore, only results from samples
collected from 2007 were retained for the further assessment, and data from samples collected before
that year (n = 871 (total); n = 438 for PFOS and n = 433 for PFOA) were excluded.
Close attention was paid to data reported for suspect samples.17 As inclusion of these samples may
lead to an overestimation of the contamination levels, the CONTAM Panel decided to exclude them
(n = 480 (total); n = 240 for both PFOS and PFOA) from further analysis. However, it should be kept in
mind that some of the remaining samples may also have been collected in a more targeted way.18
The Commission Recommendation 2010/161/EC19 recommends a maximum LOQ of 1 lg/kg for the
monitoring of PFASs in food. The LODs/LOQs of the PFOS and PFOA data reported to EFSA varied between
laboratories, between food matrices and substances, with notably lower LODs/LOQs for drinking water while
higher LODs/LOQs were frequently reported for edible offal (particularly for liver) and ﬁsh meat. Due to a
high percentage of results below LOD/LOQ in combination with high LODs/LOQs, substantial differences
between LB and UB scenarios were observed, increasing the uncertainty associated with the dietary
exposure estimates. In order to reduce this impact, but not exclude data on foods mainly contributing to the
exposure to PFOS and PFOA, an evaluation of LOQs was performed. This evaluation was based on the EFSA
internal guidance on the application of LOD/LOQ cut-offs. A special attention was paid to food categories,
which are considered to be potential important contributors to the dietary exposure to PFOS and PFOA. LOQ
cut-offs were ﬁnally applied to two food categories, namely ‘Fish and ﬁsh products’ and ‘Drinking water’. To
identify the most appropriate cut-off value for these food categories, the distributions of the quantiﬁed
values (values above LOQ) as well as the reported LOQ were evaluated at the appropriate FoodEx level/food
category. A percentile (90th to 95th) derived from the quantiﬁed values in each respective food group was
selected as the cut-off value and subsequently applied as cut-offs to the LOQs reported for these food
categories (Appendix A, Table A.2). A value of 14 lg/kg was selected as LOQ cut-off for the PFOS data in
the category ‘Fish and ﬁsh products’, a value of 0.01 lg/kg as LOQ cut-off for the PFOS data on ‘Drinking
water’ and a value of 10 lg/kg as LOQ cut-off for the PFOA data on ‘Fish and ﬁsh products’. Using this
approach, a total of 41 data points (20 analytical results for PFOS and 21 analytical results for PFOA) were
excluded. Out of these, 98% were results below LOD/LOQ. Appendix A, Table A.2 shows the effect of these
cut-offs on the occurrence values for the selected food categories. More details on distribution of LOQs for
different PFOS and PFOA and across different food categories are given in Section 3.1.1.3.
Finally, in the ﬁnal data set a total of 1,392 analytical results (n = 698 results on PFOS and n = 694
results on PFOA) were excluded as described in Appendix A, Table A.3.
Recoveries were reported only for 49% of the PFOS data and for 50% of the PFOA data. The PFOS
and PFOA analytical results were submitted to EFSA as corrected for recovery in approximately 50% of
cases. 44% of results were not corrected for recovery and for 6% of the results this information was
not given. For results which were reported as not corrected for recovery, but for which the recovery
rates were available, the results were corrected and used for exposure assessment.
Table 3: Analytical data for PFOS and PFOA as reported before applying exclusion criteria
PFASs(a) Acronyms Number of samples % LC
Perﬂuorooctane sulfonic acid PFOS 10,889 74
Perﬂuorooctanoic acid PFOA 10,522 91
Total 21,411 83
LC: left-censored.
(a): Includes analytical data on linear PFOS (n = 179) and branched PFOS (n = 179).
17 Suspect sampling is deﬁned as a selection of an individual product or establishment in order to conﬁrm or reject a suspicion of
non-conformity. It is not a random sampling, therefore, there is no sample extracted from the population.
18 Targeted samples are based on certain sampling criteria e.g. monitoring the background contamination in matrices with high
accumulation potential or controlling compliance with the maximum levels laid down in the relevant legislation.
19 Commission Recommendation of 17 March 2010 on the monitoring of perﬂuoroalkylated substances in food (2010/161/EU).
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Approximately, 73% of the PFOS and 76% of the PFOA data were obtained for samples collected
within ofﬁcial monitoring programs, 11% of the PFOS and 7.9% of the PFOA data were collected within
diet studies and the remaining data within other programmes or combination of programmes. Regarding
the sampling method, a small part of the analytical results (14% for PFOS and 11% for PFOA) were
obtained from pooled samples meaning that the result represented an average of a number of samples
taken in equal parts from different consignments/batches and pooled together for the laboratory analysis.
Since the level of aggregation for pooled samples matched the level of classiﬁcation of the individual
samples (only similar food matrices were pooled together) results from pooled samples were retained for
further evaluation. To ensure a proportionate representation of the individual samples and thus an
accurate use of occurrence data in assessing the dietary exposure, the mean concentrations per food
category were calculated by weighting the reported analytical results for the number of samples pooled.
All analytical results were expressed on whole weight basis, thus no conversion had to be applied.
The ﬁnal validated data set available for dietary exposure assessment contained 20,019 analytical
results for food samples analysed for PFOS (n = 10,191) and PFOA (n = 9,828).
The analytical results included in the ﬁnal data set (n = 20,019) and considered for the estimation
of dietary exposure to PFOS and PFOA, were obtained from 16 different European countries. Most of
the results were from Germany (12,532 analytical results; 6,255 data for the PFOS and 6,277 data for
the PFOA), followed by Norway and France (Figure 3). It is worth mentioning that the origin of the
samples was not always the European country reporting the data, i.e. the data set also contained
samples originating from North and South America, Africa, Asia and Australia, but they were collected
in Europe. The samples were collected between 2007 and 2015 with the majority being between 2007
and 2011 (Figure 4).
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Figure 3: Distribution of analytical results for PFOS and PFOA across different European countries
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Figure 5 illustrates the number of analytical results divided in quantiﬁed results and left-censored
data (results below LOD/LOQ) per substance and food category at FoodEx Level 1.
The most frequently analysed food categories were ‘Meat and meat products including edible offal’
(n = 3,700 for PFOS, n = 3,650 for PFOA) and ‘Fish and other seafood’ (n = 3,504 for PFOS, n = 3,484
for PFOA). A substantial number of data was also available for the food categories ‘Vegetable and
vegetable products’, ‘Milk and dairy products’ and ‘Drinking water’. Other food categories were less
represented. The data set was characterised by a high proportion of left-censored data, with more
than 80% of left-censored data for all food categories except ‘Fish and other seafood’ (63% of left-
censored data for PFOS), ‘Fruit and fruit products’ (75% and 70% of left-censored data for PFOS and
PFOA, respectively) and ‘Meat and meat products’ (78% of left-censored data for PFOS) (Figure 5).
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PFOA: perﬂuorooctanoic acid; PFOS: perﬂuorooctane sulfonic acid.
Figure 4: Distribution of analytical results for PFOS and PFOA divided by sampling year
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3.1.1.1. PFOS
PFOS occurrence data were available for 18 FoodEx level 1 food categories (Figure 5). The
concentrations of linear and branched isomers (n = 179 for each) reported for the same samples were
summed and added to the PFOS occurrence data set for exposure assessment. Therefore, the ﬁnal
data set for PFOS available for the exposure assessment comprised a total of 10,012 analytical results.
An overview of the number of data points available for the exposure assessment, the percentage of
results below LOD/LOQ, the mean and 95th percentile concentrations for PFOS, are presented in
Appendix A, Table A.4 (excel ﬁle – under ‘Supporting information’ Section on the web page).
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Figure 5: Distribution of analytical results divided in quantiﬁed results and left-censored data (results
below the limit of detection (LOD)/limit of quantiﬁcation (LOQ)) per substance and food
category at FoodEx Level 1
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The highest number of available data points correspond to the food category ‘Meat and meat
products’ (n = 3,677), in particular to ‘Edible offal, farmed animals’, and to the food category ‘Fish and
other seafood’ (n = 3,497), in particular to ‘Fish meat’. Other well-represented food categories were
‘Vegetables and vegetable products’ (n = 684), ‘Milk and dairy products’ (n = 492) and ‘Drinking water’
(n = 451).20 The highest mean PFOS concentration was obtained for the food category ‘Meat and
meat products’ (LB mean = 28.6 lg/kg; UB mean = 29.1 lg/kg), followed by ‘Fish and other seafood’
food category (LB mean = 2.08 lg/kg; UB mean = 2.59 lg/kg).
In the food category ‘Meat and meat products’, quantiﬁed values were found in a number of food
categories at FoodEx level 2: in livestock meat, in poultry, game mammals, edible offal of farmed
animals, edible offal of game mammals, preserved meat and sausages. The levels were particularly high
for liver samples of game mammals (LB/UB mean = 215/215 lg/kg; quantiﬁed results ranged from
0.002 lg/kg to 3.480 lg/kg) with only 3% of results below LOD/LOQ. In total, 96% of the quantiﬁed
results were on wild boar liver and therefore, the mean concentration for the food category ‘liver of game
mammals’ was strongly inﬂuenced by the results obtained on the wild boar liver samples. It is important
to mention, that with exception of three results, all data on liver of game mammals were reported by one
country (Germany). However, those results were obtained in nine different laboratories and samples
were collected each year between 2007 and 2015. Excluding offal (for both game and farmed animals),
the mean concentration in the category ‘meat and meat products’ was LB/UB = 0.55/0.75. A possible
explanation for such high PFOS concentrations found in wild boar liver is given in Sections 1.3.5 and
3.1.2. Regarding other types of meat, elevated levels were also observed for pork liver and mutton/lamb
liver. This can be explained by high bioaccumulation of PFOS in animal liver, which may be considered as
the main target organ (Cui et al., 2009; M€ueller et al., 2011; Vestergren et al., 2013).
In the food category ‘Fish and other seafood’, PFOS was quantiﬁed in all food categories at FoodEx
level 2 (with exception of ﬁsh products with only one result available), including ﬁsh and seafood,
unspeciﬁed, ﬁsh meat, ﬁsh offal, crustaceans and water molluscs. The highest PFOS concentrations
were measured in ﬁsh offal (LB mean = 4.51 lg/kg; UB mean = 5.05 lg/kg), followed by ﬁsh meat
(LB mean = 2.24 lg/kg; UB mean = 2.77 lg/kg). Within the food category ‘ﬁsh meat’, the highest
mean concentrations were observed for babel, perch, anchovy, roach, bream and carp.
In the food category ‘Milk and dairy products’, the quantiﬁed results represented only 2% of the
samples analysed. The mean concentrations ranged from 0.003 lg/kg (LB mean) to 0.21 lg/kg (UB
mean). In the food category ‘Eggs and egg products’, 12% of the analytical results were above
LOD/LOQ (LB mean = 0.26 lg/kg; UB mean = 0.51 lg/kg).
Across foods of plant origin, PFOS was found in root vegetables, bulb vegetables, fruiting
vegetables, brassica vegetables, leaf vegetables and fungi, with the highest mean concentrations
measured in wild edible fungi (LB mean = 0.90 lg/kg; UB mean = 1.11 lg/kg).
For the category ‘Drinking water’, PFOS was found above LOD/LOQ in 12% of the analytical results,
with the mean concentration ranging from 0.0004 lg/kg (LB mean) to 0.003 lg/kg (UB mean).
For the seven food categories, ‘Grains and grain-based products’, ‘Fruit and vegetable juices’,
‘Alcoholic beverages’, ‘Herbs, spices and condiments’, ‘Food for infants and small children’, ‘Composite
food’ and ‘Snacks, desserts and other foods’, PFOS was not detected or quantiﬁed in any of the samples.
3.1.1.2. PFOA
PFOA occurrence data were available for 18 FoodEx level 1 food categories (Figure 5). The PFOA
concentrations were much lower than those measured for PFOS, in particular for ‘Meat and meat
products’ and ‘Fish and other seafood’. This is supported by studies ﬁnding that the bioaccumulation of
PFOA is generally lower than for PFOS (Conder et al., 2008; Cui et al., 2009). On the other hand, it is
important to note, that quantiﬁed results were found for PFOA in a few samples of some food
categories (i.e. ‘Grains and grain-based products’, ‘Alcoholic beverages’, ‘Herbs, spices and condiments’
and ‘Composite food’), for which PFOS was not detected or quantiﬁed in any of the samples. An
overview of the number of data points available for exposure assessment, the percentage of results
below LOD/LOQ, the mean and 95th percentile concentrations of PFOA are presented in Appendix A,
Table A.5 (excel ﬁle - under ‘Supporting information’ Section on the web page).
‘Meat and meat products’ (n = 3,650) was the most frequently analysed food category. Considering
Foodex Level 2 food categories, the highest proportion of quantiﬁed values (41%) and the highest
concentrations were found in ‘Edible offal, game mammals’ with a mean PFOA concentration of
20 Concentrations of linear PFOS and branched PFOS were summed for some samples, and thus the number of analytical results
may be lower as compared to Figure 5.
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5.53/8.18 lg/kg (LB/UB). With the exception of one result, all quantiﬁed results in this food category
were from liver of game mammals (LB mean = 5.46 lg/kg; UB mean = 8.11 lg/kg; quantiﬁed results
ranged from 1.1 lg/kg to 789 lg/kg), with as many as 97% of the samples being wild boar liver.
Therefore, the mean concentration of ‘liver of game mammals’ was highly inﬂuenced by the results for
the wild boar liver samples. With the exception of three results, all data on liver of game mammals
were reported by one country (Germany). The analyses were performed by nine different laboratories
and the samples were collected each year between 2007 and 2015. A possible explanation to such
high PFOA concentrations found in wild boar liver is given in Sections 1.3.5 and 3.1.2. In comparison
to wild boar liver data, PFOA concentrations found in the ‘Edible offal, farmed animals’ were much
lower (LB mean = 0.05 lg/kg; UB mean = 1.39 lg/kg) and comprised only 3% of quantiﬁed results.
Excluding offal (for both game and farmed animals), the mean concentration in the category ‘meat
and meat products’ was LB/UB = 0.10/0.34 for PFOA. Quantiﬁed results were obtained also for a few
samples of livestock meat, poultry, game mammals, and pastes, pa^tes and terrines, generally with low
PFOA concentration reported.
In the food category ‘Fish and other seafood’ (n = 3,484), a mean concentration of 0.22 lg/kg/
0.88 lg/kg (LB/UB), was found for ﬁsh meat with 6% of the samples having quantiﬁed values; the
highest mean concentrations were observed for carp, mackerel and whiteﬁsh. Similar concentrations
were measured in crustaceans (LB mean = 0.14 lg/kg; UB mean = 0.97 lg/kg), but the proportion of
quantiﬁed results was higher (24%). PFOA was found in 7% of water molluscs with a mean
concentration ranging from LB mean of 0.03 lg/kg to UB mean of 0.57 lg/kg.
Within the food category ‘Milk and dairy products’ (n = 476), PFOA was reported to be above LOD/LOQ
in 6 of the 476 analytical results (mainly cow milk and Gouda cheese) and the mean concentration was
0.02 lg/kg/0.21 lg/kg for (LB/UB). In food category ‘Eggs and egg products’, PFOA was found in 8% of
the samples (LB mean = 0.11 lg/kg; UB mean = 0.40 lg/kg). In the category ‘Drinking water’, PFOA was
quantiﬁed in 22% of samples analysed, with a mean concentration of 0.009/0.01 lg/kg (LB/UB).
PFOA was quantiﬁed in 13% of the samples reported in the food category ‘Vegetables and vegetable
products’ (n = 621), and these samples were mainly carrots, lettuce and spinach. The PFOA
concentrations were rather low (LB mean = 0.006 lg/kg; UB mean = 0.21 lg/kg). Out of 205 samples
available for the food category ‘Fruit and fruit products’, PFOA was quantiﬁed in 30% of the samples,
mainly for apples and oranges. The mean PFOA concentration in this food category was 0.005/0.30 lg/kg
(LB/UB).
In the following food categories, only a very limited number of quantiﬁed results was reported:
‘Grains and grain-based products’, two wheat and one oat sample (up to 0.03 lg/kg), ‘Legumes, nuts
and oilseeds’, one pea and one bean sample (up to 0.03 lg/kg), ‘Starchy roots and tubers’, two potato
samples (up to 1.03 lg/kg), ‘Herbs, spices and condiments’, one herb sample (3.00 lg/kg), ‘Sugar and
confectionery’, four honey samples (up to 0.47 lg/kg), ‘Animal and vegetable fats and oils’, one butter
sample and one margarine sample (0.02 lg/kg for both), ‘Alcoholic beverages’, one beer sample
(0.05 lg/kg) and ‘Composite food’, one sample of prepared salad (0.01 lg/kg).
For the three food categories, ‘Fruit and vegetable juices’, ‘Food for infants and small children’, and
‘Snacks, desserts and other foods’, PFOA was not detected or quantiﬁed in any of the samples.
3.1.1.3. Analytical methods used to generate the current occurrence data
In cases where classiﬁcation of the analytical method used for determination of PFOS and PFOA in
food was reported by the European Countries, most results were obtained by LC–MS/MS based
methods (88%). Very few (< 1%) results were reported as obtained using gas chromatography (GC)
based methods. For the remaining data (12%), no information on analytical methods was reported.
LODs/LOQs were reported for 99% of the ﬁnal data set, and varied between substances, the
method used, the food matrix and the laboratory. In the Commission Recommendation 2010/161/EC, a
LOQ below 1 lg/kg is recommended for monitoring of PFASs in food. As described above, some very
few results using analytical methods with particularly high LOD/LOQ were not included in the ﬁnal data
set. In the ﬁnal data set, 72% of the LOQs for PFOS and 67% of the LOQs for PFOA were ≤ 1 lg/kg.
The highest sensitivity (median LOQ = 0.2 lg/kg for PFOS and median LOQ = 0.4 lg/kg for PFOA)
was observed for results from GC based methods. For samples analysed by LC-MS/MS based methods,
the median LOQ was 1.0 lg/kg, both for PFOS and PFOA.
Across food categories, LOQs > 1 lg/kg were mainly observed in the food categories ‘Meat and
meat products’ (particularly for offal) ‘Fish and other seafood, Fruit and fruit products’, ‘Grains and
grain-based products’ and ‘animal and vegetable fats and oils’. On the other hand, for ‘Drinking water’,
the LOQs were very low (all below 0.50 lg/kg).
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The distribution of the LOQs across Foodex Level 1 food categories is illustrated in Figure 6.
3.1.2. Comparison of previous and current occurrence
There is a vast amount of data in the public domain on the occurrence of PFASs in foods and
drinks from various regions around the world or from multi-national studies. The literature data were
not systematically checked for possible duplicate occurrence in the data sets in Section 3.1.1. This
might have resulted in a partial overlap between the data reported in the scientiﬁc literature and the
data reported to EFSA and used in the current exposure assessment. But most of these data are in
line with ranges reported in Section 3.1.1 and supports the calculations that have been made using
data submitted to EFSA from European Countries. Some of the data reported are generated from
samples associated with potential contamination sources, and in these cases, reported concentrations
are often higher.
Levels of PFASs in foods were recently reviewed by Vestergren and Cousins (2013).
Many different ﬁsh species from different global regions have been analysed for PFASs meaning
that ﬁsh is probably the best studied of all food types in terms of this contaminant group. This is
because several PFASs are present in ﬁsh at higher concentrations than in other food groups and
because they are also useful as a marker of environmental quality resulting in their use as
environmental indicators. PFOS is usually the PFAS that is present at the highest concentration in ﬁsh
and shellﬁsh (Hoff et al., 2003; Kannan et al., 2005; Gulkowska et al., 2006; Furdui et al., 2007;
Tittlemier et al., 2007; Bossi et al., 2008; Ericson et al., 2008; Berger et al., 2009; Del Gobbo et al.,
2008; Nania et al., 2009; Ostertag et al., 2009; H€olzer et al., 2011) with concentrations ranging
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typically from < 0.5 to 23 lg/kg where there is no apparent contamination incident. Lean predatory
ﬁsh usually have the highest concentrations of PFOS (Bossi et al., 2008; Berger et al., 2009; van
Leeuwen et al., 2009) and the trophic level of the species has a strong inﬂuence on the concentrations
found (see also Section 1.3.5). Farmed ﬁsh and shellﬁsh samples usually have lower concentrations of
PFOS when compared to wild ﬁsh (van Leeuwen et al., 2009), and water contamination and industrial
release usually accounts for increased levels of contamination (Berger et al., 2009). Concentrations of
PFOS exceeding 100 lg/kg have been reported from some areas with known local pollution sources
(Hoff et al., 2003; Kannan et al., 2005; H€olzer et al., 2011; Hradkova et al., 2012). PFOA is found at
consistently lower levels in ﬁsh, typically between < 0.1 and 0.25 lg/kg, and as a result of this a large
proportion of the data reported is left-censored, i.e. below reporting limits (LODs/LOQs). Data on
temporal trends, geographical and species variation are sparse, with most data in mussels and ﬁsh and
shellﬁsh sampled from near ﬁreﬁghting training sites (Hoff et al., 2003).
PFASs have been measured in food items purchased from several outlets in several studies (3M
Company, 2001; Food Standards Agency, 2006; Tittlemier et al., 2007; Ericson et al., 2008; Ericson-
Jogsten et al., 2009; Clarke et al., 2010; Schecter et al., 2010), but many of these studies did not have
adequate sensitivity. Such studies used market basket surveys and were from the US (3M Company,
2001; Schecter et al., 2010), Canada (Tittlemier et al., 2007), the UK (Food Standards Agency, 2006;
Clarke et al., 2010) and Spain (Ericson et al., 2008; Ericson-Jogsten et al., 2009). Most data for US foods
were left-censored with reporting limits of 0.02–0.5 lg/kg depending on the compound and food type,
but the highest reported levels were for PFOA in butter (1.07 lg/kg), olive oil (1.80 lg/kg), apples
(2.35 lg/kg) and PFOS in milk (0.85 lg/kg). PFOA was found in meat and ﬁsh products at levels
between < 0.02 and 0.3 lg/kg (Schecter et al., 2010). A study of Canadian foods found high levels of
PFOA in microwave popcorn (3.6 lg/kg) and roast beef (2.6 lg/kg), and PFOS was found at high
concentrations in beef steak (2.7 lg/kg) and saltwater ﬁsh (2.6 lg/kg) (Tittlemier et al., 2007). In the
UK, a total diet survey reported high levels of PFOS at 10 lg/kg and PFOA at 1 lg/kg in a composite
sample consisting of potato based products (Food Standards Agency, 2006). Food of animal origin was
the primary source of PFOS in samples from Spain with concentrations ranging from < 0.03–0.654 lg/kg
(Ericson et al., 2008; Ericson-Jogsten et al., 2009). PFOA was only found in milk (0.056 lg/kg) and
lettuce (0.164–0.179 lg/kg). In a duplicate diet study from Germany, PFOS and PFOA were measured in
70 and 97 out of 214 samples. Mean concentrations of PFOS and PFOA were 0.06 and 0.69 lg/kg,
respectively (Fromme et al., 2007). However, it was later found that the analysis of these samples was
inﬂuenced by matrix effects, and re-analysis of the duplicate diet samples using improved methodology,
indicated that dietary intake of PFOA and PFOS was overestimated (Vestergren et al., 2012).
K€arrman et al. (2009) reported PFOS (0.008–0.087 lg/kg) and PFOA (0.008–0.040 lg/kg) in 20
duplicate diet samples from Japan.
Advances in analytical technology have meant that recent studies are able to achieve better
detection limits and therefore studies using them contain fewer left censored data (Haug et al., 2010a;
Lacina et al., 2011; Noorlander et al., 2011; Vestergren et al., 2012). In these studies, despite different
countries of origin and sampling strategies, the reported concentrations for PFASs show a similar
proﬁle with respect to contamination with PFASs. Fish had higher concentrations of PFOS
(0.013–5.400 lg/kg) compared with other food types. This was followed by meat, meat products and
chicken eggs which had concentrations of PFOS in the range 0.013–1.281 lg/kg – although there were
some anomalies, such as a pooled Swedish egg sample that contained an unusually large amount of
PFOS. PFOA has similar concentrations in food samples of both vegetable and animal origin
(< 0.003–0.102 lg/kg), whereas PFOS is generally higher in foods of animal origin. These differences
in homologue patterns may result from different pollution sources, or could derive from different
uptake and elimination pathways in terrestrial and aquatic food webs (see Section 1.3.5).
Most of the studies above focus on widely consumed staple food samples that constitute the bulk of
the diet, but there are a few studies reported that have included food that has at some point been in
contact with greaseproof packaging materials. For example, high concentrations of PFOA (3.6 lg/kg)
have been reported in microwave popcorn.
Vestergren et al. (2012) investigated changes in concentration of PFASs over time using archived
market basket surveys. Little change was seen for PFASs in most food categories between the years
1999, 2005 and 2010. Egg-, meat-, dairy- and potato-based samples, however, did show some
differences. Egg samples from 1999, were found to contain between 30 and 100 times more PFOS
(1.281 lg/kg) than in eggs taken in the following years. The meat sample also contained decreasing
concentrations of PFOS over the sampling period. Conversely, increasing concentrations of PFOA were
found in the dairy and potato samples.
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Johansson et al. (2014) also reported temporal trends in dietary exposure to PFASs. Archived
samples of eggs, milk and farmed rainbow trout collected between 1999 and 2010, which covered a
period when major production changes occurred, were assessed. The results showed signiﬁcantly
decreasing concentrations of PFOS in ﬁsh (p < 0.002) and eggs (p < 0.001). Concentrations of PFOS in
ﬁsh and eggs decreased by a factor of 10 and 40, respectively. In eggs there was also a statistically
signiﬁcant decreasing trend for PFOA.
The consistency between the current occurrence data of PFOS and PFOA as submitted to EFSA
(Section 3.1.1) and the occurrence data reported in the literature was evaluated. Since much of the
literature data did not provide the mean concentration (LB and UB) required for an accurate
comparison, the evaluation should be considered as indicative.
A vast majority of the PFOS and PFOA data reported to EFSA were on ﬁsh meat conﬁrming that ﬁsh is
probably the best studied food source of PFASs. The PFOS data had more samples that were not left
censored and had higher concentrations measured, as compared to PFOA (mean LB–UB = 2.2–2.8 lg/kg,
max UB = 211 lg/kg for PFOS; mean LB–UB = 0.2–0.9 lg/kg, max = 35.5 lg/kg for PFOA). The
literature data showed similar ﬁndings and the concentration ranges reported in the literature were in line
with the mean concentrations reported to EFSA.
PFOS and PFOA levels for milk and eggs submitted to EFSA are consistent to those reported in the
literature, while for other foods of animal origin an accurate comparison was not possible due to
limited information (e.g. information on meat type missing). The consistency was observed also for
lettuce, while for other foods of vegetable origin (e.g. olive oil, apple, potatoes, etc.), PFAS levels
reported to EFSA were at the mean lower than those reported in the literature.
In a study by Stahl et al. (2012), high concentrations of PFOS, and to some extent also PFOA, were
found in liver and muscle from wild boars collected in Hesse, Germany. Almost all of the more than
500 animals were below 2 years of age. The mean concentration of PFOS in liver and muscle (wet
weight) was reported to be 117 ng/g (median 49 ng/g; max. 1,780 ng/g) and 1.38 ng/g (max
28.6 ng/g), respectively, and the corresponding concentrations of PFOA were reported to be 4.02 ng/g
(max 45 ng/g) and < 0.1 ng/g (max 7.4 ng/g), respectively. It should be noted that the range of PFOS
in liver was very wide, ranging from < 0.5 ng/g to 1,780 ng/g despite the relatively homogeneous
character of the samples. Stahl et al. (2012) reported that these levels are in agreement with previous
studies of wild boars reported in only locally available bulletins. Considering the wide range of PFAS
concentrations in livers, despite the small variation in age, the explanation to the high concentrations
is likely to be found in their intake of contaminated material. Wild boars are omnivorous and in order
to ﬁnd their food they generally root in the soil. This and other aspects of feeding behaviour, including
access to dumpsites that often contain municipal waste with household waste that could attract groups
of wild boars, may inﬂuence exposure for wild boar. Consequently, there is an obvious risk that boars
feeding at dumpsites and other contaminated sites could be exposed to high levels of PFOS and other
environmental contaminants. These ﬁndings were in line (within the same order of magnitude) with
those found in a study reported in conference proceedings by Brambilla et al. (2016). Thus,
environmental sources can be an important consideration especially for PFOS and PFOA in meat
tissues from wild animals (see Section 1.3.5).
3.1.3. Food processing
3.1.3.1. Migration from food contact materials, including non-stick coatings used on
cookware
Domingo (2012) conducted a review of work done up until the date of the review.
Polytetraﬂuoroethene (PTFE) cookware was found to contain only residual PFOA in the low lg/kg range,
but PFOA was found in the bag paper from microwave popcorn at concentrations up to 300 lg/kg
(Begley et al., 2005). Analysis of PFOA in tubing made from ﬂuorinated ethylene-propene (FEP)
copolymer, in sealants made from PTFE ﬁlm, and in cookware that had been coated with PTFE, together
with migration experiments conducted using PTFE ﬁlm, suggested that ﬂuoropolymer food contact
materials were not likely to be a major source of PFASs. Heating of the cookware to temperatures
greater than those likely to be reached during normal domestic practise, did not increase the amount of
PFOA available for migration. PFCAs, particularly PFOA, and ﬂuorotelomer alcohols (FTOHs) were
released from coated cookware at normal cooking temperatures (179–233°C surface temperature), and
therefore have the potential to migrate into food during the cooking process. PFOA was found to
volatilise and was present in the gas phase at concentrations ranging from 7 to 337 ng per pan
(11–503 pg/cm2) in the four brands of non-stick frying pans tested (Sinclair et al., 2007).
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Fluorotelomers 6:2 FTOH and 8:2 FTOH were also found. On repeat use, there was a clear decrease for
the telomeres but results were inconsistent for PFOA; one pan showing a decrease and the other no
change. The vapour within a prepacked microwave popcorn bag contained PFOA at 5–34 lg/kg, but no
detectable amounts were found to have volatilised from plain white corn kernels that had been ‘popped’
in a container made from polypropylene. On the surface of the packaging from one brand of microwave
popcorn, several PFCAs and FTOHs were found at concentrations ranging from 0.5 to 6.0 ng/cm2,
suggesting that manufacture of the non-stick coating did not completely remove residual PFOA.
Still et al. (2013) investigated the mass balance of PFASs as a result of industrial production and
packaging processes in butter production, and found that phase separation processes could affect
concentrations of PFASs in lipophilic and aqueous phases. Storage of butter in packaging coated with a
ﬂuorinated polymer increased butter levels of both PFCAs, PFSAs and FTOH.
In summary, there are only a limited number of studies reported about transfer of PFASs used in
coating products on cookware. These studies demonstrate that the use of these materials is a
potential additional source of contamination that can lead to an increase in exposure to PFASs,
although the additional contribution is likely to be small compared with other sources. Occurrence data
and exposure estimated based on raw food products will not take this into account, and so will have
an impact of reducing overall exposure estimates.
3.1.3.2. Effect of cooking not related to coatings on cookware
Del Gobbo et al. (2008) measured differences in the levels of 17 different PFASs in 18 ﬁsh species
as a result of cooking (baking, boiling and frying). It was reported that all cooking processes
investigated, led to a reduction in PFCAs with baking producing the largest effect; after baking samples
for 15 min at 163°C, PFCAs were not detected in any of the samples.
In a review on the effect of cooking on various metals and organic contaminants in foodstuffs,
Domingo (2011) found that it was the cooking process that had the greatest impact rather than the
food type that was being cooked. Different cooking methods could either reduce or increase the levels
of chemical contaminants in food. Although it was reported that cooking procedures whereby fat is
released or removed from the product should tend to reduce the total concentrations of organic
contaminants, this was not necessarily the case for PFASs since they are not as lipophilic as some
other organic contaminants.
Xiao et al. (2012) reported that human exposure to PFOS could result from the sorption of PFOS
from contaminated water to food during food preparation (boiling in water), and the effect was
enhanced when table salt was used.
Bhavsar et al. (2014) reported that although concentrations of PFOS in ﬁsh ﬁllets generally increased
during cooking, total amounts of PFOS largely remain unchanged; this was said to be due to the
concentration effect that occurs during weight loss as a result of the cooking process. Relatively minor
changes after cooking varied according to ﬁsh species and cooking method. Vassiliadou et al. (2015)
found that the concentrations of the detected PFASs in ﬁsh were in most cases higher after frying or
grilling, the amount of the increase being consistent with weight loss due to water evaporation.
Lyu et al. (2015) showed that the PFOS degraded at a faster rate with increased boiling times, but
was slower with a higher hydronium level or with oxygenation.
In summary, the literature above covers the few papers describing the impact of cooking on PFASs
in foods. This limited number of studies gives an inconsistent view about whether or not losses or
increases occur.
3.2. Dietary exposure assessment
3.2.1. Current exposure assessment
The CONTAM Panel assessed the chronic dietary exposure (following the methodology described in
Section 2.2.1) to PFOS and PFOA.
Prior to linking occurrence and consumption data, some adjustments were carried out on both data
sets to obtain as accurate exposure estimates, as possible. First, consumption data were grouped
according to the same food categories as described for the occurrence data (food categories as used
to estimate chronic dietary exposure; see Appendix A, Tables A.6 and A.7 as excel ﬁles – under
‘Supporting information’ Section on the web page).
When no occurrence data were available or all occurrence data within a composite food were left-
censored, the mean concentration of the main ingredient adjusted by a factor corresponding to the part
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of the portion within the meal was applied. For food category ‘Fish and seafood based meals’ where
no/or no adequate occurrence data were available, it was assumed that ﬁsh meat represents 70% of the
composite meal and the mean concentration of ‘ﬁsh meat’ adjusted by a factor of 0.7 was used. ‘Meat-
based meals’ and ‘Egg-based meals’ were treated as follows: the mean concentration of ‘livestock meat’
and ‘poultry’ adjusted by a factor of 0.5 and ‘eggs, fresh’ adjusted by a factor of 1.0, were used,
respectively. For simpliﬁcation and consistency, the exposure resulting from composite food was added to
the food category of the main contributor: ‘Fish and seafood based meals’ to ‘Fish and other seafood’,
‘Meat-based meals’ to ‘Meat and meat products’, and ‘Egg-based meals’ to ‘Eggs and egg products’.
Some food categories were considered not suitable for use in the exposure calculation due to either
a very low number of samples (< 6 analytical results) (including some citrus and stone fruits, melons
and green beans for both PFOS and PFOA and for PFOA only table grapes, peas, sweet corn, fennel,
oats, herbs, margarine), or by all data left-censored consisting of the Foodex 1 categories indicated in
Sections 3.1.1.1 and 3.1.1.2. In addition, for the other Foodex 1 categories, many of the
subcategories contained all left censored data, i.e. for PFOS, food groups (with > 20 analytical results),
included cow milk yoghurt, turkey meat, ﬁsh oil, potatoes, tomatoes and asparagus. For PFOA, such
food groups included cow milk yoghurt, sheep milk, cooked sausage, mutton, lamb and chicken meat,
ﬁsh oil, potatoes and French fries, beer pastries and cakes (see Appendix A, Tables A.4 and A.5 as
excel ﬁles – under ‘Supporting information’ Section on the web page).
Overall, it should be kept in mind that a high proportion of left-censored data has a major impact
on the exposure estimates; the exposure is likely to be underestimated with the lower-bound approach
whereas it may be even highly overestimated with the UB approach.
The contribution (%) of each food category to the overall mean exposure of individual PFASs was
calculated for each age group and dietary survey. Estimations of exposure using the LB approach,
which is considered to be less inﬂuenced by results below LOD/LOQ, were used to explain the
contribution of the different food categories.
3.2.1.1. PFOS
Table 4 shows summary statistics of the estimated chronic dietary exposure to PFOS using the
available consumption and occurrence data. Detailed mean and 95th percentile dietary exposure
estimates for each of the 35 dietary surveys are presented in Appendix A, Table A.8 (excel ﬁle – under
‘Supporting information’ Section on the web page).
Table 4: Summary statistics of estimated chronic dietary exposure to PFOS (ng/kg bw per day)
across European countries
Age group
Minimum Median Maximum
LB UB LB UB LB UB
Mean dietary exposure in total population (ng/kg bw per day)
Infants 0.25 1.77 0.39 2.25 1.23 5.71
Toddlers 0.45 3.48 0.75 7.52 2.36 12.0
Other children 0.44 2.51 0.83 4.41 2.98 7.85
Adolescents 0.18 1.27 0.45 2.79 1.59 4.71
Adults 0.29 1.07 0.61 1.96 1.93 4.08
Elderly 0.46 1.34 0.61 1.98 1.81 3.22
Very elderly 0.33 1.52 0.65 1.92 1.05 2.45
95th percentile dietary exposure in total population (ng/kg bw per day)
Infants(a) 0.90 5.15 1.19 6.37 4.34 14.0
Toddlers(a) 1.26 10.2 2.09 14.0 4.10 17.5
Other children 1.12 6.32 2.43 9.44 23.7 26.9
Adolescents 0.50 3.14 1.39 5.63 10.9 12.9
Adults 0.99 3.36 1.95 4.55 11.6 12.7
Elderly 1.41 3.53 1.94 4.23 9.49 10.8
Very elderly(a) 1.16 3.35 1.83 3.75 3.70 5.20
bw: body weight; LB: lower bound; UB: upper bound.
(a): The 95th percentile estimates obtained from dietary surveys/age classes with less than 60 observations may not be
statistically robust (EFSA, 2011b) and have therefore not been included in this table.
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The highest chronic dietary exposure to PFOS was estimated for the youngest population groups.
Concerning the mean estimated dietary exposure, the highest LB estimates were obtained for other
children with a maximum exposure of 2.98 ng/kg bw per day, while the UB maximum exposure was
observed for toddlers (12.0 ng/kg bw per day). The highest 95th percentile estimates were observed
for other children with LB and UB estimates of 23.7 and 26.9 ng/kg bw per day, respectively. High
maximum 95th percentile LB and UB exposure estimates were observed also for adolescents and adult
populations due to high consumption of ﬁsh and ﬁsh products reported by a group of high consumers
in three dietary surveys.
The dietary exposure estimates obtained for speciﬁc groups of the population, namely ‘Pregnant
women’ and ‘Lactating women’, were within the range of exposure estimates in adult populations (see
Appendix A, Table A.9 as excel ﬁle – under ‘Supporting information’ Section on the web page).
The contribution of individual food categories to the total LB mean chronic dietary exposure for
PFOS varied between the dietary surveys. This is explained by the speciﬁc food consumption patterns
in different European countries and even in different regions of one country. Relative contributions of
the different food categories to the total estimated intakes, grouped by age classes, are shown in
Appendix A, Table A.9 excel ﬁle – under ‘Supporting information’ Section on the web page).
Overall, the main contributors to the LB mean chronic dietary exposure to PFOS were the food
categories ‘Fish and other seafood’ (contributing up to 86% in adults), followed by ‘Meat and meat
products’ (contributing up to 52% in the elderly) and ‘Eggs and egg products’ (contributing up to 42%
in infants).
Particularly, ‘Fish meat’ had the highest contribution to the overall PFOS LB mean exposure among
the food subgroups within ‘Fish and other seafood’, in all age groups (up to 79% in the elderly). For
infants, toddlers and other children, also ‘Fish offal’ made an important contribution (up to 40%);
however, this was only true for few surveys. On the other hand, ‘Crustaceans’ and ‘Water molluscs’
contributed less.
Despite high PFOS concentrations measured in liver of game mammals, the exposure to PFOS from
this food is negligible as the consumption of such products was reported by only a limited number of
subjects (only three subjects consuming liver of game mammals reported in the Comprehensive
database). Within the ‘Meat and meat products’, the most important contributing subcategory was
‘Cooked sausage’ (up to 19% in toddlers and other children) and ‘Edible offal, farmed animals’ (up to
20% in very elderly).
‘Eggs and egg products’ was also an important contributor to the overall LB mean PFOS exposure,
particularly for infants (up to 41%). Since the levels of PFOS in eggs were not particularly high, the
relevant contribution of this food category is likely mainly driven by its relatively high consumption.
‘Milk and dairy products’ had the highest contribution to the overall PFOS LB mean exposure of
toddlers (up to 13%), adolescents (up to 12%) and other children (up to 11%). Given the low mean
PFOS concentration measured in milk, the exposure is driven by high consumption of this food group,
particularly in young age groups, with the exception of infants who usually consume infant formulae,
and in fact, the contribution of milk for infants was rather low (up to 4%).
For infants, also ‘Fruits and fruit products’, particularly ‘Pear’ (up to 45%) made an important
contribution to the LB mean PFOS exposure. However, this ﬁnding must be interpreted with caution
due to a limited number of results on pears available for the exposure assessment.
‘Drinking water’ had the highest contribution to the overall LB mean exposure to PFOS in the infant
age group (up to 10%), while in other age groups ‘drinking water’ contributed less (up to 3% in adults).
The contribution of other food categories was minor.
3.2.1.2. PFOA
Table 5 shows summary statistics of the estimated chronic dietary exposure to PFOA using the
available occurrence and consumption data. The detailed mean and 95th percentile dietary exposure
estimates for each of the 35 dietary surveys are presented in Appendix A, Table A.10 (EXCEL sheet).
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Similarly to PFOS, also for PFOA, the highest exposure estimates were observed in the young
population groups. For the mean estimated dietary exposure, the highest LB and UB exposure
estimates were observed for toddlers with maximum estimates of 2.61 and 12.1 ng/kg bw per day,
respectively. At the 95th percentile exposure (highly exposed population), the highest PFOA exposure
estimates were observed for toddlers with LB and UB intakes estimates of 5.37 and 23.9 ng/kg bw per
day, respectively. In comparison, the PFOA exposure estimates for adult population groups were
approximately ﬁvefold lower when considering the 95th percentile exposure. The obtained dietary
exposure estimates for speciﬁc groups of the population, namely ‘Pregnant women’ and ‘Lactating
women’, were within the range of exposure estimates for adult populations (see Appendix A,
Table A.11 as excel ﬁle – under ‘Supporting information’ Section on the web page).
The contribution of individual food categories to the LB mean chronic dietary exposure to PFOA
varied between the dietary surveys, which may be explained by the speciﬁc food consumption patterns
in the different European countries and even in different regions of one country. Relative contributions
of the different food categories to the total estimated intakes, grouped by age classes, are shown in
Appendix A, Table A.11 as excel ﬁle - under ‘Supporting information’ Section on the web page).
Overall, the most important contributors to the mean chronic dietary exposure to PFOA, across all
age groups for the LB scenario, were the food categories ‘Milk and dairy products’ (contributing up to
86% in toddlers), followed by ‘Drinking water’ (contributing up to 60% in infants) and ‘Fish and other
seafood’ (contributing up to 56% in very elderly).
It is important to mention that the contribution of ‘Milk and dairy products’, represented only by
cow milk and Gouda cheese, was based on a very limited number of quantiﬁed values available for
these foods (only 2% for cow milk and only 10% for Gouda cheese). This limitation should be kept in
mind when interpreting the results.
The ‘usual’ main contributors to PFASs exposure, namely ‘Fish and other seafood’ and ‘Meat and
meat products’, did not contribute considerably/as expected to the overall LB mean PFOA exposure.
This was due to the fact, that the PFOA concentration levels for these two food categories were rather
low with exception of very speciﬁc foods, i.e. carp, as compared to other ﬁsh species and liver of
game animals, as compared to other meat types. Since the carp and liver of game animals are rarely
consumed, the overall exposure from ‘Fish and other seafood’ and ‘Meat and meat products’ was not
particularly high. As an example, the carp was an important contributor only in three European
countries reporting a common consumption of this ﬁsh species.
Table 5: Summary statistics of the chronic dietary exposure to PFOA (ng/kg bw per day) across
European countries
Age group
Minimum Median Maximum
LB UB LB UB LB UB
Mean dietary exposure in total population (ng/kg bw per day)
Infants 0.50 2.50 0.70 3.79 1.44 8.06
Toddlers 0.34 4.02 2.01 8.78 2.61 12.1
Other children 0.34 2.29 1.00 4.83 2.16 9.74
Adolescents 0.26 1.55 0.50 2.77 0.85 4.09
Adults 0.22 1.24 0.32 1.59 0.60 3.28
Elderly 0.21 1.20 0.32 1.86 0.44 2.85
Very elderly 0.21 1.28 0.33 1.83 0.49 2.87
95th percentile dietary exposure in total population (ng/kg bw per day)
Infants(a) 1.52 7.29 1.80 8.93 3.76 17.8
Toddlers(a) 2.12 10.9 3.88 15.9 5.37 23.9
Other children 0.72 5.73 2.06 9.63 3.58 16.1
Adolescents 0.68 3.77 1.01 5.66 1.60 7.62
Adults 0.54 2.75 0.66 3.48 1.11 5.82
Elderly 0.52 3.12 0.69 3.68 0.96 5.16
Very elderly(a) 0.49 2.98 0.63 3.54 0.85 4.25
bw: body weight; LB: lower bound; UB: upper bound.
(a): The 95th percentile estimates obtained from dietary surveys/age classes with less than 60 observations may not be
statistically robust (EFSA, 2011b) and have therefore not been included in this table.
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For the other important contributors to the LB mean chronic dietary PFOA exposure, ‘Eggs and egg
products’ contributed up to 40% in adults, ‘Potatoes and potatoes products’ contributed up to 11% in
toddlers, ‘Meat and meat products’ contributed up to 9% in the elderly, ‘Fruit and fruit products’
contributed up to 8% in toddlers and ‘Vegetables and vegetable products’ contributed up to 5% in
pregnant women. Other food categories contributed considerably less (up to 0.6%).
3.2.2. Comparison of previous and current exposure
On the basis of data reported in the scientiﬁc literature, there is still insufﬁcient data to make
reliable dietary exposure estimates. In common with the current exposure assessment, there are
uncertainties due to left censored data, and many reports are not clear whether upper or lower bound
data has been used (see Section 3.6.1). There have been many studies that link data from blood
monitoring studies to overall exposure and show that blood can be a useful matrix. For many
individuals and locations, drinking water can be a signiﬁcant contributor to overall exposure to PFASs.
As with the ﬁndings reported in the current exposure Section above (Section 3.2.1), ﬁsh and meat
products such as offal are generally the highest reported sources of dietary exposure to PFOS, except
where contaminated drinking water has been used to prepare dishes with high water content. For PFOA
and other PFCAs, the main sources of exposure are milk and dairy products, ﬁsh and other seafood, and
also eggs and egg products (Saito et al., 2004; Quinones and Snyder, 2009; Rayne and Forest, 2009).
Some speciﬁc reported exposure estimates are discussed below in approximate chronological order
of publication. Since the studies were conducted in a variety of ways (Total Diet Study (TDS) or market
basket, using local water or distilled water for cooking, etc.), it is not possible to make direct
comparisons between estimates.
Average dietary exposure of Canadians to PFASs was reported by Tittlemier et al. (2007). Exposure
to the sum of PFCAs and PFOS was estimated to be 250 ng per day using results from TDS samples
taken in 2004.
A study by Trudel et al. (2008) found that in North America and Europe, exposure to PFOS and
PFOA was in the range of 3–220 ng/kg bw per day and 1–130 ng/kg bw per day, respectively, for a
70 kg person. Most of this was from the intake from foods and drinking water.
Intake of PFASs in the Catalan region of Spain was reported by Ericson et al. (2008) determined by
the analysis of 36 composite foodstuffs purchased from random locations. Exposure to PFASs from
food was estimated for various age/gender groups. Only PFOS, PFOA, and one other PFAS were found
in foodstuffs. The dietary intake of PFOS was estimated to be 62.5 or 74.2 ng per day (assuming LB or
medium bound (MB), respectively). Fish, followed by dairy products and meats, were the main
contributors to PFOS intake.
In 2008, BFR assessed PFOS and PFOA exposure. PFOS dietary exposure estimates calculated in LB
and UB scenarios ranged from 2.3 to 3.7 ng/kg bw per day in average consumers and from 24 to
26 ng/kg bw per day in high consumers (95th percentile occurrence and 95th percentile consumption).
For PFOA, the dietary exposure estimates ranged from 0.71 to 0.95 ng/kg bw per day in average
consumers and around 13 ng/kg bw per day in high consumers (BfR, 2008).
Fromme et al. (2009) reviewed information published for PFASs in environmental media that could
have an impact on human exposure in Western Countries. In particular, PFASs in indoor and ambient
air, house dust, drinking water and food were considered. The average (and upper) daily exposure
including all potential routes was found to be 1.6 ng/kg bw per day (8.8 ng/kg bw per day) for PFOS
and 2.9 ng/kg bw per day (12.6 ng/kg bw per day) for PFOA in adults in the general population based
on median and 95th percentile intake rates from a duplicate diet.
A dietary intake estimate for the UK (Clarke et al., 2010) was performed on the basis of the
analysis of 252 food samples. This study estimated that the UB dietary intake was 10 ng/kg bw per
day for average adult consumers.
A study by Noorlander et al. (2011) estimated dietary exposure for the Dutch population on the
basis of analysis of pooled samples from a market basket survey and combining it with a food
consumption survey for 6,250 people. The median long-term intake for PFOS was estimated at
0.3 ng/kg bw per day and for PFOA 0.2 ng/kg bw per day, with corresponding 99th percentile intakes
of 0.6 and 0.5 ng/kg bw per day, respectively.
In a Norwegian study comprising 175 men and women with a wide range of sea food consumption,
individual dietary intakes were estimated based on data from food frequency questionnaires and a
database of PFOS and PFOA concentrations in food purchased in Norway. Median intakes of 1.2 and
0.55 ng/kg bw per day for PFOS and PFOA were estimated, respectively. The estimated intakes were
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signiﬁcantly correlated to the serum levels measured in the same individuals using multiple linear
regression analysis (Haug et al., 2010b).
A limited time-trend analysis for the Swedish population was conducted by Vestergren et al. (2012)
using samples collected in 1999, 2005 and 2010. The dietary exposure to PFOS varied between 0.86
and 1.44 ng/kg bw per day, and the major contributors were ﬁsh and meat. The dietary exposure to
PFOA was estimated to be in the range 0.35–0.69 ng/kg bw per day, and low levels (0.008–0.062 ng/kg
per day) found in several food categories with associated high consumption such as cereals, dairy
products, vegetables and fruit contributed most to the total intake. Dietary intakes of PFOS and PFOA
estimated in this study were 4–10 times lower when compared to previous exposure modelling studies.
The ﬁrst assessment of exposure to PFASs for the Belgian population was reported by Cornelis
et al. (2012). PFOS and PFOA were measured in a variety of local foods, in dust from homes and
ofﬁces, in drinking water and in human serum. The data were combined with data taken from the
literature. Using the combined data set, intake from the different sources was calculated for children
and adults, and dietary exposure was found to be most signiﬁcant. For adults, the average dietary
intake was 24.2 (P95 40.9) ng PFOS/kg bw per day and 6.1 (P95 9.6) ng PFOA/kg bw per day,
whereas for children the dietary intake was about 3 times higher. Potatoes contributed 48 and 28% to
the intake of PFOS by children and adults, respectively and for ﬁsh and seafood this was 57 and 10%,
respectively. Exposure to PFOA came primarily from fruit and vegetables.
Brantsaeter et al. (2013) estimated individual dietary intakes of PFOS and PFOA for 487 pregnant
Norwegian women, and median intakes of 44.6 and 34.2 ng/day were reported, respectively. This
corresponds to median estimated intakes of 0.64 and 0.49 ng/kg bw per day for PFOS and PFOA,
respectively when assuming a body weight of 70 kg. The intake estimates were based on data from
food frequency questionnaires and a database of PFOS and PFOA concentrations in food purchased in
Norway (Brantsaeter et al., 2013).
Klenow et al. (2013) estimated dietary exposure to selected PFASs for four selected European
states including Belgium, the Czech Republic, Italy and Norway. These countries were selected to
represent Western, Southern, Eastern and Northern Europe, and were part of the EU project
PERFOOD. Seven selected PFASs, including PFOS and PFOA were assessed. Food items were selected
on the basis of consumption and those known to have higher levels of PFASs. Average dietary
exposure was generally below or close to 1 ng/kg bw per day for all seven PFASs for adults
(18–64 years) and children (3–9 years). Exposure estimates did not exceed 4 ng/kg bw per day even
in populations with high consumption.
A Total Diet Study (TDS) conducted in France between 2007 and 2009 (Riviere et al., 2014)
concluded that the mean dietary exposure estimates for PFOA and PFOS in adults, were 0.74 and
0.66 ng/kg bw per day (UB) respectively. For high consumers (95th percentile), exposure to PFOA was
estimated to be 1.50 ng/kg bw per day. For PFOS, the estimated intake was 1.15 ng/kg bw per day
(UB). Due to the large amount of data where concentrations were below the LOD (left-censored),
calculated exposures largely depended on the analytical limits, and there was a large difference
between LB and UB estimates, resulting in lower exposure values calculated when compared to those
reported in other studies which used analytical methods with higher LOD values. The mean exposure
to PFOS was estimated to be 0.67 ng/kg bw per day in women of childbearing age, the 95th
percentile, UB exposures, were 1.62 ng/kg bw per day for PFOA and 1.17 ng/kg bw per day for PFOS.
In children, the mean UB exposure to PFOS was estimated to be 1.38 ng/kg bw per day. The 95th
percentile, UB exposures, were estimated to be 3.24 ng/kg bw per day for PFOA and 2.88 ng/kg bw
per day for PFOS.
EFSA reported details of occurrence and dietary exposure to PFASs in food in 2012 (EFSA, 2012).
The report summarised occurrence data for PFASs collected in 13 European countries during the
period 2006–2012. The report considered 54,195 analytical results covering a list of 27 PFASs. The
overall proportion of quantiﬁed results was very low due to high LODs of the methods used, resulting
in a large amount of left censored data. PFASs were found more frequently in ﬁsh and other seafood,
and in meat and meat products (liver in particular) than in other food groups. For PFOS, the highest
UB mean exposure estimate for the adult population was 5.2 ng/kg bw per day, and the highest 95th
percentile estimate was 10 ng/kg bw per day. For toddlers, the age class having the highest exposure,
estimates were about three times higher. For PFOS and across all age groups, ‘Fish and other seafood’
(50–80%) followed by ‘Fruits and fruit products’ (8–27%) and ‘Meat and meat products’ (5–8%)
contributed most to the total PFOS intake. For PFOA, the mean chronic dietary exposure for adults was
up to 4.3 ng/kg bw per day, and about triple for toddlers (the age class having the highest exposure).
The food groups responsible for the largest proportion of the exposure to PFOA for all age groups
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were ‘Fruits and fruit products’ (18–39%) and ‘Fish and other seafood’ (7.6–27%), but high variations
were observed as a result of different dietary habits.
The occurrence data used for the present exposure assessment for PFOS and PFOA were similarly
characterised by a high proportion of results below LOD/LOQ, and with the highest mean concentrations
reported for ﬁsh and meat, in particular for liver. As compared to exposure estimates reported in 2012
(EFSA, 2012), the current LB and UB estimated PFOS exposure is on average 30% lower, and besides ﬁsh
and meat, also the food category ‘Eggs and egg-based products’ was among the most important
contributors to the mean PFOS exposure. For PFOA, the current exposure estimates are on average
fourfold higher using the LB approach and on average 30% lower using the UB approach as compared to
the 2012 assessment. Milk and drinking water were the main contributors to the mean PFOA exposure.
In the 2008 opinion (EFSA, 2008), the exposure estimates were based on a much smaller data set and
indicative dietary intakes of PFOS of 60 ng/kg bw per day for average consumers, and 200 ng/kg bw per
day for high consumers of ﬁsh were reported. Indicative average and high level dietary exposure
estimates for PFOA of 2 and 6 ng/kg bw per day were reported, respectively. The intake estimates
reported in the 2008 opinion were made on the basis of a lack of satisfactory analytical data, and many
assumptions were made in order to derive the exposure estimates.
3.2.3. Non-dietary exposure
PFOS and PFOA are extremely persistent and thus the environmental degradation can be
considered negligible (Kissa, 2001). On the other hand, precursors of PFOS and PFOA may be
biodegraded, and thus contribute to the internal dose of those compounds. Further information on
precursors is given in Section 1.3.5.
As PFOS, PFOA and their precursors have been produced in large volumes and used in a wide
variety of consumer products, the indoor environment might be contaminated with these compounds.
In particular, exposure to PFOS and PFOA may occur through inhalation of indoor air as well as with
dermal contact and ingestion of house dust. Exposure due to direct contact with consumer products
may also occur.
3.2.3.1. Exposure through air and dust
As PFOS and PFOA have low volatility, the exposure through air is mainly due to inhalation of
volatile PFOS and PFOA precursors (Stock et al., 2010). Generally, the concentrations of precursors are
higher in indoor than outdoor air, and the between-room variability is considerable (Harrad et al.,
2010; Haug et al., 2011a; Ericson-Jogsten et al., 2012; Fromme et al., 2015).
Exposure to PFOS and PFOA may also occur through ingestion of house dust. The concentrations in
various houses may differ substantially, and often some samples have much higher concentrations
than others, thus resulting in a log-normal distribution of the data set (Harrad et al., 2010). Also, for
dust, exposure through biodegradation of precursors may happen, and in a review by Eriksson and
K€arrman (2015) it was reported that the concentrations of some of the precursors in dust from various
countries were similar or even higher than the concentrations of PFOS and PFOA (Eriksson and
K€arrman, 2015).
3.2.3.2. Dermal exposure
Exposure to PFOS and PFOA through dermal contact with consumer products can occur, and as for
dust and air, indirect exposure from biodegradation of precursors may contribute to the exposure. Both
PFOS, PFOA and precursors have been found in a large number of products including carpets, textiles,
waxes, paints, food contact materials, non-stick cookware and personal care products (Begley et al.,
2005; Washburn et al., 2005; Sinclair et al., 2007; Fujii et al., 2013; Liu et al., 2014a; Kotthoff et al.,
2015). The dermal absorption of PFOS and PFOA has been reported to be low (e.g. the dermal
absorption of (APFO) was only 0.048% (Fasano et al., 2005)), but little is known about the precursors.
Even though knowledge is limited, so far the dermal exposure to PFOS and PFOA has been thought to be
low. Trudel et al. (2008) found that the contribution to the total uptake dose was less than 1% in any of
the scenarios for dermal exposure from wearing of treated clothes, from deposition of spray droplets on
skin while impregnating, from skin contact with treated carpet and with upholstery, and from deposition
of dust on skin. This was also the case for infants, toddlers and children. However, a more recent study
indicates that the potential for dermal absorption of PFOA is signiﬁcant in both mouse and human skin
and that of dermal absorption is dependent on the ionisation state (Franko et al., 2012).
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3.2.3.3. Relative contribution to overall exposure
Based on available exposure data from the literature, total intakes as well as relative proportions of
the intakes for adults have been modelled or measured for PFOS and PFOA (Trudel et al., 2008;
Fromme et al., 2009; Vestergren and Cousins, 2009; Egeghy and Lorber, 2011; Haug et al., 2011b).
These studies indicate that for background exposed adults, consumption of food is generally the major
source of exposure for PFOS and PFOA (> 70%), but several studies have shown that drinking water
may be the main exposure source in areas with contaminated drinking water (Emmett et al., 2006;
H€olzer et al., 2008; Vestergren and Cousins, 2009). For instance, in the paper by Vestergren and
Cousins (2009), drinking water contributed to around 75% of the exposure in a scenario with point
sources of drinking water contamination.
To exemplify, the relative proportion of various pathways to the overall exposure of PFOS and PFOA
have been assessed in a background exposed Norwegian study population (n = 41), where individual
intakes from diet, dust and air were calculated (Haug et al., 2011b). Food contributed to 67–84% of
the median total intake for PFOA and 88–99% for PFOS using different exposure factors such as the
dust ingestion rate. Similarly, the median relative contribution from drinking water varied between
0.57% and 0.68% for PFOS, and 9.1% and 11% for PFOA. Dust contributed to 0.41–1.6% of the
median PFOS intake and 5–14.8% of the PFOA intake. The median intake of PFOS from air contributed
to 0.1% to 11% of the overall exposure, while it was 0.13–10.6% for PFOA. It is worth mentioning,
that on an individual basis the relative contribution from different exposure pathways varied a lot.
3.3. Hazard identiﬁcation and characterisation
3.3.1. Toxicokinetics
3.3.1.1. Experimental animals
3.3.1.1.1. PFOS
Based on animal experiments, mainly performed in rodents, the EFSA opinion published in 2008
(EFSA, 2008) reported that orally administered PFOS is well absorbed but poorly eliminated. It is
mainly found in the liver, kidneys and blood with lower levels in most other organs including the
central nervous system. After absorption, PFOS binds to albumin and to liver fatty acids binding protein
(L-FABP), which may contribute to its high retention in the liver. It can cross the placenta and enter
the fetus where it is mainly located in the liver. Repeated administration results in hepatic
bioaccumulation. PFOS is not known to be metabolised and the elimination of the parent compound in
rats occurs mostly in urine and to a lesser extent via faecal excretion.
Animal studies have shown that PFOS is excreted in bile and undergoes extensive intestinal
reabsorption, resulting in a prolonged elimination half-life of the compound (Yu et al., 2011; ATSDR,
2015). Whereas gender inﬂuence on biliary excretion of PFOS remains unexplored, several studies
carried out in rodents and non-human primates indicate limited differences between males and
females in PFOS elimination (De Silva et al., 2009; Chang et al., 2012).
Chang et al. (2009) investigated the toxicokinetics of PFOS in rats exposed to this chemical during
gestation and lactation. Sprague–Dawley rats were administered daily oral doses of either vehicle
control or PFOS (as potassium salt) at 0.1, 0.3 and 1.0 mg/kg bw per day, from gestational day (GD)
0 (day positive for mating) through to postnatal day (PND) 20. In addition, pregnant females received
the same doses through to GD 19 and sacriﬁced on GD 20 in order to obtain maternal and fetal serum
and tissue samples at the end of gestation. Serum, liver and brain PFOS concentrations were
determined by LC–MS/MS through PND 21 in dams and PND 72 in pups. PFOS appeared to
concentrate in the livers of dams and pups, with liver PFOS concentrations in pups at least twice as
high as corresponding serum concentrations. At GD 20 and for the lowest dose tested, liver average
concentrations were 8.3 and 3.2 lg/g for dams and fetuses, whereas in brain PFOS concentrations
were 0.15 and 1.23 lg/g, respectively. At PND 21, for the same dose group, PFOS hepatic
concentrations were 5.98 and 5.28 lg/g for male and female pups, respectively, whereas in brain
PFOS concentrations were 0.22 and 0.23 lg/g, respectively. Whereas liver concentrations were
essentially the same in both sexes, marked differences were observed between males and females in
serum PFOS concentrations but only on PND 72.
In a study in which pregnant Sprague–Dawley rats were exposed daily by gavage to PFOS at doses
of 0.1, 0.6 and 2.0 mg/kg bw per day from GD 2 to 21, concentrations found in the heart of weaned
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rats at PND 21 were 0.8, 4.1 and 9.6 lg/g, respectively and were approximately twofold higher than in
serum (Xia et al., 2011).
The tissue distribution of radioactivity was investigated in adult male C57/BL6 mice following dietary
exposure for 1, 3 or 5 days to 0.031 mg/kg bw per day or 23 mg/kg bw per day of 35S-PFOS
(Bogdanska et al., 2011). The highest levels were detected in the liver, lung, blood and kidney. The
PFOS distribution pattern varied according to the dose, showing a lower proportion in the blood and a
higher proportion in the tissues, particularly the liver, at the highest dose tested. Both radioactivity
counting and whole-body autoradiography revealed the presence of PFOS in all tissues examined,
including thymus and bone (comprising bone marrow). At both doses, in most of the tissues, including
liver, lung, kidney and brain, the level of PFOS increased with the length of exposure.
Borg et al. (2010) investigated the distribution of radioactivity in dams, fetuses (GD 18 and 20) and
pups (PND 1) following gavage administration of 35S-PFOS (12.5 mg/kg bw) to C57/BL6 mice at GD
16. In the dams, the liver and lungs exhibited the highest concentrations of radioactivity at all the
time-points, whereas in the fetuses and pups, the kidneys and liver contained the highest
concentrations on GD 18 and the lungs and liver on GD 20 and PND 1. The hepatic concentration of
35S-PFOS in the fetuses and the pups was about 1.7-fold lower than in the maternal liver. In fetuses
and pups, the level in brain was similar at all the time-points, corresponding to the level in maternal
blood but was 3.8- to 5.4-fold higher than in the maternal brain. Regional differences in the
distribution within the brain were observed, with a somewhat lower level in the perinatal cortex.
In pregnant CD-1 mice administered daily by gavage with 0.3 or 3 mg PFOS/kg bw per day
throughout gestational and lactation periods, average concentrations of PFOS measured in maternal
livers at PND 21 were 49.1 and 338.9 lg/kg, respectively and were approximately 3 times higher than
in serum (Wan et al., 2014). At the same time, the levels of PFOS found in pup livers were 20.1 and
243.0 lg/g, respectively, which was about twice the PFOS concentration in pup sera.
A series of studies was undertaken by Chang et al. (2012) to determine the toxicokinetics of PFOS
in rats, mice and monkeys. The absorption of ingested PFOS in male Sprague–Dawley rats given a
single oral dose of potassium 14C-PFOS at 4.2 mg/kg was estimated to be > 95%, based on the
retention in the carcass (excluding the gastrointestinal tract and its contents). Following a single
intravenous (i.v.) dose of 14C-PFOS (4.2 mg/kg bw, administered as potassium salt), an average of
30.2% of the radioactivity was recovered in the urine of male rats over 89 days and an average of
12.6% was found in faeces over 64 days. On day 89 post-dose, 25.2% and 2.8% of the administered
dose was found in liver and plasma, respectively. Two days following a single oral dose of 14C-PFOS
(4.2 mg/kg bw) the urinary and faecal elimination corresponded to 2.24% and 3.52% of the dose,
respectively. Additional experiments were carried out with unlabelled PFOS in male and female
Sprague–Dawley rats, CD-1 mice and cynomolgus monkeys. The principal differences observed
between species in the toxicokinetic parameters measured were in elimination rates. The serum
elimination half-lives ranged from 33 to 37 days in rodents, whereas it was approximately 120 days in
monkeys.
Tarazona et al. (2016) investigated the toxicokinetics of PFOS in female white New Zealand rabbits
administered by gavage at a dose of 0.2 lg/kg bw, 3 days a week (equivalent to a daily dose of
0.085 lg/kg bw) during 102 days, followed by a depuration period of 129 days. The serum
concentrations of PFOS were measured by LC–MS. PFOS was found to be totally absorbed and the
Cmax value was 20.42 lg/L and was observed at the end of the exposure period. The steady-state
concentration was estimated at about 36 lg/L and could be reached after approximately 1 year. The
serum elimination half-life was estimated to be 87 days.
Two studies suggested isomer-speciﬁc disposition following per os exposure to rats. In a ﬁrst
experiment, Benskin et al. (2009) administered by gavage a single dose of perﬂuorinated compounds to
male Sprague–Dawley rats. The dose consisted of 400 lg/kg bw PFOS (270 lg/kg bw n-PFOS), 500 lg/kg
bw PFOA (400 lg/kg bw n-PFOA), 390 lg/kg bw perﬂuorononanoic acid (PFNA) (200 lg/kg bw n-PFNA
and 190 lg/kg bw iso-PFNA), and 30 lg/kg bw perﬂuorohexane sulfonic acid (PFHxS) isomers which were
present as impurities in the PFOS standard. The concentration of PFOS isomers in tissues decreased in the
order liver > lung > kidneys > blood > spleen > heart > testes > intestine > muscle > brain > fat. At
day 3, tissues showed equivalent isomer proﬁles. For most perﬂuorinated isomers, including PFOS,
branched isomers had lower blood half-lives than the corresponding linear isomer. The exception to this
trend was for 1 m-PFOS, which was three fold more persistent in blood (t½ = 102 days) than linear PFOS
(t½ = 33.7 days). For most tissues, depuration half-lives were lower than in blood. However, in the liver, all
PFOS isomer half-lives were between a factor of 1.8 (n-PFOS) and 3.8 (unidentiﬁed branched PFOS isomer)
longer than those in blood and did not show the same trend as blood, wherein branched isomers had
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shorter half-lives compared to those of the linear isomer. The 1m-PFOS isomer, which had the longest half-
life in blood, had no measurable elimination from the liver at all. To conﬁrm these ﬁndings, male and female
Sprague–Dawley rats were dietary exposed to the same mixture of isomers for 12 weeks, followed by a
12-week depuration period. The diet contained 500 ng/g PFOA (80% n-PFOA), PFOS (70% n-PFOS), and
linear and isopropyl perﬂuorononanoate (De Silva et al., 2009). At the end of the exposure period, the
concentration in blood of branched PFOS isomers was generally higher than for n-PFOS. The highest
concentrations were observed for 1 m-PFOS. However, due to the fact that there was no strong evidence
for steady-state being reached in males or females for any isomer after 12 weeks of exposure, these
results must be interpreted with caution. With the exception of 1 m-PFOS, which exhibited longer
elimination half-lives than the n-isomer, elimination rates of the major branched PFOS isomers were not
statistically different from n-PFOS.
In addition to PFOS binding to rat L-FABP, which may contribute to PFOS high retention in rat liver
(EFSA, 2008), PFOS is known to bind to serum proteins. Recently, relative binding afﬁnity of PFOS
isomers to whole calf serum and human serum were investigated (Beesoon and Martin, 2015),
demonstrating a higher binding afﬁnity of linear PFOS to serum proteins, relative to branched isomers.
This result was conﬁrmed by the measurement of the dissociation constants (Kd) of individual PFOS
isomers with human serum albumin. Linear PFOS was much more tightly bound (Kd = 8 [4] 108 M)
than branched PFOS isomers (Kd from 8 [1] 105 M to 4 [2] 104 M). These data could partly
explain the longer half-life generally observed for linear PFOS compared to branched isomers (Benskin
et al., 2009; De Silva et al., 2009).
Whereas several papers identiﬁed the role of renal organic anion transporters in the disposition of
PFOA in rats (see following sections), the role of these proteins in the transport of PFOS in mammals is
not established.
In summary, the data published during the last years provide further evidence that PFOS is readily
absorbed after dietary exposure, binds to serum albumin and accumulates primarily in the liver. It can be
transferred to the fetus during gestation and elimination rates may differ signiﬁcantly according to
species. Branching of the perﬂuoroalkyl chain may have an impact on the toxicokinetics of PFOS. In the
serum, PFOS is bound to albumin, linear alkyl chains displaying a stronger binding than branched chains.
Although no studies were identiﬁed on speciﬁc renal transporters for PFOS, resorption of PFOS from the
glomerulate ﬁltrate via transporters in the kidney tubules is believed to be a major contributor to the long
half-life of this compound. The serum elimination half-lives in rats and mice were slightly higher than one
month, whereas in rabbits and monkeys, the serum elimination half-life was 3–4 months.
3.3.1.1.2. PFOA
As described in the previous EFSA opinion (EFSA, 2008), oral intake of PFOA results in rapid and
almost complete absorption. In rats, PFOA is mainly found in the liver, kidneys and blood with lower
levels in many other organs including the brain. PFOA can be transferred to the fetus during gestation.
Major gender difference and dose dependence in tissue concentrations and half-lives were described
for PFOA disposition in rats. Studies conducted in vivo and in vitro have not found metabolites of
PFOA. Elimination half-lives of about 1 day and 1 week were measured in female and male rats,
respectively. In cynomolgus monkey, the elimination half-life was estimated at approximately one
month but limited gender differences were observed regarding the disposition of PFOA in this species.
Although urinary excretion was found to be the major route of elimination in most of the investigated
species, strong differences were observed in rats between males and females. In the ﬁrst 24 h, in
females, most of the ingested dose was eliminated in urine, whereas in males urinary excretion
represented less than 10% of dose. Protein-binding and expression of transporters were found to play
an important role in determining distribution and elimination of PFOA in experimental animals.
More recently, a series of studies on the disposition of PFOA in rodents was undertaken and some of
them provided details on the mechanisms contributing to the sex differences in elimination of PFOA in
rats. Cui et al. (2009, 2010) investigated the distribution and elimination of PFOA in male Sprague–
Dawley rats. Animals were given 5 or 20 mg PFOA/kg bw by gavage, once a day for 4 weeks. At the end
of the experiment and for both concentrations tested, levels in main target organs were in the order of
kidney > liver > lung > blood  heart > testes > spleen  brain. No dose-related accumulation was
found. This study conﬁrmed that urine was the main excretion route for PFOA in rats. During the ﬁrst
24 h, about 18–22% of the administered PFOA was eliminated in urine, depending on the dose, whereas
faecal excretion was about 7–8%.
Rigden et al. (2015) investigated the urinary excretion of PFOA in male Sprague–Dawley rats
administered this compound (10, 33 or 100 mg/kg bw per day) by gavage for 3 consecutive days.
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They found that 17  6%, 36  10%, and 56  14% of the total dose administered was eliminated
in urine in the low-, medium- and high-dose group, respectively, showing that the fraction of PFOA
excreted in urine increased with the dose administered.
Studies conducted in rats have demonstrated that PFOA is excreted in bile and undergoes extensive
reabsorption from the gastrointestinal tract (ATSDR, 2015). Sex differences in elimination of PFOA
have been observed in hamsters, but unlike the rat, male hamsters excreted PFOA more rapidly than
females (ATSDR, 2015).
As reviewed by Han et al. (2012), biliary excretion does not seem to be a major factor contributing
to the gender- or species-dependent elimination of PFOA, in contrast to renal elimination. The process
of renal elimination, including glomerular ﬁltration, tubular secretion and tubular reabsorption, depends
on the afﬁnity of PFOA to bind to plasma proteins (mainly serum albumin) and organic anion transport
proteins (OATs). Only the unbound fraction of PFOA in blood is available for glomerular ﬁltration,
whereas cellular uptake (transporting into the cell) and efﬂux (transporting out of the cell) is mediated
by OATs. Male and female rats showed no gender difference in the binding of PFOA to serum proteins.
Han et al. (2012) compared the published literature on PFOA-serum albumin binding parameters
determined in bovine rat and human, on the basis of the association constant (Ka) and the number of
binding sites. The binding afﬁnity was found to vary from 101 to 103 M for low afﬁnity binding site
and from 104 to 106 M for the high afﬁnity binding site, with limited differences between species or
between males and females. In a recent study, it was shown that PFOA could bind into site I in
subdomain IIA of bovine serum albumin (Chen et al., 2015).
In contrast to serum albumin binding, carrier-mediated PFOA renal transport was shown to be sex
hormone-regulated and species-related (Han et al., 2012). In rat, OAT1 and OAT3 which are localised
in the basolateral membrane of the proximal tubular cells, facilitate PFOA renal tubular secretion,
whereas the organic anion-transporting polypeptide (Oatp) 1a1, which is expressed in the apical
membrane of the proximal tubular cells has been shown to transport PFOA from the urine back into
the proximal tubule cells, facilitating renal reabsorption (Buist et al., 2002; Nakagawa et al., 2008;
Yang et al., 2009a; Weaver et al., 2010). Oatp1a1 mRNA and Oatp1a1 expression level are both
markedly higher in male than in female rat kidney (Yang et al., 2009a). In addition, this renal
transporter was shown to be regulated by sex hormones (Gotoh et al., 2002), suggesting that
Oatp1a1-mediated tubular reabsorption could be the mechanism for the sex-dependent renal
elimination of PFOA in rats. In humans, (see Section 3.3.1.2.2 for further details), OAT4 (not
expressed in rats) and urate transporter 1 (URAT1), but not Oatp1a2 (the closest orthologous of rat
Oatp1a1), were shown to mediate PFOA renal tubular reabsorption (Yang et al., 2010), whereas OAT1
and OAT3 have been reported to mediate PFOA renal tubular secretion (Han et al., 2012). These data
suggest that gender and species differences in PFOA half-lives are, at least in part, driven by
expression of transporters in the kidney.
PFOA was reported to be able to bind to L-FABP and thus to compete with some natural ligands of this
protein (Luebker et al., 2002; Woodcroft et al., 2010); however, in experimental animals as in humans,
the afﬁnity was less than for PFOS (Luebker et al., 2002; Zhang et al., 2013a; see also Section 3.3.1.2.2).
To evaluate the disposition of PFOA in the pregnant and lactating dam and offspring, pregnant
CD-1 mice received a single dose of 0.1, 1 or 5 mg PFOA/kg bw by gavage on GD 17 (Fenton et al.,
2009). Maternal and pup ﬂuids and tissues were collected over time. Pups exhibited signiﬁcantly higher
serum PFOA concentrations compared to their respective dams: for example, a single 0.1 mg/kg PFOA
per os administration to a pregnant mouse induced circulating serum PFOA concentrations of
44–216 ng/mL in dams and 117–326 ng/mL in pups. The body burden in pups increased after birth
until at least PND 8, regardless of dose. The milk/serum distribution ratio ranged from slightly more
than 0.1 to over 0.5 in mice, depending on dose, with the lowest doses tested demonstrating the
highest ratios over time. These values are in agreement with previous studies in rats reporting a
distribution ratio of 0.1 (Hinderliter et al., 2005).
Macon et al. (2011) measured the concentration of PFOA in offspring from CD-1 mice dosed daily
by gavage for all or half of the gestation time. In the full-gestation study, mice were administered 0.3,
1.0, and 3.0 mg PFOA/kg bw per day, from GD 1 to 17. In the late-gestation study, mice were
administered 0.01, 0.1 and 1.0 mg PFOA/kg bw per day from GD 10 to 17. PFOA concentrations
remained elevated in liver and serum for up to 4 weeks. In female offspring corresponding to full
gestation exposure to 1 mg PFOA/kg bw per day for instance, the concentration in serum was 11
026  915 ng/mL, 1,247  208 ng/mL and 71  8 ng/mL at PND 7, PND 28 and PND 84,
respectively. In liver, at the same sampling times, concentrations were 8,134  740 ng/g,
2,007  560 ng/g and 55  12 ng/g, respectively, whereas in brain the concentration was
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479  41 ng/g at PND 7 but below LOQ (35 ng/g) at PND 28 and PND 84. Similar values and trends
were reported in male offspring. Values observed in the serum of female offspring from the late
gestation exposure study (1 mg PFOA/kg bw per day group) were 16,305  873 ng/mL,
11,880  1,448 ng/mL and 2,025  281 ng/mL at PND 1, PND 7 and PND 21, respectively.
The concentrations of PFOA found in serum of female offspring from CD-1 and C57Bl/6 dams
exposed to PFOA by gavage (0.01, 0.1, 0.3 or 1.0 mg/kg bw per day) between GD 1 and 17 (Tucker
et al., 2015) were in accordance with those previously reported by Macon et al. (2011) under similar
experimental conditions.
In a study dealing with the developmental effects of PFOA in mice female offspring prenatally exposed
to 0.3 mg PFOA/kg bw per day throughout gestation period, Koskela et al. (2016) found that the
concentration in pooled tibias and femurs was 3.0 and 3.7 ng PFOA/g at 13 and 17 months, respectively.
Isomer-speciﬁc disposition of PFOA in rodents was investigated by Benskin et al. (2009) in male
Sprague–Dawley rats administered by gavage a single dose of 500 lg/kg bw PFOA (400 lg/kg bw
n-PFOA) in mixture with PFOS, PFNA and PFHxS (see methodological details in Section 3.3.1.1.1). The
concentration of PFOA isomers in tissues decreased in the order liver > blood > kidneys >
lungs > heart > testes > spleen > fat > intestine > muscle > brain > fat, with the linear isomer being
predominant in all samples at all sampling times. In blood, the half-life of linear PFOA was 13.4 days
whereas for branched isomers it varied from 1.28 days to 9.10 days. Tissue half-lives were either similar
to or less than those estimated for blood. Preferential elimination of branched isomers occurred primarily
via urine. In another study (De Silva et al., 2009), male and female Sprague–Dawley rats were dietary
exposed to the same mixture of isomers for 12 weeks, followed by a 12-week depuration period (see
methodological details in Section 3.3.1.1.1). At the end of the exposure period, the relative
accumulation in blood of branched PFOA isomers was generally lower than for n-PFOA. The blood
depuration half-life for n-PFOA was 9.1 days (only estimated in males). Two minor unidentiﬁed branched
isomers had half-lives longer than that of n-PFOA (t½ = 16.0 days and 21.2 days, respectively). Linear
PFOA was found to more strongly bind to human serum albumin compared to branched PFOA isomers
(Beesoon and Martin, 2015), but no data were identiﬁed regarding the isomer-speciﬁc binding to OATs.
Overall, these data conﬁrm the extensive gastrointestinal absorption of PFOA. In plasma, most of
PFOA was found to be bound to proteins, the primary PFOA-binding protein being serum albumin.
PFOA is not metabolised and is predominantly distributed to blood and liver. It can cross the blood–
placenta barrier and enter the fetus where it is mainly found in the liver. It is excreted unchanged
primarily via the kidneys. Biliary and faecal excretion also contribute to the elimination of PFOA, which
may be subject to extensive enterohepatic recirculation. The gender and species differences in serum
half-life are mainly due to hormonally regulated renal reabsorption of PFOA by organic ion transporters
expressed in membranes of kidney proximal tubule cells.
3.3.1.2. Humans
3.3.1.2.1. PFOS
Studies of the absorption of PFOS in humans following oral exposure were not identiﬁed. However,
indirect evidence of oral absorption of PFOS was provided in studies showing signiﬁcant associations
between environmental levels (e.g. drinking water) and concentrations in human serum, suggesting
that PFOS is readily absorbed (ATSDR, 2015). PFOS binds to proteins (mainly albumin) in serum
(Kerstner-Wood et al., 2003; Zhang et al., 2009; Luo et al., 2012) and mainly accumulates in the liver,
kidney and blood (Olsen et al., 2003a; Perez et al., 2013). As far as it is known, PFOS is not
metabolised in humans and its renal clearance is very low, probably due to active renal reabsorption.
Elimination half-lives of PFOS in humans were estimated to vary between 4.5 and 7.4 years with
limited gender or age differences in workers (EFSA, 2008; ATSDR, 2015). A recent study reported the
shortest elimination half-life of 1.9 years, based on the annual decline from 2008 to 2012 (n = 302) of
PFOS concentration in the serum of workers from a ﬂuorochemical plant in China (Fu et al., 2016).
Perez et al. (2013) measured the concentrations of 21 PFASs in 99 samples of autopsy tissues
(brain, liver, lung, bone and kidney) from subjects who had been living in Tarragona (Catalonia, Spain).
PFOS was predominantly found in liver (median value: 41.9 ng/g, range: LOD–405), kidney (55 ng/g,
range: LOD–269) and lung (28.4 ng/g, LOD–61.8); mean concentration in brain was 4.9 ng/g (range:
LOD–22.5), whereas no trace of PFOS was found in bones. LOD was 3 ng/g for liver, lung, brain and
bone samples, and 6 ng/g for kidney.
Yeung et al. (2013a) investigated 12 PFASs in serum samples (n = 25) from liver donors with no
known liver disease and histologically normal liver tissues (n = 9) collected during liver resection
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surgery. The median PFOS concentration was 7.29 ng/mL (range 1.43–34.9 ng/mL) and 5.03 ng/g
(range 1.30–10.8) in serum and liver, respectively.
When incubated with separate human-derived plasma fractions, PFOS was found to be highly
bound to albumin (99.8%) and to low-density lipoproteins (95.6%), whereas binding to alpha- and
gamma-globulins was 59.4% and 24.1%, respectively (Kerstner-Wood et al., 2003). A binding constant
of 2.2 9 104 M and a binding ratio of PFOS to human albumin of 14 moles PFOS/mole albumin were
reported by Chen and Guo (2009). Distribution and binding to human donor plasma lipoprotein
fractions was investigated by Butenhoff et al. (2012a). Percent binding of PFOS (10 lg/mL in saline) to
isolated human plasma protein fractions in saline at 100% physiological concentration was 95.6%. The
majority of PFOS was found in lipoprotein-depleted plasma. Plasma density gradient fractionation
indicated that 9% of PFOS distributes to lipoprotein-containing fractions.
K€arrman et al. (2006) found that average concentrations of PFOS in plasma was only 1.2 times
higher than in whole blood, whereas Ehresman et al. (2007) found that whole blood concentrations of
PFOS were approximately half that of plasma or serum, irrespective of the concentration. These values
suggest that there was no selective retention of PFOS by red blood cells. More recently, Hanssen et al.
(2013) investigated the relative distribution of PFASs between plasma and whole blood in both
maternal and umbilical cord samples. For PFOS, the median ratio was 2.05 for cord samples and 1.90
for maternal samples.
Jin et al. (2016) investigated the isomer-speciﬁc partitioning of several PFASs between plasma and
blood cells. For total PFOS, the mean plasma:whole blood concentration ratio was 1.5  0.4. The
mean n-PFOS percentages in plasma and in whole blood were the same (approximately 50%),
whereas the majority of branched isomers was found in the plasma, following the rank order of
1m > 4m > 3 + 5m > Σm2 > iso > n. Linear PFOS chains display stronger protein binding than
branched chains (Beesoon and Martin, 2015).
Several studies have examined maternal–fetal transfer, measuring the concentrations of
perﬂuoroalkylated compounds in maternal and cord serum or plasma. In studies reporting PFOS
concentrations in matched mother–infant pairs, fetal–maternal ratio was in the 0.3–0.6 range (ATSDR,
2015; Manzano-Salgado et al., 2015).
Zhang et al. (2013b) examined the distribution of PFOS between maternal blood, cord blood, the
placenta and amniotic ﬂuid. Compared to the mean PFOS value in maternal blood, the mean levels in
the cord blood, placenta and amniotic ﬂuid were 21%, 56% and 0.14% of the mean levels in the
mother’s blood, respectively.
Elimination of absorbed PFOS occurs in urine and bile. Renal elimination includes glomerular
ﬁltration and tubular secretion as well as the process of reabsorption. The renal clearance values for
PFOS, as estimated by Harada et al. (2005), are 0.012 mL/kg per day for men and 0.019 mL/kg per
day for women, which are low in comparison with the values found in experimental animals. Analyses
of individual isomers of PFOS in paired Chinese human blood and urine samples were performed by
Zhang et al. (2013c). The average renal clearance for linear PFOS was found to be 0.045 mL/kg per
day (95% conﬁdence interval (CI): 0.032–0.057) in young females (age < 50 years) and 0.031 mL/kg
per day (95% CI: 0.021–0.042) in male and older female group. Older females and males have longer
estimated half-lives than young females, suggesting the importance of monthly menstruation as a
pathway for excretion. The estimate of the half-life of PFOS in menstruating women was 4.0 years vs
4.7 years in men (Wong et al., 2014). For branched PFOS, depending on isomers, renal clearance
varied from 0.019 mL/kg per day to 0.093 mL/kg per day in the ﬁrst group and from 0.016 mL/kg per
day to 0.063 mL/kg per day in the second group. Among the major PFOS isomers, 1m-PFOS had the
lowest renal clearance efﬁciency, followed by n, iso, 4m and 3 + 5m (Zhang et al., 2013c). Linear
PFOS chains display stronger binding than branched chains (Beesoon and Martin, 2015).
Harada et al. (2007) showed that biliary excretion of PFOS was important in humans, with a
clearance estimated at 2.98 mL/kg per day. However, 97% of PFOS excreted into bile was estimated
to be reabsorbed from the gastrointestinal tract. In the same paper, it was found that the presence of
PFOS in the cerebrospinal ﬂuid (CSF) was very low, with a median ratio of PFOS concentrations in
CSF/PFOS concentrations in serum of 0.09, suggesting that PFOS cannot easily pass through the
blood–brain barrier.
Based on serum analysis, the mean half-life in retired U.S. ﬂuorochemical production workers (24
males, 2 females) (Olsen et al., 2007) was 5.4 years (95% CI: 3.9–6.9 years; geometric mean:
4.8 years, 95% CI 4.0–5.8). Estimates for the two females in the same study were 4.9 and 6.8 years.
Transfer of PFOS to breast milk appears to be a signiﬁcant route of elimination of PFOS during
breastfeeding and consequently an important exposure route for nursing infants. The ratio of the
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concentrations in milk vs plasma was calculated to be in the range 0.01–0.02 (K€arrman et al., 2007;
Kim et al., 2011a; Liu et al., 2011). Mondal et al. (2014) investigated the association of breastfeeding
with maternal PFOS serum concentrations, but also with infant PFOS serum concentrations. Each
month, breastfeeding was associated with a 3% decrease in maternal serum concentration of PFOS,
but resulted concomitantly in a 4% increase in infant PFOS serum concentration.
Papadopoulou et al. (2016) determined PFOS concentrations in plasma samples of 3-year-old
children collected in 2010–2011 and maternal serum samples collected around delivery at 2007–2008
in Norway. A positive correlation was found between maternal and child concentrations of PFOS
(Spearman’s correlation coefﬁcients: 0.52) and PFOS levels in children serum (4.76  0.49 ng/mL),
were equivalent to those in maternal plasma (5.55  0.45 ng/mL). Every month of breastfeeding was
associated with an increase of 3.3% PFOS plasma levels in toddlers, independently of maternal
prenatal PFOS concentration.
In summary, these data indicate that PFOS is extensively absorbed in humans and readily
distributes in plasma, liver, kidney and lung. In plasma, PFOS is mainly bound to albumin and to a
lesser extent, to globulins. Both urine and bile are PFOS routes of excretion, with a biliary resorption
rate of 97%, which could contribute to the long half-life in humans (5.4 years). In women, breast milk
and menstruation ﬂuids are additional elimination routes of PFOS. Urinary excretion of PFOS is
dependent on the isomeric composition of the mixture present in blood and the gender/age/kidney
function of the individuals. PFOS has been detected in umbilical cord blood, breast milk and plasma
samples of breastfed toddlers indicating that maternal transfer occurs pre- and postnatally.
Further information on factors that may have an impact on the internal doses of PFASs is given in
Section 3.3.2.6.
3.3.1.2.2. PFOA
PFOA is absorbed from the gastrointestinal tract in humans. In a clinical study conducted by
Elcombe et al. (2013), reported by IARC (2016), a group of 43 subjects from age 39 to 78 years, all
with tumours of varying tissue origin, and comprising an equivalent number of males and females,
were given an oral dose of 50–1,200 mg of a puriﬁed straight-chain isomer of the ammonium salt of
PFOA each week, for up to 6 weeks. Rapid absorption was observed with a peak plasma concentration
noted at ca 1.5 h. No age or sex differences were found.
It has been estimated that more than 90% of PFOA was bound to serum albumin in human blood
(IARC, 2016). A binding constant of 2.7 9 105 M and a binding ratio of PFOA to human albumin of
5.8 moles PFOS/mole albumin were reported by Chen and Guo (2009). PFOA also has afﬁnity for
human serum transthyretin (TTR) and for L-FABP (IARC, 2016). Weiss et al. (2009) tested the binding
capacity of PFOA and PFOS to TTR and found that the binding potency of these PFASs was
approximately 15-fold lower than the natural ligand thyroxine. However, in a study examining the
correlation between PFOS exposure and TTR-bound thyroxine, no association was found (Audet-
Delage et al., 2013, see Section 3.3.4.6.3)
Perez et al. (2013) measured the concentrations of 21 perﬂuoroalkylated substances in 99 samples of
autopsy tissues (see above). PFOA was predominantly found in bone (median value: 20.9 ng/g, range:
LOD–234), followed by the lung (median value: 12.1 ng/g, range: LOD–87.9), the liver (median value:
4.0 ng/g, range: LOD–98.9) and the kidney (median value: 1.5 ng/g, range: LOD–11.9). PFOA was not
detected in the brain. LOD was 3 ng/g for liver, kidney and bone samples, 2.4 ng/g for brain and 6 ng/g
for lung. In matched samples of serum and liver from subjects who underwent liver transplantation
(Yeung et al., 2013a; see above for details), PFOA levels ranged from 0.44 to 45.5 ng/mL and 0.10 to
2.3 ng/g, respectively. Because these results are different from a liver-to-serum ratio of approximately 1,
as previously reported by Maestri et al. (2006) in non-occupationally exposed humans, the authors
suggested that pathological changes in the diseased liver may alter the distribution of PFOA within the
liver, thus affecting its partitioning between serum and liver compartments.
The average concentration of PFOA in plasma from the general population was found to be 1.2–1.4
times higher than in whole blood (K€arrman et al., 2006; Jin et al., 2016). However, for occupationally
exposed groups concentrations of PFOA in blood was approximately half that of plasma or serum
(Ehresman et al., 2007). Hanssen et al. (2013) found that the relative distribution of PFOA between
plasma and whole blood in both maternal and umbilical cord samples was 1.8 and 2.0, respectively. All
these values suggest that there was no selective retention of PFOA by red blood cells.
The isomer-speciﬁc partitioning of PFOA between plasma and blood cells was investigated by Jin
et al. (2016) in 60 samples collected from the Chinese population. The linear isomer was found to be
predominant (> 90%) in plasma and whole blood samples, the percentage of n-PFOA in plasma being
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somewhat higher than that in whole blood, but the difference was not statistically signiﬁcant. Linear
PFOA is more strongly bound to human serum albumin compared to branched PFOA isomers (Beesoon
and Martin, 2015).
PFOA can be transferred to the fetus during pregnancy. ATSDR reported fetal/maternal serum ratios
ranging from 0.32 to 1.30 (ATSDR, 2015). In recent studies conducted in Europe, this ratio was close
to 0.8 (Cariou et al., 2015; Manzano-Salgado et al., 2015).
Elimination of absorbed PFOA occurs in urine and bile. The renal clearance values for PFOA, as
estimated by Harada et al. (2005), were 0.033 mL/kg per day for men and 0.027 mL/kg per day for
women. Biliary clearance for PFOA was estimated to be 1.06 mL/kg per day (Harada et al., 2007),
which is substantially higher than renal clearance in humans and might represent a major excretion
route. However, approximately 89% of the PFOA excreted into bile was estimated to be reabsorbed
from the gastrointestinal tract (Harada et al., 2007). More recently, Fujii et al. (2015) estimated that
the reabsorption of PFOA excreted in bile was 98%. The ratio of the median concentration of PFOA in
the cerebrospinal ﬂuid samples to the concentration in serum was found to be 0.018, suggesting that
crossing the blood–brain barrier occurs at a very limited extent (Harada et al., 2007). This ﬁnding was
supported by the work of Fujii et al. (2015) who reported a cerebrospinal ﬂuid/serum ratio of 0.031.
OAT1 and OAT3 on the basolateral membrane of human proximal tubular cells have been identiﬁed
as contributing to renal secretion of PFOA, whereas OAT2 is not involved in this process. Besides
secretion, PFOA can also be reabsorbed by transport from the tubular lumen across the brush-border
membrane into the proximal tubular cell. Two human renal brush-border membrane carriers, OAT4,
which is only expressed in human kidney, and URAT1 are involved in the initial step in the reabsorption
of PFOA (Nakagawa et al., 2009; Yang et al., 2010; Han et al., 2012). The polymorphism of OATs in
human populations and its consequence in the toxicokinetics of drugs and contaminants they transport
have been reported in a limited number of articles. Naturally occurring genetic variants of OAT4 were
identiﬁed in public databases and by resequencing DNA samples from individuals comprising four
distinct ethnic groups. Nine total non-synonymous variants demonstrating altered transport of
endogenous substrates were identiﬁed (Shima et al., 2010), but no publications focused on PFOA were
identiﬁed.
The studies investigating the fate of radiolabelled PFOA in rodents (Vanden Heuvel et al., 1991;
Kemper, 2003; ATSDR, 2015) failed to detect any biotransformation product in urine, faeces or tissues
of exposed animals. Fluorine-19 nuclear magnetic resonance (NMR) analysis of various body ﬂuids and
liver of rats administered a single intraperitoneal (i.p.) dose of PFOA displayed resonances of the
parent compound but did not reveal any evidence of metabolism. Radiolabelled PFOA was not
metabolised when incubated with human liver, kidney or intestine subcellular fractions (Kemper and
Nabb, 2005) and no metabolites were detected in studies conducted in humans.
Han et al. (2012) estimated that in humans the percentage of tubular reabsorption of PFOA was
99.94% and reported a renal clearance of 0.03 mL/kg per day. Fujii et al. (2015) estimated renal, bile
and faecal clearances in humans. The values reported were 0.044  0.01, 2.62  3.6 and
0.052  0.05 mL/kg per day, respectively. The renal clearance of PFOA individual isomers was
investigated by Zhang et al. (2013c). The average renal clearance for linear PFOA was found to be
0.29 mL/kg per day in young females (age < 50 years) and 0.79 mL/kg per day in male and older female
group. For branched PFOA, renal clearance varied from 0.57 mL/kg per day to 1.2 mL/kg per day in the
ﬁrst group and from 0.39 mL/kg per day to 0.92 mL/kg per day in the second group, depending on
isomers. All these values are higher than those described previously by Harada et al. (2005) and Han
et al. (2012). For branched PFOA, the elimination half-lives were estimated to vary from 0.53 to
1.4 years in young females and from 1.3 to 2.5 in all males and other females, depending on the
isomers, whereas for linear PFOA, the half-lives in both groups were approximately 2.5 years. These
values are comparable with the data published for humans (from 2.3 to 8.5 years), as previously
reported (EFSA, 2008; ATSDR, 2015). Elimination rates were not different in males and females.
Maternal–infant transfer of PFOA via breast milk was investigated by several groups during the last
decade. The ratio of the concentrations in milk vs plasma was calculated to be in the range 0.03–0.12
(ATSDR, 2015), indicating that the transfer occurs at a signiﬁcant extent, representing an important
excretion for lactating mothers, but also a critical exposure route for nursing infants. The lactational
transfer of PFOA was recently studied by Mondal et al. (2014), showing that each month,
breastfeeding was associated with 3% decrease in maternal serum concentration of PFOA, but
resulted concomitantly in 6% increase in infant PFOA serum concentration.
In Norway, PFOA concentrations in plasma of children at the age of 3 years were found to be
positively and signiﬁcantly correlated with levels of PFOA measured in serum of mothers collected
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around delivery (Spearman’s correlation coefﬁcients: 0.55) (Papadopoulou et al., 2016). Approximately
98% of the samples for children had higher concentrations than in those of their mothers’. Every
month of breastfeeding was associated with an increase of 4.7% in PFOA plasma levels in toddlers,
independently of maternal prenatal PFOA concentrations.
In summary, these data indicate that once absorbed PFOA distributes in plasma, liver, kidney, lung
and bone and does not undergo metabolism. In plasma, PFOA is mainly bound to albumin. PFOA is
eliminated primarily in the urine, with lesser amounts eliminated in the faeces. Biliary excretion of
PFOA was signiﬁcantly higher than serum clearance via the urine, but does not substantially contribute
to overall elimination, due to high biliary reabsorption. Humans have a high estimated percentage of
PFOA renal tubular reabsorption (99.94%) due to the high afﬁnity of PFOA for human uptake transport
proteins such as OAT1, OAT3 and URAT1. Several studies estimated the half-lives of PFOA in humans,
most of them suggesting values between 2 and 4 years. In women, breast milk and menstruation
ﬂuids contribute to the elimination of PFOA. The half-lives of the branched chain PFOA isomers are
shorter than those for the linear molecules, suggesting that renal resorption is less efﬁcient with the
branched chains. PFOA has been detected in umbilical cord blood, breast milk and plasma samples of
breastfed toddlers indicating that maternal transfer occurs pre- and postnatally.
Further information on factors that may have an impact on the internal doses of PFASs is given in
Section 3.3.2.6.
3.3.1.3. PBPK modelling
Physiologically based pharmacokinetic models are quantitative descriptions of the absorption,
distribution, metabolism and excretion (ADME) of chemicals in biota based on inter-relationships
among key physiological, biochemical and physicochemical determinants of these processes (WHO/
IPCS, 2010). These models are not only used to translate external exposures into an internal (target)
dose in the body, but are also developed to extrapolate between different routes of exposure and
between different species.
Several PBPK models of PFOA and PFOS have been reported in rodents, monkeys and humans,
including during gestation and lactation for rats and humans (see ATSDR, 2015). This subsection will
mainly focus on monkey and human models.
Loccisano et al. (2011) developed a PBPK model for simulating the kinetics of PFOA and PFOS in
monkeys and humans. The monkey model was based on multi-compartmental models developed by
Andersen et al. (2006) and Tan et al. (2008) for simulating the kinetics of plasma and urinary PFOA
and PFOS in monkeys following intravenous and oral dosing. The models described by these authors
evaluated the quantitative role of renal reabsorption via high efﬁciency transporters in controlling the
persistence of PFOA and PFOS in monkeys (Andersen et al., 2006; Tan et al., 2013). The model
simulations were consistent with the observed serum data in both intravenous and repeated oral
dosing studies with PFOA and PFOS at different exposure levels. The PBPK model published by
Loccisano et al. (2011) for monkeys contains compartments for plasma, gut, liver, kidney, renal ﬁltrate,
fat, skin and rest of the body. Data utilised in developing and evaluating the monkey model included
single-dose intravenous and oral studies and repeated-dose oral studies conducted in Cynomolgus
monkeys (Seacat et al., 2002; Noker and Gorman, 2003; Butenhoff et al., 2004a). Only the free
fraction of PFOA and PFOS in plasma was assumed to be available to partition into tissues. Tissue–
plasma partition coefﬁcients were derived from observations in rodents. For PFOA, the partition
coefﬁcients were estimated from tissue concentration data reported by Kudo et al. (2007) following a
single intravenous dose of PFOA to male Wistar rats. For PFOS, the partition coefﬁcients were derived
from tissue concentration data resulting from 5 days of dietary dosing in male C57Bl/6 mice (DePierre,
personal communication cited by Loccisano et al., 2011). A description of saturable renal reabsorption
was implemented in the ﬁltrate compartment, using the transporter maximum and the transporter
afﬁnity constant as parameters. Given the limited sex difference in the elimination kinetics in monkeys
(Butenhoff et al., 2004a), the same parameters for renal tubular reabsorption of PFOA and PFOS were
used for males and females. Binding of PFOA and PFOS in the liver was assumed to be negligible. The
physiological parameters for the monkey model were described in Loccisano et al. (2011). The model
simulation was consistent with available pharmacokinetic data for monkeys.
The monkey PBPK model was extrapolated to humans (Loccisano et al., 2011). For both PFOA and
PFOS, the parameters used for humans such as the tissue–plasma partition coefﬁcient, the free fraction
in plasma or the transporter afﬁnity constant were those previously described for monkey. The
transporter capacity was adjusted for each chemical to get the correct half-life, which is higher in humans
compared to monkeys. Physiological parameters for the human model were those reported by Brown
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et al. (1997). Data used in evaluating the human model consisted of serum measurements in residents
from Little Hocking (Ohio, USA) or Arnsberg (Germany) who were exposed to PFOA-contaminated
drinking water. It was assumed that drinking water was the only source of exposure to PFOA. The
adequacy of the model to predict PFOA and PFOS concentrations in humans was also assessed on the
basis of the available data from American Red Cross adult blood donors and from retired ﬂuorochemical
workers reported by Olsen et al. (2007, 2008). In general, PFOA and PFOS intakes and exposure
durations were not known with certainty in the populations examined by Olsen et al. (2007) and, as a
result, the data provided by these authors do not yield conﬁdent evaluations of the ability of the human
model to predict intake-plasma level relationships. Follow-up monitoring after a cessation or decrease in
exposure can provide data that allow evaluation of the ability of the model to accurately simulate
elimination kinetics. Predicted declines in serum PFOA concentrations encompassed observed group
mean declines when the transporter maximum (Tm) for renal tubular reabsorption was set to yield
elimination half-times of 2.3 or 3.8 years. Group mean declines in serum PFOS were well predicted for
some but not all populations, when the Tm for renal tubular reabsorption was optimised to yield an
elimination half-time of 5.4 years. In addition to renal reabsorption which is considered as the main
process responsible for the long half-lives of PFOA and PFOS in humans, plasma protein binding is
another possible cause of this slow clearance. A better characterisation of this binding and consequently
of the free fraction estimate would probably improve the model prediction.
Because the PBPK model developed by Loccisano et al. (2011) resulted in an overestimation of the
concentrations of PFOA and PFOS in various tissues of people from the Tarragona region (Spain), with
the exception of PFOS in liver and kidney, Fabrega et al. (2014) decided to adapt it to estimate the
PFAS content in human tissue compartments. In addition to plasma, gut, liver, fat, kidney, renal ﬁltrate
and the remaining body compartments, the adapted PBPK model included lungs and brain. Since it is
not a potential site of absorption and/or accumulation, skin was removed. Model calibration and
evaluation was conducted on the basis of data on PFOA and PFOS levels in food and drinking water
from Tarragona County (Domingo et al., 2012a,b) and by using concentration levels in human tissues
from people living in the same area (Ericson et al., 2007; Perez et al., 2013). The Fabrega model was
calibrated and evaluated by using the same set of experimental data based on autopsy tissues from
subjects residing in the Tarragona County area. According the WHO guidance (WHO/IPCS, 2010), the
Fabrega model cannot be considered as formally validated because evaluation with independent data
was not performed. A sensitivity analysis was carried out to understand the degree of inﬂuence of
input parameters on the ﬁnal outcome (Fabrega et al., 2016). The elimination constants (transporter
maximum and transporter afﬁnity constant) as well as the free fraction and the intake were the most
inﬂuential parameters. The evaluation of the PBPK model by visual comparison of the simulation results
with experimental values as suggested by Chiu et al. (2007) indicates that the concentrations of both
PFOS and PFOA fell within the range of the model simulations, resulting in the model being considered
valid. In contrast, according to the statistical treatment (Student’s t-test), the model was not validated
for the PFOS in lungs and kidneys, as well as for PFOA in brain and lungs.
The human model described in Loccisano et al. (2011) as well as the PBPK models for PFOA and
PFOS in pregnant, lactating, fetal and neonatal rat (Loccisano et al., 2012) were subsequently
extended to include simulations of pregnancy and lactation in humans (Loccisano et al., 2013). The
changes made to the adult human model were the addition of mammary tissue, placenta, and fetal
compartments, and a milk compartment for lactation. Only the mother was assumed to have direct
exposure to PFASs, and only the free fraction of chemical in plasma was assumed to be available for
uptake into tissues. Transport into tissues was ﬂow-limited. Clearance of PFASs in the mother occurs
by urinary elimination from the ﬁltrate compartment in both models; clearance in the infant is
described with a generic ﬁrst-order rate constant from the central compartment. Fetal exposure to
PFASs is through placental transfer, which is described as a bidirectional transfer process (from mother
to fetus and fetus to mother) between free chemical in the placenta and fetal plasma. Placental
transfer was described as a simple diffusion process, although the possibility that placental transport is
also facilitated by an active transport process cannot be ruled out. OAT4, which is expressed in human
kidney proximal tubule cells, is also expressed in human placenta and may also play a role in transport
of PFOA and PFOS there. However, the possible roles that these transporters play in placental
transport of PFOA and PFOS remains to be elucidated; thus, a description using simple diffusion was
used in the current model. Rate constants for placental transfer were initially those from the rat model,
adjusted to yield predicted maternal/fetal plasma ratios that agreed with observed maternal/fetal ratios
in cord blood. An amniotic ﬂuid compartment was included in the rat models and also in the human
models. Transfer rates between the amniotic ﬂuid compartment and the fetal body are described as
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simple diffusion and were the same as those used in the rat model. Transport of chemical from fetal
plasma into the rest of fetal body compartment was also ﬂow-limited.
The lactation model included additional compartments for mammary milk and a lumped
compartment representing the infant. Transfer of PFASs to milk is simulated as ﬂow-limited exchange
between plasma and milk, governed by mammary tissue blood ﬂow and a milk/plasma partition
coefﬁcient. Only the free fraction of chemical in plasma was available for transfer into milk. The infant
was exposed only through milk, and breastfeeding lasted for 6 months post-partum. The milk/plasma
partition coefﬁcient was calibrated to yield predictions of observed milk/plasma ratios. Transfer from
maternal milk to infants is the product of the milk concentration and milk production rate (assumed to
be equal to sucking rate). The pregnancy and the lactation models for PFASs were evaluated by
comparing predicted maternal/fetal plasma ratios and predicted maternal plasma/milk ratios,
respectively, with observations from various human monitoring studies.
The agreement between the predicted and observed concentrations of PFOA and PFOS in maternal
plasma or milk, or in infant or cord plasma was good, with the ratios of predicted to observed
concentrations all within a factor of 2. The sensitivity analysis identiﬁed the model parameters for
which additional data would be most helpful. Data on plasma protein binding of PFOS and PFOA and
how that is affected by pregnancy, placental transfer kinetics, and renal resorption of PFOS and PFOA
in pregnant and lactating women, the fetus, and infant would improve model predictions. One
application of the lactation and pregnancy models is the comparison of internal dose in the pregnant
mother and fetus and lactating mother and nursing infant. During gestation, maternal and fetal levels
of PFOA are similar and both decrease as gestation progresses. For PFOS, the same trend of
decreasing concentration is observed; however, the maternal levels of PFOS are about twice what is
observed in the fetus. During lactation, however, the concentration of PFOS and PFOA in the infant is
equal to or higher than the mother’s concentration, indicating that milk is a route of excretion for the
mother and also that intake in breast milk is a substantial source of exposure for the infant. Another
application of the model is to estimate maternal exposure to PFOA and PFOS using observed maternal
blood PFOS and PFOA concentrations from biomonitoring studies in pregnant or lactating women.
3.3.1.4. Transfer
The transfer of a mixture of PFASs from contaminated feed into the edible tissues of 24 fattening
pigs was investigated by Numata et al. (2014). The animals were fed the contaminated diet for
21 days. The mean concentration of PFOS was 137  13 lg/kg and represented approximately 30%
of total PFASs; the mean concentration of PFOA was 22.4  2.6 lg/kg. The BAF (ratio of the
concentration in the tissue vs concentration in feed) for PFOS was found to be 17.9, 9.7 and 503 in
whole animals, meat and liver, respectively. The BAFs for PFOA were estimated to be 7.9, 5.3 and 32.8
in whole animals, meat and liver, respectively.
In sheep fed over a 21-day period a corn silage contaminated by both PFOS (90 lg/kg dry matter)
and PFOA (33 lg/kg dry matter), resulted in a dietary exposure of approximately 1.3 lg/kg bw per
day and 0.5 lg/kg bw per day, respectively. The concentrations of PFOS and PFOA in milk over the
whole exposure period were in the ranges 3.4–8.9 lg/L and 0.2–0.7 lg/L (ranges between animals),
respectively, and the ratios of milk to plasma were 1:17 and 1:20, respectively. The estimated transfer
of PFOS and PFOA into sheep milk was ≤ 2% and ≤ 0.4%, respectively (Kowalczyk et al., 2012).
In similar conditions (28 days dietary exposure to a mixture of PFASs), the PFOS transfer into milk,
from dairy cows, was investigated by Kowalczyk et al. (2013). On the basis of the daily intake of PFAS-
contaminated grass silage and hay, the total intake of PFOS and PFOA were 7.6  3.2 lg/kg bw per
day and 2.0  1.2 lg/kg bw per day, respectively. The estimated transfers of PFOS and PFOA into
milk were found to be approximately 5 and 0.1%, respectively.
In a published thesis (Dennh€ofer, 2011), female Japanese quails were dosed for 6 weeks with an
equal amount PFOS and PFOA through feed (0.38, 0.66, 1.16 or 2.0 mg PFOS and PFOA/kg feed;
0.19, 0.33, 0.58 or 1.000 mg PFOS and PFOA/kg bw per day) or drinking water (0.66 or 1.16 mg
PFOS and PFOA/L drinking water; 0.33 or 0.58 mg PFOS and PFOA/kg bw per day). Both compounds
were excreted in eggs and accumulating in tissues (liver and muscle) in a dose-related manner.
Concentrations of PFOA measured on day 35 in eggs from the feed trial were 1.6  0.2, 3.4  0.2,
4.9  1.2 and 12  3.1 mg/kg dry weight (dw), respectively. Concentrations of PFOS were
3.3  0.05, 6.6  1, 9  2.1 and 29.8  6 mg/kg dw, respectively. In eggs, measured PFOA
concentrations from the water trial were 6.4  0.5 and 11.5  0.6 mg/kg dw; PFOS concentrations
were measured as 11.1  3.6 and 23.6  3.1 mg/kg dw, respectively. In the liver, 0.4–0.8% of the
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total cumulative dose were found for PFOA and 0.2–0.8% for PFOS. The muscle tissue contained
0.6–3.6% of the total cumulative dose of PFOA and 0.4–1.6% of the total cumulative dose of PFOS.
Martin et al. (2003a) exposed juvenile rainbow trout (Oncorhynchus mykiss) to a mixture of PFCAs
and PFSAs for 34 days in the diet. The concentration of PFOS in feed was 0.54 mg/kg and represented
8.3% of total PFASs. The PFOS BAF was 0.32  0.05, indicating that dietary exposure does not result in
bioaccumulation of PFOS in juvenile trout. This result was conﬁrmed by Goeritz et al. (2013) in adult
rainbow trout dietary exposed for 28 days to a mixture of PFASs. The concentration of PFOS in feed was
0.50 mg/kg and represented 20% of total PFASs. In these experimental conditions, a BAF of 0.42 was
calculated for PFOS. In rainbow trout dietary exposed to PFAS mixtures in which PFOA amounted to
0.42 mg/kg (Martin et al., 2003a) or 0.5 mg/kg (Goeritz et al., 2013), the PFOA BAF was 0.04. In a study
performed by Mortensen et al. (2011), juvenile Atlantic salmon (Salmo salar) were force-fed at days 0, 3
and 6 gelatine capsules containing PFOS or PFOA (each dose corresponding to 0.2 mg/kg bw). Levels of
PFOS continuously increased in the blood, liver and kidney during the treatment period, whereas a
steady state was observed after 3 days in the salmons exposed to PFOA. At the end of the exposure
period, the PFOS average concentrations in whole blood, liver and kidney were approximately 3.0, 3.5
and 1.5 ng/g tissue, respectively, whereas for PFOA, the values were approximately 0.8, 0.3 and 0.4 ng/
g tissue, respectively.
3.3.2. Biomonitoring
3.3.2.1. Selection of biomarker and appropriate matrix for assessing internal dose
Due to high persistency, PFOS and PFOA are not metabolised in the human body, and can thus be
measured unchanged in biological matrices. The preferred matrix for measuring internal doses of PFOS
and PFOA in humans is blood, and due to practical reasons speciﬁcally plasma or serum (Butenhoff
et al., 2006). Some studies have assessed the distribution of PFOS and PFOA between whole blood,
serum and plasma, and the concentrations in whole blood need to be multiplied with 2 to be
comparable with serum or plasma (Ehresman et al., 2007).
Studies on breast milk and urine have also been conducted, but the concentrations are considerably
lower when compared to blood, thus making the determinations more challenging (Haug et al., 2011b;
Kim et al., 2011a, 2014; Liu et al., 2011; Li et al., 2013; Zhang et al., 2013c). The breast milk
concentrations are usually around 0.9–2% and 1.8–9% of the maternal serum/plasma concentrations
for PFOS and PFOA, respectively (K€arrman et al., 2007; Haug et al., 2011b; Kim et al., 2011a; Liu
et al., 2011). Furthermore, breast milk as a sample matrix is suitable only for a limited part of the
general population, which is not particularly interesting for compounds that are bioaccumulative.
Concentrations of PFOS and PFOA in non-invasive matrices such as hair and nails have been
determined in a few studies, but so far it is unclear how to compare the results to concentrations in
other biological matrices (Li et al., 2013; Alves et al., 2014, 2015). A limited number of studies have
also measured other biological matrices from humans, such as liver and amniotic ﬂuid, but usually with
the aim to explore the distribution of PFOS and PFOA in the body rather than for biomonitoring
purposes (Jensen et al., 2012; Stein et al., 2012; Perez et al., 2013; Yeung et al., 2013a).
3.3.2.2. Time trends
Due to changes in production and use of PFOS and PFOA, the exposure and thus also blood levels
are thought to vary over time (see Section 1.3.4). To explore trends, several European time trend
studies have been conducted (K€arrman et al., 2007; Haug et al., 2009; Wilhelm et al., 2009;
Sundstr€om et al., 2011; Glynn et al., 2012; Schr€oter-Kermani et al., 2013; Yeung et al., 2013b,c;
Axmon et al., 2014; Nøst et al., 2014; Gebbink et al., 2015; Liu et al., 2015; Bjerregaard-Olesen et al.,
2016; Stubleski et al., 2016). In general, increasing concentrations of PFOS and PFOA were observed
from the early 1970s until around year 2000, while the concentrations have in most studies been
observed to decrease after that.
To illustrate this, the results from a German study using samples from the German Environmental
Specimen bank (Yeung et al., 2013b,c) are presented below. This study was chosen as it presents
results for both genders, has satisfactory quantiﬁcation limits and includes many sampling years.
Samples were collected from students (age 20–29 years) in two cities: M€unster (270 samples,
approximately 10 samples per year from 1982 to 2009, mean age 24 years) and Halle (150 samples,
approximately 10 samples per year from 1995 to 2009, mean age 23 years). Both in M€unster and
Halle, approximately the same number of men and women were included in the study.
www.efsa.europa.eu/efsajournal 53 EFSA Journal 2018;16(12):5194
PFOS and PFOA in food
PFOS: In the samples from M€unster, the mean PFOS concentration increased from 27.5 ng/mL
(males) in 1,982 to 41 ng/mL in 1986, and then it gradually decreased to 25 ng/mL in 1991 for males.
Following this, the concentration was quite stable up to 2001 when it started decreasing more rapidly.
In 2009 the mean concentration in males was 7.1 ng/mL. A similar trend was observed for the Halle
samples, a quite stable mean concentration for males around 20–25 ng/mL was observed between
1995 and 1999 and then the concentration has been gradually decreasing to a mean of 6.9 ng/mL in
males 2009.
PFOA: The trend for PFOA in the M€unster samples was very similar to the trend for PFOS, except
that no particular decrease in the concentration was observed between 1990 and 2009. The mean
concentration for males in 1982 was 7.59 ng/mL, while the highest mean concentration for males of
23.4 ng/mL was observed in 1986. The mean concentration for males in 2009 was 3.45 ng/mL. For
the samples from Halle, the PFOA mean concentration for males was quite stable around 5–8 ng/mL
from 1995 to 2000, when it started decreasing. The mean concentration in males in 2009 was
2.73 ng/mL.
3.3.2.3. Levels in general European populations with serum or plasma samples collected
from 2007–2008 and onwards
Concentrations of PFOA and PFOS in plasma and serum from European adults and children are
described in detail in Tables 6 and 7. Included in the tables are results from European studies on
general populations, where samples have been collected in 2007–2008 and onwards. Only results from
the most recent years have been described for the time trend studies. In Table 8, descriptive statistics
summarising all studies included in Tables 6 and 7 are shown, for both adults and children.
As can be seen from Table 8, the minimum and maximum concentrations of PFOS and PFOA for
individuals varied quite a lot. However, ratios between the highest and lowest median concentrations
were in the range 6–18. Thus, it can be concluded that, even though the design, populations (e.g.
sex, age, race), analytical methods and geographic location vary between the studies, the median
concentrations of PFOS and PFOA are similar. This is also true when comparing with general
populations worldwide (Haines and Murray, 2012; Wan et al., 2013; Zhang et al., 2014a; Khalil et al.,
2016).
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Table 6: Concentrations of PFOS and PFOA in general European adult populations with serum or plasma samples collected from 2007–2008 and onwards
Year Country Study population
Median,
ng/mL
Geometric
mean,
ng/mL
Arithmetic
mean,
ng/mL
Min,
ng/mL
Max,
ng/mL
Reference
PFOS (total)
2007 Sweden n = 10, women, mean age; 48 years (range
36–56 years). Serum
10.2 NR NR NR NR Axmon et al. (2014)
2010–2011 Sweden n = 270, women, median age: 50 years
(range 22–75 years). Serum
11.20 NR NR 3.89
(P5)
25.41 (P95) Bjermo et al. (2013)
2008–2010 Sweden n = 153 males, mean age: 67 years
(53–79 years). Whole blood
8.6 8.5 10 1.7 29 Bao et al. (2014)
2007–2011 Sweden n = 201, men with prostate cancer. Median
age 67 years (range 49–79 years). Serum
9.0 NR 11 1.4 69 Hardell et al. (2014)
2007–2011 Sweden n = 186, men without prostate cancer.
Median age 67 years (range 50–79 years).
Serum
8.3 NR 10 1.7 49 Hardell et al. (2014)
2008–2011 Sweden n = 150, primiparous women, within the
third week after delivery. The county has a
known contamination of the drinking water
with PFAS. Mean age 30.2 years (range
21–40 years). Serum
6.6** NR 7.0** 0.21** 20** Gyllenhammar et al.
(2015)
2010 Sweden n = 36 pools of serum. Primiparous women
living in Uppsala county, donated serum
samples within the third week after delivery.
Age 19–41 years
NR NR NR 5.1 7.6 Glynn et al. (2012)
2012 Sweden n = 3 pools primiparous women living in
Uppsala County, donated serum samples
within the fourth week after delivery. Serum
NR NR NR 5.61** 6.73** Gebbink et al. (2015)
2011–2014 Sweden n = 579, men and women, 80 years 7.6*** 7.8*** 9.4*** 0.2*** 65*** Stubleski et al. (2016)
2007–2008 Norway n = 41, women, mean age: 36.7 years
(range 25–45 years). Serum
6.7 NR 6.9 2.3 15 Haug et al. (2011b)
2007–2008 Norway n = 123, pregnant women. Plasma 4.99 NR 5.37 1.63 17.7 G€utzkow et al. (2012)
2007–2008 Norway n = 99, pregnant women. Plasma 5.5 NR 5.6 1.4 11.0 Granum et al. (2013)
2007–2009 Norway n = 391, pregnant women, age: mean 31
(18–43 years). Serum
8.03 NR 8.81 0.3 35.8 Berg et al. (2014)
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Year Country Study population
Median,
ng/mL
Geometric
mean,
ng/mL
Arithmetic
mean,
ng/mL
Min,
ng/mL
Max,
ng/mL
Reference
2012–2014 Norway n = 74, 59 consumers and 15 non-
consumers of ﬁsh from AFFF-affected
waters. Median age 58.5 years (range
32–79 years). Serum
27.4(HC)
13.2(NC)
28.0(HC)
9.56(NC)
44.6(HC)
14.5(NC)
10.1
(HC, P10)
1.76
(NC, P10)
127
(HC, P90)
32
(NC, P90)
Hansen et al. (2016)
2008–2009 Denmark n = 247, adult men. Mean age: 19.6 years.
Serum
7.79 NR 8.46 4.28
(P5)
14.59
(P95)
Joensen et al. (2013)
2011 Denmark n = 200 samples of serum from pregnant
women. Serum
8.4 NR 9.1 3.1 26 Vorkamp et al. (2014)
2010–2012 Denmark n = 392, newly pregnant women. Serum 8.10 NR NR 1.25
(P5)
26.12
(P95)
Jensen et al. (2015)
2011 Denmark n = 145, women, mean age: 41 years
(range 31–52 years). Plasma
7.57 NR 8.30 2.52 24.38 Mørck et al. (2015)
2008–2013 Denmark n = 1507, pregnant women, primiparous,
median age between 29 and 31 for the four
quartiles of participants. Serum
8.3 NR NR 6.0
(IQR)
10.8 (IQR) Bach et al. (2016)
2007–2009 Faroe
Islands
n = 487, pregnant women, mean age:
30.6 years. Serum
8.26 NR NR 6.22 (IQR) 10.71 (IQR) Timmermann et al. (2017)
2010–2013 Greenland n = 207 pregnant women age > 18 years,
Inuits. Serum
10.15 10.50 12.46 2.46 61.3 Long et al. (2015)
2008–2009 France n = 38 Pregnant women, mean age
34.6 years (range 26–45 years). Serum
2.9 NR 3.2 0.062 13 Porpora et al. (2013)
2008 France n = 478, age 18 and 75 years, males and
females, had current residence in targeted
areas and had a ﬁshing license. Serum
12.1 13.4 18.8 1.9 392.3 Denys et al. (2014)
2010–2013 France n = 100 pregnant women, median age of
32 years (20–46 years). Serum
3.065 NR 3.67 0.316 24.5 Cariou et al. (2015)
2007–2009 Germany n = 44, pregnant women, mean age:
33 years (range 21–43 years), samples
collected during pregnancy. Plasma
3.2 NR 3.5 NR NR Fromme et al. (2010)
2010 Germany n = 18, male and female, age 20–29 years.
Plasma
3.7 3.8 NR 1.9 12.1 Schr€oter-Kermani et al.
(2013)
2008 Italy n = 230; 109 women and 121 men, the age
ranged from 20 to 65 years. Serum
6.31 5.77 6.86 0.06 29.6 Ingelido et al. (2010)
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Year Country Study population
Median,
ng/mL
Geometric
mean,
ng/mL
Arithmetic
mean,
ng/mL
Min,
ng/mL
Max,
ng/mL
Reference
2011–2012 Italy n = 549 women, mean age: 27.7 (range
20–40 years). Serum
2.43** NR 3.06** 0.34** 58.9** De Felip et al. (2015)
2009–2010 Spain n = 46, males and females, age:
19–53 years. Whole blood
NR NR 0.77 0.09 3.35 Gomez-Canela et al.
(2015)
2010–2012 Slovakia n = 120. Pregnant women. Age range
18–45 years. Plasma
1.69 1.60 1.79 < LOQ(a) (NR) 3.3 Uhl (2016)
2010–2012 Austria n = 114. Pregnant women. Age range
18–45 years. Plasma
1.77 1.82 2.01 0.65 3.8 Uhl (2016)
2015 Czech
Republic
n = 300, men and women, mean age
40.8 years. Serum
2.43 2.29 NR 0.072 51.1 Sochorova et al. (2016)
PFOA
2007 Sweden n = 10, women, mean age; 48 years (range
36–56 years). Serum
2.93 NR NR NR NR Axmon et al. (2014)
2010–2011 Sweden n = 270, women, median age: 50 years
(range 22–75 years). Serum
2.25 NR NR 0.76
(P5)
5.05 (P95) Bjermo et al. (2013)
2008–2010 Sweden n = 153 males, mean age: 67 years
(53–79 years). Whole blood
1.9 1.8 2.0 0.35 6.4 Bao et al. (2014)
2007–2011 Sweden n = 201, men with prostate cancer. Median
age 67 years (range 49–79 years). Serum
2.0 NR 2.3 0.320 15 Hardell et al. (2014)
2007–2011 Sweden n = 186, men without prostate cancer.
Median age 67 years (range 50–79 years).
Serum
1.9 NR 2.0 0.345 8.4 Hardell et al. (2014)
2008–2011 Sweden n = 150, primiparous women, within the
third week after delivery. The County has a
known contamination of the drinking water
with PFAS. Mean age 30.2 years (range
21–40 years). Serum
1.5** NR 1.6** 0.2** 13** Gyllenhammar et al.
(2015)
2010 Sweden n = 36 pools of serum. Primiparous women
living in Uppsala county, donated serum
samples within the third week after delivery.
Age 19–41 years
NR NR NR 1.4 2.0 Glynn et al. (2012)
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Year Country Study population
Median,
ng/mL
Geometric
mean,
ng/mL
Arithmetic
mean,
ng/mL
Min,
ng/mL
Max,
ng/mL
Reference
2012 Sweden n = 3 pools primiparous women living in
Uppsala County, donated serum samples
within the fourth week after delivery. Serum
NR NR NR 1.29** 1.73** Gebbink et al. (2015)
2011–2014 Sweden N = 579, men and women, 80 years 2.5 2.5 2.8 0.33 15 Stubleski et al. (2016)
2007–2008 Norway n = 41, women, mean age: 36.7 years
(range 25–45 years). Serum
1.4 NR 2.0 0.28 22 Haug et al. (2011b)
2007–2008 Norway n = 123, pregnant women. Plasma 1.12 NR 1.25 0.36 4.24 G€utzkow et al. (2012)
2007–2008 Norway n = 99, pregnant women. Plasma 1.1 NR 1.1 0.2 2.7 Granum et al. (2013)
2007–2009 Norway n = 391, pregnant women, age: mean 31
(18–43 years) Serum
1.53 NR 1.70 0.28 11.0 Berg et al. (2014)
2012–2014 Norway n = 74, 59 consumers and 15 non-
consumers of ﬁsh from AFFF-affected
waters. Median age 58.5 years (range
32–79 years). Serum
2.42 (HC)
2.21 (NC)
2.40 (HC)
1.93 (NC)
2.55 (HC)
2.35 (NC)
1.43 (HC, 10P)
0.62 (NC, 10P)
3.80 (HC,
90P)
5.01 (NC,
10P)
Hansen et al. (2016)
2008–2009 Denmark n = 247, adult men. Mean age: 19.6 years.
Serum
3.02 NR 3.46 1.82
(P5)
6.15
(P95)
Joensen et al. (2013)
2011 Denmark n = 200 samples from pregnant women.
Serum
1.8 NR 2.2 0.31 9.7 Vorkamp et al. (2014)
2010–2012 Denmark n = 392, newly pregnant women. Serum 1.58 NR NR 0.31
(P5)
9.71
(P95)
Jensen et al. (2015)
2011 Denmark n = 145, women, mean age: 41 years
(range 31–52 years). Plasma
1.59 NR 1.8 0.35 8.19 Mørck et al. (2015)
2008–2013 Denmark n = 107, pregnant women, primiparous,
median age between 29 and 31 for the four
quartiles of participants. Serum
2.0 NR NR 1.5
(IQR)
2.6 (IQR) Bach et al. (2016)
2007–2009 Faroe
Islands
n = 487, pregnant women, mean age:
30.6 years. Serum
1.40 NR NR 0.95 (IQR) 1.95 (IQR) Timmermann et al. (2017)
2010–2013 Greenland n = 207, pregnant women age > 18 years,
Inuits. Serum
1.19 1.19 1.34 0.29 6.21 Long et al. (2015)
2008–2009 France n = 38, pregnant women, mean age
34.6 years (range 26–45 years). Serum
2.4 NR 2.9 0.2 9.1 Porpora et al. (2013)
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Year Country Study population
Median,
ng/mL
Geometric
mean,
ng/mL
Arithmetic
mean,
ng/mL
Min,
ng/mL
Max,
ng/mL
Reference
2008 France n = 478, age 18 and 75 years, males and
females, had current residence in targeted
areas and had a ﬁshing license. Serum
3.9 3.9 4.7 0.4 80.8 Denys et al. (2014)
2010–2013 France n = 100, pregnant women, median age of
32 years (20–46 years). Serum
1.045 NR 1.22 0.309 7.31 Cariou et al. (2015)
2007–2009 Germany n = 44, pregnant women, mean age:
33 years (range 21–43 years), samples
collected during pregnancy. Plasma
2.4 NR 2.6 NR NR Fromme et al. (2010)
2010 Germany n = 18, male and female, age 20–29 years.
Plasma
3.2 3.1 NR 0.8 8.7 Schr€oter-Kermani et al.
(2013)
2008 Italy n = 230; 109 women and 121 men, the age
ranged from 20 to 65 years. Serum
3.59 3.32 4.15 0.22 51.9 Ingelido et al. (2010)
2011–2012 Italy n = 549, women, mean age: 27.7 (range
20–40 years). Serum
1.55** NR 1.70** < LOQ(a)
(0.1)**
9.99** De Felip et al. (2015)
2009–2010 Spain n = 46, males and females, age:
19–53 years. Whole blood
NR NR 0.45 < LOQ(a)
(0.03)
1.08 Gomez-Canela et al.
(2015)
2010–2012 Slovakia n = 120, pregnant women. Age range
18–45 years. Plasma
4.88 4.05 5.57 0.9 17 Uhl (2016)
2010–2012 Austria n = 114, pregnant women. Age range
18–45 years. Plasma
1.70 1.65 1.78 < LOQ(a) (NR) 3.3 Uhl (2016)
2015 Czech
Republic
n = 300, men and women, mean age
40.8 years. Serum
0.756 0.716 NR 0.028 8.97 Sochorova et al. (2016)
AFFF: aqueous ﬁlm forming foam; P5: 5th percentile; P10: 10th percentile; P90: 90th percentile; P95: 95th percentile; HC: high consumers; NC: non-consumers; IQR: Interquartile range; NR: not
reported; LOQ: limit of quantiﬁcation; **: reported in ng/g; ***: Linear PFOS.
(a): The term LOQ has been used for both limit of quantiﬁcation, limit of detection and method detection limit.
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Table 7: Concentrations of PFOS and PFOS in general European children populations with serum or plasma samples collected from 2007–2008 and
onwards
Year Country Study population
Median,
ng/mL
Geometric
mean,
ng/mL
Arithmetic
mean,
ng/mL
Min,
ng/mL
Max,
ng/mL
Reference
PFOS (total)
2011 Denmark n = 145, children, mean age: 8.7 years (range 6–11 years).
Plasma
8.63 NR 9.02 2.77 23.01 Mørck et al. (2015)
2007–2009 Germany n = 44, infants, age: 6 months. Plasma 3.0 NR 3.3 NR 8.1
(P95)
Fromme et al. (2010)
2007–2009 Germany n = 24, infants, age: 19 months. Plasma 1.9 NR 2.2 NR 4.6
(P95)
Fromme et al. (2010)
2007–2008 Germany n = 112, children, mean age 6.6 years. Plasma 3.58 NR 3.93 1.70 17.7 Wilhelm et al. (2015)
2009–2010 Germany n = 101, children, mean age 8.5 years. Plasma 3.30 NR 3.69 1.34 16.5 Wilhelm et al. (2015)
2010–2011 Norway n = 112, toddlers, age: 3 years. Serum 4.63 4.76 NR 1.20 18.38 Papadopoulou et al. (2016)
2012–2013 Italy n = 25, children and adolescents, with diabetes type 1,
mean age 8.04 years (range 3.15–13.1 years). Serum
0.95 1.09 1.53 0.48 6.68 Predieri et al. (2015)
2012–2013 Italy n = 19, children and adolescents, control group, mean age
8.04 years (range 1.88–13.6 years). Serum
0.49 0.54 0.56 0.47 0.93 Predieri et al. (2015)
PFOA
2011 Denmark n = 145, children, mean age: 8.7 years (range 6–11 years).
Plasma
3.02 NR 3.20 1.40 6.65 Mørck et al. (2015)
2007–2009 Germany n = 44, infants, age: 6 months. Plasma 6.9 NR 8.0 NR 19.5
(P95)
Fromme et al. (2010)
2007–2009 Germany n = 24, infants, age: 19 months. Plasma 4.6 NR 5.1 NR 11.4
(P95)
Fromme et al. (2010)
2007–2008 Germany n = 112, children, mean age 6.6 years. Plasma 4.58 NR 5.01 1.77 12.1 Wilhelm et al. (2015)
2009–2010 Germany n = 101, children, mean age 8.5 years. Plasma 3.56 NR 3.88 1.93 7.98 Wilhelm et al. (2015)
2010–2011 Norway n = 112, toddlers, age: 3 years. Serum 2.63 2.77 NR 0.99 8.89 Papadopoulou et al. (2016)
2012–2013 Italy n = 25, children and adolescents, with diabetes type 1,
mean age 8.04 years (range 3.15–13.1 years). Serum
0.49 0.52 0.53 0.46 0.83 Predieri et al. (2015)
2012–2013 Italy n = 19, children and adolescents, control group, mean age
8.04 years (range 1.88–13.6 years). Serum
0.48 0.50 0.50 0.45 0.67 Predieri et al. (2015)
P95: 95th percentile; NR: not reported.
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3.3.2.4. Levels in blood from occupationally exposed adults
Elevated serum concentrations have been observed in ﬂuorochemical production workers (Olsen,
2015), with mean concentrations of both PFOS and PFOA in the range of 500–7,000 ng/mL (Fromme
et al., 2009). A detailed discussion on levels in ﬂuorochemical production workers can be found in
Olsen (2015).
Two Nordic studies have reported elevated concentrations of PFOA in serum from professional ski
waxers compared to background exposed adults. A median PFOA concentration of 112 ng/mL whole
blood (range 4.8–535 ng/mL) was observed in the Swedish study (Nilsson et al., 2010) and 50 ng/mL
serum (range 20–174 ng/mL) in the Norwegian study (Freberg et al., 2010).
In a study from Australia, elevated serum concentrations of PFOS (median of 66 ng/mL) were
observed in ﬁreﬁghters when compared to the general population (Rotander et al., 2015) Furthermore
increased PFOA concentrations were reported in blood from US ﬁreﬁghters (Tao et al., 2008; Shaw
et al., 2013; Dobraca et al., 2015).
3.3.2.5. Levels in blood from populations with elevated drinking water exposure
Elevated concentrations of PFOS and PFOA have been observed in several US communities, which
have been affected by environmental releases that have contaminated the drinking water. In an area
in Minnesota (USA) where the levels in the drinking water in some wells were above the state’s health
risk limits for PFOA and/or PFOS, the geometric mean serum concentrations for persons drinking water
from the wells were three to four times higher for PFOS and PFOA than what has been reported in the
general US population (MDH, 2012). A similar situation was registered in Alabama (USA), where two to
four times higher serum concentrations of PFOS and PFOA when compared to the general US
population were observed (ATSDR, 2013). In the Mid-Ohio River Valley in the USA, six water districts
were contaminated with PFOA. In an extensive assessment of blood from almost 67,000 persons, the
geometric mean concentration for PFOA was more than ﬁve times higher than the concentrations
reported in the general adult population (Frisbee et al., 2009).
In Arnsberg, Germany an area with elevated drinking water levels was identiﬁed (Skutlarek et al.,
2006). Following this, a biomonitoring study was conducted and elevated concentrations of PFOA with
geometric mean concentrations of 23.4, 23.6 and 30.3 ng/mL for children, women and men,
respectively were observed (H€olzer et al., 2008). Several measures were introduced, and two years
later the levels had declined with 39% and 26% for women/children and men, respectively (Brede
et al., 2010). Another episode of contamination of drinking water has been reported in Ronneby
County, Sweden. In a ﬁrst screening, blood samples from adults and children were analysed and
Table 8: Summary statistics describing serum concentrations of PFOS and PFOA in European adult
and children populations based on studies included in Tables 6 and 7 (2007–2015)
Concentration in ng/mL(a)
Adults Children
PFOA PFOS PFOA PFOS
Statistics based on
medians reported
in studies included
in Tables 6 and 7
Median 1.9 7.7 3.3 3.2
Mean 2.1 7.5 3.3 3.3
Minimum 0.76 1.7 0.49 0.49
Maximum 4.9 27.4 6.9 8.6
Number of studies 32 32 8 8
Information based
on individual
samples reported
in studies included
in Tables 6 and 7
Minimum individual
samples
0.03 0.06 0.45 0.47
Maximum individual
samples
80.8 392.3 19.5 (P95) 23.0
Country reporting
maximum
individual samples
France France Germany Denmark
Reference for
maximum
Denys et al.
(2014)
Denys et al.
(2014)
Fromme et al.
(2010)
Mørck et al.
(2015)
P95: 95th percentile.
(a): For studies reporting the concentrations ng/g it was assumed that 1 g = 1 mL of serum/plasma.
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elevated levels of a number of PFASs were found. Concentrations up to around 60 and 1,200 ng/mL
were observed for PFOA and PFOS, respectively (Jakobsson et al., 2014).
These episodes with environmental releases resulting in increased exposure to the general
populations, reveals that even though most general populations worldwide are exposed to PFOS and
PFOA to a similar extent, a considerably higher exposure might be experienced (Post et al., 2012).
3.3.2.6. Factors that may have an impact on the internal dose
Humans are exposed to PFOS and PFOA from the conception throughout their lives. Several studies
have measured concentrations of these contaminants in paired samples of maternal blood and cord
blood, demonstrating considerable transplacental transfer and high correlations between maternal and
cord blood (Apelberg et al., 2007a; Kim et al., 2011a; G€utzkow et al., 2012; Ode et al., 2013; Porpora
et al., 2013; Zhang et al., 2013b; Zhang and Qin, 2014; Fisher et al., 2016). After birth, breast milk
has been identiﬁed as a major source of exposure to PFOS and PFOA (Fromme et al., 2010; Haug
et al., 2011b; Papadopoulou et al., 2016). Pre- and postnatal exposure has also been described in a
two-generation pharmacokinetic model, which was validated using measured concentrations in children
(Verner et al., 2016). The model showed that the daily intake through breastfeeding and the internal
PFOS and PFOA concentrations can be much higher in nursing infants than in mothers.
No clear regional differences in exposure to PFOS and PFOA have been observed for general
populations. However, there are indications of lower prevalence of these compounds in low-income
countries (Kannan et al., 2004; Fromme et al., 2009). Several biological factors may inﬂuence the body
burden of PFOS and PFOA, including age, gender and ethnicity. An increase of contaminant levels in
body ﬂuids with age has been well documented for polychlorinated legacy POPs, such as PCBs (Laden
et al., 1999), however for PFOS and PFOA, the age dependency seems to be more questionable
(Fromme et al., 2009). As described by Nøst et al. (2014), age dependency is complicated to assess as
the exposure to these contaminants has changed over time, and thus it is difﬁcult to distinguish
between the effect of changes in the exposure and accumulation due to age. Furthermore, several
other factors also have an impact on the PFAS levels, and thus complicates the assessments of age
dependency. However, as several of these compounds have long elimination half-lives (see
Section 3.3.1), accumulation with age is anticipated. On the other hand, the exposure to infants and
toddlers might be higher than the exposure to adults, among others because of low body weight for
infants and toddlers, resulting in higher blood levels for children compared to adults.
Differences in blood concentrations of PFOS and PFOA between sexes have been observed in a
large number of studies (Fromme et al., 2009; Ingelido et al., 2010; Haines and Murray, 2012; Bjermo
et al., 2013), with levels in females usually being lower than in males. Sex-related differences in
exposure (Kato et al., 2015), physiological differences including urinary elimination due to renal
reabsorption (Han et al., 2012), menses (Wong et al., 2014), pregnancy and lactation (Brantsaeter
et al., 2013) are likely causes of this. Studies from the US indicate ethnic differences in body burdens
of PFOS and PFOA, with mean serum concentrations of Mexican Americans being lower compared to
non-hispanic whites (Calafat et al., 2007; Khalil et al., 2016). Inconsistent results on associations
between PFOS and PFOA concentrations in blood and body weight/body mass index (BMI) for adults
have been reported. Some studies have reported inverse associations (Eriksen et al., 2011; Kato et al.,
2014; Lauritzen et al., 2016), while others have found positive (Halldorsson et al., 2008) or no
associations (Rylander et al., 2009). Several studies have assessed the impact of socio-economical
status on the concentrations of PFOS and PFOA in blood. Many studies have found increasing PFOS
and PFOA concentrations with increasing income (Calafat et al., 2007; Nelson et al., 2012; Brantsaeter
et al., 2013; Jain, 2014; Kato et al., 2014; Sagiv et al., 2015), while the inﬂuence of education is not
as consistent (Apelberg et al., 2007b; Calafat et al., 2007; Halldorsson et al., 2008; Nelson et al.,
2012; Brantsaeter et al., 2013; Jain, 2014; Kato et al., 2014; Sagiv et al., 2015).
3.3.2.7. Linear and branched isomers
As has been described above (see Section 1.3.1) PFOS and PFOA may exist as both linear and
branched isomers, whereof some of the branched isomers are chiral compounds. In most
biomonitoring studies, the sum of linear and branched isomers are reported. However, determining
isomer patterns have been of particular interest for exploring sources of exposure (Martin et al., 2010;
Miralles-Marco and Harrad, 2015). Miralles-Marco and Harrad (2015) have summarised the relative
proportion of linear PFOS in blood from various studies, and found that it could vary from around 50%
to 80%. In contrast, the relative proportion of linear PFOA in blood was found to be around 98%
(Beesoon et al., 2011).
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3.3.2.8. Summary
To summarise, the most commonly used matrix for biomonitoring of PFOS and PFOA is blood, and
speciﬁcally serum or plasma. Following an increase from the early 1970s, decreasing concentrations of
these two compounds have been observed in many time trend studies after the year 2000. For PFOS,
the medians of the median concentrations in serum/plasma in the studies included in this opinion are
7.7 ng/mL (range 0.06–392.3 ng/mL) and 3.2 ng/mL (range 0.47–23.0 ng/mL) for adults and children,
respectively. Similarly, medians of the median concentrations for PFOA are 1.9 ng/mL (range
0.03–80.8 ng/mL) and 3.3 ng/mL (range 0.45–19.5 (95th percentile) ng/mL). As can be seen from the
range, for some individuals in general populations, much higher concentrations of PFOS and PFOA
have been reported, and this is also the case for occupationally exposed adults as well as for persons
experiencing elevated exposure from for instance contaminated drinking water. Several other factors
may have an inﬂuence on the concentrations measured in serum or plasma, such as; age, gender and
socio-economical status.
3.3.3. Toxicity in experimental animals
With a few exceptions, information is missing whether linear or branched forms of PFASs were
applied in acute, subchronic and chronic toxicity studies, as outlined below.
3.3.3.1. Acute toxicity
In the EFSA, 2008 scientiﬁc opinion on PFOS, PFOA and their salts (EFSA, 2008), an oral LD50 value
for PFOS of 251 mg/kg bw was reported for CD rats. Oral LD50 values of PFOA were found to be 680
and 430 mg/kg bw in male and female CD rats, respectively. The target organ identiﬁed was the liver.
A further study conﬁrmed an oral LD50 > 500 mg/kg bw in male rats and an LD50 between 250 and
500 mg/kg bw in female animals (EFSA, 2008). Table 9 lists the available acute toxicity studies for
PFOS and PFOA published since 2007. In accordance with the previous EFSA, 2008 opinion, it can be
concluded that PFOS and PFOA have moderate acute toxicity after oral administration.
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Table 9: Acute studies
Substance (Purity) Species/dose route/doses Most sensitive endpoints
Highest dose
with no effect
(mg/kg bw)
Signiﬁcant
effect level
(mg/kg bw)
LD50
mg/kg
bw
Reference
PFOS
PFOS (potassium salt,
86.9% purity)
Sprague–Dawley rats (f)
No/sex/group: 5–15
Single oral application: 0 or 15 mg/kg bw
Decreases in serum total T3,
T4 and reverse T3 within
24 h
N/A 15 N/A Chang et al.
(2008)
PFOS (potassium salt,
≥ 98% purity)
Wistar rats (m)
No/sex/group: 2–3
Single oral application: 0, 125, 250, or
500 mg/kg bw
Ultrasound-evoked
convulsions
125 250 > 250
< 500
Sato et al. (2009)
PFOS (potassium salt,
≥ 98% purity)
ICR mice (m)
No/sex/group: 2–3
Single oral application: 0, 125, 250, or
500 mg/kg bw
Ultrasound-evoked
convulsions
N/A 125 ~ 500 Sato et al. (2009)
PFOS (98% purity) C57Bl/6 mice (m)
No/sex/group: 10
Oral gavage: 0, 300, 400, 500, 600, or
700 mg/kg bw
N/A N/A N/A 579 Xing et al. (2016)
PFOA
PFOA (free acid, 96%
purity)
C57Bl/6 mice (m)
No/sex/group: 4–5
Single i.p. administration: 0 or 40 mg/kg bw
Decr mRNA and protein of
Oatp1a1
Oatp1a4, Oatp1b2
N/A
40
40
N/A Cheng and
Klaassen (2008a)
PFOA (96% purity) C57Bl/6 mice (m)
No/sex/group: 5
single i.p. administration: 0 or 40 mg/kg bw
Incr mRNA and protein of
Cyp2B
Cyp4A
N/A
40
40
N/A Cheng and
Klaassen (2008b)
PFOA (> 90% purity) Wistar rats (m)
No/sex/group: 2–3
Single oral application:
250–1,000 mg/kg bw
N/A 1,000 N/A N/A Sato et al. (2009)
bw: body weight; f: female; i.p.: intraperitoneal; m: male; N/A: not applicable; PFOA: perﬂuorooctanoic acid; PFOS: perﬂuorooctane sulfonic acid; T3: triiodothyronine; T4: thyroxine.
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3.3.3.2. Repeated dose toxicity
3.3.3.2.1. PFOS
In the EFSA, 2008 opinion (EFSA, 2008), the liver was considered to be the major target organ for
repeated dose toxicity of PFOS in rodent studies, as indicated by increased liver weight, vacuolisation and
hypertrophy of hepatocytes, and induction of peroxisomal b-oxidation. PFOS was also found to reduce
body weight and serum levels of cholesterol, triglycerides and triiodothyronine. Male rats appeared to be
more sensitive than females. A study on cynomolgus monkeys served to determine the earliest
measurable response of primates to PFOS exposure and to reduce uncertainty in human health risk
assessment. Male and female animals received the potassium salt of PFOS at 0, 0.03, 0.15 or 0.75 mg/kg
bw per day for 26 weeks (Seacat et al., 2002). Only the 0.75 mg/kg bw per day dose exerted toxicity,
such as mortality of one-third of male monkeys, decreased body weights, increased liver weights with
hepatocellular hypertrophy and vacuolation, lowered serum total cholesterol, lowered triiodothyronine
concentrations (without evidence of hypothyroidism), and lowered oestradiol levels. In the liver, no
evidence for peroxisomal or cell proliferation could be obtained. No adverse effects occurred at a dose of
0.03 mg/kg bw per day. At 0.15 mg/kg bw per day some serum parameters were altered occasionally,
such as inorganic phosphate or total thyroxine. In the EFSA, 2008 opinion (EFSA, 2008) it was concluded
that monkeys show a steep dose response and are more sensitive than rats.
Since the release of the EFSA opinion numerous further studies on repeated dose toxicity have
been published. These are listed in Table 10.
Most studies focused on hepatic effects of PFOS. Elevated relative liver weight and induction of
enzymes, being indicative of enhanced peroxisomal b-oxidation, could be seen in a consistent way.
The most sensitive parameter observed was a statistically signiﬁcant increase in the relative liver
weight in female Sprague–Dawley rats, occurring at a dose of 0.15 mg/kg bw per day after 28 days of
treatment (Curran et al., 2008). This increase was based on a clear dose-dependent increase in
absolute liver weight, which reached signiﬁcance at the next higher dose of 1.43 mg/kg bw per day.
Similar observations are reported by Yu et al. (2009) at 0.25 mg/kg bw in male rats after 91 days of
treatment. With regard to further effects in the liver, elevated peroxisomal b-oxidation could be
observed at doses of 1.3–3.7 mg/kg bw after 28 days of treatment in rats of both sexes (Curran et al.,
2008; Elcombe et al., 2012). Elevated intrahepatic lipid levels, and increased liver enzymes and
lowered lipids in the serum occur mostly at somewhat higher doses.
Two studies compared the effects in male and female rats, i.e. Curran et al. (2008) observed
similar serum and liver concentrations of PFOS in both sexes and also the impact on liver
transaminases was comparable between male and female rats. Kim et al. (2011b) did not ﬁnd any
gender difference with regard to the induction of relative liver weight. In males, elevated Cyp4A1
mRNA was observed at 5 mg/kg bw per day.
A further sensitive parameter appears to be the decrease of serum T4 levels occurring at 0.25 mg/kg
bw per day in male rats after 91 days of treatment (Yu et al., 2009). The authors stated that induction
of hepatic enzymes, involved in the metabolism of thyroid hormones, could account for this effect.
In summary, the rodent liver appears to be the major target organ for repeated dose toxicity of
PFOS, as indicated by increased liver weight, hypertrophy of hepatocytes, and induction of peroxisomal
b-oxidation, which agrees with the EFSA opinion of 2008 (EFSA, 2008).
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Table 10: Repeated dose toxicity studies for PFOS
Substance
(Purity)
Species/Experimental design
and doses
Most sensitive
endpoints
Highest dose with
no effect (mg/kg
bw per day)
Signiﬁcant
effect level
(mg/kg bw
per day)
Serum/tissue level of PFOS Reference
PFOS (potassium
salt, linear form,
≥ 98% purity)
Sprague–Dawley rats (m,f)
No/sex/group: 15
Duration: 28 days
Diet: 2, 20, 50 or 100 mg/kg in
chow;
(equivalent to: 0, 0.14, 1.33, 3.21
or 6.34 mg/kg bw per day for
males;
0, 0.15, 1.43, 3.73 or 7.58 mg/kg
bw per day for females)
Incr rel liver weight (m)
Incr rel liver weight (f)
Decr serum T4 level (m, f)
Decr serum cholesterol (f)
Incr mRNA of Cyp4A22 (m)
Incr mRNA of ACOX 1 (m)
Incr mRNA of ACOX 1
Cyp4A22, (f)
0.14
N/A
0.14/0.15
1.43
0.14
1.33
1.43
1.33
0.15
1.33/1.43
3.73
1.33
3.21
3.73
Concentration (in lg/g) in males:
At 0.14 mg/kg bw per day in
serum 0.95  0.13
liver 48.3  5.8
At 1.33 mg/kg bw per day in
serum 13.5  1.5
liver 560  104
Concentration (in lg/g) in
females:
At 0.15 mg/kg bw per day in
serum 1.5  0.23
liver 43.4  6.8
At 1.43 mg/kg bw per day in
serum 15.4  1.6
liver 717  59
At 3.73 mg/kg bw per day in
serum 31.9  3.6
liver 597  158
Curran et al.
(2008)
PFOS (potassium
salt, 98% purity)
Sprague–Dawley rats (m)
No/sex/group: 10
Duration: 28 days
Gavage: 0, 5, 20 mg/kg bw per
day
Incr relative liver weight
Incr relative kidney weight
Incr relative testis weight
N/A 5
5
5
Concentration (in lg/g or mL) at
5 mg/kg bw per day:
Blood. 72  25.7
Liver: 345  40
Kidney: 93.9  13.6
Lung: 46.6  17.8
Heart: 168  17.
Testis: 39.5  10
Brain: 13.6  1
Cui et al.
(2009)
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Substance
(Purity)
Species/Experimental design
and doses
Most sensitive
endpoints
Highest dose with
no effect (mg/kg
bw per day)
Signiﬁcant
effect level
(mg/kg bw
per day)
Serum/tissue level of PFOS Reference
PFOS (tetrabutyl
ammonium salt,
98% purity)
C57Bl/6 (H-2) mice (m) No/sex/
group: 4
Duration: 10 days
Diet: 0, 0.001%, 0.005%, 0.02%;
(equivalent to 2, 10, 40 mg/kg bw
per day)
Incr liver weight
Decr spleen weight
Decr thymus weight
Decr body weight
Decr body fat weight
2
10
10
10
10
10
40
40
40
40
Concentration (in lg/g or mL) in
serum at
0 mg/kg bw per day:
0.029  0.01
2 mg/kg bw per day: 50.8  2.5
10 mg/kg bw per day:
96.7  5.2
40 mg/kg bw per day: 340  16
Qazi et al.
(2009a)
PFOS (potassium
salt, purity not
speciﬁed, Fluka)
Wistar rat (m)
No/sex/group: 5–6
Duration: 13 weeks
Diet: 0, 2, 8, 32 or 128 ppm
(equivalent to 0, 0.1–0.2, 0.4–0.8,
1.5–3.5, 5.6–13.9 mg/kg bw per
day)
Decr body weight
Incr rel liver weight
Incr rel brain weight
0.4–0.8
0.41
0.41
1.5–3.5
1.6
1.6
Concentrations in (mg/kg) at
PFOS doses of 0.4–0.8 mg/kg bw
per day:
Serum: 44.1  5.6
Brain: 6.9  1.4
Liver: 135  42.7
Kidney: 36  11.2
Concentrations in (mg/kg) at
PFOS doses of 1.5–3.5 mg/kg bw
per day:
Serum: 177  20
Brain: 22.3  114
Liver: 647  113
Kidney: 188  46.8
Kawamoto
et al. (2011)
PFOS (potassium
salt, > 98% purity,
3M)
Sprague–Dawley rats (m/f)
No/sex/group 12
Duration: 28 days
Gavage: 0, 1.25, 5, 10 mg/kg bw
per day
Incr relative liver weight
(m, f)
Incr mRNA of f CYP4A1 (m)
Incr serum aspartate
aminotransferase (AST) (m)
5
1.25
5
10
5
10
Kim et al.
(2011b)
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Substance
(Purity)
Species/Experimental design
and doses
Most sensitive
endpoints
Highest dose with
no effect (mg/kg
bw per day)
Signiﬁcant
effect level
(mg/kg bw
per day)
Serum/tissue level of PFOS Reference
PFOS (potassium
salt, 86.9%
purity)
Sprague–Dawley rats (m)
No/sex/group: 10
Duration: 1, 7, 28 days
Diet: 20 or 100 ppm;
(equivalent to 0, 1.7  0.3 and
7.9  2.1 mg/kg bw per day)
Incr hepat. ACOX activity
(day 28)
Incr rel liver weight (day 28)
Incr hepat. proliferation
(day 7)
Incr hepat. proliferation
(day 28)
Incr hepat. apoptotic index
(day 7)
Decr serum cholesterol
(day 28)
N/A
N/A
N/A
1.7
N/A
N/A
1.7
1.7
1.7
7.9
1.7
1.7
Concentrations (lg/g or lg/mL)
at 2.4 mg/kg bw per day in
Serum: 34.9  3.9 (day 7) and
94.3  11.6 (day 28)
Liver: 70.1  11 (day 7) and
235.3  20.9 (day 28)
Elcombe
et al. (2012)
PFOS (98%
purity)
CD-1 mice (m)
No/sex/group: 4
Duration: 3,7,14,21 days
Gavage: 0, 1, 5, 10 mg/kg bw per
day
Incr rel liver weight (day 7)
Incr total hep triglycerides
(day 7, 21)
Decr serum LDL/VLDL level
(day 21)
Incr hepat. ACOX mRNA
(day 7)
N/A
1
1
1
1
5
5
5
NR Wan et al.
(2012)
PFOS (> 98%
purity)
Balb/c mice (m)
No/sex/group: 4
Duration: 14 days
Gavage: 0, 5 or 20 mg/kg bw per
day
Incr abs and rel liver weight
Incr hepatic lipid
concentration
Decr serum HDL-cholesterol
Decr serum triglycerides,
cholesterol, LDL-cholesterol
N/A
N/A
N/A
5
5
5
5
20
NR Wang et al.
(2014a)
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Substance
(Purity)
Species/Experimental design
and doses
Most sensitive
endpoints
Highest dose with
no effect (mg/kg
bw per day)
Signiﬁcant
effect level
(mg/kg bw
per day)
Serum/tissue level of PFOS Reference
PFOS (98%
purity)
C57BL/6J mice (m) No/sex/group:
10
Duration: 30 days
Gavage: 0, 2.5, 5, 10 mg/kg bw
per day
Incr rel liver weight
Incr ALP
Incr AST
Incr ALT
Incr GGT
N/A
2.5
N/A
2.5
N/A
2.5
5
2.5
5
2.5
Serum concentrations (lg/mL)
at 2.5 mg/kg bw day: 70.2  2.4
at 5 mg/kg bw per day:
130.6  6.5
Xing et al.
(2016)
PFOS (> 98%
purity, linear form)
Sprague–Dawley rats (m)
No/sex/group: 8–10
Duration: 91 days
Drinking water: 0, 1.7, 5 or
15 mg/L
(equivalent to 0.09, 0.25 or
0.75 mg/kg bw per day(a))
Incr rel & abs liver weight
Decr total serum T4
Decr mRNA of hepatic
deiodinase 1
Incr mRNA of hepatic
UGT1A
0.09
0.09
0.25
0.09
0.25
0.25
0.75
0.25
Serum concentrations (lg/mL)
at 0.09 mg/kg bw per day:
5  0.3
at 0.25 mg/kg bw per day:
33.6  2.1
at 0.75 mg/kg bw per day:
88.2  4.2
Yu et al.
(2009)
PFOS (> 98%
purity, linear form)
Wistar rats (f)
No/sex/group: 12–13
Duration: 5 days
Gavage: 0, 0.2, 1 or 3 mg/kg bw
per day
Decr total serum T4
Decr total serum T3
Incr mRNA of hepatic Oatp2
0.2
1
1
1
3
3
Serum concentrations (lg/mL)
at 0.2 mg/kg bw per day:
1.1  0.1
at 1 mg/kg bw per day:
8.2  0.1
at 3 mg/kg bw per day:
33.5  1.8
Yu et al.
(2011)
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Substance
(Purity)
Species/Experimental design
and doses
Most sensitive
endpoints
Highest dose with
no effect (mg/kg
bw per day)
Signiﬁcant
effect level
(mg/kg bw
per day)
Serum/tissue level of PFOS Reference
PFOS (87% purity,
from 3M)
C57Bl/6 mice (m)
No/sex/group: 5–6
Duration: 21–23 days
Diet: 0, 0.003%, 0.006%, 0.012%
(equivalent to 6, 12 or 24 mg/kg
bw per day(a))
Incr rel liver weight
Incr serum ALT
Hepatic steatosis
Incr hepatic triglycerides
N/A
N/A
N/A
N/A
6
6
6
6
NR Zhang et al.
(2016a)
ACOX: acyl-CoA oxidase; ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; bw: body weight; f: female; GGT: gamma-glutamyl transferase; HDL: high-
density lipoproteins; LDL: low-density lipoproteins; m: male; N/A: not applicable; NR: not reported; Oatp: organic anion-transporting polypeptide; PFOA: perﬂuorooctanoic acid; PFOS:
perﬂuorooctane sulfonic; T3: triiodothyronine; T4: thyroxine; UGT: uridine 50-diphospho-glucuronosyl transferase; VLDL: very low-density lipoprotein.
(a): Calculated using EFSA default values (EFSA, 2012).
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3.3.3.2.2. PFOA
In the EFSA opinion 2008 (EFSA, 2008), the liver was considered to be the major target organ for
subacute toxicity of PFOA in rodent studies, as indicated by increased relative liver weight and the
induction of hepatic peroxisomal b-oxidation. A special focus was given to studies on cynomolgus
monkeys to eliminate uncertainties in human health risk assessment. In a 90-day oral toxicity study on
rhesus monkeys applying doses of 0, 3, 10, 30 and 100 mg/kg bw per day, PFOA resulted in mortality
of all monkeys at week 5, at 100 mg/kg bw per day, and three monkeys from the 30 mg/kg bw per
day group at week 3 (Goldenthal et al., 1978). In another study, male cynomolgus monkeys received
PFOA at 0, 3, 10 or 30 (reduced to 20) mg/kg bw per day for 26 weeks (Butenhoff et al., 2002). The
liver weight was increased dose dependently due to mitochondrial proliferation. Signs of liver injury
were not found at either 3 or 10 mg/kg bw per day, while hepatic damage and reduced body weight
became evident at 30/20 mg/kg bw per day. There were no further treatment-induced changes. A
NOAEL could not be derived, due to increased liver weight at 3 mg/kg bw per day. It was concluded
that the liver appears to be a target organ of PFOA also in primates. In the EFSA opinion 2008 the
lowest NOAEL identiﬁed was 0.06 mg/kg bw per day, derived from a subchronic study in male rats. In
this study (Perkins et al., 2004), animals were treated with 0, 0.06, 0.64, 1.94 and 6.5 mg/kg bw per
day for 13 weeks. Elevated absolute and relative liver weights, an induction of peroxisomal b-oxidation
and mild hepatocellular hypertrophy were seen at 0.64 mg/kg bw per day.
Since the release of the EFSA opinion in 2008 additional studies on repeated dose toxicity of PFOA
have been published. These are listed in Table 11.
Studies in rats and mice from 2008 onwards conﬁrmed that the liver is the main target organ for
PFOA induced toxicity, as indicated by increased relative liver weights. Son et al. (2008) observed a
LOAEL of 0.49 mg/kg bw per day for increases in relative liver weight in mice. Elevated liver enzymes
in serum occurred at doses of about 2.5 mg/kg bw per day in mice in two independent studies (Son
et al., 2008; Yang et al., 2014). Evidence for liver damage was also obtained by enhanced lipid
peroxidation, as indicated by elevated hepatic malondialdehyde concentrations at daily doses of
2.5 mg/kg bw per day (Yang et al., 2014). Some alterations in kidney and serum thyroid hormone
levels were observed at higher PFOA doses. All studies used male animals impairing any comparison
between sexes. PFOA elevated the relative liver weight and exhibited similar serum concentrations in
rats and mice at a similar dose range, indicating that both species appear to have the same sensitivity
towards PFOA.
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Table 11: Repeated dose toxicity studies for PFOA
Substance
(Purity)
Species/Experimental design
and doses
Most sensitive
endpoints
Highest dose with
no effect (mg/kg
bw pe day)
Signiﬁcant effect
level (mg/kg bw
per day)
Serum/tissue level of
PFOA
Reference
PFOA (ammonium
salt, > 98%
purity)
ICR mice (m)
No/sex/group: 5–6
Duration: 21 days
Drinking water: 0, 2, 10, 50 or
250 mg/L;
(equivalent to 0, 0.49  0.04,
2.64  0.15, 17.63  1.15,
47.21  3.57 mg/kg bw per day)
Incr rel liver
weight
Incr serum ALT
N/A
0.49
0.49
2.64
NR Son et al. (2008)
PFOA (96%
purity)
Sprague–Dawley rats (m)
No/sex/group: 10
Duration: 28 days
Gavage: 0, 5, 20 mg/kg bw per
day
Incr rel liver
weight
Incr rel kidney
weight
Incr rel testis
weight
N/A
N/A
N/A
5
5
5
Concentration (in lg/g or mL)
at 5 mg/kg bw per day:
Blood. 39.2  14.4
Liver: 218  21
Kidney: 228  37
Lung: 63  11.3
Heart: 35.5  17.66
Testis: 16.7  16.9
Brain: 10.5  9.8
Cui et al. (2009)
PFOA (ammonium
salt, > 98%
purity)
29S4/SvlmJ mice (m)
No/sex/group: 9–10
Duration: 4 weeks
Gavage: 0, 12.5, 25, 50 lmol/kg
bw per day; (equivalent to 0, 5.4,
10.8, 21.5 mg/kg bw per day)
Incr rel liver
weight
Incr ALT
Incr serum
triglycerides
Decr serum
cholesterol
N/A
N/A
N/A
5.4
5.4
5.4
5.4
10.8
Concentration (in lg/g or mL)
at 5.4 mg/kg bw per day:
Blood. 20.6  2.4
Liver: 181.2  6.3
at 10.8 mg/kg bw per day:
Blood. 46.9  3.2
Liver: 198.8  15.4
at 21.5 mg/kg bw per day:
Blood. 64.2  6.5
Liver: 211.6  13.3
Minata et al. (2010)
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Substance
(Purity)
Species/Experimental design
and doses
Most sensitive
endpoints
Highest dose with
no effect (mg/kg
bw pe day)
Signiﬁcant effect
level (mg/kg bw
per day)
Serum/tissue level of
PFOA
Reference
PFOA (> 96%
purity)
Balb/c mice (m)
No/sex/group: 4
Duration: 14 days
Gavage: 0, 5, 10 or 20 mg/kg bw
per day
Incr relative liver
weight
Decr serum
triglycerides
N/A
5
5
10
NR Wang et al. (2013a)
PFOA (96%
purity)
Kunming mice (m)
No/sex/group: 4
Duration: 14 days
Gavage: 0, 2.5, 5, 10 mg/kg bw
per day
Incr relative liver
weight
Incr serum ALT
Incr hepatic
malondialdehyde
level
N/A
N/A
N/A
2.5
2.5
2.5
NR Yang et al. (2014)
ALT: alanine aminotransferase; bw: body weight; m: male; N/A not applicable; NR not reported; PFOA: perﬂuorooctanoic acid; PFOS: perﬂuorooctane sulfonic acid.
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3.3.3.3. Developmental and reproductive toxicity
3.3.3.3.1. PFOS
In the EFSA, 2008 opinion (EFSA, 2008), a review article on developmental toxicity (Lau et al., 2004),
and an OECD report (2002) were reviewed. Data were available from different animal species including
rabbits, mice and rats, the latter being used in a two-generation study. EFSA (2008) summarised effects
regarding fetal or neonatal survival or defects that are generally detected below doses at which maternal
toxicity occurs with the exception of perhaps one study in New Zealand white rabbits (Case et al., 2001).
Reduction in fetal weight, cleft palate, anasarca, bone effects and cardiac abnormalities were observed.
Dose–response curves were steep, with a high mortality rate being observed early after birth. Studies
aiming to determine sensitive windows of development, point to a late gestational period as being
particularly sensitive. The authors of the study in question were able to derive LOAELs, NOAELs and or
were able to perform benchmark dose analysis. The values for parental effects were more sensitive than
those obtained for effects in F1 and F2 generations of a two-generation reproduction study. The most
sensitive LOAEL of 0.4 mg/kg bw per day and corresponding NOAEL of 0.1 mg/kg bw per day was
derived for overall parental effects (Luebker et al., 2005). This study was used by FSANZ to derive a TDI
of 20 ng/kg bw per day (FSANZ, 2017). This TDI was based on decreased parental and offspring body
weight gain which became apparent in this multigeneration reproductive toxicity study in rats. Because of
the marked variation in the half-life of PFOS amongst species, authors applied a pharmacokinetic
modelling approach on the use of the NOAEL. Furthermore, a default uncertainty factor was set to
account for pharmacokinetic differences. The CONTAM Panel noted that the compound used in the study
by Luebker et al. (2005) had a purity of 86.9%, raising the question of whether the observed effects and
their magnitude are due to PFOS exposure only.
The following sections review the literature after the publication of the EFSA opinion in 2008, and
Table 12 summarises the studies listed here.
Neonatal survival and teratology
ICR mice which were orally exposed by gavage during gestation (GDs 0–18) to 0, 1, 10 and 20 mg/kg
bw per day of PFOS (K+ salt) produced a number of developmental defects which were detectable both in
prenatal and postnatal outcomes. All neonates were alive at birth and died within hours, probably from
lung atelectasis and severe dilatation of intracranial blood vessels as suggested from histological
examination of tissues from neonates (Yahia et al., 2008). For dams exposed to 20 mg/kg bw per day, a
reduction in body weight gain from PND 11 onwards was noted which was associated with reduced food
consumption and increased water intake. A statistically signiﬁcant increase in liver weight was observed
at 10 and 20 mg/kg bw per day, while livers of dams dosed with 20 mg/kg bw per day were hypertrophic.
The number of pups was unaffected by the treatment, but survival rate at 10 mg/kg bw per day was
reduced to 55% and at the 20 mg/kg bw per day, pups survived only for a few hours after birth. In
addition, the statistically signiﬁcant occurrence of a number of developmental/teratological phenotypes
became apparent, including, reduced body weight (10, 20 mg/kg bw per day), cleft palate (10, 20 mg/kg
bw per day), delayed ossiﬁcation (20 mg/kg bw per day), delayed eruption of incisors (10, 20 mg/kg bw
per day), wavy ribs (10, 20 mg/kg bw per day), curved fetus and spina biﬁda occulta (both 10, 20 mg/kg
bw per day). The only malformations which were also detectable at 1 mg/kg bw per day were sternal
defects.
C57BL/6J-Apc+/+ female mice mated with C67BL6J-Min/+ male mice were used to comparatively test
whether PFOA and PFOS have obesogenic effects and stimulate an increase in spontaneous intestinal
tumorigenesis (Ngo et al., 2014). The experiment was performed in two blocks using gestational
exposure from GD 1 to GD 17. In block 1, animals were treated with 0, 0.1 and 3 mg/kg bw per day,
whereas doses of 0, 0.01 and 0.1 mg/kg bw per day were given in block 2. In the tested doses, PFOS
(like PFOA) neither acted as an obesogen nor did it stimulate increases in tumorigenesis. The mild
toxicity effects of PFOA (see Section 3.3.3.3.2) were not observed for PFOS.
A study by Era et al. (2009) aimed to unravel the mechanism responsible for the cleft palate
phenotype caused by PFOS exposure. A sharp increase in incidences of cleft palate was detected
following exposure of 13 mg/kg bw per day (7.3% incidence) and 20 mg/kg bw per day (78.3%
incidence). This sharp increase of cases of cleft palate was paralleled by a comparatively small increase
of serum levels of PFOS from 110.7  13.4 lg/mL at 13 mg/kg bw per day to 138.6  0.9 lg/mL at
20 mg/kg bw per day. Overall, this dose–response relationship for cleft palate was interpreted by the
authors as a threshold mechanism. Fusion potential was investigated using explant cultures from
solvent- and PFOS-treated animals. No statistically signiﬁcant differences between cultures were found,
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pointing to the prevention of elevation of the palatal shelves as a mechanism, as fusion potential was
retained upon exposure.
A statistically signiﬁcant increase in mortality rate of 22% at PND 3 was found at 2 mg PFOS/kg bw
per day in a study in which pregnant Sprague–Dawley rats were exposed to 0, 0.1, 0.6 and 2 mg/kg
bw per day (Xia et al., 2011). The ﬁndings included a statistically signiﬁcant decreased body weight at
birth, which persisted in surviving pups at later time points (PNDs 7, 14 and 21). Transmission electron
microscopy revealed morphological changes of the mitochondria in the heart following exposure to
2 mg/kg bw per day of PFOS.
To shed light into the mechanism of developmental growth retardation by PFOS, emphasis was
given on placental production of hormones of the PRL family (Lee et al., 2015). Ten pregnant CD1
mice per group were treated with PFOS at 0, 0.5, 2, 8 mg/kg bw per day, from GD 11 to 17. On GD
17, the animals were sacriﬁced. On the maternal side, a decrease in body weight gain over time was
observed at 8 mg/kg bw per day. The number of pregnant mice and the number of implantations was
not signiﬁcantly different among treatment groups. However, placental weight, placental capacity and
number of resorptions and dead fetuses were dose dependently reduced in a statistically signiﬁcant
manner, compared to untreated controls. These ﬁndings were accompanied by histopathological
changes (necrotic areas) in the placenta, detectable at 0.5 mg/kg bw per day. Dose-dependent
decreases in the numbers of glycogen trophoblast cells in the junctional zone and the number of
sinusoidal trophoblast giant cells in the labyrinth zone were noted. Statistical signiﬁcance was reached
at 0.5 mg/kg bw per day for sinusoidal trophoblast giant cells and at 2 mg/kg bw per day for glycogen
trophoblast cells. Fetal weight was also shown to be reduced, while statistical signiﬁcance was only
noted at 2 and 8 mg/kg bw per day. There was a statistically signiﬁcant, dose-dependent increase in
the number of resorptions and dead fetuses which was accompanied by a decreased number of live
fetuses, attaining statistical signiﬁcance at 2 and 8 mg/kg bw per day. On a molecular level, a dose-
dependent decrease of placental expression of members of the prolactin family of genes was detected
which correlated with decreased concentrations of mPL-II, mPLP-Ca and mPLP-K in serum, with effects
for the latter two reaching statistical signiﬁcance at 0.5 mg/kg bw per day. A correlation between
placental levels of prolactin family members and fetal weight was apparent.
Metabolic Effects
The effects of perinatal exposure to PFOS on glucose metabolism were investigated in a study by
Wan et al. (2014). Six- to eight-week-old pregnant CD-1 mice (6 dams per group) were treated orally
with 0.3 or 3 mg/kg bw per day from day of mating until PND 21. Vehicle-treated animals served as a
control. Two pups per dam were sacriﬁced on PND 21, as were the mothers. All other pups were
subjected to a follow-up experiment in which animals were either fed a standard rodent diet or a high
fat diet. The experiment was terminated on PND 63. On the maternal side, an increased liver weight
was detected at 3 mg/kg bw per day and an increased HOMA-IR index at 0.3 and 3 mg/kg bw per
day, although fasting glucose and insulin levels were not statistically altered in comparison to controls.
Body weights of the offspring did not signiﬁcantly differ in control and treatment groups. Relative liver
weights were increased in both sexes at 3 mg/kg bw per day, compared to controls. At the same dose
the hepatic mRNA expression levels of Cyp4a14, Lpl, Cd36, Ir and Igf-r1 were signiﬁcantly elevated in
both sexes, whereas the levels of Prl-r and Igf-1 were found to be downregulated, thereby correlating
to elevated serum and tissue levels of PFOS. Fasting glucose levels at PND 21 in both genders were
not statistically signiﬁcantly altered. Fasting serum insulin levels were elevated at both doses (0.3 and
3 mg/kg bw per day) in male but not in female offspring at PND 21. The HOMA-IR index was however
not affected. In PND 63 animals, the accumulating PFOS levels following exposure to 0.3 and 3 mg/kg
bw per day were signiﬁcantly higher in both sexes in animals fed high fat diet when compared to
animals fed regular diet. In animals fed the regular diet, the relative liver weight was only elevated in
males at 3 mg/kg bw per day, whereas fasting serum glucose was elevated in males and females in
response to both doses (0.3 and 3 mg/kg bw per day). Fasting insulin serum levels were only elevated
in response to the high dose. Oral glucose tolerance test did not produce statistically signiﬁcant
differences between treatment groups. This was different in animals fed the high fat diet. Liver weight
was again only increased in males following treatment with 3 mg/kg bw per day. In both sexes, fasting
insulin serum levels were elevated at 3 mg/kg bw per day, which was also the case for fasting serum
glucose levels in males. In females at PND 63, fasting serum glucose levels followed a dose–response
relationship. AUC in the oral glucose tolerance test was elevated in both sexes at 3 mg/kg bw per day.
The HOMA-IR index was signiﬁcantly different in both sexes at 3 mg/kg bw per day, between exposed
and control groups, as well as between animals fed regular diet and high fat diet.
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Cardiovascular Biology
In the study by Xia et al. (2011, see above section for study description), the heart to body weight
ratio increased in response to treatment with 2 mg/kg bw per day of PFOS. To investigate this further,
the hearts of weaned (PND 21) offspring were investigated with ultrastructure analysis by electron
microscopy for mitochondrial injury and for global gene expression proﬁling by microarray as well as
consecutive quantitative polymerase chain reaction (qPCR) and Western blot analyses. Signiﬁcant
vacuolisation and inner membrane injury at 2 mg/kg bw per day were detected as indicators of cardiac
mitochondrial injury, which was associated with changes of expression of genes relevant for
mitochondrial function.
In another gestational exposure study, the impacts of several environmental compounds, including
PFOS, on blood pressure were compared (Rogers et al., 2014). Exposure of pregnant Sprague–Dawley
rats to 18.75 mg/kg bw per day of PFOS, by gavage, during GDs 2–6, resulted in delayed maternal
weight gain and reduced birth weights of male and female offspring. A statistically signiﬁcant increase
in blood pressure was detected at PND 7 in males, which persisted at least until PND 52. An even
more pronounced elevated blood pressure was detected in females at PND 37 and 65.
Male reproductive system
To study the impact of PFOS on the male reproductive system, 8-week-old CD-1 male mice were
treated with 0, 1, 5 and 10 mg/kg bw per day of PFOS for 7, 14 or 21 days (Wan et al., 2011).
Decreased body weight at PND 19–21 at the 10 mg/kg bw per day dose and an increased liver weight
at the 5 and 10 mg/kg bw per day dose were noted. Serum testosterone levels and epididymal sperm
counts were decreased at 10 mg/kg bw per day. Gene expression analysis by qPCR in the 21-day
treatment group in the testes, revealed a dose-dependent downregulation of steroidogenic enzymes,
including Cyp11a1, Cyp17a1, Hsd3b, Hsd17b and Star. All effects reached the level of statistical
signiﬁcance at 5 and 10 mg/kg bw per day, and the expression levels for Hsd17b at 1 mg/kg bw per
day. Lhr was found to be downregulated at the two highest doses, Fshr at 10 mg/kg bw per day.
Other genes which were downregulated at 5 and/or 10 mg/kg bw per day in the 21 day treatment
comprise Igf1, Igf1r. Two members of the inhibin subunit family were found to be downregulated at all
three doses.
Zhao et al. (2014) treated pregnant Sprague–Dawley rats with 5 and 20 mg/kg bw per day of PFOS
from GD 1 to GD 19. A reduced body weight at 20 mg/kg bw per day was noted for mothers, which
was also detectable in male offspring at 5 and 20 mg/kg bw per day. In male pups, testosterone levels
were reduced in response to treatment with PFOS (20 mg/kg bw per day), whereas progesterone
levels were decreased at 5 and 20 mg/kg bw per day. The reduction of testosterone was accompanied
by a decreased number of Leydig cells and an increased apoptosis rate at the same dose. Total testis
weight in offspring was decreased at 20 mg/kg bw per day, as was the anogenital distance, a general
marker for male reproductive differentiation.
In conclusion, PFOS clearly affects developmental processes with the impact on maternal liver
weight (0.3 mg/kg bw per day) placental physiology (0.5 mg/kg bw per day) and on aspects of
glucose homoeostasis (0.3 mg/kg bw per day) being the most sensitive endpoints. A NOAEL for these
effects was not identiﬁed.
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Table 12: PFOS reproductive and developmental toxicity
Substance/
(Purity)
Species/Experimental
design and doses
Most sensitive
endpoints
Highest dose with no effect
(mg/kg bw per day)
Signiﬁcant effect
level (mg/kg bw
per day)
Serum/tissue levels
of compound
Reference
Mother Offspring Mother Offspring
PFOS (98%
K+-Salt)
ICR mice
15 dams/group (5 each
selected for speciﬁc
endpoints
Exposure: 0, 1, 10, 20
mg/kg bw per day, GD 1
–17/18
Reduced weight gain
Increased liver weight
Liver hypertrophy
Decreased neonatal
survival
Developmental/
teratological alterations
Sternal defects
10
1
10
1
1
N/A
20
10
20
10
10
1
NR Yahia et al.
(2008)
PFOS (98%
K+-Salt)
C57BL/6J-Apc+/+ female
mated with C67BL6J-Min/+
males (n = 20/21)
Exposure: 0, 0.1, 3 mg/kg
bw per day experimental
block 1 per drinking water
0, 0.01, 0.1, 3 mg/kg per
bw day experimental block
2 per drinking water
GD 1–17
ApcMin/+ genotype mice
were terminated at
11 weeks of age for
tumorigenesis. Wild-type
mice were kept until week
20 for obesogenic effects
No obesogenic effects, no
intestinal tumorigenesis
Comparative study
approach revealed that
mild toxicity effects seen
for PFOA did not occur in
response to PFOS
0.1 mg/kg bw per day:
2.2/2.7 lg/mL in GD 18
Dams, 0.48/0.54 lg/mL
dams after weaning and
0.38/0.3 lg/mL pups
after weaning
3.0 mg/kg bw per day:
36.6/44.6 lg/mL in GD
18 dams; 17.2/22.2
lg/mL Dams after
weaning and N/A pups
after weaning
Ngo et al.
(2014)
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Substance/
(Purity)
Species/Experimental
design and doses
Most sensitive
endpoints
Highest dose with no effect
(mg/kg bw per day)
Signiﬁcant effect
level (mg/kg bw
per day)
Serum/tissue levels
of compound
Reference
Mother Offspring Mother Offspring
PFOS (purity
98%, K+-salt)
ICR mice
Exposure 0, 9, 13, 20,
30 mg/kg bw per day by
gavage
GD 1–14/18
Additionally: 20 mg/kg bw
per day GD 1–15 and
50 mg/kg bw per day GD
11–15
Dams 5–8
Fetuses: 67–103 (examined
animals, total number
higher)
Liver weight increase
Liver weight decrease
Sharp increase in cleft
palate between 13 and
20 mg/kg bw per day=>
threshold mechanism
13
50% effective
dose expected
17.7 mg/kg bw
per day
13
13
50% effective
concentration
for cleft palate
121 lg/mL
20
20
20
In dams 30 mg/kg bw
per day lead to
162.3 lg/mL
Era et al.
(2009)
PFOS (purity
98%, salt not
speciﬁed)
Sprague–Dawley rats
Exposure: 0, 0.1, 0.6,
2 mg/kg bw per day, per
gavage GD 2–21
Dams: 10 per group
Follow-up offspring:
Neonatal survival PND 4
(all), survivors until PND 21:
6 per group
Increase mortality of
offspring at 2 mg/kg bw
per day
Reduced body weight
offspring
Increased heart to body
weight ratio at PND
Cardiac mitochondrial
injury
Altered expression levels
of genes
0.6
0.6
0.6
0.6
0.6
2
2
2
2
2
Serum, dose-dependent
increase: 4.26 lg/mL at
2 mg/kg bw per day
Heart, dose-dependent
increase: 9.59 lg/g at
2 mg/kg bw per day
Xia et al.
(2011)
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Substance/
(Purity)
Species/Experimental
design and doses
Most sensitive
endpoints
Highest dose with no effect
(mg/kg bw per day)
Signiﬁcant effect
level (mg/kg bw
per day)
Serum/tissue levels
of compound
Reference
Mother Offspring Mother Offspring
PFOS (purity
98%, salt not
speciﬁed)
CD1 mice
Exposure: 0, 0.3, 3 mg/kg
bw per day GD 1–PND 21
Dams: 6 per group (sacriﬁce
after weaning (PND 21))
Offspring: animals per
treatment equally
distributed in a low- and a
high-fat feeding group.
Termination on PND 63
Increased liver weight
Increased HOMA-IR
Liver weight increase
Elevated fasting glucose
Additional effects related
to high fat diet
0.3
N/A
N/A
N/A
3
0.3
0.3
0.3
Serum levels at
0.3 mg/kg bw per day:
0.3 lg/mL in males and
0.51 lg/mL in females
Serum levels at
3 mg/kg bw per day:
3.36 lg/mL in males
and 3.4 lg/mL in
females
Liver levels at
0.3 mg/kg bw per day:
4 lg/g in males and
3.3 lg/g in females
Liver levels at
3 mg/kg bw per day:
12.3 lg/g in males and
13.8 lg/g in females
Values for F1 adults on
standard diets. Values
on high fat diet higher
for both genders
Wan et al.
(2014)
PFOS (source,
purity and salt
not speciﬁed)
Sprague–Dawley rats
Exposure: 18.75 mg/kg bw
per day
GD 2–6 by gavage
10–12 Offspring animals per
group
Delayed weight gain
Reduced birth weight both
genders
Increase blood pressure
in male offspring from
PND 7–52
Increase blood pressure in
female offspring from PND
37–65
N/A
N/A
N/A
N/A
18.75
18.75
18.75
18.75
NR Rogers et al.
(2014)
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Substance/
(Purity)
Species/Experimental
design and doses
Most sensitive
endpoints
Highest dose with no effect
(mg/kg bw per day)
Signiﬁcant effect
level (mg/kg bw
per day)
Serum/tissue levels
of compound
Reference
Mother Offspring Mother Offspring
PFOS (purity
not speciﬁed,
K+-salt)
CD1 mice
Exposure: 0, 0.5, 2, 8
mg/kg bw per day, GD
11–16
10 dams per group
Body weight decrease
Dose-dependent decrease
of placental weight and
capacity
Dose-dependent increase
of number of resorptions
and dead fetuses
Decrease in the numbers of
glycogen trophoblast cells
in the junctional zone and
the number of sinusoidal
trophoblast giant cells in
the labyrinth zone
Decrease of mPL-II, mPLP-
Ca and mPLP-K expression
levels and serum
concentrations
2
N/A
N/A
N/A
N/A
8
0.5
0.5
0.5
0.5
NR Lee et al.
(2015)
PFOS, purity
not speciﬁed
Sprague–Dawley rats
Exposure: 0, 5, 20, mg/kg
bw per day, GD 1–GD 19
n = 4 per group
Decreased body weight
Decreased body weight
Decreased testis weight
Change anogenital
distance
Increased apoptosis rate
in testis
Decreased number of
Leydig cells
Decreased testosterone
Decreased progesterone
5
N/A
5
5
5
5
5
N/A
20
5
20
20
20
20
20
5
NR Zhao et al.
(2014)
bw: body weight; f: female; GD: gestational day; m: male; N/A: not applicable; NR; not reported; PFOA: perﬂuorooctanoic acid; PFOS: perﬂuorooctane sulfonic acid; PND: postnatal day.
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3.3.3.3.2. PFOA
In their previous opinion, the CONTAM Panel derived a TDI for PFOA of 1.5 lg/kg bw from liver
effects occurring in a subchronic study with male rats EFSA (2008). Data on developmental and
reproductive toxicity studies using exposure to low doses of PFOA were limited. In fact, the most
sensitive endpoint identiﬁed for developmental and reproductive toxicity originated from a study by
Abbott et al. (2007). In this study, a reduction in neonatal survival was observed at 0.6 mg/kg bw per
day which resulted in a NOAEL of 0.3 mg/kg bw per day.
In addition, from a two-generation reproduction study on PFOA, in which Sprague–Dawley rats
were given 1, 3, 10 or 30 mg/kg bw per day PFOA, by oral gavage, NOAELs for reproductive function
(30 mg/kg bw per day), sexual maturation (10 mg/kg bw per day) and for body weight as well as
increased liver weight (< 1 mg/kg bw per day) in both parental and F1 male animals could be derived
(Butenhoff et al., 2004b). In another study using a comparative approach pregnant wild-type
129S1/SvlmJ and PPAR knock-out mice were treated with 0.1–20 mg/kg bw per day of PFOA. Both
toxicological and mechanistic ﬁndings were obtained. Toxicologically a NOAEL of 0.3 mg/kg bw per day
could be derived for neonatal survival which was lower than the one for eye opening (1 mg/kg bw per
day). The most sensitive parameter was a change in liver weight in offspring at the lowest dose
investigated (0.1 mg/kg bw per day). Mechanistically, knockout of PPARalpha (PPARa) apparently had
no effect on outcomes directly related to pregnancy but was involved in the detected postnatal effects,
e.g. on liver weight, eye opening and growth defects, which occurred at high doses (Abbott et al.,
2007). Different species were investigated by Lau et al. (2004), Lau et al. (2006). In the teratological
studies (reviewed by Lau et al., 2004), PFOA was investigated in rabbits and rats. No teratological
effects were reported for rabbits below 50 mg/kg bw per day whereas NOAELs could be derived for
maternal (5 mg/kg bw per day) and developmental toxicity (150 mg/kg bw per day) in rats. In their
second study, exposure of pregnant CD-1 mice from GD 1 until birth with 1, 3, 5, 10, 20, 40 mg/kg bw
per day resulted in numerous effects including resorption of litters, reduced percentage of live fetuses,
reduced weight of fetuses, reduced postnatal survival and growth deﬁcits. Although these parameters
showed that endpoints were affected at different doses, none of the parameters were affected in the
1 mg/kg bw per day dose group.
FSANZ recently derived a TDI for PFOA of 160 lg/kg bw from the NOAEL for fetal toxicity in a
study in mice on developmental and reproductive toxicity (Lau et al., 2006). Another candidate point
of departure resulted from the same study for maternal toxicity. The Swedish EPA in addition
considered, but did not use, changes in mammary gland development (Macon et al., 2011) and body
weight gain (Hines et al., 2009). These studies are discussed in more detail below.
The following section reviews the literature after the publication of the EFSA opinion in 2008, and
Table 13 summarises these studies.
It is noteworthy that 4 studies reported biological effects at doses in the exposure range of
0.01 mg/kg bw per day. These studies are discussed below in the Section ‘Studies reporting low dose
biological responses’.
Studies reporting low dose biological responses
In three studies, biological effects in response to PFOA were detected at a dose of 0.01 mg/kg bw
per day (Hines et al., 2009; Macon et al., 2011; Tucker et al., 2015). For another study, a BMDL5 of
6.2 lg/kg per day was calculated for the decrease of triglyceride levels (using a BMD) approach (Slob,
2002) with the PROAST software versions 38.0 and 38.1 (www.rivm.nl/proast)). However, authors
judged this value as borderline informative, because in their analysis a BMDU/BMDL ratio of 100, was
calculated (Van Esterik et al., 2016). These studies reporting effects at low doses comprise the
investigation of metabolic endpoints (Hines et al., 2009; Van Esterik et al., 2016) and of mammary
gland development (Macon et al., 2011; White et al., 2011; Tucker et al., 2015). Since none of the
studies provides a direct link to potential adverse outcomes, the CONTAM Panel could not consider
these data as a reference point of departure for reasons speciﬁed in the sections below.
In a study with CD-1 mice exposed to PFOA at 0, 0.01, 0.1, 0.3, 1 or 5 mg/kg bw per day, by
gavage, from GD 1 to 17, no difference in live pup numbers was observed, while postnatal mortality
was not assessed (Hines et al., 2009). However, as brieﬂy mentioned above a transient body weight
gain of the pups at the mid-age observation group (21–33 weeks) was observed for 0.01–0.3 mg/kg,
which was accompanied by a transient increase in serum levels of leptin and insulin in the 0.01 and
0.1 mg/kg groups. At 18 months of age, abdominal fat weight and relative amounts of white fat were
decreased in the 1 mg/kg bw per day and 5 mg/kg bw per day exposure groups, the 3 mg/kg bw per
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day group was not assessed. Interscapular brown fat weight and relative brown fat weight were
signiﬁcantly increased at 18 months relative to control. Authors claim low dose effects in response to
PFOA exposure. This study was discussed as a potential point of departure in the report of the
Swedish EPA on PFAS (Report 6513, Swedish EPA, 2012). The effect on leptin could not be detected in
a study with a similar design using two diets (Quist et al., 2015), a control diet, which was the same
as in the study above (Hines et al., 2009) and an experimental high fat diet. In animals, which were
fed the control diet, the effect of PFOA on leptin could not be found when analysed at PND 91 (Quist
et al., 2015). Due to the inconsistency of the leptin response within studies of a similar design, and
because of the lack of a link of transiently elevated leptin to an adverse outcome the CONTAM
Panel decided not to use this study further.
Van Esterik et al. (2016) investigated whether early exposure to low doses of PFOA could program
C57BL/6JxFVB hybrid mice for metabolic impairment later in life. No general developmental and
reproductive toxicity effects became apparent. Whenever possible, authors subjected dose–response
data obtained to BMD modelling (BMD) approach (Slob, 2002) with the PROAST software versions 38.0
and 38.1 (www.rivm.nl/proast). In males, a dose-dependent decrease in body weight was observed
from PND 4 until 21 weeks, when the diet was changed from normal diet to high fat diet. In females,
this effect persisted even after feeding of a high fat diet for 2 weeks, with a BMDL5 of 849 lg/kg bw
per day. Male organ metrics were only affected for absolute and relative liver weight, which increased,
and tibial length, which decreased. Female organs were not affected except for a decrease in femur
and tibia length, femur weight and weight of the quadriceps femoris muscle. The effects were weak as
indicated by high BMDL levels. Absolute and relative weights of perigonadal and particularly perirenal
(BMDL5 of 65 lg/kg bw per day) fat pads exhibited a negative dose–response relationship. On the
histopathological level, the two parameters eosinophilic appearance and karyomegaly in the liver were
altered (p = 0.07) at 300 and 3,000 lg/kg bw per day. No statistically signiﬁcant histopathological
changes were found in the brown adipose tissue. To explain the metabolic phenotypes, both lipid
parameters and endocrine parameters involved in the regulation of energy homoeostasis were
investigated. None of the parameters showed a signiﬁcant response to PFOA in males, while a dose-
dependent decrease of cholesterol (BMDL5 402 lg/kg bw per day) and triglycerides (BMDL5 6.2 lg/kg
bw per day) became apparent in females. Because the parameter triglycerides had borderline
informative value (BMDU/BMDL = 100), the authors considered the next lowest effect, namely the
BMDL for perirenal fat pad weight in females at 65 lg/kg bw per day, as more relevant.
Delay of mammary gland development, as a consequence of PFOA exposure, was reported in a
study in which pregnant CD-1 mice, which were either treated during the entire gestational period (GD
1–17; 0, 0.3, 1.0, 3 mg/kg bw per day) or during the second half of gestation (GD 10–17; 0, 0.01,
0.1, 1.0 mg/kg bw per day; Macon et al., 2011). Prenatal PFOA exposure elevated relative liver
weights transiently even in the 0.3 mg/kg treatment group in both females and males. Although this
effect dissipated at PND 7 it has to be stated that it occurred at a dose that was lower than the
previously reported LOAEL in CD-1 mice (Lau et al., 2006; Wolf et al., 2008a). At higher doses, the
liver weight remained higher for longer periods. Exposure during the entire gestational period led to
statistically signiﬁcant changes in mammary gland development scores at the lowest dose of 0.3 mg/
kg bw per day for examinations of the gland at PND 14, 21, 42 and 84. Late gestational exposure
during PND 10–17 lead to similar results for doses of 0.1 and 1 mg/kg bw per day. The overall
developmental score, summary evaluation of longitudinal and lateral growth, D longitudinal and D
lateral growth, terminal end buds (TEB) and terminal ends, at PND 21 was signiﬁcantly changed at
doses of 0.01 mg/kg bw per day and higher. As this summary assessment was more sensitive than the
assessment of each of the individual parameter, the latter were listed in addition, with the number of
terminal endbuds as being the most sensitive individual parameter showing signiﬁcant reduction at
0.1 mg/kg bw per day. These low-dose effects of PFOA were conﬁrmed for CD-1 mice in a
comparative study with CD-1 and C57Bl/6 mice (Tucker et al., 2015). In this study, timed pregnant
dams were given oral daily doses of 0, 0.01, 0.1, 0.3 or 1.0 mg mg/kg bw per day of PFOA from GD 1
to 17. Mammary gland developmental scores (1 = poor development; 4 = best) were derived from
whole mount preparations at PND 21, 35 and 56 for CD-1 mice and on PND 21 and PND 61 for C57Bl/
6 mice. The mammary gland development score comprised the assessment of lateral and longitudinal
epithelial growth, branching density, changes in epithelial growth, appearance of budding from ductal
tree, number of differentiating duct ends and the presence or absence of terminal end buds. No
treatment group showed an effect on absolute and relative body weight or liver weight. Neither was
puberty onset affected by the respective treatments. However, mammary gland development scores
were decreased. At 0.01 mg/kg bw per day this decrease became apparent in CD-1 mice in tissues of
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PND 35 and PND 56 whole mounts. It was signiﬁcantly decreased for all three time periods observed
in the 0.1, 0.3 and 1.0 mg/kg bw per day treatment groups. Data for individual items of the scoring
process are not available. C57Bl/6 mice responded less sensitively and only for the treatment at 0.3
and 1.0 mg/kg bw per day, at PND 21 and 61. Authors concluded that the mammary gland is the most
sensitive pubertal parameter, regardless of the strain. In an additional study, White et al. (2011)
investigated whether gestational exposure to PFOA or gestational exposure followed by a chronic,
lifelong, low dose exposure through the drinking water containing 5 ppb of PFOA, would impact on
lactational function and subsequently on the development of the offspring. To address this issue CD-1
mice received 0, 1 or 5 mg/kg bw per day of PFOA from GD 1 to GD 17. Two additional groups of
mice were ﬁrst gestationally treated with 0 or 1 mg/kg bw per day as described above and then
received lifelong exposure to 5 ppb of PFOA through the drinking water. Mammary gland development
at PND 22, 42 and 63 was assessed in the F1 offspring and then also in the F2 offspring, following
breeding with F1 offspring. The measured mammary gland score was correlated to general
developmental parameters like live fetuses, prenatal loss, postnatal survival, lactational parameters,
body and liver weight. Authors conclusively showed that lifelong exposure to 5 ppb in the drinking
water is sufﬁcient to reduce mammary gland developmental score at PND 22, PND 42 and PND 63 in
F1 offspring, as well as at PND 42 in F2 offspring. Maternal mammary gland indices during weaning
(PND 22) were improved in F0 dams following exposure and decreased in F1 dams at weaning (PND
22). However, at none of the investigated time points an impact on the number of live fetuses,
prenatal loss, postnatal survival, body and liver weight became apparent following chronic exposure to
5 ppb of PFOA through the drinking water. In addition, in a lactational challenge test with F1 dams at
PND 10, no statistically signiﬁcant impact on milk volume or timed nursing behaviour could be found.
The authors concluded that the delay in mammary gland development, which translated also in
histopathological changes of the organ, did neither result in deﬁcits in lactation nor in deﬁcits in
growth and survival, which can be regarded as proxy measures of nutritional support.
Despite the fact that responses in the mammary gland occurred at low doses, the CONTAM
Panel decided not to use the data on mammary gland development for the risk assessment. The
observations for the developmental score at 0.01 mg/kg bw per day in the mammary gland are
generally speaking, indicative for a delayed pubertal transition of the mammary gland. Delayed
developmental transition, as such, cannot be considered as an adverse health outcome. Furthermore,
the developmental score summarises results of several individual parameters and none of the
individual ones were as sensitive as the sum parameter (0.1 mg/kg bw per day and above). In
addition, pubertal development was not generally affected, because no inﬂuence of PFOA exposure on
vaginal opening could be detected. At present, it is not clear whether this biological effect occurring at
a low dose has to be regarded as adverse. The transition of the mammary gland during puberty is
regarded as a highly sensitive window of susceptibility for interference with environmental impacts in
humans and rodents. This interference thereby appears to be linked to breast cancer risk with the
terminal end buds as the most fragile structure in the rodent mammary gland (Martinson et al., 2013).
This is long known in the ﬁeld of chemical carcinogenesis of the mammary gland (Russo and Russo,
1996), whereas the concept of the terminal endbud structure as a target for chemoprevention of
mammary gland carcinogenesis was established more recently (Hilakivi-Clarke, 2007). In summary, the
developing mammary gland represents a sensitive structure for environmental inﬂuences modifying the
risk for the development of breast cancer.
Maternal effects and neonatal survival
Since the release of the EFSA opinion in 2008, a number of gestational exposure studies have been
performed to study the impact of PFOA (salt unknown, 90% pure) on the pregnant female as well as
on their offspring. In a study which was primarily aimed to characterise neonatal mortality (Yahia
et al., 2010), 15–19 pregnant ICR mice were treated by gavage at doses of 1, 5, 10 mg/kg bw per day
from GD 0 to 17 for dams euthanised on GD 18 for the assessment of prenatal parameters. Exposure
from GD 0 to 18 was used for all parameters, which were assessed postnatally. For evaluation, 5–9
dams/group were euthanised on GD 18, the other 10 dams were maintained in the study to give birth.
On the maternal side the major effects were related to liver weight gain and changes in serum
biochemical parameters. A dose-dependent increase in liver weight became apparent, with weight gain
changes at 5 and 10 mg/kg bw per day reaching the level of statistical signiﬁcance. Out of 20
parameters measured, 12 were statistically different at 10 mg/kg bw per day, three (total protein,
globulin and phosphorus) at 5 mg/kg bw per day and 2 (phosphorus and blood urea nitrogen) at
1 mg/kg bw per day. In pups, neonatal survival was affected. All died within 6 h after birth in the
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10 mg/kg bw per day group, whereas 16% of pups died within 4 days of observation following
treatment with 5 mg/kg bw per day. This effect was not detectable for PFOS in the comparative
experimental setup used. In addition, the liver weight of the pups was signiﬁcantly changed in a
non-linear manner. For the lowest dose (1 mg/kg bw per day), an increase in liver weight was
detected, whereas exposure to 5 and 10 mg/kg bw per day of PFOA decreased liver weight. The
number of live pups was also found to be reduced to 49% at PND 7 in a study in which CD-1 mice
were gavage dosed with 5 mg/kg bw per day of PFOA, to study expression of PPAR in fetal and post-
natal mouse tissues (Abbott et al., 2012). C67BL6J-Min/+ mice were used as another model to
comparatively test whether PFOA and PFOS have obesogenic effects and stimulate an increase in
spontaneous intestinal tumorigenesis in these mice (Ngo et al., 2014). PFOA neither acted as an
obesogen nor did it stimulate increases in tumorigenesis. However, there was a lower survival of pups
at 3 mg/kg bw per day and an increased liver weight at low doses of PFOA (as low as 0.01 mg/kg bw
per day), which however, showed no dose dependency.
Survival rate was shown to be dependent on the PPARa status. In a comparative study, Albrecht et al.
(2013) used pregnant 129/Sv mice, which carried either a wild-type mPPARa, were null-mutated or were
humanised by expressing hPPARa. Following treatment with 3 mg/kg bw per day of PFOA from GD 1 to
17, a reduced neonatal survival was found in mice carrying the wild-type mPPARa but not in humanised
or knockout mice. These observations point to species differences in the responsiveness to PFOA through
PPARa, which is further substantiated by the observation that lg orders of ammonium perﬂuoroctanoate
may activate mouse PPARa in vivo but not the human counterpart in humanised Svv/129 genetically
modiﬁed mice carrying a hPPARa Tet-Off construct (Nakamura et al., 2009). With this study, the results
of Abbott et al. (2007) could be conﬁrmed for mPPARa, but also showed that hPPARa seems not
responsive.
Hepatotoxicity
In this study, hepatotoxicity was comparatively investigated using CD-1 mice, as well as 129/Sv
wild-type and PPARa knockout mice. Animals thereby underwent the same experimental protocol. In
brief, mice were exposed from GD 1 to 17 to 0, 0.01, 0.1, 0.3, 1 or 5 mg/kg bw per day PFOA and
tissues of the offspring were collected at 18 months of age (Filgo et al., 2015). No statistical
signiﬁcance could be reached for tumorigenic alterations in CD1 mice. Numerous non-neoplastic
alterations in livers of CD-1 mice were noted, among them dose-dependent increases in Ito cell and
centrilobular hepatocyte hypertrophy following prenatal PFOA exposure, reaching the level of
signiﬁcance above controls at 5 mg/kg bw per day PFOA. No signiﬁcant neoplastic alterations were
found in 129/Sv wild-type and PPARa knockout mice. Non-neoplastic lesions were numerous again with
bile duct hyperplasia and bile duct hyaline droplet accumulation being dose dependent in 129/Sv
PPARa knockout, but not in wild-type mice. The author0s main conclusions were based on the fact that
liver lesions occured in all three animal models, with occurence in PPARa knockout animals thereby
pointing to the fact that these lesions occur independent of PPARa (Filgo et al., 2015).
Mammary gland
For interference of mammary gland development by exogenous substances, several windows of
susceptibility have been identiﬁed (Martinson et al., 2013), among them the pubertal period. To cover
this period of mammary gland development a comparative study in Balb/c and C57BL/6 mice was
performed in which animals were orally treated with 0, 1, 5, 10 mg/kg bw per day PFOA (ammonium
salt, 98% pure) by oral gavage for 4 weeks starting at PND 21 (Yang et al., 2009b). An increase in
absolute liver weight (5, 10 mg/kg bw per day) and relative liver weight (1, 5, 10 mg/kg bw per day)
was observed in both strains. Regarding reproductive parameters, a signiﬁcant delay in vaginal
opening was observed for 1 mg/kg bw per day and no vaginal opening at all for 5 and 10 mg/kg bw
per day in Balb/c mice. The picture in C57BL/6 mice was slightly different with a signiﬁcant delay of
vaginal opening at 5 mg/kg bw per day and no vaginal opening at 10 mg/kg bw per day. Strain
speciﬁc differences were also resolved for uterine development. For uterine parameters a dose
dependent decrease of absolute and relative weight was observed for uteri of Balb/c mice, whereas
1 mg/kg bw per day PFOA increased absolute and relative uterine weight in C57BL/6 mice and only
10 mg/kg bw per day lead to a decrease in uterine weight. To assess mammary gland development,
three parameters of the developing mammary gland were investigated: ductal length, number of
terminal endbuds and number of terminal ducts. In Balb/c mice, a signiﬁcant reduction of all three
parameters was observed for 5 and 10 mg/kg bw per day. In C57BL/6 mice, this decrease of all three
parameters was only observed for 10 mg/kg bw per day PFOA, whereas 1 and 5 mg/kg bw per day of
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PFOA increased the number of terminal end buds and stimulated terminal ducts, with the effect for
5 mg/kg bw per day reaching the level of statistical signiﬁcance. Since the two mice strains responded
with different sensitivity, which might be indicative for strain speciﬁcity, Balb/C mice were also treated
with 0.1 mg/kg bw per day of PFOA. At this dose no ﬁndings were noted compared to the control.
Follow-up studies investigated the PPARa dependency of the observed effects. Using 5 mg/kg bw per
day of PFOA in a comparative approach to treat C57BL/6 mice and PPARa knock-out mice, revealed
that the stimulating effect in the mammary gland is independent of this receptor (Zhao et al., 2010a).
In contrast, the decrease in mammary gland development at high doses (7.5 mg/kg bw per day) was
found be strictly dependent on PPARa (Zhao et al., 2012). Another study comparatively investigated
the role of the timing of exposure to PFOA (0, 3, 5 mg/kg bw per day) in utero vs postnatal and in
addition included cross-fostering of pups to create groups of treated/untreated pups nursed by
treated/untreated dams (White et al., 2009). Irrespective of the timing of exposure and irrespective of
the fact whether in utero only or by lactation too, mammary gland development was retarded with the
exception of lactational exposure at 3 mg/kg bw per day.
Uterus
Low dose effects of PFOA were tested in an immature uterotrophic assay in CD-1 mice (Dixon
et al., 2012) using 0, 0.01, 0.1 and 1 mg/kg bw per day doses of PFOA. A statistically signiﬁcant
increase of 1.48-fold (total uterine weight) and 1.46-fold (relative uterine weight) was detected for the
0.01 mg/kg bw per day treatment group. This oestrogenic effect was only minimally, if at all supported
by an extended histological analysis of uterine, cervical and vaginal tissue.
Male reproductive parameters
Zhang et al. (2014b) exposed 8-week-old male BalbC mice with 0.31, 1.25, 5 and 20 mg/kg bw per
day PFOA for 28 days. Reduced testis weight became apparent at 20 mg/kg bw per day. At 5 mg/kg
bw per day, sperm count was reduced, sperm motility and sperm progression increased, as was the
percentage of teratosperm. At 1.25 mg/kg bw per day, a mild disturbance of the histology of the
seminiferous tubules became apparent and the testosterone and progesterone levels were found to be
decreased at this dosage of 1.25 mg/kg bw per day.
Eight-week-old 129/Sv mice, which were wild type regarding mPPARa, or null-mutated or
humanised by expressing hPPARa, were treated for 42 days with either 0, 1 or 5 mg/kg per day with
the ammonium salt of PFOA. Potential impacts on the male reproductive system were investigated.
Although the sperm count was not altered, sperm abnormalities became apparent at 1 and 5 mg/kg
per day in wild-type and humanised mice, which were absent in PPARa null-mutated mice and were
associated with decreased testosterone levels at the same doses (Li et al., 2011). Changes in the
expression levels of several genes analysed were observed at the same dose ranges as physiological
effects.
Bone
Bone samples derived from the experiment performed by Onishchenko et al. (2011) were analysed
for bone effects. Six pregnant C57Bl/6 dams per group were exposed to 0.3 mg/kg bw per day of
PFOA throughout gestation, vehicle treatment served as a control. The offspring was sacriﬁced at the
age of 13 (n = 5) or 17 (n = 5) months. The periostal areas and medullary areas, but not the cortical
areas of the femurs, were increased at 17 months of age, the bone mineral density of the femur
remained unaffected. While periostal and medullary areas were changed similarly in the tibia, tibial
bone mass was decreased both at 13 and 17 months of follow up (Koskela et al., 2016).
Biomechanical properties were unchanged.
In conclusion, PFOA clearly impacts on developmental processes e.g. mammary gland development
and on metabolic processes at doses as low as 0.01 mg/kg bw per day. However, these developmental
changes represent biological effects and a health risk can be deduced, indirectly. The most sensitive
pathological change was noted at 0.1 mg/kg bw per day for increased liver weight in pups.
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Table 13: PFOA reproductive and developmental toxicity
Substance/
(Purity)
Species/Experimental design
and doses
Most sensitive
endpoints
Highest dose with
no effect (mg/kg
bw per day)
Signiﬁcant effect
level (mg/kg
bw per day)
Serum/tissue levels
of compound
Reference
Mother Offspring Mother Offspring
PFOA,
ammonium
salt > 98%
pure
CD-1 mice
Exp. 1: 0,1, 3, or 5 mg/kg bw per
day; n = 5, 5, 8, 7 dams
Exp. 2: 0, 0.01, 0.1, 0.3, 1 or
5 mg/kg bw per day; n = 14 dams
except for 5 mg/kg bw per day
n = 10
Exposure GD 1–17
Transient body weight
gain at mid age
observation group
of the pups
(21–33 weeks)
Increase of insulin and
leptin 0.01–0.1 mg/kg
bw per day.
N/A
N/A
0.01–0.3
0.01
Hines et al. (2009)
PFOA,
ammonium
salt > 98%
pure
CD1 mice
Full gestational study (GD 1–17):
0, 0.3, 1, 3 mg/kg bw per day,
dams (n = 13)
Late gestational study: 0, 0.01,
0.1, 1.0 mg/kg bw per day, dams
(n = 7–13)
Offspring: 7–9 animals per litter
Full gestational
exposure:
Transient (until PND 7)
increase in liver weight
Decreased mammary
gland developmental
score
Late gestational
exposure:
decreased mammary
gland developmental
score
number of
terminal endbuds
N/A
N/A
N/A
0.01
0.3
0.3
0.01
0.1
Serum at 0.3 mg/kg
bw per day: 4,980
(PND 7) – 16 ng/mL
(PND 84)
Liver at 0.3 mg/kg bw
per day: 2,078 (PND
7) – 43 ng/g (PND 84)
Serum at 0.01 mg/kg
bw per day: 284.5
(PND 1) – 16.5 ng/mL
(PND 21)
Serum at 0.1 mg/kg
bw per day:
2,303.5 ng/mL (PND
1) – 131.7 ng/mL
(PND 21)
Macon et al. (2011)
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Substance/
(Purity)
Species/Experimental design
and doses
Most sensitive
endpoints
Highest dose with
no effect (mg/kg
bw per day)
Signiﬁcant effect
level (mg/kg
bw per day)
Serum/tissue levels
of compound
Reference
Mother Offspring Mother Offspring
PFOA,
ammonium
salt 98% pure
CD-1 mice, 163 dams equally
distributed to treatment groups,
6–7 females and 3–4 males per
litter after birth
C57Bl/mice, 41 dams divided to 5
groups, litter sizes > 5 were
maintained
Exposure 0, 0.01, 0.1, 0.3
1.0 mg/kg bw per day, GD 1–17
CD-1 mice: Decrease
of mammary gland
development score
C57Bl/6 mice:
Decrease of mammary
gland development
score
0.01 (PND
21)
N/A (PND
35, PND 56)
0.1 (all time
points)
0.1 (PND 21)
0.01 (PND
35, PND 56)
0.3 (all time
points)
Serum at 0.01 and
0.1 mg/kg bw per
day: 74.8 ng/mL (PND
21) 14.3 ng/mL (PND
35), < LOQ (PND 56)
Serum at 0.1 mg/kg
bw per day:
457.3 ng/mL (PND 21)
Serum at 0.1 mg/kg
bw per day: 247.1
(PND 21), 27.7 ng/mL
(PND 61)
Serum at 0.3 mg/kg
bw per day:
891.3 ng/mL (PND
21), 9.3 ng/mL (PND
61)
Tucker et al. (2015)
bw: body weight; f: female; GD: gestational day; m: male; LOQ: limit of quantiﬁcation; PFOA: perﬂuorooctanoic acid; PND: postnatal day.
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Substance/
(Purity)
Species/Experimental
design and doses
Most sensitive
endpoints
Highest dose with no
effect (mg/kg bw per
day)
Signiﬁcant effect level
(mg/kg bw per day) Serum/tissue levels
of compound
Reference
Mother Offspring Mother Offspring
PFOA,
ammonium salt
98% pure
Pregnant CD-1 mice
receiving 0, 1, 5 mg/kg bw
per day PFOA by oral
gavage from GD 1 to 17.
Pregnant CD-1 mice
receiving 0 and 1 mg/kg bw
per day PFOA by gavage
from GD 1 to 17 and
additional drinking
containing 5 ppb of PFOA
from GD 7 until termination
of the experiment for P0,F1
and F2 generations
Dams: n = 5–12
Litter size neonates F1:
12–13 pups
Litter size neonates F2: 10
pups
Postnatal survival (F1) 1 5 P0 dams at weaning
(PND 22)
Control + 5 ppb:
74.8 ng/mL
1 mg/kg bw per day:
6,658 ng/mL
1 mg/kg bw per day +
5 ppb: 4,772 ng/mL
5 mg/kg bw per day:
26,980 ng/mL
White et al.
(2011)
F1 developmental
indices mammary gland
without PFOA in drinking
water (PND 22, 42, 63)
N/A 1 F1 pups PND 22
Control + 5 ppb:
21.3 ng/mL
1 mg/kg bw per day:
2,444 ng/mL
1 mg/kg bw per day +
5 ppb: 2,744 ng/mL
5 mg/kg bw per day:
10,045 ng/mL
F1 developmental
indices mammary gland
with PFOA in drinking
water (PND 22, 42, 63)
N/A 5 ppb F1 pups PND 42
Control + 5 ppb:
48.9 ng/mL
1 mg/kg bw per day:
610 ng/mL
1 mg/kg bw per day +
5 ppb: 558 ng/mL
5 mg/kg bw per day:
1,581 ng/mL
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Substance/
(Purity)
Species/Experimental
design and doses
Most sensitive
endpoints
Highest dose with no
effect (mg/kg bw per
day)
Signiﬁcant effect level
(mg/kg bw per day) Serum/tissue levels
of compound
Reference
Mother Offspring Mother Offspring
F1 maternal indices
mammary gland without
PFOA in drinking water
(PND 10)
N/A 1 F1 pups PND 63
Control + 5 ppb:
66.2 ng/mL
1 mg/kg bw per day:
211 ng/mL
1 mg/kg bw per day +
5 ppb: 187 ng/mL
5 mg/kg bw per day:
760 ng/mL
F1 maternal indices
mammary gland with
PFOA in drinking water
(PND 10)
N/A 5 ppb F1 dams at weaning
(PND 22)
Control + 5 ppb:
86.9 ng/mL
1 mg/kg bw per day:
9.3 ng/mL
1 mg/kg bw per day +
5 ppb: 173 ng/mL
5 mg/kg bw per day:
18.7 ng/mL
F2 developmental
indices mammary gland
without PFOA in drinking
water (PND 63)
N/A 1 F2 pups PND 22
Control + 5 ppb:
26.6 ng/mL
1 mg/kg bw per day:
4.6 ng/mL
1 mg/kg bw per day +
5 ppb: 28.5 ng/mL
5 mg/kg bw per day:
7.8 ng/mL
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Substance/
(Purity)
Species/Experimental
design and doses
Most sensitive
endpoints
Highest dose with no
effect (mg/kg bw per
day)
Signiﬁcant effect level
(mg/kg bw per day) Serum/tissue levels
of compound
Reference
Mother Offspring Mother Offspring
F1 developmental
indices mammary gland
without PFOA in drinking
water (PND 42)
N/A 5 ppb F2 pups PND 42
Control + 5 ppb:
57.4 ng/mL
1 mg/kg bw per day:
0.4 ng/mL
1 mg/kg bw per day +
5 ppb: 72.8 ng/mL
5 mg/kg bw per day:
0.4 ng/mL
F1 pups PND 62
Control + 5 ppb:
68.5 ng/mL
1 mg/kg bw per day:
1.1 ng/mL
1 mg/kg bw per day +
5 ppb: 69.2 ng/mL
5 mg/kg bw per day:
1.2 ng/mL
PFOA Na+ Salt
> 99%
Female C57BL/6J mice
mated with male FVB mice
Supplemented through feed:
0, 0.017, 0.056, 0.17, 0.56,
1.75.6 and 17 mg/kg bw
per day
(Corresponding exposure: 0,
3, 10, 30, 100, 300, 1,000
and 3,000 lg/kg bw per
day)
Feeding to females was
started 2 weeks prior to
mating and maintained
through mating, gestation
and lactation
(6 F0 females)
Litter size
Body weight
perirenal fat pads
(negative dose–response
relation)
Cholesterol (female
offspring)
Triglycerides (female
offspring)
0.3
BMDU (week
25) 5,645
lg/kg bw
per day
BMDU
362 lg/kg bw
per day
BMDU
1,284 lg/kg
bw per day
BMDU
623 lg/kg bw
per day
1
BMDL (week
25) 849 lg/kg
bw per day
BMDL 65 lg/kg
bw per day
BMDL 402 lg/
kg bw per day
BMDL 6.2 lg/kg
bw per day
(borderline
informative,
BMDU/
BMDL = 100)
Van Esterik
et al. (2016)
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Substance/
(Purity)
Species/Experimental
design and doses
Most sensitive
endpoints
Highest dose with no
effect (mg/kg bw per
day)
Signiﬁcant effect level
(mg/kg bw per day) Serum/tissue levels
of compound
Reference
Mother Offspring Mother Offspring
Follow up of 9 offspring
animals per sex into juvenile
and adult stages
Switch to high fat diet at
21 weeks
PFOA
ammonium
salt, 97.99%
pure
129S1/SvlmJ wild-type and
PPARa knockout mice, 0.1,
0.3, 0.6, 1, 3, 5, 10, 20 mg/
kg bw per day, GD 1–17
Relative liver weight
Relative liver weight
Postnatal survival
0.6
N/A
0.3
1
0.1
0.6
Serum at 0.6 and
1 mg/kg bw per day:
17.4 and 26.3 lg/mL
Serum at 0.1 mg/kg
bw per day : 0.8 lg/
mL
Serum at 0.3 and
0.6 mg/kg bw per
day: 2.15 and
3.81 lg/mL
Abbott et al.
(2007)
PFOA
ammonium
salt, 98% pure
CD1 mice, GD 1–birth, 0, 1,
3, 5, 10, 20, 40 mg/kg bw
per day
Liver weight
resorption of litters,
reduced percentage of
live fetuses, reduced
weight of fetuses,
reduced postnatal
survival and growth
deﬁcits (ossiﬁcation)
N/A
1
1
3
Lau et al.
(2006)
PFOA, purity
90%, salt
unknown
ICR mice, 15–19 dams/
group, 1, 5, 10 mg/kg bw
per day, exposure GD 1–17/
18
Dose dependent liver
weight gain,
Signiﬁcant change of 12
out of 20 metabolic
parameters with
phosphorus and urea
levels being most
sensitive
1
N/A
5
1
Yahia et al.
(2010)
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Substance/
(Purity)
Species/Experimental
design and doses
Most sensitive
endpoints
Highest dose with no
effect (mg/kg bw per
day)
Signiﬁcant effect level
(mg/kg bw per day) Serum/tissue levels
of compound
Reference
Mother Offspring Mother Offspring
Decreased neonatal
survival
Increased liver weight
1
N/A
5
1
PFOA
ammonium
salt, 98% pure
C57BL/6J-Min/+-mice
10–24 dams/group
0.1 and 3 mg/kg bw per day
(study 1) and 0.01 and
0.1 mg/kg bw per day
(study 2)
Exposure: GD 1 to 14–18
Decreased neonatal
survival (not detectable
for PFOS)
Small increase of liver
weight at 0.01 mg/kg
bw per day, but not at
0.1 mg/kg bw per day
0.1
N/A
3
0.01 (not
detectable at
0.1)
Serum levels in pups
at 0.01/0.1/3 mg/kg
bw per day: 12–26,
213–216/N/A ng/mL
Ngo et al.
(2014)
PFOA
ammonium
salt, 98% pure
CD-1 mice, 5 dams/group,
5 mg/kg bw per day,
exposure GD 1–17
Decreased neonatal
survival
N/A 5 Abbott et al.
(2012)
PFOA
ammonium
salt, 98% pure
BALB/c and C57BL/6 mice
(comparative approach);
n = 20
0, 1, 5, 10 mg/kg bw per
day
Exposure: PND 21 for
28 days (pubertal period)
Increase of relative liver
weight in both strains
Delayed vaginal opening
Balb/c mice
Delayed vaginal opening
C57BL/6 mice
Dose dependent
decrease uterine wet
weight in Balb/c mice
Increase of uterine wet
weight for C57/BL6 mice
Reduction of ductal
length, number of
N/A
N/A
1
N/A
N/A
1
1
1
5
1
1
5
Yang et al.
(2009b)
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Substance/
(Purity)
Species/Experimental
design and doses
Most sensitive
endpoints
Highest dose with no
effect (mg/kg bw per
day)
Signiﬁcant effect level
(mg/kg bw per day) Serum/tissue levels
of compound
Reference
Mother Offspring Mother Offspring
terminal endbuds and
number of terminal
ducts in Balb/c mice
Increase of mammary
gland parameters in
C57/BL6 mice
N/A 1
PFOA
ammonium
salt, 98% pure
CD1 mice
Full gestational study (GD
1–17): 0 (n = 48), 3
(n = 28), 5 (n = 36) mg/kg
bw per day (pregnant dams)
cross-fostering during
lactational exposure leading
to 7 groups
Early life effects cross foster
and restricted-exposure
study at 5 mg/kg bw per
day
Mammary gland
development retardation
irrespective of the timing
of exposure
N/A 3 White et al.
(2009)
PFOA
ammonium
salt, 98% pure
CD1 mice
PND 18, 3-day uterotrophic
assay 0, 0.01, 0.1, 1 mg/kg
bw per day (n = 8)
1.46-fold increase of
uterine wet weight.
Further supported by
histopathological
examination
N/A 0.01 Dixon et al.
(2012)
PFOA
ammonium
salt, 98% pure
BALB/c mice, adult
0, 0.31, 1.25, 5, 20 mg/kg
bw per day, n = 16, 28 days
Sperm count reduced,
sperm motility, sperm
progression increased,
percentage of
teratosperm increased
Testosterone and
progesterone levels
decreased
Mild phenotype in
seminiferous tubules
1.25
0.31
0.31
5
1.25
1.25
Zhang et al.
(2014b)
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Substance/
(Purity)
Species/Experimental
design and doses
Most sensitive
endpoints
Highest dose with no
effect (mg/kg bw per
day)
Signiﬁcant effect level
(mg/kg bw per day) Serum/tissue levels
of compound
Reference
Mother Offspring Mother Offspring
PFOA
ammonium
salt, 98% pure
129/Sv wild-type, PPARa
knockout mice, humanised
PPARa mice, adult
0, 1, 5 mg/kg per day,
n = 8–10, 42 days
Sperm abnormalities,
decreased testosterone
level
N/A 1 Li et al. (2011)
PFOA
ammonium
salt, 98% pure
CD-1 mice, 12, 12, 14, 13,
12, and 6 pregnant dams
resulting in 29, 29, 37, 26,
31, and 21 female offspring,
exposure 0.01, 0.1, 0.3, 1,
5 mg/kg bw per day, GD 1–
17
129/Sv WT mice, 7, 7, 5, 3,
and 5 pregnant dams
resulting in 10, 10, 8, 6, and
8 female offspring, exposure
0, 0.1, 0.3, 0.6, 1 mg/kg bw
per day, GD 1–17
129/Sv PPARa ko mice, 5, 9,
8, 7, and 9 pregnant dams
resulting in 6, 10, 10,9, and
9 female offspring, exposure
0.1, 0.3, 1, 3 mg/kg bw per
day, GD 1–17
Investigation at 18 months
CD1 mice: Several non-
neoplastic alterations in
livers
129/Sv mice: bile duct
hyperplasia in 129/Sv
PPARa knockout, but not
wild-type mice
liver lesions can occur
independent of PPARa
1
1
5
5
Filgo et al.
(2015)
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Substance/
(Purity)
Species/Experimental
design and doses
Most sensitive
endpoints
Highest dose with no
effect (mg/kg bw per
day)
Signiﬁcant effect level
(mg/kg bw per day) Serum/tissue levels
of compound
Reference
Mother Offspring Mother Offspring
PFOA salt not
speciﬁed, 96%
pure
C57BL/6/Bkl female mice
Exposure 0, 0.3, mg/kg bw
per day, during gestation,
n = 6 dams per group
Periostal areas and
medullary areas of the
femur were increased at
17 months of age, the
bone mineral density of
the femur unaffected.
Tibial bone mass was
decreased both at 13
and 17 months.
Biomechanical properties
unaffected
N/A 0.3 Bone levels:
13 months: control
0.73 ng/g, PFOA
3 ng/g
17 months: control
0.64 ng/g, PFOA
3.7 ng/g
Koskela et al.
(2016)
bw: body weight; f: female; GD: gestational day; m: male; N/A: not applicable; LOQ: limit of quantiﬁcation; PFOA: perﬂuorooctanoic acid; PFOS: perﬂuorooctane sulfonic acid; PND: postnatal day.
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3.3.3.4. Neurotoxicity
From 2008 to 2016, several studies were published on neurotoxicity of PFOS and PFOA and they
are summarised in Table 14.
3.3.3.4.1. PFOS
Acute exposure
Yang et al. (2009c) treated male Wister rats (5/group) with a single dose of PFOS (0, 12.5, 25 or
50 mg/kg bw) given once by oral gavage. The spontaneous motor ability was decreased when
compared to controls. Five days after treatment, the content of glutamate was signiﬁcantly decreased
in the hippocampus at the dose of 50 mg/kg bw. In cortex, the glutamate content was lowered also at
the dose of 25 mg/kg bw.
Repeated exposure
Liu et al. (2010a) treated adult male Sprague–Dawley rats (8–10/group) with the potassium salt of
PFOS at 0, 1.7, 5.0 or 15.0 mg/L (0.153, 0.45 or 1.35 mg/kg bw per day) in drinking water for 91
consecutive days. Even at the lowest dose, there was an increase in CaMKII and c-jun in cortex and
hippocampus.
In a study by Long et al. (2013a), adult C57BL6 mice were treated with 0, 0.43, 2.15 or 10.75 mg/kg
bw per day, via gavage for a period of 3 months. Impairment in spatial learning and memory were
observed after exposure to 2.15 or 10.75 mg/kg bw per day. There was an increase in apoptosis in the
hippocampus accompanied by increased glutamate, and decreased dopamine in caudate putamen in the
10.75 mg/kg bw per day PFOS group.
In a study by Salgado et al. (2015), adult male rats were treated with 3 or 6 mg PFOS/kg bw daily
for 28 days. At the end of the treatment, the serum levels of prolactin and oestradiol were measured,
as well as the concentrations of dopamine and its metabolites (DOPAC and HVA), and GABA in the
anterior and mediobasal hypothalamus. The levels of prolactin and oestradiol in the serum were
reduced at both doses, while the concentrations of both GABA and dopamine were increased in the
anterior hypothalamus only. In addition, the ratios of DOPAC and HVA to dopamine were decreased,
indicating a reduced dopamine metabolism in the anterior hypothalamic area. These data suggest that
the inhibition of prolactin secretion by PFOS in adult male rats is mediated by the periventricular
hypophysial dopaminergic neurons, GABA-ergic cells from the supraoptic and paraventricular nuclei, as
well as by oestradiol. Exposure to 6 mg PFOS/kg bw per day decreased the expression of DRD1 mRNA
in the amygdala and upregulated the expression DRD2 in frontal cortex and hippocampus (Salgado
et al., 2016).
Developmental exposure
Comparative studies with 1.4 and 21 lmol/kg bw of PFOS (0.75 mg/kg bw and 11.3 mg/kg bw)
and PFOA (0.58 mg/kg bw and 8.7 mg/kg bw) were performed by Johansson et al. (2008, 2009). The
treatment consisted of a single gavage treatment to NMRI mice at postnatal day 10. Behavioural
parameters (locomotion, rearing and total activity), and habituation were investigated in 2- and
4-month-old mice. Reduced locomotion and reduced rearing at an early observation period was
detectable at the high dose (11.3 mg/kg bw), a reduced total activity at this early observation period
(0–20 min) was detectable in 2-month-old mice with both doses of PFOS (0.75 mg/kg bw and
11.3 mg/kg bw). Similar effects were induced by 0.75 mg/kg bw in 4-month-old mice (Johansson
et al., 2008). After exposure to 11.3 mg/kg bw, increased levels of CAMKII, GAP43 as well as
synaptophysin were detected in the hippocampus and cortex, respectively (Johansson et al., 2009).
Butenhoff et al. (2009) performed a developmental exposure study according to test guideline EPA
OPPTS870.6300 and OECD 426 with 25 female rats per dosing group. Pregnant Sprague–Dawley rats
received oral doses of 0.0, 0.1, 0.3 or 1.0 mg/kg bw per day of PFOS (potassium salt) from gestational
day 0 until PND 20. Offspring were observed through to PND 72, when the animals were killed and
underwent macroscopic necropsy and neuropathological examination. Locomotor activity, acoustic
startle reﬂex, and learning and memory were also tested in different subsets of pups originating from
different litters. For male offspring, a LOAEL for maternal exposure of 0.3 mg/kg bw per day could be
derived based on increased locomotor activity at PND 17. The associated LOAEL for female offspring was
described to be a maternal dose of 1 mg/kg bw per day based on the increase in activity at PND 21.
In a study by Liu et al. (2010b), gene expression of calcium-dependent signalling molecules was
analysed following dietary exposure to 3.2 mg/kg food per day of PFOS through gestation and
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lactation of Wistar rats. Downregulation of calmodulin (CaM) and upregulation of Ca2+/calmodulin-
dependent kinase II (CaMKII) and cAMP-response element-binding (CREB) expression in the
hippocampus suggest that the neurotoxic effects of PFOS may be mediated by changed molecules in
calcium signalling pathways.
Zeng et al. (2011a) exposed pregnant Sprague–Dawley rats to 0.1, 0.6, 2 mg/kg bw per day of
PFOS via gavage from GD 0 to GD 20. Ultrastructural and molecular analyses performed on
hippocampi from pups at PND 0 and PND 21 showed a reduction of the active zone of the synapses at
all three doses investigated, whereas a decrease in the number of vesicles per lm2 was signiﬁcantly
reduced following exposure to 0.6 and 2 mg/kg bw per day. These ultrastructural alterations were
associated with a dose dependent down regulation of synapsin1 (Syn1), synapsin2 (Syn2) and
synaptophysin (Syp) expression at both investigated time points (PND 0 and PND 21). The effects on
synapsin3 (Syn3) were less pronounced and reached statistically signiﬁcant at 0.6 and 2 mg/kg bw per
day at PND 0. These ﬁndings provide a morphological and molecular hint for the impairment of
cognitive functions induced by PFOS. By using a similar experimental model and the same doses of
PFOS, Zeng et al. (2011b) showed an inﬂammation-like glial response in the hippocampus at PND 0,
and in both hippocampus and cortex at PND 21.
Onishchenko et al. (2011) performed a comparative study between PFOS and PFOA at the dose of
0.3 mg/kg bw per day in C57BL/6/Bkl mice. Pregnant mice were exposed throughout gestation using
palatable food bits to avoid gastric gavage. On PND 21, pups were subcutaneously injected with a
sterile microtransponder and their behaviour examined in the home cage. PFOS exposed males showed
reduced locomotor activity in a new surrounding. In addition, muscle strength of PFOS exposed males
was signiﬁcantly reduced as shown in the hanging wire test. These data appear to contradict the report
by Butenhoff et al. (2009), but the following differences in experimental design may account for the
diverging results: (1) species: rat vs mouse; (2) time of testing: juvenile (PND 17) vs young adult
(1.5–2 months); and (3) time of testing in relation to exposure: during exposure vs ~ 2 months after
the exposure ceased. In addition, sex-related differences are consistent in both studies.
In a study by Hallgren et al. (2015), male NMRI mice were exposed to PFOS (11.3 mg/kg bw) by
gavage at PND 10. The expression of genes related to cholinergic signalling was analysed 24 h and
2 months after exposure in the cerebral cortex and the hippocampus. 24 h after exposure, there was
signiﬁcant downregulation of cortical AChE and b2 nicotinic receptor, and a signiﬁcant upregulation of
m5 muscarinic receptor. At the age of 2 months, no signiﬁcant change in gene expression regulation
was found in either cortical or hippocampal samples. In spontaneous exploration, PFOS-exposed mice
display lower activity than controls.
Wang et al. (2015a) used the same study design as in the microarray study from 2010 (Wang
et al., 2010). Wistar rat dams were exposed to 5 or 15 mg/L PFOS throughout gestation and until
weaning to investigate gene expression in the hippocampus at PND 7 and PND 35. Rats prenatally
exposed to PFOS (15 mg/L) displayed impaired spatial learning and memory, and downregulation of
plasticity-related genes, which may explain the decline in learning and memory abilities.
In a study by Zhang et al. (2016b), pregnant Sprague–Dawley rats were exposed to PFOS in
drinking water (1.7, 5 or 15 mg/L, 0.15, 0.45, 1.35 mg/kg bw per day) from GD 0 until PND 21. After
weaning, the exposure regimen was continued in offspring until PND 90. The pups exposed to the
highest dose were cross-fostered as described in Wang et al., 2015a. The protein and mRNA
expression of proteins related to Alzheimer’s disease (AD) pathology (Tau, App, BACE-1, PS-1 and
GSK-3b) was analysed in hippocampal homogenates at PND 90. The authors report that exposure to
PFOS particularly at the highest dose leads to an increase in AD-like pathology, including Tau
hyperphosphorylation and Ab1-42 accumulation in the hippocampus. These data suggest that the
exposure to PFOS may be aetiologically relevant for the development of aging-related
neurodegenerative diseases.
Hallgren and Viberg (2016), using the same exposure regimen previously described (see Hallgren
et al., 2015), observed a downregulation in the expression of dopamine receptor 5 (DRD5) in the
cortex, and an upregulation of the expression of tyrosine hydroxylase (TH) in the hippocampus at PND
11. At the age of 2 months, the authors report a signiﬁcant downregulation of hippocampal TH and
DRD2 in PFOS-exposed mice, which may explain the alterations in spontaneous activity.
3.3.3.4.2. PFOA
In the studies by Johansson et al. (2008, 2009) reported also in the PFOS Section, NMRI mice were
exposed to PFOA (0.58 mg/kg bw and 8.7 mg/kg bw), at PND 10. Behavioural parameters
(locomotion, rearing and total activity), and habituation were investigated in 2- and 4-month old mice.
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Reduced locomotion and rearing at an early observation period (0–20 min) was only detectable at the
high dose (8.7 mg/kg bw). Reduced total activity was detectable in 2-month-old mice with both doses
of PFOA (0.58 mg/kg bw and 8.7 mg/kg bw). The effects were more pronounced when mice were
4 months old. The reduced activity at the high dose persisted in any of the 20 min intervals examined
until 80–100 min, then behaviour switched and PFOA-treated animals became hyperactive in the
100–120 min interval.
Onishchenko et al. (2011), also reported in the PFOS Section, reports on the effects of PFOA at
(0.3 mg/kg bw per day) in C57BL/6 mice. Pregnant mice were exposed throughout gestation (GD
1–PND 0) using palatable food bits to avoid gastric gavage. On PND 21, the pups were subcutaneously
injected with a sterile microtransponder to monitor locomotor activity in the home cage. The effects on
behaviour were sex-dependent as follows: the exposed males were more active than the controls,
while the exposed females showed decreased activity. In addition, only the females exposed to PFOA
show decreased motor coordination in the rotarod test. However, the circadian distribution of inactive
periods (typically associated with sleeping) displayed a similar pattern in both sexes: exposed mice
have less inactive periods overall, and the most consistent change occurring in the light (inactive)
phase of the dark–light cycle.
In a study investigating the effects of simultaneous exposure to PFOA and MeHg (Cheng et al.,
2013), adult female Wistar rats were exposed to PFOA in drinking water (10 lg/mL (10 ppm)) from
GD 1 until PND 21. The effect induced by PFOA alone was an increase in locomotor activity at PND 36.
Sobolewski et al. (2014) exposed C57Bl/6 mice to PFOA 0.1 mg/kg bw per day, alone or in
combination with mixtures of endocrine disruptors, via palatable food between GD 7 and PND 21. The
offspring were tested starting from PND 60 to investigate cognitive and motor functions. The male rats
exposed to PFOA alone displayed increased horizontal movement, decreased resting time, and
decreased habituation upon repeated testing. In the novel object recognition test (assessing
non-spatial hippocampal-dependent memory), both male and females exposed to PFOA showed lower
exploration during the initial phase, with males having overall lower time exploring the objects.
Summary
Altogether, it appears that both PFOS and PFOA exert neurotoxic effects at doses of 0.1–0.3 mg/kg
bw per day or higher. The analysis of behaviour shows that the most frequent alterations observed are
related to locomotor activity. While PFOS exposure mostly decreases spontaneous activity, PFOA
increases it. A sex-related difference has been observed in several developmental exposure studies
with males being more sensitive than females.
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Table 14: Neurotoxicity
Substance
(Purity)
Species/Experimental design
and doses
Most sensitive endpoints
Highest
dose with
no effect
(mg/kg bw
per day
Signiﬁcant effect
level (mg/kg bw
per day)
Serum/tissue
concentration
Reference
Perﬂuorooctane sulfonic acid (PFOS)
PFOS Rat, Wistar, gastric perfusion single
dose 0, 12.5, 25, 50 mg/kg bw
(n = 5/group)
Decreased motor ability
Decreased glutamate content in
cortex
12.5 (mg/kg) 25 (mg/kg) NR Yang et al.
(2009c)
PFOS; purity
> 98%
Rat, Sprague–Dawley repeated oral
exposure, 91 days1.7, 5, 15 mg/L
(0.153, 0.45, 1.35 mg/kg bw per
day(a)) (n = 8–10, per group)
Increased CaMKII and c-Jun
expression in the hippocampus
and cortex
N/A 0.153 Brain: 0.56, 3.25, 17.21
lg/g
Liu et al.
(2010a)
PFOS; purity
analytical
grade
Mouse, C57Bl/6 repeated oral
exposure, start at 8 weeks for
3 months 0.43, 2.15, 10.75 mg/kg
bw per day (n = 15 per group)
Increased apoptosis and glutamate
in the hippocampus and decreased
dopamine in the caudate putamen
0.43 2.15 NR Long et al.
(2013a)
PFOS; purity
N/A
Rat, Sprague–Dawley repeated
oral exposure, PND 60, killed at
the end of treatment 3, 6 mg/kg
bw per day for 28 days (n = 7 per
group)
Increased activity of the
hypothalamic DA system
N/A 3 NR Salgado et al.
(2015)
PFOS; purity
N/A
Rat, Sprague–Dawley repeated
oral exposure, PND 60, killed at
the end of treatment 0.5, 1, 3,
6 mg/kg bw per day for 28 days
(n = 6 per group)
Downregulation of mRNA
expression for DRD1 in amygdala;
Upregulation of DRD2 in frontal
cortex and hippocampus
N/A 6 NR Salgado et al.
(2016)
PFOS; purity
> 98%
Mouse, NMRI developmental
exposure, single dose, PND 101.4,
21 lmol/kg bw gavage (0.75,
11.3 mg/kg bw) oral (n = 4–7 per
group)
Decreased locomotor activity N/A 11.3 (mg/kg bw) at
age 2 months; 0.75
(mg/kg bw) at age
4 months
NR Johansson et al.
(2008)
PFOS; purity
> 98%
Mouse, NMRI developmental
exposure, single dose, PND
1,021 lmol/kg gavage bw
(11.3 mg/kg bw) oral (n = not
reported)
Increased CAMKII, GAP43 and
synaptophysin protein level in
hippocampus; synaptophysin and
Tau protein level in cortex;
N/A 11.3 (mg/kg bw) NR Johansson et al.
(2009)
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Substance
(Purity)
Species/Experimental design
and doses
Most sensitive endpoints
Highest
dose with
no effect
(mg/kg bw
per day
Signiﬁcant effect
level (mg/kg bw
per day)
Serum/tissue
concentration
Reference
PFOS; purity
N/A
Rat, Sprague–Dawley
developmental exposure, GD
0–PND 200.1, 0.3, 1 mg/kg bw
per day, oral (n = 5 or 15 or 20
per group, each pup derived from
different litters)
Increased locomotor activity 0.1 0.3 NR Butenhoff et al.
(2009)
PFOS; purity
> 98%
Rat, Wistar developmental
exposure, GD 1–PND 1; GD 1–PND
21; PND 1–PND 213.2 mg/kg feed
per day oral (n = 10 per group,
each pup from different litters)
Gene expression (microarray) in
cerebral cortex
N/A 3.2 Serum & brain at PND 1, 7,
14, 21, 35
Wang et al.
(2010)
PFOS; purity
> 98%
Rat, Wistar developmental
exposure, GD 0–PND 0; GD 0–PND
35; PND 0–PND 353.2 mg/kg feed
per day oral (n = 6 per group,
each pup from different litters;
12–14 litters)
Downregulation of CaM and
upregulation of CaMKII and CREB
expression in the hippocampus
N/A 3.2 (mg/kg food per
day)
Brain at PND 1, 7, and 35 Liu et al.
(2010b)
PFOS; purity
> 98%
Rat, Sprague–Dawley
developmental exposure, GD
2–210, 0.1, 0.6, 2 mg/kg bw per
day, oral(n = 10 dams/exposure)
Upregulation of astrocyte markers
(GFAP and S100B) in hippocampus
at PND 0, and in both
hippocampus and cortex at PND
21
N/A 0.1 PND 0, serum: ND, 1.5,
24.6, 45.7 ppm
PND 0, hippocampus: ND,
0.6, 7.4, 17.4 ppm
PND 0, cortex: ND, 0.4, 5.2,
13.43 ppm
PND 21, serum: ND, 0.4,
1.9, 4.3 ppm
PND 21, hippocampus: ND,
0.3, 1.6, 6.1 ppm
PND 21, cortex: ND, 0.1,
1.0, 3.7 ppm
Zeng et al.
(2011b)
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Substance
(Purity)
Species/Experimental design
and doses
Most sensitive endpoints
Highest
dose with
no effect
(mg/kg bw
per day
Signiﬁcant effect
level (mg/kg bw
per day)
Serum/tissue
concentration
Reference
PFOS; purity
> 98%
Rat, Sprague–Dawley
developmental exposure,
GD 0–200, 0.1, 0.6, 2 mg/kg bw
per day, oral (n = 10 dams/
exposure)
Downregulation of synaptophysin
and synapsin 2 at PND 0.
Downregulation of synapsin 1 & 2;
length of synaptic active zone in
CA1 at PND 21
N/A 0.1 Serum and hippocampus at
PND 0: ND; 1.5; 24.6;
45.7 ppm; ND, 0.6, 7.4,
17.4 ppm.
At PND 21: ND, 0.4, 1.9,
4.3 ppm; ND, 0.3, 1.6,
6.1 ppm.
Zeng et al.
(2011a)
PFOS; purity
0.96
Mouse, C57Bl/6 developmental
exposure, GD 1–PND 00.3 mg/kg
bw per day, oral (n = 6 per group
each pup derived from different
litters)
Decreased locomotor activity in
males only
N/A 0.3 Brain: 3.1 lg/g; liver:
11.8 lg/g
Onishchenko
et al. (2011)
PFOS; purity
N/A
Mouse, NMRI developmental
exposure, single dose, PND
1,021 lmol/kg bw(11.3 mg/kg bw)
oral (n = 4–7 per group)
Gene expression: downregulation
of AChE, nAChR-b2 in cortex, and
upregulation of mAChR-5 in
hippocampus at PND 11;
decreased locomotor activity at
age 2 months
N/A 11.3 (mg/kg bw) NR Hallgren et al.
(2015)
PFOS; purity
> 98%
Rat, Wistar developmental
exposure, GD 1–PND 0; GD 1–PND
35; PND 0–PND 355, 15 mg/L
(0.45, 1.35 mg/kg bw per day(a))
oral (n = not reported)
Decreased mRNA expression of
GAP-43
N/A 5 mg/L (0.45 mg/kg
bw per day(a))
NR Wang et al.
(2015a)
PFOS; purity
> 98%
Rat, Sprague–Dawley
developmental exposure, GD
0–PND 90; PND 0–90; GD 0–PND
01.7, 5, 15 mg/L in drinking water
(0.15, 0.45, 1.35 mg/kg bw per
day(a)) oral (n = 3 or 6 per group,
from at least 3 litters)
Increased mRNA expression and
phosphorylation of Tau and mRNA
expression of App
N/A 1.7 mg/L
(0.15 mg/kg bw per
day(a))
Serum: 18.5, 59.3, 288
lg/mL after continuous
exposure; 1.9 lg/mL after
prenatal exposure; 220
lg/mL after only postnatal
exposure to 1.35 mg/kg bw
per day
Zhang et al.
(2016b)
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Substance
(Purity)
Species/Experimental design
and doses
Most sensitive endpoints
Highest
dose with
no effect
(mg/kg bw
per day
Signiﬁcant effect
level (mg/kg bw
per day)
Serum/tissue
concentration
Reference
PFOS; purity
N/A
Mouse, NMRI developmental
exposure, single dose, PND
1,021 lmol/kg (11.3 mg/kg bw)
oral (n = 4–7 per group)
Gene expression: downregulation
of DRD5 in cortex, and
upregulation of TH in the
hippocampus at PND 11;
downregulation of DRD2 and TH in
cortex at age 2 months
N/A 11.3 (mg/kg bw) NR Hallgren and
Viberg (2016)
Perﬂuorooctanoic acid (PFOA)
PFOA; purity
0.96
Mouse, NMRI developmental
exposure, single dose, PND 101.4,
21 lM/kg bw (0.58; 8.7 mg/kg
bw) oral (n = 4–7 per group) per
group)
Decreased locomotor activity N/A 8.7 mg/kg at age
2 months; 0.58 mg/
kg at ages 4 months
NR Johansson et al.
(2008)
PFOA; purity
0.96
Mouse, NMRI developmental
exposure, PND 1,021 lM/kg bw
(8.7 mg/kg bw) oral (n = not
reported)
Increased CAMKII, GAP43,
synaptophysin and Tau protein
level in hippocampus;
synaptophysin and Tau protein
level in cortex;
N/A 8.7 mg/kg NR Johansson et al.
(2009)
PFOA; purity
> 98%
Mouse, C57Bl/6 developmental
exposure, GD 1–PND 00.3 mg/kg
per bw day oral (n = 6 per group
each pup derived from different
litters)
Increased locomotor activity in
males only
N/A 0.3 mg/kg bw per
day
Brain: 0.7 lg/g; liver
16.3 lg/g
Onishchenko
et al. (2011)
PFOA, MeHg
(alone or in
combination);
purity N/A
Rat, Wistar developmental
exposure, GD 1–PND 2,110 lg/ml
(10 ppm) in drinking water
Increased locomotor activity at
PND 36
N/A 10.12 mg/kg per
day
NR [only for MeHg] Cheng et al.
(2013)
PFOA; purity
N/A
Mouse, C57Bl/6 developmental
exposure, GD 7–PND 21PFOA
0.1 mg/kg bw per day; oral
(n = 9 per group)
Males: Increased locomotor activity
at age 2 months
N/A 0.1 mg/kg bw per
day
NR Sobolewski
et al. (2014)
bw: body weight; f: female; GD: gestational day; m: male; N/A: not applicable; NR: not reported; LOQ: limit of quantiﬁcation; PFOA: perﬂuorooctanoic acid; PFOS: perﬂuorooctane sulfonic acid;
PND: postnatal day.
(a): Conversion from mg/L to mg/kg bw calculated using EFSA guidance on selected default values. Oral deﬁnes exposure via ingestion of drinking water, food, or via gavage.
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3.3.3.5. Immunotoxicity
3.3.3.5.1. PFOS
The following studies on PFOS are summarised in Table 15.
Short-term exposure studies
Qazi et al. (2009b) carried out a number of studies to investigate immunotoxicity of PFOS. The ﬁrst
study investigated the effect of PFOS on circulating neutrophils and the inﬂammatory response of
macrophages following LPS stimulation. PFOS (the tetraammonium salt, 98% purity) was administered
to groups of 8 male C57BL/6 (H-2b) mice via the diet at 0.001% or 0.02% (corresponding to 2 or
40 mg/kg bw per day when calculated using EFSA default values (EFSA Scientiﬁc Committee, 2012))
for 10 days. Half of the animals were given an i.v. dose of LPS. 0.02% PFOS was reported to give a
total intake of 6 mg/animal over the 10 days (equivalent to 40 mg/kg bw per day). Following 0.02%
PFOS administration, body weight, thymus, spleen and epididymal fat weights were reduced compared
to controls. Food consumption was also reduced by 25%, and a signiﬁcant reduction in the number of
total white blood cells and lymphocytes, but not neutrophils, was observed. Moreover, 0.02% PFOS
markedly reduced the number of macrophages in the bone marrow, but not the spleen or peritoneal
cavity. The ex vivo production of TNF-a and IL-6 by macrophages isolated from animals treated with
0.02% PFOS was modestly increased. Moreover, PFOS enhanced the ex vivo production of TNF-a and
IL-6 by peritoneal and bone marrow (but not splenic) macrophages stimulated with LPS either in vitro
or in vivo. These results may indicate immunomodulatory activity, but cannot rule out that the effects
are secondary to a general toxic effect. In two subsequent studies by the same authors (Qazi et al.,
2009a, 2012), the results were largely conﬁrmed, i.e. effects on the thymus and thymocytes as well as
effects on the spleen (weights and cellularity) were noted, but always in the context of other general
toxicity. In the study by Qazi et al. (2012), recovery from exposure effects was investigated. In a
10-day recovery study, food consumption and body weight recovered, whereas relative weights of
liver, thymus, and spleen remained unchanged or showed slight recovery. The number of myeloid cells
recovered after 10 days, but none of the subpopulations of B-cell lineage did.
Wang et al. (2011a) administered a regular diet or high fat diet containing 10% more lard and 3%
more cholesterol with PFOS (98% purity, 0, 5, 20 mg/kg bw per day) via oral gavage for 14 days
(vehicle not given) to groups of BALB/c mice (8 male or female mice). In the regular diet groups,
5 mg/kg bw per day PFOS and more signiﬁcantly increased the relative liver weight and 20 mg/kg bw
per day PFOS reduced body weight and food consumption compared with controls. The thymus and
spleen showed atrophy (72.7% and 42.8% in males, and 41.6% and 42.8% in females, respectively),
while the ventral fat was signiﬁcantly decreased. Vasodilation and congestion were also reported in the
thymus at both dose levels. The cortico-medullary junction was virtually indistinguishable at 20 mg/kg
bw per day, as well as dilation of the splenic sinus. In the high-fat diet groups, 20 mg/kg bw per day
signiﬁcantly increased thymus and spleen atrophy, and signiﬁcantly decreased thymus and spleen
weights, compared with controls (85.1% and 50.0% in males and 76.6% and 35.9% in females,
respectively). Histopathologically, more serious atrophy was observed in the immune organs, and
adipocytes were found in the lobules of the thymus in high fat diet animals fed 20 mg/kg bw per day
PFOS. Apoptotic bodies in the cytoplasm of thymocytes and splenocytes were also reported, with
similar ﬁndings between high fat and regular fat diet animals dosed with PFOS, and PPARa and IL-6
expression was upregulated in both the thymus and spleen at both dose levels. These results suggest
that PFOS may indirectly attack the immune organs by interfering with lipid metabolism, leading to
co-senescence of the thymus and spleen.
In a study by Vetvicka and Vetvickova (2013), PFOS (purity 85%, in phosphate buffered saline) was
administered at 20 mg/kg bw per day via oral gavage to groups of 5 female BALB/c mice for 7 days.
PFOS signiﬁcantly inhibited phagocytosis (by peripheral blood neutrophils) and NK splenic activity. It
also suppressed T-lymphocyte proliferation but not B-cell proliferation. A signiﬁcant decrease in
cellularity of both the spleen and thymus was observed, although splenocyte subpopulations were not
affected. Also, from this study, it cannot be ruled out that these effects on immune parameters
resulted from general toxic effects as at this concentration all these effects were seen while also body
weights were depressed from day 4 of treatment while liver mass was increased (Vetvicka and
Vetvickova, 2013).
However, in line with direct effects of PFOS on components of the immune system, PFOS was
reported to induce apoptosis in splenocytes and thymocytes isolated from mice exposed to PFOS
(potassium salt, purity 98%), at 1, 5 or 10 mg/kg bw per day for 7 days (Zhang et al., 2013d). A
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signiﬁcant increase in the number of G1 cell populations was seen after treatment with 5 mg/kg bw
per day in splenocytes and in thymocytes treated with 10 mg/kg bw per day. In both cell types
harvested from mice exposed at the two highest doses, ROS production was increased and
mitochondrial membrane potential reduced. PFOS also increased the activities of superoxide
dismutase, catalase and glutathione reductase, and decreased glutathione-S-transferase and
glutathione peroxidase activities in splenocytes. The expression of Bax, caspase-9, p53 and caspase-3
were signiﬁcantly increased by > 5 mg/kg bw per day PFOS compared with controls, whereas Bcl-2
expression was signiﬁcantly downregulated by PFOS (> 5 mg/kg bw per day) (Zhang et al., 2013d).
Zheng et al. (2009) administered PFOS (potassium salt, purity > 98%) at 0, 5, 20 or 40 mg/kg bw
per day via oral gavage to groups of 12 male C57BL/6 mice for 7 days. The immune system was
investigated functionally by sensitising animals to SRBC by an i.p. dose of SRBCs 5 days before
sacriﬁce. Body weight and food intake were signiﬁcantly decreased following doses of 20 and
40 mg/kg bw per day. At both doses, splenic and thymic cellularity was markedly decreased, serum
corticosterone was signiﬁcantly increased, and T- and B-lymphocyte proliferation was reduced.
Lymphocyte subpopulations were also decreased in the top two dose groups, compared with controls.
Analysis of T-lymphocytes subpopulations in the spleen and thymus showed signiﬁcant decreases at 40
or 20 mg/kg bw per day, respectively. NK-cell activity, lymphocyte proliferation and plaque-forming
activity (IgM dependent) were reduced at lower exposure doses, i.e. at 5 mg/kg bw per day, indicating
a speciﬁc immunotoxic effect. In another study by the same group (Zheng et al., 2011), PFOS
administered via oral gavage to groups of 12 male C57BL/6 mice at 0, 5 or 20 mg/kg bw per day for
7 days caused decrements in body weight, relative thymic and splenic weights at the highest dose,
and dose-dependent increased relative liver weight at the two highest doses. Serum corticosterone
was also signiﬁcantly increased at the top dose. Signiﬁcant increased secretion of IL-4 from
splenocytes was reported at 20 mg/kg bw per day) while a decreased number of lymphocytes
secreting IL-2 was also seen. In all dose groups, total levels of IgM were signiﬁcantly reduced in a
dose-related fashion. In contrast, levels of total IgG were elevated at 5 mg/kg bw per day while
unaffected at 20 mg/kg bw per day.
Taken together, there are several signs of immune effects due to short-term PFOS exposure, some
of which may be indirect effects of PFOS via general toxicity. PFOS may indirectly inﬂuence the
immune organs by interfering with lipid metabolism, leading to co-senescence of the thymus and
spleen. Some effects remain even after exposure while general toxic effects resolve, while in addition,
functional immune effects, in particular speciﬁc antibody production and NK activity, are seen at lower
doses without overt toxicity. These point at a direct immunotoxic effect that may be dependent on
induction of apoptosis in lymphocytes.
Studies using exposure periods up to 28 days
Vetvicka and Vetvickova (2013) administered PFOS at 20 mg/kg bw per day via oral gavage to
BALB/c mice (groups of 5 females) for 21 days (purity 85%). To study antibody responses, animals
were treated for 1 week then injected twice (one week apart) with ovalbumin. While an effect on body
weight was observed, signiﬁcantly reduced NK splenic activity and antibody responses were also noted
in the exposed animals at this dose.
Qazi et al. (2010) administered PFOS via the diet to groups of 5 male B6C3F1 mice at 0.25 mg/kg
bw per day for 28 days. The total administered dose (TAD) was 7 mg/kg bw (equivalent to a TAD of
5.55 mg/kg bw PFOS anion). Body weight was reduced signiﬁcantly although food consumption and
serum corticosterone levels were not altered. Relative liver mass was signiﬁcantly elevated (5.3  0.12
vs control 4.8  0.14), whereas no effects were reported for thymus, spleen or fat. No effects on
circulating lymphocytes, the number of cells in the thymus or spleen, the number of plasma cells
secreting anti-SRBC IgM, the levels of IgM, IgG directed to SRBCs or IgM antibody response to TNP
were recorded (Qazi et al., 2010).
Mollenhauer et al. (2011) administered PFOS (in potassium salt, purity > 98%) at 0, 0.0331, 0.0993
or 9.3 mg/kg bw per day to female B6C3F1 mice (5/group) via oral gavage for 28 days, to yield a TAD
of 1, 3 or 300 mg/kg bw (reported as free ion doses). Some animals were also dosed with i.p. LPS. At
the highest dose level, body weight and relative spleen weight were reduced whereas relative liver
weight was signiﬁcantly increased. At 1 mg/kg TAD, serum TNF-a was reduced whilst serum IL-6 was
increased, but these changes were not seen at higher doses, hence no dose–effect relationship was
established. Variable effects were noted for various parameters (TNF-a by peritoneal macrophages
following in vitro LPS stimulation; IL-6, TNF-a, IL-1 or IL-10,) but only at the higher dose at which
effects on body weights were also noted.
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In another study, Fair et al. (2011) administered PFOS (potassium salt, purity > 98%) to female
B6C3F1 mice (groups of 5 or 10 animals/treatment, depending on endpoint under consideration) at 0,
3.31, 16.6, 33.1 or 166 lg/kg bw per day by oral gavage in Milli-Q water containing 0.5% Tween 20
for 28 days (TAD of 0.1, 0.5, 1 or 5 mg/kg bw). In this study, no effects on body weight, adrenal,
spleen, thymus, lung, liver, kidney or brain relative weights were reported for PFOS-exposed animals,
but relative uterine weight was reduced by 49% at 5 mg/kg bw. Some immune parameters were not
inﬂuenced, such as ex vivo production of IL-4, IL-5 and IL-6 following in vitro stimulation by either
anti-CD3 or PMA at any PFOS dose level. Ex vivo production of IL-6 following anti-CD40-stimulated
B-lymphocytes in vitro was, measured only at 0.1 and 1 mg/kg bw TAD. Anti-CD40 stimulated IL-6
production was increased at both concentrations, but to the same extent, hence did not show a clear
dose–response relationship. IL-6 production in LPS-stimulated B-lymphocytes was also increased at
both concentrations, which was statistically signiﬁcant only 1 mg/kg bw TAD.
Lefebvre et al. (2008) administered PFOS (potassium salt, ≥ 98% purity) via the diet at 0, 2, 20, 50
or 100 mg/kg diet for 28 days to groups of 15 male or female Sprague–Dawley rats (calculated doses
stated in the paper; males, 0.14  0.02, 1.33  0.24, 3.21  0.57 and 6.31  1.35 mg/kg bw per
day; females 0.15  0.02, 1.43  0.24, 3.73  0.57, 7.58  0.68 mg/kg bw per day). There were
two concurrent study protocols: one in which animals were only exposed to PFOS, the other where
animals were also immunised to keyhole limpet haemocyanin (KLH), to investigate functional immune
parameters, i.e. antibody production to KLH and delayed-type hypersensitivity to KLH. In the study
performed according the ﬁrst protocol, body weight of both males and females was depressed by 50
and 100 mg/kg diet and the relative liver weight was increased, relative to controls, in a dose–
response manner, in both sexes. The numbers of apoptotic lymphocytes in the thymus were increased
from 50 mg/kg diet in males and at 100 mg/kg diet in female rats. A trend towards increasing T cells
and T-helper cells, and decreasing B cells, with increasing dose levels of PFOS was seen in both sexes.
Signiﬁcant elevation of levels of IgG, IgG2a and IgG2c was reported with increasing PFOS dose,
whereas serum IgG1 levels were reduced at 2 and 20 mg/kg diet. In the study performed according
the second protocol, there was just a trend towards increasing IgG speciﬁc for KLH in males, but not
in females. The delayed hypersensitivity response to KLH was not altered by PFOS. Also, T-cell and
B-cell proliferation ex vivo following Con A or LPS stimulation of splenocytes were not altered by PFOS
treatment.
Peden-Adams et al. (2008) also administered doses of PFOS (potassium salt, purity > 98%, 0, 0.166,
1.66, 3.31, 16.6, 33.1 or 166 lg/kg bw per day) to B6C3F1 mice (groups of 5 male or female) via oral
gavage (0.5% Tween 20 in Milli-Q water) for 28 days. The TAD over 28 days was 0, 0.005, 0.05, 0.1,
0.5, 1 or 5 mg PFOS/kg bw (reported as free ion doses). There were no signs of overt toxic effects on
body weight or organ masses (spleen, thymus, liver, kidney, gonads (uterus or testes)) following PFOS
exposure, nor was the cellularity and viability of spleen and thymus. NK-cell activity was not altered in
females but was signiﬁcantly increased by 2- to 2.5-fold in males exposed to ≥ 0.5 mg/kg bw TAD. In
contrast, plasma lysozyme was unaltered in males but was increased in females at 0.1 and 5.0 mg/kg
bw TAD. SRBC-speciﬁc IgM response was suppressed in males (52–78%) and females (50–74%) at
≥ 0.05 and ≥ 0.5 mg/kg bw TAD, respectively. In males, T-cell CD4/CD8 subpopulations in the thymus
were not affected by PFOS whereas the numbers of all T-cell subpopulations were altered in the spleen
at ≥ 0.1 mg/kg bw TAD (CD4-/CD8+ and CD4-/CD8- were increased whilst CD4+/CD8 and CD4+/CD8+
were decreased). In females, the numbers of T-cell populations were minimally affected by PFOS.
Splenic CD4–/CD8+ cells were decreased at ≥ 0.1 mg/kg TAD, whereas CD4+/CD8 were decreased at
0.1 and 0.5 mg/kg bw TAD only. In a separate experiment, female mice were dosed with 0.344 mg
PFOS/kg bw per day for 21 days (TAD, 0.7 mg/kg bw) and, 7 days before termination, animals were
injected i.v. with TNP. Serum levels of TNP-speciﬁc IgM were signiﬁcantly suppressed (62%) compared
with controls, following challenge with TNP-LPS. The authors determined a LOAEL of 0.05 mg/kg bw
TAD for males and 0.5 mg/kg bw TAD for females (i.e. a LOAEL of 1.66 lg/kg per day). Serum
concentrations in male mice at 0.05 mg/kg bw TAD were 14-fold lower than those measured in humans
with occupational exposure to PFOS (Peden-Adams et al., 2008).
Guruge et al. (2009) administered PFOS (potassium salt, purity not given) at lower doses (0, 5 or
25 lg/kg bw per day) via oral gavage to groups of 30 female B6C3F1 mice for 21 days prior to virus
inoculation with mouse-adapted inﬂuenza virus A/PR/8/34 (H1N1). Animals were observed for signs of
morbidity and mortality for a further 20 days. Body weight and organ masses were not affected by
PFOS treatment. The survival rates on day 20 after virus infection were 46%, 30% and 17% in controls,
5 and 25 lg/kg bw per day, respectively. Hence, a dose-dependent increase in mortality related to
inﬂuenza infection was seen in PFOS-treated animals, being signiﬁcantly at 25 lg/kg bw per day.
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The conclusions drawn based on the short-term studies are supported by the outcome of the
studies in which somewhat longer exposure (up to 28 days) was investigated. Whereas effects on
various immune parameters were observed, often they were observed in the presence of more general
toxicity. However, functional effects on the immune system, albeit not always consistently, were noted
in the absence of overt toxicity, i.e. at levels as low as 3.3 lg/kg bw per day.
Subchronic exposure studies
Dong et al. (2009, 2011) investigated the chronic effects of PFOS on immunotoxicity in male
C57BL/6 mice. PFOS (potassium salt, purity 98%) was administered via oral gavage (in deionised
water in 2% Tween 80) to groups of 10 mice at dose levels of 0, 8.3, 83.33, 416.67, 833.33 or
2,083.33 lg/kg bw per day for 60 days (to achieve total doses of 0.5, 5, 25, 50 or 125 mg/kg bw).
Body weight was depressed by PFOS in a dose-dependent manner, food consumption was signiﬁcantly
reduced at 50 and 125 mg/kg bw TAD and relative spleen, thymus and kidney weights were reduced
at 25 and 50 mg/kg bw liver weight was increased from 5 mg/kg bw TAD. Serum corticosterone was
signiﬁcantly increased from 50 mg/kg bw TAD. B-lymphocyte and T-lymphocyte proliferation was
reduced at 50 and 125 mg/kg bw TAD, respectively. A dose level of 5 mg/kg bw TAD also resulted in a
signiﬁcant increase in NK cell activity, whilst 50 and 125 mg/kg bw TAD resulted in a signiﬁcant
reduction in NK cell activity. The NOAEL and LOAEL, based on liver mass, were 0.5 and 5 mg/kg bw
TAD, respectively, indication that in this study immune parameters investigated were not the most
sensitive. In contrast to this were results of a follow-up study by the same group (Dong et al., 2011).
In this follow-up study, the subchronic effects of PFOS on type 1 (IL-2 and IFN-c) and type 2 (IL-4 and
IL-10) cytokines were evaluated in male C57BL/6 mice (Dong et al., 2011). K+PFOS was administered
via oral gavage to groups of 12 male mice at dose levels of 0, 8.3, 16.7, 83.33, 416.7 or 833.3 lg/kg
bw per day for 60 days (to achieve total doses of 0.5, 1, 5, 25, 50 or 125 mg/kg bw). Animals were
immunised with SRBCs on day 54 and serum was obtained from 6 animals per dose group for SRBC
speciﬁc IgM analysis 7 days later. Body weight was signiﬁcantly reduced at 50 mg/kg bw TAD and food
consumption was reduced by 33%. No signiﬁcant changes in body weight or food consumption were
reported at any other dose level. Relative spleen, thymus and kidney weights were signiﬁcantly
reduced at 50 mg/kg bw TAD. Relative liver weight was signiﬁcantly increased from 25 mg/kg bw TAD.
There were no changes in serum corticosterone levels at any dose. Speciﬁc IgG2 and delayed
hypersensitivity response to SRBCs were not signiﬁcantly altered by the PFOS dosing. However, PFOS
caused a dose-related increase in IL-4 and IL-10 secretion at 5 and 50 mg/kg bw TAD, respectively,
whereas IL-2 and IFN-c were decreased at 50 mg/kg bw TAD. A TAD dose of 50 mg/kg bw
signiﬁcantly decreased the number of IL-2+ and IL-10+ -secreting lymphocytes. A dose-related
decrease in the synthesis of SRBC-speciﬁc IgM levels in sera was reported at doses of 5 mg/kg bw
TAD and higher, and speciﬁc IgG, IgG1 and IgE were signiﬁcantly elevated at 50 mg/kg bw TAD,
indicating that functional effects on the immune system were noted at doses not causing other toxicity.
A further study by Dong et al. (2012a) investigated the subchronic effects of PFOS on inﬂammation
in male C57BL/6 mice administered K+PFOS (0, 8.3, 16.7, 83.33, 416.7 or 833.3 lg/kg bw per day) via
oral gavage (in deionised water in 2% Tween 80) to groups of 12 male mice for 60 days (to achieve
total doses of 0.5, 1, 5, 25, 50 or 125 mg/kg bw). One day after the cessation of dosing, 6 animals
per group were injected with LPS. Body weight and a reduction in food consumption were depressed
by PFOS at > 25 mg/kg bw TAD, in a dose-related manner. Dose-related decreases in relative spleen,
thymus and kidney weights were also reported. At 125 mg/kg bw TAD, total peritoneal cells were
reduced although the total number of macrophages (CD11b+) was signiﬁcantly increased. PFOS
markedly increased the ex vivo production of TNF-a, IL-1b, and IL-6 in peritoneal and splenic
macrophages when stimulated either in vitro or in vivo with LPS. An increase in gene expression of
TNF-a, IL-1b and c-myc was reported at from 50 mg/kg bw, and IL-6 at 125 mg/kg bw TAD (Dong
et al., 2012a).
The same group showed that PFOS also induced apoptosis and necrosis in primary splenocytes and
thymocytes isolated from mice treated with PFOS at 1, 5 or 50 mg/kg bw per day for 60 days (Dong
et al., 2012b). An increase in apoptotic cells was seen in splenocytes and thymocytes following 5 and
50 mg/kg bw per day PFOS exposure respectively, compared with controls. Necrosis was only seen in
both cells after treatment with the highest concentration. At 50 mg/kg bw per day mitochondrial
membrane potential and associated Bcl-xl expression was decreased compared with controls, while
p53 was signiﬁcantly increased. Bcl-2 and Bax expression remained unchanged following PFOS
exposure (Dong et al., 2012b).
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Also, the subchronic studies showed functional effects on the immune system in the absence of
other toxicities. As such, the data are in line with the outcome of the short-term and medium-term
exposure studies. In addition, a possible mechanism by which some of the immunotoxic effects are
caused may be the induction of apoptosis in lymphocytes.
Data on effects of exposure to PFOS on hypersensitivity response in animals are inconsistent.
Dietary exposure to PFOS (4 mg/kg diet through 12 weeks of age) was associated with greater airway
sensitivity to methacholine; however, the association was not consistent as other airway measures did
not support hyperresponsiveness (i.e. no effect on airway resistance, tissue resistance or elastance)
and some results suggested suppression (e.g. blunted OVA-induced rise in leucocytes and
macrophages in BALF) (Ryu et al., 2014). Dong et al. (2011) reported that oral PFOS exposure
(0.8333 mg/kg bw per day via gavage) for 60 days was associated with increased antigen-speciﬁc IgE
levels following SRBC challenge.
Based on these results, it can be concluded that PFOS disturbs homoeostasis of the immune system
and is therefore immunotoxic at doses as low as 1.66 lg/kg bw per day.
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Table 15: Immunotoxicity PFOS
Substance/
(Purity)
Species/Experimental design
and doses
Most sensitive endpoints
Highest dose with
no effect (mg/kg
bw per day)
Signiﬁcant effect
level (mg/kg bw
per day)
Serum/tissue
levels of
compound
Reference
PFOS, 98% Mice (4–8 males per group),
administered via diet for 10 days,
at 0.001 or 0.02% (2 or 40 mg/kg
bw per day) (0.02% equals a total
of 6 mg/animal over 10 days)
Several immune parameters up or
down, but also body weight gain
N/A 0.02% (40 mg/kg bw
per day)
340 lg/mL Qazi et al.
(2009a,b)
PFOS, 98% Mice (4 males), restricted food
diet, 10 days, 0.001, 0.002, 0.02
(1.6, 3.1 or 23.5 mg/kg bw per
day)
Reduced B-cell numbers 0.02% (23.5 mg/kg
bw per day)
0.002% (3.1 mg/kg
bw per day)
NR Qazi et al.
(2012)
PFOS, 98% Mice (8 per group, males and
females), gavage, 5, 20 mg/kg bw
per day, 14 days
Thymus and spleen histopathology,
but in addition to liver effects and
PPARa changes
5 20 25.2 lg/mL
4,89 lg/mL
Wang et al.
(2011a)
PFOS, 85% Mice (5 females per group),
gavage, 20 mg/kg bw per day,
7 days
Values various immune parameters
reduced, but in addition to body
weights
N/A 20 NR Vetvicka and
Vetvickova
(2013)
PFOS, 98% Mice (12 males per group),
gavage, 1, 5, 10 mg/kg bw per
day, 7 days
Ex vivo apoptotic parameters in
splenocytes and thymocytes up
and down
N/A 1 NR Zhang et al.
(2013d)
PFOS, 98% Mice (12 males per group),
gavage, 5, 20, 40 mg/kg bw per
day, for 7 days
Reduced NK activity, antibody
response, lymphocyte proliferation
N/A 5 NR Zheng et al.
(2009, 2011)
PFOS, 85% Mice (5 females per group),
gavage, 20 mg/kg bw per day,
21 days
Reduced antibody response and
NK activity, but accompanied by
body weight effects
N/A 20 NR Vetvicka and
Vetvickova
(2013)
PFOS Mice (5 males per group), food,
0.25 mg/kg bw per day for
28 days
Effects on body weight and liver
No immune effects
0.25 N/A NR Qazi et al.
(2010)
PFOS, 98% Mice (5 females per group),
gavage, 0.0331, 0.0993,
9.3 mg/kg bw per day, 28 days
TNF-a and IL-6 up and down, but
no dose response
N/A 0.0331 NR Mollenhauer
et al. (2011)
PFOS, 98% Mice (5–10 females), gavage,
3.31, 16.6, 33.1), 166 lg/kg bw
per day, 28 days
Increased ex vivo IL-6 N/A 3.31 lg/kg bw per day
(0.00331 mg/kg bw
per day)
NR Fair et al.
(2011)
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Substance/
(Purity)
Species/Experimental design
and doses
Most sensitive endpoints
Highest dose with
no effect (mg/kg
bw per day)
Signiﬁcant effect
level (mg/kg bw
per day)
Serum/tissue
levels of
compound
Reference
PFOS, 98% Mice (15 males per group), diet,
0.14, 1.33, 3.21, 6.31 mg/kg bw
per day, 28 days
Reduced total IgG1 levels in serum N/A 1.33 NR Lefebvre
et al. (2008)
PFOS, 98% Mice (5 males or females per
group), gavage, 0.166, 1.66, 3.31,
16.6, 33.1, 166 lg/kg per day,
28 days
Reduced speciﬁc antibody
response
0.166 lg/kg per day
(0.000166 mg/kg bw
per day)
1.66 lg/kg bw per day
(0.00166 mg/kg bw
per day)
131 ng/mL
91.5 ng/mL
Peden-Adams
et al. (2008)
PFOS Mice (30 female mice per group),
gavage, 5, 25 lg/kg per day,
21 days
Reduced survival after challenge
with inﬂuenza virus
5 lg/kg per day
(0.005 mg/kg bw per
day)
25 lg/kg per day
(0.025 mg/kg bw per
day)
670 ng/mL
189 ng/mL
Guruge et al.
(2009)
PFOS, 98% Mice (10–12 males per group),
gavage, 8.3, 16.7, 83.33, 416.7,
833.3 lg/kg bw per day for
60 days
IL-4 and IL-10, apoptotic
lymphocytes, gene expression
TNF-a, IL-1b, values up and down
8.3 lg/kg per day
(0.0083 mg/kg bw per
day)
83.33 lg/kg bw per
day
(0.0833 mg/kg bw per
day)
8.21 lg/mL Dong et al.
(2009, 2011,
2012a)
bw: body weight; IgG: immunoglobulin G; IL: interleukin; NK: natural killer (cell); N/A: not applicable; NR: not reported; PFOS: perﬂuorooctane sulfonic acid; PPAR: peroxisome proliferator-
activated receptors; TNF: tumour necrosis factor.
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3.3.3.5.2. PFOA
The following studies on PFOS are summarised in Table 16.
Short-term exposure on immunotoxicity parameters in mice
Vetvicka and Vetvickova (2013) investigated the immunotoxic effects of PFOA and PFOS in mice.
PFOA (purity 96%, in phosphate buffered saline) was administered at 20 mg/kg bw per day via oral
gavage to female BALB/c mice (groups of 5 mice) for 7 days. Body weight was depressed from day 4
of treatment while liver mass was increased. Mice showed signiﬁcant inhibition of phagocytosis and
natural killer (NK) cell activity, and decreased antibody responses compared to controls. No
signiﬁcantly effect was seen on cellularity in the spleen, but signiﬁcant reduction of cellularity was
noted in the thymus. In the spleen, signiﬁcantly suppressed T-lymphocyte proliferation, inhibited
B-lymphocyte proliferation, inhibited phagocytosis and reduced NK were noted. The CONTAM
Panel noted that whereas this study indicates that several immune parameters, including functional
parameters, are inﬂuenced by PFOA at the concentration of 20 mg/kg bw per day for 7 days, there
was a simultaneous effect on body weight gain and liver, it cannot be ruled out that some of these
effects are indirect effects rather than direct effects of PFOA exposure.
DeWitt et al. (2008) performed an oral exposure experiment in female C57BL/J mice, in which
initial doses of 0 or 30 mg/kg bw per day PFOA (98% purity, ammonium salt) were administered by
oral gavage (using a water vehicle) for 10 days, after which time half the group was treated with the
vehicle alone (recovery group) whilst the remaining half was given further daily doses for days 11–15
(constant group). Eight mice per group were used for endpoints, with the exception of antibody
production where 16 animals/dose were used. At 30 mg/kg bw per day, signiﬁcantly reduced body
weights were noted. Body weights recovered in animals in the recovery group. Relative liver weights
were signiﬁcantly increased in both the constant and recovery groups, while IgM synthesis after
immunisation to sheep red blood cells (SRBCs) was signiﬁcantly decreased compared with controls in
both constant and recovery groups. In subsequent dose–response studies by this group (DeWitt et al.,
2009), female C57BL/6N mice received PFOA via drinking water at doses of 3.75, 7.5, 15 or 30 mg/kg
bw per day or 0.94, 1.88, 3.75 or 7.5 mg/kg bw per day for 15 days, and were immunised
intravenously with SRBC for immunoglobulin responses or bovine serum albumin (BSA) on day 10 of
exposure to assess delayed hypersensitivity response. SRBC-speciﬁc IgM synthesis was suppressed at
≥ 3.75 mg/kg bw per day in a dose-dependent manner, but no effects of PFOA treatment on delayed
hypersensitivity were reported (DeWitt et al., 2008). The CONTAM Panel notes that again, this study
indicates that oral exposure to PFOA leads to decreased values of immune parameters. Whereas at the
higher concentration used, there is an effect on body weight and liver, for which reason it cannot be
concluded whether the decrement was due to direct effects on the immune system or represent
indirect effects. However, the dose–response studies reveal effects on the antibody response to Sheep
red blood cells at lower concentrations, i.e. from 3.75 mg/kg bw per day. As there were no effects on
body weight at these doses, direct effects seem evident. The CONTAM Panel noted that especially the
humoral arm of the immune system seems affected; delayed type hypersensitivity responses were not
affected.
In order to further shed light on whether effects of PFOA on the immune system were direct
effects, or rather present indirect effects through an inﬂuence on corticosterone levels that may be
inﬂuenced by PFOA exposure, the same authors (Dewitt et al., 2009) performed a study in which
NH4
+PFOA (98% purity; 3.75, 7.5 or 15 mg/kg bw per day) was administered via drinking water for 10
consecutive days (groups of 6 animals/treatment group) to female C57BL/6N mice that were either
adrenalectomised or sham-operated. After exposure the mice were immunised with SRBCs. Serum
corticosterone levels were signiﬁcantly higher in sham-surgical animals exposed to 15 mg/kg bw per
day by approximately 157% compared with controls, whereas levels were not signiﬁcant different in
adrenalectomised, PFOA dosed animals. Exposure to 15 mg/kg bw per day reduced body weight in
both sham-operated and adrenalectomised mice, and signiﬁcantly reduced IgM titres in sham-operated
as well as in adrenalectomised animals, by 15% and by 18%, respectively. Following exposure to
7.5 mg/kg bw per day PFOA, body weight was reduced in adrenalectomised mice, and reduced
immunoglobulin M (IgM) titres by 11.8% in adrenalectomised animals. The CONTAM Panel notes that
this study indicates that in mice functional effects of exposure to PFOA is observed while there was still
an effect on body weights, but that the effect appears independent from corticosterone levels.
Qazi et al. (2009b) investigated the effect of PFOA on circulating neutrophils and the inﬂammatory
response of macrophages following lipopolysaccharide (LPS) stimulation after oral exposure.
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NH4
+PFOA, 98% purity, was administered via the diet to male (C57BL/6 (H-2b)) mice at 0.001% or
0.02% (corresponding to 2 or 40 mg/kg bw per day, when calculated using EFSA default values (EFSA
Scientiﬁc Committee, 2012)) for 10 days (groups of 8 mice/analysis group), following which half of the
animals were given an intravenous dose of LPS. 0.02% PFOA was reported to give a dose of
5.2 mg/animal over the 10 days (doses/kg bw were not reported). Food consumption and body weight
were reduced following 0.02% PFOA administration. At this concentration, also reduced numbers of
total white blood cells, lymphocytes and neutrophils was observed. Moreover, PFOA markedly reduced
the number of macrophages in the bone marrow, but not in the spleen or peritoneal cavity, despite
overall cellularity being strikingly reduced. The ex vivo production of TNF-a was modestly increased by
peritoneal and bone marrow macrophages but reduced in spleen cells following PFOA (0.02%
(40 mg/kg bw per day) exposure. IL-6 was also increased in peritoneal cells, but not in bone marrow
cells. In vitro stimulation of peritoneal, bone marrow and spleen cells with LPS enhanced the
production of both TNF-a and IL-6 and the in vivo exposure to PFOA potentiated these ex vivo TNF-a
and IL-6 responses. The serum levels of these cytokines in response to in vivo LPS stimulation was
elevated by 0.02% PFOA. The authors conclude that the results are consistent with an
immunosuppressive effect of 0.02% PFOA in the diet and an augmented inﬂammatory response to LPS
at that concentration. The Panel considers that in this study effects of exposure are noted, but at a
dose where there is also a considerable effect of feed intake and body weight.
Qazi et al. (2009a) performed subsequent studies to investigate cellular composition of the thymus
and spleen following exposure to PFASs. PFOA was administered to groups of 4 male C57BL/6 (H-2b)
mice via the diet at 0 or 0.02% (40 mg/kg bw per day) for 10 days. Following exposure, food
consumption, body weight, liver weight and epididymal fat weights were markedly depressed. In
addition, relative thymus and spleen weight were reduced. There were marked decreases in total
thymocytes and splenocytes following exposure to PFOA and the morphology of the thymus was
signiﬁcantly different to controls (the thymic cortex of exposed animals was smaller and virtually
devoid of cells and the cortical/medullary junction was not distinguishable).
In a further study (Qazi et al., 2012), groups of four male C57BL/6(H-2) mice were administered
doses of 0, 0.001, 0.002 or 0.02% (indicated by author corresponding to 0, 1.6, 3.1 or 23.5 mg/kg bw
per day) in the PFOA diet for 10 consecutive days, following which recovery was allowed for a further
10 days. In separate experiment, control animals were fed a restricted diet (35% reduction in normal
daily food consumption) to allow comparison of organ effects with high-dose PFOA, which had
previously been shown to reduce dietary intake. Again, at 0.02% PFOA (23.5 mg/kg bw per day),
signiﬁcant reductions in food intake, body weights, and relative weights liver and epididymal fat pads
were reported. In addition, reduced weights of thymus and spleen, and marked reductions in the
numbers of thymocytes (96%), splenocytes (64%) and bone marrow cells (27%) were also reported,
as well as B-lymphoid and myeloid cells. Dietary restriction in control animals reduced body weight and
relative weights of liver, thymus, spleen and epididymal fat pads. The total numbers of B-lymphoid
cells and pro/pre-B and immature B cells were reduced by dietary restriction in a similar manner to
PFOS-treated animals. Exposure to 0.002% PFOA (3.1 mg/kg bw per day) signiﬁcantly reduced the
number of B-lymphoid cells without any effect on myeloid cells. In the 10-day recovery study, food
consumption and body weight recovered, whereas relative weights of liver, thymus, spleen showed
only slight recovery. The numbers of myeloid cells recovered after 10 days, but none of the
subpopulations of B-cell lineage. The CONTAM Panel notes that the studies by Qazi et al. (2009a,b,
2012) show effects on cellular composition of the thymus, spleen, and bone marrow, and that the
effects observed are in line with an immunosuppressive and inﬂammatory activity of PFOA. Some
effects are similar to effects noted after food restriction, and may be associated with inhibition of food
consumption. The CONTAM Panel notes that recovery of an effect on food consumption and body
weight takes place after terminating exposure, while effects on immune parameters, once established,
are still evident after terminating exposure.
Studies using longer exposure periods
Vetvicka and Vetvickova (2013) administered PFOA (20 mg/kg bw per day; purity 96%, in
phosphate buffered saline) via oral gavage to groups of 5 female BALB/c mice for 21 days. For
antibody formation, animals were treated for one week then injected twice (one week apart) with
ovalbumin, and total antibodies to ovalbumin determined. Effects on body weights were not reported.
PFOA signiﬁcantly reduced NK splenic activity, total antibodies to ovalbumin and the formation of IgM
directed against tri-nitrophenyl (TNP).
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Son et al. (2009) administered PFOA (ammonium salt, 98% pure) in drinking water ((0, 2, 10, 50
or 250 mg/L (ppm)), equivalent to 0, 0.49  0.04, 2.64  0.15, 17.63  1.15, 47.21  3.57 mg/kg
bw per day) for 21 days to Male ICR mice (5–6/group). Mean body weight was decreased in a
dose-dependent manner and markedly decreased at 250 ppm (26% reduction at 250 ppm compared
with 19% gain in controls). In the spleen, CD8 + lymphocyte populations were decreased by
approximately 50% compared with controls at all dose levels and CD4 + lymphocyte populations were
increased at 50 and 250 ppm (43% and 106%, respectively). In the thymus, exposure to 250 ppm
signiﬁcantly increased CD8+ lymphocytes (110%) whereas CD4+ was not altered. Atrophy, with
decreased thickness of the cortex and medulla, and more densely arranged lymphoid cells in the
cortex, were also reported. PFOA at 250 ppm also increased the expression of proinﬂammatory
cytokines TNF-a, IL-1b and IL-6 in the spleen but not in the thymus and C-myc expression was
increased in both the spleen and the thymus.
Loveless et al. (2008) administered NH4
+ PFOA (100% pure, 0, 0.3, 1, 10, 30 mg/kg bw per day)
via oral gavage to groups of 20 male CD-1 mice and 10 male CD rats for 29 days. Mice and rats in the
30 mg/kg bw per day group were either given an i.v. dose of SRBCs or NANO pure water for 5 days
from day 23 or 24, respectively (termed 30/0 mg/kg bw per day group). In mice, 10 and 30 mg PFOA/
kg bw per day caused a marked loss in body weight and a tripling in liver weight. 10 and 30 mg/kg
bw per day also caused a 2.3-fold increase in serum corticosterone, a moderate reduction in
triglycerides (47% and 32% of controls, respectively), an increase in blood neutrophils and monocytes,
and a decrease in peripheral blood lymphocytes (at 30 mg/kg bw per day only). Immune effects
included reduced IgM titres to SRBCs (at the 10 and 30 mg/kg bw per day), decreased spleen and
thymus weights and numbers of cells in these. In rats, doses of 10 mg/kg bw per day and higher
caused a reduction in body weight and an increase in relative liver weights and liver hepatocellular
hypertrophy (moderate), with evidence of hepatocellular necrosis. Haemoglobin and haematocrit were
slightly (91% and 92%) but signiﬁcantly reduced at 10 and 30 mg/kg bw per day, respectively, and
reticulocytes were moderately increased in the 30 mg/kg bw per day group, associated with extra-
medullary haematopoiesis. Unlike mice, no effects on SRBC-IgM titres were reported. In the 30 mg/kg
bw per day group, increased haematopoiesis in the spleen was reported, but no changes in total
spleen cell number or thymocyte number was seen.
Ryu et al. (2014) studied effects of dietary exposure to PFOA (4 mg/kg diet through 12 weeks of
age) that they found associated with increased airway hyperresponsiveness in male and female mice
following methacholine. However, they compared only one exposure dose to controls and therefore the
results are not informative as to whether or not there is a dose response.
Taken together, the CONTAM Panel notes that the evidence available suggests that exposure to
PFOA has effects on the immune system in vivo. The immunotoxic effects in vivo were revealed by the
cellular composition of bone marrow, spleen, and thymus, and functional effects were noted to include
decreased antibody responses to T-cell dependent antigens and increased speciﬁc IgE antibody
responses and inﬂammatory responses. These data suggest a dysregulation of the immune system,
with different inﬂuences on innate vs acquired immunity. Effects were usually seen at doses that also
induce general toxic effects such as on food intake and body weights. Whereas efforts have been
made to rule out indirect effects, such as through corticosterone, indirect effects cannot be ruled out.
On the other hand, recovery experiments show that immune effects may be longer lived than effects
on body weight and liver. Based on the 28-day oral exposure study of Loveless et al. (2008), the
NOAEL for systemic toxicity was 0.3 mg/kg bw per day based on single-cell/focal hepatocellular
necrosis at 1 mg/kg bw per day. The NOAEL for immunotoxicity was 1 mg/kg bw per day based on
suppression of anti-SRBC IgM titre.
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Table 16: Immunotoxicity PFOA
Substance/
(Purity)
Species/Experimental
design and doses
Most sensitive endpoints
Highest dose with
no effect (mg/kg
bw per day)
Signiﬁcant effect
level (mg/kg bw
per day)
Serum/tissue levels
of compound
Reference
PFOA, 97% Mice (5 females per group),
7 days, gavage, 20 mg/kg
bw per day
Several immune parameters
reduced, but also body weight
gain and liver
N/A 20 NR Vetvicka and
Vetvickova (2013)
PFOA, 98% Mice (16 females), 10 days,
gavage, 0, 30 mg/kg bw per
day. Followed by nil or
exposure for 5 days
Reduced antibody responses
but also body weight gain
N/A 30 NR DeWitt et al.
(2008)
PFOA, 98% Mice (6 males), Drinking
water for 15 days
3.75, 7.5, 15, 30 mg/kg bw
per day or
0.94, 1.88, 3.75, 7.5 mg/kg
bw per day
Reduced antibody response 3.75 7.5 35.33 lg/ml Dewitt et al.
(2009)
PFOA, 98% Mice (4–8 males per group),
food for 10 days, 0.001 or
0.02% (2 or 40 mg/kg bw
per day) (0.02% equals a
total of 5.2 mg/animal over
10 days)
Values several immune
parameters up or down, but
also body weight gain
N/A 0.02% (40 mg/kg bw
per day)
NR Qazi et al.
(2009a, b)
PFOA, 98% Mice (4 males per group),
restricted food diet, 10 days,
0.001, 0.002, 0.02 (1.6, 3.1
or 23.5 mg/kg bw per day)
Reduced B-cell numbers 0.002% (3.1 mg/kg
bw per day)
0.02% (23.5 mg/kg
bw per day)
NR Qazi et al. (2012)
PFOA, 96% Mice (5 females per group),
gavage, 20 mg/kg bw per
day, 21 days
Various immune parameters
reduced
N/A 20 NR Vetvicka and
Vetvickova (2013)
PFOA, 100% Mice (5–6 males per group),
drinking water, 21 days,
0.49, 2.64, 17.63,
47.21 mg/kg bw per day
Reduced CD8 levels N/A 0.49 NR Son et al. (2009)
PFOA, 100% Mice (10–20 males), gavage,
0.3, 1, 10, 30 mg/kg bw per
day, 29 days
Various immune parameters
reduced, but also body weight
gain, liver
1 10 NR Loveless et al.
(2008)
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Substance/
(Purity)
Species/Experimental
design and doses
Most sensitive endpoints
Highest dose with
no effect (mg/kg
bw per day)
Signiﬁcant effect
level (mg/kg bw
per day)
Serum/tissue levels
of compound
Reference
PFOA, 100% Rats, gavage (10–20 males,
0.3, 1, 10, 30 mg/kg bw per
day, 29 days
Body weight, haematopoiesis,
but no immune effects
No immune effects N/A NR Loveless et al.
(2008)
PFOA Mice (8–10 females per
group, diet, 4 mg/kg diet at
day 2 of gestation though to
12 weeks of age
Increased airway
hyperresponsiveness
N/A 4 mg/kg diet 4.8 lg/mL Ryu et al. (2014)
bw: body weight; N/A: not applicable; NR: not reported; PFOA: perﬂuorooctanoic acid.
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3.3.3.6. Genotoxicity
In 2008, EFSA concluded that, based on the negativity in a large series of in vitro and/or in vivo
short-term tests at gene and/or chromosome or DNA repair levels, genotoxicity does not appear to be
a property of PFOS and that the weight of evidence indicates an indirect (non-genotoxic) mechanism
for the carcinogenicity of PFOS (EFSA, 2008). For PFOA, notwithstanding the positive results in an
in vitro chromosomal assay in CHO cells at a toxic concentration, EFSA concluded that the negative
outcome in a comprehensive series of in vitro and in vivo short-term tests at gene and/or chromosome
level indicates that PFOA is devoid of signiﬁcant genotoxic activity (EFSA, 2008). This section
summarises available PFAS genotoxicity studies published since 2007.
The CONTAM Panel has identiﬁed one study of genotoxicity in humans. In 604 fertile men from
Greenland, Poland and Ukraine, no associations were found between PFASs in serum (PFOS, PFOA,
PFNA and PFHxS) and sperm chromatin structure, apoptotic markers in semen or reproductive
hormones in serum (Specht et al., 2012). The authors concluded that exposure to PFOS, PFOA, PFNA
and PFHxS in these fertile men are not associated with DNA damage in sperm cells.
Tables 17 and 18 list all available in vitro and in vivo genotoxicity studies identiﬁed since 2007 for
PFOS and PFOA, respectively.
PFOS increased mutation frequencies at redBA/gam gene loci in gpt delta transgenic mouse
embryonic ﬁbroblasts (Wang et al., 2015b). PFOS failed to induce DNA strand breaks in SHE cells
(Jacquet et al., 2012a) and DNA strand breaks or micronuclei in human HepG2 cells (Eriksen et al.,
2010; Florentin et al., 2011). In another HepG2 study, concomitantly with increased ROS production, a
non-dose-dependent increase in strand breaks was observed (Wielsøe et al., 2015). PFOS induced
micronuclei and DNA strand breaks in rat bone marrow and peripheral blood (Celik et al., 2013; Eke
and Celik, 2016), but did not increase mutation frequencies in gpt delta transgenic mice. DNA damage
followed PFOS treatment was observed in Caenorhabditis elegans, green mussels, earthworms and
zebraﬁsh (Table 17).
PFOA did not induce mutations in bacteria (Fernandez Freire et al., 2008; Buhrke et al., 2013), but
increased mutation frequency at CD59 loci in human hamster hybrid cells at the highest applied
(cytotoxic) concentration after long-term (16 days) incubation (Zhao et al., 2010b). Four studies
reported no genotoxic effects (DNA strand breaks, micronuclei) after PFOA treatment in HepG2
(Florentin et al., 2011; Eriksen et al., 2010), V79 (Buhrke et al., 2013) and SHE cells (Jacquet et al.,
2012b). Three studies reported increased micronuclei, strand breaks and 8OHdG in HepG2 (Yao and
Zhong, 2005; Wielsøe et al., 2015) and TK6 cells (Yahia et al., 2014). In two studies these effects
were accompanied by an increase in cellular ROS. The CONTAM Panel identiﬁed for PFOA no recent
genotoxicity studies in animals.
The CONTAM Panel concluded that for PFOS and PFOA the available data are inconclusive. Recent
studies provide some evidence that the observed effects are related to oxidative stress (Yao and
Zhong, 2005; Wielsøe et al., 2015; Guo et al., 2016). The CONTAM Panel identiﬁed no evidence for a
direct genotoxic mode of action, either in vitro or in vivo.
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Table 17: In vitro and in vivo genotoxicity of PFOS
Test system Cells/animals Concentration/Treatment Result Comment Reference
In vitro
Mutation frequencies at
redBA/gam gene loci
(Spi-assay)
gpt delta transgenic
mouse embryonic
ﬁbroblasts
0, 1–20 lM, 24 h Positive
≥ 10 lM
At 10 lM (24 h) no effects on cell viability; at
20 lM 50% decrease in cell viability and
increased y-H2AX (foci not quantiﬁed,
signiﬁcantly increased Western Blot signal);
catalase treatment decreased PFOS induced
mutations and the number of y-H2AX positive
cells
Wang et al. (2015b)
Micronuclei(CBMN) HepG2 cells 0, 5–300 lM, 24 h Negative Signiﬁcant cytotoxicity ≥ 300 lM, 24 h; no
signiﬁcant ROS induction (5–300 lM, 1 or 24 h)
Florentin et al. (2011)
DNA strand breaks and
FPG sensitive sites
(Comet assay)
HepG2 cells 0, 100, 400 lM, 24 h Negative Signiﬁcant increase in ROS production (DCFH-
DA), 0.4–2,000 lM, 3 h400 lM for 24 h resulted
in a LDH release of 43%
Eriksen et al. (2010)
DNA strand breaks
(Comet assay)
HepG2 cells 0, 5–300 lM, 1 or 24 h Negative Signiﬁcant cytotoxicity from ≥ 300 lM, 24 h; no
signiﬁcant ROS induction (5–300 lM, 1 or 24 h)
Florentin et al. (2011)
0, 0.2–20 lM, 24 h Positive
≥ 0.2 lM
Cytotoxicity > 20 lM, 24 h; no dose
dependency, positive for ROS (DCFDA
ﬂuorescence) ≥ 0.2 lM
Wielsøe et al. (2015)
SHE cells 0, 0.00037–93 lM, 5 or 24 h Negative PFOS induced SHE cell transformations (7 days
treatment) at non-cytotoxic concentrations
(0.37, 3.7 lM)
Jacquet et al. (2012a)
In vivo
Micronuclei Rat 0, 0.6–2.5 mg/kg, 30 days,
via gavage every 48 h
Positive
≥ 1.25 mg/kg
Erythrocytes in bone marrow; ≥ 0.6 mg/kg
increased number of polychromatic erythrocytes
and increased damage as assed by comet assay
scores
Celik et al. (2013)
Micronuclei, Comet
Assay
Rat 0.6–2.5 mg/kg, 30 days, via
gavage every 48 h
Positive
(all doses)
Peripheral blood; 2.5 mg/kg ~ 1% LD50, 0.6 mg/
kg no behavioural or neurotoxic effects
Eke and Celik (2016)
Transgenic animal
mutation assay
gpt delta transgenic
mouse
1.5, 4, 10 mg/kg per day via
oral gavage for 28 days
Negative Mutation frequencies (Spi-) and frequencies of
micronucleated polychromatic erythrocytes
increased, but not in a signiﬁcant manner
Wang et al. (2015b)
DNA damage(Hus-1:
GFP Foci)
Caenorhabditis elegans 0, 0.25–25 lM
(12–60 h)
Positive
≥ 0.25 lM,
24 h
Also positive for ROS, decreased number of
germ cells, mitotic cell cycle arrest
Guo et al. (2016)
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Test system Cells/animals Concentration/Treatment Result Comment Reference
Comet assay (alkaline) Green mussel (Perna
viridis)
0, 0.01–1,000 lg/L for
7 days
Positive
≥ 100 lg/L
Liu et al. (2014b)
Comet assay (alkaline) Paramecium caudatum 0, 10, 30, 100 lM (1, 3 h)
0, 10, 30 lM (24 h)
Negative 100 lM PFOS for 6 h 100% toxicity Kawamoto et al. (2010)
Comet assay (alkaline) Earthworms 0, 0.25–8 lg/cm2, 48 h Positive
≥ 0.25 lg/cm3
Xu et al. (2013)
Comet assay (alkaline)
Micronuclei
Zebraﬁsh 0, 0.4–1.6 mg/L, 30 days
incubation of embryos
Positive
≥ 0.4 mg/L
Positive
≥ 0.8 mg/L
Measured in peripheral blood cells; signiﬁcance
not given
Measured in peripheral blood cells; signiﬁcance
given
Du et al. (2014)
DNA strand breaks
(alkaline precipitation)
Gull (Larus
michahellis) eggs
0, 100, 200 ng/g egg
(injected)
Negative Parolini et al. (2016)
DCFDA: dichloroﬂuorescin diacetate; DCFH-DA: dichlorodihydroﬂuorescein diacetate; LDH: lactate dehydrogenase; PFOS: perﬂuorooctane sulfonic acid; ROS: reactive oxygen species; SHE: Syrian
hamster embryo.
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Table 18: In vitro and in vivo genotoxicity studies of PFOA
Test system Cells/animals
Concentration/
Treatment
Result Comment Reference
In vitro
Bacterial reverse
mutation assay (Ames
test)
S. Typhimurium TA98,
TA100, TA102, TA104
100, 500 lM (S9)
100, 500 lM (+S9)
Negative
Negative
Fernandez Freire et al. (2008)
S. Typhimurium TA98,
TA100, TA1535, TA1537,
TA1538
5 lmol/plate (S9)
5 lmol/plate (+S9)
Negative
Negative
Only highest applied non-cytotoxic dose
shown; mean of two independent
experiments
Buhrke et al. (2013)
Mutation frequencies at
CD59 gene loci
Human hamster hybrid cells
(AL)
0–200 lM,
1–8 days
0–200 lM, 16 days
Negative
Positive at
200 lM
Cytotoxicity at ≥ 100 lM, 1 day;
induction of ROS and decrease of PFOS
induced mutations by treatment with ROS
scavenger
Zhao et al. (2010b)
Mitochondrial-DNA deﬁcient
AL cells
0–200 lM, 16 days Negative
Micronuclei(CBMN) HepG2 cells 0, 5–400 lM, 1 or
24 h
Negative Signiﬁcant cytotoxicity ≥ 200 lM, 24 h; no
signiﬁcant ROS induction (5–400 lM, 1 or
24 h)
Florentin et al. (2011)
Micronuclei HepG2 cells 0, 50–400 lM, 24 h Positive
≥ 100 lM
Also positive for strand breaks, 8-OHdG
(≥ 100 lM, 3 h) and ROS (≥ 100 lM, 2 h);
both dose dependent
Yao and Zhong (2005)
Micronuclei(OECD 487) V79 cells 10 lM (S9, +S9),
3 h (+21 h post-
incubation)
Negative IC50 (neutral red) 47 lM, 72 h Buhrke et al. (2013)
DNA strand breaks and
FPG sensitive sites
(Comet assay)
HepG2 cells 0, 100, 400 lM,
24 h
Negative Signiﬁcant increase in ROS production
(DCFH-DA), 0.4–2,000 lM, 3 h
400 lM for 24 h resulted in a LDH release
of ≤ 5%
Eriksen et al. (2010)
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Test system Cells/animals
Concentration/
Treatment
Result Comment Reference
DNA strand breaks
(Comet assay)
HepG2 cells 0, 5–400 lM, 1 or
24 h
0, 0.2–20 lM, 24 h
0, 50–400 lM, 1 h
Negative
Positive ≥ 10 lM
Positive ≥ 50 lM
Signiﬁcant cytotoxicity ≥ 200 lM, 24 h; no
signiﬁcant ROS induction (5–400 lM, 1 or
24 h).Cytotoxicity > 200 lM, 24 h; positive
for ROS (DCFDA ﬂuorescence) ≥ 0.2 lMAlso
positive for micronuclei, 8-OHdG (≥ 100 lM,
3 h)and ROS (≥ 100 lM, 2 h); both dose
dependent
Florentin et al. (2011)
Wielsøe et al. (2015)
Yao and Zhong (2005)
Syrian hamster embryo
(SHE) cells
0, 0.00037–300 lM
(0–124 lg/mL, 5 or
24 h
Negative PFOA alone did not induce SHE cell
transformation frequency in a 7 day
treatment; the combination BaP/PFOA
induced cell transformation at all PFOA
concentrations tested
Jacquet et al. (2012b)
DNA strand breaks
(Comet assay)
Human lymphoblastoid
(TK6) cells
0, 125, 259,
500 ppm, 2 h
Positive
≥ 250 ppm
The authors state that cells are viable (as
measured by trypan blue). However, data
are not shown.
Yahia et al. (2014)
8-OHdG(LC-MS/MS) Human lymphoblastoid
(TK6) cells
0, 125, 259,
500 ppm, 2 h
Positive
≥ 250 ppm
The authors state that cells are viable (as
measured by trypan blue). However, data
are not shown.
Yahia et al. (2014)
In vivo
Comet assay Green mussel (Perna viridis) 0, 0.01–1,000 lg/L
for 7 days
Positive
≥ 1,000 lg/L
Liu et al. (2014b)
Comet assay (alkaline) Paramecium caudatum 0, 10, 30, 100 lM
(1, 3 h)
0, 10, 30 lM (24 h)
(positive)
100 lM, 12 and
24 h
At pH 13 but not at pH 12.1 DNA migration Kawamoto et al. (2010)
DCFDA: dichloroﬂuorescin diacetate; DCFH-DA: dichlorodihydroﬂuorescein diacetate; LDH: lactate dehydrogenase; PFOA: perﬂuorooctanoic acid; ROS: reactive oxygen species; SHE: Syrian hamster
embryo; SOD: superoxide dismutase; TrxR: thioredoxin reductase.
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3.3.3.7. Long-term toxicity and carcinogenicity
When evaluating rodent long-term studies performed before 2008, PFOS was found to be
hepatotoxic and to induce tumours in the liver. It was also stated that there was limited evidence for
the induction of thyroid and mammary gland tumours (EFSA, 2008). For non-neoplastic effects, in the
liver a NOAEL for PFOS of 0.14 mg/kg bw per day was derived for male and female rats. Based on the
absence of genotoxicity of PFOS in a series of genotoxicity assays, a liver tumour-promoting effect of
this compound has been assumed, an effect largely attributed to a PPARa agonism mode of action.
Before 2008, several carcinogenicity studies have been evaluated showing that PFOA induces not
only hepatomegaly, but also hepatocellular adenomas, Leydig cell adenomas and pancreatic acinar cell
hyperplasia in rodents (EFSA, 2008). Based on negative results in a series of genotoxicity tests an
indirect (non-genotoxic) mechanism for carcinogenicity was assumed. This was conﬁrmed in a two-
stage assay for hepatocarcinogenesis, i.e. liver carcinogenesis was promoted in male rats initiated with
diethylnitrosamine, followed by treatment with PFOA for 12 months.
It was assumed that the induction of liver tumours in rats by PFOA is mediated largely by a PPARa
agonism mode of action. However, evidence has been gained for PPARa-independent effects of PFOA,
which might contribute to carcinogenesis, e.g. the induction of Leydig cell tumours may be due to
hormonal imbalance resulting from induction of the cytochrome P450 enzyme and aromatase or
interference with hormone receptors (ATSDR, 2015). The mechanism of PFOA-induced pancreatic
acinar cell tumours remains to be elucidated. It was suggested that PPARa stimulation might alter bile
ﬂow, bile acid composition and the subsequent release of cholecystokinin (CCK), which may promote
pancreatic cell proliferation and tumour formation (ATSDR, 2015).
In 2016, EPA (US EPA, 2016b) evaluated PFOA and concluded that data were insufﬁcient to
understand the mode of action underlying PFOA-induced testicular and pancreatic tumours. According
to EPA’s Cancer Guidelines tumorigenic effects of chemicals in animals are presumed to be relevant for
humans in case of absence of sufﬁcient data to establish a mode of action.
In 2016, IARC (2016) evaluated PFOA and stated that there is limited evidence for carcinogenicity
in experimental animals and moderate evidence for mechanisms of PFOA-associated carcinogenesis,
including some evidence for these mechanisms being operative in humans. The compound was
assigned to group 2B as being possibly carcinogenic to humans (Group 2B).
Following the EFSA opinion of 2008 (EFSA, 2008), no new studies in mammalians have been
conducted so far. However, old studies were published in more detail and material thereof was
subjected to histopathological re-evaluation. Some new data have been generated in a trout two
stage-hepatocarcinogenesis model.
3.3.3.7.1. PFOS
Butenhoff et al. (2012b) re-evaluated a two-year toxicity and cancer bioassay in male and female
Sprague–Dawley rats, published ﬁrst by Thomford (2002). The potassium salt of PFOS (86.9% purity;
impurities: 4.73% PFHxS; 0.71% PFCAs (perﬂuorobutanoic acid; perﬂuoropentanoic acid; PFOA); 1.45%
metals (calcium, magnesium, sodium, nickel, iron); 0.59% inorganic ﬂuoride) was applied for 104 weeks
at dietary doses of 0, 0.024, 0.098, 0.242, 0.984 mg/kg bw per day to males and at 0, 0.029, 0.120,
0.299, 1.251 mg/kg bw per day to females. Additional groups were fed the highest dose for the ﬁrst
52 weeks, after which they were fed control diet until study termination. PFOS caused reductions in body
weight in males fed the highest dose, which was evident throughout the observation period of
104 weeks. Male rats exhibited a statistically signiﬁcant increased survival at the two highest treatment
levels. In groups receiving the highest dose of PFOS, serum levels of total cholesterol (in males) and of
glucose were decreased, while urea nitrogen was elevated. Statistically signiﬁcant increases in
hepatocellular adenoma were observed in males and females at the highest PFOS dose. In this treatment
group, a single hepatocellular carcinoma occurred in a female animal. There were no treatment-related
ﬁndings for thyroid gland, kidney or bladder (see Table 19). The authors concluded that the liver tumour
formation may be due to a PPARa/CAR/PXR-mediated mode of action (see Section 3.3.5.5).
Benninghoff et al. (2012) used a two-stage chemical carcinogenesis model in trout to study
whether PFOS and PFOA are complete carcinogens or tumour promoters. For further details, see
Section 3.3.5.5. Hepatocarcinogenesis was initiated by aﬂatoxin B1 (AFB1). Thereafter, trout received
100 mg/kg PFOS (2.5 mg/kg bw per day) for 5 days per week, for 6 months via the diet. PFOS
enhanced the incidence but not the size of liver tumours when compared with AFB1-initiated animals
fed control diet. No tumours occurred in the liver in the group treated with PFOS only. This indicates
some tumour-promoting effects of PFOS in the liver of trout.
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To conclude, the re-evaluation of the long-term carcinogenicity study conﬁrmed that the liver is the
main target organ for chronic toxicity and carcinogenicity of PFOS. The data, obtained so far, provide
some evidence that PFOS may act as a tumour promoter in the liver of rats and ﬁsh.
3.3.3.7.2. PFOA
In a former 2-year carcinogenicity study with the ammonium salt of PFOA (97.2% purity, linear and
branched) male and female Sprague–Dawley rats (50/group) were fed 0, 30 or 300 mg/kg
(corresponding to 0, 1.3 or 14.2 mg/kg bw per day for males and 0, 1.6 or 16.1 mg/kg bw per day for
females) (Sibinski, 1987). There were signiﬁcant increases in the incidence of Leydig cell tumours in
the highest dose group. Although the authors concluded that proliferative lesions in the mammary
gland were not elevated above the historical control level and normal expected background incidence
in this rat strain, the outcome of the study was heavily discussed. As a result, a pathology working
group reviewed the original slides. In 2010, a consensus was published that the incidence of
mammary-gland neoplasms was not affected by chronic dietary administration of PFOA (Hardisty et al.,
2010).
Butenhoff et al. (2012b) also re-evaluated this study and presented many details, which have not
been published before. In males receiving 14.2 mg/kg bw per day, mean body weights were lower and
survival in these rats was greater than that seen either in the 1.3 mg/kg bw per day or the control
group. In both sexes, the highest dose elevated liver weight, hepatocellular hypertrophy, portal
mononuclear cell inﬁltration, hepatocellular vacuolation (without hepatocellular necrosis), and increased
ALT, AST and ALP in serum. A signiﬁcant elevation of Leydig cell tumours occurred in males fed
14.2 mg/kg bw per day, while tumours of the liver and acinar pancreas were not increased dose
dependently. For ﬁbroadenomas in the mammary gland, the incidences were 22%, 42% and 48% in
the controls, at 1.6 mg/kg bw per day and at 16.1 mg/kg bw per day, respectively. However, only the
increase in the highest dose group was signiﬁcant when compared with concurrent controls (see
Table 19). Caverly-Rae et al. (2014) re-evaluated material of the Butenhoff study and found a
signiﬁcantly elevated incidence of pancreatic acinar cell hyperplasia in the highest dose group. The
re-evaluation process did not obtain evidence for tumour formation in the pancreas.
In a 2-years study, male Sprague–Dawley rats received PFOA at 14 mg/kg bw per day (Cook et al.,
1994; Biegel et al., 2001). There was a signiﬁcant increase in the incidence of Leydig cell adenomas,
liver cell adenomas and pancreatic acinar cell tumours in the treated rats. The pancreatic lesions were
re-evaluated, by Caverly-Rae et al. (2014). A signiﬁcant increase in the incidence of pancreatic acinar
cell hyperplasia was identiﬁed but no evidence for pancreatic tumours were obtained. This supported
the assumption that the pancreas is a target of PFOA.
Benninghoff et al. (2012) used a two-stage chemical carcinogenesis model in trout to study
whether PFOA is a complete carcinogen or a promoter of aﬂatoxin B1 (AFB1) or N-methyl-N-nitro-N-
nitrosoguanidine (MNNG)-induced liver cancer. PFOA was applied for 5 days per week, for 6 months,
via the diet at a dose of 2,000 mg/kg (approximately 50 mg/kg bw per day). PFOA enhanced the
incidence and size of liver tumours when compared with AFB1- or MMNG-initiated animals fed control
diet. No tumours occurred in the liver in the group treated with PFOA only. This indicates tumour-
promoting effects of PFOA in the liver of trout.
To conclude, no new study was published since 2008. Two studies showed that PFOA induced
Leydig cell tumours, which was conﬁrmed by the re-evaluation of one of the studies. This tumour
entity occurs frequently in rodents, due to disturbances in the hypothalamic–hypophyseal–gonadal
axis, which regulates testosterone production by Leydig cells via release of luteotropic hormone. Any
increase in luteotrophic hormone increases the risk for growth stimulation and tumour promotion of
Leydig cells in the rodent testis. However, this tumour entity is very rare in humans and the human
relevance of the ﬁndings in the animal bioassays is not known.
The re-evaluation process conﬁrmed that in one study PFOA induced liver cell adenomas and in the
other not. Both studies applied 14 mg/kg bw per day as maximal PFOA dose to male Sprague–Dawley
rats. The reason for the differences in tumour outcomes is presently unclear. In rainbow trout, PFOA is
a liver tumour promoter, indicating a phylogenetically more or less independent mode of action of
PFOA in the liver and supporting the assumption that PFOA may be a hepatic tumour promoter in
other species as well. Several re-evaluation processes on the material obtained from one study
brought inconsistent data with regard to the tumourigenic effect of PFOA in the mammary gland.
The CONTAM Panel concluded that, due to lack of consistent data and knowledge on the mode of
action, it cannot be excluded that PFOA is carcinogenic to humans. This assessment agrees with the
classiﬁcation of PFOA by IARC as a group 2B carcinogen.
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Table 19: Long-term toxicity and carcinogenicity
Substance
(Purity)
Species/Experimental
design and doses
Most sensitive endpoints
Highest dose
with no effect
(mg/kg bw
per day)
Signiﬁcant
effect level
(mg/kg bw
per day)
Serum/tissue level of PFOS Reference
Perﬂuorooctane sulfonic acid (PFOS)
PFOS
(potassium
salt, 86.9%
purity)
Sprague–Dawley rats (m/f)
No/sex/group: 60–70
Duration: 103–106 weeks
Diet at 0, 0.5, 2, 5, or
20 mg/kg
(For males equivalent to
0, 0.024, 0.098, 0.242,
0.984 mg/kg bw per day
For females equivalent to
0, 0.029, 0.120, 0.299,
1.251 mg/kg bw per day)
Incr serum urea nitrogen (f, wk 53)
Incr serum urea nitrogen (m, wk 53)
Incr serum ALT (m, wk 14 + 53)
Hepatic centrolob hypertrophy
(m, wk 104)
Hepatic adenoma (m, wk 104)
Hepatic adenoma (f, wk 104)
0.12
0.024
0.242
0.024
0.242
0.299
0.299
0.098
0.984
0.098
0.984
1.251
Concentrations in (lg/mL)
serum (f, wk 14) at 0.029 mg/kg bw
per day: 7.0  1; at 0.12 mg/kg bw
per day: 27.3  2.3
Serum (m, wk 14) at 0.024 mg/kg bw
per day: 4  0.8; at 0.098 mg/kg bw
per day: 17.1  1.2
Liver (m, wk 14) at 0.242 mg/kg bw
per day: 358  28.8; at 0.984 mg/kg
bw per day: 568  107
Liver (m, wk 104) at 0.242 mg/kg bw
per day: 70.5  63.1; at 0.984 mg/kg
bw per day: 189  141
Liver (f, wk 104) at 0.299 mg/kg bw
per day: 131  61.4, at
1.251 mg/kg bw per day: 381  176
Butenhoff
et al.
(2012b)
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Substance
(Purity)
Species/Experimental
design and doses
Most sensitive endpoints
Highest dose
with no effect
(mg/kg bw
per day)
Signiﬁcant
effect level
(mg/kg bw
per day)
Serum/tissue level of PFOS Reference
Perﬂuorooctanoic acid (PFOA)
PFOA
(ammonium
salt, 97.2%
purity, linear
& branched)
Sprague–Dawley rats (m/f)
No/sex/group: 50–65
Duration: 104 weeks
Diet: 30 or 300 ppm
(Equivalent to: males: 1.3,
14.2 mg/kg bw per day;
females: 1.6, 16.1 mg/kg
bw per day)
Incr serum ALT (m, month 3–18)
Incr serum AST (m, month 6–12)
Incr serum ALP (m, month 3–6 s)
Hep hypertrophy (m, wk 104)
Brain weight (m, wk 104)
Spleen weight (f, wk 104)
Fibroadenoma in mammary gland
(f, wk 104)
Leydig cell adenoma (m, wk 104)
N/A
N/A
N/A
1.3
N/A
N/A
1.6
1.3
1.3
1.3
1.3
14.2
1.3
1.6
16.1
14.2
Butenhoff
et al., 2012b
ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; bw: body weight; f: female; m: male; N/A: not applicable; PFOA: perﬂuorooctanoic acid; PFOS:
perﬂuorooctane sulfonic acid; wk: week.
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3.3.4. Observations in humans
In this section, a number of epidemiological studies in humans are referred to and assessed. Under
the various subheadings (per outcome) the basic order is chronological, but if a speciﬁc cohort is
re-examined later, then this breaks the chronological order, so that several studies of a speciﬁc
outcome in the same cohort are placed together.
Many different cohorts have been studied. The largest one, called C8, has been used in several
studies, and is therefore described here.
The C8 cohort is named after the DuPont C8 plant in West Virginia where PFOA was used in the
production of ﬂuoropolymers since 1952. The plant contaminated the drinking water in several water
districts in Ohio and West Virginia. In 2001, a group of residents ﬁled a class-action lawsuit due to the
PFOA exposure. As part of a pre-trial settlement a baseline survey was conducted, including extensive
questionnaires and blood sampling in 2005–2006. Serum was analysed for PFOA and PFOS. The levels
of PFOA were much higher than in other general population samples from this period, while levels of
PFOS were in the same range as in other studies, since PFOS was not used or emitted at the C8 plant.
The cohort consists of about 69,000 individuals (adults and children) who had consumed drinking
water contaminated by PFOA from the C8 plant. Some (about 4,000) had also been working at the
plant. Later also previous exposure to PFOA (since 1952) was retrospectively estimated using
quantiﬁed exposure in a subset of participants at recruitment combined with data on area of residence
and previous occupation (Shin et al., 2011a). Part of the participants in the C8 cohort were
re-examined in 2010. Some studies have only examined residents never working at the C8 plant, while
other studies included both workers and residents-only.
3.3.4.1. Acute outcomes
No human observations on acute effects (effects after short-term exposure) were found.
3.3.4.2. Fertility and pregnancy outcomes
3.3.4.2.1. Birth weight as continuous outcome
Several studies have examined associations between PFOS and PFOA in pre-pregnancy (n = 2),
pregnancy (n = 11) samples or cord blood (n = 4) and birth weight (Table 20). Fewer studies (n = 6,
Table 21) have reported associations with more clinically relevant outcomes such as low birth weight
(LBW, < 2,500 g), or small for gestational age (SGA: birth weight < 10th percentile of average for
gestational age and gender) as these outcomes require a relatively large sample size.
Birth weight as continuous outcome: samples drawn prior to or at delivery
A brief summary of studies that have either prospectively (n = 13) or cross sectionally (n = 4, cord
blood) examined associations between serum concentrations of PFOS and/or PFOA with birth weight
as continuous outcome are presented in Table 20. Studies with fewer than 100 participants (Inoue
et al., 2004; Callan et al., 2016; Lee et al., 2016) were excluded from this review as they were
considered to be insufﬁciently powered, taking into consideration that there were several larger studies
available. Of these 17 studies, 7 reported a signiﬁcant inverse association for PFOA, while 6 studies
reported a signiﬁcant inverse association for PFOS. Most of the other studies also reported inverse
associations, although statistical signiﬁcance was not reached. In those studies, this may at least partly
be explained by modest sample size (8 studies had < 300 participants). This conclusion is also
supported by the fact that in larger studies (n ~ 700–1,500), reporting inverse associations with birth
weight, the observed effect size was relatively modest. The smaller studies were, on the other hand,
divergent both in terms of the effect size and direction of the observed associations (a few studies
even reported non-signiﬁcant positive association with birth weight). The exposure ranges in the
studies on birth weight differed widely with mean/median maternal serum or cord blood levels ranging
from 0.9 to 31.0 ng/mL for PFOA and 1.0 to 35.3 ng/mL for PFOS.
With respect to individual studies, the study by Darrow et al. (2013) was one of several studies
from the C8 cohort that examined associations between exposures to PFOA and birth outcomes. The
other studies (Nolan et al., 2009; Stein et al., 2009; Savitz et al., 2012a,b) relied on indirect or
retrospective measures of exposures. In the study by Darrow et al. (2013), serum samples from 710
women were drawn pre-pregnancy at enrolment (2005–2006) and associations with birth weight were
examined among pregnancies occurring until 2010. More than 99% of all births occurred within
3 years from the drawing of the blood sample. Serum PFOA concentrations were substantially elevated
with the mean (SD) for serum PFOA being 31.0 ng/mL (50.5) while serum PFOS levels were
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comparable to those observed in the general population. No association was observed for PFOA while
a signiﬁcant inverse association was observed for PFOS. Some care must be taken when comparing
this study to the other studies in Table 20, as it is difﬁcult to predict if and how the time interval
between drawing of pre-pregnancy serum samples and later delivery may have had on the effect
estimates, despite adjustment. Since PFOA has a shorter half-life than PFOS and drinking water
concentrations were rapidly decreasing when subjects were recruited (Avanasi et al., 2016)
pre-pregnancy concentrations for PFOA may have been a less accurate marker for pregnancy exposure
compared PFOS. Still, one strength of this study is, however, that pre-pregnancy serum samples
should be less inﬂuenced by physiological changes in pregnancy such as increased glomerular ﬁltration
rate (Verner et al., 2015) and hemodilution (Savitz, 2007) that may act as a confounder for the
association with birth weight. Darrow et al. (2013) also reported results for pregnancies that occurred
prior to enrolment (retrospective analyses), thereby including 1,470 births as compared to 710 births
for the prospective analyses. Results were similar or slightly weaker compared to the prospective
analyses. In a comparable but much smaller study, Robledo et al. (2015) examined sex speciﬁc (113
boys and 117 girls) associations between pre-pregnancy serum samples of PFOS and PFOA and birth
weight. No signiﬁcant associations were observed.
With respect to the larger studies summarised in Table 20, Fei et al. (2007) reported a signiﬁcant
inverse association between maternal serum concentrations (n = 1,400) of PFOA (mean 5.6 ng/mL)
and birth weight with a modest reduction of 5 g in birth weight per 1 ng/mL increase in maternal
concentrations (corresponding to around 50–60 g reduction in birth weight over the effective exposure
range). No association was observed for PFOS. In another large (n = 1,250) study by Lenters et al.
(2016) a ~ 3-fold increase in maternal PFOA (mean 1.6 ng/mL) concentrations was signiﬁcantly
associated with a 79 g reduction in birth weight. The corresponding reduction for PFOS (mean
9.4 ng/mL) was a 69 g, which was non-signiﬁcant. Similarly, Whitworth et al. (2012a) reported a
borderline signiﬁcant inverse association between maternal concentrations of PFOA (median 2.2 ng/mL,
n = 901) of 106 g comparing the highest to lowest quartile of exposure. The corresponding
non-signiﬁcant reduction in birth weight for PFOS (median 13.0 ng/mL) was 85 g. In another large
study (n = 1,507) by Bach et al. (2016), with relatively low serum concentrations (median for PFOS and
PFOA of 2.0 and 8.3 respectively) no associations with birth weight were observed. Only nulliparous
women were included in that study.
Overall, the effect estimates reported in Table 20 for PFOA were slightly stronger compared to
those reported for PFOS. Some caution is necessary when comparing the effect estimates, as authors
either reported their associations based on categorical exposure (tertiles or quartiles) or they reported
their effect estimates per 1-unit increase on a logarithmic scale (natural logarithm (Ln ~ 3-fold and
Log10 = 10-fold increase in exposure). It also has to be taken into consideration that cord blood
concentrations are lower than those in maternal serum (Fei et al., 2007). As a result, associations
among studies using cord blood may appear to occur at lower levels than those observed in studies
using maternal serum.
With respect to confounder control, all studies accounted for important host factors including
maternal weight and parity and length of gestation. Many of these studies also accounted for socio-
occupational status or education in their adjusted models (Washino et al., 2009; Fei et al., 2007; Chen
et al., 2012; Whitworth et al., 2012a; Wu et al., 2012; Bach et al., 2016; Lenters et al., 2016; Wang
et al., 2016). The study by Whitworth et al. (2012a) was the only study that accounted for serum
albumin in their adjusted models. The argument for including serum albumin was, according to the
authors, that serum albumin levels have been associated with adverse pregnancy outcomes. Given the
strong binding of PFASs to serum albumin this adjustment may have inﬂated their conﬁdence intervals.
The authors noted in their publication that serum albumin appeared to be a confounder for the
PFOS-birth weight association, while adjustment for albumin had limited inﬂuence on their effect
estimate for PFOA.
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Table 20: Studies examining associations between serum concentrations of PFOS and PFOA in pregnancy or at birth with birth weight as a continuous
outcome. Signiﬁcant associations are indicated in bold
Study Study year Country N Sample Outcome Unit for b(a)
PFOA PFOS
Median or
mean
(ng/mL)
b (95% CI)
Median
or
mean
(ng/mL)
b (95% CI)
Pregnancy serum or cord blood concentrations
Lauritzen et al.
(2017)(b)
1986–1988 NO 265 Week 17–20 Birth
Records
g/1-Ln 1.6 37 (99, 174) 9.7 74 (31, 178)
SE 159 Week 17–20 Birth
Records
g/1-Ln 2.3 359 (596, 122) 16.4 292 (500, 84)
Maisonet et al.
(2012)
1991–1992 UK 447 Week 10–28 Birth
Records
T3 vs T1 3.7 133 (237, 30) 19.7 140 (238, 42)
Fei et al. (2007) 1996–2002 DK 1,400 Week 4–14 Birth
Records
g/1-ng/mL 5.6(c) 11 (21, 0.5) 35.3(c) 0.5 (2.3, 1.4)
Wang et al.
(2016)
2000–2001 TW-boys 117 3rd trimester Birth
Records
z-score/1-Ln 2.0(d) 0.04 (0.05, 0.12)
TW-girls 106 3rd trimester Birth
Records
z-score/1-Ln 2.0(d) 0.08 (0.18, 0.01)
Lenters et al.
(2016)(e)
2002–2004 GL/PO/UA 1,250 2nd-3rd
trimester
Birth
records
g/1-Ln 1.4(d) 79 (137, 20) 9.4(d) 69 (153, 15)
Kobayashi et al.
(2017)
2002–2005 JP 177 Week 24–41 Birth
records
g/1-Ln 1.4 49 (130, 32) 5.3 56 (163, 51)
Apelberg et al.
(2007a)
2004–2005 US 293 Cord blood Birth
Records
g/1-Ln 1.6 161 (270, 52) 5.0 69 (149, 10)
Washino et al.
(2009)
2002–2005 JP 429 Week 25–35 Birth
Records
g/1-Log10 1.3 75 (192, 42) 5.2 149 (297, 1)
Hamm et al.
(2010)
2005–2006 CA 252 Week 15–16 Birth
Records
T3 vs T1 1.5 15 (107, 137) 7.8 71 (CI:55, 197)
Wu et al. (2012) 2007 CN 167 At delivery Self-report g/1-Log10 11.5 267 (573, 37) – –
Whitworth et al.
(2012a)
2003–2004 NO 901 Week 17 Birth
Records
Q4 vs Q1 2.2 106 (220, 7) 13.0 85 (194, 24)
Kwon et al.
(2016)
2006–2010 KR 268 Cord Blood Birth
records
g/1-Log(f) 0.9 78 (154,-2) 0.6 49 (96, 3)
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Study Study year Country N Sample Outcome Unit for b(a)
PFOA PFOS
Median or
mean
(ng/mL)
b (95% CI)
Median
or
mean
(ng/mL)
b (95% CI)
Chen et al.
(2012)
2004–2005 TW 429 Cord blood Birth
Records
g/1-Ln 1.8(d) 19 (64, 25) 5.9(d) 110 (176, 45)
Shi et al. (2017) 2012 CN 170 Cord blood Birth
Records
g/1-Log10 1.1 162 (128, 454) 1.0 160 (12, 332)
Bach et al.
(2016)
2008–2013 DK 1,507 < 13 weeks Birth
Records
Q4 vs Q1 2.0 7 (10, 23) 8.3 8 (30, 14)
Pre-pregnancy serum concentrations
Darrow et al.
(2013)(g)
2005–2006 US 710 Pre-
pregnancy(d)
Self-report g/1-Ln 31.0(d) 5 (22, 33) 15.6(d) -49 (-90, -8)
Robledo et al.
(2015)
2005–2008 US-boys 113 Pre-
pregnancy(d)
Self-report g/1-SD of Ln 5.0(d) 5 (85, 95) 21.6(d) 38 (73, 148)
US-Girls 117 Pre-
pregnancy(d)
Self-report g/1-SD of Ln 3.2(d) 62 (159, 36) 12.4(d) 14 (81, 110)
CI: conﬁdence interval; SD: standard deviation; T: tertile; Q: quartile; NO: Norway; SE: Sweden; UK: the United Kingdom; GL: Greenland; PO: Poland; UA: Ukraine; DK: Denmark; US: United
Sates; JP: Japan; CA: Canada; CN: China; KR: Korea (South); TW: Taiwan.
Hamm et al. (2010): T3: > 10 ng/mL for PFOS and > 2.1 ng/mL for PFOA. T1 < 6.1 ng/mL for PFOS and < 1.1 for PFOA.
Whitworth et al. (2012a): Q4: > 16.6 ng/mL for PFOS and > 3.0 ng/mL for PFOA. Q1 < 10.3 ng/mL for PFOS and < 1.7 ng/mL for PFOA.
Maisonet et al. (2012): T3: > 23 ng/mL for PFOS and > 4.4 ng/mL for PFOA. T1 < 16.6 ng/mL for PFOS and < 3.1 for PFOA.
Wu et al. (2012): recruitment of 108 women from contaminated e-waste are with median of 17.0 ng/mL and 59 subjects from less contaminated are with median of 6.3 ng/mL.
(a): b: the regression coefﬁcient for the linear association between PFOS and PFOA exposure and change in birth weight. The unit is given in the column to the right which can be either
continuous (g birth weight per unit increase in terms of ng/mL, SD or Log/LN-transformed exposure; or mean change in birth weight when exposure is modelled as binary (that is T1 vs T3).
(b): This study oversamples SGA cases and reported results from NO and SE participants separately.
(c): Mean.
(d): Geometric mean.
(e): Only term births included (gestation weeks 37–42). For consistency with other results reported in the Table, the adjusted linear regression estimates as reported in supplemental tables are
shown (not penalised regression coefﬁcients where other contaminants have been adjusted for, as reported in the main text).
(f): No logarithmic base given.
(g): Blood samples drawn at enrolment (2005–2006) but serum concentrations are associated with pregnancies occurring after recruitment until 2010. Greater than 99% of all birth occurred within
3 years from the drawing of the blood sample.
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Birth weight as dichotomous outcome: samples drawn prior to or at delivery
Only 6 of the 17 studies reviewed in Table 20 examined associations between concentrations of
PFOS and PFOA and low birth weight (< 2,500 g) or small for gestational age (SGA). In addition, one
study from the C8 cohort examined retrospectively, the relationship between baseline serum
concentrations of PFOS and PFOA with pregnancies occurring up to 5 years earlier (Stein et al., 2009).
A summary of study characteristics and the effect estimates are shown in Table 21.
Overall, ﬁndings from these studies were divergent. As an example, a nested case–control study of
265 and 159 mother child pairs from Norway and Sweden (pregnancies from 1986 to 1988),
respectively, where SGA children were oversampled (Lauritzen et al., 2017) reported an increased risk
of SGA related to PFOA among the Swedish but not the Norwegian participants. A borderline
signiﬁcant positive association was also observed for PFOS. It is worth noting, however, that maternal
concentrations of PFOS and PFOA were considerably higher among the Swedish compared to the
Norwegian participants (see Table 21). A signiﬁcant positive association was also observed between
PFOS concentrations and low birth weight in the retrospective study by Stein et al. (2009). Non-
signiﬁcant associations were reported for the other four studies reviewed in Table 21.
A limitation of the studies reviewed in Table 21 is the relatively small samples size and low power. As
an example, only the studies by Stein et al. (2009) and Fei et al. (2007) were sufﬁciently powered (at
b = 0.8 at a = 0.05) to detect an association corresponding to an OR of ~ 1.5 and ~ 1.6 for LBW and
SGA, respectively. In the study by Fei et al. (2007) a non-signiﬁcant association for SGA was observed
with odds ratios centred around 1. For LBW which had a prevalence of ~ 1.7%, Fei et al. (2007) only had
a power of ~ 50% to detect the observed odds ratio of ~5 when comparing the highest to the lowest
quartile of maternal concentration for PFOS. All the other studies in Table 21 had a power less than 80%
to detect any association below ~ 3, due to limited samples size. With only 16 SGA cases there is limited
information that can be drawn from the effect estimates reported by Hamm et al. (2010).
C8-studies on low birth weight using indirect retrospective measures of exposure
Savitz et al. (2012a) examined retrospectively associations between estimated previous exposure to
PFOA in relation to self-reported birth outcomes, including term low birth weight (n = 399 cases), for
11,737 pregnancies (1990–2006). Past exposures were derived from measured serum concentrations
at enrolment into the C8-project (2005–2008). In a later case–control study (Savitz et al., 2012b), the
authors extracted information from birth records (as opposed to self-report in the other study)
resulting in 918 term low birth weight cases and 3,616 controls. No association with low birth weight
were observed in both studies with OR centred around 1. Similarly, Nolan et al. (2009) reported null
associations when comparing birth weight distributions across different water services (used as proxy
for PFOA exposure). No consistent associations with preterm delivery or birth defects were observed in
these studies either.
The strength of these two studies are the wide range of exposure to PFOA in the study population,
which should be less prone to disturbances due to physiological changes in pregnancy compared to
studies relying on serum concentrations in background exposed population. However, relying on
retrospective exposure assessment extrapolating several years backwards in time, or using water
services as proxy for exposure is a major limitation. Despite limitations, these studies were sufﬁciently
powered to examine rare outcomes such as low birth weight and they do not provide indications to
support that PFOA may be associated with low birth weight or major birth defects.
Summary
Although not all studies reported signiﬁcant inverse association with birth weight it appears that
there is an overall tendency towards an inverse correlation between concentrations of PFOS/PFOA and
birth weight. This conclusion is based primarily on the results reported in the larger studies as lack of
consistency among some of the studies reviewed in Table 21 may be inﬂuenced by relatively small
sample sizes. What complicates matters further is the fact that there is evidence to suggest that the
inverse association between PFOA and PFOS may be partly explained by maternal physiology. One
suggested mechanism is confounding by maternal glomerular ﬁltration rate that is positively related to
the rate of excretion of PFOS and PFOA; as well as being a positive predictor of birth weight (Morken
et al., 2014). PBPK models for PFOS and PFOA have suggested that around half, but not all, of the
effect size for birth weight may be explained by this mechanism (Verner et al., 2015).
Despite the fact that studies reporting results on LBW and SGA were generally underpowered or
limited due to use of retrospective exposure assessment, there were no strong indications that the
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observed decrease in birth weight translates into increased risk of LBW or SGA. In that context, the
biological relevance of an inverse association with birth weight on its own is unclear. Whether a
modest reduction in birth weight is an indication of some adverse events that will become apparent
later cannot, however, be excluded. Overall, despite relatively consistent inverse associations being
observed, some uncertainty about the causality of these ﬁndings remains.
PFOS and PFOA in food
www.efsa.europa.eu/efsajournal 129 EFSA Journal 2018;16(12):5194
Table 21: Studies examining the association between serum concentrations of PFOS and PFOA during pregnancy and low birth weight and small for
gestational age
Study Outcome Total no cases/N or %
PFOA PFOS
Comparison (ng/mL) OR (95% CI) Comparison (ng/mL) OR (95% CI)
Pregnancy serum or cord blood concentrations
Lauritzen et al. (2017) SGA from NO 91/265 Per 1-Ln 0.7 (0.3, 1.3) Per 1-Ln 0.7 (0.4, 1.2)
SGA from SE 52/159 Per 1-Ln 5.3 (1.7–16.4) Per 1-Ln 2.5 (0.9–6.8)
Fei et al. (2007) LBW(a) 24/1,400 < 3.9 vs > 7.0 2.4 (0.3, 22.3) < 6 vs > 43 L 4.8 (0.6, 41.2)
Fei et al. (2007) SGA(a) 121/1,400 < 3.9 vs > 7.0 1.0 (0.6, 1.7) < 6 vs > 43 L 1.0 (0.6, 1.7)
Hamm et al. (2010) SGA 16/252 < 1.1 vs > 2.1 1.3 (0.4, 4.5) < 6.1 vs > 10 0.3 (0.1, 0.7)
Whitworth et al. (2012a) SGA(a) 60/901 < 1.7 vs > 3.0 1.0 (0.3, 2.8) < 10.3 vs > 16.6 1.3 (0.5, 3.4)
Pre-pregnancy serum concentrations, prospective(b)
Darrow et al. (2013) LBW 46/783 < 6.9 vs > 37.2 1.06 (0.3, 3.5) < 8.6 vs > 21.4 0.82 (0.3, 2.7)
Serum concentrations, drawn close to pregnancy(b)
Stein et al. (2009) LBW 5.0%(c) ≤ 21.3 vs > 21.3 0.7 (0.5, 1.2) ≤ 17.7 vs > 17.7 1.5 (1.1, 1.9)
CI: conﬁdence interval; OR: odds ratio; LBW: low birth weight; SGA: small for gestational age.
(a): The Table only shows the effect estimate for the dichotomous comparison between the highest and lowest exposure groups as deﬁned in these studies. Consistent with these non-signiﬁcant
ﬁndings the p-value for trend was in all cases > 0.10 (for PFOA the p for trend was 0.13 for LBW in the study by Fei et al. (2007). No trend test was performed by Hamm et al. (2010) as
exposure was dichotomised as high vs low (binary).
(b): Blood samples drawn at enrolment (2005–2006) but serum concentrations are associated with pregnancies occurring after recruitment until 2010. Greater than 99% of all birth occurred within
3 years from the drawing of the blood sample.
(c): Total no cases/N: 80/1589 for PFOA, 243/4561 for PFOS.
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3.3.4.2.2. Preterm delivery
Many of the studies reviewed above in relation to birth weight also examined associations with
preterm delivery (gestational age less than 259 days). Overall, no consistent associations were
observed for PFOA and as an example Chen et al. (2012) observed a positive association between
maternal PFOS (mean 5.9 ng/mL) concentrations and preterm delivery (odds ratio 2.5 (95% CI: 1.5,
4.1) per ~ 3-fold increase in PFOS concentrations; n = 429 with 40 preterm cases). No association was
observed for PFOA. On the other hand, Whitworth et al. (2012a) (n = 901, 35 preterm cases)
observed a signiﬁcant inverse associations between maternal concentrations of PFOS (odds ratio of 0.3
(95% CI: 0.1, 1.0) comparing > 16.6 vs < 10.3 ng/mL) and PFOA (odds ratio of 0.1 (95% CI: 0.03,
0.6) > 3.0 vs < 1.7 ng/mL) and preterm delivery. Other studies found no signiﬁcant associations
between any of the maternal PFOS and PFOA concentrations examined and preterm delivery (Fei
et al., 2007; Hamm et al., 2010; Darrow et al., 2013; Bach et al., 2016).
Concerning results from non-prospective studies based on the C8 cohort, the retrospective studies by
Savitz et al. (2012a,b) reviewed above in relation to birth weight found no consistent association
between relatively high maternal exposures to PFOA (estimated exposure) and preterm delivery. On the
other hand, the retrospective study by Stein et al. (2009) that examined measured serum concentrations
of PFOA in relation to previous birth outcomes observed an increased risk of preterm delivery at relatively
high exposure (odds ratio of 1.4 (95% CI: 1.1, 1.7) comparing > 121 vs < 20 ng/mL, n = 1,571, 329
preterm cases).
In the light of these divergent ﬁndings, there is insufﬁcient evidence to suggest that maternal
exposure to PFOS and PFOA is associated with increased risk of preterm delivery.
3.3.4.2.3. Birth defects and stillbirths
To date, mainly exposure to PFOA, and in a few cases PFOS, have been examined in relation to
stillbirth and/or birth defects. All these studies have been based on subjects recruited into the C8
cohort. The overall ﬁndings have been null. As an example, Stein et al. (2014a) found no indications
among participants from the C8 cohort that exposure to PFOA (median ~10 ng/mL) was associated
with birth defects. In this study, a total of 10,262 births occurring from 1990 to 2006 were included,
resulting in 325 birth defects, recorded through maternal report. Exposure during pregnancy was
estimated based on serum samples drawn in 2005–2006 when the women were recruited. Although
there was a signiﬁcant increased risk of brain defects (odds ratio 2.6 (95% CI: 1.2, 5.1)), this effect
estimate was based on only 13 cases and would need to be replicated before any conclusions can be
drawn. For the other defects examined including gastrointestinal, kidney, craniofacial, eye, limb,
genitourinary and heart, no associations were detected. These null ﬁndings are in line with other
reports focusing on PFOA and/or PFOS exposures in subjects from the C8 cohort (Stein et al., 2009;
Nolan et al., 2010; Savitz et al., 2012a). No associations with stillbirths have been reported from these
studies either (Stein et al., 2009; Savitz et al., 2012b)
These C8-studies (all except Nolan et al. (2010) were reviewed in detail in the Section on birth
weight (Section 3.3.4.2.1) partly covered the same population but differed in terms of how exposure
was retrospectively assessed. As such, these studies cannot be considered as independent and a
notable limitation of these studies is that their retrospective assessment of exposure may be prone to
misclassiﬁcation. Still based on these ﬁndings, there is currently no evidence to suggest that exposure
to PFOS at background levels, or elevated exposure to PFOA, are associated with birth defects or
stillbirths.
3.3.4.2.4. Time to pregnancy
In a subcohort of 1,240 women from the Danish National Birth cohort, Fei et al. (2009) observed
a relatively strong positive association between maternal serum concentrations of PFOA (median
5.5 ng/mL) and PFOS (median 35.5 ng/mL) in pregnancy and infertility deﬁned as time to pregnancy
of more than 12 months. Serum samples were drawn in weeks 6–12 of gestation and information on
time to pregnancy were recorded though telephone interviews at around week 12 of gestation.
Comparing women in the highest (> 43 ng/mL) to the lowest (< 26 ng/mL) quartile of maternal PFOS
concentrations the odds ratio of infertility was 1.8 (95% CI: 1.1, 3.0). The corresponding odds ratio
when comparing the highest (> 6.9 ng/mL) to lowest (< 3.9 ng/mL) quartile of PFOA concentrations
was 2.5 (95% CI: 1.5, 4.4). Although the p value for linear trend was strongly signiﬁcant for PFOS
(p = 0.03) and PFOA (p = 0.006), clear dose response was lacking as the odds ratios in the three
upper quartiles were all elevated and comparably in magnitude (~1.7 to 2.5) compared to the lowest
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quartile. Still, this ﬁrst study published in 2007 provided some evidence to suggest that PFOS and
PFOA could potentially reduce fecundity. Results, stratiﬁed by parity, were not reported in this study.
Velez et al. (2015) examined associations between maternal serum concentrations of PFOS and
PFOA (median: 4.7 and 1.7 ng/mL, respectively) with subfecundity and infertility (deﬁned as time to
pregnancy > 12 months or infertility treatment in the index pregnancy) among 2001 women recruited
before week 10 of gestation in 10 cities across Canada, in 2008–2011. Blood samples were drawn
during the ﬁrst trimester. Maternal PFOA concentrations were associated with longer time to
pregnancy, that was also reﬂected in increased odds of infertility (OR for infertility: 1.3 (95%: 1.1,
1.5)). The associations for PFOS were in the same direction but were not signiﬁcant. Results, stratiﬁed
by parity, were not reported in this study and no adjustment was made for parity.
Other studies have, however, not been in line with these ﬁndings. Whitworth et al. (2012b)
examined using a case–control analysis nested within the Norwegian Mother and Child Cohort Study
(2003–2004), the association between second trimester maternal concentrations (median) of PFOS
(13.0 ng/mL) and PFOA (2.2 ng/mL) with subfecundity deﬁned as time to pregnancy of more than
12 months. The analysis was based on 416 cases and 485 randomly selected controls. Overall, an
increased risk of subfecundity was observed with an odds ratio of 1.6 (95% CI: 1.1, 2.3) when
comparing those with concentrations of > 16.6 ng/mL vs < 10.3 ng/mL for PFOS and 2.0 (95% CI:
1.4, 3.0) when comparing those with concentrations of > 3.0 ng/mL vs < 1.7 ng/mL for PFOA. When
stratifying by parity (~50% were primiparous) the corresponding odds ratios for PFOS were 0.7 (95%
CI: 0.4, 1.3) and 2.1 (95% CI: 1.2, 3.8) for primiparous and parous women respectively. For PFOA,
the corresponding odds ratios were 0.5 (95% CI: 0.2, 1.2) and 2.1 (95% CI: 1.0, 3.4) for primiparous
and parous women, respectively. The authors concluded that the increased risk that was driven by the
result from parous women could be explained by reverse causation. The argument was that
breastfeeding is an important route of elimination for both PFOS and PFOA. After breastfeeding,
concentrations of PFOS and PFOA increase again until equilibrium is reached between the rate of
uptake and elimination. If most parous women in this population had previously breast fed their infant,
higher body burden of PFOS and PFOA among parous women could be explained by longer inter-
pregnancy interval. As a result, the apparent increase in risk of subfecundity among parous women
only may simply reﬂect longer inter-pregnancy interval rather than direct toxicity of these compounds,
particularly as no association was observed for primiparous women.
Jørgensen et al. (2014) examined the relationship between serum concentrations of PFOS (median
10.6 ng/mL) and PFOA (median 1.7 ng/mL) with time to pregnancy in 938 pregnant women from
Greenland (48%), Poland (22%) and Ukraine (30%). No consistent associations were observed for
time to pregnancy or infertility deﬁned as time to pregnancy of more than 13 months.
Another study (Vestergaard et al., 2012) enrolling 222 Danish ﬁrst time pregnancy planning women
(1992–1995) that were followed for six menstrual cycles or until conception, examined associations
between pre-pregnancy serum concentrations of PFOS (35.5 ng/mL) and PFOA (5.6 ng/mL) with time
to pregnancy. No association with time to pregnancy was observed.
A cohort of 501 US couples who were followed over a 12-month period (Buck Louis et al., 2013)
observed no association with fecundity for quantiﬁed maternal pre-pregnancy concentrations (means)
of PFOS (20.1 ng/mL) and PFOA (5.0 ng/mL).
Finally Bach et al. (2015a), observed no association between maternal serum concentrations
(medians) of PFOS (8.3 ng/mL) and PFOA (2.00 ng/mL) with time to pregnancy, among 1,372 women
from the Aarhus Birth Cohort (2008–2013). Serum samples were drawn during pregnancy prior to
week 20 of gestation and time to the current pregnancy was recorded through questionnaires in early
pregnancy.
In conclusion, given the potential for reverse causality and null associations reported in all
(Vestergaard et al., 2012; Whitworth et al., 2012b; Buck Louis et al., 2013; Jørgensen et al., 2014;
Bach et al., 2015a) but two studies (Fei et al., 2009; Velez et al., 2015), there is insufﬁcient evidence
to suggest that exposure to PFOS/PFOA may adversely affect fecundity.
3.3.4.2.5. Miscarriage
In a subset of women from the C8 cohort (n = 1,129), Darrow et al. (2014) examined
prospectively the associations between serum concentrations (medians) of PFOS (14.3 ng/mL) and
PFOA (18.0 ng/mL) in relation to miscarriage in the subsequent pregnancy. Serum samples were
drawn in 2005–2006 and information on later pregnancy outcomes were collected in follow-up
interviews conducted in 2008–2011. No association was observed between serum concentrations of
PFOA and miscarriage. However, for PFOS the odds ratio for miscarriage per threefold increase in serum
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PFOS concentrations was 1.21 (95% CI: 0.94, 1.55). In these analyses, the same subject could be
included more than once through different pregnancies over the follow-up period (repeated
miscarriages). In a subanalysis restricted to the ﬁrst pregnancy conceived after drawing of the serum
sample, the corresponding odds ratio was strengthened 1.34 (1.02, 1.76). The association for PFOS
was more pronounced among primiparous compared to multiparous subjects. The primiparous women
do not have the same risk of reverse causation pathway as has been suggested for time to pregnancy.
Concerning the shape of the relationship further, the authors noted lack of clear dose response as the
odds ratios were signiﬁcantly elevated (1.7–1.9) in all four quintiles above the referent (lowest) quintile.
In addition, two other publications from the C8 cohort have reported non-signiﬁcant associations
between exposures to PFOA and PFOS and risk of miscarriages (Stein et al., 2009; Savitz et al.,
2012a). For more detailed description of the design of these studies, see Section 3.3.4.2.1 on birth
weight. The retrospective design of these studies is, however, a limitation.
Using a case–control design nested within a prospective cohort of 2,874 women from Odense
Denmark, Jensen et al. (2015) examined the association between serum concentrations (medians) of
PFOS (8.0 ng/mL) and PFOA (1.5 ng/mL) with risk of miscarriage. Of the women recruited into the
cohort, 88 suffered miscarriage and 56 of those had stored serum samples drawn prior to week 12 of
gestation. These 56 cases were compared with 336 randomly selected controls from the cohort who
had serum drawn prior to week 12 of gestation. In addition, 51 miscarriage cases were compared to
204 controls that were matched on parity and gestational day of serum sampling. No association was
observed for PFOS or PFOA.
Indications of increased risk of pregnancy loss related to PFOS (median 12.2 ng/mL) and PFOA
(median 3.3 ng/mL) were also not observed in a cohort of 501 US couples recruited preconception
(Buck Louis et al., 2016). Of these 501 women, 344 became pregnant and of these 98 suffered
pregnancy loss. However, information on 24 out of the 344 pregnancies was missing due to loss to
follow-up. In the same study, the authors also examine associations between PFOS and PFOS with sex
ratios (Bae et al., 2015). No signiﬁcant differences were observed.
Although the report of increased risk of miscarriage reported for PFOS (Darrow et al., 2014) is
noteworthy, particularly given relatively large sample size and prospective design ﬁndings from other
studies have been inconsistent. There is therefore only limited evidence to suggest that PFOS or PFOA
are associated with increased risk of pregnancy loss.
3.3.4.2.6. Pregnancy hypertension
A total of ﬁve studies from the C8 cohort (Nolan et al., 2010; Stein et al., 2009; Savitz et al.,
2012a,b; Darrow et al., 2014) and one from the Norwegian Mother and Child Cohort Study (Starling
et al., 2014) have examined associations between PFAS and pregnancy hypertension and/or
preeclampsia.
In the study by Stein et al. (2009), a total of 1,589 and 4,566 pregnancies were included in the
analyses for PFOA and PFOS, respectively. These participants had provided blood samples at
enrolment (2005–2006) and provided information on pregnancy outcomes and complications in past
pregnancies up to 5 years prior to recruitment. For PFOA the inclusion criteria were that the women
had lived in the same water district from the start of pregnancy and until enrolment. No such
restriction was needed for PFOS because unlike PFOA, exposure should reﬂect background levels.
Serum PFOS (median 13.6 ng/mL) and PFOA (median 21.2 ng/mL) concentrations at enrolment were
used as markers of exposure during previous pregnancies and information on preeclampsia was based
on maternal self-report. Overall when modelling exposure as continuous maternal PFOS or PFOA
concentrations at recruitment, PFOS/PFOA were not associated with preeclampsia occurring in previous
pregnancies over the past 5 years. Odds ratios per interquartile range (10–50 ng/mL for PFOA and
9–18 ng/mL for PFOS) were 1.1 (95% CI: 0.9, 1.4) for PFOA and 1.1 (0.9, 1.3) for PFOS. However,
when comparing maternal concentrations among those below the 50th percentile (< 13 ng/mL) with
those above the 90th (> 23 ng/mL) percentile for PFOS the odds ratio showed an increased risk 1.6
(95% CI: 1.2, 2.3) of preeclampsia for PFOS while no such risk was observed for PFOA (> 121 ng/mL
vs < 21; OR 0.9 (95% CI: 0.5, 1.8)).
Nolan et al. (2010) compared the likelihood of pregnancy complications according to exposure to
PFOA contaminated drinking water using PFOA concentrations in different water services in the Little
Hocking district in Ohio as a proxy for exposure. Based on their simple group comparison (individual
exposure not quantiﬁed) using outcomes extracted from the Ohio Department of Health (n = 1,548
pregnancies), no association with pregnancy hypertension or eclampsia was observed. The obvious
limitation of this study is the lack of exposure assessed on an individual basis.
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Darrow et al. (2013) examined women from the C8 cohort who provided a blood sample at
enrolment (2005–2006) and completed at least one follow-up interview, and reported at least one live
birth between 2005 and 2010. In the follow-up questionnaire, women were asked about their
reproductive history since enrolment. Birth outcomes and pregnancy complications were extracted
through health records. Pregnancy-induced hypertension (with or without proteinuria) was deﬁned as
the onset of hypertension after the 20th week of gestation. A total of 1,600 retrospective and
prospective pregnancies (hereof 106 cases) were included in their main analyses but when restricting
their samples to prospective pregnancies only (occurring after drawing of the blood sample), only 770
pregnancies were included (43 cases). Maternal concentrations in the samples drawn at enrolment
for the 5th, 50th and 95th percentile were 3.7, 14.3 and 114 ng/mL for PFOA and 5.1, 13.9 and
31.8 ng/mL for PFOS. Maternal PFOA concentrations were associated with pregnancy induced
hypertension when both prospective and retrospective cases were included (OR: 1.27 (95% CI: 1.05,
1.55) per ~3-fold increase in exposure) while the corresponding effect estimate was similar but non-
signiﬁcant when only prospective cases were examined (1.23 (95% CI: 0.92, 1.64)). The
corresponding effect estimates for PFOS were 1.47 (95% CI: 1.06, 2.04) when retrospective and
prospective cases were included; and 2.02 (95% CI: 1.11, 3.66) when only prospective cases were
included. Taking into considerations loss of statistical power when retrospective cases were excluded
and the similar effect estimates observed for both analyses PFOS and PFOA appeared to be associated
with induced pregnancy hypertension.
Savitz et al. (2012a) examined retrospectively, associations between estimated past exposures to
PFOA in relation to self-reported preeclampsia (n = 730 cases), for 10,186 pregnancies occurring
between 1990 and 2006. Past exposures were derived from measured serum concentrations at
enrolment into the C8-project (2005–2006). Estimated maternal concentrations of PFOA was positively
associated with increased risk of self-reported preeclampsia (odds ratio of 1.13 (95% CI: 1.00, 1.28)
per ~3-fold increase in exposure). When comparing those with concentrations > 63.1 ng/mL to those
with < 6.8 ng/mL the odds ratio indicated around 20% increase in risk (1.2 (95% CI: 1.0, 1.6)).
In a later case–control study (Savitz et al., 2012b) on the same population, the authors extracted
information from birth records (as opposed to self-reporting in their previous study) resulting in 224
cases of pregnancy induced hypertension and 3,604 controls. No association was observed between
estimated maternal concentrations of PFOA with pregnancy-induced hypertension (odds ratio of 1.02
(95% CI: 0.86, 1.21) per ~ 3-fold increase in exposure). Also when comparing those with
concentrations > 21.0 ng/mL to those with < 6.8 ng/mL, no increased risk was observed (1.0 (95%
CI: 0.7, 1.5)).
In a case–control study nested within the Norwegian Mother and Child Cohort study, Starling et al.
(2014) examined prospectively the association between serum PFOS/PFOA levels in samples drawn
around gestation weeks 17–20 and preeclampsia. A total of 466 cases and 510 controls recruited in
2003–2007 were included in their analyses. Only women with no previous live- or stillbirths and no
history of chronic hypertension were included in the study. Preeclampsia cases (occurring after week
20) were identiﬁed based on medical health records and the accuracy of this outcome assessment had
previously been assessed in a validation study. The 5th, 50th and 95th percentiles for PFOA were 2.1,
2.8 and 5.2 ng/mL, respectively. The corresponding numbers for PFOS were 9.7, 12.9 and 25.5 ng/mL
in this large prospective study, no association with validated cases of preeclampsia were observed and
the reported hazard ratios for PFOS and PFOA were tightly centred around 1.0.
As a part of a lawsuit settlement the C8 Science Panel previously concluded that there was a
‘probable link’ between PFOA exposure and pregnancy-induced hypertension. The words ‘probable link’
would indicate that it was more likely than not, that among class action members a connection existed
between PFOA exposure and pregnancy induced hypertension in the exposed community. Although a
link between exposure to either PFOA and PFOS and pregnancy induced hypertension or preeclampsia
was observed in some but not all of the ﬁve C8 studies reviewed above, the large prospective study
from the Norwegian Mother and Child Cohort study found not indications of an association between
PFOS and PFOA with validated cases of preeclampsia (Starling et al., 2014). The PFOS concentrations
in that study were comparable to those reported by Stein et al. (2009) and Darrow et al. (2013)
where a positive association with preeclampsia was observed. However, the PFOA concentrations
among the Norwegian participants were far lower compared to those observed in the C8 studies. Due
to lack of replication in other independent data there is insufﬁcient evidence to suggest that PFOS or
PFOA are associated with pregnancy induced hypertension or preeclampsia.
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3.3.4.3. Developmental outcomes
3.3.4.3.1. Neurodevelopment
Fei et al. (2008) studied the association between PFOS and PFOA and Apgar score and
developmental milestones (e.g. sitting, walking, language, as reported by mothers) in a sample from
the Danish National Birth Cohort (N = 1,400) recruited between 1996 and 2002. The study was funded
by 3M. PFOS and PFOA were determined in plasma of the pregnant women in the ﬁrst trimester
(mean levels around 35 and 5.5 lg/L). Development was assessed by telephone interviews with
mothers at 6 and 18 months. A number of potential confounders were adjusted for. There was no
consistent association between PFOS or PFOA levels and overall or any speciﬁc developmental delay.
This Danish cohort was also used to study associations between PFOS and PFOA during pregnancy
and behavioural and coordination problems in children (N = 787 and N = 586) at 7 years of age (Fei
and Olsen, 2011). Such problems were identiﬁed with validated questionnaires by parents. Mean PFOS
and PFOA levels were 34 and 5.5 lg/L. There were no positive associations between PFOS or PFOA
levels and behavioural and coordination problems.
Liew et al. (2014) studied the association between PFOS and PFOA in pregnant women and the risk
of cerebral palsy (CP) in their children in a case–control study (156 CP cases and 550 controls) from
the same Danish birth cohort. Cases were collected from a National CP register with validated
diagnoses. Median PFOS and PFOA levels were 28 and 4.1 lg/L. A number of potential confounders
were taken into account. For an increase in ln PFOS with one unit (an increase by a factor 2.7), the OR
for CP was 1.7 (95% CI 1.0–2.8) in boys and 0.7 in girls. For ln PFOA, the corresponding OR among
boys was 2.1 (95% CI 1.2–3.6), while it was 0.8 among girls.
Finally, Liew et al. (2015) also performed a case–control study of attention-deﬁcit hyperactivity
disorder (ADHD) and autism in the same cohort. Cases of ADHD (N = 220) and autism (N = 220) were
randomly selected among cases identiﬁed in the cohort by linking with national disease registries, and
random controls were selected from the cohort, frequency-matched for sex. Median PFOS and PFOA
levels in maternal plasma were 27 and 4.0 ng/mL. A number of potential confounders were adjusted
for. Relative risks in the fourth quartile of PFOS and PFOA were 0.8 (95% CI: 0.6–0.98) and 1.1 (95%
CI: 0.9–1.4) for ADHD and 0.9 (95% CI: 0.6–1.3) and 1.0 (95% CI: 0.7–1.4) for autism.
The C8 cohort, consisting of individuals exposed to PFOA-contaminated drinking water was used for
studying associations between PFOS and PFOA and neuropsychological performance at age
6–12 years, as reported by Stein et al. (2013). The authors approached families if children had been
living in the same district, had serum PFOS/PFOA levels determined in 2005–2006, and whose parents
had agreed to further studies. In total, 320 children could be included in the study. Extensive
neuropsychological testing was performed in 2009–2010. Performance was compared with estimated
PFOA exposure in the pregnant mothers (modelled exposure from drinking water at geocoded
addresses) and with PFOS/PFOA levels in the children 3–4 years before neuropsychological testing.
Mean PFOS and PFOA levels in the children in 2005–2006 (at a mean age of 6 years) were 21 and
92 lg/L (median PFOA 35 lg/L). The mean estimated PFOA in the pregnant mothers was 116 lg/L. A
large number of potential confounders were taken into account. For several outcomes, there were
indications of a neuroprotective effect of PFOA exposure, but overall the results provided no support
for adverse effects of PFOS/PFOA on neuropsychological functioning at 6–12 ages.
The Danish Aarhus birth cohort was used by Strøm et al. (2014) to study the association between
serum PFOS and PFOA in the mothers (pregnancy week 30) and risk of ADHD and depression during
follow-up through year 2010 (age of about 22 years). PFOS/PFOA levels were as indicated above, and
a number of potential confounders were adjusted for. The cases (ADHD N = 27, depression N = 104)
were ascertained from hospital registers and prescription of relevant medications. In addition, the
authors studied associations with scholastic performance in the 9th grade (age about 16 years). No
signiﬁcant associations were found between PFOS and PFOA and any of these outcomes. Point
estimates for the HR of diagnoses were below one for the third tertiles of PFOS/PFOA while the slopes
for scholastic performance were slightly negative.
Chen et al. (2013) studied the associations between PFOS and PFOA in cord blood of 239 infants
and neurodevelopment at 2 years of age from Taiwan. Development (cognitive, language, gross-motor,
ﬁne motor, social and self-help) was assessed by trained staff. Mean PFOS and PFOA levels were 7.0
and 2.5 lg/L. Potential confounders, related to mothers, and the home environment were included in
the statistical models. PFOS in cord blood was associated with slower overall development, mainly in
the motor domains, but to some extent also in the self-help domain. There were some similar
tendencies for PFOA, but none of them statistically signiﬁcant.
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Braun et al. (2014) examined associations between PFOS and PFOA in pregnant mothers (N = 175)
in Ohio (the HOME study), and autistic behaviour (a Social Responsiveness Scale, SRS, based on
questionnaires to mothers) in their children at 4–5 years of age. The GM levels were 13 lg/L for PFOS
and 5.6 lg/L for PFOA in the women (mostly at 16 weeks), recruited in 2003–2006. A number of
potential confounders were adjusted for. There were no statistically signiﬁcant associations between
PFOS or PFOA and results from the SRS scale; the beta coefﬁcient was slightly positive for PFOS and
slightly negative for PFOA.
The HOME cohort was also used to study associations between PFOS/PFOA and clinical
neurobehavioural examination at 5 weeks of age in 327 children (Donauer et al., 2015). There was a
borderline association between maternal log10 PFOA level and one of 11 neurobehavioural scales (low
muscle tone/hypotonic, N = 84). In an additional analysis using about half of the children without any
signs of abnormal behaviour as reference, the risk of being hypotonic increased signiﬁcantly with
higher maternal PFOA levels (OR 3.8, 95% CI: 1.1–13 and relative risk 2.2, 95% CI: 1.1–4.6 per
10-fold increase of PFOA). No associations were found for PFOS levels.
Finally, the HOME cohort was used to study associations between maternal serum PFOS/PFOA
(levels as above) and executive function (ﬂexibility, goal planning, and information processing), as
estimated from a parent-reported questionnaire (named BRIEF) in about 200 children at 5 and 8 years
of age (Vuong et al., 2016). There was a signiﬁcant association between maternal serum PFOS and
worse executive functions in children (about 7% higher (worse) scores per 2.7-fold increase in
maternal serum PFOS.
Ode et al. (2014) performed a case–control study of the association between ADHD and PFOS and
PFOA in children aged 8–12 years, based on 206 cases of ADHD and 206 controls from Malmo,
Sweden. Classiﬁcation of ADHD was based on clinical diagnosis at a child psychiatry department. PFOS
and PFOA levels were measured in bio-banked cord serum samples from cases and controls. A number
of potential confounders were adjusted for. Median levels of PFOS and PFOA were 6.8 and 1.8 lg/L.
OR for ADHD were 0.81 (95% CI: 0.50–1.3) for PFOS and 1.1 (0.67–1.7) for PFOA.
Forns et al. (2015) studied the association between PFOS and PFOA in breast milk and cognitive
and psychomotor development (parental questionnaires) in children at 6 and 24 months in a
Norwegian birth cohort. The analyses were performed in 896 children of mothers recruited in 2003–
2009 with data on neuropsychological development (parent-completed questionnaires) and PFOS/PFOA
in breast milk. The median levels of PFOS and PFOA in breast milk were 0.11 and 0.040 ng/mL. A
number of potential confounders were adjusted for. No associations were found between the outcomes
and breast milk PFOS/PFOA. It was noted that PFOS/PFOA in breast milk reﬂects not only early
postnatal exposure, but also prenatal exposure since correlations have been reported with PFOS/PFOA
in maternal serum.
In a Taiwanese cohort of 430 pregnant women, serum PFOS and PFOA levels were measured in the
third trimester (year 2000–2001) and then 120 children could be followed up at 5 and 8 years of age
for assessing IQ (Wang et al., 2015c). The median maternal serum PFOS was 13 ng/mL and for
serum-PFOA the median was 2.5 ng/mL. After adjustment for a number of potential confounders, no
statistically signiﬁcant associations were found between maternal PFOS/PFOA and children’s IQ at 5 or
8 years of age.
A birth cohort (INUENDO) combining data on pregnant mothers and their children (N = 1,106) from
three different countries (Greenland, Ukraine and Poland) examined associations between maternal
serum levels of PFOS/PFOA (at different stages of gestation) and neurobehavioural development
(parental questionnaires) at about 8 years of age (Høyer et al., 2015a). The participation rate was
high in Greenland but low in Ukraine and Poland. A number of potential confounders were adjusted
for. Median maternal serum concentrations of PFOS were 20, 5.0 and 8.0 ng/mL in Greenland,
Ukraine, and Poland. PFOA concentrations were 1.8, 1.0 and 2.7 ng/mL, respectively. PFOA was
associated with higher behavioural scores (mainly hyperactivity) in Ukraine children (OR 6.3, 95% CI
1.3–30 in the upper tertile), but not in children from the other countries. There were no associations
between maternal PFOS/PFOA levels and motor problems.
Two Taiwanese birth cohorts were used to examine the association between PFOS/PFOA in cord
blood and ADHD-related symptoms (parental questionnaires) in 282 children at 7 years of age (Lien
et al., 2016). The response rate for follow-up was low. The mean PFOS and PFOA levels were 4.8 and
1.6 ng/mL. A number of potential confounders were adjusted for. No associations were found between
PFOS/PFOA levels and ADHD-related symptoms.
Oulhote et al. (2016) studied associations between maternal serum PFOS/PFOA in the end of
pregnancy and child behaviour (parent-reported scales) in 539 Faroese children (born 1997–2000) at
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7 years of age. In addition, associations between children’s behaviour and their PFOS/PFOA levels (at
age 5 and 7) were examined. No associations with maternal levels (PFOS 27 ng/mL, PFOA 3.2 ng/mL)
were found and no consistent associations with children’s PFOS levels. There were, however, several
signiﬁcant ﬁndings when behaviour was compared with serum PFOA levels in the children at age 5
(PFOS 17 and PFOA 4.1 ng/mL) – see Section 3.3.4.4.
Goudarzi et al. (2016) examined associations between PFOS/PFOA in maternal blood and
neurobehavioural development (clinical examination) in Japanese children from the Hokkaido birth
cohort at 6 (N = 173) and 8 months (N = 133). The median maternal PFOS and PFOA levels were 5.7
and 1.2 ng/mL, respectively. A number of potential confounders were adjusted for. There were no
overall associations between maternal PFOS/PFOA levels and neurodevelopment at 18 months. At
6 months, higher maternal log-transformed PFOA levels were associated with lower scores in one of
the developmental scales in girls, but not in boys.
Dutch children were examined by Quaak et al. (2016) for associations between PFOS/PFOA in cord
blood and parental-assessed scales for ADHD and ‘externalising behaviour’ (attention problems and
aggressive behaviour) in 59 children. A number of potential confounders were taken into account. No
associations were found for ADHD, while for externalising behaviour a signiﬁcant negative association
(‘protective effect’) with PFOA was found in boys (N = 34).
3.3.4.3.2. Growth in infancy and childhood, overweight, metabolic risk factors
In the Danish National birth cohort associations between PFOS and PFOA during pregnancy and
(maternally reported) weight, height, and BMI at 5 and 12 months for 1,010 of the children were
studied by Andersen et al. (2010). A number of potential confounders were adjusted for. Weight and
BMI were inversely related to prenatal PFOS and PFOA (means 33 and 5.2 lg/L). One lg/L increases
in PFOS and PFOA were associated with 9 g and 43 g lower weight at 12 months.
In the same cohort, adiposity was examined in 811 children at age 7 (Andersen et al., 2013).
Median prenatal PFOS and PFOA levels were 34 and 5.3 ng/mL). Weight, height and waist
circumference were measured by mothers and noted in a mailed questionnaire. A number of potential
confounders were adjusted for. There was no association between PFOS or PFOA levels and BMI, waist
or risk of overweight.
Halldorsson et al. (2012) performed a longitudinal study of the association between PFOS and PFOA
in serum in 665 pregnant women, recruited in 1988–1989 from the Aarhus cohort, Denmark, and risk of
overweight (BMI, waist circumference, insulin, leptin and adiponectin) in their offspring at 20 years of
age. Mean PFOS and PFOA were 22 and 3.7 lg/L. Several potential confounding factors were taken into
account. In the female offspring, BMI was signiﬁcantly higher (point estimate 1.6 units) in the fourth
quartile (Q4) of PFOA compared to the ﬁrst (Q1). For waist, the signiﬁcant difference between Q4 and
Q1 was 4.3 cm. No such associations were found for PFOS. There were similar associations for male
offspring, but not statistically signiﬁcant. There were also positive associations between PFOA in the
mothers and insulin, and leptin in the offspring, and inverse associations with adiponectin.
Maisonet et al. (2012) studied the association between prenatal PFOS and PFOA (serum levels in
pregnant mothers; median 20 and 3.7 ng/mL) and birth weight and weight at 20 months in 447 girls
from Avon, UK (Avon Longitudinal Study of Parents and Children (ALSPAC) study). The girls were
selected for another study (of menarche). A number of potential confounders were adjusted for.
Findings on birth weight are reported in Section 3.3.4.2.1 Girls in the upper tertile of maternal PFOS
weighed about 400 g more at 20 months than girls in the ﬁrst (referent) tertile, and when adjusted for
height the difference was 500 (95% CI 208–791) g. Birth weight in the third tertile of PFOS had,
however, been lower. No association was found with maternal PFOA.
The ALSPAC cohort was also used by Maisonet et al. (2015) to study the association between
prenatal serum levels of PFOS/PFOA and blood lipids in girls at 7 (n = 115) and 15 (n = 87) years of
age. Some covariates were adjusted for. No consistent tendencies were found for PFOS, while blood
lipids were highest in children born to mothers in the second PFOA tertile, indicating a nonlinear
relation. Moreover, within the lowest PFOA tertile, there were signiﬁcant associations between prenatal
PFOA and total and LDL cholesterol.
de Cock et al. (2014a) studied the association between PFOS and PFOA and growth (weight,
height, head circumference) during the ﬁrst year in 61 Dutch children. PFOS and PFOA were analysed
in cord plasma, and in breast milk in the mothers. Mean PFOS and PFOA levels in cord plasma were
only 1.6 and 0.9 lg/L, respectively. A number of potential confounders were taken into account. No
associations were found between PFOS and growth. For PFOA, an association with height was
reported, but the authors do not report in which direction.
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The INUENDO cohort (see above) was used to study associations between maternal PFOS/PFOA
levels and offspring overweight and central obesity (waist-to-hip ratio), but only in the children from
Greenland (N = 531) and Ukraine (N = 491) (Høyer et al., 2015b). No consistent associations were
found between maternal PFOS/PFOA levels and children’s risk of overweight. The risk of having a high
waist-to-hip ratio tended to be increased in the upper two tertiles of PFOA in Greenland (RR: 1.4, 95%
CI: 0.6–3.3) and Ukraine (RR: 1.8, 95% CI: 0.4–7.2) and in a combined analysis the RR was 1.4
(1.05–1.8) for one unit increase of ln PFOA.
A Faroese mother–child cohort (recruited 2007–2009) was used by Karlsen et al. (2017) to study
the associations between maternal PFOS and PFOA levels and overweight at 18 months and 5 years of
age. Median PFOS and PFOA levels 2 weeks post-partum were 8.3 and 1.4 ng/mL. A number of
potential confounders were adjusted for. The risk of overweight at age 5 (but not at 18 months) was
increased in the upper tertile of PFOA (RR: 1.9, 95% CI: 1.1–3.3). There was also a tendency towards
an association between PFOS and overweight at 18 months (RR: 1.2, 95% CI: 0.98–1.6), but not at
5 years.
Associations between maternal plasma PFOS/PFOA in early pregnancy and adiposity in children
were examined by Mora et al. (2017) in a US birth cohort. BMI, waist circumference, and skinfold
thickness were measured at about 3 and 8 years of age (1,006 and 876 children, participation rate 61
and 53% of children with prenatal PFOS/PFOA levels). At 8 years also, fat mass was estimated (using
DXA). A number of potential confounders were adjusted for. Serum albumin and estimated pre-
pregnancy GFR were also taken into account. Median maternal PFOS and PFOA levels were 25 and
5.6 ng/mL. No consistent associations were found between maternal PFOS/PFOA and adiposity at
about 3 years of age or adiposity in boys at about 8 years. In girls, however, there were non-
signiﬁcant tendencies towards positive associations between PFOS and PFOA and most adiposity
measures.
Fleisch et al. (2017) studied associations between prenatal (maternal plasma at about 10 weeks of
gestation in 1999–2002) PFOS/PFOA and glucose homoeostasis (glucose, insulin, HOMA-IR), leptin and
adiponectin in about 500 children from Boston at the median age of eight years. A number of potential
confounders were adjusted for. GM maternal PFOS and PFOA were 24 and 5.3 ng/mL. Associations
between prenatal PFOS/PFOA and insulin resistance, leptin and adiponectin were null. Associations
examined cross-sectionally using PFOS/PFOA in children’s plasma showed an inverse association
between PFOS/PFOA and HOMA-IR.
Associations between prenatal PFOS/PFOA exposure (serum levels in mothers at week 16) and
adiposity at the age of 8 in 204 US children from the HOME study, were reported by Braun et al.
(2016). GM for PFOS and PFOA were 13 and 5.4 ng/mL. A number of potential confounders were
adjusted for. A non-linear positive association was found for PFOA, with increased BMI, waist
circumference and risk of overweight or adiposity in tertile 2 vs tertile 1, but not in tertile 3. There was
no association between PFOS and adiposity.
3.3.4.3.3. Puberty and semen quality
Using a nested case–control design Christensen et al. (2011) examined the association between
maternal concentrations of PFOS and PFOA with age of menarche in the British ALSPAC cohort. They
selected 218 early menarche cases, which reported age at menarche before 11.5 years (median
11.1 years) and 230 random controls (mean age at menarche year 12.6 years). Age at menarche was
assessed through self-reported questionnaires administered with 2-year intervals between the age of
8–13. Serum PFOS and PFOA concentrations (median 19.8 and 3.7 ng/mL, respectively) were
quantiﬁed in archived serum samples taken during pregnancy (1991–1992). In short no association
was observed with early age of menarche with odds ratios tightly centred around 1.
In a Danish population-based prospective cohort, Kristensen et al. (2013) examined the association
between maternal concentrations of PFOS and PFOA (median: 21.1 and 3.6 ng/mL, respectively) taken
around week 30 of gestation and age at menarche and reproductive hormones in 343, 19- to 21-year-
old, female offspring. Age at menarche was assessed through self-reported questionnaires and blood
samples were drawn during clinical examination. Some potential confounders were adjusted for, but
not maternal age at menarche. Female offspring of mothers with maternal PFOA concentration of
≥ 4.3 ng/mL had on average 5.3 (95% CI: 1.3, 9.3) months later age of menarche compared to
female offspring of mothers whose PFOA concentrations were < 3.0 ng/mL. No consistent associations
were observed with reproductive hormones among those females who provided information on
contraceptive pill use (n = 171) and in those who provided information on non-use (n = 75). The
analyses on reproductive hormones were complicated due to frequent use of contraceptives.
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From the same Danish cohort, Vested et al. (2013) examined the prospective association between
serum concentrations of PFOS and PFOA (median: 21.2 and 3.8 ng/mL, respectively) with semen
quality in 169 male offspring at 19–21 years of age. Serum samples were drawn in week 30 of
gestation and semen quality was assessed using standard clinical procedures. Some potential
confounders were adjusted for. When outcomes were log-transformed, maternal serum concentrations
of PFOA were associated with lower offspring sperm concentrations (p for trend 0.01) and lower sperm
count (p for trend 0.001) which corresponded to around 34% reduction in both outcomes when
comparing offspring of mothers with serum concentrations above 4.4 and below 3.2 ng/mL,
respectively. Maternal PFOA concentrations were also signiﬁcantly associated with higher levels of
luteinising hormone and follicle stimulating hormone in these male offspring.
3.3.4.3.4. Summary
In summary, 30 longitudinal studies in 18 cohorts were identiﬁed with PFOS/PFOA measurements in
serum of pregnant mothers, in cord blood or in breast milk and follow up of various outcomes in
children between 6 months and 22 years. Most studies have examined associations between prenatal
or perinatal exposure to PFOS/PFOA and later neurobehavioural development and overall they do not
provide support for any association. This conclusion is still valid based on the quality and consistency
of the studies, for example if most weight is put on studies of large size, good quality of outcome
(measured/tested vs parent-reported), good confounder control. Several of the neurobehavioural
studies examined the risk of ADHD/hyperactivity at prenatal exposure (Ode et al., 2014; Strøm et al.,
2014; Liew et al., 2015; Lien et al., 2016; Quaak et al., 2016) but no increased risk related to
PFOS/PFOA was found.
For overweight in early childhood, the studies are not consistent (Andersen et al., 2010; Maisonet
et al., 2012; de Cock et al., 2014a; Karlsen et al., 2017). In later childhood or adolescence, some
studies show positive associations with overweight in subgroups (Halldorsson et al., 2012; Karlsen
et al., 2017; Mora et al., 2017), while others do not (Andersen et al., 2013; Høyer et al., 2015b), or
show exposure-response relationships, which are difﬁcult to interpret (Braun et al., 2016). For other
outcomes (Halldorsson et al., 2012; Maisonet et al., 2015; waist-to-hip ratio: Høyer et al., 2015b,
insulin and leptin; Fleisch et al., 2017), the data are insufﬁcient (one or two studies for each of these
outcomes). The CONTAM Panel concludes that there is insufﬁcient support for associations between
prenatal exposure to PFOS or PFOA and early life neurobehavioural development or overweight.
Although the two studies on associations between prenatal (maternal blood) exposure to PFOS/
PFOA and age at menarche appear consistent, the ALSPAC study (Christensen et al., 2011) was only
designed to test the hypothesis that PFOS and/or PFOA might be associated with earlier age at
menarche. If PFOS/PFOA are associated with later age at menarche, then the ALSPAC study would by
design (sampling only early age at menarche cases) not detect that. Since age at menarche has a
relatively strong heritability component not accounting for this potential confounder in the study by
Kristensen et al. (2013) is a clear limitation. Although the results on semen quality by Vested et al.
(2013) are interesting, limited conclusions can be drawn from a single epidemiological study and
replication is needed. As a result, these three studies provide insufﬁcient evidence to conclude on
casual associations with PFOS/PFOA.
3.3.4.4. Neurotoxic outcomes
3.3.4.4.1. Studies in children
Associations between PFOS and PFOA and ADHD and learning problems in children were
investigated by Stein and Savitz (2011). This was a cross-sectional study in the C8 cohort exposed to
PFOA from contaminated drinking water. The PFOS and PFOA levels were measured in serum in
2005–2006 in about 11 000 children aged 5–18 years. The mean PFOS and PFOA levels were 23 lg/L
(median 20) and 66 (median 28) lg/L. Classiﬁcation of ADHD was based on interviews (diagnosis
made in the health sector, or medication against ADHD). A number of potential confounders were
adjusted for. There was no signiﬁcantly increased OR for ADHD in the three upper quartiles of PFOS
compared with the ﬁrst (Q1; reference) quartile (upper limit of Q1 = 14.8 lg/L). Neither was the OR
increased in the three upper quartiles of PFOA (upper limit of Q1 = 13 lg/L). The OR for ADHD in the
fourth quartile (Q4) of PFOS was 1.09 (95% CI: 0.93–1.29). The OR in Q4 for PFOA was 0.76 (95%
CI: 0.64–0.90). Similar tendencies were found for ADHD medication. No positive associations between
PFOS or PFOA were found for the outcome ‘learning problems’.
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The same sample of children was also examined for the association between child behaviour and
serum PFOA by Stein et al. (2014b). The assessment of behaviour in this study was based on a large
number of clinical scales for assessment of executive function, ADHD-like behaviour, emotional or
behaviour problems, as reported by the children’s mothers and teachers. A number of potential
confounders were adjusted for. The median PFOA level was 35 lg/L. In summary, the associations
indicated a protective effect of high PFOA in boys, especially from mothers’ reports, while in girls,
mothers’ report indicated adverse effects of high PFOA, which was not supported by teachers’ reports.
Gump et al. (2011) studied the association between PFOS and PFOA and impulsivity in a cross-
sectional study of 83 children aged 9–11 years from north-west USA. Impulsivity was assessed by a
procedure reinforcing delayed response in a computer task, which could be learned during the task.
Mean PFOS and PFOA levels were 9.9 and 3.2 lg/L. A number of potential confounders were taken
into account. Higher PFOS and PFOA levels were inversely associated with the (reinforced) response,
which was assumed to indicate less ability to inhibit the optimal delay in response, and thus increased
impulsivity.
Hoffman et al. (2010) performed a cross-sectional study of the association between PFOS and
PFOA and diagnosis of ADHD (51 cases) in 571 children aged 12–15 years, examined in the US
National Health and Nutrition Examination Survey (NHANES) 1999–2004. Median PFOS and PFOA
levels in serum were 23 and 4.4 lg/L. The classiﬁcation of ADHD was based on parental interviews
(diagnosis made in the health sector or medication against ADHD). A number of potential confounders
were adjusted for. An interquartile range (IQR) increase of PFOS (16 lg/L) increased the OR for ADHD
by a factor of 1.6 (95% CI: 1.1–2.3), and an IQR increase in PFOA (2.7 lg/L) increased the OR for
ADHD by a factor 1.4 (95% CI: 1.04–1.3).
As mentioned in the section on neurodevelopment (Section 3.3.4.3.1), Oulhote et al. (2016)
studied associations between child behaviour (parent-reported scales) at age 7, and PFASs levels in the
children at age 5 and 7 years in 539 Faroese children. There were no consistent associations with
children’s PFOS levels. There were, however, several signiﬁcant ﬁndings when behaviour was
compared with serum PFOA levels in the children at age 5 (median PFOS 17 and PFOA 4.1 ng/mL):
peer relation, conduct problems, internalisation problems and autism screening scores. Associations
were driven by effects in girls, while in boys the direction was the opposite. In a structural
equation model, adjusted also for pre- and postnatal PCB and Hg blood levels there was a signiﬁcant
association between total postnatal PFAS levels (PFOS, PFOA and other PFASs at age 5 and 7) and
scores of total behaviour difﬁculties.
3.3.4.4.2. Studies in adults
In the C8 cohort, cross-sectional associations between PFOS/PFOA and self-reported memory
impairment were examined in 21,000 adults ≥ 50 years of age (Gallo et al., 2013). The GM PFOS and
PFOA levels in 2005–2006 were about 22 and 43 ng/mL. A number of potential confounders were
adjusted for. About 20% reported some memory impairment. Statistically signiﬁcant inverse
(‘protective’) associations were found between PFOS as well as PFOA and memory impairment. The
OR for memory impairment was 0.85 (95% CI 0.76–0.94) for Q5 vs Q1 of serum PFOS. For serum
PFOA the OR was 0.79 (95% CI 0.71–0.88). The authors discuss anti-inﬂammatory effects of PFOS/
PFOA (via PPARgamma) or residual confounding, as possible explanations.
Power et al. (2013) performed a cross-sectional study on the associations between serum levels of
PFOS and PFOA and self-reported memory problems or confusion periods in about 1,800 individuals,
aged 60–85 years, from the NHANES 1999–2008. A number of potential confounders were taken into
account. The GM for PFOS was 23 lg/L and for PFOA 4.1 lg/L. The authors found no signiﬁcant
associations between PFOS or PFOA and these cognitive symptoms. The OR for memory problems or
confusion was 0.90 (0.78–1.03) for a doubling of serum PFOS and 0.92 (95% CI: 0.78–1.09) for a
doubling of serum PFOA. The OR for memory problems was signiﬁcantly below 1.0 in some
subanalyses of diabetics.
Berk et al. (2014) studied the cross-sectional association between self-reported depressive
symptoms and serum PFOS/PFOA in 5,400 individuals > 18 years in NHANES surveys 2005–2010.
PFOS/PFOA levels are not presented. There were relatively strong inverse (‘protective’) associations
between PFOS/PFOA levels and depressive symptoms after adjustment for some potential
confounders: OR 0.66 (95% CI 0.47–0.93) for Q4 vs Q1 of PFOS, and OR 0.61 (95% CI 0.43–0.87) for
Q4 vs Q1 of PFOA.
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3.3.4.4.3. Summary
In summary, these eight cross-sectional studies, ﬁve in children and three in adults, examined
various neurobehavioural, neuropsychiatric and cognitive outcomes without ﬁnding consistent adverse
associations with serum levels of PFOS or PFOA. Several studies found inverse (‘protective direction’)
associations.
3.3.4.5. Immune outcomes
Several human observational studies have examined associations between PFOS and PFOA with
immune outcomes such as asthma, allergies, serum antibody response to vaccination and propensity
for infections. For asthma and allergies, only few prospective studies have been conducted while those
studies that have examined antibody response to vaccination have had more robust design. Studies
looking at propensity for infection have mostly been based on parental recall several months back in
time with the exception of one study where infections were recorded regularly during the follow-up
period with help of text messages (Dalsager et al., 2016). The results from these studies are
summarised below.
3.3.4.5.1. Cross-sectional studies on asthma and allergies in children and adults
Dong et al. (2013) examined association between serum concentrations of PFOS and PFOA and
asthma in 10- to 15-year-old Taiwanese children. The study recruited 231 children who had received a
doctor’s diagnosis of asthma in the previous year and 225 non-asthmatic controls. The median
concentrations for PFOS and PFOA were around 33 and 1 ng/mL, respectively. A signiﬁcant positive
association with doctor-diagnosed asthma was observed for both PFOS and PFOA. Comparing the
highest to the lowest quartile of PFOS concentrations the OR for increased risk of asthma was 2.6
(95% CI: 1.5, 2.5) and the corresponding OR for PFOS was 4.1 (95% CI: 2.2, 7.4). A signiﬁcant
increase in serum concentrations of IgE, eosinophilic counts, and eosinophilic cationic protein was
observed with higher PFOS and PFOA concentrations among asthmatic cases, while a modest
non-signiﬁcant increase was observed among controls. The Spearman correlation coefﬁcient between
PFOS and PFOA was 0.64. No mutual adjustments for PFOS and PFOA were reported. Such analyses
would have been helpful for interpreting these ﬁndings as it cannot be excluded that the relatively
strong associations reported by PFOS and PFOA are partially confounded by each other (or other PFAS
reported in this study). Using the same study Zhu et al. (2016) reported some sex speciﬁc associations
for immunologic markers of asthma but overall these results were unclear.
In another cross-sectional study of 12- to 19-year-old children and young adults (n = 638) from the
NHANES, Stein et al. (2016a) examined the associations between (PFOS and PFOA (mean 15.0 and
3.6 ng/mL, respectively) and self-reported asthma, wheeze, allergy and rhinitis. Sensitisation to 19
different allergens was also measured (plants, dust mite, pets, cockroach, shrimp, rodents, mould and
food). For all these outcomes no consistent associations were observed.
Concerning studies among adults, a cross-sectional study from the US examined associations
between PFOS and PFOA concentrations (median 31.4 and 12.3 ng/mL, respectively) and asthma
among 458 New York State employees and National Guard personnel assigned to work in the vicinity
of the World Trade Centre after its collapse in 2011 (Tao et al., 2008). Non-signiﬁcant differences in
PFOS and PFOA concentrations were observed among subjects classiﬁed as symptomatic and
asymptomatic. In this selected population concentrations of PFOS and PFOA were higher than in the
general US population at the time, possibly due to prior occupational contact with these chemicals.
In another study, Anderson-Mahoney et al. (2008) compared the expected rates for various disease
outcomes (controlling for age and gender) with those observed among 566 adults from Ohio that were
exposed to PFOA from contaminated drinking water. A median serum level of 327 ng/mL had
previously been reported among a random sample of 74 residents from this population (Emmett et al.,
2006). A comparison with data from an NHANES study revealed higher rates of chronic bronchitis,
shortness of breath on stairs and asthma as assessed by questionnaires in this exposed population.
Due to the potential socioeconomic and lifestyle differences between the exposed communities and the
general US population the results from this study are at best hypothesis generating.
Buser and Scinicariello (2016), examined in NHANES (2005–2006), the cross-sectional association
between serum PFOS and PFOA concentrations (median: 15.0 and 3.6 ng/mL, respectively) with food
sensitisation (deﬁned as having at least one food-speciﬁc IgE level ≥ 0.35 kU/L) in 637 participants. A
prospective association with any food allergy in NHANES 2005–2006 and food allergies (self-reported:
yes to the question ‘What foods are you allergic to’) in NHANES 2007–2010 was also examined
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(n = 701). No association was observed with food sensitisation. Serum PFOA were associated with
increase odds of any food allergies but the odds ratios were unstable with wide conﬁdence intervals
and there was no clear dose response. The use of any food allergy as outcomes can be regarded as
relatively unprecise.
Osuna et al. (2014) examined pre- and postnatal association between PFSO and PFOA in a small
pilot study of 28 children from the Faroese Islands. Although the authors reported inverse association
between PFOS with anti-actin IgG the results from this small pilot study do not provide much insight in
the absence of further replication.
3.3.4.5.2. Prospective studies on asthma and allergies in children and adults
In a study from Japan, Okada et al. (2012) examined associations between maternal serum
concentrations of PFOS and PFOA (median 5.2 and 1.3 ng/mL, respectively) with cord blood IgE
concentrations (n = 231) and offspring food allergies, eczema, wheezing, up to 18 months of age
(n = 343). Maternal serum was drawn during the second trimester and offspring outcomes on allergies
and infections were determined by use of a questionnaire to mothers. No associations were observed
with offspring allergies or infections at 18 months of age. A signiﬁcant inverse association was
observed between maternal concentrations of PFOA and cord blood IgE levels in female offspring only.
In a later study, Okada et al. (2014) examined associations between prenatal exposure to PFOS
and PFOA (mean 5.0 and 2.0 ng/mL, respectively) and allergic diseases at 12 and 24 months post-
partum among infant 2,063 mother child pairs from the Hokkaido Study on Environment and Children’s
Health 2003–2009. No consistent associations were observed with odds ratios at higher exposures
being below 1.
In Taiwan, Wang et al. (2011b) examined the association between serum cord blood concentrations
of PFOS and PFOA (median 5.5 and 1.7 ng/mL, respectively) with both cord blood levels of IgE and
children’s levels of IgE levels and atopic dermatitis when the children were 2 years of age (n = 244).
In their cross-sectional analyses, cord blood concentrations of PFOA and PFOS were associated with
higher cord blood IgE levels. In their prospective analyses, no associations were observed with
children’s serum levels of IgE or atopic dermatitis at 2 years of age.
A study of 1,238 pregnant women from Canada found no association between maternal serum
concentrations of PFOS and PFOA (mean 4.7 and 1.0 ng/mL, respectively) and cord blood
concentrations of IgE (Ashley-Martin et al., 2015).
3.3.4.5.3. Vaccination response
Grandjean et al. (2012), in a study from the Faroe Islands, examined the association between both
prenatal and postnatal exposures to PFOS, PFHxS and PFOA with children’s antibody concentrations
against tetanus and diphtheria at ages 5 and 7 years (n = 462–587). Serum antibody concentrations
were quantiﬁed both pre- and post-booster at ages 5.0 and 5.2, respectively. Concentrations (mean)
of PFOS (27.3 ng/mL), PFHxS (4.4 ng/mL), and PFOA (3.2 ng/mL), were quantiﬁed in maternal serum
drawn around gestation week 32. The corresponding mean concentrations in children’s serum drawn
at age 5 (prebooster) were 16.7, 0.6 and 4.1 ng/mL, respectively. Maternal serum concentrations and
offspring serum concentrations at age 5 were examined individually, in relation to antibody response at
age 5, both pre- and post-booster and at a mean age of 7.5 years. In addition, associations with
PFOS, PFOA and PFHxS were examined, combined using structural equation modelling. The main
ﬁndings of this study were as follows:
• Maternal PFAS concentrations: Maternal PFOS concentrations were inversely associated with
diphtheria antibody concentrations at age 5 pre- and post-booster (the latter almost
signiﬁcant) while a decrease in diphtheria antibody concentrations at age 7 was observed with
increasing PFOA levels. Modelling the combined exposure to PFOS, PFOA and PFHxS, using
structural equations, a twofold increase in maternal concentrations of this combined exposure
was associated with a 48% (95% CI: 68, 16) decrease in offspring diphtheria antibody
concentrations at age 5 prebooster and 42% (95% CI: 66 to 1) decrease in antibody
concentrations at age 7. No association was observed between maternal concentrations and
offspring tetanus antibody concentrations at age 5 and 7 when these three PFASs were
examined individually or combined.
• Offspring PFAS concentrations at 5 years prebooster: Cross-sectional, individual or combined
serum levels of PFOS, PFHxS and PFOA at age 5 years were not associated with prebooster
tetanus or diphtheria antibody concentrations at age 5. However, a relatively strong inverse
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association was observed for these serum levels of PFOS, PFHxS and PFOA at age 5 years,
with serum antibody concentrations to tetanus at 5 and 7 years post-booster. Although on two
out of six occasions these associations did not reach formal statistical signiﬁcance the decrease
in tetanus antibody concentrations was, for individual compounds, consistent and ranged
between -10% and -36% for each twofold increase in exposure. Similar, but slightly less
pronounced inverse trends were observed for diphtheria antibody concentrations at ages 5 and
7 post-booster (statistically signiﬁcant for PFOS and PFOA at age 7). When modelling the
combined exposure to PFOS, PFHxS and PFOA a twofold increase in serum levels exposure at
age 5 was associated with 59% (95% CI: 76, 29) and 46% (67, 10) decrease in
serum antibody response to tetanus and diphtheria at age 7 years, respectively.
• Clinical relevance: The authors noted that the odds ratio for antibody concentrations being
below the protective level for diphtheria at age 7 for a twofold increase in PFOS and PFOA
concentrations at age 5, were 2.4 (95% CI: 0.9–6.4) and 3.3 (95% CI: 1.4, 7.5), respectively.
Based on ﬁndings from the same cohort as used in the Grandjean et al. (2012) study, confounding
by polychlorinated biphenyls (PCBs)21 could be suspected as both maternal concentrations (Heilmann
et al., 2016) and offspring concentrations at 5 years (Heilmann et al., 2010) have been associated with
reduced antibody response to the same vaccines. Acknowledging the possibility for confounding
(Grandjean et al., 2012), the authors reported the Spearman correlation between PCBs (sum) and
PFOS during pregnancy, which was 0.24. The corresponding correlation for the offspring at age 5 was
0.08. These weak correlations essentially rule out strong confounding by PCBs because of in utero or
lactational exposures22; and because of offspring own exposures at age 5. This was also demonstrated
when the authors adjusted for breast milk concentrations (taken in days 4–5 post-partum) of PCBs and
offspring concentrations at age 5. Without adjustment for PCBs the change in diphtheria concentration
at age 7 years per twofold increase in offspring serum concentrations of PFOS at age 5 years was
28% (95% CI: 46 to 3). After further adjustment for maternal pregnancy concentrations and
offspring PCBs concentrations at age 5 years, the corresponding estimate was 38% (95% CI: 56,
12). The low correlations observed for PCBs and PFOS in this population, particularly in the children,
also suggest that these compounds did not share the same sources of exposure. The same argument
applies for PFOA, which was even less correlated with PCBs than PFOS in the Grandjean et al. (2012)
study. As a result, confounding by PCBs is considered unlikely. However, even if confounding by PCBs
is considered unlikely, effect modiﬁcation by PCBs is theoretically possible, i.e. that the decrease of
antibody response in children with higher PFOS exposure could depend on concomitant exposure to
PCBs (effect modiﬁcation).
Granum et al. (2013) examined, in a subset of children from the Norwegian Mother and Child
Cohort study, the associations between maternal serum concentrations at delivery (mean) of PFOS
(5.6 ng/mL), and PFOA (1.1 ng/mL) with serum antibody concentrations in 50 children that had
followed a routine vaccination program with vaccines against tetanus and Haemophilus inﬂuenza type
B (Hib) administered at ages 3, 5 and 12 months, and vaccination against measles and rubella at
15 months. In covariate-adjusted models maternal serum concentrations of PFOS and PFOA were
inversely associated with offspring antibody concentration to rubella at age 3 years (n = 50). No
associations were, however, observed for Hib, tetanus or measles antibodies.
Stein et al. (2016a) examined cross-sectionally the associations between (mean) PFOS (20.8 ng/mL)
and PFOA (4.1 ng/mL) concentrations with serum antibody concentrations to measles, mumps and
rubella among 1,188 children and adolescents (12–19 years) from NHANES. Higher concentrations of
PFOS and PFOA were signiﬁcantly associated with lower serum antibody concentrations for rubella and
mumps (somewhat stronger for PFOS). The observed effect size for mumps and rubella ranged from
3% to 13% decrease in antibody concentrations per twofold increase in exposure.
Apart from these three studies (Grandjean et al., 2012; Granum et al., 2013; Stein et al., 2016a)
that focused on the exposure during pre- and postnatal development, three comparable studies have
also been conducted in adults.
Looker et al. (2014) examined, among 411 US adults, associations between serum concentrations
of PFOA and PFOS and antibody response following inﬂuenza vaccination, and self-reported occurrence
21 PCB congeners 138, 153 and 180 were quantiﬁed in maternal serum during pregnancy or breast milk postnatally and in
offspring serum at age 5 years. Serum PFOS concentrations were also quantiﬁed in maternal serum during pregnancy and
offspring serum at age 5 years.
22 Pregnancy serum and breast milk concentrations of PCBs are highly correlated and both concentrations are strong
determinants of offspring own concentrations during early infancy.
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of recent (< 12 months) respiratory infections. Participants had been exposed to PFOA contaminated
drinking water and were enrolled into the C8 project in 2005–2006, but were again followed-up and
recruited into this study in 2010. Median serum concentrations of PFOA and PFOS in 2010, prior to
vaccination, were 31.5 and 9.2 ng/mL, respectively. After vaccination seroconversion for inﬂuenza type
B, A/H1N1 and A/H2N3 was 62%, 84% and 65%, respectively. Mean antibody concentrations for
inﬂuenza type B at 21  3 days post vaccination was signiﬁcantly lower among those in the highest
compared to lowest quartile of PFOA exposure while non-signiﬁcant changes were observed for PFOS.
However, in covariate adjusted models, where exposure and outcome were both log-transformed, non-
signiﬁcant changes were observed in all cases, although a borderline-signiﬁcant inverse association
(p = 0.09) was observed between PFOA and A/H2N3 antibody response. No associations were
observed for either PFOS or PFOA when using self-reported colds or inﬂuenza as an outcome.
Kielsen et al. (2016) examined the relationship between serum concentrations (median for PFOS
and PFOA was 9.5 ng/mL and 1.7 ng/mL, respectively) with changes in antibody concentrations for
tetanus and diphtheria following booster vaccination in twelve healthy Danish volunteers. Changes in
antibody concentration were deﬁned as the difference in concentrations between day 4 and 10 after
vaccination. This outcome was used based on the assumption that stable antibody concentrations
would be reached 10 days after the vaccination. The baseline concentration of PFOS was inversely
associated with the rate of increase in diphtheria antibody concentrations between 4 and 10 days, with
a 11.9% (95% CI: 0.3, 21.9) decrease observed per doubling of PFOS exposure. The corresponding,
but non-signiﬁcant, decrease in antibody concentrations for PFOA was 8.2% (95% CI: 20.9, 6.4).
The corresponding effect estimates for tetanus were non-signiﬁcant for both PFOS and PFOA.
Stein et al. (2016b) examined the association between serum concentrations (mean) of PFOS
(5.2 ng/mL) and PFOA (2.3 ng/mL) with immune response following vaccination against inﬂuenza
(FluMist). A total of 78 subjects from the US, aged 18–49 provided a baseline blood sample and were
then immunised. Blood samples were then drawn after 48–72 h and again, after at least 30 days after
vaccination. A total of 13 immune outcomes were explored including cytokine, chemokine and
immunoglobulin concentrations in serum. Seroconversion was measured by haemagglutinin inhibition
and seroconversion by immunochemistry. Overall, no signiﬁcant associations were observed between
baseline concentrations of serum PFOS/PFOA with the outcomes explored. When interpreting these
results, it is worth noting the FluMist generated a limited systemic response to the vaccination (only
9%, as measured by haemagglutinin inhibition and 25%, as measured by immunohistochemistry). This
would mean that even if there is a true association between PFOS and/or PFOA and reduced antibody
response to FluMist, such an association would be difﬁcult to detect.
3.3.4.5.4. Infections
In the previously mentioned study by Granum et al. (2013) maternal concentrations of PFOS and
PFOA were also examined in relation to common cold in the offspring that was assessed by parental
report at ages 1, 2 and 3 years (n = 99). The authors observed a signiﬁcant positive association
between the total number of reported episodes of common cold in the offspring, up to 3 years of age
(n = 99) and maternal PFOA, but not PFOS, after adjustment for potential confounders. For PFOA, a
positive association with a number of reported episodes of gastroenteritis was also observed.
In a similarly designed but larger study, Dalsager et al. (2016) examined associations between
maternal serum concentrations (median) for PFOS (8.1 ng/mL) and PFOA (1.7 ng/mL), among 649
mother–child pairs from Odense, Denmark. Maternal serum samples were drawn prior to week 16 of
gestation and episodes of infection were recorded every 2 weeks over 12 months from birth, using
mobile phone text messages (parental report). Both, the number of days and information on
symptoms (grouped into 11 different categories) were recorded. Among the 649 participants, 354
reported symptoms, ranging from rare events such as blood in stools (n = 4) to temperature over 38.5
degrees (n = 283) and runny nose (n = 337). Maternal PFOS concentrations in the upper tertile (above
10.2 ng/mL) compared with the lowest (below 6.9 ng/mL) were signiﬁcantly associated with increased
proportion of days with fever (incidence rate-ratio: 1.7 (95% CI: 1.2, 2.2), p-trend = 0.001), while this
was not the case for PFOA. An increased odds ratio of experiencing days with fever above the median
was found for PFOS (OR: 2.4 (95% CI: 1.3, 4.1)) and for PFOA (OR: 2.00 (95% CI: 1.1, 3.6)). No
associations were observed for coughing, nasal discharge, diarrhoea or vomiting.
At least two other studies have not found associations between maternal concentrations of PFASs
and offspring propensity for infections. Fei et al. (2010a) examined in a subset of participants from the
Danish National Birth Cohort (n = 1,400, 1996–2002), associations between maternal concentrations of
PFOS and PFOA and risk of hospitalisation due to infectious diseases, up to 2008. Information on
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hospital admission was extracted from nationwide registries. Mean concentrations for PFOS and PFOA
in maternal serum, drawn in gestation week 4–14, were 35 and 5.6 ng/mL, respectively. At the end of
follow-up 26% of the offspring had been hospitalised at least once. Offspring age at end of follow-up
ranged from 6 to 11 years. In this study, no associations were observed between maternal
concentrations of PFOS and PFOA with offspring hospitalisation. The authors noted that they were only
able to examine associations with resistance to infections in general, and the study was not designed
to examine if prenatal exposure could predict occurrence of speciﬁc infections.
Okada et al. (2012) also found no association between second trimester maternal serum
concentrations (median) of PFOS (5.2 ng/mL) and PFOA (1.3 ng/mL) and offspring otitis media
(parental report) up to 18 months of age (n = 343).
3.3.4.5.5. Summary
Based on the studies reviewed above, there is not much evidence to suggest that PFOS or PFOA
are associated with asthma and allergies in children and adults. This conclusion is based on the
relatively weak designs of existing studies, which have mostly been cross-sectional (Tao et al., 2008;
Dong et al., 2013; Buser and Scinicariello, 2016; Stein et al., 2016a; Zhu et al., 2016) or comparing
rates of asthma using simple group comparisons (Anderson-Mahoney et al., 2008), making it difﬁcult
to draw any conclusions on causality. Results from studies focusing on developmental exposures to
PFOS and PFOA and later allergies and/or asthma (Wang et al., 2011b; Okada et al., 2012, 2014;
Ashley-Martin et al., 2015) have been inconsistent. Based on these ﬁndings, there is little evidence to
suggest that early life exposures to PFOS or PFOA are causally related to allergies or asthma in
children.
In contrast to asthma and allergy, there is relatively strong evidence to suggest that serum
concentration of PFOS and PFOA are adversely associated with antibody response, following
vaccination reported in most (Grandjean et al., 2012; Granum et al., 2013; Looker et al., 2014; Kielsen
et al., 2016) but not all (Stein et al., 2016b) studies conducted so far. As expected, stronger and more
pronounced associations have been observed in children where the immune system is rapidly
developing (Grandjean et al., 2012; Granum et al., 2013) compared to adults who frequently fail to
seroconvert in these experiments (Looker et al., 2014; Stein et al., 2016b). In studies that have not
used direct vaccination challenge, similar associations for PFOS and PFOA have been reported in early
infancy as a result of prenatal exposure (Granum et al., 2013). Comparable, but more modest
associations have also been observed cross-sectionally in 12- to 19-year-old children (Stein et al.,
2016a).
Whereas a decreased antibody response to vaccination may lead to reduced protection to the
pathogen at which the vaccine is targeted, a decrement in responses may also imply a reduced
functionality of the immune system in a broader sense. In terms of clinical relevance, two different
studies have suggested that maternal PFOS and/or PFOA concentrations may result in increased
propensity of infections in the offspring during the ﬁrst months of life (Granum et al., 2013; Dalsager
et al., 2016) but other studies found no association with infections (Fei et al., 2010a; Okada et al.,
2012). This inconsistency may reﬂect the broad outcome deﬁnitions used in some of these studies as
well as the difﬁculty of recording accurately symptoms and duration of infection using parental report.
Although the study by Dalsager et al. (2016) was perhaps the most robust by recording symptoms and
duration of infection every 2 weeks over the 12-month follow-up period, further replication is needed
to conﬁrm these ﬁndings.
As with all observational studies, ﬁndings of statistically signiﬁcant associations are by no means
evidence that the observed association is causal. However, the study by Grandjean et al. (2012) and
later studies have a strong experimental component where antibody production is initiated through
vaccination and the increase in antibody concentrations is then followed prospectively in relation to
baseline concentrations of PFOS and PFOA. A potential confounder would, therefore, have to be (1) a
determinant of antibody production initiated and (2) a determinant of exposure. For PFOS and PFOA
dietary and other lifestyle predictors of exposures are, however, not well characterised. Main sources
of confounding for many of the outcomes reviewed in this opinion are determinants of excretion that
affect circulating concentrations of PFOS and PFOA, as well as of the outcome under consideration.
These determinants of excretion include glomerular ﬁltration rate, blood loss, faecal excretion and
hemodilution. None of these factors appear likely to affect serum antibody concentrations.
Confounding also appears unlikely, as similar associations with serum antibody concentrations, using
the same vaccines, have been reported in both children (Grandjean et al., 2012) and adults (Kielsen
et al., 2016), where physiological function and lifestyle should differ substantially. Although
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confounding in observational studies can never be fully excluded, the CONTAM Panel concludes that
the association between PFOS and PFOA, with serum antibody concentrations, is likely to be causal.
3.3.4.6. Endocrine outcomes
3.3.4.6.1. Puberty, menopause and menstrual cycle
Lopez-Espinosa et al. (2011) performed a cross-sectional study in the US C8 cohort (drinking water
contaminated with PFOA) on the association between PFOS and PFOA and delayed puberty in about
3,000 boys and 3,000 girls aged 8–18 years. Median PFOS and PFOA levels were 20.2 and 28.2 lg/L,
respectively. In girls, age of puberty was based on a combination of menarche (by questionnaire) and
serum oestradiol. In boys, it was based on serum testosterone. A number of potential confounders
were adjusted for. Puberty in boys was estimated to have occurred signiﬁcantly later (about
4–6 months) in the third and fourth quartile of PFOS compared to the ﬁrst quartile. No association was
found for PFOA. In girls, puberty had occurred signiﬁcantly later (6–10 months) in the third and fourth
quartiles of PFOS compared with the ﬁrst quartile. For PFOA the point estimates for the upper three
quartiles, was a delay of about 5 months compared with the ﬁrst quartile.
The C8 cohort was also used to study the association between PFOS and PFOA and early
menopause (Knox et al., 2011a). PFOS and PFOA levels were examined in 26,000 women aged
18–65 years. Median PFOS and PFOA levels were 16 and 23 lg/L in women 43–51 years, and 22 and
33 lg/L in women above 51 years. The study was restricted to about 18,000 non-pregnant women
who did not use birth control pills or hormone replacement therapy, and who had not had
hysterectomy. Menopause (yes/no) was asked for, and serum oestradiol was determined. After
adjustment for several potential confounders, the ORs of having experienced menopause were
signiﬁcantly higher in the upper four quintiles of PFOS and PFOA compared with the ﬁrst quintile, e.g.
2.1 (1.6–2.8) in the ﬁfth quintile of PFOS and 1.7 (1.3–2.3) in the ﬁfth quintile of PFOA. Serum
oestradiol was negatively associated with PFOS, but there was no association with PFOA levels. The
authors considered reverse causation as a possible cause of the association between lower PFOS/PFOA
at late menopause (loss of PFASs in menstrual blood), but that it could not explain the association with
oestradiol.
For PFOA, Taylor et al. (2014) observed signiﬁcantly higher risk (HR 1.4, 95% CI 1.1–1.8 for third
vs ﬁrst tertile) of early menopause among 20- to 65-year-old women from NHANES (1999–2010). No
such association was observed for PFOS. The authors noted that their ﬁndings could be explained by
reverse causation, which is also consistent with results from physiologically based pharmacokinetic
models (Wong et al., 2014).
Lyngsø et al. (2014) examined the cross-sectional association between serum concentrations of
PFOS and PFOA (median: 8.0 and 1.5 ng/mL, respectively) with irregular menstrual cycles in 1,623
pregnant women from Greenland, Poland and Ukraine. Serum samples were drawn during the ﬁrst
trimester in pregnancy, and information on menstrual cycle characteristics in the period before
pregnancy was retrospectively obtained through self-reported questionnaires. Short and long cycles
were deﬁned as equal or less than 24 days and greater and equal than 32 days, respectively. There
was a borderline signiﬁcant association between PFOA and long menstrual cycle (OR: 1.8 (95% CI:
1.0, 3.3)). No signiﬁcant association was observed for PFOS. Higher odds of long menstrual cycles
would be consistent with lower rate of excretion of these compounds, making reverse causation a
likely explanation.
Based on the few studies conducted so far there is little evidence to suggest that exposure to PFOS
or PFOA are related to the development of puberty, menopause or menstrual cycle length.
3.3.4.6.2. Endometriosis
Louis et al. (2012) studied the association between PFOS and PFOA and endometriosis in a cross-
sectional study of 600 US women aged 18–44 years. Most of the women were seeking clinical care
due to symptoms (operative sample, diagnosis by laparoscopy/laparotomy) but some of them
(N = 127) constituted a population-based sample (diagnosis by MRI). The geometric mean in the two
sample levels were 6–7 lg/L for PFOS and 2–3 lg/L for PFOA. Odds ratios for endometriosis (per ln
change of PFOS and PFOA; i.e. an increase by a factor of 2.7), adjusted for age and BMI in the
operative sample were 1.4 (95% CI: 0.98–2.0) for PFOS and 1.9 (95% CI: 1.2–3.1) for PFOA.
Adjusting also for parity reduced the ORs, but may represent over-adjustment. In the smaller
population sample, the ORs were similar with wider conﬁdence intervals.
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Campbell et al. (2016) examined cross-sectionally the association between serum concentrations of
PFOS and PFOA (means 16.3 and 3.5, respectively) with endometriosis in 753 women aged
20–50 years from NHANES (2003–2006). Log-transformed PFOS and PFOA as continuous variables
were not signiﬁcantly associated with increased odds of endometriosis. However, when exposure was
classiﬁed by quartiles there was a signiﬁcant trend of increased risk with higher PFOS/PFOA, although
the odds ratios did not increase monotonically.
Based on the results from these two cross-sectional studies and in the absence of prospective
studies, there is insufﬁcient evidence that PFOS and PFOA is associated with endometriosis.
3.3.4.6.3. Thyroid function
Thyroid disease in adults and children
Emmett et al. (2006) examined the association between serum PFOA levels (median 354 and
interquartile range 771 ng/mL) and self- or parent-reported thyroid disease and TSH among 371
individuals aged 2–89 years, exposed via contaminated drinking water in the C8 area. No association
was observed between PFOA and thyroid disease or TSH in analyses unadjusted for potential
confounders.
In another study from the same area, 566 exposed residents recruited in 2003 had more often
self-reported ‘thyroid problems’ than expected using compared expected rates from NHANES
2001–2002 (Anderson-Mahoney et al., 2008). However, the validity of this ecological comparison is
uncertain for example due to selection bias.
Melzer et al. (2010) examined the association between serum levels of PFOS and PFOA and
self-reported physician-diagnosed thyroid disease (ever, and current with medication, type unspeciﬁed)
with or without medication in about 4,000 participants in NHANES surveys from 1999 to 2006. Thyroid
disease was reported by 292 women and 69 men. Mean PFOS levels were 19 ng/mL in women and
25 ng/mL in men. For PFOA these levels were 3.8 and 4.9 lg/L. A number of potential confounders
were taken into account. For women, the ORs for thyroid disease were elevated in the upper two
quartiles of PFOA, while no such association was found for PFOS. ORs tended to be elevated also for
men, but based on few cases. There was no information on whether the thyroid disease cases had
been diagnosed as hyper- or hypothyroidism.
Lopez-Espinosa et al. (2012) examined cross-sectional associations between PFOS (median 29 ng/mL)
and PFOA (20 ng/mL) with total T4 and TSH among about 12,000 children in the C8 cohort aged
1–17 years. A number of potential confounders were adjusted for. The OR for parent-reported
hypothyroidism (39 cases) increased with serum PFOA (OR 1.5, 95% CI: 1.0–2.4), but the OR for
subclinical hypothyroidism (based on high TSH) was 1.0. Ln PFOS, but not PFOA was signiﬁcantly
associated with total T4 levels (~2% increase in the highest PFOS quartile).
Winquist and Steenland (2014a) examined the association between retrospectively estimated PFOA
exposure and thyroid disease among about 32,000 subjects from the C8 cohort. Medical records were
reviewed in participants who reported functional thyroid disease or medication for it in questionnaires
administered 2008–2011, and 2000 validated cases of hyper- or hypothyroidism were used in the
analyses. Median PFOA in 2005–2006 was 24 ng/mL. Previous exposure to PFOA (since 1952) was
retrospectively estimated using quantiﬁed exposure in a subset of participants at recruitment,
combined with data on area of residence and previous occupation (Shin et al., 2011a). Data were
analysed retrospectively and prospectively by Cox regression. In the retrospective analyses there was a
signiﬁcant positive association between estimated exposure to PFOA and thyroid disease with a hazard
ratio of about 1.3 when comparing the highest four quintiles of cumulative exposure with the lowest
quintile. The point estimates were increased for hypo- as well as hyperthyroidism, although not
signiﬁcantly. The association was driven by women, and mainly by hyperthyroidism, and no association
was observed for males. In the prospective analyses, based on fewer cases, cumulative PFOA levels
tended to increase the risk of thyroid disease (hypothyroidism) among men, but not in women. For
prospective analyses based only on measured PFOA levels in 2005–2006, there were no associations
with thyroid disease. Using data from the 2007–2010 NHANES surveys with a total of 1,181 adults,
Wen et al. (2013) examined cross-sectional associations between PFOS (GM 14 ng/mL), and PFOA
(GM 4.2 ng/mL) with free and total T3 and T4, TSH, and thyroglobulin. The authors then deﬁned
subclinical hypothyroidism and hyperthyroidism as TSH > 5.43 and TSH < 0.24 mlU/L, respectively. A
threefold increase in serum PFOS concentration was associated with increased risk of subclinical
hypothyroidism in females (OR: 3.0, 95% CI: 1.1–8.1, based on 9 cases) and males (OR: 2.0, 95% CI:
1.2–3.3, based on 15 cases). The same was true for PFOA in females (OR: 7.4, 95% CI: 1.1–48), but
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not for men. There was a positive association between log-transformed PFOA and T3 in females, but
no association with (log-transformed) TSH, free T4 or free T3.
Thyroid hormones in adults
Olsen and Zobel (2007) examined cross-sectional associations between serum PFOA levels and
thyroid hormones in about 500 3M workers from three 3M plants in the US and Belgium. There was an
overall inverse association between serum PFOA and free T4, but no association with total T3 or T4.
There was also a tendency towards a positive association between PFOA and TSH.
Dallaire et al. (2009) studied cross-sectional associations between PFOS and thyroid hormones in
621 Canadian Inuits with a mean serum PFOS of 18 ng/mL, adjusted for a several confounders. PFOS
was correlated (r about 0.5) with many PCB congeners. There was a negative association between
PFOS and TSH, a positive association with free T4 but a negative association with total T3 and TBG.
The authors discussed if the reason could be a competition between PFOS and free T4 for transport
proteins as found in rats.
Bloom et al. (2010) compared serum PFOS/PFOA levels, cross-sectionally, with levels of thyroid
hormones in 31 New York anglers. No signiﬁcant associations were found.
Chan et al. (2011) performed a cross-sectional study of pregnant (15–20 weeks) Canadian women
subject to antenatal screening. Out of 974 maternal sera, the authors selected all (N = 96 ‘cases’) with
normal TSH but low (< 10 percentile) free T4 and age-matched controls (N = 175), among women
with normal TSH and free T4 levels between the 50th and 90th percentiles. PFOS and PFOA were
measured in these sera. Thus the a priori hypothesis was that PFOS/PFOA would cause
hypothyroxinemia (still with normal TSH). Odds ratios (adjusted for potential confounders) for being a
case at a threefold increase in PFOS/PFOA were 0.9 (95% CI 0.6–1.2) for PFOS and 0.9 (95% CI 0.7–
1.2) for PFOA.
Knox et al. (2011b) examined associations between PFOS/PFOA and thyroid function (T4, T3
uptake, and TSH) in the C8 cohort. Analyses were based on 52 000 adults, without self-reported prior
thyroid disease. Mean PFOS and PFOA levels in women were 20 and 69 lg/L and 27 and 104 lg/L in
men. When adjusting for a number of potential confounders, T4 levels increased across PFOS and
PFOA quintiles, T3 uptake decreased across PFOS and PFOA quintiles, while TSH levels were
unchanged. The differences between Q5 and Q1 were < 10%. Effects were slightly stronger in women
than in men. No obvious threshold was seen and there was probably a slight but signiﬁcant difference
already between the ﬁrst and second quintile. The combination of slightly increased thyroxin and
unchanged TSH was interpreted as a likely increase of thyroxine-binding globulin (TBG) in serum,
which was not measured. Consistent with this hypothesis, serum albumin (which only binds a minor
part of T4) was weakly, but signiﬁcantly positively associated with PFOS and PFOA levels.
Ji et al. (2012) examined the association between serum concentrations of PFOS/PFOA and total T4
and TSH among 633 Koreans aged < 12 years. Median serum levels were 8.0 ng/mL for PFOS and
2.7 ng/mL for PFOA. A number of potential confounders were adjusted for. There were no associations
between PFOS or PFOA and TSH or T4.
Jain (2013) examined associations between PFOS/PFOA and thyroid hormones in 1,540 individuals
≥ 12 years from the NHANES survey 2007–2008. Those with thyroid problems or medications, current
pregnancy or missing variables had been removed. The mean serum PFOA was 4.1 ng/mL, and the
mean serum PFOS level was not reported. A number of potential confounders were taken into
account. TSH was higher in the upper tertile of serum PFOA, but not associated with serum PFOA as a
continuous variable. PFOA was positively associated with total T3 but not with free T3 or free T4.
There were no associations between serum PFOS and thyroid hormones.
The association between PFOS/PFOA and TSH was examined cross-sectionally in 903 pregnant
women (about 18th week of gestation) in the Norwegian Mother and Child cohort, MoBa (Wang et al.,
2013b). About half of the women had been selected due to subfecundity. Those who reported
previous thyroid disease were excluded. The GM of serum PFOS and PFOA were 13 and 2.1 ng/mL.
Several potential confounders were adjusted for. There was a statistically signiﬁcant association
between serum PFOS and ln TSH, but the magnitude of association was limited. The risk of ‘high’ TSH
(> 7.5 IU/mL) was not associated with serum PFOS. For serum PFOA no association was found.
Lin et al. (2013a) examined cross-sectional associations between PFOS/PFOA and thyroid hormones
(TSH, free T4) in 567 Taiwanese individuals aged 12–30 years. GM was 7.8 ng/mL for serum PFOS and
2.7 ng/mL for serum PFOA. A number of potential confounders were adjusted for. There were no
signiﬁcant associations between PFOS/PFOA and thyroid hormones.
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Audet-Delage et al. (2013) studied the hypothesis that PFOS binds to one of the circulating thyroid
hormone binding proteins, TTR. In a cross-sectional study of 120 Inuit women, the association
between PFOS (GM 11 ng/mL) and TTR-bound T4 was studied cross-sectionally. No association with
PFOS was shown.
Wang et al. (2014b) performed a cross-sectional study of PFOS/PFOA and thyroid hormones (TSH,
T3, T4 and free T4) in 285 pregnant mothers (third trimester) in Taiwan with no known thyroid
disease, and thyroid hormones were also measured in cord blood in 116 of their neonates. The median
maternal PFOS and PFOA were 13 and 2.4 ng/mL, respectively. Several potential confounders were
adjusted for. There were no signiﬁcant associations between PFOS/PFOA and maternal or cord blood
thyroid hormones.
Shrestha et al. (2015) examined associations between PFOS (GM 32 ng/mL) and PFOA (GM 9.2 ng/mL)
and thyroid hormones (TSH, T4, free T4, T3) in 87 US adults aged 55–74 without underlying thyroid
disease. After adjustment for potential confounders (including PCB) there was a statistically signiﬁcant
association between serum PFOS and T4 and free T4.
Webster et al. (2014) examined associations between PFOS/PFOA levels and thyroid hormones in
152 pregnant (measured twice in early second trimester) Canadian non-smoking women. The median
serum PFOS and serum PFOA levels were 4.8 and 1.7 ng/mL. Analyses were adjusted for week of
gestation and presence of TPO antibodies (positive in 14 women, indicating possible autoimmune
thyroid disease). Overall there were no signiﬁcant associations between PFOS/PFOA and thyroid
hormones. However, in the 14 women with TPO antibodies there was a signiﬁcant positive association
between PFOS and PFOA levels and TSH (but not with free T4).
Lewis et al. (2015) studied associations between PFOS/PFOA and thyroid hormones (TSH, T4, free
t4, T3, free T3) in 1,682 individuals 12–80 years enrolled in NHANES 2011–2012. Median serum PFOS
and PFOA levels were 4–10 ng/mL (in various age groups) and 1.5–2.6 ng/mL (in various age groups)
in adult females, 8–11 ng/mL (in various age groups) and 2.4–2.5 ng/mL (in various age groups) in
adult males, and slightly lower in adolescents. There were no overall associations between PFOS/PFOA
and thyroid hormones. In results stratiﬁed by sex and four age groups, there were a few signiﬁcant
ﬁndings for the most important hormones (TSH, free T4 and free T3): a positive association between
PFOS and TSH in male adolescents, a negative association between PFOA and TSH in female
adolescents, positive associations between PFOS and PFOA vs free T4 in women aged 20–39 years,
and a positive association between PFOA and free T4 in female participants aged 60–80 years.
Berg et al. (2015) examined associations between PFOS/PFOA and thyroid hormones in 375
pregnant women in Norway. PFOS/PFOA were measured around gestation week 18, and thyroid
hormones (TSH, free T4, T4, free T3, T3) as well as thyroid hormone binding proteins were measured
in the same samples, and also 3 days and 6 weeks post-partum. Median PFOS and PFOA levels were
8.0 and 1.5 ng/mL. Some potential confounders were adjusted for and also binding proteins in
repeated measures analyses (mixed effects models). There was a positive association between PFOS
and TSH, but no associations with the other hormones and no associations between PFOA and
hormone levels.
Kato et al. (2016) studied associations between PFOS/PFOA and thyroid hormones in 392 Japanese
mother–infant pairs in the Hokkaido study. Median maternal serum PFOS and PFOA levels (24–
41 weeks of gestation) were 5.2 and 1.2 ng/mL. Thyroid hormones (FSH and free T4) were
determined in mothers in early pregnancy (around week 11) and also in their infants at age 4–7 days.
In models adjusted for potential confounders, there was an inverse association between maternal
PFOS and maternal TSH, but not free T4, and there were no associations between PFOA and thyroid
hormones. There was a signiﬁcant positive association between maternal PFOS and infants’ TSH, but
no other associations between PFOS/PFOA and infants’ thyroid hormones.
Webster et al. (2016) studied associations between PFOS/PFOA and thyroid hormones (TSH, T4,
free T4, T3, free T3) in 1,525 adults from NHANES 2007–2008, excluding those with a history of
thyroid disease. GM PFOS and PFOA levels were 14 and 4.2 ng/mL. Several confounders were
adjusted for, and results were also stratiﬁed for presence of thyroid peroxidase antibodies (TPOab,
present in 9%) and urinary iodine classiﬁed as low (< 100 lg/L) in 26%. In individuals with normal
urinary iodine and no TPOab there was a slight (1%) increase in free T3 at an IQR increase of PFOA,
but no association for the other hormones and null for PFOS. However, in 26 individuals with TPOab
and low urinary iodine, there were positive associations between PFOS/PFOA and TSH, and free T3,
and an inverse association with free T4 (PFOS only). The authors suggest that the results could
support a ‘multiple hit’ hypothesis with those who have TPO antibodies and low urinary iodine (about
1% of the US population) being a sensitive group.
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In a study of 157 mother–infant pairs, Yang et al. (2016) examined cross-sectional associations
between maternal concentrations of PFOS/PFOA and maternal and infant thyroid hormones (TSH, free
T4, T4, free T3, T3). Median maternal serum PFOS and PFOA were 4.4 and 1.6 ng/mL, while cord
serum levels were 1.2 ng/mL for PFOS and PFOA. In analyses adjusted for potential confounders,
there was an inverse association between maternal PFOS and maternal TSH. There was also an
inverse association between maternal PFOA and infant free T3 and between infant PFOS and infant
free T3.
Thyroid hormones in newborns and children
de Cock et al. (2014b) examined the association between PFOS/PFOA in cord plasma with T4 levels
in heel prick blood spots among 64 Dutch newborns (4–7 days old). Median PFOS and PFOA levels
were 1.6 and 0.9 ng/mL. A number of potential confounders were adjusted for. No association with T4
was observed among boys, while T4 was signiﬁcantly higher in the fourth quartile of PFOA
concentrations among the girls.
As mentioned above, Wang et al. (2014b) found no signiﬁcant associations between PFOS/PFOA in
maternal serum and cord blood thyroid hormones.
Shah-Kulkarni et al. (2016) examined associations between PFOS/PFOA and thyroid hormones
(TSH, T4, T3) in cord blood of 279 newborns from Seoul, Korea. GM levels were 0.66 (PFOS) and 0.91
(PFOA) ng/mL. Several potential confounders were adjusted for. There were no signiﬁcant associations
between ln PFOS or PFOA and any of the cord blood thyroid hormones.
Kim et al. (2016) compared serum concentrations of PFOS/PFOA between 27 cases of infants with
congenital hypothyroidism and 13 control infants. Concentrations of PFOA (median: 5.4 vs 2.1 ng/mL)
were signiﬁcantly higher in the cases compared to controls, while PFOS levels were similar (5.3 vs
4.1 ng/mL). There were no positive associations between PFOS/PFOA and thyroid antibodies. Maternal
PFOS/PFOA levels were not available.
As mentioned above, Yang et al. (2016) found an inverse association between maternal PFOA and
infant free T3 and between infant PFOS and infant free T3.
As mentioned above, Kato et al. (2016) found a signiﬁcant positive association between maternal
PFOS and infant TSH.
The above studies are summarised in Table 22.
Summary
In summary, four studies from the C8 cohort and two from NHANES studied thyroid disease. The
study by Melzer et al. (2010) did not differentiate between hyper- and hypothyroidism, and the
disease occurrence was self-reported. The study by Wen et al. (2013) suggests that PFOS and PFOA
may increase the risk of hypothyroidism, but it was cross-sectional and based on few cases and not
consistent with the overall result for thyroid hormones. Also, the C8 study by Winquist and Steenland
(2014a) suggests that PFOA may increase the risk of thyroid disease, especially hypothyroidism in
females, but there was no average increase in TSH (Knox et al., 2011b) in those without thyroid
disease.
Associations between serum levels of PFOS and/or PFOA and thyroid hormones were analysed in
twenty cross-sectional studies (and transthyretin-bound T4 in one study). Fourteen of them examined
associations in adults only, three of them combined analyses in pregnant women with analyses in
newborns, and three studies examined only outcomes in newborns. The most important biomarkers
for assessment of thyroid function are TSH, free T4 and free T3, where T3 is the active hormone.
Changes in free hormones are a result of changes in thyroid function, governed by pituitary-derived
TSH, while levels of total T4 and T3 also are affected by levels of thyroid binding proteins, and may
therefore change without clinical implications for thyroid function. At normal pituitary function, TSH is
the most sensitive marker of hypothyroidism and increases before lower levels of T4 or T3 are
detected. Primary hyperthyroidism is accompanied by high levels of free and total T3 and T4, and also
by an abnormally low TSH.
Most studies examined TSH levels. Only two of them (Wang et al., 2013b; Berg et al., 2015) found
a signiﬁcant positive overall association between PFOS and TSH. None of the studies showed an
overall association with PFOA. In addition, there were some positive ﬁndings in subgroups. Eleven
studies examined free T4. Positive associations were found only in two studies, Dallaire et al. (2009) in
Inuits, and Shrestha et al. (2015), in a small group of elderly. One study (Olsen and Zobel, 2007)
reported an inverse association between PFOA and free T4. Few studies examined free T3, and two of
them (Kim et al., 2016; Yang et al., 2016) reported a possible association.
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Therefore, overall, the studies do not support an association between PFOS/PFOA and changes in
thyroid hormones. This is true also if only the large studies (> 500), with adjustment for potential
confounders, in non-occupationally exposed populations are considered (Dallaire et al., 2009; Knox
et al., 2011b; Ji et al., 2012; Jain, 2013; Lin et al., 2013a; Wang et al., 2013b; Lewis et al., 2015;
Webster et al., 2016). Neither are there any consistent associations between PFOS/PFOA in maternal
or cord serum in six studies examining such associations.
The CONTAM Panel concluded that there is insufﬁcient support for associations between PFOS or
PFOA and thyroid disease or changes in thyroid hormones.
Table 22: Reports on associations between serum levels of PFOS and/or PFOA and thyroid disease
of thyroid hormones
Author
Population,
country and
number of
subjects
Type
Serum PFOS/
PFOA levels
(ng/mL)
Findings Comments
Thyroid disease
Emmett et al.
(2006)
C8, general pop,
N = 371
CS High, mean
PFOA 354
PFOA vs thyroid disease
and TSH: null
No confounding
adjustment. Not
informative
Anderson-
Mahoney et al.
(2008)
C8, general pop,
N = 566
CS,
ecological
No serum data Self-reported ‘thyroid
problems’ more common
than in NHANES
No confounding
adjustment.
Non-informative
ecological study
Melzer et al.
(2010)
NHANES, USA,
4,000
CS, L PFOS 19 in
women and 25
in men. PFOA
3.8 and 4.9
PFOA: OR for thyroid
disease + in women.
PFOS: Null
Disease self-
reported. Adjusted
for potential
confounders
Lopez-
Espinosa et al.
(2012)
C8, 12,000
children
1–17 years
CS, L Median PFOS 29,
median PFOA 20
PFOA: OR for hypo-
thyroidism increased, but
not OR for high TSH.
PFOS vs T4+
Few (39) cases.
Adjusted for potential
confounders
Winquist and
Steenland
(2014a)
C8, 32,000
(including 3,700
workers)
L Yearly historical
serum PFOA
modelled and
calibrated vs
measured levels.
median PFOA 26
in 2005-6
Thyroid disease
(N = 2,000) vs modelled
PFOA + in females
(retrospective analyses),
and (+) in males
(prospective analyses)
Adjusted for potential
confounders. Cases
of thyroid disease
validated in medical
records
Wen et al.
(2013)
NHANES, USA,
1,181
CS PFOS: 14
PFOA: 4.2
PFOS vs hypothyroidism +
in women and men
PFOA vs hypothyroidism +
and T3+ for women
Adjusted for potential
confounders. Few
(24) cases.
Diagnoses based on
cut-offs for TSH. Not
consistent with
results on continuous
scale
Thyroid hormones
Olsen and
Zobel (2007)
Occup (3M),
USA and
Belgium, 506
CS Median PFOS
720, median
PFOA 1100
PFOA vs FT4, and TSH
(+). Results for PFOS not
given
Adjusted for potential
confounders
Dallaire et al.
(2009)
Inuits, 621,
Canada
CS PFOS GM 18 PFOS vs TSH, FT4+ Adjusted for potential
confounders
Bloom et al.
(2010)
NY anglers, 31 CS PFOS GM 20
PFOA GM 1.3
Null Too small study to be
informative
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Author
Population,
country and
number of
subjects
Type
Serum PFOS/
PFOA levels
(ng/mL)
Findings Comments
Chan et al.
(2011)
Pregnant
women, Canada,
96 + 175
CS,
analysed
as case–
control
PFOS GM 15
PFOA GM 3.2
Cases: high FT4,
Controls: normal FT4,
Both: normal TSH.
No association btw PFOS
or PFOA and case/ctrl
status
Matched + further
adjustment for
potential
confounders
Knox et al.
(2011b)
C8, adults,
520,000
CS PFOS mean in
women 20 and
27 in men. PFOA
69 in women
and 104 in men
PFOS vs T4+, TSH null
PFOA vs T4+, TSH null
Adjusted for potential
confounders.
Authors’
interpretation:
increase in TBG
Ji et al. (2012) Adults, Korea,
633
CS PFOS median
8.0
PFOA median
2.7
Null for TSH and T4 Adjusted for potential
confounders
Jain, 2013 NHANES, USA,
≥ 12 years,
1,540
CS PFOA mean 4.1,
PFOS not
reported.
PFOA vs TSH (+), T3+,
but null for FT3, FT4.
PFOS vs TSH (+)
Adjusted for potential
confounders
Wang et al.
(2013b)
Pregnant
women, Norway,
903
CS PFOS GM 13
PFOA GM 2.1
PFOS vs TSH +
PFOA: null
Adjusted for potential
confounders
Lin et al.
(2013a)
Young
individuals,
Taiwan, 567
CS GM PFOS 7.8
GM PFOA 2.7
PFOS vs TSH, FT4 null
PFOA vs TSH, FT4 null
Adjusted for potential
confounders
Audet-Delage
et al. (2013)
Inuit women,
Canada, 120
CS GM PFOS 11 PFOS vs transthyretin-
bound T4 null
Adjusted for potential
confounders
Wang et al.
(2014b)
Pregnant
women, 285
newborns,
Taiwan, 116
CS PFOS median 13
PFOA median
2.4
PFOS vs TSH, T3, T4,
FT4: null
PFOA vs TSH, T3, T4,
FT4: null
Adjusted for potential
confounders
Shrestha et al.
(2015)
Elderly, USA, 87 CS PFOS: GM 32
PFOA: GM 9.2
PFOS vs FT4, T4+
PFOA vs T4 (+)
Adjusted for potential
confounders (also
PCB)
Webster et al.
(2014)
Pregnant
women, Canada,
152
CS PFOS median
4.8
PFOA median
1.7
Overall null. In 14 women
with TPO antibodies PFOS
and PFOA vs TSH+
Adjusted for
gestational week and
TPO antibodies
Lewis et al.
(2015)
NHANES, USA,
1682, results by
age groups
CS PFOS: medians 4
–11
PFOA: medians
1.5–2.6
Overall null.
Some signiﬁcant ﬁndings
in subgroups by age and
sex)
Adjusted for potential
confounders
Berg et al.
(2015)
Pregnant
women, Norway,
375
CS, but
repeated
sampling
PFOS: median
8.0
PFOA: median
1.5
PFOS vs TSH+, null for
FT4, T4, FT3, T3.
PFOA: null
Hormones measured
three times. Adjusted
for some potential
confounders
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3.3.4.6.4. Duration of breastfeeding
In the light of ﬁndings from animal studies suggesting that PFOA might impair lactation (White
et al., 2007, see also Section 3.3.3.3), these ﬁndings were followed up on in human observational
settings where associations between concentrations of PFOS and PFOA in pregnancy has been
examined as predictors of duration of breastfeeding.
Fei et al. (2010b) examined the association between maternal concentrations of PFOA (median
5.2 ng/mL) and PFOS (median 33 ng/mL) with duration of any breastfeeding and exclusive
breastfeeding using Cox-proportional hazard model, among 1,346 women from the Danish National
Birth Cohort (1996–2002). Maternal serum samples were drawn between weeks 4 and 14 of gestation
and information on duration of breastfeeding was extracted through telephone interviews at months 6
and 18 post-partum. Overall, maternal PFOS and PFOA concentrations were signiﬁcantly associated
with shorter duration of any breastfeeding and exclusive breastfeeding. As an example, the hazard
ratio for termination of exclusive breastfeeding was 1.37 (95% CI: 1.14, 1.64) in the fourth quartile of
PFOS and 1.37 (95% CI: 1.12, 1.69) in the fourth quartile of PFOA (p for trend < 0.01 in both cases).
However, when stratifying by parity, the association was only present among multiparous women (55%
of the women, p for trend < 0.01 in all cases) while no association was observed among primiparous
women (45% of the women, p for trend > 0.20 in all cases). One explanation of these inconsistent
ﬁndings could be reverse causation. That is, longer lactation in previous pregnancy would lead to
Author
Population,
country and
number of
subjects
Type
Serum PFOS/
PFOA levels
(ng/mL)
Findings Comments
Kato et al.
(2016)
Mother–infants
pairs, Japan,
392
CS PFOS median
5.2
PFOA median
1.2
Maternal PFOS vs mat.
and infant TSH+
PFOA: null
Adjusted for potential
confounders
Webster et al.
(2016)
Adults NHANES,
USA, 1,525
CS PFOS GM 14
PFOA GM 4.2
No TPOab and normal
U-I: PFOS vs FT3 + but
null for TSH, T3, T4, FT4
and for PFOA. TPOab and
low U-I: Several sign.
assoc for PFOS and PFOA
Adjusted for potential
confounders.
26 out of 1,525 had
TPO antibodies and
low U-iodine
de Cock et al.
(2014b)
Newborns,
Netherlands, 64
CS PFOS median
1.6
PFOA median
0.9
PFOS vs T4 (heel prick):
null.
PFOA vs T4 in girls +
Adjusted for potential
confounders
Shah-Kulkarni
et al. (2016)
Newborns,
Korea, 279
CS PFOS GM 0.7
and PFOA 0.9 in
cord blood
PFOS and PFOA vs TSH,
T4, T3: null
Adjusted for potential
confounders
Kim et al.
(2016)
27 cases of
infants with
congenital
hypothyroidism,
13 controls
CS PFOS: Medians
5.3 and 4.1.
PFOA: Medians
5.4 and 2.1
PFOA higher in cases. No
associations btw PFOS or
PFOA and antibodies
No confounding
adjustment Maternal
levels not available
Yang et al.
(2016)
Mother–infant
pairs, Beijing,
157
CS PFOS: maternal
4.4, infant 1.2
PFOA: maternal
1.6, infant 1.2
Maternal PFOS vs
maternal TSH: –
Maternal PFOA vs Infant
FT3: –
Infant PFOS and infant
FT3: –
Adjusted for potential
confounders
CS: cross-sectional (study); FT4: free T4; FT3: free T3; GM: geometric mean; L: longitudinal (study); N: number of subjects;
PFOA: perﬂuorooctanoic acid; PFOS: perﬂuorooctane sulfonic acid; T3: triiodothyronine; T4: thyroxine; TPO: thyroid peroxidase;
TSH: thyroid stimulating hormone. A ‘+’ sign denotes a positive association and a ‘–’ denotes an inverse association.
PFOS and PFOA in food
www.efsa.europa.eu/efsajournal 153 EFSA Journal 2018;16(12):5194
lower concentrations in the next pregnancy and women who with long duration of exclusive
breastfeeding are likely to breastfeed their offspring in a similar manner in the next pregnancy.
Romano et al. (2016) also examined the association between maternal PFOS (median 5.5 ng/mL)
and PFOA (13.9 ng/mL) concentrations among 336 US women from the HOME study (2003–2006). For
most women (~90%) maternal serum samples were drawn around week 16 of gestation but if not
available, serum samples drawn around week 26 of gestation were used. Women in the highest
(> 7.6 ng/mL) compared to lowest quartile (< 3.8 ng/ml) of PFOA exposure had 1.77 (95% CI: 1.23,
2.54) and 1.41 (95% CI: 1.06, 1.87) higher relative risk of terminating any breastfeeding before 3 and
6 months, respectively. No clear differences were observed between primiparous (n = 43%) and
multiparous (n = 57%) women in sensitivity analyses. However, the conﬁdence intervals for the effect
estimates were inﬂated in these stratiﬁed analyses, reﬂecting low statistical power making these
analyses inconclusive.
Timmermann et al. (2017) examined associations between serum PFOS and PFOA concentrations
and duration of breastfeeding by combining two Faroese birth cohorts formed in 1997–2000 and
2007–2009 with 640 and 490 pregnant women, respectively (n = 1,130 in total). Both cohorts relied on
serum samples drawn in week 34–36 of gestation. Duration of breastfeeding was based on maternal
report at 18 months in the 1997–2000 cohort. However, in the 2007–2009 cohort, duration of
breastfeeding was assessed by maternal report 5 years post-partum. In this combined data the median
(25th to 75th percentile) for PFOS was 19.5 ng/mL (8.7–28.2) and for PFOA 2.4 ng/mL (1.5–3.6). A
doubling of PFOS and PFOA levels was associated with shorter mean duration of breastfeeding of 1.4
(95% CI 0.6, 2.1) and 1.3 (95% CI 0.7, 1.9) months. The corresponding mean reduction in exclusive
breastfeeding for PFOS and PFOS were 0.3 (95% CI: 0.1, 06) and 0.5 (95% CI: 0.3, 0.7) months per
doubling of exposure, respectively. These associations were more pronounced among primiparous
women.
Overall, the results of these three studies suggest that concentrations of both PFOS and PFOA may
predict shorter duration of breastfeeding. Although examining length of breastfeeding may suggest
problems with lactation it is an indirect measure. A more direct question capturing problems of
establishing and maintaining milk supply would have provided better insight. In addition, since there is
a well-deﬁned mechanism for reverse causation which is in line with the results by Fei et al. (2010b)
and that the other large study by Timmerman relied partly on maternal report on breastfeeding
several years later (5 years post-partum), these three studies do not allow ﬁrm conclusions to be
drawn on the link between exposure to PFOS and PFOA and duration of breastfeeding.
3.3.4.6.5. Semen quality and sex hormones
Joensen et al. (2009) examined the cross-sectional association between serum concentrations of
PFOS, PFOA with semen quality and sex hormones in a sample of 105 Danish men of around 19 years
of age. Blood and semen samples were collected during clinical examination in 2003 when these men
were reporting for military service. The mean serum PFOS and PFOA concentrations were 24.5 and
4.9 ng/mL, respectively. When these men were categorised according to high, medium or low
exposure based on the sum of PFOS and PFOA concentrations, signiﬁcantly lower semen quality
(concentration and % normal sperm) were observed in the highest compared to lowest group of
exposure. However, when looking at the association between PFOS and PFOA, individually no
association with semen quality or sex hormones were observed. The strength of this study was that
the men recruited were a representative sample of young men who did not have knowledge of their
own fertility.
Results from later cross-sectional studies, measuring semen quality by standard clinical procedures,
have been null:
• A similarly designed cross-sectional study by Joensen et al. (2013) of 247 19-year-old Danish
men reporting for military service found no association between concentrations (median) of
PFOS (7.8 ng/mL) and PFOA (3.0 ng/mL) and semen quality. Serum PFOS concentrations
were, however, inversely associated with testosterone, calculated free testosterone, and free
androgen index. But with over 100 associations tested in their analyses the few signiﬁcant
associations reported may have been results of chance ﬁndings,
• In a cross-sectional study of 256 males who along with their partners were attending an
in vitro fertilisation clinic, Raymer et al. (2012) reported no association between PFOS (median
6.4 ng/mL) or PFOA (1.3 ng/mL) and semen quality. In this study serum concentrations of
PFOA were positively correlated with luteinising hormone.
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• In two cross-sectional studies among 548 (Specht et al., 2012) and 588 (Toft et al., 2012) men
from Greenland, Ukraine, and Poland (same study population), no consistent association was
observed between serum concentrations of PFOS and PFOA (medians 18.4 and 3.8 ng/mL,
respectively) and semen quality or reproductive hormones. The authors noted that there was
an inverse association between PFOS exposure and sperm morphology but taken into
consideration that a total of 50 statistical tests were performed, this association may have
occurred simply by chance. In this population, Specht et al. (2012) examined associations
between PFOS or PFOA with sperm DNA fragmentation, apoptosis or reproductive hormones.
No consistent associations were observed.
• Louis et al. (2015) examined the association between serum PFOS/PFOA concentrations
(median: ~ 20 and 5 ng/mL, respectively) and semen quality among 501 male partners of
couples from Texas and Michigan (US) who were discontinuing contraception. No consistent
association between serum PFOS/PFOA concentrations and sperm quality were observed.
Although some signiﬁcant associations were observed (of varying direction) the number was
not greater than expected from the around 70 different associations tested for in their
analyses.
In summary, among adult males the overall evidence from these cross-sectional studies does not
support the hypothesis that serum PFOA and PFOS concentrations are predictors of semen quality or
adverse changes in reproductive hormones.
3.3.4.7. Metabolic outcomes
3.3.4.7.1. Serum lipids
Several early studies of associations between occupational exposure to PFOS and/or PFOA and
serum lipids (Ubel et al., 1980; Gilliland and Mandel, 1996; Olsen et al., 1999, 2000; Olsen and Zobel,
2007; Sakr et al., 2007a,b) were reviewed in the previous assessment (EFSA, 2008). It was concluded
that some studies showed associations between PFOA and serum lipids but others did not. Mean or
median levels of PFOS and PFOA were usually around or above 1,000 lg/L. Most of the studies were
cross-sectional. The largest one, in about 1,000 workers (Sakr et al., 2007a) and funded by DuPont,
found a signiﬁcant positive association between serum PFOA and serum cholesterol. The magnitude of
the association was 4 mg/dL (about 2%) higher total cholesterol (TC) at an increase of serum PFOA
with 1 lg/mL (1,000 lg/L) and somewhat stronger in participants not taking lipid-lowering medication.
A few studies had a longitudinal design. Olsen et al. (2003b), in collaboration with 3M, showed a
signiﬁcant association between change of serum PFOA and change of cholesterol (about 3% increase
per increase of serum PFOA with 1 lg/mL) in 174 workers, but no such association for serum PFOS.
Another longitudinal study, funded by DuPont, performed by Sakr et al. (2007b) found a signiﬁcant
positive association between serum PFOA and serum cholesterol in about 450 workers with repeated
measurements of PFOA and cholesterol. The point estimate of the magnitude of the association was
an increase of serum cholesterol with 1 mg/dL for each increase of serum PFOA with 1 lg/mL
(1,000 lg/L). The two longitudinal studies had no information on use of lipid-lowering medication. An
early cross-sectional study was performed by Emmett et al. (2006) in 371 residents exposed to high
PFOA in drinking water (median serum PFOA 354 ng/mL). Potential confounders were not adjusted for.
The correlation coefﬁcient between serum PFOA and serum cholesterol was not statistically signiﬁcant.
After 2007–2008 several studies have been performed in the general population. They are listed in
Table 23 together with the studies reviewed by EFSA for the 2008 Opinion (EFSA, 2008).
In most of the studies, a number of potential confounders were adjusted for (usually age, sex, BMI,
smoking, and often also some measure of SES and physical exercise, and sometimes use of
lipid-lowering drugs, use of alcohol, etc.).
Steenland et al. (2009) examined associations between PFOS and PFOA and serum lipids cross-
sectionally in the C8 cohort. The study included about 46,000 adults > 18 years of age not taking
cholesterol-lowering medications. Median PFOS and PFOA levels were 20 and 27 lg/L. Blood samples
were delivered at any time of the day and were analysed for total and HDL cholesterol, and
triglycerides. LDL cholesterol was estimated from total cholesterol, HDL cholesterol and triglycerides. A
number of potential confounders were adjusted for. Total and LDL cholesterol, and triglycerides
increased signiﬁcantly by each decile of PFOS and PFOA, while no clear trend was found for HDL. The
ratio total cholesterol/HDL also increased with increasing PFOS and PFOA. Although the magnitude of
association was modest (about 4% increase in total cholesterol from the lowest deciles to the
medians, corresponding to differences in PFOS and PFOA of about 15 lg/L), the OR of high cholesterol
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increased by 40–50% from the lowest to the highest quartiles of PFOS and PFOA, corresponding to an
increase of PFOS with about 15 lg/L and PFOA with about 60 lg/L. Associations between total
cholesterol and PFOS/PFOA remained statistically signiﬁcant also after mutual adjustment, but with an
attenuation of 20–30% (Steenland et al., 2009).
A similar cross-sectional study of 12,500 children 1–18 (mean 11) years from the C8 cohort was
reported by Frisbee et al. (2010). The mean PFOS and PFOA levels were 23 and 69 ng/mL. A number
of potential confounders were adjusted for. Total, LDL and HDL cholesterol were positively associated
with PFOS. Total and LDL cholesterol and triglycerides were positively associated with PFOA. The
slopes were consistently steeper in the lower ends of serum PFOS and PFOA level distributions. Total
and LDL cholesterol increased by 8.5 and 5.8 mg/dL from quintile 1 to quintile 5 of PFOS and by 4.6
and 3.8 mg/dL for PFOA. The ORs for abnormally high total and LDL cholesterol were increased in the
ﬁfth quintile of PFOS compared with the ﬁrst quintile (Total: OR: 1.6, 95% CI: 1.4–1.9; LDL: 1.6, 95%
CI: 1.3–1.9). For PFOA the corresponding ORs were 1.2, 95% CI: 1.1–1.4 and 1.4, 95% CI: 1.2–1.7).
A cross-sectional study of associations between PFOS and PFOA and expression of a number of
genes (from whole blood RNA) involved in cholesterol metabolism was performed in 290 individuals
from the C8 cohort (Fletcher et al., 2013). The study was performed in 2010, 4–5 years after the
baseline study and a number of potential confounders were taken into account. GM mean for PFOS
was 8.3 lg/L and for PFOA 41 lg/L. Signiﬁcant associations were found between PFOS/PFOA and the
expression of several genes involved in transport and clearance of cholesterol. The associations were,
however, different for PFOS and PFOA, and differed between men and women. There were no
associations between the expression of these genes and levels of total cholesterol, LDL or HDL
cholesterol.
A longitudinal study of changes in serum lipids and changes in serum PFOS and PFOA was
performed in a subgroup of participants from the C8 study (Fitz-Simon et al., 2013). These individuals
had participated in the cross-sectional C8 study in 2005–2006, and were followed up with new serum
samples in 2010. Those who had reported taking lipid-lowering drugs were excluded, leaving 560
participants for the study. During follow-up, the GM PFOS fell from 19 to 8.2 lg/L and PFOA fell from
75 to 31 lg/L. The GM levels of serum lipids changed little during follow-up. The authors examined
associations between (log-transformed) changes in serum lipids and (log-transformed) changes in
PFOS and PFOA within individuals, adjusted for a number of potential confounders at baseline and at
follow-up, also taking into account changes in these confounders from baseline to follow-up. A 50%
decrease in PFOS (a decrease of about 10 lg/L) was associated with a 3.2% (95% CI 1.6–4.8%)
decrease in total cholesterol and a 5.0% (95% CI 2.5–7.4) decrease in LDL cholesterol. For a 50%
decrease in PFOA, the corresponding decrease was 1.7% (95% CI 0.3–3.0%) for total cholesterol and
3.6% (95% CI 1.5–5.7%) for LDL cholesterol. In summary, this longitudinal study, although limited in
size, provides relatively strong support for a positive causal association between serum PFOA and
serum cholesterol.
Winquist and Steenland (2014b) performed a longitudinal study of associations between modelled
PFOA exposure and self-reported (questionnaire data) hypercholesterolaemia (with medication),
coronary artery disease and hypertension in 28,500 participants in the C8 community cohort and 3,700
workers from the C8 plant. PFOA intake was modelled based on PFOA in drinking water, water
consumption and other factors (Winquist et al., 2013). A pharmacokinetic model was then used to
generate estimated yearly PFOA serum concentrations (Shin et al., 2011a). For the workers, serum
PFOA levels were estimated from work histories and historical serum PFOA levels among employees
(Woskie et al., 2012). Modelled serum PFOA levels were calibrated and validated against measured
levels at baseline in 2005–2006 (Winquist et al., 2013), showing a Spearman correlation coefﬁcient of
0.71. In the workers the median was 113 lg/L and in the general population 24 lg/L. Retrospective
analyses of self-reported disease (hypercholesterolaemia, coronary artery disease and hypertension)
were performed from the age of 20 years (but not before 1,952 when the C8 plant started) through
2005–2006, and the median duration of follow-up was 33 years. Prospective analyses were performed
from the baseline survey (2005–2006) and until the follow-up questionnaire (2008–2011); median
duration of follow-up 4.4 years. Self-reported coronary artery disease was validated against medical
records with good agreement. Hypercholesterolaemia and hypertension were not validated. A number
of potential confounders were adjusted for, also allowing these confounders to vary over time. In the
retrospective analyses of the combined data-set the hazard ratios (HR) for hypercholesterolaemia were
increased in quintiles (Q) 2–5 of modelled cumulative exposure (serum PFOA) when Q1 was used as
reference, e.g. HR 1.24 (95% CI 1.15–1.33) in Q2 and 1.19 (95% CI 1.12–1.28) in Q5. Analyses based
on yearly PFOA levels (i.e. serum PFOA in the year of diagnosis) gave similar results. To some extent
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this was the case also for retrospective analyses of the community cohort only, but in Q4 and Q5
the HRs were just below 1.1 and not statistically signiﬁcant from zero. Prospective analyses (from
2005–2006 to 2008–2011) showed no positive associations with serum PFOA levels. HRs for Q2–Q5
were all below 1.0 and for Q5 (HR about 0.85) even the upper 95% conﬁdence limit was below 1.0.
There were no positive associations between modelled PFOA levels (cumulative or yearly) and self-
reported coronary heart disease or hypertension, in retrospective or prospective analyses. In the
prospective analyses for coronary heart disease the point estimates for HRs for Q2–Q5 were around
0.7 and for Q2, Q3, and Q5, the upper 95% CL was below 1.0. In summary, retrospective analyses
show signiﬁcant positive associations between long-term estimated serum PFOA levels and self-
reported high cholesterol levels with medication. The prospective analyses show, however, rather an
inverse association. The prospective analyses should have higher quality, but the power is lower. The
retrospective analyses will be much inﬂuenced by individuals entering the cohort early and by the
years with highest PFOA levels (about 1995–2007). If PFOA levels are causally related to
hypercholesterolaemia, it is puzzling that the association between estimated serum PFOA and coronary
artery disease tends to be inverse. Taken together this large longitudinal study does not provide
convincing evidence for a causal association between serum PFOA and increased serum cholesterol.
A cross-sectional study of the association between PFOS and PFOA and cholesterol, body weight
and insulin resistance was performed in 860 adults 20–80 years of age, not taking cholesterol-lowering
medication, from NHANES 2003–2004 (Nelson et al., 2010). Median serum PFOS and PFOA levels were
20 lg/L and 3.8 lg/L. Total cholesterol (TC) and non-HDL cholesterol (total minus HDL) in serum were
determined in all participants and LDL cholesterol in half of them. A number of potential confounders
were adjusted for. TC was about 7% higher (13 mg/dL higher) in the fourth quartile (Q4) of PFOS
than in the ﬁrst quartile (Q1); the difference in PFOS between Q4 and Q1 was 27 lg/L. The result for
non-HDL cholesterol and LDL showed similar results, but for LDL the association was not statistically
signiﬁcant. There were signiﬁcant associations with TC and non-HDL also for PFOA, with somewhat
smaller differences in blood lipids between Q4 and Q1 (borderline signiﬁcance), but much stronger
slopes in linear regression models. An increase of PFOA with 5 lg/L (the approximate difference
between Q4 and Q1) corresponded to an increase of TC with 6 mg/dL.
Cha^teau-Degat et al. (2010) examined the association between PFOS and blood lipids cross-
sectionally in 723 adults (mean age 37 years) of Inuit origin in Nunavik, Northern Quebec. The
geometric mean PFOS level was 19 lg/L. In models (with PFOS in quartiles) adjusted for age, sex BMI
and smoking, there was a signiﬁcant positive association between PFOS and TC, and HDL. The ratio
TC/HDL was negatively associated with PFOS. In models further adjusted for other potential
confounders (varying between lipid outcomes) such as lipid-lowering drugs, and n-3 PUFAs, a positive
association remained for HDL, but was not statistically signiﬁcant for TC (p = 0.09). The negative
association with TC/HDL ratio remained statistically signiﬁcant.
Lin et al. (2011) studied the association between PFOS and PFOA and various metabolic outcomes:
glucose homoeostasis (plasma glucose, serum insulin, HOMA-IR), blood lipids (HDL, LDL, total
cholesterol, triglycerides), serum CRP, and adiponectin in a cross-sectional study of 287 young people
from Taiwan, who had been subject to a mass urine screening. Most of them were in the age range
20–30 years and the median PFOS and PFOA levels were 8.9 and 2.4 lg/L. No signiﬁcant associations
were found between PFOS or PFOA and the metabolic biomarkers in adjusted models including a
number of potential confounders.
Wang et al. (2012) performed a cross-sectional study of associations between serum PFOS/PFOA
and blood lipids in 55 male workers at a ﬂuorochemical plant and 132 nearby residents in China. The
median PFOS and PFOA levels were 33 and 1,600 ng/mL in the workers, and 34 and 280 ng/mL in the
nearby residents. The authors also examined liver enzymes (see Section 3.3.4.7.2) and micro-RNA.
Analyses were adjusted for age and BMI, since they found smoking and alcohol habits not to be
associated with blood lipids. No associations were found between PFOS/PFOA and blood lipids, with
the exception of a slight inverse association between ln serum PFOA and HDL.
Fisher et al. (2013) examined associations between PFOS and PFOA and plasma lipids, glucose
homoeostasis, and metabolic syndrome in 2,700 fasting participants aged 18–74 years in the national
Canadian Health Measures Survey (CHMS). The GM PFOS and PFOA levels were 8.4 and 2.5 lg/L,
increasing with age, and male sex. In analyses adjusted for these factors and a number of other
potential confounders, there were no associations between PFOS or PFOA and glucose homoeostasis
or metabolic syndrome. For plasma lipids, there were weak non-signiﬁcant associations between PFOS/
PFOA and cholesterol. The OR for high cholesterol was 1.4 (0.9–2.1) in the highest quartile of PFOS
with Q1 as reference, and 1.5 (0.9–2.6) in the highest quartile of PFOA.
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Eriksen et al. (2013) performed a cross-sectional study of the association between whole blood
lipids and PFOS and PFOA in plasma in samples collected in 1993–1997 in 753 individuals, aged 50–
65 years, from the Danish Cancer and Health cohort. These individuals were originally random controls
to cases diagnosed with certain types of cancer and most of them were men. A number of potential
confounders were adjusted for. Mean PFOS and PFOA levels were 36 and 7 lg/L. Total cholesterol was
signiﬁcantly associated with PFOS and PFOA, about 4–5 mg/dL (2%) higher per interquartile range
(about 5 lg/L for PFOS and about 4 lg/L for PFOA).
Fu et al. (2014) performed a small (N = 133) cross-sectional study of the association between
PFOS and PFOA and blood lipids in a Chinese sample aged 0–80 (mean 30) years, coming for a health
check-up. Analyses were adjusted for age, gender and BMI, but there was no information on use of
lipid-lowering medications. The median PFOS and PFOA levels were low: 1.5 and 1.4 lg/L. There was
a statistically signiﬁcant association between total cholesterol and LDL and PFOA, but not for PFOS.
In a cross-sectional study of 891 pregnant women, Starling et al. (2014) studied the association
between PFOS and PFOA and blood lipids. A number of potential confounders were adjusted for. Mean
PFOS and PFOA levels were 13 and 2.3 lg/L. Total cholesterol was signiﬁcantly associated with PFOS,
about 4 mg/dL (2%) higher per interquartile range (about 6 lg/L). There was no signiﬁcant
association with PFOA. There was also a signiﬁcant association between ln-transformed PFOS and total
cholesterol, indicating a less steep slope at higher PFOS levels. There was also a signiﬁcant positive
association between PFOS and HDL, and a borderline association with LDL, of the same relative
magnitude as for total cholesterol. Point estimates for the association between blood lipids and PFOA
were positive but far from statistically signiﬁcant. In this study also serum albumin levels were
available. Associations between PFOS and HDL were attenuated (about 15%) when serum albumin
was added to the models, but associations were still signiﬁcant.
Geiger et al. (2014a) performed a cross-sectional study of the association between PFOS/PFOA and
serum lipids in 815 adolescents (12–18 years) from the NHANES surveys 1999–2008. The mean PFOS
and PFOA levels were 18 and 4.2 ng/mL. A number of potential confounders were adjusted for. Total
and LDL cholesterol levels were positively associated with PFOS and PFOA, when tertile 3 was
compared with tertile 1 and when ln PFOS/PFOA were entered in adjusted models as continuous
variables. Moreover, the adjusted odds ratios for abnormally high total and LDL cholesterol in youth
were increased in the upper tertiles of PFOS (OR 1.5, 95% CI 1.1–2.2 and OR 1.8, 95% CI 1.1–2.8)
and PFOA (OR 1.5, 95% CI 1.1–2.1 and OR 1.6, 95% CI 1.0–2.5) compared with the ﬁrst tertiles.
Zeng et al. (2015) performed a cross-sectional study of the associations between PFOS and PFOA
and blood lipids among 225 healthy school children aged 12–15 years in Taiwan. Median PFOS and
PFOA levels were 29 and 1.0 ng/mL, respectively. A number of potential confounders were adjusted for.
There were signiﬁcant positive associations between PFOS and PFOA on the one hand and total and
LDL cholesterol and triglycerides on the other, while there were no signiﬁcant associations with HDL.
Total cholesterol was 22 mg/dL higher in the upper quartile (median 62 ng/mL) compared with the
lower quartile (median 8.4 ng/mL). For PFOA, the shape of the association was difﬁcult to interpret. An
increase of ln PFOA with one unit (about threefold increase) was associated with 5–7 mg/dL increase in
TC and LDL, but the analyses per quartile indicated that the association was due to blood lipids in the
upper PFOA quartile (median 2 ng/mL).
The ALSPAC cohort referred to regarding developmental outcomes (see Section 3.3.4.3) was also
used by Maisonet et al. (2015), to study the association between prenatal serum levels of PFOS/PFOA
and blood lipids in girls at 7 (n = 115) and 15 (n = 87) years of age. Some covariates were adjusted
for. No consistent tendencies were found for PFOS, while blood lipids were highest in children born to
mothers in the second PFOA tertile, indicating a nonlinear relation. Moreover, within the lowest PFOA
tertile, there were signiﬁcant associations between prenatal PFOA and total and LDL cholesterol.
Skuladottir et al. (2015) examined, in a cross-sectional study, associations between serum PFOS
and PFOA and total cholesterol in 854 Danish pregnant women. The mean PFOS and PFOA levels were
22 and 4.1 ng/mL. A number of potential confounders were adjusted for, also intake per day of major
food groups (meat and meat products, dairy products, ﬁsh, vegetables, fruits and cereals) as well as
saturated fat. There was a positive association between intake of meat and PFOS/PFOA, and a
negative association between intake of vegetables and PFOS/PFOA but no such associations with
cholesterol. For saturated fat, however, there was a positive association with PFOS (but not PFOA) as
well as with cholesterol. However, when food groups or saturated fat were included in regression
models, the positive associations between PFOS/PFOA and cholesterol remained essentially unchanged.
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Summary
In summary, there are 26 studies (in 16 cohorts) published on associations between PFOS and/or
PFOA and serum lipids. Sixteen studies in the general population have been published after the
previous EFSA assessment (EFSA, 2008). Most of them (Steenland et al., 2009; Frisbee et al., 2010;
Nelson et al., 2010; Eriksen et al., 2013; Fitz-Simon et al., 2013; Fu et al., 2014; Geiger et al., 2014a;
Starling et al., 2014; Skuladottir et al., 2015; Zeng et al., 2015) show signiﬁcant positive associations
between PFOS and/or PFOA and total cholesterol, and results for LDL cholesterol (fewer studies) are
similar while associations for HDL were usually null. Some show tendencies towards positive
associations or the results are difﬁcult to interpret. Only two of these studies (Lin et al., 2011; Wang
et al., 2012) show clear null results.
The authors of the cross-sectional studies have usually been cautious when discussing their results,
noting that the results do not prove causality. In almost all of the papers cited above, the authors have
noted that the ﬁndings in humans are not consistent with the results in experimental animals, showing
a PPARa-mediated decrease in serum lipids after administration of PFOS or PFOA (at high dose).
Potential mechanisms for the opposite ﬁndings in humans have been discussed only in vague terms.
The large study by Steenland et al. (2009) was commented on in a paper by Kerger et al. (2011).
These authors noted that although there was a signiﬁcant dose–response relationship between
PFOS/PFOA and total cholesterol, other criteria used to help assessing causality were not fulﬁlled. The
authors were concerned that complex relations between PFOS/PFOA and factors having a very strong
association with cholesterol (such as BMI, age, and menopause status) might bias the dose response
and that the lowest decile of C8 may not be the most appropriate reference stratum.
Several explanations, other than a causal effect of PFOS/PFOA, for the positive associations
between PFOS/PFOA and increased serum lipids have been discussed.
First, there is the possibility that PFOS/PFOA bind to serum lipoproteins (see Toxicokinetics
Section 3.3.1.2). Then increasing serum lipids could result in higher levels of PFOS/PFOA, i.e. a case of
‘reverse causation’. Binding of PFOS/PFOA to serum proteins or lipoproteins have been investigated in
two studies. Han et al. (2003) found that > 90% of PFOA in serum was bound to serum albumin, in
rats as well as in humans. Butenhoff et al. (2012a) conﬁrmed that albumin would bind more PFOS and
PFOA than would lipoprotein fractions. The authors then examined binding of PFOS and PFOA in a
single human plasma sample (from a blood donor, total serum PFOS 25 ng/mL and PFOA 9 ng/mL) in
various plasma and lipoprotein fractions. The largest parts of PFOS and PFOA were found in the
plasma fraction depleted of lipoproteins but containing albumin. Using density gradient
ultracentrifugation, the authors found that < 5% of PFOS was found in lipoprotein fractions (0.8% in
LDL, 3.3% in HDL), but when spiking the sample with PFOS at 8,000 ng/mL, 8.5% was bound to
lipoprotein fractions (1.8% in LDL and 4.4% in HDL). For PFOA the binding was lower, probably ≤ 1%.
Irrespective of whether e.g. 10% or 1% of PFOS/PFOA are bound to the plasma lipoprotein fractions,
changes in plasma PFOS/PFOA will only occur if a change in cholesterol causes a change of the
distribution of PFOS/PFOA between plasma and non-plasma compartments (e.g. liver, kidney). If only
the distribution within the plasma compartment changes, e.g. if an increase in cholesterol increases
the fraction of PFOS/PFOA bound to cholesterol, but decreases the fraction bound to albumin, then the
total plasma concentration of PFOS/PFOA will be unchanged, and there will be no ‘reverse causation’.
If an increase in cholesterol will indeed increase the size of the plasma PFOS/PFOA compartment
(relative to other body pools), it could potentially be important, but the slopes between PFOS/PFOA
and cholesterol, would not be compatible with the empirical results. For example, if 10% of plasma
PFOS/PFOA is bound to cholesterol, then a 10% increase of total cholesterol would cause a 1%
increase of plasma PFOS/PFOA – and the slope in a regression with cholesterol as the dependent
variable would be extremely steep (10% increase in cholesterol at 1% increase in plasma PFOS/PFOA,
and a 100% increase at a 10% increase in plasma PFOS/PFOA). And if only 1% of PFOS/PFOA is
bound to cholesterol, the slopes would be even more extreme. The slopes in the studies cited above
are completely different. For example, in the study by Nelson et al. (2010), an increase of PFOS from
about 10 ng/mL in quartile 1 to 40 ng/mL in quartile 4 (an increase by 400%) was associated with an
increase of total cholesterol by only 14 mg/dL (about 7%). In the longitudinal study by Fitz-Simon
et al. (2013), a 50% decrease in PFOS (a decrease of about 10 lg/L) was associated with only a 3.2%
(95% CI 1.6–4.8%) decrease in total cholesterol. Regarding albumin, this is not much of an issue,
since serum albumin has not been used as a dependent variable at PFOS/PFOA exposure. Nelson et al.
(2010) adjusted for albumin and found that the associations between PFOS/PFOA and serum lipids
remained similar. Starling et al. (2014) did the same, and found that the associations were only slightly
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attenuated. Thus the data available on PFOS/PFOA binding to plasma lipids and other compartments
indicate that ‘reverse causation’ is very unlikely to explain the relatively consistent reports on
associations between PFOS/PFOA and blood lipids.
A second possible non-causal explanation is confounding. Diet could be a confounder if a diet rich
in items, which increase serum cholesterol is also rich in PFOS/PFOA. Intake of saturated or animal fat
was, however, adjusted for in several studies (Nelson et al., 2010; Eriksen et al., 2013; Skuladottir
et al., 2015) where positive associations were found between PFOS/PFOA and serum lipids. The study
by Skuladottir et al. (2015) also examined the impact of major food groups without ﬁnding that dietary
habits would affect the results. Thus it seems unlikely that associations between PFOS/PFOA and
plasma lipids are due to confounding by saturated fat or other common dietary items.
Another potential source of confounding could be related to intestinal reabsorption of PFOS/PFOA.
As has been described in the Section on toxicokinetics (Section 3.3.1.2), PFOS/PFOA are excreted in
bile, but to a high extent (according to one study 97% for PFOS and 89% for PFOA) reabsorbed in the
intestine. Nevertheless, clearance by this route may be as important as by renal excretion. Factors
which decrease reabsorption will lead to a lower body burden of PFOS/PFOA. If such factors also are
associated with lower cholesterol there will be confounding. Such confounding has, however, not been
documented.
Finally, there is the possibility of confounding by other environmental factors, which covary with
intake of PFOS/PFOA and also increase serum lipids. No such factors have however been
demonstrated.
In conclusion, the opinion by the CONTAM Panel is that it is likely that associations between serum
PFOS and PFOA levels and serum cholesterol are causal, i.e. that increased levels of PFOS and PFOA
cause increased levels of serum cholesterol. For the PFOA association, there is no further increase
above a serum level of about 25 ng/mL. Increased serum cholesterol, especially the LDL fraction, is
associated with increased cardiovascular risk, also in the ‘normal range’ (cholesterol levels of 5–
6 mmol/L, 190–230 mg/dL) (Lewington et al., 2007; Piepoli et al., 2016) in prospective observational
studies. Also, treatment with cholesterol-lowering drugs decreases cardiovascular risk (Mihaylova et al.,
2012; Piepoli et al., 2016). For example, a 5% increase in total cholesterol will increase the risk of
cardiovascular disease by at least 5%, which is a clinically relevant risk.
Table 23: Reports on associations between serum levels of PFOS and/or PFOA and serum levels of
lipids
Author
Population
country and
Number of
subjects
Type
PFAS levels in
ng/mL
Findings Comments
Studies reviewed in EFSA, 2008
Ubel et al.
(1980)
Occup (3M),
USA, 57
CS High, 1,000–
70,000 of organic
F
Probably null Incomplete presentation
Gilliland and
Mandel (1996)
Occup (3M),
USA, 115
CS High, mean serum
ﬂuorine 3,300
Null
Olsen et al.
(1999)
Occup (3M),
USA, 295
CS High, mean PFOS
about 2,000
Unclear, inconsistent Incomplete presentation
Olsen et al.
(2000)
Occup (3M),
USA, 265
CS High, mean PFOA
about 6,000
Null Incomplete presentation
Olsen et al.
(2003b)
Occup (3M),
USA and
Belgium 518
(CS) and 174 (L)
CS + L High, mean PFOS
and PFOA about
1,000
CS: PFOS vs TC and
TG +
CS: PFOA vs TC and
TG +
L: PFOA vs TC and TG
+ PFOS: Null
No info on lipid-lowering
medications
Olsen and
Zobel (2007)
Occup (3M),
USA and
Belgium, 506
CS High, mean PFOS
about 1,000,
mean PFOA about
2,000
PFOA vs HDL 
PFOA vs TG +
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Author
Population
country and
Number of
subjects
Type
PFAS levels in
ng/mL
Findings Comments
Sakr et al.
(2007a)
Occup (DuPont),
USA, 1,025
CS High, median
PFOA 400 median
200
PFOA vs TC, LDL,
VLDL +
null for HDL and TG
Info on lipid-lowering
medications available.
When excluding those,
betas increased (since
older workers had more
medications and higher
PFOA)
Sakr et al.
(2007b)
Occup (DuPont),
USA, 454
with > 2
measurements
of PFOA
L High, mean PFOA
about 1,000
PFOA vs TC +
Null for LDL, HDL and
TG
Good longitudinal design
and analyses. No info on
lipid-lowering
medications
Emmett et al.
(2006)
General pop
exposed in C8
area, 371
CS High, mean PFOA
354
Null Crude statistics
(correlation coefﬁcient).
No confounding control
Later studies
Steenland
et al. (2009)
C8, 46,000
adults
CS Median PFOS 20
median PFOA 27
PFOS and PFOA vs TC,
LDL and TG +
Null for HDL
Lipid lowering meds
excluded. Associations
shown also in the low
deciles where slopes were
steepest
Frisbee et al.
(2010)
C8, 12,500
children
1–18 years
CS Mean PFOS 23
Mean PFOA 69
PFOS vs TC, LDL and
HDL +
PFOA vs TC, LDL and
TG +
Steeper slopes in the
lower quintiles
Fletcher et al.
(2013)
C8, 290 CS GM PFOS 8.3
GM PFOA 41
PFOS and PFOA vs
genes involved in
transport or clearance
of cholesterol +
Different genes for PFOS
and PFOA, and the genes
were not associated with
cholesterol
Fitz-Simon
et al. (2013)
C8, 560 L GM PFOS 10 -> 8
GM PFOA 75 ->31
Change in PFOS and
PFOA vs change in TC
and LDL +
Good longitudinal design.
Lipid-lowering meds
excluded
Winquist and
Steenland
(2014b)
C8, 32,000
(28,500 from
general pop +
3,700 workers at
C8 plant)
L Median PFOA in
2005: workers
113 and general
pop 24. Modelled
cumulative PFOA:
20 percentile
215 ng/mL*yr and
80 percentile
1,820 ng/mL*yr
PFOA vs self-reported
hypercholesterolaemia
in retrospective
analyses +
Null (close to inverse)
in prospective analyses
Retrospective analyses
(mean 33 yrs) until 2005–
2006. Prospective
analyses (mean 4 yrs)
from 2005–2006 until
2008–2011. Inverse
relation btw PFOA and
self-reported coronary
artery disease
Nelson et al.
(2010)
NHANES, USA,
860 adults
CS Median PFOS 20
Median PFOA 3.8
PFOS and PFOA vs TC,
non-HDL and LDL
(subgroup) +
Adjustment also for
serum albumin did not
affect results. Adjustment
also for saturated fat
Cha^teau-Degat
et al. (2010)
Canada, Inuits,
723
CS GM PFOS 19 PFOS vs TC (+), HDL
+, non-HDL +, LDL null,
chol/HDL ratio 
Lin et al.
(2011)
Taiwan, 287 (12
–30 years)
CS Median PFOS 8.9
Median PFOA 2.4
PFOS and PFOA vs TC,
LDL, HDL, TG all null
Fisher et al.
(2013)
Canada CHMS,
2,700
CS GM PFOS 8.4
GM PFOA 2.5
PFOS and PFOA vs TC
(+)
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3.3.4.7.2. Liver
Some early studies of associations between occupational exposure to PFOS and/or PFOA and
possible effects on liver (Olsen et al., 2003b; Sakr et al., 2007a,b) and a small community study
(Emmett et al., 2006) were available when the previous assessment was performed by EFSA (EFSA,
2008), but this outcome was not speciﬁcally commented on.
Olsen et al. (2003b) examined the association between serum PFOS and PFOA and serum liver
function tests in a cross-sectional study of 518 3M employees in Belgium and USA. Mean PFOS and
PFOA levels were about 1,000 ng/mL (given as 1 ppm). In unadjusted analyses, levels of ALT and
gamma glutamyl transferase (GGT) were signiﬁcantly higher in quartile 4 vs quartile 1 (adjusted
analyses not presented). Adjusted logistic regression analyses were performed on the number of
individuals with liver function tests above the reference range. Point estimates for the odds ratios of
abnormal ALT was 2.1 (95% CI 0.6–7.3) and for GGT it was 2.0 (95% CI 0.7–5.8).
Emmett et al. (2006) studied the association between serum PFOA in a cross-sectional study of 371
residents exposed to high PFOA in drinking water (median serum PFOA 354 ng/mL) in the C8 area.
Potential confounders were not adjusted for. The regression coefﬁcients for serum liver function tests
vs serum PFOA were not statistically signiﬁcant.
Author
Population
country and
Number of
subjects
Type
PFAS levels in
ng/mL
Findings Comments
Wang et al.
(2012)
China, 55
workers and 132
nearby residents
CS Median PFOS
33/34
Median PFOA
1630/280
PFOS:null for TC, LDL,
HDL
PFOA null apart for –
for HDL in workers
No information on lipid-
lowering drugs. Limited
confounder adjustment
Eriksen et al.
(2013)
Denmark DCH,
753
CS Mean PFOS 36
Mean PFOA 7.1
PFOS vs TC +
PFOA vs TC +
Lipid-lowering meds
excluded. Adjustment also
for intake of eggs and
animal fat
Fu et al.
(2014)
China, 133 CS Median PFOS 1.5
Median PFOA 1.4
PFOS vs TC, LDL null
PFOA vs TC, LDL +
Starling et al.
(2014)
Norway, 891
(pregnant
women)
CS Median PFOS 13
Median PFOA 2.3
PFOS vs TC +, HDL +,
LDL (+), TG null
PFOA vs TC, HDL, LDL,
TG null
Adjustment for serum
albumin reduced betas by
15%
Geiger et al.
(2014a)
NHANES, USA,
815
(12–18 years)
CS Mean PFOS 18
Mean PFOA 4.2
PFOS vs TC, LDL +,
HDL and TG null
PFOA vs TC, LDL +,
HDL and TG null
Zeng et al.
(2015)
Taiwan, 225
(14 years)
CS Median PFOS 29
Median PFOA 1.0
PFOS vs TC, LDL,
TG +, HDL null
PFOA vs TC, LDL,
TG +, HDL null
Maisonet et al.
(2015)
UK, 88–115.
Exposure in
pregnant women,
outcome in
children
L Median PFOS 20
Median PFOA 3.6
PFOS vs TC, LDL, HDL,
TG: possibly nonlinear
PFOA vs TC, LDL, HDL,
TG: possibly nonlinear
Difﬁcult to interpret.
Increasing at low levels
and decreasing at high
levels. serum lipids highest
in second PFOA tertile
Skuladottir
et al. (2015)
Denmark, 854
(pregnant
women)
CS Mean PFOS 22
Mean PFOA 4.1
PFOS vs TC +
PFOA vs TC +
Adjustment for food
groups (meat, vegetables,
ﬁsh etc.) or saturated fat
did not affect the results
C8: study performed in the ‘C8’ area where drinking water was contaminated by PFOA from a DuPont plant; CHMS: Canadian
Health Measures Survey; CS: cross-sectional study; DCH: Diet Cancer and Health; GM: geometric mean; HDL: High density
lipoprotein; L: longitudinal study; LDL: low-density lipoprotein (cholesterol); N; number of subjects; Occup: occupationally
exposed; TC: total cholesterol; TG: triglycerides; VLDL: very low-density lipoprotein; yr: year.
A ‘+’ sign denotes a positive association, ‘(+)’ denotes a strong tendency or borderline statistical signiﬁcance, and a ‘’ denotes
an inverse association.
PFOS and PFOA in food
www.efsa.europa.eu/efsajournal 162 EFSA Journal 2018;16(12):5194
Sakr et al. (2007a) studied the association between serum PFOA and serum liver function tests in
about 1,000 workers at DuPont with a median serum PFOA of about 400 ng/mL (0.4 ppm). In
confounder-adjusted analyses, there was a signiﬁcant association between serum PFOA and GGT, and
a tendency towards an association also with AST and ALT, but not bilirubin. The magnitude of
association was small: liver enzymes were log-transformed and GGT increased by 5% per increase of
serum PFOA by 1,000 ng/mL.
Sakr et al. (2007b) also performed a smaller longitudinal study in about 450 workers with repeated
measurements of PFOA and liver function tests. There was a signiﬁcant positive association between
serum PFOA and ALT and an inverse relation between serum PFOA and total bilirubin. The magnitude
of the associations was small; an increase of serum ALT with 1–2% per increase of serum PFOA with
1,000 ng/mL. No association was found for AST, GGT or alkaline phosphatase (ALP).
From 2008 and onwards, further studies in the general population have been published.
A cross-sectional ecological study of health status in a sample of inhabitants in the C8 area was
reported by Anderson-Mahoney et al. (2008). Prevalences of self-reported symptoms and diseases
were compared with prevalences in NHANES 2001–2002, taking age and gender into account.
Prevalence ratios were not found to be increased for ‘liver problems’.
Associations between PFOS and PFOA and biomarkers of liver function were examined by Gallo et al.
(2012) in a cross-sectional study of 47,000 adults in the C8 cohort. Median (IQR) PFOS and PFOA levels
were 20 (14–29) and 28 (14–71) lg/L. In multivariable models, ALT was weakly but signiﬁcantly
associated with PFOS and PFOA, while no consistent results were found for GGT or direct bilirubin. The
magnitude of association for ALT was about 2% increase in ALT at an IQR increase of PFOS or PFOA.
The OR for high ALT (about 11% of the population) was 1.25 (95% CI 1.1–1.4) in the highest decile of
PFOS and 1.5 (1.3–1.8) in the highest decile of PFOA when decile 1 was used as a reference.
Lin et al. (2010) examined associations between PFOS and PFOA and liver function tests (ALT, GGT
and total bilirubin) in 2,200 adults from NHANES surveys 1999–2004. The mean serum PFOS was
25 ng/mL and for serum PFOA it was 4.6 ng/mL. In adjusted models, there were signiﬁcant positive
associations between ln serum PFOA and serum levels of ALT and GGT, but not bilirubin. For PFOS,
there was a borderline positive association with ALT only. The magnitude of the association indicated
an increase of serum ALT with about 5% and serum GGT with about 2% at a doubling of serum PFOA.
Darrow et al. (2016) performed a longitudinal study of associations between modelled historical
PFOA exposure and biomarkers of liver injury in 28,800 participants in the C8 community cohort and
1,900 workers from the C8 plant examined in 2005–2006. PFOA intake was modelled based on PFOA
in drinking water, water consumption and other factors (Winquist et al., 2013). A pharmacokinetic
model was then used to generate estimated yearly PFOA serum concentrations, including 2005–2006
when liver function tests were performed (Shin et al., 2011a). For the workers, serum PFOA levels
were estimated from work histories and historical serum PFOA levels among employees (Woskie et al.,
2012). Modelled serum PFOA levels were calibrated and validated against levels measured in a
subgroup in 2005–2006 (Winquist et al., 2013), showing a Spearman correlation coefﬁcient of 0.71.
The median PFOA in 2005–2006 was 17 ng/mL (93 among ever C8 workers and 15 among never
C8-workers). Retrospective analyses of self-reported, but medically validated, liver disease were
performed from the age of 20 years (but not before 1952 when the C8 plant started) through
2008–2011, and the median duration of follow-up was 33 years. The survival analysis of liver disease
was performed in a somewhat larger group (31,600, including 3,700 workers). There was a signiﬁcant
positive association between serum ALT in 2005–2006 and modelled cumulative PFOA levels or
modelled serum PFOA for 2005–2006. There were signiﬁcant negative associations between serum
direct bilirubin and modelled PFOA levels. There was no association with GGT. There was a 6%
increase in ALT in the ﬁfth quintile of ALT compared with the ﬁrst quintile using modelled cumulative
exposure and 5% using modelled serum PFOA in 2005–2006. The odds ratios for serum ALT above
normal were signiﬁcantly increased in quintiles 2–4 of cumulative exposure, highest in quintile 4 (OR
1.20, 95% CI: 1.06–1.35). Associations were weaker for modelled serum PFOA in 2005–2006, but
mostly statistically signiﬁcant. There were no signiﬁcant associations between modelled serum PFOA
and liver disease, in fact point estimates of hazard ratios for quintile 5 were below 1, for example 0.87
(0.6–1.3) for enlarged liver, fatty liver or liver cirrhosis (427 cases in the total cohort).
Wang et al. (2012) examined associations between PFOS/PFOA and liver enzymes in a sample of
Chinese workers and residents (see Section 3.3.4.7.1 on serum lipids), ﬁnding essentially null results.
Gleason et al. (2015) studied associations between serum PFOS/PFOA and serum levels of liver
function biomarkers (ALT, AST, GGT and ALP) in a cross-sectional study of about 4,300 individuals from
NHANES surveys 2007–2010. The median levels of PFOS and PFOA were 11 ng/mL and 3.7 ng/mL. A
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number of potential confounders were adjusted for. Signiﬁcant positive associations were found
between serum PFOA and ln-transformed levels of ALT, AST, GGT and bilirubin, and the results were
similar when calculating odds ratios of having a liver function biomarker higher than the 75th
percentile of levels in the NHANES surveys. The magnitude of the association corresponded to an
increase of liver function biomarkers with 2–4% at a doubling of serum PFOA. For serum PFOS, the
only statistically signiﬁcant association was with total bilirubin.
Rantakokko et al. (2015) studied serum PFOS and PFOA levels in extremely obese subjects
undergoing bariatric surgery. There were some inverse associations between PFASs levels and grade of
histologic inﬂammation in the liver. No association was found between PFOS or PFOA and liver
enzymes 12 months after surgery.
The above studies are summarised in Table 24.
In summary, some early studies in occupationally exposed workers indicated that serum levels of
PFOA may affect ALT, a liver enzyme (Sakr et al., 2007a,b). A large cross-sectional study of the C8
cohort (Gallo et al., 2012) showed an association between serum levels of PFOS/PFOA and ALT, and
this was supported in a study using modelled PFOA exposure based on PFOA intake from drinking
water (Darrow et al., 2016). These studies found no associations with GGT or bilirubin. Two NHANES
studies (Lin et al., 2010; Gleason et al., 2015) found associations between serum levels of PFOA and
ALT and GGT, while results for serum PFOS were inconsistent.
Common causes of elevated liver enzymes such as ALT are obesity, insulin resistance, high alcohol
consumption, various medications, hepatitis and various systemic diseases. BMI and alcohol was
adjusted for in the studies summarised above. Five cross-sectional studies (Sakr et al., 2007a; Lin
et al., 2010; Gallo et al., 2012; Gleason et al., 2015; Darrow et al., 2016) found an association
between serum PFOA and ALT. There was some support also from two longitudinal studies (Sakr et al.,
2007b; Darrow et al., 2016). It seems likely that the association between PFOA and ALT is causal. It is,
however, unclear if this is clinically relevant, because the magnitude of association seems to be very
small, and no association with liver disease has been shown. The study by Darrow et al. (2016) had a
relatively good power to assess liver disease, and diagnoses were validated in medical records, but no
increased risk related to PFOA exposure was found. The most common liver disease associated with an
increase of serum ALT is non-alcoholic fatty liver disease (NAFLD), including liver steatosis only, or
non-alcoholic steatohepatitis (NASH), which also includes inﬂammation and/or ﬁbrosis. The main
pathophysiologic factor for NAFLD is the metabolic syndrome, characterised by central obesity, insulin
resistance, and often also hypertension, increased TG and decreased HDL. However, no association
between serum PFOA and the metabolic syndrome has been shown – see next Section (3.3.4.7.3).
Therefore, even if there is a causal association between serum PFOA and serum ALT, which is likely, it
is not possible to conclude that increased serum PFOA will cause NAFLD.
The CONTAM Panel concludes that a causal positive association between PFOA and ALT is likely, but
that the adversity of a change within the reference range has not been shown. For PFOS, data are
inconsistent. However, in the C8 cohort, which is very large, an association was also found between
PFOA and ALT above the reference range (Gallo et al., 2012). The CONTAM Panel considered this to be
an adverse effect of PFOA in spite of the argument raised above against adversity of an increase of
serum ALT within the reference range.
Table 24: Reports on associations between serum levels of PFOS and/or PFOA and liver disease or
serum markers of liver function
Author
Population,
country and N
Type
Serum PFAS levels
in ng/mL)
Findings Comments
Olsen et al.
(2003b)
Occup (3M), USA
and Belgium 518
CS Mean PFOS and PFOA
about 1,000
PFOS and PFOA vs ALT
and ALP in males +
(unadjusted). GGT and
total bilirubin –
Abnormal ALT and
GGT (+)
ALP null
Alcohol habits
differed in
USA and
Belgium.
Overall not
very
informative
Sakr et al.
(2007a)
Occup (DuPont),
USA, 1,025
CS Median PFOA 400,
median 200
PFOA vs GGT + ALT
(+) Bilirubin, ALP null
Adjusted for
some
potential
confounders
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Author
Population,
country and N
Type
Serum PFAS levels
in ng/mL)
Findings Comments
Sakr et al.
(2007b)
Occup (DuPont),
USA, 454
with > 2
measurement of
PFOA
L Mean PFOA about
1,000
PFOA vs ALT +,
bilirubin – GGT, ALP
null
Adjusted for
some
potential
confounders
Emmett et al.
(2006)
General pop
exposed in C8 area,
371
CS Mean PFOA 354 ng/
mL
PFOA vs AST, ALT,
GGT, ALP null
No
confounding
adjustment.
Not
informative
Anderson-
Mahoney et al.
(2008)
C8, N = 566 CS,
ecological
No serum data PFOA (ecological) vs
self-reported
symptoms and liver
diseases null
Crude non-
informative
ecological
study
Gallo et al.
(2012)
C8, 47,000 CS Median PFOS 20,
median PFOA 28 ng/
mL.
PFOS vs ALT +, and
‘high’ ALT + (decile 10
vs decile 1). GGT and
direct bilirubin null
PFOA vs ALT +, and
‘high’ ALT + (D10 vs
D1). GGT and direct
bilirubin null
Adjusted for
potential
confounders
Lin et al.
(2010)
NHANES, USA
2,200, adults
CS Mean PFOS 25 ng/mL,
mean PFOA 4.6 ng/mL
PFOA vs ALT + GGT +,
bilirubin null
PFOS vs ALT (+)
Adjusted for
potential
confounders
Darrow et al.
(2016)
C8, USA, 28,800
from C8 community
and 1,900 C8
workers.
For survival analysis
(liver disease)
31,600, including
3,700 workers.
CS, L Yearly serum PFOA
modelled (historical
PFOA exposure,
calibrated against
measured PFOA.
Median PFOA at 2005–
6 when examined
15 ng/mL (general
pop) and 93 ng/mL
(workers)
CS: Modelled PFOA vs
ALT +, abnormal ALT
+, direct bilirubin -,
GGT null.
L, retrospective:
Modelled PFOA vs ALT
+, liver disease (-)
Adjusted for
potential
confounders
Wang et al.
(2012)
China, 55 workers
and 132 nearby
residents
CS Median PFOS 33/34
and PFOA 1,630/280
PFOS and PFOA vs
ALT: Null
Limited
confounder
adjustment
Gleason et al.
(2015)
NHANES, USA,
4,300
CS Median PFOS 11 ng/
mL, median PFOA
3.7 ng/mL
PFOS vs bilirubin +,
ALT, AST, GGT null.
PFOA vs ALT, AST,
GGT, and bilirubin +
Adjusted for
potential
confounders
Rantakokko
et al. (2015)
Extremely obese
subjects 213–215
undergoing surgery,
Finland, 161
CS Mean PFOS 3.9 ng/
mL, mean PFOA
2.6 ng/mL
PFOA vs inﬂammation
(histology) in the liver
–. PFOS vs
inﬂammation
(histology) in the liver
(–).
PFOS and PFOA vs ALT
12 months after
surgery null
Adjusted for
potential
confounders.
Special group,
limited
relevance
ALT: alanine aminotransferase; AST: aspartate aminotransferase; C8: study performed in the ‘C8’ area where drinking water was
contaminated by PFOA from a DuPont plant; CS: cross-sectional study; HDL: High density lipoprotein; L: longitudinal study; GGT:
gamma-glutamyl transferase; Occup: occupationally exposed; PFOA: perﬂuorooctanoic acid; PFOS: perﬂuorooctane sulfonic acid.
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3.3.4.7.3. Diabetes, obesity, and metabolic syndrome
Lin et al. (2009) examined cross-sectional associations between PFOS and PFOA and glucose
homoeostasis and metabolic syndrome in 1,443 adults and adolescents (12–19 years) from NHANES
samples 1999–2004. Data were available on fasting plasma glucose and insulin, and beta cell function
and insulin resistance were assessed. Plasma glucose, blood lipids, waist, blood pressure and
medications were used to deﬁne metabolic syndrome. In adults, PFOS and PFOA tended to be positively
associated with lower plasma glucose, and higher insulin levels, resulting in favourable associations with
beta cell function, but also with increased insulin resistance (for PFOS). Among indicators of metabolic
syndrome, HDL cholesterol increased with higher serum PFOS, but the overall risk of metabolic syndrome
was not signiﬁcantly increased. In adolescents PFOS and PFOA levels were signiﬁcantly inversely related
to weight and plasma glucose, but overall risk of metabolic syndrome was not signiﬁcantly decreased.
In the C8 cohort, cross-sectional analyses were performed of associations between serum PFOA
and type 2 diabetes, and PFOA and fasting glucose in non-diabetics (MacNeil et al., 2009). The median
PFOA level in the total population, > 50,000 people, was 28 lg/L. The main analyses of diabetes were
restricted to individuals who had been living in the same water district > 10 years, 1,055 persons with
type 2 diabetes conﬁrmed in medical records and about 12,000 without type 2 diabetes. Prevalence
odds ratios were calculated for deciles of PFOA with the lowest decile as reference, adjusted for age
and other potential confounders. All the other nine deciles had adjusted ORs below 1.0 (varying
between 0.58 and 0.87), without any trend. Thus the results did not support the hypothesis that high
PFOA levels would increase the risk of type 2 diabetes. Neither were there any indications of increased
fasting glucose in the higher PFOA deciles.
The association between estimated exposure to PFOA in the ﬁrst 20 years of life and overweight or
obesity at age 20–40 years was examined in 8,764 participants from the C8 cohort by Barry et al.
(2014). Exposure to PFOA in the ﬁrst few years of life was based on maternal serum PFOA and later
exposure on PFOA in drinking water. The median estimated serum PFOA in the ﬁrst three year of life
was only 3.8 ng/mL (more than 50% had only background exposure), but in about 20% it was
> 10 ng/mL. BMI at follow-up was calculated from self-reported weight and height. A number of
potential confounders were adjusted for. There were no associations between estimated PFOA in the
ﬁrsts few year of life or the average over the ﬁrst 20 years and risk of overweight or obesity.
A longitudinal study of the association between PFOA and risk of type 2 diabetes was performed in
about 28,500 community residents and 3,700 workers from the C8 cohort (Karnes et al., 2014).
Annual serum concentrations of PFOA were estimated from PFOA in drinking water, and work histories
as described above (Section 3.3.4.7.2; Darrow et al., 2016). The median cumulative lifetime exposure
(the main metric used) was about 360 ng/ml-years (e.g. 10 years of serum PFOA 36 ng/mL). The
diabetes diagnosis (N > 4,000) was self-reported in 2008–2011, but it was validated in medical records
in 93% of the cases. A number of potential confounders were adjusted for. No associations were found
between cumulative exposure to PFOA and incidence of diabetes, as analysed with Cox-regression with
or without a lag time before year of diagnosis. Nor was there any association between lifetime PFOA
and serum glucose, as measured in 2008–2011.
Steenland and Woskie (2012) performed a cohort mortality study on various malignant and
non-malignant outcomes in 5,791 DuPont workers employed at any time between 1948 and 2002.
Exposure to PFOA was estimated annually for each worker on the basis of job category and serum
concentrations in a subgroup (drawn 1979–2004, mean concentration ~350 ng/mL), and cumulative
exposure was estimated. There were 38 deaths from diabetes which resulted in a standardised
mortality rate of about 1.9 (95% CI 1.4–2.6) compared to a reference group of other DuPont workers,
but not different from a reference group of the general US population. There was no dose–response
trend vs estimated cumulative exposure.
Melzer et al. (2010) examined the occurrence of self-reported physician-diagnosed diabetes in a
cross-sectional study of 3,974 adults in NHANES 1999–2006. The actual aim of the study was to
investigate thyroid disease. The mean serum PFOS and PFOA levels were 22 and 4.3 ng/mL. There
were no signiﬁcant associations between PFOS or PFOA and ever diabetes diagnosis. Point estimates
of ORs in quartile 4 were below 1.
A cross-sectional study of the association between PFOS and PFOA, and body weight and insulin
resistance was performed in 860 adults 20–80 years of age, not taking cholesterol-lowering medication
from NHANES 2003–2004 (Nelson et al., 2010), see also Section 3.3.4.7.1. Median serum PFOS and
PFOA levels were 20 lg/L and 3.8 lg/L. No consistent associations were found between PFOS or PFOA
and body weight, BMI or insulin resistance (HOMA-IR).
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As mentioned above (Section 3.3.4.7.1), Lin et al. (2011) studied the association between PFOS
and PFOA and glucose homoeostasis (plasma glucose, serum insulin, HOMA-IR), and adiponectin in a
cross-sectional study of 287 young people from Taiwan, who had been subject to a mass urine
screening. The median PFOS and PFOA levels were 8.9 and 2.4 lg/L. No signiﬁcant associations were
found in adjusted models between PFOS or PFOA and markers of glucose homoeostasis, or
adiponectin.
As mentioned above (Section 3.3.4.7.1), Fisher et al. (2013) examined associations between
PFOS/PFOA and glucose homoeostasis, and metabolic syndrome in 2,700 fasting Canadians aged
18–74 years. The GM PFOS and PFOA levels were 8.4 and 2.5 lg/L. In adjusted analyses, there were
no associations between PFOS or PFOA and glucose homoeostasis or metabolic syndrome.
Lind et al. (2014) studied the association between diabetes, insulin secretion, and insulin
resistance, and serum levels of linear PFOS (linear isomer of PFOS (L-PFOS)) and PFOA in a cross-
sectional study of a population-based sample of 1,016, 70-year-old individuals in Sweden. The mean
L-PFOS and PFOA levels were 13 and 3.3 ng/mL. There were no signiﬁcant associations between PFOS
or PFOA levels and these outcomes, but for PFOA the OR for diabetes was nearly signiﬁcantly
decreased if a nonlinear logistic regression model was used. There was, however, a weak association
between the proinsulin/insulin ratio and PFOA.
A cross-sectional study of the association between PFOS/PFOA and glycemic control and overweight
was performed in a representative sample of 499 Danish children (part of the European Youth Heart
(EYHS) study), aged 8–10 years in 1997 (Timmermann et al., 2014). The median serum PFOS and
PFOA levels were 42 and 9.3 ng/mL. A number of potential confounders were adjusted for. Overall, no
associations were found between PFOS or PFOA and plasma glucose, insulin, beta cell function
(HOMA-beta), insulin resistance (HOMA-IR), BMI, waist circumference or skinfold thickness. There was,
however, an interaction between BMI and plasma insulin, and in the subgroup of overweight children
(N = 59), there were signiﬁcant positive associations between PFOS/PFOA and insulin, but not with
glucose. Thus, there were also signiﬁcant associations between PFOS/PFOA and HOMA-beta and
HOMA-IR.
The same cohort was studied longitudinally by Domazet et al. (2016), this time with outcome
measurements in 2003 (at age 15, N = 201) and 2009 (at age 21, N = 202) vs PFOS/PFOA at age 9
(1997). The authors now found positive associations between serum PFOS determined at 9 years of
age and BMI, waist circumference and skinfold thickness at 15 years of age, and for waist and skinfold
thickness also at age 21. For serum PFOA at age 9, there were some tendencies in the same directions
for these overweight outcomes at age 15, but not statistically signiﬁcant. There were no similar
associations between PFOS/PFOA at 15 years of age and overweight outcomes at 15 or 21 years of
age, instead higher PFOA at age 21 was associated with lower waist circumference. Regarding glucose
homoeostasis there were no clear ﬁndings when comparing PFOS/PFOA at age 9 with these outcomes
at age 15 or 21.
Predieri et al. (2015) compared serum PFOS/PFOA levels in 25 children (mean age 8 years) at
onset of type 1 diabetes with 19 ‘control’ children (mean age 11 years) referred to the same clinic due
to short stature. Mean PFOS in the diabetic children (1.5 ng/mL) was signiﬁcantly higher than in the
controls (0.6 ng/mL), while mean PFOA was 0.5 ng/mL in both groups. Potential confounders were not
adjusted for.
In a small prospective study, Zhang et al. (2015) examined the association between PFOS/PFOA
and gestational diabetes (GDM) in USA. In a cohort of women who discontinued contraception
with the intent of becoming pregnant, 258 had a pregnancy lasting > 28 weeks and 28 of them
developed GDM. In serum samples collected at enrolment, GM PFOS and PFOA levels were about 12
and 3.2 ng/mL. The OR of GDM per SD increase of PFOA (0.43 ng/mL) was 1.9 (1.1–3.0). For PFOS it
was 1.1 (0.8–1.7).
A cross-sectional study of associations between PFOS/PFOA and glucose homoeostasis among 571
Taiwanese adults from outpatient cardiology clinics (but free of self-reported coronary heart disease,
stroke or diabetes) was reported by Su et al. (2016). Mean serum PFOS was 3.2 ng/mL and mean
PFOA was 8.0 ng/mL. Glycated haemoglobin and glucose levels at fasting as well as during an oral
glucose tolerance test were associated with PFOS (signiﬁcant increase with increasing PFOS) and PFOA
(signiﬁcant decrease with higher PFOA), when a number of potential confounders were adjusted for.
The adjusted OR for diabetes was 3.4 (95% CI: 1.2–9.7) in Q4 for PFOS and 0.16 (95% CI:
0.05–0.50) in Q4 for PFOA.
The association between PFOS/PFOA levels in early pregnancy and development of GDM and
impaired glucose tolerance (IGT) at the end of pregnancy, was examined in a prospective study
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of 1,259 women in Canada (Shapiro et al., 2016). GMs for serum PFOS and PFOA were 4.6 and
1.7 ng/mL, and 44 developed GDM and 49 IGT. No associations were found between PFOS or PFOA
levels and risk of GDM or IGT.
In summary, 15 studies were identiﬁed on the associations between PFOS and or PFOA and glucose
homoeostasis or diagnosis of diabetes (Lin et al., 2009, 2011; MacNeil et al., 2009; Melzer et al., 2010;
Nelson et al., 2010; Steenland and Woskie, 2012; Fisher et al., 2013; Karnes et al., 2014; Lind et al.,
2014; Timmermann et al., 2014; Predieri et al., 2015; Zhang et al., 2015; Domazet et al., 2016; Shapiro
et al., 2016; Su et al., 2016). Two of them (Zhang et al., 2015; Shapiro et al., 2016) examined the risk
of gestational diabetes. Overall, the results do not indicate adverse effects on glucose homoeostasis or
increased risk of diabetes. There were some indications that PFOA may increase insulin production.
Several of these studies (Lin et al., 2009; Nelson et al., 2010; Timmermann et al., 2014; Domazet et al.,
2016) also examined adiposity, as did some other studies (Barry et al., 2014). Overall, the results do not
indicate an increased risk of overweight or obesity due to exposure to PFOS or PFOA. Thus, the CONTAM
Panel concludes that there is no evidence that PFOS or PFOA increases the risk of metabolic syndrome.
3.3.4.8. Kidney and Uric acid
3.3.4.8.1. Kidney
Shankar et al. (2011b) performed a cross-sectional study of the association between serum PFOS/
PFOA and estimated glomerular ﬁltration rate (eGFR), based on the MDRD equation in 4,600 participants
≥ 20 years in NHANES surveys from 1999 to 2008. The median PFOS and PFOA levels were 19 and
4.1 ng/mL. In models adjusted for various potential confounders eGFR was 6.7 mL/min/1.73 m2 lower in
the fourth quartile of serum PFOS and 5.7 mL/min lower in Q4 of PFOA. The OR for eGFR < 60 mL/min
(deﬁned as chronic kidney disease, CKD) was 1.8 (95% CI: 1.0–3.3) in Q4 for serum PFOS and 1.7 (95%
CI: 1.0–2.9) in Q4 for serum PFOA. The authors mention that reverse causality cannot be excluded.
The occupational cohort of DuPont workers mentioned in the Section on diabetes (3.3.4.7.3)
examined mortality in chronic kidney disease. There were only 13 cases, which was higher than
expected using other DuPont workers as reference group (Steenland and Woskie, 2012).
The association between PFOS/PFOA and eGFR (Schwarz formula) was examined in 9,660 children
and adolescents aged 1–18 years (mean 12 years) from the C8 cohort by Watkins et al. (2013). The
median serum levels of PFOS and PFOA were 20 and 28 ng/mL in 2005–2006. Analyses are mainly
reported by PFOA quartiles, and median serum PFOA in Q1-Q4 were 9.1, 19, 41, and 139 ng/mL. The
eGFR was 2.9 mL/min/1.73 m2 lower in Q4 for PFOS compared with Q1, and for PFOA the difference
between Q4 and Q1 was 0.8 mL/min. Most of this difference was found already between Q1 and Q2.
An IQR for ln-transformed PFOA (1.63), corresponded to 0.7 mL/min lower eGFR. When the analysis
for PFOA was repeated but using estimated serum PFOA (from drinking water, see above), there was
no association between estimated serum PFOA and eGFR. Therefore, the authors conclude that
reverse causation is a likely cause of the association between (measured) serum PFOA and eGFR, i.e.
that lower GFR causes higher serum PFOA, rather than vice versa.
Dhingra et al. (2016) examined the association between PFOA exposure and diagnosed chronic
kidney disease (CKD) in a retrospective cohort study in about 28,000 adults in the C8 cohort. Cases of
CKD from 1951 up to about 2010, validated in medical records, with data on covariates and absence of
other kidney disease were included in the analyses (N = 397, 187 of which were diabetics). Yearly
serum PFOA levels were estimated from models of PFOA in drinking water (described above). The mean
and median cumulative exposure was 3.3 and 0.6 mg/mL*year (for example corresponding to 11 year
with 300 ng/mL). Mean and median levels in 2005–2006 were 83 and 28 ng/mL. The authors also
performed a prospective cohort study, analysing only new-onset cases after 2005–2006 (N = 212 out of
the 397 cases). A number of potential confounders were adjusted for. No associations were found
between estimated cumulative PFOA exposure and CKD in the retrospective cohort study (HR for upper
quintile 1.24, 95% CI: 0.9–1.8) or in the prospective study (HR for upper quintile 1.12, 95% CI:
0.7–1.8). Sensitivity analyses using year-speciﬁc serum PFOA also showed no associations with CKD.
Kataria et al. (2015) studied, cross-sectionally, the association between PFOS/PFOA and kidney
function (and uric acid) among 1,960 adolescents in NHANES 2003–2010. Median PFOS and PFOA levels
were 12.8 and 3.5 ng/mL. A number of potential confounders were adjusted for. An inverse association
was found between PFOS/PFOA and eGFR (Schwartz formula); point estimate 9.5 mL/min/1.73 m2
lower eGFR in the fourth quartile of PFOS and 6.6 mL/min lower in the fourth quartile of PFOA. The
overall median eGFR was 140 mL/min/1.73 m2. The authors discuss the possibility of reverse causality,
but express doubt that a moderate decrease of GFR could ‘cause’ a large increase in PFOS/PFOA.
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In summary, three cross-sectional studies found a relatively strong association between serum
PFOS/PFOA and estimated GFR. Authors in all studies mention the possibility of reverse causality as a
possible explanation for these ﬁndings. Although there may be some ‘reverse causality’, it is not realistic
that a decrease of eGFR by 5–10% could cause a several-fold increase in serum PFAS. However, eGFR is
very poorly correlated with measured GFR in the normal GFR range. The equations are based not only
on serum creatinine, but also on age, sex, height and weight, and these latter variables are associated
with serum levels of PFOS/PFOA. Therefore, adjustment for these variables is complicated. For PFOA
the longitudinal study of the C8 cohort showed no signiﬁcant association with chronic kidney disease.
The CONTAM Panel concludes that the evidence is insufﬁcient that PFOS/PFOA exposure causes
reduced GFR or kidney disease. The possibility of reverse causality is very relevant also for other
outcomes based on serum markers, which are eliminated by renal excretion, e.g. uric acid.
3.3.4.8.2. Uric acid
Steenland et al. (2010) examined the association between PFOS and PFOA and serum uric acid
(UA) in the C8 cohort. In 55,000 adults > 20 years of age the median PFOS and PFOA levels were 20
and 28 lg/L. In models adjusted for various potential confounders, serum UA increased signiﬁcantly
with each decile of PFOS and PFOA, with differences in serum UA between the highest and the lowest
deciles of about 5%. The association between PFOA and serum UA was present also for the lowest
deciles, with PFOA levels similar to those in the US population. The OR for hyperuricemia was about
1.3 (95% CI: 1.2–1.4) for the highest quintile of PFOS and 1.5 (95% CI: 1.4–1.6) in the highest
quintile of PFOA.
Another cross-sectional study of the association between serum PFOS and PFOA and serum UA was
performed in 3,900 participants ≥ 20 years in NHANES surveys from 1999 to 2006 (Shankar et al.,
2011a). The median PFOS and PFOA levels were 18 and 4.5 lg/L. In models adjusted for various
potential confounders, serum UA increased signiﬁcantly with each quartile of PFOS and PFOA, with
differences in serum UA between the highest and the lowest quartiles of about 5–8%. The ORs for
hyperuricemia were signiﬁcantly increased in the upper three quartiles of PFOS and the upper two
quartiles of PFOA compared with the lowest quartile. Possible mechanisms discussed were oxidative
stress in the liver and competition between PFOS/PFOA and UA regarding organic anion transporters in
the kidney.
Lin et al. (2013b) examined associations between PFOS/PFOA and serum UA in a cross-sectional
study of 644 young people from Taiwan, who had been subject to a mass urine screening. The focus of
the study was carotid intima-media thickness. Most of them were in the age 20–30 years and the GM
PFOS and PFOA levels were about 7.9 and 2.6 ng/mL. No signiﬁcant associations were found between
PFOS or PFOA and serum UA in adjusted models including a number of potential confounders.
Geiger et al. (2013) performed a cross-sectional study of the association between PFOS/PFOA and
serum UA in 1,772 adolescents (12–18 years) from NHANES surveys 1999–2008. The mean PFOS and
PFOA levels were 18 and 4.3 ng/mL. A number of potential confounders were adjusted for. Serum UA
was weakly, but signiﬁcantly associated with PFOS and PFOA. The ORs for hyperuricemia were 1.7
(95% CI: 1.1–2.5) for PFOS and 1.6 (95% CI: 1.1–2.3) for PFOA.
Kataria et al. (2015) studied, cross-sectionally, the association between PFOS/PFOA and serum UA
(and kidney function) among 1,960 adolescents in the NHANES 2003–2010. Median PFOS and PFOA
levels were 12.8 and 3.5 ng/mL. A number of potential confounders were adjusted for. Serum UA was
0.21 mg/dL higher in the fourth quartile of PFOS and 0.19 mg/dL in the fourth quartile of PFOA
(overall median 5.0 mg/dL). Also, the adjusted ORs for high serum UA (deﬁned as fourth quartile)
were increased in the fourth quartiles of PFOS/PFOA. The main focus of the study was kidney function
(see above).
In the cross-sectional study by Gleason et al. (2015), mentioned above (Section 3.3.4.7.2 on Liver)
associations between serum PFOS/PFOA and serum UA were examined in about 4,300 individuals from
NHANES surveys 2007–2010. The median levels of PFOS and PFOA were 11 ng/mL and 3.7 ng/mL. A
number of potential confounders were adjusted for. A signiﬁcant positive association was found
between ln serum PFOA and serum UA, and the OR for high serum UA (above 75%) was 1.9 (95% CI
1.4–2.6) while there was no such association for PFOS.
Associations between PFOS/PFOA and serum UA were examined in a cross-sectional study of 225
Taiwanese children (12–15 years) by Qin et al. (2016). The mean PFOS and PFOA levels were 29 and
0.5 ng/mL. There was a signiﬁcant association between ln serum PFOA and uric acid in a model
adjusted for potential confounders, and the adjusted OR for high serum UA was 2.2 (95% CI 1.3–3.6).
No signiﬁcant associations were found for PFOS.
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In summary, seven studies examined associations between PFOS/PFOA and serum UA. Four of
them found a positive association between serum PFOS and serum UA and six of them found such an
association for serum PFOA. The associations may well be causal, but they may also be confounded by
glomerular ﬁltration rate (GFR). It is well known that reduced GFR increases serum UA (which is
eliminated by renal excretion). If a lower GFR increases serum levels of PFASs, then this can also
explain associations between PFAS and serum UA. Thus, the evidence is insufﬁcient to conclude that
exposure to PFASs causes increased levels of uric acid in serum.
3.3.4.9. Carcinogenicity outcomes
3.3.4.9.1. Occupational exposures or high exposures due to local contamination
Steenland and Woskie (2012) found signiﬁcant dose–response mortality trends for malignant and
non-malignant renal disease (12 and 13 cases, respectively) with estimated higher PFOA exposures
among 5,791 occupationally exposed DuPont chemical plant workers form West Virginia. A minimum of
1-day employment was sufﬁcient to be included in the study at any time between 1948 and 2002.
Exposure to PFOA was estimated annually for each worker on the basis of job category and by taking
into considerations serum concentrations from 1,308 workers (drawn 1979–2004, mean concentration
~350 ng/mL). Comparing the highest (> 2,700 ppm) and lowest (< 904 ppm) quartile of exposure
among exposed workers, the standardised mortality ratios were 2.7 (95% CI: 1.2, 5.3) for kidney cancer
and 8.6 (95% CI: 3.5, 17.7) for chronic renal disease. However, when comparing all exposed workers to
unexposed workers from other DuPont factories as referent, the standardised mortality ratios were 3.1
(95% CI: 1.7, 5.3) for chronic renal disease and 1.3 (95% CI: 0.7, 2.2) for kidney cancer.
Two similar studies among 3M factory workers from Minnesota have also been conducted. These
workers were also occupationally exposed to (APFO) and the outcomes covered by these studies were
mortality rates and cancer incidences. Both studies overlap considerably in terms of the subjects
included but differ in length of follow-up and methodology used for exposure assessment. In this
population, the mean serum concentration among 145 participants providing blood samples in 2,000
was ~800 ng/mL. In both studies one of the inclusion criteria among exposed workers was a minimum
of 365 days employment:
• Lundin et al. (2009) examined cause-speciﬁc mortality rates among workers who had been
employed at 3M from 1947 to 1997 with end of follow-up in 2002. Workers were grouped
according to presumed ‘deﬁnite’, ‘probable’ and ‘minimal’ exposure to PFOA depending on the
workers position and role within the manufacturing process. The results from this study
suggested that moderate and high compared to low exposure to PFOA was positively
associated with prostate cancer (16 cases in total), with hazard ratios (HR) of 3.0 (95% CI:
0.9, 9.7) and 6.6 (95% CI: 1.1, 37.7), respectively. These ﬁndings were in line with two
previous reports from this cohort (Gilliland and Mandel, 1993; and Lundin et al., 2009). No
consistent associations were observed for bladder or liver cancers.
• Later Raleigh et al. (2014) compared mortality rates and cancer incidence among 4,668 3M
Minnesota workers exposed to ammonium PFOA between 1947 and 2002. As comparison
group, they used factory workers from Minnesota and Wisconsin that had not been
occupationally exposed to ammonium PFOA (n = 4,359). Exposure to PFOA was estimated
using task-based job exposure, taking into consideration among other things, work history
records, monitoring data, average annual production. Based on these group comparisons, the
authors found no signiﬁcant differences in hazard rates for dying from cancers of the liver,
pancreas, testes, kidney and breast. In contrast to previous studies for this same cohort, no
association was also observed with prostate cancer (24 cases in total). The HR for dying from
bladder cancer were slightly elevated among workers in the highest quartile of exposure (HR:
1.7 (95% CI 0.9, 3.2)).
Apart from the occupational studies described above, a few studies (some partly overlapping) have
examined associations between different PFAS and incidence of cancer in the C8 Health Study Project.
Although actual serum concentrations were available for a subset of participants providing a baseline
blood samples (2005–2006), historical exposure at time of death or cancer diagnoses had to be
estimated back in time, based on residence history and other predictors of exposure; and in some
cases, using the baseline serum sample as reference point. In short, the results from these studies are
as follows:
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• Vieira et al. (2013) examined associations between PFOA exposure and cancer among
residents living near the C8 plant (n = 25,107). In their analyses, the authors included as
outcomes incidence of 18 cancers (excluding kidney, pancreatic, testicular and liver cancers
reported in later paper), diagnosed from 1996 through 2005. Exposure to PFOA was based on
simple group comparison according to residence. Subjects were ranked according to estimated
historical exposure to contaminated drinking water, which was based on several assumptions
relating to duration of residence in a particular location. The authors reported positive
association between high (estimated as > 110 ng/mL in serum) exposure to PFOA and kidney
cancer (OR: 2.0 (95% CI: 1.0, 3.9)). Non-signiﬁcant differences were observed for 17 other
cancer outcomes examined, although the OR for testicular cancer (OR 2.8 (95% CI 0.8, 9.2))
and prostate cancer (OR 1.5 (95% CI: 0.9, 3.3.)) were slightly elevated.
• Using part of the same cohort as Vieira et al. (2013), Barry et al. (2013) examined associations
between PFOA with 21 different types of cancers ((including kidney, pancreatic, testicular and
liver cancers. In contrast to Vieira et al., 2013) they re-interviewed the cohort in 2008–2011
and included all cancer cases that could be veriﬁed between 1952 and 2011. A total of 32,254
subjects were included with 2,507 cancer cases. PFOA concentrations were estimated based
on residence history and other predictors of PFOA exposure in this community and these
estimates were validated against baseline PFOA concentrations in a subset of participants (Shin
et al., 2011a,b). The mean serum levels in 2005–2006 among non-occupationally exposed and
occupationally exposed residents were 24 and 113 ng/mL respectively. In this cohort, PFOA
concentrations were positively associated with kidney and testicular cancer. In terms of the
effect size, the hazard ratios were 1.10 (95% CI: 0.98, 1.24) and 1.34 (95% CI: 1.00, 1.79)
for kidney and testicular cancers respectively, for 1-unit increases in ln-transformed serum
PFOA. Effect estimates for colorectal, prostate and liver cancers were non-signiﬁcant and
centred around NULL.
• Innes et al. (2014) examined the association between baseline (2005–2006) concentrations
(median) of PFOS (20 ng/mL) and PFOA (28 ng/mL) and colorectal cancer among 47,359
subjects form the C8 cohort. Colorectal cancer cases were diagnosed between 1966 and until
recruitment in 2006. In short, a strong inverse association was observed between measured
baseline (2005–2006) concentrations of PFOS and PFOA with colorectal cancers occurring
between 1966 and 2006. These associations were stronger among cases occurring closer to
the blood sample measurement. Although the authors adjusted from self-reported anaemia it
is quite possible that blood loss related to tumour progression and or treatment (surgery) may
account for these associations (blood loss is a known pathway of PFOA excretion). Particularly
as anaemia might have been underdiagnosed during the long retrospective period. These
results are also in contrast to the results reported from Barry et al. (2013) where exposure
was estimated based on residence history. Without replication in another independent study
the results from this study are inconclusive.
• Concerning results on prostate cancer form the C8 cohort, a cross-sectional study by
Ducatman et al. (2015) using the blood samples collected in 2005–2006, among 25,412
participants, found no association between measured serum levels of PFOA with Prostate-
Speciﬁc Antigen above 4.0 (686 cases, 2.7%), which is a marker of prostate disease, including
prostate cancer.
• Alexander and Olsen (2007) examined association between exposure to PFOS retrospectively
according to work history records among 1,400 occupationally exposed workers and bladder
cancer. The total number of cancer cases was six from questionnaire survey and 5 from death
certiﬁcates. In this underpowered study, no association was observed.
3.3.4.9.2. Background exposed population
Eriksen et al. (2009) investigated prospectively the associations between plasma levels (mean) of
PFOS (33.9 ng/mL) and PFOA (6.2 ng/mL) and cancer risk among participants in the Danish Cancer
Society Cohort. From enrolment, between 1 December 1993, and 31 May 1997, and through 1 July
2006, 713 participants with prostate cancer, 332 with bladder cancer, 128 with pancreatic cancer, and
67 with liver cancer were identiﬁed. A subcohort of 772 participants were randomly selected for
comparison. Non-signiﬁcant associations were observed for all the outcomes examined although for
PFOS there was a borderline non-signiﬁcant increased risk observed for prostate cancer (incidence rate
ratio of 1.38 (95% CI: 0.99, 1.93) comparing the highest vs the lowest quartile). One methodological
limitation in this study is the use of one baseline blood sample. Environmental levels were increasing
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during the time of baseline recruitment between 1993 and 1997 (Haug et al., 2009) but then
decreased rapidly during the follow-up period. It is unclear if ranking subjects based on just one
sample is sufﬁciently accurate to detect any risk.
Hardell et al. (2014) examined the association between serum concentrations (median) of PFOS
(8.7 ng/mL) and PFOA (2.0 ng/mL) among 201 newly diagnosed cases with prostate cancer from
€Orebro Sweden (2007–2011); and 186 controls matched for age and area of residence. Non-signiﬁcant
associations were observed for PFOS and PFOA when comparing concentrations among cases and
controls. However, in a subset of participants with heredity as risk factor (number of cases ranging
between 6 and 11 and number of controls ranging between 19 and 24) a signiﬁcantly increased risk
was observed for both compounds (odds ratios ~2.5). Given the small number of heritable cases,
these ﬁndings would need to be replicated to provide better indication if there is a potential gene -
environment interaction.
Bonefeld-Jørgensen et al. (2014) examined in a case–control (250 cancer cases and 233 matched
controls) setting the association between approx. median exposure PFOS (~30 ng/mL) and PFOA
(~5 ng/mL) with breast cancer using blood samples drawn in early pregnancy among women
participating in the Danish National Birth Cohort (1996–2002, mean age ~30 years). No associations
with breast cancer were observed.
3.3.4.9.3. Summary
Overall studies among background exposed population provide little evidence to suggests that
exposure to PFOS and PFOA is associated with increased cancer risk. The strengths of these studies
are that they have relied on direct quantiﬁcation of exposure in serum as opposed to estimating
exposure through indirect measures. Two studies (Eriksen et al., 2009; Hardell et al., 2014) have
suggested that prostate cancer may be a relevant outcome to examine further, at least in the case of
PFOS. However, these ﬁndings are only suggestive.
Occupational studies and studies among individuals being exposed through contaminated drinking
water (the C8 cohort) have predominantly focused on exposure to PFOA (but not PFOS) and cancer
incidence and/or mortality. These studies have often been partly overlapping (Lundin et al., 2009;
Barry et al., 2013; Vieira et al., 2013; Raleigh et al., 2014). In all but one of these studies (Innes
et al., 2014), retrospective assessment of PFOA was used based on residence/occupation and other
predictors of past exposure. Although ranking of subjects with respect to past exposure may in some
cases provide reliable estimates (Shin et al., 2011a), there is still a great deal of uncertainty when
taking into consideration changes in production volume of PFOA from the early 1950s to present day;
as well as changes in industrial hygiene over time. In addition, many of these studies examined
association between past exposure to PFOA with cancer cases occurring from the early 1950s to 2000
(Lundin et al., 2009; Barry et al., 2013; Innes et al., 2014; Raleigh et al., 2014). Temporal changes in
incidence rates, diagnoses, changes in other risk factors and survival changes from the 1950s to
present may result in biased non-comparable outcomes. What inﬂuence this may have on the reported
associations is difﬁcult to predict. It is therefore not surprising that the overall results for the high
exposure studies are inconsistent. Still these studies have suggested that high exposure to PFOA may
potentially increase risk of kidney, testicular and bladder cancer. Some suggestions of a modest
association with prostate cancer (Eriksen et al., 2009; Lundin et al., 2009; Vieira et al., 2013) have
also been reported.
Based on the review above, it is concluded that studies among background and occupationally
exposed individuals provide limited evidence to suggest that exposure to PFOS and PFOA are associated
with increased cancer risk. This conclusion is in line with the conclusion from the recent IARC report on
PFOA (IARC, 2016), which concluded that there was limited evidence for carcinogenicity.
3.3.4.10. Cardiovascular outcomes
Sakr et al. (2009) studied ischaemic heart disease (IHD) mortality in a retrospective cohort of 4,747
DuPont workers who had ever worked at the APFO plant from start of production in 1948 until the end
of 2002. Exposure to PFOA was categorised as low, medium or high, based on job titles and serum
PFOA by these job titles in a 2004 survey, and a cumulative exposure index was created for each
worker based on duration of work multiplied by the estimated exposure intensity for the job titles.
Workers were then categorised in quartiles of cumulative exposure. Risk of IHD was estimated using
survival analysis (Cox-regression), adjusted for age, sex, race, and calendar year, but no information
was available on smoking or other individual IHD risk factors. The median duration of employment was
23 years and the median estimated cumulative exposure was 5.1 ppm-years (integrative measure, e.g.
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5 years with an average level of 1,020 ng/mL = 1.02 ppm). No overall signiﬁcant increase in IHD
morality (239 deaths) was found in the highest quartile of estimated PFOA exposure (relative risk 1.1,
95% CI 0.7–1.7) using the lowest quartile as a reference. When various lags (latency times) were
tested, there was a tendency towards an increased risk at 10-year lag, but not at 5, 15 or 20 years lag.
Simpson et al. (2013) assessed the associations between exposure to PFOA and incidence of stroke
among 35,000 individuals ≥ 20 years of age from the C8 cohort ((1,900 workers and 28,500 residents
exposed via drinking water. Serum PFOA determinations were available for most of them in 2005–2006
median 113 ng/mL in workers and 24 ng/mL in residents). Historical serum PFOA levels were also
estimated as described previously for the C8 cohort (Section 3.3.4.7.1 on serum lipids). Incidence of
stroke was compared with estimated cumulative serum PFOA (as a continuous variable or by quintiles)
using Cox-regression based on 825 validated cases of stroke, and adjustment for potential
confounders. The hazard ratios in quintiles 2–4 were all signiﬁcantly above 1.0 (reference quintile 1),
but the HR in Q5 was only 1.13 (95% CI 0.9–1.4) and there was no signiﬁcant trend. There was no
association with estimated serum PFOA as a continuous variable. When restricting the observation to
the period before 1999, there were some signiﬁcant positive associations between estimated
cumulative serum PFOA and stroke. A smaller prospective substudy (252 cases occurring after
inclusion in 2005–2006) showed no association with cumulative serum PFOA.
As mentioned in the Section on serum lipids (Section 3.3.4.7.1), Winquist and Steenland (2014b)
performed retrospective and prospective analyses of associations between modelled PFOA levels
(cumulative or yearly) in the C8 cohort and self-reported coronary heart disease or hypertension, but
without ﬁnding any positive associations. In the prospective analyses for coronary heart disease, the
point estimates for HRs for Q2–Q5 were around 0.7.
Min et al. (2012) examined cross-sectional associations between serum PFOA and serum
homocysteine (often associated with cardiovascular risk) and blood pressure in about 2,200 adults
from NHANES surveys 2003–2006. The GM serum PFOA level was 4 ng/mL. Analyses were adjusted
for a number of potential confounders and for serum PFOS (which was correlated with serum PFOA,
but no information on levels is given). Log-transformed serum homocysteine increased signiﬁcantly
with increasing log-transformed serum PFOA, but the magnitude of association was minimal. There
was a signiﬁcant positive association between serum PFOA and systolic blood pressure (about 2 mm
Hg at a doubling of serum PFOA). The OR for hypertension was 1.7 (95% CI 1.2–2.4) when comparing
the highest quartile of serum PFOA with the lowest, and the trend was statistically signiﬁcant.
Shankar et al. (2012) performed a cross-sectional study on the association between PFOA and self-
reported cardiovascular disease as well as peripheral arterial disease (PAD), deﬁned as an ankle-brachial
index blood pressure of < 0.9. They studied 1,200 participants in NHANES 1999–2003 aged ≥ 40 years.
The median serum PFOA was about 4 lg/L. Adjusting for a number of potential confounders (including
total cholesterol), the OR for self-reported physician-diagnosed coronary heart disease, heart attack or
stroke was 2.0 (95% CI 1.1–3.6) and the OR for PAD was 1.8 (1.03–3.1). Analyses stratiﬁed for sex,
smoking and BMI showed point estimates of OR similar to those in the total group.
The same group studied cross-sectional associations between PFOS/PFOA and blood pressure in
1,655 children (age 12–18 years) participating in NHANES surveys 1999–2008 (Geiger et al., 2014b).
Mean serum PFOS and serum PFOA levels were 18 and 4.4 ng/mL. A number of potential confounders
were adjusted for. Linear regression showed no associations between PFOS/PFOA and blood pressure.
The ORs for high blood pressure (above the 95% percentile) in the upper quartiles were 0.69 (95% CI
0.4–1.2) for PFOS and 0.77 (95% CI 0.4–1.6).
Lin et al. (2013b) studied, cross-sectionally, the association between intima-media thickness (as a
measure of atherosclerosis) in the carotid artery (CIMT) and serum levels of PFOS and PFOA in 644
individuals from Taiwan, aged 12–30 years. Recruited at a mass-screening of urine (Section 3.3.4.7.1;
Lin et al., 2011), serum PFOS and serum PFOA were about 7.9 and 2.6 ng/mL. There was a slight
positive but statistically signiﬁcant trend of increase in CIMT with increasing serum PFOS after
adjustment for potential confounders (5% increase in Q3 and 4% in Q4). No such association was
found for serum PFOA. Similar results were found be the same authors (Lin et al., 2016) when
analysing some additional subjects and performing some subanalyses.
Watkins et al. (2014) studied DNA methylation in 685 adults from the C8 cohort examined
longitudinally with follow-up in 2010. DNA methylation (in a region called LINE-1) in blood leucocytes
collected in 2010 was positively associated with PFOS in 2005–2006 as well as PFOS in 2010. The
authors comment that hypomethylation has been associated with increased serum lipids and
cardiovascular risk, but in the present study DNA methylation was instead increased. No association
was found for PFOA.
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Mattsson et al. (2015) performed a case–control study (nested in a cohort) of the association
between PFOS/PFOA and incident coronary heart disease (CHD, fatal or non-fatal). Cases and
age-matched controls (231 pairs) were obtained from a cohort of 1,782 men living in rural Sweden.
Median serum PFOS and PFOA at recruitment 1990–1991 were 22 and 4.1 ng/mL. For part of the age-
control pairs still alive, blood samples were collected also in 2002–2003, and then levels had decreased
about 10%. There were no associations between PFOS/PFOA and risk of CHD (OR for Q4 of serum
PFOS 0.9, 95% CI: 0.6–1.6 and OR for Q4 of serum PFOA 0.9, 95% CI: 0.7–1.8).
Lind et al. (2017) studied cross-sectional associations between L-PFOS and PFOA in serum in about
1,000 elderly Swedish individuals (Lind et al., 2014; Section 3.3.4.7.3 on diabetes, obesity, and
metabolic syndrome). No signiﬁcant associations were found between PFOS/PFOA and CIMT, carotid
atherosclerotic plaques or the echogenicity of the plaques.
In summary, ﬁve cross-sectional and four longitudinal studies (Sakr et al., 2009; Simpson et al.,
2013; Winquist and Steenland, 2014b; Mattsson et al., 2015) examined associations between
PFOS/PFOA and cardiovascular outcomes (mortality, coronary heart disease, stroke, hypertension and
atherosclerosis). Altogether, these studies do not show any clear causal association between
PFOS/PFOA and cardiovascular disease. However, if there is only a small increase of relative risk
(1.05–1.1), these studies would not be able to demonstrate it.
3.3.4.11. Other studies/various outcomes
An early cross-sectional study of a population sample from the area with contaminated water from
the C8 plant was published by Emmett et al. (2006). It was a (mainly random) sample of 371
inhabitants who had been living in the affected water district for at least two years. About 90% were
adults, and 18 of them had been occupationally exposed at the C8 plant. The median PFOA level was
354 lg/L. The authors examined a number of serum and blood biomarkers and found essentially no
associations with thyroid hormone levels, liver and kidney function tests, cholesterol levels or
haematological variables. Nor were there any signiﬁcant associations between PFOA levels and
self-reported liver or thyroid disease.
A cross-sectional ecological study of health status in a sample of inhabitants in the C8 area was
reported by Anderson-Mahoney et al. (2008). Prevalences of self-reported symptoms and diseases
were compared with prevalences in NHANES 2001–2002, taking age and gender into account.
Prevalence ratios were found to be increased for cardiovascular problems, respiratory disease, kidney
disease and diabetes.
3.3.4.11.1. Ulcerative colitis
Steenland et al. (2013) studied the association between PFOA and incidence of a number of
autoimmune diseases (ulcerative colitis, Crohn’s disease, rheumatoid arthritis, type-1 diabetes, multiple
sclerosis and systemic lupus erythematosus) in 32,254 individuals from the C8 cohort, 12% of which
had been working at the C8 plant. Exposure to PFOA (since 1952) was retrospectively estimated using
serum PFOA levels in a subset of participants at recruitment combined with data on area of residence,
drinking water intake, previous occupation (job-exposure matrix), and a pharmacokinetic model. The
participants (or next of kin for 4% of participants) were interviewed in 2008–2011 regarding
autoimmune diseases. A number of potential confounders were adjusted for. Only cases validated
against medical records were considered. Associations were analysed by Cox-regression (from birth or
from year 1952). A signiﬁcant positive trend was found for ulcerative colitis (151 cases) with an
increased relative risk already in the second PFOA quartile (RR 1.8; 95% CI: 1.04–3.0) increasing to
RR 2.9 (95% CI: 1.7–5.0) in the forth quartile. A separate prospective analysis based on measured
serum PFOA in 2005–2006 and follow-up until 2008–2011 showed increased point estimates for the
RR, but statistically non-signiﬁcant (only 30 cases). There was no increased risk of other autoimmune
diseases.
Associations between PFOA and the incidence of various diseases were studied by Steenland et al.
(2015) in 3,713 workers from the C8 cohort. These workers were also included in several studies of
disease incidence in the combined C8 cohort of residents and workers (Barry et al., 2013; Steenland
et al., 2013; Winquist and Steenland, 2014a,b). In the present paper, workers were studied separately.
The workers or next of kins (6%) were interviewed in 2008–2011. For a large number of deceased
workers, next of kin interviews could not be performed. About half of the workers had their serum
PFOA level determined in 2005 (median 113 ng/mL). For all workers, yearly serum PFOA levels were
estimated retrospectively as described above. Diseases were validated in medical records, apart from
some common diseases: osteoarthritis, hypertension and hypercholesterolaemia. A number of potential
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confounders were adjusted for. Associations were analysed by Cox-regression (from year 1951 or from
age 20). Signiﬁcant positive trends were found for ulcerative colitis (28 cases) and rheumatoid arthritis
(29 cases). The only statistically signiﬁcant relative risk in quartile 4 was for ulcerative colitis (RR 6.6;
95% CI: 1.5–29) when a ten-year lag was used. There was no increased risk of self-reported
osteoarthritis.
In summary, these results from the C8 cohort suggest an association between serum PFOA (but
not PFOS) and risk of ulcerative colitis. More studies are needed to assess this hypothesis.
3.3.4.11.2. Osteoarthritis and rheumatoid arthritis
Innes et al. (2011) examined cross-sectional associations between PFOS/PFOA and self-reported
physician-diagnosed osteoarthritis in about 49,000 individuals > 20 years of age in the C8 cohort.
Median PFOS and PFOA levels were 20 and 28 ng/mL. More than 3,700 individuals reported
osteoarthritis, which was (as expected) strongly affected by age, but also with a number of other
potential confounders. There was a signiﬁcant positive association between PFOA and osteoarthritis. In
multivariable adjusted models the prevalence odds ratio in the highest quartile of PFOA was 1.3 (95%
CI: 1.1–1.5), and it was signiﬁcantly increased also in the third quartile (> 28 ng/mL). For PFOS there
was an association in the opposite direction. The OR in quartile 4 of PFOS was 0.8 (95% CI: 0.7–0.9).
The authors discuss the possibility that inﬂammation or PPAR-mediated changes in bone metabolism
could be involved, but cannot explain the divergent ﬁndings for PFOA and PFOS.
Uhl et al. (2013) performed a cross-sectional study of PFOS/PFOA and self-reported physician-
diagnosed osteoarthritis in 3,809 individuals 20–84 years of age in NHANES surveys 2003–2008. The
median PFOS and PFOA levels in serum were 13.6 and 4.2 ng/mL. A number of potential confounders
were adjusted for. There was a signiﬁcant positive association between PFOS and osteoarthritis with ORs
2.0 (95% CI: 1.4–3.5) and 1.8 (1.1–3.0) in the third and fourth quartiles. For PFOA, there was a borderline
signiﬁcant increase in Q4 (OR 1.6; 95% CI: 0.99–2.4). In sex-stratiﬁed models, the ORs for PFOS were
similar for women and men (although the increase was not statistically signiﬁcant) while for PFOA the
increase was only found among women (OR in Q4 2.0; 95% CI: 1.2–3.2). In men, the OR in Q4 was 0.8
(95% CI: 0.4–1.7). The authors discuss the same possible mechanisms as did Innes et al. (2011), and
state that the reason for increased susceptibility in women might be endocrine effects by PFOA.
In the afore-mentioned studies by Steenland et al. (2013, 2015) where ulcerative colitis was
studied, there was no association between PFOA and rheumatoid arthritis (Steenland et al., 2013) or
osteoarthritis (Steenland et al., 2015).
In summary, the three cross-sectional studies on osteoarthritis (Innes et al., 2011; Steenland et al.,
2013; Uhl et al., 2013) provide only limited support for an association between PFOA and risk of
osteoarthritis, and for PFOS the results are inconsistent.
3.3.4.11.3. Bone mineral density
Lin et al. (2014) studied cross-sectionally the association between serum PFOS/PFOA and bone
mineral density as well as self-reported fracture in 2,339 individuals aged ≥ 20 years from NHANES
surveys 2005–2008. Bone mineral density was assessed using dual-energy X-ray absorptiometry (DXA)
of the spine and the hip. Self-reported physician-diagnosed history of fracture of hip, wrist or spine
was collected from a questionnaire. Geometric means of PFOS and PFOA were 15 and 4.0 ng/mL. A
number of potential confounders were adjusted for. Effect modiﬁcation of sex and menopause status
was examined. There was no overall association between PFOS/PFOA and bone mineral density. In
pre-menopausal women, there was a small signiﬁcant inverse association between PFOS and lumbar
spine bone mineral density (about 2% per threefold increase of PFOS), but no association for hip or
wrist, no association in men or post-menopausal women, and no associations with PFOA. No
associations were found between PFOS/PFOA and fracture.
Khalil et al. (2016) used the NHANES survey 2009–2010 for a similar cross-sectional study of
associations between PFOS/PFOA and bone mineral density (measured by DXA) in spine and femur, as
well as self-reported physician-diagnosed osteoporosis. In 1914 individuals age 12–80 years, the mean
serum PFOS and PFOA levels were 13 and 3.7 ng/mL. A number of potential confounders were
adjusted for. In women, bone mineral density in femur was signiﬁcantly lower in the highest quartile of
PFOS. The association was signiﬁcant in 368 post-menopausal women but not in 590 pre-menopausal
women. No association with PFOS was found for spine bone mineral density. In men, non-signiﬁcant
associations with PFOS in the same direction were found, but signiﬁcant only for bone mineral density
in the femoral neck. Associations between PFOA and bone mineral density in women were generally in
the same (inverse) direction as for PFOS, but not statistically signiﬁcant. The adjusted odd ratio for
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osteoporosis in women (77 cases) was increased in the upper quartile of PFOA (OR 2.6, 95% CI:
1.01–6.7), but not in the upper quartile of PFOS (OR 1.1, 95% CI: 0.4–3.2).
In summary, these two cross-sectional NHANES studies show some inverse associations on
associations between PFOS/PFOA and bone mineral density, but only in subgroups and for some sites,
with limited consistency between the two studies. The magnitudes of the associations were small and
may be due to residual confounding and/or reverse causation. The latter would be mediated by higher
PFOS/PFOA in women with early menopause, which in turn decreases bone mineral density.
3.3.4.11.4. C-reactive protein
Genser et al. (2015) in a paper on multi-level regression analysis based on the C8 cohort, present
slight but statistically signiﬁcant associations between serum PFOA and C-reactive protein, within water
districts as well as between water districts. Because serum CRP is a well-known risk factor for
cardiovascular disease, this may be relevant in the discussion of cardiovascular risk in PFOA-exposed
populations.
3.3.5. Mode of action
3.3.5.1. Liver Toxicity
3.3.5.1.1. PPARa transactivation, hepatic peroxisomal b-oxidation and hepatomegaly
PFOS and PFOA were found to affect the liver of rodents by increasing the absolute and/or relative
weight of the organ (see Section 3.3.3.2). This was often found to be associated with centrilobular
hypertrophy of hepatocytes. Subsequent analyses of liver tissue samples revealed that PFOS and PFOA
increase the expression and activity of peroxisomal b-oxidation enzymes, accompanied by the
intrahepatic proliferation of peroxisomes.
The induction of peroxisomal b-oxidation of PFOS or PFOA in rodents is primarily due to
transactivation of the nuclear receptor PPARa, as shown in mice lacking the PPARa receptor (EFSA,
2008). Wolf et al. (2008a) addressed the question whether the induction of liver growth by PFOA is
also mediated by PPARa. CD-1 mice, WT and PPARa -/- mice (SV/129 background) were treated with
seven daily gavages of the ammonium salt of PFOA (1, 3 or 10 mg/kg bw per day). PFOA induced
dose-dependent hepatocyte hypertrophy, peroxisome proliferation and labelling index (LI) of
proliferating cell nuclear antigen (PCNA) labelled hepatocytes in WT mice. In KO mice, 10 mg PFOA/kg
bw per day caused also a dose-dependent increase in relative liver weight and LI but also hepatocyte
vacuolation, for which the authors could not provide a reasonable explanation. The vacuolation was
due to a diffuse accumulation of variably sized cytoplasmic vacuoles with fuzzy borders, which might
have contributed to elevated relative liver weights and the enhanced hepatocellular replication.
Also human liver is affected by PPARa ligands. Hypolipidemic drugs of the ﬁbrate type are ligands
of PPARa and are prescribed frequently to lower elevated plasma triglyceride levels in humans. The
activities of peroxisomal, mitochondrial and/or microsomal fatty acid oxidation are induced by this type
of compounds. So far occurrence of hepatomegaly or intrahepatic peroxisome proliferation has not
been reported for patients receiving treatment with ﬁbrates. Due to lack in liver biopsies, products of
PPARa target genes were determined in patients’ sera and elevated protein levels of APOA2, ANGPTL4
and FGF21, conﬁrmed that PPARa agonists are able to activate effectively this receptor in human liver
(Kersten and Stienstra, 2017).
For functional studies, a transgenic mouse strain was generated with the murine PPARa being
replaced by the human counterpart. The transgene showed intrahepatic expression at levels similar to
those of the WT animals (Cheung et al., 2004). Upon treatment with the very potent peroxisome
proliferator Wy-14.643, hPPARa mice showed lowered serum triglycerides and elevated peroxisomal,
mitochondrial, and microsomal fatty acid oxidation enzymes, albeit at a somewhat lower extent than in
wild-type mice. In contrast to the WT controls, hPPARa mice did not exhibit hepatomegaly,
hepatocellular DNA synthesis or elevated expression of cell cycle genes. Cheung et al. (2004) deduced
that the regulation of lipid metabolism by PPARa is disconnected from the regulation of cell proliferation.
One study investigated the effect of PFOA in the PPARa-humanised murine model (Nakamura et al.,
2009). Male WT, PPARa-/- and hPPARa mice received the ammonium salt of PFOA at 0, 0.1 or 0.3 mg/kg
bw per day for 2 weeks by gavage. PFOA increased both hepatic mRNA and/or protein levels of PPARa
target genes (Cyp4a10, peroxisomal thiolase, bifunctional protein) and the relative liver weight only in
WT but not in PPARa-/- or hPPARa mice. In PFOA-treated hPPARa animals, concentrations of
cholesterol and triglycerides in the liver and serum remained unaffected while in the WT animals, PFOA
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left the serum lipid levels unchanged but increased the intrahepatic concentrations of cholesterol and
triglycerides. From these studies, Cheung et al. (2004) and Nakamura et al. (2009) concluded that
hPPARa might be less functionally active than the mouse variant and may not be associated with the
activation of signaling cascades leading to liver growth. It has been suggested that the differences in
the transactivation efﬁcacy between hPPARa and its wild-type counterpart in the murine model may be
due to species-speciﬁc features in coactivator recruitment and/or sequence of cis-acting DR-1 elements
in the promoter region of the genes (Viswakarma et al., 2010).
In reporter gene assays, nuclear receptors and the responsive element of the luciferase promoter
may be well attuned to each other, which allows for comparing the pure transcriptional activation of
the human or rodent PPARa by ligands in an identical cellular background. When using COS-1 cells for
this assay, the lowest observed effects concentrations for PFOA were 1 lM/10 lM and for PFOS
90 lM/30 lM at the murine/human PPARa, respectively (Wolf et al., 2008b). This indicates that PFOA
is more potent than PFOS and that the human receptor shows similar afﬁnities or transactivation
capacities by PFASs as the murine counterpart. Bjork and Wallace (2009) compared the gene
expression patterns induced by PFOS and PFOA in rat and human hepatocytes. As observed by Wolf
et al. (2008b), PFOA was more potent than PFOS in inducing transcripts (ACOT1, CYP4A11) in primary
rat hepatocytes. Further experimentation with PFOA revealed that the compound elevated mRNA of
ACOX and ACOT1 solely in rat hepatocytes but failed to do so in human hepatocytes or human HepG2
cells at concentrations of up to 200 lM. A signiﬁcant induction of CYP4A11 at 20 lM of PFOA became
evident in primary human hepatocytes, which occurred at 5 lM in the rat counterparts. This is some
evidence that species-speciﬁc features in gene regulatory processes, i.e. the interaction of the receptor
with the promoter region and/or coactivator recruitment at the individual gene level may account for
the absent or weak response in human liver cells to PFOA.
When PFOS and PFOA were compared to other PFASs in in vitro studies, there was a trend towards
elevated transcriptional activation of both rodent and human PPARa with increasing chain length up to
the length of C9 and a trend to lower activity for PFASs with chains of > C9 (Wolf et al., 2008b; Bj€ork
and Wallace, 2009; Naile et al., 2012). Wolf et al. (2014) investigated whether binary combinations of
PFOS and PFOA act in an additive fashion to activate PPARa in a mouse one-hybrid in vitro model. At
low concentrations, all combinations produced concentration–response curves that resembled highly
the predicted curves for both, i.e. response addition and concentration addition. However, at higher
concentrations the response curves deviated from the predicted models.
3.3.5.1.2. Other nuclear receptors
Since 2008, in vivo and in vitro studies addressed the question whether further nuclear receptors
may be involved in mediating the action of PFOS and PFOA. Rosen et al. (2008) compared the
transcript proﬁles of the livers of WT and PPARa-/- mice treated with PFOA for 7 days. It was shown
that 85% of the genes altered by PFOA were dependent on PPARa. The PPARa-independent genes
were often involved in lipid homoeostasis and xenobiotic metabolism. These effects may be due to
activation of PPARgamma, CAR (constitutive activated/androstane receptor) or the transcription factor
Nrf2 (nuclear factor erythroid 2-related factor 2). By the analyses of transcriptome patterns induced by
PFOS or PFOA in rat and human primary hepatocytes, Bjork et al. (2011) deduced that multiple
receptor systems, such as PPARa, CAR, PXR and LXRa, are activated by these compounds. The
activation of PXR by PFOS was conﬁrmed by Bijland et al. (2011). Ren et al. (2009) determined the
potential role of CAR/PXR in mediating effects of PFOS and PFOA in rat liver by performing a meta-
analysis of transcript proﬁles from published studies. The authors concluded that PFOA and PFOS
activate PPARa, CAR and PXR in rats, but not in chicken and ﬁsh. Long et al. (2013b) reported that
1 nM-100 lM of PFOS or PFOA failed to transactivate the aryl hydrocarbon receptor (AhR) in a
reporter gene assay using mouse hepatoma cells (Hepa1.12cR). This high level of complexity may
explain that Naile et al. (2012) observed compound-speciﬁc effects on transcript levels of 7 genes,
involved in fatty acid and cholesterol synthesis in rat H4IIE hepatoma cells, e.g. PFOA induced
peroxisomal 3-ketoacyl-CoA thiolase about sevenfold, while PFOS downregulated the gene by
approximately ﬁvefold.
3.3.5.1.3. Cytotoxicity
PFOS and PFOA may exert cytotoxicity, as shown in in vivo experiments. Elevated serum levels of
AST or ALT were found in rodents at 2.5 mg/kg bw per day of PFOS (30 days of treatment) or PFOA
(14 days of treatment), respectively (Yang et al., 2014; Xing et al., 2016). PPARa regulates synthesis,
conjugation, and transport of cytotoxic bile acids, and thus is essential for the homoeostasis of these
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potentially harmful endogenous compounds. Minata et al. (2010) tested the hypothesis that activation
of PPARa protects against chemically induced hepatobiliary injuries in rodents which may mask the
potential toxicity of PFOA. WT and PPARa–/– mice (9–10/group) were treated with ammonium salt of
PFOA (> 98% purity; 0, 5.5, 10.8, 21.6 mg/kg bw per day; by gavage) for 4 weeks. In WT mice,
PFOA induced dose-dependent hepatocellular damage. Some cholangiopathy could be observed at
10.8 and 21.6 mg/kg bw per day. In PPARa–/– mice, PFOA produced marked fat accumulation, severe
cholangiopathy, hepatocellular damage, apoptotic cells, especially in bile ducts, oxidative stress and
upregulation of TNF-a mRNA. Thus, PPARa appears to be protective against PFOA-induced
hepatobiliary injury. Also Wolf et al. (2008a) observed liver toxicity of PFOA in mice lacking PPARa (see
above). These ﬁndings indicate that in WT animals hepatocellular damage appears to be predominant
while in animals without functional PPARa cytotoxicity occurs mainly in the biliary tract.
The reasons for the cytotoxic effects of PFOS and PFOA are not elucidated in detail so far, but may
be due to an altered hepatocellular lipid metabolism, as outlined in Section 3.3.3.2. Due to enhanced
peroxisomal b-oxidation, which generates hydrogen peroxide in the ﬁrst step of long-chain fatty acid
degradation, it was assumed that peroxisome proliferators, like PFOS and PFOA, may enhance the
formation of reactive oxygen species and consequently of lipid peroxidation products in the liver.
Also effects on mitochondria may contribute to the cytotoxicity of PFOA. Walters et al. (2009)
treated male Sprague–Dawley rats (5/group) with the ammonium salt of PFOA (no further
speciﬁcations) at 0 or 30 mg/kg bw per day by gavage for 28 days. This treatment induced genes
associated with mitochondrial biogenesis indicated by a preferential stimulation of mitochondrial DNA
transcription. The authors suggested that this was via activation of the peroxisome proliferator-
activated receptor (Pgc)-1a pathway. Implication of the Pgc-1a pathway is consistent with
PPARgamma transactivation by PFOA. Mashayekhi et al. (2015) treated isolated rat liver mitochondria
with relatively high concentrations of PFOA (0.5–1.5 mM). This caused ROS elevation in both
mitochondrial complexes I and III, mitochondrial membrane potential collapse, swelling, cytochrome c
release and decreased ATP level, which induces apoptosis or necrosis.
Further biochemical alterations may affect the urea cycle. Walters and Wallace (2010) administered
0 or 30 mg/kg bw of PFOA to adult male Sprague–Dawley rats via daily gavage for 28 days. They
found decreased hepatic mRNA and/or protein of urea cycle genes (Cps1, Ass1, Asl) and of the
ammonia generating gene Gls2. However, the amount of S133 phosphorylated CREB, a regulator of
urea cycle gene transcription, was increased. The authors concluded that PFOA favours the catabolism
of lipids over proteins and thereby suppresses urea cycle gene expression.
3.3.5.1.4. Altered hepatocellular lipid metabolism
It has been assumed that the PFOS/PFOA-induced peroxisomal b-oxidation of long-chain fatty acids
enhances the intrahepatic generation of hydrogen peroxide, which may cause subsequent lipid
peroxidation. Indeed, elevated hepatic malondialdehyde levels were reported after in vivo treatment of
mice with PFOA (2.5 mg/kg bw per day) for a period of 14 days (Yang et al., 2014).
In theory, the elevated activity of peroxisomal b-oxidation should degrade long-chain fatty acids
and the intrahepatic content of lipids should decrease. However, several studies reported on an
increased hepatic lipid content after treatment of mice with PFOS at 5 mg/kg bw per day for 14 days
(Wang et al., 2014a). This may be due to intrahepatic accumulation of triglycerides, as described for
PFOS (6 mg/kg bw per day, Zhang et al., 2016a) and other PFASs (Kawashima et al., 1995; Zhang
et al., 2008; Wang et al., 2015d). Wan et al. (2012) investigated this effect systematically and
reported that PFOS elevated hepatic gene expression levels of fatty acid translocase (FAT/CD36) and
lipoprotein lipase (Lpl), while serum levels of very-low-density lipoproteins and the rate of
mitochondrial b-oxidation were reduced. The authors concluded that the altered lipid metabolism
caused the intrahepatic accumulation of fatty acids and triglycerides. Such hepatic lipid overloading
may lead to steatohepatitis and may be considered a symptom for severe metabolic disturbances
predisposing for hepatic inﬂammation and necrosis.
In contrast to enhanced lipid content as described above, reduced lipid content in murine
hepatocytes was seen occasionally, as reported for PFOA (Yan et al., 2015). The authors focused on
the MoA of PFOA-induced alterations in hepatocellular cholesterol metabolism. Generally, the synthesis
of cholesterol is regulated tightly by endogenous cholesterol. In the endoplasmic reticulum, SREBP
(sterol regulatory element-binding protein 1 and 2) serves as intracellular cholesterol sensor and main
regulator of cholesterol biosynthesis. The transcriptional regulation of SREBPs is generally enhanced by
SREBPs through a feed-forward mechanism, insulin signalling and LXR-RXR heterodimers (Bengoechea-
Alonso and Ericsson, 2007; Jeon and Osborne, 2012). In the presence of cholesterol, the SREBP
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protein binds to SCAP and INSIG-1. If cholesterol is lacking, SREBP maturation takes place, i.e.
INSIG-1 dissociates from the SREBP-SCAP complex, which allows the complex to migrate to the Golgi
apparatus, where SREBP is cleaved. When being cleaved, SREBP translocates to the nucleus, and acts
as a transcription factor for low-density lipoprotein (LDL) receptor and HMG-CoA reductase. The LDL
receptor scavenges circulating LDL from the blood, and HMG-CoA reductase is one of the key enzymes
in the cholesterol biosynthesis.
Yan et al. (2015) observed that transcriptional activities of PPARa and SREBPs were enhanced by
PFOA in mouse livers, as shown by upregulation of target genes. PFOA treatment enhanced also
hepatic SREBP maturation, while proteins blocking the ER-Golgi transport of SREBP precursors
(INSIG1, INSIG2), or being involved in SREBP proteolysis were decreased. The transcript levels of miR-
183-96-182, which is thought to regulate SREBP maturation, were elevated by PFOA. The authors
concluded that PFOA induced maturation of SREBPs by activating the miR-183-96-182 cluster. Although
SREBP was activated in this study, the total hepatic cholesterol was reduced. The authors hypothesised
that this may be due to PPARa activation resulting in cholesterol deﬁciency in the liver, followed by
secondary SREBP maturation.
3.3.5.2. Blood lipids
PFOS and PFOA were shown to lower serum triglycerides and/or cholesterol levels in rodents at
1.7 mg/kg bw per day and 10 mg/kg bw per day, respectively (Minata et al., 2010; Elcombe et al.,
2012; Wang et al., 2013a). The opposite is true in humans showing a positive correlation between
plasma cholesterol and PFOS/PFOA serum concentrations and in some, but not in all studies also a
positive association between elevated triglycerides and PFOS and/or PFOA (see Section 3.3.4.7.1).
It is known since decades that PPARa agonists decrease serum triglyceride levels in rodents and
humans. Via activation of PPARa they increase the activity of lipoprotein lipase, which causes a
decrease in triglyceride levels. LDL changes from small, dense morphology to large particles that are
more rapidly cleared by the liver. In this organ, the induced peroxisomal b-oxidation may contribute to
the degradation of long-chain fatty-acids, deriving from the triglycerides. PPARa activation also
increases HDL production. It may be deduced that PFASs with documented PPARa trans-activation,
may act in a similar way.
The effect of PFOS and PFOA on plasma cholesterol levels appears to be more complex. In contrast
to observations in rodents, human studies show a positive correlation between plasma cholesterol and
PFOS as well as PFOA serum concentrations. This observation contrasts to effects of other PPARa
agonists, prescribed to patients suffering from elevated blood lipids. Bezaﬁbrate, fenoﬁbrate or
gemﬁbrozil are known to lower not only serum triglycerides but also the hepatic production and
release of LDL-cholesterol, albeit to a moderate and variable extent.
In general, cholesterol is transported via chylomicrons, VLDL, LDL, IDL or HDL. Chylomicrons carry
cholesterol from the intestinal tract to muscle and other tissues for energy or fat production. Unused
cholesterol remains in chylomicron remnants and is taken up by the liver. Cholesterol, not used for bile
acid synthesis, is released from the liver via VLDL, containing apolipoprotein B100 and apolipoprotein
E, and being degraded by lipoprotein lipase in blood endothelium to IDL. If IDL is not taken up by
blood vessels or liver, IDL is losing gradually triacylglycerols in the bloodstream until it becomes
LDL with high cholesterol concentration. Thus, LDL particles are the major blood cholesterol carriers.
LDL molecules contain apolipoprotein B100, recognised by LDL receptors in peripheral tissues. LDL
receptors are used up during cholesterol absorption, and its synthesis is regulated by SREBP.
Accordingly, LDL receptor synthesis is activated in case of intracellular deﬁciency in cholesterol and vice
versa. HDL particles are important for the cholesterol transport back to the liver, a process known as
reverse cholesterol transport.
The positive correlation between cholesterol and PFOS/PFOA serum concentrations in humans and
the inverse correlation in rodents might be explained by the fact that the hypolipidemic activity of
PPARa may be activated more readily in rodents than in humans. To simulate the situations in humans
several studies investigated the impact of PFASs on rodents fed with a high-fat diet. Rebholz et al.
(2016) studied PFOA effects in C57BL/6 and BALB/c mice, kept on a fat- and cholesterol-rich diet. This
resulted in marked hypercholesterolaemia in C57BL/6 mice but less robust hypercholesterolaemia in
BALB/c mice. The PFOA-induced hypercholesterolaemia was associated with increased liver masses
and altered expression of genes associated with hepatic sterol output, speciﬁcally bile acid production.
Wang et al. (2014a) fed male BALB/c mice with regular or high fat diets and treated the animals with
PFOS for 2 weeks. PFOS induced lipid accumulation in hepatocytes, which was more pronounced in
the high fat diet group than in groups on standard chow. Independent of the diet, all PFOS-treated
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mice showed reduced levels of serum lipid and lipoprotein. The authors concluded that PFOS may
inhibit the secretion and normal function of low-density lipoproteins.
Further mechanistic studies focused on the effect of PFASs on the production of VLDL and HDL.
Bijland et al. (2011) used APOE*3-Leiden.CETP (E3L.CETP) mice, which harbour attenuated clearance
of apoB-containing lipoproteins and exhibit a human-like lipoprotein metabolism on a Western-type
diet. Mice were kept on a Western-type diet with PFOS for 4–6 weeks. PFOS increased weight and
triglyceride content of the liver and markedly reduced plasma triglycerides, very low-density lipoprotein
(VLDL), non-HDL-cholesterol, HDL-cholesterol and HDL production. The reduction in VLDL was mainly
due to enhanced lipoprotein lipase-mediated VLDL-triglyceride clearance and decreased production of
VLDL-triglyceride and VLDL-apolipoprotein B. The decreased VLDL-TG production was mostly due to
lowered secretion of VLDL from the liver, resulting in intrahepatic lipid accumulation. Also the hepatic
concentrations of cholesteryl esters and free cholesterol were elevated. This was associated with
decreased faecal bile acid excretion and decreased hepatic expression of Cyp7a1.
As outlined above, it has been shown that the serum cholesterol lowering effect of PFOS or PFOA
in rodents may be due to an impaired export of cholesterol by hepatocytes. Zhang et al. (2016a)
observed that one PFOS molecule forms stable ion-pairs with two molecules of choline. Subsequently
they tested the hypothesis that this mechanism results in hepatic steatosis. Groups of mice received
PFOS in combination with either a standard diet a marginal methionine/choline-deﬁcient (mMCD) diet
or a diet, supplemented with choline. mMCD aggravated PFOS effects like hepatic steatosis and
triglyceride accumulation, signs of oxidative stress, and increases in serum levels of ALT, bile acids and
bilirubin. Interestingly, in these animals serum PFOS concentrations became higher while liver PFOS
concentrations were lower. In contrast to mMCD, supplemental dietary choline prevented PFOS-
induced effects, such as elevations in serum ALT, intrahepatic accumulation of triglyceride and
oxidative damage. The authors concluded that PFOS may cause hepatic steatosis by reducing the
choline required for hepatic VLDL production and export by forming an ion pair with choline.
As outlined above, Nakamura et al. (2009), treated male wild-type, PPARa-/- and hPPARa mice with
0.1 or 0.3 mg/kg bw per day of the ammonium salt of PFOA for 2 weeks. This relatively low dose of
PFOA elevated the intrahepatic concentration of total cholesterol in WT animals, but left the plasma
concentrations unaffected. In hPPARa mice, the basal level of total cholesterol in plasma was
signiﬁcantly higher than in the WT controls but was not increased further by PFOA. Furthermore, PFOA
elevated transcript and/or protein levels of PPARa target genes only in the liver of wild-type animals, but
not in hPPARa mice. The authors concluded that hPPARa may be less responsive to PFOA than that of
wild-type mice when a relatively low dose is applied. The same group investigated the effect of higher
doses of PFOA (1 or 5 mg/kg bw per day) in WT and hPPAR mice after a treatment period of 6 weeks
(Nakagawa et al., 2012). Again, a higher basal total cholesterol level in plasma was observed in the
humanised mice when compared to WT controls. When applying 5 mg PFOA/kg bw per day, the
intrahepatic cholesterol concentrations were not affected while total cholesterol in plasma was lowered
in both, hPPARa and WT animals. This indicates that in hPPARa mice, PFOA-induced effects on the
cholesterol metabolism are divergent to WT animals at the low doses only, when insufﬁcient
transactivation of hPPARa may occur. There is one mechanistic study in humans. Fletcher et al. (2013)
investigated the expression of genes involved in cholesterol metabolism in 290 individuals exposed to
PFOS and PFOA via drinking water. In men there were reduced mRNA levels of genes involved in
cholesterol transport (Niemann Pick type C1, NPC1; ATP-binding cassette subfamily G, ABCG; PPARa) at
elevated PFOA levels. In women, there were elevated levels of mRNA of a gene being important for
cholesterol mobilisation (neutral cholesterol ester hydrolase 1, NCEH1). There was also a positive
association between PFOS levels and expression of genes involved in both cholesterol mobilisation and
transport in women (NCEH1, PPARa), but this was not observed in men. The authors concluded that
these alterations may partly explain the development of hypercholesterolaemia by PFOS and PFOA.
To conclude, there is no clear mechanistic explanation for the observation that PFOS reduces the
blood cholesterol level in rodents and exert the opposite effect in humans. The same holds for PFOA,
although involvement of PPARa in mediating these divergent responses cannot be excluded.
3.3.5.3. Immunotoxicity
Both in rodent and in human studies, effects on the immune system have been noted (see Sections
3.3.3.5 and 3.3.4.5). An important outcome of both exposure to PFOS and PFOA was the depression
of antibody responses to vaccination. Different components of the immune system come into action
while producing speciﬁc antibodies, such as macrophages/antigen presentation cells, and lymphoid
cells. In vitro studies, using these cells, or cell lines representing these cells, have been carried out.
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Brieger et al. (2011) isolated peripheral blood mononuclear cells (PBMCs) from heparinised whole
blood collected from eleven human donors. They incubated the cells with 15.6, 31.3, 62.5, 125, 250 or
500 lg/mL PFOA (ammonium salt) for 24, 48 and 72 h to assess cytotoxicity, or with 0, 1, 10 or
100 lg/mL PFOA and concanavalin A to investigate the effect on cell proliferation. A decrease in
viability of PBMCs was observed following exposure to 250 and 500 lg/mL. In the absence or
presence of concanavalin A, PFOA induced no signiﬁcant differences in numbers of proliferating T
lymphocytes. There was a linear relationship between LPS-stimulated TNF-a and IL-6 release and the
donor’s past PFOA exposure.
Corsini et al. (2011) investigated the in vitro immunotoxic potential of PFOA (ammonium salt) and
PFOS (potassium salt) on human peripheral blood leucocytes (PBLs) from whole blood, and the
macrophage like cell line THP-1. Cells were incubated with 0, 0.1, 1 or 10 lg/mL PFOA alone or in the
presence of LPS or PHA. PFOA caused no cytotoxic effects on whole blood cells or THP-1 cells at up to
100 lg/mL for 48 h. PFOA induced a dose-related decrease in LPS-induced TNF-a release in PBLs
whereas IL-6 and IL-8 were unaffected. Following PHA stimulation of PBLs, PFOA (10 lg/mL)
decreased the release of T-cell derived cytokines IL-4 and IL-10, whereas IFN-c was unaffected. In
THP-1 cells, PFOA decreased LPS-induced TNF-a release as well as TNF-a mRNA levels (≥ 10 lg/mL),
and caused a signiﬁcant reduction in IL-8 release (≥ 100 lg/mL). Promoter activity for NF-jB was also
shown to be reduced in a dose-dependent manner, conﬁrming NF-jB as a cellular target for PFOA. In
studies using THP-1 cells, PFOA-induced inhibition of cytokine release at 100 lg/mL was reversed in
cells in which PPARa silencing was applied. PFOA inhibited LPS-induced phosphorylation of p65,
necessary for NF-jB transcription. PFOA also activated PPARa in THP-1 cells but did not prevent I-jB
degradation.
Singh et al. (2012) incubated HMC-1 cells (mast cell line) with PFOA to assess histamine release
(25–150 lM PFOA for 24 h) and intracellular calcium (200 lM PFOA for 10 min). mRNA analysis,
nuclear protein extraction and western blotting (1 h treatment at 50–200 lM) were also undertaken.
PFOA induced a time- and concentration-dependent release of histamine from HMC-1 cells and
increased intracellular levels of calcium. The gene expression of TNF-a, IL-1b, IL-6, IL-8 and b-actin
were all increased dose dependently, peaking at 12 h after exposure. Phosphorylation of p38 was also
increased in HMC-1 cells following exposure to ≥ 50 lM PFOA as well as the translocation of p65
NF-jB to the nucleus and degradation of IjBa. In addition a dose-dependent activation of caspase-1
and COX-2 were reported.
These in vitro studies support immunotoxicity by PFOA as evidenced by animal and by human
studies, showing effects on cells of the immune system, shedding some light on possible molecular
interactions such as NF-jB as a target for PFOA.
In the study by Brieger et al. (2011), PBLs from eleven human donors were also incubated with
3.9, 7.8, 15.6, 31.3, 62.5 or 125 lg/mL PFOS (potassium salt) for 24, 48 and 72 h to assess
cytotoxicity, or with 0, 1, 10 or 100 lg/mL PFOS and ConcanavalinA to investigate cell proliferation. No
signiﬁcant reduction in cell viability was observed although limited solubility prevented the higher
concentrations being used. No signiﬁcant effect was noted on cell proliferation. PBMCs were also
treated with LPS or PHA in the presence of 0, 0.1, 1, 10 or 100 lg/mL PFOS to assess cytokine
release. Basal TNF-a and IL-6 levels were increased slightly following PFOS exposure for 48 h. In the
presence of LPS, TNF-a release was reduced by 100 lg/mL PFOS. In contrast, IL-6 release was slightly
enhanced, although not signiﬁcantly. Blood-donor plasma PFOS levels were associated with
LPS-induced IL-6 release, but not of TNF-a.
Midgett et al. (2015) noted suppressed IL-2 production by Jurkat cells after exposure to PFOS
in vitro. Human PBLs from whole blood and THP-1 cells were treated with 0, 0.1, 1 or 10 lg/mL PFOS
(potassium salt) in the presence of LPS or PHA. PFOS induced a dose-related decrease in TNF-a
and IL-6 release in PBLs, whereas IL-8 was unaffected. Regarding PHA stimulation of PBLs, PFOS
(0.1 lg/mL) decreased the release of the T-cell derived cytokines, IL-4, IL-10 and IFN-c. PFOS caused
no cytotoxic effects on whole blood cells or THP-1 cells at up to 100 lg/mL PFOS for 48 h, but
prevented LPS-induced IjB degradation. IjB degradation is required for NF-jB translocation to nuclei.
In studies using THP-1 cells, the effect of PFOS on LPS-induced cytokine release was unaffected by
PPARa silencing (Corsini et al., 2011). In a later study by the same authors, human PBLs and THP-1
cells were also incubated with PFOS (0.1–10 lg/mL) in the presence of LPS or PHA (PBLs) in order to
examine the effects on the inﬂammatory cytokine response (Corsini et al., 2012). PFOS inhibited the
release of TNF-a, IL-6, IL-10 and IFN-c from PBLs and THP-1 cells. PFOS also prevented LPS induced
I-jB degradation and inhibited NF-jB activation in THP-1 cells by inhibiting LPS-induced
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phosphorylation of P65, necessary for NF-jB transcription. PFOS did not activate PPARa in THP-1 cells
(Corsini et al., 2012).
Zhang et al. investigated PFOS-induced apoptosis in murine N9 immune microglial cells (Zhang
et al., 2011) and immunocytes (Zhang et al., 2013d). In N9 cells, typical apoptotic cell morphology
was observed at 50 lM (condensed chromatin and cellular swelling), 100 lM (chromatin margination
and loss of cell volume) and 200 lM (punctate distorted cell membrane). Apoptotic peaks and the
percentage of apoptotic cells were also increased in a dose-dependent manner (2.24, 3.97, 8.32,
20.81, 33.26 and 58.72% for 0, 5, 10, 50, 100 and 200 lM, respectively). PFOS (50 lM) also caused
disruption of mitochondrial membrane potential after 24 h exposure, and 5 lM PFOS increased
expression of p53, Bax, caspase-3 and caspase-6 after 24 and 48 h). Quantities of 50 and 100 lM
PFOS downregulated expression of Bcl-2 after treatment for 24 and 48 h.
Lv et al. (2015) studied effects of in vivo exposure of mice to 2.5–10 mg/kg per day for 31 days
followed by a one week recovery period. Global gene expression proﬁling of the spleens and QRT-PCR
analysis affected genes involved in cell cycle regulation and NRF2 oxidative stress response, and
upregulated those in T-cell, calcium signalling and p38/MAPK signalling pathways.
Based on these results, it may be suggested that PFOS could disturb homoeostasis in lymphoid and
other immune related cells, partly by interfering with lipid metabolism and by impacting NF-jB
transcription and affecting gene expression of apoptotic regulators, all resulting in apoptosis and
eventually depressed immune functionality and activation of T-cell receptor signalling and calcium ion
inﬂux.
Pennings et al. (2016) studied associations between PFASs exposure measured in maternal blood
and gene expression in cord blood in a human cohort. Results from this cohort, was already described
in 3.3.4.5.3. (Granum et al., 2013) and indicated an exposure related decrement in antibody responses
to vaccination. Pennings et al. (2016) identiﬁed 52 genes out of 19,595 tested in this cohort, that were
associated with exposure as well as with rubella titres and/or common cold episodes in the offspring
up to 3 years of age. The gene set contains several immunomodulatory (and immune associated
genes) and suggests PPARdelta and NF-jB to be involved in the modes of action. Whereas PFOA and
PFOS may share common modes of action, there are also differences, as PFOA was not able to
suppress IL-2 production by Jurkat cells in vitro, whereas PFOS could (Midgett et al., 2015).
In concert, the in vitro information supports the in vivo ﬁndings that both PFOS and PFOA inﬂuence
the immune system. This could be brought about by impacting NF-jB transcription and affecting gene
expression of apoptotic regulators, resulting in apoptosis and eventually depressed immune
functionality and activation of T-cell receptor signalling. PFASs may modulate gene regulation, perhaps
through certain PPARs, which may be involved in the regulation of immune responses. Yet, there may
also be differences in the effects caused by PFOA and PFOS, respectively, as cytokine proﬁles in
lymphoid cells were reported to be differentially affected in one study.
This information on the mode of action of PFOA and PFOS corroborate the ﬁndings in humans that
PFOA and PFOS exposure may be adversely associated with a reduced antibody response following
vaccination as indicated in Section 3.3.4.5.3 and possibly to an increased propensity for infection.
From this information, it is however not possible to conclude which PFASs may be the more potent to
cause such effects.
3.3.5.4. Birth weight
Reduction of birth weight represents an effect, which was associated with human exposure to PFOS
and PFOA (see Section 3.3.4.2.1). Whether there is a correlate in toxicological studies in rodents is
debated. Koustas et al. (2014), for example, selected PFOA effects on fetal growth for their prototypic
application and testing of the navigation guide systematic review method on animal data. Using this
approach, their major conclusion was that the review provided sufﬁcient and clear evidence for PFOA
effects on fetal mammalian as well as on non-mammalian growth and thereby supports effects on
reduced human birth weight in epidemiological studies (see Section 3.3.4.2.1). The inﬂuence of PFOS
and PFOA on fetal growth was consistently seen in animal studies, the effect became usually apparent
at higher doses of these compounds than doses at which the most sensitive endpoint was identiﬁed in
the respective study (see Section 3.3.3.3). Since the effective animal serum concentrations were
estimated to be several orders of magnitude higher than those in humans, Negri et al. (2017)
concluded that the available toxicological evidence, at least in a quantitative perspective, does not
support the epidemiological associations.
Mechanistically, the effects of PFOS and PFOA on birth weight in human and animal studies could
be due to reduced growth, as well as to a disturbed energy balance. Hormones of the growth
PFOS and PFOA in food
www.efsa.europa.eu/efsajournal 182 EFSA Journal 2018;16(12):5194
hormone/IGF-1 axis are intimately linked to growth control. In 6- to 9-year-old children, Lopez-
Espinosa et al. (2016) showed an inverse relation between serum levels of PFOS and IGF-1,
suggesting an impact of PFOS on the level of this growth mediating hormone. This association was
accompanied by reduced levels of sex hormones in the exposed population. A ﬁrst hint pointing to the
involvement of a disturbance in the growth hormone/IGF-1 axis after exposure to PFOS and PFOA
comes from observations in salmon species (Spachmo and Arukwe, 2012), where a downregulation of
the expression of members of these axes in response to PFOS and PFOA was observed.
Two studies showed, that exposure to peroxisome proliferators, amongst them PFOA (0.02% added
to chow meaning 200 mg/kg feed) for 7 days, leads to a considerable reduction of body weight in
mice (Xie et al., 2002, 2003). In the same study it was also shown that this massive weight loss is
paralleled by a considerable loss of white adipose tissue in mice. This could not be explained by a
reduced food intake observed the 2nd day. Shabalina et al. (2015) followed up on this observation in a
similar experiment with 0.02% compound added to chow, an observation period of 10 days using wild-
type and UCP-1 knock-out mice. In this follow-up study, PFOA and PFOS induced reduction in food
intake. This effect was more pronounced in response to PFOA than to PFOS and by far more
pronounced in WT animals than in UCP-1 knock-out mice. The overall response to PFOA and PFOS
correlated with an upregulated expression of UCP-1 in brown adipose tissue of animals (Shabalina
et al., 2015). Usually activation of UCP-1 and its binding to the inner mitochondrial membrane in
brown adipose tissue triggers the rapid generation of large amounts of heat in the brown adipose
tissue (Symonds et al., 2015). The effect on body weight reduction mediated through UCP-1
upregulation in response to PFOS and PFOA in the comparative study with UCP-1 wild-type and
knockout mice was only to a minor degree due to increased thermogenesis and not due to food
aversion, as tested in a food preference test. It was therefore assumed that it rather represents a
direct effect of UCP-1 expression on food uptake (Shabalina et al., 2015). PFOS- and PFOA-induced
upregulation of UCP-1 in the light of the developmental biology of brown adipose tissue with a ﬁrst
appearance around mid-gestation, an increase until birth and a gradual loss through childhood,
adolescence and adulthood (Symonds et al., 2015), may contribute to the observed reduction of birth
weight in epidemiological studies (see Section 3.3.4.2.1).
3.3.5.5. Carcinogenicity
3.3.5.5.1. Liver
In a carcinogenicity study in rats, performed before 2008, PFOS was found to be tumorigenic in the
liver (EFSA, 2008). This was conﬁrmed by the re-evaluation of the histological material (Butenhoff
et al., 2012b). Due to the absence of genotoxicity of PFOS in a series of assays, it was assumed that
the tumourigenic activity is based largely on a tumour-promoting effect of this compound. This
assumption was substantiated in a trout two-stage chemical hepatocarcinogenesis model (Benninghoff
et al., 2012).
There are three carcinogenicity studies on PFOA, which were conducted before 2008. In two of
these studies, PFOA induced the formation of liver tumours. The third study applied a two stage model
of hepatocarcinogenesis and found that PFOA acts as a liver tumour promoter in rats.
Many compounds with a documented PPARa-agonistic mode of action are liver tumour promoters in
long-term rodent bioassays. It was deduced that the PPARa-mediated induction of liver growth and/or
alterations in lipid-metabolism may be causally involved in rodent hepatocarcinogenesis. This was
conﬁrmed when applying PPARa-/- mice, which often were found to be insensitive towards the
tumour-promoting effects of peroxisome proliferators. However, there are exceptions. Liver injury and
hepatocarcinogenesis were observed in knockout animals, when exposed in utero to PFOA (Filgo et al.,
2015) or postnatally to di-ethylhexylphthalate in a long-term study (Ito et al., 2007). It was
hypothesised that an increase in oxidative stress and an intrahepatic deregulation of synthesis and
secretion of bile acids cause a higher susceptibility of the knock-out mice (Ito et al., 2007; Li et al.
2017).
PPARa-humanised transgenic mice were used to study whether hPPARa mediates not only
metabolic alterations but also liver growth, an effect considered causally involved in
hepatocarcinogenesis. When treated with the peroxisome proliferator fenoﬁbrate, mice expressing
hPPARa, showed reduced serum triglycerides and induction of PPARa target genes in the liver and
various other organs to an extent being close to that of WT animals. However, no hepatomegaly or
hepatocyte proliferation was evident in these mice. This may indicate that PPARa regulates enzymes of
lipid metabolism and liver growth by different modes of action (Yang et al., 2008). The peroxisome
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proliferator WY-14.643 induced peroxisomal b-oxidation in humanised mice, but did not promote liver
tumour formation (Morimura et al., 2006). This indicates that transactivation of hPPARa by some
peroxisome proliferators may alter lipid metabolism but fails to induce liver growth and liver tumour
formation in rodents (Corton et al., 2014). Observations in patients, subjected to long-term ﬁbrate
therapy, support the concept that hPPARa mediates rather metabolic effects than growth in human
liver as well (see Section 3.3.5.1).
3.3.5.5.2. Testis
Before 2008, two independent carcinogenicity studies have brought evidence that PFOA induces
Leydig cell adenomas in rats (EFSA, 2008). One of the studies was subjected to re-evaluation
conﬁrming the enhanced occurrence of this tumour entity (Butenhoff et al., 2012b). While Leydig cell
tumours occur frequently in rats and mice, they are diagnosed rarely in humans. This is largely due to
quantitative and qualitative species differences in Leydig cell response to hormonal stimuli (Rasoulpour
et al., 2014). In rodents, there are several modes of actions for the induction of this tumour by
chemical compounds. In most cases, the primary causes are reduced bioavailability or impaired activity
of testosterone leading to sustained increases in circulating luteotrophic hormone, which stimulates
growth of Leydig cells. This growth stimulation leads to hypertrophy/hyperplasia and ultimately to
tumour formation in the testis.
Previous studies reported on lowered serum testosterone and increased oestradiol levels in male
PFOA-treated rats (Cook et al., 1992; Biegel et al., 1995; Liu et al., 1996). This hormonal dysbalance
may be due to induction of the cytochrome P450 isoenzymes, involved in steroid hormone
biosynthesis, and of aromatase, the key enzyme of oestrogen biosynthesis (Kraugerud et al., 2011;
Gorrochategui et al., 2014; Kang et al., 2016). There is some evidence that also PPARa may be
involved in the inhibition of testosterone biosynthesis (Gazouli et al., 2002; Li et al., 2011). Reduced
serum testosterone levels, lower reproductive organ weights, and elevated sperm abnormalities were
found in PFOA-treated male WT and humanised PPARa mice, but not in knock-out animals.
Furthermore, PFOA-treated WT and humanised PPARa animals showed a lowered conversion of
cholesterol to pregnenolone and androstanedione in the testis.
3.3.5.5.3. Pancreas
Two studies on the carcinogenicity of PFOA in the pancreas of Sprague–Dawley rats brought
contradictory results (Sibinski, 1987; Biegel et al., 2001; Butenhoff et al., 2012b). While one study
reported an enhanced occurrence of acinar cell adenoma, the other one could not ﬁnd any tumorigenic
alterations despite of the same PFOA dose and rather similar experimental conditions. Histological
material of the two studies was re-evaluated (Caverly-Rae et al., 2014). The tumour occurrence in one
of the studies was not conﬁrmed. However, evidence for pancreatic hyperplasia was found in both
studies indicating that the growth of this organ may be induced by PFOA.
Pancreatic hyperplasia is considered to proceed the development of adenoma and carcinoma.
However, the likelihood for progression has not been studied in detail so far. The proposed MoA for the
induction of pancreatic acinar cell proliferative lesions by PFOA and further PPARa agonists is based
essentially on investigations of WY14.643 (Obourn et al., 1997). In WY-14.643-treated rats, hepatic
PPARa activation changed the bile acid composition and decreased the total output of bile acids, which
caused enhanced secretion of cholecystokinin (CCK) from the intestinal mucosa. In the rat, CCK binds
to acinar CKK1 receptor and acts as a growth factor for this cell type. In humans, however, exocrine
pancreatic secretion is regulated by a neuronal, cholinergic pathway. In addition, human pancreatic
cells do not express functional CCK receptors (Adler et al., 1991; Ji et al., 2001). Thus, this MoA of
pancreatic tumour formation appears to be irrelevant for humans.
3.4. Critical effects, dose–response assessment and derivation of a
health-based guidance value
As described below, associations between serum levels of PFOS/PFOA and several health outcomes
were considered to be causal and adverse. The majority of these studies were not available for the
previous opinion in 2008. In addition, the toxicokinetics of PFOS/PFOA are very different in animals
and humans. For the present opinion, the CONTAM Panel decided to use human observations when
assessing critical effects and for derivation of an HBGV.
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3.4.1. Critical effects
In the Sections on Observations in humans (Section 3.3.4), the CONTAM Panel assessed a large
number of epidemiological studies on a number of different health outcomes. Exposure was based on
serum/plasma levels of PFOS and/or PFOA, in most cases measured, but in a few cases also estimated
from historical serum levels. The following outcomes were considered potential critical effects, i.e.
effects for which the evidence of causal associations with exposure to PFOS or PFOA were considered
sufﬁcient:
• increased serum cholesterol (indicating an increased risk of future cardiovascular disease);
• increased prevalence of abnormal serum levels of ALT (indicating an effect on hepatocytes);
• decreased antibody response after vaccination (indicating impaired immune function);
• decreased birth weight ((which may increase risk of low birth weight below 2,500 g) and risk
of future disease).
The rationale for selecting these potential critical effects is presented below, as well as the issue of
adversity. For other outcomes described in Section 3.3.4 the evidence for causal associations with
PFOS/PFOA were considered insufﬁcient.
3.4.1.1. Serum cholesterol
As described in Section 3.3.4.7.1 and Table 23, 26 studies from 16 different cohorts published on
associations between PFOS and/or PFOA and total cholesterol in serum, show consistent positive
associations between these PFASs and both serum total cholesterol and for LDL cholesterol.
As elaborated in the same section, it has been discussed whether these associations are not caused
by exposure to PFOS or PFOA, but instead are the results of reverse causation or confounding. The
CONTAM Panel concluded that reverse causation is not likely, and that confounding has been examined
by adjustment and by special sensitivity analyses.
Many of the studies referred to in Section 3.3.4.7.1 found associations with serum cholesterol both
for PFOS and PFOA, and these two compounds were often correlated. In two of the studies used for
dose–response assessment this was the case, being the studies by Nelson et al. (2010) and Eriksen
et al. (2013) with Spearman correlation coefﬁcients of 0.65 (Nelson et al., 2010) and 0.70 (Eriksen
et al., 2013). However, in the largest study based on the C8 cohort exposed to PFOA-contaminated
drinking water (Steenland et al., 2009) the correlation was modest (Spearman 0.32). With a data set
of 46,000 adults, separate effects of the two compounds can more easily be disentangled. If PFOS and
PFOA were both included in the same model, associations were still statistically signiﬁcant, but
attenuated by 20–30%.
The CONTAM Panel also noted that animal studies have shown decreased (not increased) serum
cholesterol levels after exposure to PFOS and PFOA. However, the exposure levels in these animal
studies were more than 1,000-fold higher (4–20 mg/kg bw per day; serum levels about 40 lg/mL)
than in the human studies, and the toxicokinetics in animals and humans are different. Moreover, the
mechanisms in the animal studies include activation of PPARa (see Section 3.3.5.1). As shown by
studies in transgenic mice, human and rodent PPARa appear to differ in function which may affect the
lipid/cholesterol metabolism in a species-speciﬁc way. Therefore, the CONTAM Panel considers that the
ﬁndings for cholesterol in animals cannot be used as evidence against the causal association between
PFOS/PFOA and cholesterol in humans.
Typical mean or median serum cholesterol levels in the US or European studies of associations with
PFOS/PFOA in the 1990s and 2000s have been 5–6 mmol/L (195–230 mg/dL) with an SD of about
1 mmol/L (about 40 mg/dL). The adversity of increased serum cholesterol is well established also within
the reference range where it increases the risk of cardiovascular mortality, especially ischaemic heart
disease, and to some extent ischaemic stroke (Lewington et al., 2007; Piepoli et al., 2016) in
prospective observational studies. Also, treatment with cholesterol-lowering drugs decreases the
cardiovascular risk (Mihaylova et al., 2012; Piepoli et al., 2016) at these moderate serum cholesterol
levels. This supports a conclusion that a moderate increase of serum cholesterol caused by PFOS and
PFOA is an adverse effect. The interpretation by the CONTAM Panel of the studies by Lewington et al.
(2007), Piepoli et al. (2016) and Mihaylova et al. (2012), is that a 5% increase in total cholesterol will
increase the risk of cardiovascular disease by at least 5%, which is a clinically relevant risk. This was the
reason for selecting serum cholesterol as a continuous variable, rather than relying only on the
prevalence of abnormally high cholesterol levels. Data provided (Fletcher, 2017a) showed that serum
cholesterol levels were approximately normally distributed and an increase of serum cholesterol levels
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by 5% would results in an increased prevalence of cholesterol levels above the reference range
(240 mg/dL) by more than 5%.
The adversity of increased serum cholesterol is based on its well-established causal association with
risk of cardiovascular disease, but there are only few large studies on associations between exposure
to PFOS/PFOA and cardiovascular disease.
For PFOS, only one study was identiﬁed: Lin et al. (2013b, 2016) found a slight positive but
statistically signiﬁcant trend of increase in carotid artery intima media thickness (CIMT) with increasing
serum PFOS in 644 young individuals in Taiwan, after adjustment for potential confounders (5%
increase in Q3 and 4% in Q4). CIMT is, however, not a clinically relevant outcome in young people.
For PFOA, a cross-sectional study by Shankar et al. (2012) found signiﬁcant positive associations
between serum PFOA and self-reported cardiovascular disease (coronary heart disease or stroke) with
an odds ratio of about 2 in 1,200 NHANES participants. Also, the risk of peripheral artery disease (PAD,
measured ankle-brachial index < 0.9) was signiﬁcantly increased. A study of the large C8 cohort
showed a slight, and mostly statistically signiﬁcant association between serum PFOA and the incidence
of stroke (Simpson et al., 2013). Another study of the same cohort showed, however, no increase of
coronary heart disease, and the point estimates of relative risk in the upper range of PFOA levels were
around or below 1.0 (Winquist and Steenland, 2014b). A longitudinal study in an occupational cohort
showed no statistically increased risk of ischaemic heart disease mortality. The point estimate for the
hazard ratio was 1.1 in the top quartile (5-year lag) using the lowest quartile as reference (Sakr et al.,
2009). No association between PFOA and CIMT was found in the study of young individuals from
Taiwan (Lin et al., 2013b, 2016).
Thus, there are no relevant studies of associations between PFOS and cardiovascular disease.
For PFOA, the results across studies are not consistent and they were not powered well enough to
show a small increase in risk (RR 1.05–1.1). Therefore, the epidemiological studies of PFOS/PFOA vs
cardiovascular disease are not helpful in the assessment of the adversity of increased serum
cholesterol due to exposure to these compounds.
3.4.1.2. High serum ALT
As described in Section 3.3.4.7.2 and Table 24, we identiﬁed 10 studies from eight cohorts
published on associations between PFOS and/or PFOA and serum ALT. Some were early occupational
studies with very high exposure to PFOA (Sakr et al., 2007a,b). A large cross-sectional study of the C8
cohort (Gallo et al., 2012) showed an association between serum levels of PFOS/PFOA and ALT, and
for PFOA this was supported in a longitudinal study using modelled exposure based on PFOA intake
from drinking water (Darrow et al., 2016). Two NHANES studies (Lin et al., 2010; Gleason et al., 2015)
also found associations between PFOA and ALT, while results for serum PFOS were inconsistent.
Thus, there is a consistent positive association between PFOA and ALT at high occupational
exposure, in the C8 cohort (cross-sectionally and longitudinally) and in two NHANES surveys. For PFOS
an association was only shown in one large cross-sectional study of the C8 cohort.
For other liver enzymes than ALT (e.g. GGT), or liver function tests such as bilirubin, the
information is limited or there is no consistent association with PFOA.
Common causes of elevated liver enzymes such as ALT are obesity, insulin resistance, high alcohol
consumption, various medications, hepatitis, and various systemic diseases. BMI and alcohol were
adjusted for in the studies summarised above. It seems likely that the association between PFOA and
liver enzymes is causal. However, the CONTAM Panel considers a small increase in serum ALT within
the reference range not to be an adverse effect. One reason for this is that no association between
serum PFOA and liver disease has been shown in a well-powered study with diagnoses validated in
medical records (Darrow et al., 2016). Second, the most common liver disease associated with an
increase of serum ALT is non-alcoholic fatty liver disease (NAFLD). But the main pathophysiologic
factor for NAFLD is the metabolic syndrome, characterised by central obesity, insulin resistance, and
often also hypertension, increased TG, and decreased HDL and no association between serum PFOA
and the metabolic syndrome has been shown. Third, no consistent associations have been shown with
the more liver-speciﬁc enzyme GGT or the liver function test bilirubin.
In the highly exposed C8 cohort, an association was, however, also found between serum PFOA
and serum ALT above the reference range. The CONTAM Panel considers this to be an adverse effect
of PFOA in spite of the argument raised above against adversity of a small increase of serum ALT
within the reference range. The reason for this is that an ALT level above the reference range is
clinically more relevant and less sensitive to confounding than an increase within the reference range.
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3.4.1.3. Antibody response
As described in Section 3.3.4.5.3, one study among children (Grandjean et al., 2012) and three
studies among adults (Looker et al., 2014; Kielsen et al., 2016; Stein et al., 2016b) have examined the
association between prebooster concentrations of PFOS and PFOA and serum antibody concentrations
following booster vaccination to different vaccines. For both PFOS and PFOA, relatively strong and
consistent inverse associations were observed for prenatal (~gestation week 32) and postnatal
(offspring age 5 years) exposures with offspring post-booster antibody concentrations to diphtheria at
5 and 7 years. For tetanus, similar but less pronounced associations were observed. A similar inverse
association between serum PFOS concentrations (non-signiﬁcant for PFOA) and antibody response to
diphtheria following vaccination was also observed in a small Danish study of 12 healthy adults
(Kielsen et al., 2016). Similar but not statistically signiﬁcant trends were reported in adults using three
different inﬂuenza vaccines (Looker et al., 2014, n = 411) while no such trends were observed among
78 adults where another inﬂuenza vaccine was used (Stein et al., 2016b). In these two studies among
adults, the response to the vaccination was modest to low with around 60–80% reaching protective
levels (deﬁned as fourfold increase in antibody titre) in the study by Looker et al. (2014), while the
corresponding number in the study by Stein et al. (2016b) was as low as 9%. Limited response to
the vaccination will inevitably lead to less precision in the outcome measure making it less likely that
the study is able to detect an association in cases where a true association exists.
Further support for the ﬁndings observed in the studies by Grandjean et al. (2012) and Kielsen
et al. (2016) comes from observational studies where inverse associations between maternal serum
concentration of PFOS and PFOA and serum antibody concentrations to rubella were observed when
the offspring were 3 years old (Granum et al., 2013). Signiﬁcant inverse associations with serum
antibody concentrations to rubella and mumps were also observed by Stein et al. (2016a) in 12- to
19-year-old US adolescents. Information on the timing of the vaccination of these children is lacking,
but as it is recommended in the US that children are vaccinated prior to school age, it can be assumed
that they were vaccinated before reaching adolescence. The effect noted may therefore represent an
effect caused by exposure during childhood rather than during adolescence.
In addition to effects on vaccination responses, associations between maternal concentrations of
PFOS and PFOA and offspring rate of infections have been reported in some (Granum et al., 2013;
Dalsager et al., 2016) but not all studies (Fei et al., 2010a; Okada et al., 2012). Of these studies, the
study by Dalsager et al. (2016) was considered most robust as information on infections was collected
weekly during follow-up using text message instead of relying on retrospective parental report (Okada
et al., 2012; Granum et al., 2013) or highly selected outcomes such as hospital admission to any
infection (Fei et al., 2010a).
As with all observational studies statistical signiﬁcance is by no means evidence that the observed
association is causal. However, the study by Grandjean et al. (2012) and later studies have a strong
experimental component where antibody production is initiated through vaccination and the increase in
antibody concentrations is followed prospectively in relation to baseline concentrations of PFOS and
PFOA. A potential confounder would, therefore, have to be (1) a determinant of antibody production
initiated and (2) a determinant of exposure.
As discussed in Section 3.3.4.5.3, the Faroe Island children studied by Grandjean et al. (2012) were
exposed to PCBs, which were also associated with reduced antibody response to the same vaccines.
The correlations between PCBs and PFOS/PFOA were weak, and adjustment for PCB exposure did not
attenuate associations between PFOS/PFOA and antibody response. Therefore, the CONTAM
Panel concluded that the association between PFOS and PFOA with serum antibody concentrations is
more likely to be causal than confounded. It is, however, possible that exposure to PCBs could affect
the exposure-response relation between PFOS/PFOA and antibody response.
These results from human observational studies are partly supported by experimental animal
studies. In these studies animals were exposed to either compound, and subsequently immunised to
sheep red blood cells or to KLH, models which mimic vaccination to a T-cell-dependent antigen.
Antibody responses, as measured in the serum of these animals, were reduced (see Section 3.3.3.5).
Although the animals were exposed to doses several orders of magnitude higher compared to those
observed in humans, this information is in line with the ﬁndings in humans.
The adversity of reduced antibody response is well established in the sense that a suboptimal
response to a vaccine may result in a suboptimal protection. For many vaccinations, thresholds of
antibody levels that are protective are not well known, and for practical reasons only established by
convention. Vaccination schemes are carried out so, that there is a very good protection, whereas a
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minor decrement in antibody levels may not imply a clinical consequence. However, certain individuals
that are at the lower end of the magnitude of the vaccination response may, because of exposure to
PFASs, end up having insufﬁcient titres.
In addition to indicating an inﬂuence on the protection gained after vaccination, an effect on the
vaccination response may also signify a more general effect on the functionality of the immune
system. In experimental animals, effects on antibody responses to T-cell-dependent antigens correlate
well with effects on host resistance to infections (Luster et al., 1993). For PFASs, this is in line with the
ﬁndings of effects on the incidence of infections that were observed in children.
Since the date for inclusion of the studies for this opinion, several studies on PFOS (and PFOA) have
been published on infections and vaccination related outcomes (Goudarzi et al., 2017; Grandjean et al.,
2017; Impinen et al., 2018) and the results from these studies have been in general agreement with the
conclusions drawn in this opinion. In particular, the results from the Hokkaido Study on Environment and
Children’s Health (n = 1,558) showed a positive association between maternal PFOS concentration in
pregnancy (median 4.9 ng/mL) with increased odds of infections in the offspring up to 4 years of age.
In summary, although few studies have been conducted to date, there is strong evidence to
suggest that serum concentrations of PFOS and PFOA are inversely associated with antibody response
in children. The information on possible effects on vaccination titres in adolescents and adults is
inconsistent. This may be a consequence to some extent the type of infection that the vaccine targets.
More importantly, it is generally accepted that especially the developing immune system is vulnerable
to effects of exposure to immunomodulation agents, and this is represented by the strong evidence
available in children and the inconsistent information in adolescents and adults. Effects, if any, noted in
adolescents and adults, are modest and the clinical relevance can be questioned.
Although inverse associations for PFOS and PFOA and serum antibody response have been reported
these associations have been slightly more pronounced for PFOS compared to PFOA (Kielsen et al.,
2016; Stein et al., 2016b). Furthermore, in the Grandjean et al. (2012) study, the combined exposure
to PFOS, PFHxS and PFOA was more strongly associated with serum antibody concentrations
compared to the individual associations for each of these compounds. Of these three compounds,
PFOS accounted for 78% of the total exposure and the correlation between PFOS and PFOA in the 5-
year-old children was around 0.50. A correlation of similar strength has frequently been observed
between PFOS and PFOA meaning that statistically independent associations for the two compounds
are difﬁcult to disentangle. Based on the above, there is some indirect evidence to suggest that PFOS
may be more detrimental which may simply relate to its higher concentrations. As a result, the
association for PFOA may be partly confounded by PFOS (the vice versa may also be true). For the
reasons explained above, the CONTAM Panel concluded that it is most adequate to apply benchmark
dose modelling for PFOS on the immune system using the antibody response as a continuous variable.
For the reasons explained above, the CONTAM Panel decided not to apply benchmark dose modelling
for PFOA on the Grandjean et al. (2012) study.
3.4.1.4. Birth weight
As described in Section 3.3.4.2.1, of the 17 studies reporting associations between PFOS and PFOA
(reviewed in Table 20), 7 studies reported signiﬁcant inverse association for PFOA, while 6 studies
reported signiﬁcant inverse association for PFOS. Many other studies also reported inverse associations
although formal signiﬁcance was not reached. Lack of associations for some of the non-signiﬁcant
ﬁndings may, at least in some cases, relate to either small size of the studies and low serum
concentrations. Previous reviews and meta-analyses have concluded that PFOA, and to lesser extent
PFOS, are inversely associated with birth weight (Lam et al., 2014; Bach et al., 2015b). That is also
the conclusion of the CONTAM Panel. As mentioned above, there was usually a relatively strong
correlation between PFOS and PFOA in the general population studies.
There is a well-deﬁned mechanism for confounding for birth weight. During pregnancy, increased
hemodilution and glomerular ﬁltration rate are well established determinants of PFOS and PFOA
concentrations and both factors may potentially affect birth weight. Physiological based
pharmacokinetic models have suggested that around half of the reported associations between PFOS
and PFOA with birth weight could be explained by glomerular ﬁltration rate (Verner et al., 2015). On
the other hand, the study by Darrow et al. (2013) reported an inverse association between
pre-pregnancy levels of PFOS with birth weight which would in theory eliminate such confounding by
design. However, the CONTAM Panel concluded that since a well-deﬁned confounding mechanism has
been established, the causality of the association between PFOS and PFOA and birth weight is more
uncertain than it is for other associations discussed in this Section.
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In addition, the clinical relevance of slight reduction in birth weight is unclear if the shift in the birth
weight distribution does not translate to increased prevalence of more adverse outcomes such as low
birth weight (< 2,500 g) or small for gestational age (birth weight below the 10th percentile for
gestational age and gender) that are well established predictors for neonatal mortality and morbidity.
However, despite their efforts, studies that have addressed these outcomes (see Table 20) have not
been sufﬁciently powered, and therefore this issue has not been resolved.
The CONTAM Panel concludes that there may well be a causal association between PFOS and PFOA
and birth weight, but the robustness of existing studies is hampered by a well-deﬁned mechanism of
confounding and the fact that clear biological relevance is not obvious. Nevertheless, the CONTAM
Panel found it reasonable to perform BMD modelling on important birth weight studies to examine if
potentially critical exposures with respect to birth weight, are sufﬁciently covered by outcomes judged
to be more certain with respect to causality and adversity (serum cholesterol and immune response).
3.4.1.5. Conclusion
Considering the evidence for a causal association with exposure to PFOS or PFOA for the four
outcomes above, the view of the CONTAM Panel is that the strongest support for a causal adverse
association with PFOS or PFOA is found for increased serum cholesterol (PFOS and PFOA) and
decreased antibody response in children (PFOS).
For ALT above the reference range (PFOA), the evidence is somewhat weaker, and for decreased
birth weight (PFOS and PFOA) there is still some uncertainty both regarding causality and adversity.
Nevertheless, it was decided to perform dose–response assessment for all these four outcomes.
3.4.2. Dose–response assessment
3.4.2.1. BMD modelling
As mentioned in Section 2.2.3, the BMR was considered as an increase over the response observed in
the lowest quantile and it was decided to use the median PFOS or PFOA concentration in the lowest
quantile and the corresponding response in the BMD modelling (see also Appendix B). For each outcome
several models were tested and the best ﬁtting model was used (see Section 2.2.3 and Appendix B).
For serum cholesterol, BMD modelling was performed for PFOS and PFOA for a 5% increase in total
cholesterol based on the studies with > 500 individuals and results presented by quantiles (Steenland
et al., 2009; Nelson et al., 2010; Eriksen et al., 2013).
In the speciﬁc case of BMD modelling of serum cholesterol vs serum PFOA in the C8 cohort
(Steenland et al., 2009), using the lowest decile as reference value, the BMD for a 5% increase in
cholesterol could not be modelled. This was because the dose–response curve levels off at high serum
PFOA concentrations. The median PFOA level in the lowest decile was higher (median 5.5 ng/mL) than
in other cohorts and in the biomonitoring studies (see Section 3.3.2). Use of a ‘low’ concentration of
1 ng/mL, being half of the median of the medians of serum PFOA in Europe (1.9 ng/mL, see Section
3.3.2.3, Table 8), allowed modelling (see Appendix B, model #6). The CONTAM Panel is aware that
this means an extrapolation outside the aggregated data available in the study by Steenland et al.
(2009), but it is still within the range of individual data observed in the lowest decile in the same
study. Furthermore, the model ﬁts the data well in the lowest deciles (see Appendix B, model #6),
suggesting that the uncertainty in extrapolation below the median in the ﬁrst decile is not large. The
same uncertainty applies to PFOS when extrapolating below the median of the lowest quantile, but
would for both substances be model dependent.
For the association between PFOA and serum ALT, BMD modelling was performed for an increase of
the absolute risk of ALT above its reference range (> 45 IU/L men, > 34 IU/L women), using the
studies by Gallo et al. (2012). Data showing the prevalence of ALT above the reference range,
adjusted for covariates, were provided by Fletcher, 2017b (see ‘Documentation provided to EFSA’). A
5% absolute increase in serum ALT did not occur even in the highest decile. A 3% increase of the
absolute risk (from 9% to 12%) of high ALT could however be modelled, and will allow a comparison
of the BMD for an increase in the risk of high ALT to the BMD for the other potential critical outcomes
For the association between PFOS and antibody response, a decrease in diphtheria antibody levels
was used for BMD modelling (see Appendix B). The median in the lowest decile was used as
reference. A 5% decrease was selected as a default; however, a 10% decrease was also evaluated
resulting in almost identical values.
For birth weight, a BMR of 5% was used. This value corresponds to roughly 170 g decrease in birth
weight (assuming a mean birth weight of 3.6 kg). Such decrease in birth weight is similar to that expected
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among mothers smoking during pregnancy and such a decrease in birth weight is generally considered as
clinically relevant (Butler et al., 1972). Epidemiological studies examining associations between
environment, nutrition or lifestyle, however, often report more modest associations with birth weight and
the adversity of around 50–100 g reduction in birth weight is most often unclear. In the absence of further
evidence such modest changes in birth weight are often considered within the reference range.
For each outcome, several models were tested and the best ﬁtting model was used (see Section
2.2.3 and Appendix B).
Table 25: Summary of the BMD analysis – PFOS
Human
response
variable
BMD5
(ng/mL)
BMDL5
(ng/mL)
Number of people
(cohort)
Data
type
Model used Reference
Total
Cholesterol
27 25 46,294 (C8 health
project)
Decile Lognormal
cumulative
Steenland et al.
(2009)(a),(b)
31 22 753 (Danish cohort
1996–2002)
Octile Sqrt Eriksen et al. (2013)(c)
31 21 860 (NHANES) Quartile Exponential Nelson et al. (2010)
Vaccination
response for
children
11.6 10.5 431 (Faroese birth
cohort 1997–2002)
Decile Logarithmic Grandjean et al.
(2012)(d)
Birth weight 36 21 901 (Norwegian
mother and child
cohort-MoBa)
Quartile Logarithmic Whitworth et al.
(2012a)(e)
BMD: benchmark dose; BMDL5: benchmark dose for a 5% increase; PFOS: perﬂuorooctane sulfonic acid.
(a): For Steenland et al. (2009) using a different reference value of 3.8 ng/mL PFOS in serum (half the median of the median
PFOS in Table 8) would result in BMD5 = 25 ng/mL and BMDL5 = 22 ng/mL.
(b): See also Steenland (2017) under ‘Documentation provided to EFSA’.
(c): See also Sørenson (2017) under ‘Documentation provided to EFSA’.
(d): See also Grandjean and Budtz-Jørgensen (2017) under ‘Documentation provided to EFSA’.
(e): See also Whitworth (2017) under ‘Documentation provided to EFSA’.
Table 26: Summary of the BMD analysis – PFOA
Human
response
variable
BMD5
(ng/mL)
BMDL5
(ng/mL)
Number of
people (cohort)
Data
type
Model
used
Reference
Total
cholesterol
12(b) 9.4(b) 46,294 (C8 health
project)
Decile Lognormal
cumulative
Steenland et al. (2009)(C)
12.4 9.2 753 (Danish cohort
1996–2002)
Octile Lognormal
cumulative
Eriksen et al. (2013)(d)
Alanine
transferase(a)
80 21 47,092 (C8 health
project)
Decile Logistic Gallo et al. (2012)(e)
Birth weight 14.5 10.6 1,400 (Danish
national birth
cohort 1996–2002
Decile Linear Fei et al. (2007)(f)
4.4 4.0 901 (Norwegian
mother and child
cohort)
Quartile Exponential Whitworth et al.
(2012a)(g)
BMD: benchmark dose; BMDL5: benchmark dose for a 5% increase; PFOA: perﬂuorooctanoic acid.
(a): BMD3 and BMDL3 for alanine transferase.
(b): This was modelled extrapolating to a reference value of 1 ng/mL PFOA in serum (half the median of the median PFOA in
Table 8). A 5% increase in the response observed in the lowest quantile could not be modelled.
(c): See also Steenland (2017) under ‘Documentation provided to EFSA’.
(d): See also Sørenson (2017) under ‘Documentation provided to EFSA’.
(e): See also Fletcher (2017b) under ‘Documentation provided to EFSA’.
(f): See also Danish national birth cohort (2017) under ‘Documentation provided to EFSA’.
(g): See also Whitworth (2017) under ‘Documentation provided to EFSA’.
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3.4.2.2. Model-based estimation of the relationships between plasma concentrations of
PFOA and PFOS and dietary intakes to set tolerable daily intakes
Estimation of population intakes of PFOS and PFOA based on plasma/serum concentrations can
either be performed by using a one-compartment steady-state pharmacokinetic (PK) model or using a
physiologically based pharmacokinetic (PBPK) model, in both cases assuming a constant intake rate.
This means that measured serum/plasma concentrations can be used to reconstruct past intakes. The
daily dietary intake of PFOA and PFOS associated with the BMDL5 concentrations for the potential
critical effects in the BMD analysis can thus be calculated using either a PBPK model or a
one-compartment steady-state PK model.
In the literature, several PBPK models have been applied for PFOS and PFOA in humans (Andersen
et al., 2006; Loccisano et al., 2011, 2012, 2013; Fabrega et al., 2014, 2016; Verner et al., 2015, 2016;
Wu et al., 2015; Ruark et al., 2016). Some of them (Loccisano et al., 2013; Verner et al., 2015, 2016;
Wu et al., 2015; Ruark et al., 2016) were developed to assess the pharmacokinetic behaviour of PFOA
and PFOS in pregnancy, during lactation, or at early menopause, but they are all based on the original
Loccisano et al. (2011) model.
The Loccisano et al. (2011) model is a basic PBPK model which has been applied to estimate
relationships between serum concentrations of PFOA and PFOS and dietary intakes of the same
compounds. The validation steps performed (including sensitivity analysis) for this model demonstrated
that the models were giving robust estimations (see Section 3.3.1.3).
The Loccisano et al. (2011) model was modiﬁed by Fabrega et al. (2014) and data from autopsy
tissues from residents in the area of Tarragona (Spain) were included. These data were used for
calibration of their model. The authors combined results from two studies to determine the partition
coefﬁcients (tissue/blood):
1) the tissue concentrations used were from Perez et al. (2013);
2) the blood concentrations used were from Ericson et al. (2007).
Partition coefﬁcients (tissue/blood) were calculated as the ratio between the tissue concentrations
and the blood concentration of the same chemical at steady state. However, as the partition coefﬁcients
were based on measured concentration in blood and tissue from different subjects (cadavers), the
coefﬁcients obtained are subject to relatively high uncertainty. Furthermore, the model was both
calibrated and evaluated using the same experimental data from the autopsy tissues. Thus, according
to the WHO guidance (WHO/IPCS, 2010), the Fabrega model cannot be considered as validated.
In 2017, Worley et al. published a new PBPK model for PFOA. This model contains four
compartments: plasma, liver, the rest of the body tissues and kidney (containing the kidney serum,
proximal tubule cells, and kidney ﬁltrate). A description of the gastrointestinal tract (stomach, small
intestine) is also added. The authors added in vitro and in vivo data to describe renal excretion and
reabsorption of PFOA (speciﬁc OATs).
Both the Loccisano et al. (2011) and the Worley et al. (2017) models provided acceptable and
similar prediction of PFOA plasma concentrations, which is an acceptance criteria from WHO, i.e. the
ratio between the simulated and observed data should be within a factor of 2. In both models, the
same studies from Little Hocking, Ohio, USA were used in the model validation. In addition, for the
Loccisano et al. (2011) model additional data were used for evaluation i.e. data from an exposed
population in Arnberg in Germany23 and data from Red Cross donors from six geographic locations
around the US. The comparison of model simulations with experimental data from both of these
populations show good prediction,24 and moreover, the level of exposure in these populations was
lower than the studies from Little Hocking.
In summary, the Fabrega et al. (2014, 2016) model was considered not appropriate to use.
Furthermore, although both the Worley et al. (2017) model and the Loccisano et al. (2011) model
provided acceptable prediction, the Loccisano model (2011) was evaluated using more data and at
different levels of exposure, and was thus considered the most appropriate model to use.
In conclusion, the CONTAM Panel decided to estimate the constant intake rates in ng/kg bw per
day resulting in the plasma concentrations similar to the BMDLs for the different outcomes applying
the Loccisano et al. (2011) model, which was further modiﬁed by integrating an equation describing
the increase in weight according to age and by correcting some of the parameters (see Appendix C).
23 As with the Little Hocking population, it is not known how long the people of Arnsberg were exposed to PFOA.
24 To consider a prediction to be good, the ratio between the simulated and the observed data should be within a factor of 2.
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The half-life is dependent on renal resorption through a saturable transport that is thought to be
responsible for the long half-life of PFOA and PFOS. The parameters used to describe renal resorption
are the transporter maximum (Tm) (Tm = Tmc*BW^0.75) and the transporter afﬁnity constant (Kt). The
CONTAM Panel used a Tmc of 6,000 lg/h/kg^0.75 corresponding to a half-life of 2.3 years for PFOA
and a Tmc of 3,500 lg/h/kg^0.75 corresponding to a half-life of 5.4 years for PFOS.
The estimated serum levels obtained by this model were also in acceptable agreement with those
obtained using a one-compartment steady-state PK model, and also the Worley et al. (2017) model,
supporting the robustness of the results (see Appendix C).
Conversion of the respective BMDLs (results given in Tables 25 and 26), expressed as PFOS and
PFOA concentrations in serum/plasma, into daily dietary intake estimates are given in Tables 27 and
28. The estimates presented in Table 27 and 28 correspond to the life-time continuous dietary
exposures estimates (daily ingested dose) which should not be exceeded in order not to reach the
target concentration (BMDLs) at adult age.
For example, the BMDL5 of 25 ng/mL in serum/plasma based on increased cholesterol in adults,
correspond to a dietary intake of 2.0 ng/kg bw per day for PFOS, when using the PBPK model from
Loccisano et al. (2011) (Table 27).
For children, the relation between serum concentrations of PFOS and corresponding daily intake
rates is not as straight-forward as in adults, as there is a certain ‘starting’ concentration of serum PFOS
at birth (dependent on the mother’s serum PFOS), and if breastfed, the infant will receive a higher
daily dose from breast milk than from diet after end of breastfeeding (see Appendix C (subsection C.2)
for an example) which inﬂuences the PFOS serum concentration in childhood. Therefore, the CONTAM
Panel considered it not relevant to calculate which intake rate for children after end of breastfeeding
would correspond to the BMDL5 serum level of PFOS in 5-year-old children. Instead the serum PFOS
levels in the pregnant mothers in the study by Grandjean et al. (2012) were compared with serum
PFOS levels for the other potential critical effects, and some scenarios with breastfed children were
modelled to illustrate how maternal serum PFOS levels and intake rates would be related to serum
PFOS levels in their 5-year-old children (see Appendix C).
Table 27: Summary of dietary intake estimates that by PBPK modelling predict PFOS serum
concentration at the BMDLs for potential critical effects
Human
response
variable
BMDL5
(ng/mL)
Reference
Estimated dietary intakes in ng/kg bw per day
corresponding to a BMDL5 using
the PBPK model (rounded values)
Total cholesterol(a) 25 Steenland et al. (2009) 2.0
22 Eriksen et al. (2013) 1.8
21 Nelson et al. (2010) 1.7
Birth weight(b) 21 Whitworth et al. (2012a) 1.9
BMDL5: benchmark dose for a 5% increase; PBPK: physiologically based pharmacokinetic (model).
(a): At 50 years.
(b): At 35 years, relevant age for pregnant women.
Table 28: Summary of dietary intake estimates that by PBPK modelling predict PFOA serum
concentration at the BMDLs for potential critical effects
Human
response
variable
BMDL5
(ng/mL)
Reference
Estimated dietary intakes in ng/kg bw per day
corresponding to a BMDL5 using the PBPK
model (rounded values)
Total
cholesterol(b)
9.4 Steenland et al. (2009) 0.8
9.2 Eriksen et al. (2013) 0.8
Alanine
transferase(b)
21(a) Gallo et al. (2012) 2.0
Birth weight(c) 10.6 Fei et al. (2007) 1.0
4 Whitworth et al. (2012a) 0.4
BMDL5: benchmark dose for a 5% increase; PBPK: physiologically based pharmacokinetic (model).
(a): BMD3 and BMDL3 for alanine transferase.
(b): At 50 years.
(c): At 35 years, relevant age for pregnant women.
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3.4.3. HBGV derivation
Since both toxicity as well as underlying modes of toxic action for PFOS and PFOA are not
sufﬁciently understood and might differ, but also overlap, the CONTAM Panel decided not to derive a
group HBGV for PFOS and PFOA.
3.4.3.1. PFOS
For outcomes identiﬁed in adults, the opinion of the CONTAM Panel is that the increase of serum
cholesterol is the critical effect. Three studies (Steenland et al., 2009; Nelson et al., 2010; Eriksen
et al., 2013) on serum cholesterol showed very similar BMDL5 values expressed as plasma PFOS
(21–25 ng/mL), corresponding to an estimated chronic daily intake of 1.7–2.0 (median 1.8) ng/kg bw
per day (see Section 3.4.2.2, Table 27). It is likely that adjustment for PFOA (and maybe other PFASs)
would result in somewhat higher BMDL5 values and corresponding daily intake rates (see
Section 3.4.1.1).
For children, the lowest BMDL5 is for antibody response after vaccination (10.5 ng/mL). Serum
PFOS levels in children are not in steady state and their levels will depend on maternal levels of PFOS
in serum, which will also be the most important factor determining the PFOS levels in breast milk. As
shown in Appendix C, if the maternal serum PFOS level is 7.7 ng/mL (median estimate for adults, see
Scenario 1 in Appendix C, subsection C.2), the 5-year-old child, if exclusively breastfed for 6 months, is
expected to have a serum PFOS level of about two-third the BMDL5 of 10.5 ng/mL. However, when the
maternal serum PFOS is in the range of the BMDL5 values for increase of serum cholesterol, the child’s
serum PFOS can be expected not to exceed the BMDL5 of 10.5 ng/mL; see example for a maternal
serum PFOS of 22 ng/mL, corresponding to a long-term maternal intake of 1.8 ng/kg per day (see
Scenario 2 in Appendix C, subsection C.2).
The BMDL5 for reduced birth weight (with corresponding dietary intake of 1.9 ng/kg bw per day)
was in the same range as for increased cholesterol. The CONTAM Panel noted that there is still some
uncertainty both regarding causality and adversity of reduced birth weight, and there is likely an
impact of confounding by changes in glomerular ﬁltration rate during pregnancy.
With serum cholesterol, antibody response after vaccination, and birth weight, all considered as
potential critical endpoints, the CONTAM Panel found it appropriate to weigh the overall evidence from
the human observational studies when setting an HBGV. For these endpoints, the daily calculated
intakes resulting in the critical serum concentrations were 1.7–2.0 ng/kg bw per day, depending on the
outcome and study. For the increase in serum cholesterol, the critical effect in adults, it was 1.8 ng/kg
bw and day. The CONTAM Panel noted that people are usually exposed to a mixture of PFOS and
PFOA, which both affect serum cholesterol and birth weight, but there was lack of empirical data to
quantify a possible confounding of such co-exposure.
The CONTAM Panel decided not to apply any additional uncertainty factor because the BMD
modelling was based on large epidemiological studies from the general population, including also
potentially sensitive subgroups. The CONTAM Panel also took into account that the BMD modelling was
performed on risk factors for disease rather than disease. Therefore, the CONTAM Panel considers that
1.8 ng/kg bw per day is an appropriate reference point.
The CONTAM Panel established a TWI of 13 ng/kg bw per week, in order to take into account the
long half-life of this contaminant. At constant intake rates, it will take many years to build up a plasma
concentration corresponding to the derived BMDLs. Daily variations in intake of PFOS will therefore not
affect serum PFOS levels or toxicity.
3.4.3.2. PFOA
The CONTAM Panel considers the increase of serum cholesterol to be the critical effect. Two studies
(Steenland et al., 2009; Eriksen et al., 2013) on serum cholesterol showed very similar BMDL5
expressed as serum PFOA (9.2–9.4 ng/mL). Such levels correspond to an estimated chronic daily
intake of about 0.8 ng/kg bw per day. However, the BMDL5 from the study by Steenland et al. (2009)
was based on an extrapolation to a low reference value of 1.0 ng/mL, which adds to the model
uncertainty as discussed in Section 3.4.2.1. On the other hand, the study by Steenland et al. (2009) is
much larger than the study by Eriksen et al. (2013), and therefore more appropriate for BMD
modelling. The CONTAM Panel decided to take into account both of these studies, which have their
advantages and disadvantages when deriving an HBGV for PFOA.
The issue of co-exposure to PFOS and PFOA was also considered. Since there is an association
between levels of PFOS and PFOA, it is likely that adjustment for PFOS (and maybe other PFASs)
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would result in somewhat higher BMDL5 values for PFOA. Since the exact extent of such confounding
by PFOS is unknown the CONTAM Panel decided not to adjust the estimated chronic daily PFOA intake
for other PFASs.
The CONTAM Panel considers 0.8 ng/kg bw per day to be an appropriate reference point and
established a TWI of 6 ng/kg bw per week, again based on the long half-life of this contaminant. The
TWI is protective also for increased risk of liver damage, indicated by high serum ALT (see Section
3.4.2.1, Table 26). It is protective against reduced birth weight, taking into account the fact that there
is likely to be an impact of confounding by glomerular ﬁltration rate. The CONTAM Panel decided not
to apply any additional uncertainty factor because the BMD modelling was based on large
epidemiological studies from the general population, including also potentially sensitive subgroups. The
CONTAM Panel also took into account that the BMD modelling was performed on risk factors for
disease rather than disease.
3.5. Risk characterisation
Large differences between LB and UB concentrations were observed in foods, as a result of
analytical methods being used that are not sufﬁciently sensitive. This contributes to a large difference
between LB and UB chronic dietary exposure estimates for PFOS and PFOA (see Section 3.2.1, Tables
4 and 5).
For PFOS, the mean LB dietary exposure ranged from 1.3 (adolescents) to 20.9 (other children)
ng/kg bw per week across age groups and surveys. The high (95th percentile) LB exposure ranges
from 3.5 (adolescents) to 165.9 (other children) ng/kg bw per week. This compares with the TWI of
13 ng/kg bw per week, and indicates that the mean LB exposure exceeds the TWI by up to 1.6-fold in
some surveys, whereas the high LB exposure exceeds the TWI by up to 13-fold. At UB exposure, the
TWI is exceeded in almost all surveys at mean exposure, and the high (95th percentile) UB exposures
exceed the TWI from 1.7- to 15-fold across surveys and age groups.
For PFOA, the mean LB dietary exposure estimates range from 1.5 ng/kg bw per week (elderly
and very elderly) up to 18.3 ng/kg bw per week (toddlers). The high (95th percentile) LB exposures
range from 3.4 to (very elderly) to 37.6 ng/kg bw per week (toddlers). This compares with the TWI of
6 ng/kg bw per week and indicates that the mean LB exposure exceeds the TWI by threefold in some
surveys, whereas at high LB exposure the TWI is exceeded up to sixfold. At the mean UB the TWI is
exceeded 1.4- to 14-fold across surveys and up to 28-fold at the high UB (95th percentile) exposure
(toddlers).
The CONTAM Panel considers that the true exposure level for both PFOS and PFOA is closer to the
LB than the UB values. Studies performed using the best analytical methods with high sensitivity and
high levels of quality control give results with fewer left censored data and conﬁrm occurrence in foods
at levels close to the LB estimates. This is discussed further in the Uncertainty Section (3.6.1).
Other supporting evidence is that the median blood serum levels in European populations (see
Section 3.3.2) are consistent with what would be expected based on PBPK modelling of median LB
intake data in Tables 4 and 5. The median concentrations of PFOS in European adults and children in
studies from the late 2000s were 7.7 (range 1.7–27.4) and 3.2 (range 0.49–8.6) ng/mL, which are
generally lower than the BMDL5 of 25 ng/mL for increase of serum cholesterol in adults and lower than
the BMDL5 of 10.5 ng/mL for decreased vaccination response in children (Section 3.4.2). For PFOA the
corresponding median concentrations in adults and children were 1.9 (range 0.76–4.9) and 3.3 (range
0.49–6.9) ng/mL, which are lower than the BMDL5 of 9.4 ng/mL for increase of serum cholesterol.
However, as described in Section 3.3.2, for some individuals in general populations, much higher
concentrations of PFOS (up to 392 and 23 ng/mL in adults and children respectively) and PFOA (up to
80.8 and 19.5 ng/mL in adults and children respectively) have been reported, which is also in line with
the high LB exposure estimates. Although food is the main source, exposure to PFOS, PFOA and their
precursors may also occur through inhalation of air, ingestion of dust as well as through dermal
contact with for instance consumer products, thus contributing to the internal dose of PFOS and PFOA.
The exceedances of the TWIs for PFOS and PFOA at LB exposure estimates are of concern.
3.6. Uncertainty analysis
3.6.1. Uncertainty in exposure estimates
The occurrence data were mostly reported by three countries (Germany, Norway and France) while
other countries submitted only a limited number of data. There is an uncertainty in possible regional
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differences in PFOS and PFOA contamination of food commodities and it is evident that the data set is
not fully representative for the EU food market.
There are very few data points that can be used for exposure estimates for some food categories,
especially when exploring the most detailed level of food categories. Thus, exposure from those food
groups is highly dependent on the representativeness of the limited number of measurements. The
limited number of available analytical results for particular food subgroups (i.e. pear and cow milk),
adds uncertainty to the representativeness of the mean concentration values used to estimate
exposure. Furthermore, for PFOA, ‘Milk and dairy products’ was an important contributor (up to 86%
for toddlers), however, there were only 4 and 6 quantiﬁable results for cow milk and gouda cheese,
respectively.
Additional uncertainty is introduced by exclusion of several food categories due to a very high
proportion of left-censored data, including the Foodex 1 level categories ‘Fruit and vegetable juices’,
‘Food for infants and small children’, and ‘Snacks, desserts and other foods’ for both PFOS and PFOA,
and for PFOS only ‘Grains and grain-based products’, ‘Alcoholic beverages’, ‘Herbs, spices and
condiments’ and ‘Composite food’.
In addition, for the other Foodex 1 categories, many of the subcategories contained all left
censored data, i.e. for PFOS, food groups (with > 20 analytical results) included cow milk yoghurt,
turkey meat, ﬁsh oil, potatoes, tomatoes and asparagus. For PFOA, such food groups included cow
milk yoghurt, sheep milk, cooked sausage, mutton, lamb and chicken meat, ﬁsh oil, potatoes and
French fries, beer pastries and cakes (see Appendix A Tables A.4 and A.5 as excel ﬁles – under
‘Supporting information’ Section on the web page). Food groups excluded due to limited availability of
analytical results (< 6 results per food category) included some citrus and stone fruits, melons and
green beans for both PFOS and PFOA and for PFOA only table grapes, peas, sweet corn, fennel, oats,
herbs, margarine.
Exposure estimates for PFOS and PFOA are strongly impacted by the wide range of sensitivity of
analytical methods used for their analysis. This results in many samples reported as left-censored
(< LOD/LOQ), especially for data generated using less sensitive methods. This gives a wide range of
difference between UB and LB exposure estimates. As a result, the use of the LB in this opinion tends
to underestimate, while UB tends to overestimate the dietary exposure. Exposure data generated from
more sensitive analytical methods with high levels of quality control suggest that true estimates of
exposure are closer to LB than UB estimates presented in this opinion (Haug et al., 2010b; Vestergren
et al., 2012; Brantsaeter et al., 2013; Klenow et al., 2013).
It is possible that correction for recovery has been treated in different ways by data providers.
Methods using stable isotope dilution have an internal (automatic) correction for recovery, whereas
other methods do not. It is possible that data that have been corrected for recovery have been mixed
in some cases with data that have not been corrected for recovery. There is also a possibility that data
from stable isotope methods have been in effect corrected twice, meaning that the uncertainty in
terms of correction for recovery could be in either direction.
The information on occurrence in food comes from monitoring programmes, and also from routine
measurements within the frame of ofﬁcial food controls, so they originated from both random and
targeted sampling. Targeted sampling is usually focussed on known or suspected contamination sites
and inclusion of such data may therefore result in an overestimate of exposure.
Where analytical results are reported for composite foods, the assumptions made about
composition of these items can give rise to additional uncertainties in the exposure estimate as a result
of which category the composite food is given.
Food is consumed after cooking or processing, whereas the occurrence data are based largely on
uncooked retail food samples. More of the limited amount of data in the literature is for PFOA than for
PFOS, although other PFASs are also used in food contact materials. It is unclear as to the effect of
cooking and processing on PFOS and PFOA, with some studies suggesting an increase and others a
decrease in ﬁnal food concentrations.
For calculation of current exposure, data from the last 10 years have been considered and merged.
The data have been gathered from results gained using several different methods with varying
sensitivity. Improvements in sensitivity over time may give an illusion of decreasing occurrence levels if
upper bound data are analysed, whereas this in fact can simply be a reﬂection of improved
methodology. It has therefore not been possible to analyse for time trends in the occurrence data set
but decreases in blood serum concentrations suggest that exposure has been decreasing over the last
decade. If this is the case, it could result in an overestimation of the current dietary exposure.
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While for most of the population, diet is recognised as the main source of exposure to PFOS and
PFOA, for some individuals, non-dietary sources may be signiﬁcant. Furthermore, PFOS and PFOA can
arise as a result of biodegradation of their precursors in the human body. Neither non-dietary exposure
nor exposure to precursors have been considered in the current exposure assessment. However, both
of these are taken into account when biomonitoring data are used as a measure of exposure.
Several factors may have had an impact on the representativeness of the biomonitoring data, such
as a non-equal distribution of studies between the European countries, lack of data from a large
proportion of European countries and study populations being non-representative for general
populations. Furthermore, the included studies comprised samples collected during ten years, and as
decreasing time trends have been observed in human samples from several studies, the collection time
points may have had an inﬂuence on the aggregated data such as mean and median concentrations.
3.6.2. Uncertainties in hazard identiﬁcation and characterisation
3.6.2.1. Experimental animal data
Many of the animal studies conducted on PFOS and PFOA used standards that had relatively low
purity, and the nature of the impurities was not fully characterised. There is likelihood that the
impurities could be other organoﬂuorine compounds or other chemicals with potential to inﬂuence
studies that were conducted using the material.
Uncertainty in the extent of bile excretion and the enterohepatic recycling of PFOS and PFOA, as
well as in the description of transporter mediated excretion and reabsorption, could inﬂuence the TK or
PBPK model parametrisation and consequently the risk assessment. Previous risk assessments were
based on hazard identiﬁcation and risk characterisation from studies conducted in rodents, which have
PFOS and PFOA toxicokinetic proﬁles divergent from humans.
3.6.2.2. Epidemiological studies in humans
The review of Observations in humans (Section 3.3.4) includes about 200 epidemiological studies. A
comprehensive literature review was performed (see Section 2.2.2), but there might be some further
studies not identiﬁed in the literature review. However, the CONTAM Panel ﬁnds it unlikely that such
studies would change the selection of potential critical effects and the assessment of causality,
adversity and dose response.
The human studies are all observational, since it is not possible to perform long-term clinical trials
of PFOS/PFOA exposure. Longitudinal studies are generally considered more useful than cross-sectional
studies when assessing causality of associations found in observational studies. The majority of the
studies cited in Section 3.3.4 are cross-sectional, but some of them are longitudinal, i.e. plasma levels
of PFOS/PFOA were measured before the outcome. For the C8 studies, it is known that there was
increased exposure to PFOA in drinking water long before various health outcomes were evaluated.
Selection bias may occur, especially in occupational studies where the so called ‘healthy worker
effect’ is an example, but overall the CONTAM Panel ﬁnds it unlikely that it has affected the
associations described above. There is always a risk of information bias in epidemiological studies, and
in the cross-sectional studies described in Section 3.3.4 the main sources for such bias are
misclassiﬁcation of exposure (plasma levels of PFOS/PFOA) and/or outcomes (for example serum levels
of cholesterol, liver enzymes, hormones or markers of kidney function) due to normal variability.
Misclassiﬁcation should, however, be non-differential, which will attenuate a true exposure-response
relationship. Therefore, true associations may be stronger than those observed, and in some cases
true associations may not have been detected.
Confounding is common in epidemiological studies and occurs when other factors can affect plasma
levels of PFOS/PFOA as well as the outcomes examined. Examples of factors which may be associated
with PFOS/PFOA levels are time period (decreasing levels over time), age (usually increasing with age),
sex, BMI and diet. For the critical outcomes identiﬁed in this opinion, it was concluded that all relevant
confounders where accounted for in statistical analyses. However, there is always the possibility that
some identiﬁed factor (biological or lifestyle related) that is associated with both outcome and
exposure may have acted as a confounder. Confounding by such ‘unknown’ confounder can, in theory,
always occur in observational studies. However, in the absence of any clear hypothesis on how such
confounding may occur, and repeated replication of same ﬁndings in different populations where
sources of exposure are likely to differ (such as for serum cholesterol), the existence of such an
‘unknown’ confounder appears unlikely.
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Co-exposure to several PFASs, or other contaminants correlated with PFOS/PFOA levels, also
constitutes confounding, if there are similar effects on the outcome of these various compounds. If the
correlation between plasma levels of PFOS, PFOA and other PFASs is high, it is difﬁcult to disentangle
effects from the respective compounds, and the true effect of a speciﬁc compound may be smaller
than the effect reported for that compound.
Reverse causality may occur if some outcomes will result in higher or lower plasma levels of PFOS/
PFOA. One example of this is decreased kidney function, which will decrease elimination of PFOS/PFOA
and therefore tend to increase their plasma levels. This means that an inverse association between
renal function and PFOS/PFOA may be caused by reverse causation. Another example is that less loss
of PFOS/PFOA by menstruation will tend to increase plasma levels of these compounds. Therefore, a
positive association between early menopause and plasma levels of PFOS/PFOA may be caused by
reverse causation.
Limited statistical power due to a small number of study participants will make it difﬁcult to detect
a true association between PFOS/PFOA and the outcome examined, and the absence of statistically
signiﬁcant associations in small studies therefore has limited validity. This is especially true if the
magnitude of the hypothesised effect is small. In spite of this, small studies may show spurious
associations, which cannot be replicated in larger studies.
If study participants have special characteristics (e.g. pregnant women, groups with specialised diet
or certain diseases), they may not be representative for the general population. Nevertheless, it is
important that HBGVs are protective also for sensitive subgroups of the population.
Many epidemiological studies of exposure to PFOS/PFOA use biomarkers, which are indirectly linked
to an adverse effect (usually a disease). Such examples are biomarkers of kidney function, hormones
or serum lipids. As discussed in the EFSA Guidelines on Biological relevance, there should be prior
knowledge of the relation between changes in biomarkers and organ damage or disease states, if such
biomarkers are used as potential critical effects (EFSA Scientiﬁc Committee, 2017b). Sometimes, there
is uncertainty whether changes in biomarkers are just adaptive or are clearly related to an adverse
effect.
3.6.2.2.1. Serum cholesterol
As discussed above, the associations between PFOS/PFOA and serum cholesterol are consistent
between studies and most sources of confounding have been taken into account. The most important
uncertainty is regarding adversity. While it is very well proven that increased serum cholesterol
increases the risk of cardiovascular disease, no association between plasma levels of PFOS/PFOA and
cardiovascular disease has been shown. This could be due to limited power to demonstrate a limited
increase (e.g. a 5% increase) in cardiovascular disease incidence. Another uncertainty is related to co-
exposure to several PFASs, as discussed above.
3.6.2.2.2. Serum alanine transferase
As discussed above, there is some uncertainty regarding the causality of the inverse association
between PFOS and PFOA on birth weight that has been relatively consistently reported in prospective
studies, using serum concentrations as marker of exposure. Increased elimination rate through urinary
excretion and/or increased blood volume expansion as pregnancy progresses are both modest
predictors of birth weight as well as lower serum PFOS and PFOA concentrations. As a result, there is
a well-deﬁned confounding mechanism that has not been adequately addressed in existing studies.
However, PBPK models have suggested that this mechanism may account for only around half but not
the full association (Verner et al., 2015). For birth weight there is therefore some uncertainty on the
causality as well as on the true strength of the association. The uncertainty is, however, not large
enough for the CONTAM Panel to conclude that the observed association between PFOS and PFOA
with birth weight is not adverse.
3.6.2.2.3. Birth weight
As discussed above, there is some uncertainty regarding the causality of the inverse association
between PFOS and PFOA on birth weight that has been relatively consistently reported in prospective
studies, using serum concentrations as marker of exposure. Increased elimination rate through urinary
excretion and/or increased blood volume expansion as pregnancy progresses are both modest
predictors of birth weight as well as lower serum PFOS and PFOA concentrations. As a result, there is
a well-deﬁned confounding mechanism that has not been adequately addressed in existing studies.
However, PBPK models have suggested that this mechanism may account for only around half but not
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the full association (Verner et al., 2015). For birth weight there is therefore some uncertainty on the
causality as well as on the true strength of the association. The uncertainty is, however, not large
enough for the CONTAM Panel to conclude that the observed association between PFOS and PFOA
with birth weight is not adverse.
3.6.2.2.4. Vaccination response
In the absence of any likely confounding that, to date, has not been identiﬁed, the greatest
uncertainty for the inverse association between serum PFOS and PFOA concentrations and antibody
response, following vaccinations, primarily relates to how sensitive these associations are to different
types of vaccines. That is, it is unclear if these potential adverse associations are speciﬁc to the few
types of vaccines that have been examined in studies so far, or, if this adverse association is more
general. In addition, the conclusion on adversity is based on reduced antibody response alone as a
clear link with increased rate of infection has not been demonstrated. Such studies are, however,
difﬁcult to perform. Although this can be regarded as a source of uncertainty, it is generally accepted
that failing to reach protective antibody concentrations is an adverse event.
In a study with the same group of children, it was shown that NDL-PCBs can cause a similar overall
decrease in the antibody titres as the PFASs. The correlation between the levels of PFOS and
NDL-PCBs was relatively poor and the relative decrease per doubling of the serum levels of PFOS was
larger after adjustment for NDL-PCB levels, indicating no confounding. It is, however, difﬁcult to
exclude an effect modiﬁcation.
3.6.3. Uncertainty in dose–response assessment and HBGV derivation
3.6.3.1. BMD modelling
The use of quantiles (deciles, octiles or quartiles) instead of raw data points in the BMD modelling
process increases uncertainty, because data points from different concentrations are grouped and
expressed as the median concentration. This may change the conﬁdence interval compared to the use
of individual data in either direction.
Since PFOS and PFOA are ubiquitous food and environmental contaminants, there is no such thing
as an unexposed control group. It was decided to use the median concentration of the lowest quantile
as the reference value in BMD modelling. The choice of the lowest quantile as the reference value
introduces an uncertainty, and in most cases, this would represent an underestimation of the risk.
As mentioned in Section 3.4.2.1, in the speciﬁc case of BMD modelling of serum cholesterol vs serum
PFOA, in the C8 cohort (Steenland et al., 2009), using the lowest decile as reference value, the BMD for
a 5% increase in cholesterol could not be modelled. The CONTAM Panel considered that the median
PFOA level in the lowest decile (mean 5.5 ng/mL) was higher than in other cohorts and in the
biomonitoring studies (see Section 3.3.2). As an example, the median of the medians for serum PFOA in
European populations was 1.9 ng/mL, and the 5th percentile in several studies was < 1 ng/mL. The use
of 1 ng/mL (half of the median of the medians in European studies) as a proxy for the ‘low’ serum PFOA
concentrations was therefore evaluated, resulting in a BMDL5 in the range of other values obtained for
PFOA. As it is, however, an extrapolation outside the available aggregated data points (but still within
the observable range in the lowest decile) it adds uncertainty to the result of this BMD modelling.
Although the data used for BMD modelling were adjusted for several potential confounders,
associations with PFOS and PFOA were not mutually adjusted for each other. This is another source of
uncertainty. Since levels of PFOS usually are higher (four to ﬁve times) than levels of PFOA, the
possible confounding of PFOS on PFOA is probably more important than the confounding of PFOA on
PFOS. The CONTAM Panel decided not to adjust the PFOA TWI for PFOS or the PFOS TWI for PFOA
since the extent of confounding by such co-exposure is unknown. This represents an additional source
of uncertainty.
3.6.3.2. PBPK modelling
Tissue:plasma partition coefﬁcients for PFASs for all tissues in the model were calculated from
tissue concentration data (animal data). Uncertainty remains for extrapolation from animal to human.
Whatever the data or studies used for calibration or validation (although the exposure duration is
unknown), simulated results were found inside the uncertainty range of experimental values.
Since parameterisation of PBPK models is based on empirical estimation and experimental data,
simulation results may have a high degree of uncertainty. As a consequence, the reliability of model
validation is highly affected. A number of approaches have been used to estimate the variability and
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uncertainty of PBPK models, such as Monte Carlo simulation. Nevertheless, a clear differentiation of
uncertainty and variability in modelling has not been conducted.
The most sensitive parameters are elimination constants (Tm and Kt), free fraction of PFOS or PFOA
in serum, blood ﬂow to the kidney and cardiac output (see Appendix C). For PFOS and PFOA, around
80% of the uncertainty comes from these four parameters (Fabrega et al., 2016). The variation in
reported half-lives for PFOS and PFOA is a source of uncertainty in the respective PBPK models.
There is uncertainty in the modelling of plasma levels of PFOS/PFOA in young children, especially in
terms of the contribution from breast milk. Some data on PFOS/PFOA levels in breast milk are
available, and the average intake in mL per day is known. However, there is no information on possible
differences between infants and adults regarding absorption and/or excretion of PFOS/PFOA.
Infants who are breastfed will have an additional exposure during infancy. It will vary with length of
breastfeeding and the concentration of PFOS/PFOA in breast milk. Overall, there is uncertainty in
translation of maternal intake rates of PFOS/PFOA to serum concentrations in children.
3.6.4. Summary of uncertainties
In Table 29, a summary of the uncertainty evaluation is presented, highlighting the main sources of
uncertainty and indicating an estimate of whether the respective source of uncertainty might have led
to an over- or underestimation of the exposure or the resulting risk.
For the human epidemiological studies, uncertainties have the potential to cause both over- and
underestimation of risk. For the potential critical outcomes cholesterol, vaccination response, increased
prevalence of ALT above the reference range, and decreased birth weight, the factors that would
cause an overestimation of risk are probably somewhat more important than those acting in the
opposite direction. The CONTAM Panel considered that the impact of the uncertainties on the risk
assessment of PFOS and PFOA is high and are mostly driven by uncertainty in occurrence and dietary
exposure data, and for PFOA also in BMD modelling. Overall, the risk assessment is likely to be
conservative.
Table 29: Summary of qualitative evaluation of the impact of uncertainties on the risk assessment
of PFOS and PFOA in food
Sources of uncertainty Direction
Extrapolation of occurrence data few Member States to whole Europe +/(a)
Limited occurrence data from several food groups +/
Exclusion of several food categories and food groups from the exposure assessment 
Large proportion of left-censored data in the ﬁnal data set +/
Using the substitution method at the lower bound (LB) scenario 
Using the substitution method at the upper bound (UB) scenario +
Combining data that are corrected for analytical recovery with data that are not corrected +/
Non-differential misclassiﬁcation of exposure and/or outcome in human epi studies 
Residual confounding, e.g. from life-style factors in human epi studies +/
Confounding by co-exposure in human epi studies +
Limited statistical power for rare outcomes in human epi studies 
Uncertainty regarding adversity of biomarkers in human epi studies +/
Lack of raw data points for BMD modelling +/
Use of a low quantile or the reference value based on half of the median of medians in European
studies instead of zero for BMD modelling(b)

Extent of bile excretion and gastrointestinal reabsorption +/
Uncertainty in the contribution from breastfeeding in the vaccination response in children +/
PBPK modelling +/
(a): + = uncertainty with potential to cause over-estimation of exposure/risk;  = uncertainty with potential to cause under-
estimation of exposure/risk.
(b): Although there is a possibility that this could result in an overestimation, it is much more likely to underestimate and
therefore a ‘’ has been inserted into the Table.
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4. Conclusions
PFOS and PFOA belong to the group of per- and polyﬂuoroalkyl substances (PFASs). Linear,
branched or linear/branched mixtures of PFOS and PFOA have been produced and are found in human
and environmental samples. LC–MS/MS) is commonly used to determine PFOS and PFOA in both food
and biological samples. Since the 1940s, PFASs have been produced and used in numerous
commercial and industrial applications, including textile, carpet and leather treatment (water and dirt
prooﬁng), surfactants, ﬁreﬁghting foams, metal plating and paper grease-prooﬁng treatments. The
widespread use of PFOS, PFOA and their precursors, together with their persistency, has resulted in
widespread environmental contamination.
4.1. Occurrence/Exposure
• An initial number of 21,411 results for food samples analysed for PFOS (n = 10,889) and PFOA
(n = 10,522) from 16 European countries were available for the assessment. The data set was
characterised by a high proportion of left-censored data (results below LOD/LOQ) with 74% of
left-censored data for PFOS and 91% of left-censored for PFOA. A total of 20,019 analytical
results (n = 10,191 for PFOS and n = 9,828 for PFOA) fulﬁlled the quality criteria applied and
have been considered in the assessment.
• The highest mean concentrations of PFOS and PFOA were recorded in the food category ‘Meat
and meat products’. This was affected by a high mean concentration in liver from game
mammals (LB/UB mean = 215/215 lg/kg for PFOS and LB/UB mean = 5.46/8.11 lg/kg for
PFOA).
• Excluding offal, the mean concentration in the category ‘meat and meat products’ was LB/UB
= 0.55/0.75 for PFOS and LB/UB = 0.10/0.34 for PFOA. In edible offal from farmed animals,
the concentration was for PFOS (LB/UB mean) 0.66/2.12 lg/kg and for PFOA (LB/UB mean)
0.05/1.39 lg/kg.
• High levels were also observed in ‘Fish and other seafood’ (LB/UB mean = 2.08/2.59 lg/kg for
PFOS and LB/UB mean = 0.18/0.90 lg/kg for PFOA.
• For PFOS, the LB mean dietary exposure ranges from 1.26 (adolescents) to 20.86 (other
children) ng/kg bw per week across age groups and surveys. The high (95th percentile) LB
exposure range from 3.5 (adolescents) to 165.9 (other children) ng/kg bw per week.
• For PFOA, the mean LB dietary exposure estimates range from 1.47 ng/kg bw per week
(elderly and very elderly) up to 18.27 ng/kg bw per week (toddlers). The high LB (95th
percentile) exposures range from 3.43 (very elderly) to 37.59 (toddlers) ng/kg bw per week.
• The most important contributors to the LB mean chronic exposure to PFOS were ‘Fish and
other seafood’ (contributing up to 86% in adults), especially ‘Fish meat’, followed by ‘Meat and
meat products’ and ‘Eggs and egg products’. Regarding PFOA, ‘Milk and dairy products’
(contributing up to 86% in toddlers, but based on only a few samples with detectable levels
for cow milk and gouda cheese), ‘Drinking water’ and ‘Fish and other seafood’ made the
largest contribution to the LB mean chronic exposure.
4.2. Hazard identiﬁcation and characterisation
4.2.1. Toxicokinetics
• PFOS and PFOA are readily absorbed through the gastrointestinal tract in mammals including
humans; then they distribute predominantly to the plasma and liver, are not metabolised and
are excreted in both urine and faeces.
• Biological half-lives of both PFOS and PFOA are different between species and this is mainly
due to differences in renal clearance.
• Half-lives of PFOS in rodents are slightly higher than one month, whereas in rabbits and
monkeys estimated half-lives were 3–4 months.
• Signiﬁcant gender differences in the elimination of PFOA are observed in some, but not all
species; there are no gender differences in renal clearance in humans. Half-lives of about one
day and one week were measured in female and male rats, respectively. In cynomolgus
monkeys the elimination half-life was estimated at approximately one month and limited
gender differences were observed regarding the disposition of PFOA in this species.
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• The half-lives of the branched chain PFOS and PFOA isomers are generally shorter than those
for the linear molecules, with the exception of 1 m-PFOS.
• For both PFOS and PFOA, maternal transfer occurs prenatally to the fetus and postnatally
through breastfeeding.
• The estimated half-life for PFOS in humans is approximately 5 years, whereas for PFOA,
several studies estimated a half-life between 2 and 4 years.
4.2.2. Biomonitoring
• PFOS and PFOA were detected in blood samples of almost all individuals assessed,
demonstrating ubiquitous exposure.
• In adults, the median for PFOS in the different studies ranged between 1.7 and 27.4 ng/mL
(median of medians 7.7 ng/mL). For PFOA the median in adults ranged between 0.76 and
4.9 ng/mL (median of medians 1.9 ng/mL). In children, the median for PFOS in the different
studies ranged between 0.49 and 8.6 ng/mL (median of medians 3.2 ng/mL). For PFOA the
median in children ranged between 0.49 and 6.9 ng/mL (median of medians 3.3 ng/mL).
• Using individual data, for PFOS, the concentrations in adults and children ranged from 0.06 to
392 ng/mL and from 0.47 to 23 ng/mL, respectively. For PFOA, the concentrations in adults
and children ranged from 0.03 to 81 ng/mL and from 0.45 to 19.5 (P95) ng/mL, respectively.
• The breast milk concentrations are usually around 0.9–2% and 1.8–9% of the maternal
serum/plasma concentrations for PFOS and PFOA, respectively.
• Concentrations observed in European populations were comparable to general populations
worldwide.
4.2.3. Toxicity in experimental animals
4.2.3.1. Repeated dose toxicity
• The rodent liver is a major target organ of PFOS. The most sensitive parameter was a dose-
dependent increase in the relative liver weight starting at 0.15 mg/kg bw per day.
• The effects of PFOS in rodents, i.e. increased organ weight, hypertrophy of hepatocytes, and
induction of peroxisomal b-oxidation are mediated largely by interaction of PFOS with PPARa.
• In rodents, PFOA increased absolute and relative liver weight and hepatic peroxisomal b-
oxidation at 0.64 mg/kg bw per day.
• PFOA-induced transactivation of PPARa is the major mechanism, underlying the hepatic effects.
Evidence for liver damage was found as enhanced lipid peroxidation and elevated liver
enzymes in serum at 2.5 mg/kg bw per day in mice.
4.2.3.2. Developmental and reproductive toxicity
• In rodents for PFOS, the most sensitive effects were on maternal liver weight (0.3 mg/kg bw
per day), placental physiology (0.5 mg/kg bw per day) and on glucose homoeostasis (0.3 mg/
kg bw per day).
• Following PFOA exposure, pathological alterations included increased liver weight in mouse
pups and mothers following in utero exposure at doses of 0.1 and 0.6 mg/kg bw per day
respectively.
• In adult male mice, reproductive organs and male sex hormone levels were affected at
0.31 mg/kg bw per day.
• For PFOA, biological responses at low doses (delay of mammary gland development in off-
spring animals and changes of levels of metabolic parameters) were noted at 0.01 mg/kg bw
per day in mice.
4.2.3.3. Neurotoxicity
• In rodents, both PFOS and PFOA have developmental neurotoxicity potential and widespread
effects on the expression of genes coding for proteins relevant for signal transmission in the
brain.
• In rodents, male offspring are more sensitive than females.
• The most frequent behavioural outcome reported after PFOS exposure in rodents is decreased
spontaneous activity, which on the contrary is increased by PFOA.
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4.2.3.4. Immunotoxicity
• Various structural and functional parameters are affected by PFOS in mice; the most sensitive
parameter affected by PFOS is the T-cell dependent antibody response to immunisation.
• The NOAEL for PFOS derived from the available studies is 1.66 lg/kg bw per day, based on
the suppression of anti-SRBC IgM titres in mice.
• Effects of PFOA are similar to the effects of PFOS in mice, with both structural and functional
parameters inﬂuenced.
• The NOAEL for immunotoxicity of PFOA was 1 mg/kg bw per day based on suppression of
anti-SRBC IgM titres in mice.
4.2.3.5. Genotoxicity
• No evidence for a direct genotoxic mode of action for both PFOS and PFOA was identiﬁed.
• There is some evidence for oxidative stress induced by both PFOA and PFOS.
4.2.3.6. Long-term toxicity and carcinogenicity
• PFOS was found to cause tumours in the liver of rats. Mechanistic studies suggested that the
compound may act as a tumour promoter.
• In Sprague–Dawley rats, PFOA induced Leydig cell tumours. Hormonal dysbalance appears to
be the underlying mechanism. Inconsistent effects were noted for pancreatic hyperplasia or
tumours in mammary gland and liver.
4.2.4. Human observations
For a number of outcomes listed below and described in Section 3.3.4, the evidence for causal
associations with PFOS/PFOA was considered insufﬁcient. The reasons for this included evidence from
single or few epidemiological studies, lack of statistical power, risk of bias, lack of external validity or
inconsistent ﬁndings in the published studies and these are further summarised for the respective
outcomes in Section 3.3.4.
For many of the outcomes reviewed, the majority of epidemiological studies were cross-sectional,
but for some outcomes the results from many cross-sectional studies were consistent and supported
also by a few longitudinal studies.
4.2.4.1. Fertility and pregnancy outcomes
• Epidemiological studies provide some evidence for a causal association between prenatal
exposure to PFOS and PFOA and birth weight. Despite relatively consistent ﬁndings, the role of
confounding by increased glomerular ﬁltration rate cannot be excluded and some uncertainty
on the clinical relevance of these ﬁndings exists as associations with low birth weight (deﬁned
as < 2,500 g) have not been reported.
• Epidemiological studies conducted provide insufﬁcient evidence for a causal association
between prenatal exposures to PFOS and PFOA and increased prevalence of birth defects or
stillbirths, subfecundity, risk of miscarriage or pregnancy hypertension.
4.2.4.2. Developmental outcomes
• Epidemiological studies provide insufﬁcient support for causal associations between prenatal or
perinatal exposure to PFOS/PFOA and neurodevelopment, growth in infancy or childhood,
puberty, semen quality or metabolic outcomes.
4.2.4.3. Neurotoxicity outcomes
• Epidemiological studies provide insufﬁcient support for causal associations between exposure
to PFOS/PFOA and neurobehavioural, neuropsychiatric or cognitive outcomes in childhood or
adulthood.
4.2.4.4. Immune outcomes
• Epidemiological studies suggest that exposure to PFOS, and possibly PFOA, adversely affect
serum antibody response following vaccination, with children being the most vulnerable
subgroup. This provides strong support for causal associations.
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• There are some suggestions from epidemiological studies that prenatal exposures to PFOS and
PFOA may lead to increased propensity of infection.
• Epidemiological studies provide insufﬁcient support for causal associations between exposures
to PFOS or PFOA and asthma and allergies in children and adults.
4.2.4.5. Endocrine outcomes
• Epidemiological studies provide insufﬁcient support for causal associations between exposure
to PFOS/PFOA and timing of puberty, menopause, menstrual cycle changes, endometriosis,
milk production measured as duration of breastfeeding, semen quality, sex hormones or
thyroid function.
4.2.4.6. Metabolic outcomes
• Epidemiological studies provide strong support for causal associations between exposure to
PFOS and PFOA and increased serum levels of cholesterol.
• Epidemiological studies provide support for a causal association between exposure to PFOA
and increased serum levels of the liver enzyme alanine transferase (ALT), but not for liver
disease.
• There is insufﬁcient support for causal associations with diabetes, obesity and metabolic
syndrome.
4.2.4.7. Kidney and uric acid
• Epidemiological studies provide insufﬁcient support for causal associations between exposure
to PFOS/PFOA and changes in kidney function or serum levels or uric acid.
4.2.4.8. Carcinogenicity outcomes
• Epidemiological studies provide insufﬁcient support for carcinogenicity of PFOS and PFOA in
humans. This conclusion applies to both studies conducted in occupationally exposed
individuals and in the general population.
4.2.4.9. Cardiovascular outcomes
• Epidemiological studies provide insufﬁcient support for causal associations between exposure
to PFOS/PFOA and increased risk of cardiovascular disease.
4.2.4.10. Other outcomes
• Epidemiological studies provide insufﬁcient support for causal associations between exposure
to PFOS/PFOA and risk of ulcerative colitis, osteoarthritis, rheumatoid arthritis or bone mineral
density.
4.2.5. Mode of action
4.2.5.1. Liver toxicity
• PFOS and PFOA, both ligands of the nuclear receptor PPARa, induce liver growth, proliferation
of peroxisomes and induction of peroxisomal b-oxidation in rodents.
• Elevated peroxisomal b-oxidation in rodents may lead to hepatic lipid peroxidation and
subsequently to cell death and enhanced release of liver transaminases.
• It is presently unclear by which mechanisms PFOS and PFOA may increase serum alanine
aminotransferase in humans.
4.2.5.2. Metabolic outcomes – Blood lipids
• In rodents, PFOS and PFOA may impair the release of cholesterol and/or triglycerides from the
liver causing elevated intrahepatic and lowered serum cholesterol and/or triglyceride
concentrations. These effects in rodents may not be of human relevance presumably due to
species-speciﬁc differences in the function of PPARa affecting the metabolism of lipids.
4.2.5.3. Birth weight
• In human studies, an inverse relation between PFOS and IGF-1 levels were shown, which may
be associated with a reduced growth rate.
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• In rodents, PFOS and PFOA reduced body weight, which is associated with loss of white
adipose tissue, upregulation of UCP-1 and its association with energy expenditure and
regulation of food consumption.
4.2.5.4. Immunotoxicity
• PFOS and PFOA affect lymphocytes, macrophages, and other cells of the immune system
possibly by modulation of gene regulation via PPARs, NF-jB transcription and regulation of
apoptosis.
• PFOS and PFOA share mechanisms, but may also be different as cytokine proﬁles in lymphoid
cells have shown to be differentially affected.
4.2.5.5. Carcinogenicity
• PFOS and PFOA act as tumour promoters in rodent liver. Transactivation of rodent PPARa but
not of human PPARa appears to mediate the carcinogenic activity of PPARa ligands. A similar
mechanism may be anticipated for PFOS and PFOA.
• PFOA induces Leydig cell adenomas in rat testis, caused by reduced serum testosterone levels
and compensatory releases of luteotrophic hormone, which stimulates growth of Leydig cells
and tumour formation. Leydig cell tumours occur frequently in rodents but rarely in humans.
• PFOA causes pancreatic hyperplasia, a prestage of tumour formation. As known from other
PPARa ligands, altered composition and output of bile acids may enhance the secretion of
cholecystokinin, which binds to acinar CKK1 receptor and stimulates growth of this cell type.
This MoA appears to be irrelevant for humans.
4.3. Critical effects, dose–response assessment and derivation of a
health-based guidance value
For both PFOS and PFOA, a large number of epidemiological studies in humans have been
published, most of them not being available for the previous opinion in 2008. For the present opinion,
the CONTAM Panel decided to use human observations when assessing critical effects and for
derivation of an HBGV.
Since both toxicity as well as underlying modes of toxic action for PFOS and PFOA are not
sufﬁciently understood and might differ, but also overlap, the CONTAM Panel decided not to derive a
group HBGV for PFOS and PFOA.
4.3.1. PFOS
• For outcomes identiﬁed in adults, the CONTAM Panel considers the increase of serum
cholesterol to be the critical key adverse outcome for PFOS. Three studies on serum
cholesterol showed very similar BMDL5 levels expressed as serum PFOS (21–25 ng/mL),
corresponding to an estimated chronic daily intake of 1.7–2.0 (median 1.8) ng/kg bw per day
as calculated with a PBPK-model for humans.
• It is likely that adjustment for PFOA (and maybe other PFASs) would result in somewhat higher
BMDL5 values and corresponding daily intake rates.
• The CONTAM Panel considered it not appropriate to calculate which intake rate for children
after the end of breastfeeding would correspond to the BMDL5 level for serum PFOS in 5-year
old children. Instead, the serum PFOS levels in the pregnant mothers in the critical study were
compared with serum PFOS levels for the other potential critical effects, and plasma levels in
breastfed children were modelled to illustrate how maternal serum PFOS levels and intake
rates would be related to serum PFOS levels in their 5-year old children.
• The BMDL5 for reduced birth weight was the same as for increased cholesterol. The CONTAM
Panel noted that there is still some uncertainty both regarding causality and adversity of
reduced birth weight. However, since there is likely confounding by glomerular ﬁltration rate,
an intake rate based on the BMDL5 for increased cholesterol is protective also for reduced birth
weight.
• With serum cholesterol, antibody response after vaccination, and birth weight all considered as
potential critical endpoints, the CONTAM Panel found it appropriate to weigh the overall
evidence from the human observational studies when setting an HBGV. Therefore, the
CONTAM Panel considers that 1.8 ng/kg bw per day is an appropriate reference point.
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• In order to take into account the long half-life of PFOS, the CONTAM Panel established a TWI
of 13 ng/kg bw per week. If applied for all age groups, it is protective for adverse effects on
vaccination response and reduced birth weight.
4.3.2. PFOA
• The CONTAM Panel considers the increase of serum cholesterol to be the critical effect for
PFOA. Two studies on serum cholesterol showed very similar BMDL5 expressed as serum PFOA
(9.2–9.4 ng/mL) corresponding to an estimated chronic daily intake of 0.8 ng/kg bw per day
as calculated with a PBPK-model for humans.
• The BMDL5 from the larger of the two studies was based on extrapolation to a low serum
PFOA of 1 ng/mL, but it is still within the range of individual data observed in the lowest
decile. This adds to the uncertainty of the BMDL5. The CONTAM Panel decided to take into
account both this study and the smaller one when deriving an HBGV for PFOA.
• It is likely that adjustment for PFOS (and maybe other PFASs) would result in somewhat higher
BMDL5 levels and corresponding daily intake rates.
• The CONTAM Panel considered 0.8 ng/kg bw per day to be an appropriate reference point.
• In order to take into account the long half-life of PFOA the CONTAM Panel established a TWI
of 6 ng/kg bw per week. It is protective also for increased risk of liver damage, indicated by
high serum ALT. It is protective against reduced birth weight, taking into account the fact that
there is likely to be confounding by glomerular ﬁltration rate.
4.3.3. PFOS and PFOA
• The CONTAM Panel decided not to apply any additional uncertainty factors because the BMD
modelling was based on large epidemiological studies from the general population, including
potentially sensitive subgroups. The CONTAM Panel also took into account that the BMD
modelling was performed on risk factors for disease rather than disease.
4.4. Risk characterisation
• The CONTAM Panel is aware of the fact that the present exposure assessment is highly
uncertain. Large differences between LB and UB concentrations were observed in foods, as a
result of analytical methods being used that are not sufﬁciently sensitive. This results in a large
difference between maximum UB and minimum LB chronic dietary exposure estimates for
PFOS and PFOA.
• The CONTAM Panel considers that the true exposure level for both PFOS and PFOA is closer to
the LB than the UB values. This assumption is based on two facts:
• Studies performed using the best analytical methods with high sensitivity and high levels of
quality control give results with fewer left censored data and conﬁrm occurrence in foods
at levels close to the LB estimates.
• Median LB data in this opinion are consistent with what would be expected based on
median population blood serum levels.
• For PFOS, mean LB dietary exposure ranged from 1.3 to 20.9 ng/kg bw per week, across age
groups and surveys. The high (95th percentile) LB exposure ranged from 3.5 to 165.9 ng/kg
bw per week. Therefore, a considerable proportion of the population exceeds the TWI of
13 ng/kg bw per week, by up to 1.6- and 13-fold, for mean LB and high LB exposure,
respectively.
• For PFOS, at the UB, the TWI is exceeded in all surveys at mean exposure, and the high UB
(95th percentile) exposures exceed the TWI from 1.7- to 15-fold across surveys and age
groups.
• For PFOA, mean LB dietary exposure estimates range from 1.5 to 18.3 ng/kg bw per week.
The high (95th percentile) LB exposures range from 3.4 to 37.6 ng/kg bw per week.
Therefore, a considerable proportion of the population exceeds the TWI of 6 ng/kg bw per
week, by up to 3- and 6-fold for mean LB and high LB exposure, respectively.
• For PFOA, at the mean UB, the TWI is exceeded 1.4- to 14-fold across surveys and up to
28-fold at the high UB (95th percentile) exposure for toddlers.
• The exceedances of the TWIs for PFOS and PFOA at LB exposure estimates are of concern.
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5. Recommendations
• Data obtained by more sensitive analytical methods with high levels of quality control (to avoid
matrix effects or impact of background contamination) are needed in order to increase the
proportion of quantiﬁed results and thus reduce uncertainty in the occurrence assessment and
the dietary exposure assessment. Improved reporting of data in terms of clarifying whether
upper or lower bound and clariﬁcation of whether or not data are corrected for recovery will
reduce uncertainty in exposure estimates.
• More studies on the effect of cooking and food processing would improve exposure
assessments given that most food is consumed after cooking/processing and the data reported
in the scientiﬁc literature are inconsistent regarding the impact this has on exposure.
• More longitudinal epidemiological studies are needed, in particular prospective vaccination
studies covering more varied types of vaccines and age groups, as well as more studies on
other immune outcomes in humans.
• Access to individual data in epidemiological studies is needed in order to perform accurate
dose–response analysis and risk characterisation.
• Most epidemiological studies examine associations between health-related outcomes and single
PFASs separately in spite of co-exposures. For risk assessment it would be useful, also to
report results mutually adjusted for several PFASs so conclusions can be drawn on the
independent associations of PFOS and PFOA.
Documentation provided to EFSA
• Sørenson, 2017: data provided by Mette Sørenson on 21 September 2017 and used for BMD
modelling of the Eriksen et al., 2013 study.
• Danish National Birth Cohort, 2017: data provided by Danish National Birth Cohort after
contacting the data owners in May 2017 and used for BMD modelling of the Fei et al., 2007 study.
• Fletcher 2017b: data provided by Tony Fletcher on 28 June 2017 and used for BMD modelling
of the Gallo et al., 2012 study.
• Grandjean and Budtz-Jørgensen, 2017: data provided by Philippe Grandjean and Esben Budtz-
Jørgensen on 31 August 2017 and used for BMD modelling of the Grandjean et al., 2012 study.
• Steenland, 2017: information provided by Kyle Steenland on 01 March 2017 and used for BMD
modelling of the Steenland et al., 2009 study.
• Whitworth, 2017: data provided by Kristina W. Whitworth on 13 July 2017 and used for BMD
modelling of Whitworth et al., 2012a study.
• Campbell, 2018: modiﬁcations to PBPK model codes from Loccisano et al., 2011, were received
from Jerry Campbell in February 2018.
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Appendix A – Occurrence in food, human consumption data and human dietary exposure
Tables A.4–A.11 of Appendix A can be found in the online version of this output (‘Supporting information’ section): https://efsa.onlinelibrary.wiley.com/
doi/full/10.2903/j.efsa.2018.5194
Description: Supporting tables on food and feed occurrence and human exposure.
Table A.1: Dietary surveys used for the estimation of chronic dietary exposure to PFOS and PFOA
Country
Survey
acronym
Method
Survey
period
N of days
per subject
N of subjects
Infants Toddlers
Other
children
Adolescents
(mean age)
Adults Elderly
Very
elderly
Austria ASNS - Adults 24-h dietary
recall
2010–2012 2 – – – – 308 67 25
ASNS – Children 24-h dietary
recall
2010–2012 3 – 128 237 – – –
Belgium Regional Flanders Food record 2002–2002 3 – 36 625 – – – –
Belgium Diet National 2004 24-h dietary
recall
2004 2 – – – 576 (16a) 1,292 511 704
Bulgaria NUTRICHILD 24-h dietary
recall
2007 2 861 428 433 – – – –
Cyprus Childhealth Food record 2003 3 – – – 303 (13a) – – –
Czech Republic SISP04 24-h dietary
recall
2003–2004 2 – – 389 298 (13a) 1,666 – –
Denmark DANSDA 2005-08 Food record 2005–2008 7 – – 298 377 (13a) 1,739 274 12
Denmark IAT 2006 07 Food record 2006–2007 7 826 917 – – – – –
Finland DIPP 2001 2009 Food record 2001–2009 3 500 500 750 – – – –
Finland NWSSP07 08 48-h dietary
recall
2007–2008 4 – – – 306 (13a) – – –
Finland FINDIET2012 48-h dietary
recall
2012 2 – – – – 1,295 413 -
France INCA2 Food record 2007 7 – – 482 973 (14a) 2,276 264 84
Germany VELS Food record 2001–2002 6 159 348 293 – – – –
Germany EsKiMo Food record 2006 3 - - 835 393 (11a) – – –
Germany National Nutrition Survey
II
24-h dietary
recall
2007 2 – – – 1,011 (16a) 10,419 2,006 490
Greece Regional Crete Food record 2004–2005 3 – 838 – – – –
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Country
Survey
acronym
Method
Survey
period
N of days
per subject
N of subjects
Infants Toddlers
Other
children
Adolescents
(mean age)
Adults Elderly
Very
elderly
Greece DIET LACTATION GR Food record 2005–2007 3 – – – – 65 – –
Hungary National Repr Surv Food record 2003 3 – – – – 1,074 206 80
Ireland NANS 2012 Food record 2008–2010 4 – – – – 1,274 149 77
Italy INRAN SCAI 2005 06 Food record 2005–2006 3 16 36 193 247 (14a) 2,313 290 228
Latvia EFSA TEST 24-h dietary
recall
2008 2 – 187 453 (14a) 1,271 – –
Latvia FC PREGNANTWOMEN
2011
24-h dietary
recall
2011 2 – – – – 1,002 – –
Netherlands VCP kids Food record 2006–2007 3 – 322 957 – – – –
Netherlands VCPBasis AVL2007 2010 24-h dietary
recall
2007–2010 2 – – 447 1,142 (14a) 2,057 173 –
Netherlands VCP-Elderly Food
record;24-h
dietary recall
2010–2012 2 – – – – – 289 450
Romania Dieta Pilot Adults Food record 2012 7 – – – – 1,254 83 45
Spain enKid 24-h dietary
recall
1998–2000 2 – 17 156 209 (12a) – – –
Spain AESAN Food record 1999–2001 3 – – – – 410 – –
Spain NUT INK05 24-h dietary
recall
2004–2005 2 – 399 651 (14a) – – –
Spain AESAN FIAB 24-h dietary
recall
2009 3 – – – 86 (17a) 981 – –
Sweden NFA 24-h dietary
recall
2003 4 – – 1473 1,018 (12a) – – –
Sweden Riksmaten 2010 Food record 2010–2011 4 – – – – 1,430 295 72
United
Kingdom
NDNS-
RollingProgrammeYears1-
3
Food record 2008–2011 4 – 185 651 666 (14a) 1,266 166 139
United
Kingdom
DNSIYC 2011 Food record 2011 4 1,369 1,314 – – – – –
N: number; PFOA: perﬂuorooctanoic acid; PFOS: perﬂuorooctane sulfonic acid.
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Table A.2: Use of cut-offs for the LOQs of PFOS and PFOA and food groups and its effect on the ﬁnal occurrence values
Food category
(FoodEx Level 1)
Number of results
before applying
cut-off
LC %
Mean occurrence
values before
application of cut-offs
(µg/kg)
Cut-off
applied
on LOQ
Number of
results
excluded
Number of
results after
applying
cut-off
Mean occurrence
values
after application of
cut-offs (µg/kg)
LB UB LB UB
PFOS
Fish and other seafood 3,508 64 2.09 2.66 14.0 18 3,490 2.08 2.59
Drinking water 453 88 0.00043 0.0031 0.01 2 451 0.00045 0.0028
PFOA
Fish and other seafood 3,505 93 0.19 0.91 10.0 21 3,484 0.18 0.90
LB: lower bound; LC: left-censored; LOQ: limit of quantiﬁcation; PFOA: perﬂuorooctanoic acid; PFOS: perﬂuorooctane sulfonic acid; UB: upper bound.
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Table A.3: Analytical results excluded from the ﬁnal data set used to estimate dietary exposure and
the criteria applied for exclusion
Criteria for exclusion
Number of results
excluded
PFOS PFOA Total
Outdated data (data sampled before 2007) 438 433 871
Reported as suspect samples (not random sampling) 240 240 480
Results eliminated due to application of LOQ cut-offs on ‘Fish and other seafood’ and
‘Drinking water’
20 21 41
Total 698 694 1,392
LOQ: limit of quantiﬁcation; PFOA: perﬂuorooctanoic acid; PFOS: perﬂuorooctane sulfonic acid.
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Appendix B – Benchmark Dose Modelling
The outcome results presented in the tables below were performed on data adjusted for potential
confounders, as presented by the authors in the respective publications or provided upon request from
EFSA. Thus, the results are not ‘raw’ data, but predicted values for the respective PFOS/PFOA
quantiles.
1) Steenland et al., 2009 - Total cholesterol vs PFOS
decile
Median PFOS
(ng/mL)
Mean Total
cholesterol (mg/dL)
SD
1 6.4 197.0 62
2 10.5 199.3 62
3 13.6 200.0 65
4 16.1 203.0 60
5 18.8 204.0 62
6 21.6 205.0 66
7 24.9 205.7 61
8 29.2 207.7 64
9 35.5 209.2 62
10 49.3 209.6 62
PFOS: perﬂuorooctane sulfonic acid; SD: standard deviation.
Total number of individuals in the cohort: 46,294. Data on median PFOS levels, mean total
cholesterol levels and 95% conﬁdence interval (CI) were obtained by digitising the results from the
published paper. The number of subjects per decile was assumed to be equal in each quantile, and the
SDs were calculated based on the conﬁdence intervals.
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Model: Response = a + 0.5 9 b 9 erfc(ln(Dose/c)/(20.5 9 d))
a = 196.6; b = 13.8; c = 18.2; d = 0.57
BMR: 5%
Reference value: PFOS concentration at ﬁrst decile = 6.38 ng/mL
BMD: 27 ng/mL
BMDL: 25 ng/mL
erfc: complementary error function
PFOS and PFOA in food
www.efsa.europa.eu/efsajournal 251 EFSA Journal 2018;16(12):5194
2) Eriksen et al., 2013 - Total cholesterol vs PFOS
Octile
Median PFOS
level (ng/mL)
Mean Total
cholesterol (mg/dL)
SD
1 17.0 223.0 56
2 23.7 230.3 56
3 28.4 235.6 56
4 32.2 233.0 56
5 36.9 235.0 56
6 41.1 237.5 56
7 47.9 239.0 57
8 58.5 234.0 57
PFOS: perﬂuorooctane sulfonic acid; SD: standard deviation.
Total number of individuals in the cohort: 753. Data on median PFOS levels, mean total cholesterol
levels and 95% CI were obtained through author contact. The number of subjects per octile was
assumed to be approximately equal in each quantile, and the SDs were calculated based on the
conﬁdence intervals.
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Model: Response = a + b/Dose2
a = 238.7; b = 4427
BMR = 5%
Reference value: PFOS concentration at the ﬁrst octile = 17 ng/mL
BMD: 31 ng/mL
BMDL: 22 ng/mL
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3) Nelson et al., 2010 - Total cholesterol vs PFOS
Quartile
Median PFOS
level (ng/mL)
Mean Total
cholesterol (mg/dL)
SD
1 9.9 200.0 70
2 17 205.9 70
3 24 205.0 72
4 38 213.6 72
PFOS: perﬂuorooctane sulfonic acid; SD: standard deviation.
Total number of individuals in the cohort: 860. Data on median PFOS levels, and numbers in each
quantile were available in the published paper. Mean changes in total cholesterol and SEMs were
digitised from the published paper.
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Model: Response = a + b 9 e(Dose/c)
a = 170; b = 26.8; c = 81.5
BMR = 5%
Reference value: PFOS concentration of the ﬁrst quartile = 9.9 ng/mL
BMD: 31 ng/mL
BMDL: 21 ng/mL
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4) Grandjean et al. 2012 - Immunotoxicity vs PFOS
Decile
Median PFOS
level (ng/mL)
Log2 Diphtheria
antibody concentration
(IU/mL)
Mean Diphtheria
antibody concentration
(IU/mL)
SEM
(in log scale)
1 10.29 0.170 1.12 0.258
2 12.71 0.325 1.25 0.294
3 14.21 -0.406 0.75 0.321
4 15.59 0.266 1.20 0.260
5 16.64 -0.420 0.74 0.285
6 18.17 -0.536 0.69 0.291
7 19.84 0.088 1.06 0.267
8 21.29 -0.407 0.75 0.311
9 23.60 -0.189 0.87 0.312
10 28.40 -0.591 0.66 0.280
PFOS: perﬂuorooctane sulfonic acid; SEM: standard error of mean.
Total number of individuals in the cohort: 431. Data were obtained through author contact.
Original data are given in log2, so calculations were made in that unit and then converted. The
curve below is only given to show the shape of the curve in the same mathematical space as for other
models. Numbers in each decile were approximately the same.
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Model: Response = a + b 9 ln(Dose)
a = 2.15; b = 0.435
BMR = 5%
Reference value: PFOS concentration of the ﬁrst decile point = 10.29 ng/mL
BMD: 11.6 ng/mL
BMDL: 10.5 ng/mL
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5) Whitworth et al., 2012a - Birth weight vs PFOS
Quartile Median PFOS level (ng/mL) Mean Birth weight (g) SD
1 8.46 3778 551
2 11.64 3734 636
3 14.65 3683 664
4 19.9 3676 721
PFOS: perﬂuorooctane sulfonic acid; SD: standard deviation.
Total number of individuals in the cohort : 838. Data on number of subjects per quartile, PFOS
levels, birth weight and SD were obtained through author contact.
0 10 20 30 40
3,580
3,660
3,740
3,820
3,900
3,580
3,660
3,740
3,820
3,900
Model: Response = a + b 9 ln(Dose)
a = 4072; b = 137.9
BMR = 5%
Reference value: PFOS concentration of the ﬁrst quartile = 8.46 ng/mL
BMD: 36 ng/mL
BMDL: 21 ng/mL
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6) Steenland et al. 2009 - Total cholesterol vs PFOA
Decile
Median PFOA
level (ng/mL)
Mean Total cholesterol
level (mg/dL)
SD
1 5.5 199 60
2 9.6 202 60
3 13.5 204 60
4 18.2 205 60
5 24.1 206 60
6 33.5 206 60
7 48.3 208 60
8 70.9 207 60
9 117 208 60
10 344 210 60
PFOA: perﬂuorooctanoic acid; SD: standard deviation.
Total number of individuals in the cohort: 46,294. Data on median PFOA levels, mean total
cholesterol levels and 95% CIs, were obtained by digitising the results from the published paper. The
number of subjects per decile was assumed to be equal in each quantile, and the SDs were calculated
based on the 95% conﬁdence intervals.
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Model: Response = a + 0.5 9 b 9 erfc(ln(Dose/c)/(20.5 9 d))
a = 192.8; b = 16.2; c = 7.55; d = 1.44
BMR = 5%
Reference value: PFOA concentration = 1 ng/mL25
BMD: 12 ng/mL
BMDL: 9.4 ng/mL
erfc: complementary error function
25 For serum cholesterol versus serum PFOA in the C8 cohort (Steenland et al., 2009) a 5% increase in cholesterol could not be
modelled when the lowest decile was used as reference value. This was because the dose-response curve levels off at high
serum PFOA concentrations. The median PFOA level in the lowest decile was higher (median 5.5 ng/mL) than in other cohorts
and in the biomonitoring studies (see Section 3.3.2). However, using a ‘low’ concentration of 1 ng/mL, being half of the
median of the medians of serum PFOA in Europe (1.9 ng/mL, see section 3.3.2.3, Table 8), allowed modelling.
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7) Eriksen et al. 2013 - Total cholesterol vs PFOA
Octile
Median PFOA
level (ng/mL)
Mean Total
cholesterol (mg/dL)
SD
1 3.3 223.0 56
2 4.6 226.5 56
3 5.4 231.5 56
4 6.2 229.0 56
5 7.1 226.2 56
6 7.9 237.5 56
7 9.3 229.4 57
8 11.8 235.4 57
PFOA: perﬂuorooctanoic acid; SD: standard deviation.
Total number of individuals in the cohort: 753. Data on median PFOA levels, mean total cholesterol
levels and CI, were obtained through author contact. The number of subjects per octile was assumed
to be approximately equal in each quantile, and the SDs were calculated based on the conﬁdence
intervals.
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Model: response = 0.5 9 a 9 erfc (ln(Dose/b)/(20.5 9 c))
a = 584; b = 7725; c = 26.2
BMR = 5%
Reference value26: PFOA concentration ﬁrst octile = 3.3 ng/mL
BMD: 12.4 ng/mL
BMDL: 9.2 ng/mL
erfc: complementary error function
26 Using Reference value of 1 ng/mL= BMD: 11 ng/mL, BMDL: 8.1 ng/mL
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8) Gallo et al. 2012 - Alanine Transferase vs PFOA
Decile
Median
PFOA
level (ng/mL)
Number above
reference
range
Number of
individuals
Prevalence (number
above reference
range/number of
individuals) (%)
1 5.8 417 4609 9.0
2 9.7 446 4573 9.7
3 13.5 494 4688 10.5
4 17.9 516 4678 11.0
5 24 558 4639 12.0
6 33 550 4681 11.7
7 47.2 522 4643 11.2
8 70.8 557 4642 12.0
9 118 547 4650 11.7
10 355 589 4649 12.6
PFOA: perﬂuorooctanoic acid.
Total number of individuals in the cohort : 47,092. Data were obtained through author contact.
Model: Response = a + (b/p) 9 (arctan((Dosec)/d) + p/2) (cumulative Lorentzian curve with
intercept).
a = 7.68; b = 4.44; c = 10.4; d = 6.13.
BMR = 3%
Reference value: PFOA concentration at ﬁrst decile (= 5.8 ng/mL)
BMD: 80 ng/mL
BMDL: 21 ng/mL
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9) Fei et al. 2007 - Birth weight vs PFOA
Decile
Median PFOA
level (ng/mL)
Mean Birth
weight (g)
SD
1 2.4 3737 638
2 3.2 3754 640
3 3.9 3657 650
4 4.4 3675 650
5 5.0 3696 650
6 5.5 3702 655
7 6.2 3643 660
8 7.0 3660 660
9 7.9 3690 680
10 9.7 3597 685
PFOA: perﬂuorooctanoic acid; SD: standard deviation.
Total number of individuals in the cohort : 1400. Data were obtained through author contact (the
Danish National Birth Cohort). The number of subjects per decile was assumed to be equal in each
decile.
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Model: Response = a 9 Dose + b
a = 15.1; b = 3766
BMR = 5%
Reference value: PFOA concentration at ﬁrst decile (= 2.4 ng/mL)
BMD: 14.5 ng/mL
BMDL: 10.6 ng/mL
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10) Whitworth et al. 2012a - Birth weight vs PFOA
Quartile
Median PFOA
level (ng/mL)
Mean Birth
weight (g)
SD
1 1.33 3754 593
2 1.92 3728 551
3 2.60 3739 593
4 3.69 3668 593
PFOA: perﬂuorooctanoic acid; SD: standard deviation.
Total number of individuals in the cohort: 849. Data on number of subjects in each quartile, PFOA
levels, birth weight and SD were obtained through author contact.
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Model: Response = a + b 9 eDose
a = 3759; b = 2.28
BMR = 5%
Reference value: PFOA concentration at ﬁrst quartile (= 1.33 ng/mL)
BMD: 4.4 ng/mL
BMDL: 4.0 ng/mL
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Appendix C – PBPK Modelling
C.1. Steady-state concentrations
Figures C.1 and C.2 show steady-state plasma concentrations of PFOA and PFOS, respectively,
using PBPK modelling as described in Section C.3 of this Appendix. The model codes were based on
the supplementary material in (Loccisano et al., 2011), with some modiﬁcations provided by a co-
author of the original paper (see Campbell, 2018- under ‘Documentation provided to EFSA’). When
codes differ from the original codes provided by (Loccisano et al., 2011) it is explained in notes to the
model code (see Subsections C.3.4.1 and C.3.4.2 of this Appendix).
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Estimations are from the PBPK model from Loccisano et al. (2011) (coded and simulated by Berkeley Madonna
version 8.3.18).
Figure C.1: Simulation of plasma PFOA concentration after chronic daily exposure (constant
exposure) of 0.85 ng/kg bw per day of PFOA, which is an exposure that results in a
steady-state concentration of 9.4 ng/mL, corresponding to the BMDL5 (target
concentration associated with an increase of total cholesterol from Steenland et al., 2009)
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C.2. Inﬂuence of breastfeeding for 6 months
Infants who are breastfed will have an additional exposure during infancy. It will vary with length of
breastfeeding and the concentration of PFOS/PFOA in breast milk. Breastfeeding will increase the
plasma concentrations of PFOS/PFOA at the end of infancy and also affect the daily ingested dose that
should not be exceeded after infancy in order not to reach the BMDL5 at age 5 years. In the examples
below (scenarios 1 and 2), the following assumptions have been made: the ratio between cord blood
and maternal blood PFOS concentration is 1/3 (ATSDR, 2015; Manzano-Salgado et al., 2015) and the
ratio between breast milk and maternal blood PFOS concentration is 1.5/100 (K€arrman et al., 2007;
Haug et al., 2011b; Kim et al., 2011a; Liu et al., 2011). See Subsections C.3.4.3 and C.3.4.4 in this
appendix for the modelling codes used.
C.2.1. Breastfeeding Scenario 1
In scenario 1 (Figure C.3), modelling was performed assuming a maternal concentration of 7.7 ng/mL
(median of medians for adults from opinion – see Table 8, Section 3.3.2.3 of the opinion). The starting
serum concentration of PFOS in the newborn was assumed to be 2.6 ng/mL. The PFOS concentration in
breast milk was assumed 0.12 ng/mL. The constant exposure after breastfeeding is 1.8 ng/kg per day.
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Estimations are from the PBPK model from Loccisano et al. (2011) (coded and simulated by Berkeley Madonna
version 8.3.18).
Figure C.2: Simulation of plasma PFOS concentration after chronic daily exposure (constant
exposure) of 1.8 ng/kg bw per day of PFOS, which is an exposure that results in a
steady-state concentration of 22 ng/mL, corresponding to the BMDL5 (target
concentration associated with an increase of total cholesterol from Eriksen et al., 2013).
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The resulting serum concentration in the child at 5 years of age is about 7 ng/mL.
C.2.2. Breastfeeding Scenario 2
In scenario 2 (Figure C.4), modelling was performed assuming a maternal concentration of
22 ng/mL (BMDL5 in Eriksen et al. (2013); see Table 27 of the opinion). The starting serum
concentration of PFOS in the newborn was assumed to be 7.3 ng/mL and the PFOS concentration in
breast milk was assumed to be 0.33 ng/mL. The constant exposure after breastfeeding is 1.8 ng/kg
per day. The resulting serum concentration in the child at 5 years of age is about 9.6 ng/mL.
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Figure C.3: Simulation of PFOS plasma concentration resulting from chronic daily exposure to 1.8 ng/kg
bw per day of PFOS from food after 6 months exclusive breastfeeding with milk
(800 mL/day) containing 0.12 ng/mL of PFOS and a serum PFOS at birth of 2.6 ng/mL
(corresponding to a mother’s plasma PFOS concentration of 7.7 ng/mL, median of medians
for adults from opinion), estimated from the PBPK model in Loccisano et al. (2011) with
some modiﬁcations (coded and simulated by Berkeley Madonna version 8.3.18)
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C.3. PBPK Model
C.3.1. Model description
The model from Loccisano et al. (2011) is shown in Figure C.6.
The original Loccisano model was slightly modiﬁed by integrating a growth equation based on a
French survey.27 This study (EAT for French total Diet Study) includes 4,078 subjects with age between 3
and 60 years, and 703 subjects of less than 3 years). The reported data (weight, age) from this study
allow building an equation describing the increase in weight according to age (see Figure C.5).
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Figure C.4: Simulation of PFOS plasma concentration resulting from chronic daily exposure to 1.8 ng/
kg bw per day of PFOS from food after 6 months exclusive breastfeeding with milk (800
mL/day) containing 0.33 ng/mL of PFOS and a serum PFOS at birth of 7.3 ng/mL
(corresponding to a mother’s plasma PFOS concentration of 22 ng/mL, BMDL5 in),
estimated from the PBPK model in Loccisano et al. (2011) with some modiﬁcations
(coded and simulated by Berkeley Madonna version 8.3.18)
27 Arnich N, Sirot V, Riviere G, Jean J, No€el L, Guerin T and Leblanc JC, 2012. Dietary exposure to trace elements and health risk
assessment in the 2nd French Total Diet Study. Food Chemistry and Toxicology, 50, 2432–2449.
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Brieﬂy, PFOA and/or PFOS are taken up into the plasma (i.v.) or into the gut (oral). From the gut,
PFOA and/or PFOS are transported to the liver by the portal blood. Only the free fractions of PFOA and/or
PFOS in plasma are assumed to be available for partitioning into tissues. PFOA and/or PFOS is eliminated
through the ﬁltrate compartment to storage into urine, while in the ﬁltrate compartment, PFOA and/or
PFOS can be reabsorbed back into the plasma through a saturable process with a transporter maximum
constant (Tmc) and afﬁnity constant (Kt). The Qs indicate blood ﬂows into and out of tissues. Qﬁl is not a
blood ﬂow – it is a clearance (L/h) from the plasma to the ﬁltrate compartment.
Figure C.5: Growth equation based on a French survey, describing the increase in weight according to age,
including 4,078 subjects, aged between 3 and 60 years, and 703 subjects of less than 3 years
PBPK: physiologically based pharmacokinetic (model); Kt: afﬁnity constant; PFOA: perﬂuorooctanoic acid; PFOS:
perﬂuorooctane sulfonic acid; Qs: blood ﬂows into and out of tissues – where Qﬁl is not a blood ﬂow, but is a
clearance (L/h) from the plasma to the ﬁltrate compartment; Tm: Transporter maximum.
Figure C.6: Structure of PBPK model for PFOA and PFOS in monkeys and humans from Loccisano
et al. (2011)
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The PBPK model was based on a series of differential equations. The expression to estimate the
levels of PFOA and PFOS in non-elimination tissues is:
dCi
dt
¼ Qi free ðCa Ci=Ki:pÞ
Vi
where Ci is the cellular concentration in each tissue (pg/mL), Qi is the blood ﬂow (mL/h), free means
the free amount of PFASs in plasma (unitless), Ca is the arterial concentration (pg/mL), Ki:p is the
partition coefﬁcient (unitless) and Vi is the tissue volume (mL).
The cellular concentrations of PFOA and PFOS in gut were obtained by applying this equation:
dCg
dt
¼ ðQg free ðCa Cg=Kg:pÞ þ IntakeÞ
Vg
where Cg is the cellular concentration in gut (pg/mL), Qg is the blood ﬂow to gut (mL/h), free means
the free amount of PFASs in plasma (unitless), Ca is the arterial concentration (pg/mL), Kg:p is the gut
partition coefﬁcient (unitless), Intake is theoretical daily intake (pg/h) and Vg is the gut volume (mL).
For the kidney compartment, the following equation was used:
dCk
dt
¼

Qk  free

Ca CkKk:p

þ Tm  CfilKt + Cfil

Vk
where Ck is the cellular concentration in kidney (pg/mL), Qk is the blood ﬂow to kidney (mL/h), free is
the free amount of PFASs in plasma (unitless), Ca is the arterial concentration (pg/mL), Kk:p is the gut
partition coefﬁcient (unitless), Tm is the resorption maximum (pg/h), Cﬁl is the cellular concentration
in ﬁltrate (pg/mL), Kt is the afﬁnity constant (ng/mL) and Vk is the kidney volume (mL).
Finally, PFAS concentrations in the ﬁltrate compartment were simulated by applying this equation:
dCfil
dt
¼

Qfil

free Ca Cfil

 Tm  CfilKt + Cfil

Vfil
where Cﬁl is the cellular concentration in ﬁltrate (pg/mL), Qﬁl is the blood ﬂow to ﬁltrate (mL/h), free
is the free amount of PFASs in plasma (unitless), Ca is the arterial concentration (pg/mL), Tm is the
resorption maximum (pg/h), Kt is the afﬁnity constant (ng/mL) and Vﬁl is the ﬁltrate volume (mL).
C.3.2. Model validation
The model was applied in a case study of human individuals living in Little Hocking (Ohio, USA) and
Arnsberg (Germany), and exposed to relatively high concentrations of PFOS and PFOA through
consumption of drinking water. The result was a PBPK model reasonably capable to estimate the
concentration of PFOS and PFOA in the human body.
Coding and simulations for both the PFOA and PFOS models was performed in the Berkeley–
Madonna program (Macey et al., 2000).
C.3.3. Parameters used with the software Berkeley-Madonna version 8.3.18
The parameters applied in this opinion are shown below in Table C.1.
Table C.1: Parameters for PFOS and PFOA
Parameters
Values used in the
current opinion
Values used in the original
Loccisano et al. (2011)
Integration method Rosenbrock (Stiff) Rosenbrock (Stiff)
DT min 1e-6 Not described in original publication
DT max 10 Not described in original publication
DT 0.01 Not described in original publication
Tolerance 0.01 Not described in original publication
DT: default tolerance; PFOA: perﬂuorooctanoic acid; PFOS: perﬂuorooctane sulfonic acid.
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C.3.4. Model codes applied in the PBPK model used in this Opinion
Modiﬁcations and additional information to the code were provided by a co-author of Loccisano
et al. (2011) paper (Campbell, 2018). The codes for PFOA and PFOS therefore differ from the original
code described by the authors in supplemental material (Loccisano et al., 2011).
The following changes have been done:
For PFOS, tissue/blood partition coefﬁcient (e.g. liver/blood partition coefﬁcient) has been replaced
by tissue/plasma coefﬁcient (e.g. liver/plasma partition coefﬁcient).
There are errors in the values of Tmc and Kt in the supplementary material of the original article. As
described in Table 1 of Loccisano et al. (2011) and consistent with Andersen et al. (2006), the units
are in mg, so when expressed in µg, to be consistent with other parameters in the codes, they should
be:
• For PFOA, Tmc = 6,000 and Kt = 55
• For PFOS, Tmc = 3,500 and Kt = 23
Loccisano et al. (2011) considered two half-lives (2.3 years from Bartell et al. (2010) and 3.8 years
from Olsen et al., 2007 when running the model simulations, and both appeared to be probable. The
half-life for PFOA of 2.3 years, determined by Bartell et al. (2010) seems to be more reliable as it is
based on a large sample size (100 men and 100 women) and exposure results from ingestion of
contaminated drinking water. Moreover, this value was supported by a recent paper from Li et al.
(2018), where the observed half-life for PFOA was 2.7 years. The CONTAM Panel decided to use the
half-life of 2.3 years for PFOA.
In addition, the value of QLC (cardiac output to liver), of 0.25 was corrected for the cardiac output
to the gut (0.181), resulting in a value of 0.069.
A Tinput of 24 h was applied, instead of the 0.6 h, assuming that exposure was spread over a
longer period.
The original Loccisano model was slightly modiﬁed by integrating a growth equation based on a
French survey. This study (EAT for French total Diet Study) includes 4,078 subjects with age between
3 years and 60, and 703 subjects less than 3 years). The reported data (weight, age) from this study
allow building an equation describing the increase in weight according to age.
C.3.4.1. Model codes for PFOS
Based on model codes from Loccisano et al. (2011), with slight modiﬁcations by the EFSA CONTAM
Panel. Explanation of the modiﬁcations from the original model are given in notes in the respective
model codes.
METHOD Stiff 
STARTTIME = 0 
STOPTIME=438000        ;end of simulation (h); 50 years 
DT = 0.01 
TOLERANCE = 0.01  ; default tolerance 
DTMAX = 10.0 
DTMIN = 0.000001 
year= TIME/(24*365) 
; Physiological parameters (from Brown et al., 1997) 
;fractional blood flows 
QCC = 12.5   ; Cardiac blood output (L/h/kg^0.75) 
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QFC = 0.052  ; Fraction cardiac output going to fat 
QLC = 0.069   ; Fraction cardiac output going to liver, through hepatic artery
QKC = 0.175  ; Fraction cardiac output going to kidney 
QSkC = 0.058  ; Fraction cardiac output going to skin 
QGC = 0.181  ; Fraction of cardiac output going to gut and in the liver via portal artery 
; Not used ;QfilC = 0.035  ; Fraction cardiac output to the filtrate compartment (20% of 
kidney blood flow) 
;BW = 70   ; Body weight (kg) for men; 58 kg for women 
;weight algorithm based on french survey (French total Diet Study)  
BW=3.68+4.47*year-0.093*year^2+0.00061*year^3 
;fractional tissue volumes 
VLC = 0.026  ; Fraction liver volume 
VFC = 0.214  ; Fraction fat volume 
VKC = 0.004  ; Fraction kidney volume 
VfilC = 0.0004  ; Fraction filtrate compartment volume (10% of kidney volume) 
VGC = 0.0171  ; Fraction gut volume 
VPlasC = 0.0428 ; Fraction plasma volume (58% of blood) 
Htc = 0.44                      ; hematocrit 
;for dermal exposure 
SkinTarea = 9.1*((BW*1000)**0.666) ; Total area of skin (cm^2) 
Skinthickness = 0.1 ; Skin thickness (cm) 
; Chemical-specific parameters (PFOS) 
Tmc =3500.   ; Maximum resorption rate, Changed from 3.5 in the original 
Loccisano 2011 model and expressed in µg, to be consistent with other parameters
Kt = 23.0   ; Resorption affinity, Changed from 0.023 in the original Loccisano 
2011 model and expressed in µg, to be consistent with other parameters
Free = 0.025  ; Free fraction of PFOS in plasma 
PL = 3.72   ; Liver/plasma partition coefficient 
PF = 0.14   ; Fat/ plasma partition coefficient 
PK = 0.8   ; Kidney/ plasma partition coefficient 
PSk = 0.29   ; Skin/ plasma partition coefficient 
PR = 0.2   ; Rest of the body/ plasma partition coefficient 
PG = 0.57                                    ; Gut/ plasma partition coeff.  
kurinec = 0.001  ; urinary elimination rate constant  (/h/kg^-0.25); estimated from 
Harada, et al 2005 
kurine = kurinec*BW**(-0.25)
; Free fraction of chemical in tissues 
FreeL = Free/PL                      ;liver 
FreeF = Free/PF                     ;fat 
FreeK = Free/PK                     ;kidney 
FreeSk = Free/PSk                 ;skin 
FreeR = Free/PR                  ;rest of tissues 
FreeG = Free/PG                    ;gut 
; Exposure parameters 
tchng =438000  ;Duration of exposure (h); 50 years 
;turn dose on/off 
DoseOn = IF time<tchng THEN 1.0 else 0.0 
; Dermal exposure 
Dermconc = 0.0  ; Dermal concentration (ug/mL) 
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Dermvol = 0.0  ; Dermal exposure volume (mL) 
Dermdose = Dermconc*Dermvol*1000                       ; (ug) 
Skinarea = 5  ; Exposed area on skin (cm^2) 
; Oral exposure 
Oralconc =0.0018 ; Oral uptake (ug/kg/day) 
Oraldose = Oralconc*BW ; (ug/day) 
 ;Drinking water exposure 
Drinkconc = 0.0  ; Drinking water concentration (ug/L or ppb) 
Drinkrate = 13  ; Drinking water rate (mL/kg/day) 
Drinkdose = (Drinkconc*Drinkrate/1000)*BW      ; (ug/day) 
; Inhalation exposure 
Inhalation = 0.0  ; Inhalation dose (ppm) 
Tinput = 24  ; duration of dose (h) the CONTAM Panel increased the Tinput to 24h 
(instead of 0.6) considering continuous exposure from food.
;oral dose 
Input1 = IF MOD(time,24) <=Tinput THEN Oraldose/Tinput  ELSE 0.0 
;drinking water 
Input2 = IF MOD(time,24) <= Tinput THEN Drinkdose/Tinput ELSE 0.0 
; Scaling parameters 
QC = QCC*BW**0.75  ; Cardiac output (L/h) 
QCP = QC*(1-Htc)  ; adjust for plasma flow 
QL = QLC*QCP   ; Plasma flow to liver (L/h) 
QF = QFC*QCP  ; Plasma flow to fat (L/h) 
QK = QKC*QCP ; Plasma flow to kidney (L/h) 
Qfil = 0.2*QK  ; Plasma flow to filtrate compartment (L/h); 20% of QK 
QG = QGC*QCP  ; Plasma flow to gut (L/h) 
QSk = IF Dermconc >0.0 THEN QSkC*QCP*(Skinarea/SkinTarea) else 0.0  ;plasma flow to skin 
QR = QCP - QL - QF - QK - QG -QSk ; Plasma flow to rest of the body (L/h) 
Qbal = QCP - (QR+QL+QF+QK+QG+QSk)        ; balance check--better be 0 
VL = VLC*BW   ; Liver volume (L) 
VF = VFC*BW   ; Fat volume (L) 
VK = VKC*BW   ; Kidney volume (L) 
Vfil = VfilC*BW   ; Fitrate compartment volume (L) 
VG = VGC*BW   ; Gut volume (L) 
VPlas = VPlasC*BW  ; Plasma volume (L) 
VSk = (Skinarea*Skinthickness)/1000 ; Skin volume (L) 
VR = 0.84*BW - VL - VF - VK - Vfil - VG - VPlas - VSk ; Rest of the body volume (L) 
Vbal = (0.84*BW)-(VL+VF+VK+VFil+VG+VPlas+VSk)               ; Balance check--better be 0 
Tm = Tmc*BW**0.75                   ;transporter maximum 
;>>>>>>>>>>>>>>>>>>>> Model equations <<<<<<<<<<<<<<<<<<<<<<<<<<<< 
; Plasma compartment 
APlas' = QF*CF*FreeF+(QL+QG)*CL*FreeL+QR*CR*FreeR+QSk*CSk*FreeSk+QK*CK*FreeK - 
QCP*CA*Free  - Qfil*CA*Free 
init APlas = 0.0 
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CAFree = APlas/VPlas                           ; free concentration of PFOS in plasma in ug/L (ng/mL) 
CA = CAfree/Free                                   ; total concentration in plasma  
; Gut compartment 
AG' = QG*(CA*Free-CG*FreeG) + Input1*DoseOn + Input2*DoseOn 
init AG = 0.0 
CG = AG/VG     ; Concentration in gut (ug/L) 
CVG = CG/PG     ; Concentration leaving gut (ug/L) 
; Liver compartment 
AL' = (QL*(CA*Free))+(QG*CG*Freeg) - ((QL+QG)*CL*FreeL)   ;Rate of change in liver (ug/h) 
init AL = 0.0    
CL = AL/VL     ; Concentration in liver (ug/L) 
CVL = CL/PL     ; Concentration leaving liver (ug/L) 
; Fat compartment 
AF' = QF*(CA*Free-CF*FreeF)   ; Rate of change in fat (ug/h) 
init AF = 0.0   
CF = AF/VF     ; Concentration in fat (ug/L) 
CVF = CF/PF     ; Concentration leaving fat (ug/L) 
; Kidney compartment 
AK' = QK*(CA*Free-CK*FreeK) + Tm*Cfil/(Kt+Cfil)  ; Rate of change in kidneys 
(ug/h) 
init AK = 0.0 
CK = AK/VK     ; Concentration in kidneys (ug/L) 
CVK = CK/PK      ; Concentration leaving kidneys (ug/L) 
; Filtrate compartment 
Afil' = Qfil*(CA*Free-Cfil) - Tm*Cfil/(Kt+Cfil)          ; Rate of change in filtrate compartment (ug/h) 
init Afil = 0.0 
Cfil = Afil/Vfil     ; Concentration in filtrate compartment (ug/L) 
; Storage compartment for urine 
;Adelay' = Qfil*Cfil-kurine*Adelay   
;init Adelay = 0.0 
; Urine 
;Aurine' = kurine*Adelay 
Aurine' = Qfil*Cfil - kurine*Aurine 
init Aurine = 0.0 
; Skin compartment 
ASk' = QSk*(CA*Free-CSk*FreeSk)  ; Rate of change in skin (ug/h) 
init ASk = DermDose 
CSk = ASk/VSk     ; Concentration in skin compartment (ug/L) 
CVSk = CSk/PSk    ; Concentration leaving skin compartment (ug/L)  
; Rest of the body 
AR' = QR*(CA*Free-CR*FreeR)   ; Rate of change in rest of the body (ug/h) 
init AR = 0.0 
CR = AR/VR     ; Concentration in rest of the body (ug/L) 
CVR = CR/PR     ; Concentration leaving rest of the body (ug/L) 
Display Drinkconc, Dermconc, Oralconc, Inhalation, TInput, Tmc, Kt, Free, PL,PK,PF,PR,PSK,PG, 
tchng, 
input1,input2,drinkrate,BW,QCC,QFC,QLC,QKC,QSkC,QGC,VLC,VFC,VKC,VFilC,VGC,VPlasC,kurin
ec, year , APlas, AG, AL, AF, AF, AK, ASK, AR                         ;for parameters window 
Display CA, CG, CL, CF, CR, CK, CAFREE, Qbal , year                                                                 ;for 
plotting 
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C.3.4.2. Model codes for PFOA
Based on model codes in Loccisano et al. (2011), with slight modiﬁcations by the EFSA CONTAM
Panel. Explanation of the modiﬁcations from the original model are given in notes in the respective
model codes.
METHOD Stiff 
STARTTIME = 0 
STOPTIME=438000        ;end of simulation (h); 50 years 
DT = 0.01 
TOLERANCE = 0.01 
DTMAX = 10.0 
DTMIN = 0.000001 
year= TIME/(24*365)
; Physiological parameters (from Brown, et al 1997) 
;fractional blood flows 
QCC = 12.5   ; Cardiac blood output (L/h/kg^0.75) 
QFC = 0.052  ; Fraction cardiac output going to fat 
QLC = 0.069   ; Fraction cardiac output going to liver, through hepatic artery
QKC = 0.175  ; Fraction cardiac output going to kidney 
QSkC = 0.058  ; Fraction cardiac output going to skin 
QGC = 0.181  ; Fraction of cardiac output going to gut and in the liver via portal artery 
; Not used ;QfilC = 0.035  ; Fraction cardiac output to the filtrate compartment (20% of 
kidney blood flow) 
;BW = 70   ; Body weight (kg) for men; 58 kg for women 
;weight algorithm based on french survey (French total Diet Study)  
BW=3.68+4.47*year-0.093*year^2+0.00061*year^3 
;fractional tissue volumes 
VLC = 0.026  ; Fraction liver volume 
VFC = 0.214  ; Fraction fat volume 
VKC = 0.004  ; Fraction kidney volume 
VfilC = 0.0004  ; Fraction filtrate compartment volume (10% of kidney volume) 
VGC = 0.0171  ; Fraction gut volume 
VPlasC = 0.0428 ; Fraction plasma volume (58% of blood) 
Htc = 0.44                      ; hematocrit 
;for dermal exposure 
SkinTarea = 9.1*((BW*1000)**0.666) ; Total area of skin (cm^2) 
Skinthickness = 0.1 ; Skin thickness (cm) 
; Chemical-specific parameters (PFOA) 
Tmc = 6000   ; Maximum resorption rate, changed from 6 in the original Loccisano 
2011 model and expressed in µg, to be consistent with other parameters
Kt = 55.0   ; Resorption affinity, changed from 0.055 in the original Loccisano 
2011 model and expressed in µg, to be consistent with other parameters
Free = 0.02  ; Free fraction of PFOA in plasma 
PL = 2.2   ; Liver/plasma partition coefficient 
PF = 0.04   ; Fat/ plasma partition coefficient 
PK = 1.05   ; Kidney/ plasma partition coefficient 
PSk = 0.1   ; Skin/ plasma partition coefficient 
PR = 0.12   ; Rest of the body/ plasma partition coefficient 
PG = 0.05                                    ; Gut/ plasma partition coeff.  
PFOS and PFOA in food
www.efsa.europa.eu/efsajournal 271 EFSA Journal 2018;16(12):5194
kurinec = 0.0003  ; urinary elimination rate constant  (/h/kg^-0.25); estimated 
from Harada, et al 2005 
kurine = kurinec*BW**(-0.25)
; Free fraction of chemical in tissues 
FreeL = Free/PL                      ;liver 
FreeF = Free/PF                     ;fat 
FreeK = Free/PK                     ;kidney 
FreeSk = Free/PSk                 ;skin 
FreeR = Free/PR                    ;rest of tissues 
FreeG = Free/PG                    ;gut 
; Exposure parameters 
tchng =438000 ;Duration of exposure (h); 50 years 
;turn dose on/off 
DoseOn = IF time<tchng THEN 1.0 else 0.0 
; Dermal exposure 
Dermconc = 0.0  ; Dermal concentration (ug/mL) 
Dermvol = 0.0 ; Dermal exposure volume (mL) 
Dermdose = Dermconc*Dermvol*1000                       ; (ug) 
Skinarea = 5  ; Exposed area on skin (cm^2) 
; Oral exposure 
Oralconc =0.00085 ; Oral uptake (ug/kg/day) 
Oraldose = Oralconc*BW ; (ug/day) 
 ;Drinking water exposure 
Drinkconc = 0.0  ; Drinking water concentration (ug/L or ppb) 
Drinkrate = 13  ; Drinking water rate (mL/kg/day) 
Drinkdose = (Drinkconc*Drinkrate/1000)*BW      ; (ug/day) 
; Inhalation exposure 
Inhalation = 0.0  ; Inhalation dose (ppm) 
Tinput = 24.0  ; duration of dose (h), the CONTAM Panel increased the Tinput to 24h 
(instead of 0.6) considering connuous exposure from food
;oral dose 
Input1 = IF MOD(time,24) <=Tinput THEN Oraldose/Tinput  ELSE 0.0 
;drinking water 
Input2 = IF MOD(time,24) <= Tinput THEN Drinkdose/Tinput ELSE 0.0 
; Scaling parameters 
QC = QCC*BW**0.75  ; Cardiac output (L/h) 
QCP = QC*(1-Htc)  ; adjust for plasma flow 
QL = QLC*QCP   ; Plasma flow to liver (L/h) 
QF = QFC*QCP  ; Plasma flow to fat (L/h) 
QK = QKC*QCP ; Plasma flow to kidney (L/h) 
Qfil = 0.2*QK  ; Plasma flow to filtrate compartment (L/h); 20% of QK 
QG = QGC*QCP  ; Plasma flow to gut (L/h) 
QSk = IF Dermconc >0.0 THEN QSkC*QCP*(Skinarea/SkinTarea) else 0.0  ;plasma flow to skin 
QR = QCP - QL - QF - QK - QG -QSk ; Plasma flow to rest of the body (L/h) 
Qbal = QCP - (QR+QL+QF+QK+QG+QSk)        ; balance check--better be 0 
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VL = VLC*BW   ; Liver volume (L) 
VF = VFC*BW   ; Fat volume (L) 
VK = VKC*BW   ; Kidney volume (L) 
Vfil = VfilC*BW   ; Fitrate compartment volume (L) 
VG = VGC*BW   ; Gut volume (L) 
VPlas = VPlasC*BW  ; Plasma volume (L) 
VSk = (Skinarea*Skinthickness)/1000 ; Skin volume (L) 
VR = 0.84*BW - VL - VF - VK - Vfil - VG - VPlas - VSk ; Rest of the body volume (L) 
Vbal = (0.84*BW)-(VL+VF+VK+VFil+VG+VPlas+VSk)               ; Balance check--better be 0 
Tm = Tmc*BW**0.75                   ;transporter maximum 
;>>>>>>>>>>>>>>>>>>>> Model equations <<<<<<<<<<<<<<<<<<<<<<<<<<<< 
; Plasma compartment 
APlas' = QF*CF*FreeF+(QL+QG)*CL*FreeL+QR*CR*FreeR+QSk*CSk*FreeSk+QK*CK*FreeK - 
QCP*CA*Free  - Qfil*CA*Free 
init APlas = 0.0 
CAFree = APlas/VPlas                           ; free concentration of PFOA in plasma in ug/L (ng/mL) 
CA = CAfree/Free                                   ; total concentration in plasma  
; Gut compartment 
AG' = QG*(CA*Free-CG*FreeG) + Input1*DoseOn + Input2*DoseOn 
init AG = 0.0 
CG = AG/VG     ; Concentration in gut (ug/L) 
CVG = CG/PG ; Concentration leaving gut (ug/L) 
; Liver compartment 
AL' = (QL*(CA*Free))+(QG*CG*FreeG) - ((QL+QG)*CL*FreeL)   ;Rate of change in liver (ug/h) 
init AL = 0.0    
CL = AL/VL     ; Concentration in liver (ug/L) 
CVL = CL/PL     ; Concentration leaving liver (ug/L) 
; Fat compartment 
AF' = QF*(CA*Free-CF*FreeF)   ; Rate of change in fat (ug/h) 
init AF = 0.0   
CF = AF/VF     ; Concentration in fat (ug/L) 
CVF = CF/PF     ; Concentration leaving fat (ug/L) 
; Kidney compartment 
AK' = QK*(CA*Free-CK*FreeK) + Tm*Cfil/(Kt+Cfil)  ; Rate of change in kidneys 
(ug/h) 
init AK = 0.0 
CK = AK/VK              ; Concentration in kidneys (ug/L) 
CVK = CK/PK      ; Concentration leaving kidneys (ug/L) 
; Filtrate compartment 
Afil' = Qfil*(CA*Free-Cfil) - Tm*Cfil/(Kt+Cfil)          ; Rate of change in filtrate compartment (ug/h) 
init Afil = 0.0 
Cfil = Afil/Vfil     ; Concentration in filtrate compartment (ug/L) 
; Storage compartment for urine 
;Adelay' = Qfil*Cfil-kurine*Adelay   
;init Adelay = 0.0 
; Urine 
;Aurine' = kurine*Adelay 
Aurine' = Qfil*Cfil - kurine*Aurine 
init Aurine = 0.0 
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; Skin compartment 
ASk' = QSk*(CA*Free-CSk*FreeSk)  ; Rate of change in skin (ug/h) 
init ASk = DermDose 
CSk = ASk/VSk     ; Concentration in skin compartment (ug/L) 
CVSk = CSk/PSk    ; Concentration leaving skin compartment (ug/L)  
; Rest of the body 
AR' = QR*(CA*Free-CR*FreeR)   ; Rate of change in rest of the body (ug/h) 
init AR = 0.0 
CR = AR/VR     ; Concentration in rest of the body (ug/L) 
CVR = CR/PR     ; Concentration leaving rest of the body (ug/L) 
Display Drinkconc, Dermconc, Oralconc, Inhalation, TInput, Tmc, Kt, Free, PL,PK,PF,PR,PSK,PG, 
tchng, 
input1,input2,drinkrate,BW,QCC,QFC,QLC,QKC,QSkC,QGC,VLC,VFC,VKC,VFilC,VGC,VPlasC,kurin
ec , year                         ;for parameters window 
Display CA, CG, CL, CF, CR, CK, CAFREE, Qbal , year                                                                 ;for 
plotting 
C.3.4.3. Model codes used for Breastfeeding scenario 1
Full model code:
METHOD Stiff 
STARTTIME = 0 
STOPTIME=438000        ;end of simulation (h); 50 years 
DT = 0.01 
TOLERANCE = 0.01  ; default tolerance 
DTMAX = 10.0 
DTMIN = 0.000001 
year= TIME/(24*365) 
; Physiological parameters (from Brown et al., 1997) 
;fractional blood flows 
QCC = 12.5   ; Cardiac blood output (L/h/kg^0.75) 
QFC = 0.052  ; Fraction cardiac output going to fat 
QLC = 0.069   ; Fraction cardiac output going to liver, through hepatic artery
QKC = 0.175  ; Fraction cardiac output going to kidney 
QSkC = 0.058  ; Fraction cardiac output going to skin 
QGC = 0.181  ; Fraction of cardiac output going to gut and in the liver via portal artery 
; Not used ;QfilC = 0.035  ; Fraction cardiac output to the filtrate compartment (20% of 
kidney blood flow) 
;BW = 70   ; Body weight (kg) for men; 58 kg for women 
;weight algorithm based on french survey (French total Diet Study)  
BW=3.68+4.47*year-0.093*year^2+0.00061*year^3 
;fractional tissue volumes 
VLC = 0.026  ; Fraction liver volume 
VFC = 0.214  ; Fraction fat volume 
VKC = 0.004  ; Fraction kidney volume 
VfilC = 0.0004  ; Fraction filtrate compartment volume (10% of kidney volume) 
VGC = 0.0171  ; Fraction gut volume 
VPlasC = 0.0428 ; Fraction plasma volume (58% of blood) 
Htc = 0.44                      ; hematocrit 
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;for dermal exposure 
SkinTarea = 9.1*((BW*1000)**0.666) ; Total area of skin (cm^2) 
Skinthickness = 0.1 ; Skin thickness (cm) 
; Chemical-specific parameters (PFOS) 
Tmc =3500.   ; Maximum resorption rate, Changed from 3.5 in the original 
Loccisano 2011 model and expressed in µg, to be consistent with other parameters
Kt = 23.0   ; Resorption affinity, Changed from 0.023 in the original Loccisano 
2011 model and expressed in µg, to be consistent with other parameters
Free = 0.025  ; Free fraction of PFOS in plasma 
PL = 3.72   ; Liver/plasma partition coefficient 
PF = 0.14   ; Fat/ plasma partition coefficient 
PK = 0.8   ; Kidney/ plasma partition coefficient 
PSk = 0.29   ; Skin/ plasma partition coefficient 
PR = 0.2   ; Rest of the body/ plasma partition coefficient 
PG = 0.57                                    ; Gut/ plasma partition coeff.  
kurinec = 0.001  ; urinary elimination rate constant  (/h/kg^-0.25); estimated from 
Harada, et al 2005 
kurine = kurinec*BW**(-0.25)
; Free fraction of chemical in tissues 
FreeL = Free/PL                      ;liver 
FreeF = Free/PF                     ;fat 
FreeK = Free/PK                     ;kidney 
FreeSk = Free/PSk                 ;skin 
FreeR = Free/PR                    ;rest of tissues 
FreeG = Free/PG                    ;gut 
; Exposure parameters 
tchng =438000  ;Duration of exposure (h); 50 years 
;turn dose on/off 
DoseOn = IF time<tchng THEN 1.0 else 0.0 
; Dermal exposure 
Dermconc = 0.0  ; Dermal concentration (ug/mL) 
Dermvol = 0.0                                     ; Dermal exposure volume (mL) 
Dermdose = Dermconc*Dermvol*1000                       ; (ug) 
Skinarea = 5  ; Exposed area on skin (cm^2) 
; Oral exposure 
Oralconc =IF year <0.5 THEN (0.8*0.12)/BW ELSE IF year>= 0.5 THEN 1.8e-3 ELSE 0 
; Oral uptake (ug/kg/day) 
Oraldose = Oralconc*BW ; (ug/day) 
 ;Drinking water exposure 
Drinkconc = 0.0  ; Drinking water concentration (ug/L or ppb) 
Drinkrate = 13  ; Drinking water rate (mL/kg/day) 
Drinkdose = (Drinkconc*Drinkrate/1000)*BW      ; (ug/day) 
; Inhalation exposure 
Inhalation = 0.0  ; Inhalation dose (ppm) 
Tinput = 24  ; duration of dose (h) the CONTAM Panel increased the Tinput to 24h 
(instead of 0.6) considering continuous exposure from food.
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;oral dose 
Input1 = IF MOD(time,24) <=Tinput THEN Oraldose/Tinput  ELSE 0.0 
;drinking water 
Input2 = IF MOD(time,24) <= Tinput THEN Drinkdose/Tinput ELSE 0.0 
; Scaling parameters 
QC = QCC*BW**0.75  ; Cardiac output (L/h) 
QCP = QC*(1-Htc)  ; adjust for plasma flow 
QL = QLC*QCP   ; Plasma flow to liver (L/h) 
QF = QFC*QCP  ; Plasma flow to fat (L/h) 
QK = QKC*QCP ; Plasma flow to kidney (L/h) 
Qfil = 0.2*QK  ; Plasma flow to filtrate compartment (L/h); 20% of QK 
QG = QGC*QCP  ; Plasma flow to gut (L/h) 
QSk = IF Dermconc >0.0 THEN QSkC*QCP*(Skinarea/SkinTarea) else 0.0  ;plasma flow to skin 
QR = QCP - QL - QF - QK - QG -QSk ; Plasma flow to rest of the body (L/h) 
Qbal = QCP - (QR+QL+QF+QK+QG+QSk)        ; balance check--better be 0 
VL = VLC*BW   ; Liver volume (L) 
VF = VFC*BW   ; Fat volume (L) 
VK = VKC*BW   ; Kidney volume (L) 
Vfil = VfilC*BW   ; Fitrate compartment volume (L) 
VG = VGC*BW   ; Gut volume (L) 
VPlas = VPlasC*BW  ; Plasma volume (L) 
VSk = (Skinarea*Skinthickness)/1000 ; Skin volume (L) 
VR = 0.84*BW - VL - VF - VK - Vfil - VG - VPlas - VSk ; Rest of the body volume (L) 
Vbal = (0.84*BW)-(VL+VF+VK+VFil+VG+VPlas+VSk)               ; Balance check--better be 0 
Tm = Tmc*BW**0.75                   ;transporter maximum 
;>>>>>>>>>>>>>>>>>>>> Model equations <<<<<<<<<<<<<<<<<<<<<<<<<<<< 
; Plasma compartment 
APlas' = QF*CF*FreeF+(QL+QG)*CL*FreeL+QR*CR*FreeR+QSk*CSk*FreeSk+QK*CK*FreeK - 
QCP*CA*Free  - Qfil*CA*Free 
init APlas = 0.01 
CAFree = APlas/VPlas                           ; free concentration of PFOS in plasma in ug/L (ng/mL) 
CA = CAfree/Free                                   ; total concentration in plasma  
; Gut compartment 
AG' = QG*(CA*Free-CG*FreeG) + Input1*DoseOn + Input2*DoseOn 
init AG = 0.09 
CG = AG/VG     ; Concentration in gut (ug/L) 
CVG = CG/PG     ; Concentration leaving gut (ug/L) 
; Liver compartment 
AL' = (QL*(CA*Free))+(QG*CG*Freeg) - ((QL+QG)*CL*FreeL)   ;Rate of change in liver (ug/h) 
init AL = 0.9    
CL = AL/VL     ; Concentration in liver (ug/L) 
CVL = CL/PL     ; Concentration leaving liver (ug/L) 
; Fat compartment 
AF' = QF*(CA*Free-CF*FreeF)                 ; Rate of change in fat (ug/h) 
init AF = 0.28   
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CF = AF/VF     ; Concentration in fat (ug/L) 
CVF = CF/PF     ; Concentration leaving fat (ug/L) 
; Kidney compartment 
AK' = QK*(CA*Free-CK*FreeK) + Tm*Cfil/(Kt+Cfil)  ; Rate of change in kidneys 
(ug/h) 
init AK = 0.036 
CK = AK/VK     ; Concentration in kidneys (ug/L) 
CVK = CK/PK      ; Concentration leaving kidneys (ug/L) 
; Filtrate compartment 
Afil' = Qfil*(CA*Free-Cfil) - Tm*Cfil/(Kt+Cfil)          ; Rate of change in filtrate compartment (ug/h) 
init Afil = 0.0 
Cfil = Afil/Vfil     ; Concentration in filtrate compartment (ug/L) 
; Storage compartment for urine 
;Adelay' = Qfil*Cfil-kurine*Adelay   
;init Adelay = 0.0 
; Urine 
;Aurine' = kurine*Adelay 
Aurine' = Qfil*Cfil - kurine*Aurine 
init Aurine = 0.0 
; Skin compartment 
ASk' = QSk*(CA*Free-CSk*FreeSk)  ; Rate of change in skin (ug/h) 
init ASk = DermDose 
CSk = ASk/VSk     ; Concentration in skin compartment (ug/L) 
CVSk = CSk/PSk    ; Concentration leaving skin compartment (ug/L)  
; Rest of the body 
AR' = QR*(CA*Free-CR*FreeR)   ; Rate of change in rest of the body (ug/h) 
init AR = 1.0 
CR = AR/VR     ; Concentration in rest of the body (ug/L) 
CVR = CR/PR     ; Concentration leaving rest of the body (ug/L) 
Display Drinkconc, Dermconc, Oralconc, Inhalation, TInput, Tmc, Kt, Free, PL,PK,PF,PR,PSK,PG, 
tchng, 
input1,input2,drinkrate,BW,QCC,QFC,QLC,QKC,QSkC,QGC,VLC,VFC,VKC,VFilC,VGC,VPlasC,kurin
ec, year , APlas, AG, AL, AF, AF, AK, ASK, AR                         ;for parameters window 
Display CA, CG, CL, CF, CR, CK, CAFREE, Qbal , year                                                                 ;for 
plotting 
Line codes:
A) line code for starting concentration at birth = 2.6 µg/L: 
Aplas=CA x free x Vplas= CA x Free x Vplac x BW 
CA=2.6 µg/L 
Free=0.025 
Vplac= 0.0428 
BW at birth = 3.68 
Aplas = 2.6 x 0.025 x 0.0428 x 3.68 = 0.01 
Then replace in the parameter window the following value: 
Init Aplas= 0.01 
Init AG =0.09 
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Init AL =0.9 
Init AF = 0.28 
Init AK =0.036 
Init AR = 1.0 
 
B) Line code for breast feeding scenario: 
 
PFOS Milk concentration = 0.12 µg/L 
Milk consumption =0.8 l 
 
Then the code is : 
 
Oralconc =IF year <0.5 THEN (0.8*0.12)/BW ELSE IF year>= 0.5 THEN 1.8e-3 ELSE 0 
C.3.4.4. Model codes used for Breastfeeding scenario 2
Line codes:
A) line code for starting concentration at birth = 7.3 µg/L: 
Aplas=CA x free x Vplas= CA x Free x Vplac x BW 
CA=7.3 µg/L 
Free=0.025 
Vplac= 0.0428 
BW at birth = 3.68 
Aplas = 7.3 x 0.025 x 0.0428 x 3.68 = 0.0287 
replace in the parameter window the following value: 
Init Aplas= 0.0287 
Init AG =0.2615 
Init AL =2.595 
Init AF = 0.803 
Init AK =0.103 
Init AR =2.873  
B) Line code for breast feeding scenario: 
PFOS Milk concentration = 0.33 µg/L 
Milk consumption =0.8 l 
Then the code is: 
Oralconc =IF year <0.5 THEN (0.8*0.33)/BW ELSE IF year>= 0.5 THEN 1.8e-3 ELSE 0 
C.4. Comparison with one-compartment steady-state pharmacokinetic
model
A simple one-compartment, ﬁrst-order PK model estimates the change in concentration in one
compartment over time given a speciﬁed exposure regime. It takes what comes in, or dose; subtracts
what goes out via an elimination rate constant, k; and calculates the change in concentration of a
chemical over time. This is shown conceptually by the Figure C.7.
This single-compartment, ﬁrst-order PK model which predicts PFOA concentrations in blood serum
as a function of dose, elimination rate, and volume of distribution, is used:
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dðCPÞ=dt ¼ DPðtÞ=Vd-Kp CPðtÞ
where CP is the serum concentration (ng/mL) of PFOA or PFOS, DP is the daily absorbed dose (ng/kg
bw per day), Vd is the volume of distribution (mL/kg bw) and kP is the ﬁrst-order elimination rate
(day_1). Vd and kP are assumed to be constant in this model construct. Assuming steady-state
conditions exist, one can solve for blood serum concentration as follows:
CP ¼ DP=ðKP VdÞ
Using a one-compartment steady-state PK model, serum or plasma concentrations can be
converted to external doses (intakes). The obtained external doses reﬂect the total intakes from all
exposure pathways. These intakes can be compared to current intakes from food. This kind of
conversion has previously been applied successfully for PFOS and PFOA (Fromme et al., 2007;
Vestergren and Cousins, 2009; Egeghy and Lorber, 2011; Haug et al., 2011b). The PK model predicts
the serum concentration as a function of dose (intake), elimination rate and volume of distribution (i.e.
the total amount of a PFOS or PFOA in the body divided by its concentration in the serum/plasma).
The model is based on an assumption of steady-state conditions.
Parameters are listed below:
To compare the current intakes from food with the concentrations in blood, a one-compartment
steady-state PK model was used. The assumptions on half-life and distribution volume are presented in
Table C.2.
Using both the PBPK model and the one-compartment steady-state PK model, intakes were
calculated based on the median of the median serum/plasma concentrations for the European adult
population taken from Table 8 of Section 3.3.2.3. The calculated intakes as well as the median serum/
plasma concentrations used for the calculations are presented in Table C.3.
Figure C.7: Simple one-compartment model
Table C.2: Elimination rates and half-lives used
Compound Half-life (years) Reference/comment Distribution volume Reference
PFOA 2.3 Bartell et al. (2010) 300 mL/kg Harada et al. (2005)
PFOS 5.4 Olsen et al. (2007) 300 mL/kg Harada et al. (2005)
PFOA: perﬂuorooctanoic acid; PFOS: perﬂuorooctane sulfonic acid.
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Table C.4 presents a comparison of prediction according to the Loccisano PFOA PBPK model, PFOA
Worley PBPK model and the PFOA one-compartment steady-state PK model.
Table C.5 presents a comparison of prediction according to the Loccisano PFOS PBPK model, and
the PFOS one-compartment steady-state PK model.
C.5. Sensitivity analysis
Sensitivity analysis (SA) provides a quantitative assessment of the degree of inﬂuence of input
parameters on the model results.
According WHO guidance (WHO/IPCS, 2010), sensitivity analysis results can be summarised as:
• high (absolute value greater than or equal to 0.5)
• medium (absolute value greater than or equal to 0.2 but less than 0.5)
• low (absolute value greater than or equal to 0.1 but less than 0.
Table C.3: Comparison of calculated intake resulting in similar plasma concentration of PFOS/PFOA
using a one-compartment steady-state PK model vs a PBPK model, in ng/kg bw per day
Compound
Calculated intakes
(continuous exposure)
based on serum/plasma
concentrations, in ng/kg
bw per day using a PBPK
model(a)
Calculated intakes
(continuous exposure)
based on serum/plasma
concentrations, in ng/kg
bw per day using a
one-compartment
steady-state PK model
Median serum/plasma
concentration in ng/mL for
the European adult population
taken from Table 8
(Section 3.3.2.3)
PFOA 0.17 0.5 1.9
PFOS 0.6 0.8 7.7
bw: body weight; PFOA: perﬂuorooctanoic acid; PFOS: perﬂuorooctane sulfonic acid; PBPK: physiologically based
pharmacokinetic (model); PK: pharmacokinetic (model).
(a): the PBPK model takes into account the body weight change with age.
Table C.4: Comparison between the PBPK models of Loccisano and Worley, and the one-
compartment steady-state PK model, for simulation of chronic daily exposure of PFOA
leading to the plasma concentration of 9.4 ng/mL, which is the BMDL5 for an increase of
total cholesterol from Steenland et al. (2009)
Target plasma concentration
of PFOA from BMD analysis
Intake rate in ng/kg-day estimated from
Loccisano PBPK
model
Worley PBPK
model
One-compartment
steady-state PK model
BMDL = 9.4 ng/mL
(total cholesterol)
0.85 1.2 2.3
BMD: benchmark dose; PFOA: perﬂuorooctanoic acid; PBPK: physiologically based pharmacokinetic (model); PK: pharmacokinetic
(model). Same half-life of 2.3 years was used for all models.
Table C.5: Comparison between the PBPK model of Loccisano and the one-compartment steady-
state PK model, for simulation of chronic daily exposure of PFOS leading to the plasma
concentration of 22 ng/mL, which is the BMDL5 for an increase of total cholesterol from
Eriksen et al. (2013)
Target plasma concentration
of PFOS from BMD analysis
Intake rate in ng/kg per day estimated from
Loccisano PBPK model
One-compartment
steady-state PK model
BMDL = 22 ng/mL 1.8 2.3
BMD: benchmark dose; BMDL: benchmark dose limit; PFOS: perﬂuorooctane sulfonic acid; PBPK: physiologically based
pharmacokinetic (model); PK: pharmacokinetic (model). Same half-life of 5.4 years was used for both models.
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The highest values of sensitivity analysis results (p > 0.1) were obtained for the following
parameters: Cardiac output, elimination parameters (glomerular ﬁltration rate and resorption maximum
parameters), the free fraction and the haematocrit.
For PFOA and PFOS, the parameter with the highest contribution to the SA was free fraction, and
Kt followed by oral intake, Tm, Q. kidney. In general terms, the cardiac output and volumes of tissues
showed the smallest contribution, with the only exception of Q. kidney. The reason of the high
sensitivity of Q. kidney might be due to the fact that kidney is the elimination tissue, and it has been
reported that Q. kidney is a physiological parameter with a low uncertainty.
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Appendix D – Literature search
Table D.1: Search terms
Human observations
Search terms perﬂuoro* OR pfos OR pfoa OR pfas OR ‘ﬂuorotelomer alcohol’ AND ‘human health’ OR ‘adverse
effect*’ OR ‘occupational case*’ OR occupational OR epidemiol* OR biomarker OR ‘biological
marker’ OR poison* OR ‘incidental poison*’ OR ‘case stud*’ OR adverse OR ‘case control*’ OR
‘case report*’ OR human OR adult OR man OR woman OR men OR women OR female OR male
OR child OR children OR infant OR neonate OR maternal OR cohort OR prenatal
Biomonitoring
Search terms perﬂuoro* OR pfos OR pfoa OR pfas OR ‘ﬂuorotelomer alcohol’ AND teeth OR tooth OR skin OR
bone OR sperm or semen OR tissue OR level* OR concentration* OR ‘time trend’ OR milk OR
blood OR ‘whole blood’ OR serum OR plasma OR ‘breast milk’ OR biomarker OR ‘human milk’ OR
‘cord blood’ OR urine OR ‘amniotic ﬂuid’ OR faeces OR placenta OR meconium OR hair OR nail*
OR sweat OR saliva OR level* OR concentration*
Toxicity
Search terms perﬂuoro* OR pfos OR pfoa OR pfas OR ‘ﬂuorotelomer alcohol’ AND toxicity OR toxi* OR acute
OR subacute OR subchronic OR chronic OR mutagen* OR carcino* OR cardiotox* OR genotox*
OR reprotox* OR nephrotox* OR neurotox* OR hepatotox* OR immune OR immuno* OR
hematotox* OR haematotox* OR cytotox* OR ‘developmental tox*’ OR thyroid OR endocri* OR
endocrine OR estrogen OR oestrogen OR fertility OR tumour OR tumor OR gestat* OR lactat* OR
‘DNA damage’ OR mortality OR adverse OR ‘adverse effect’ OR ‘blood lipid*’ OR ‘serum lipid*’ OR
PPAR OR ‘ex vivo’ OR ‘in vitro’ OR ‘in vivo’ OR exvivo OR invitro OR invivo OR cell* OR tissue* OR
rodent* OR mouse OR animal* OR rat* OR mice OR rabbit* OR dog* OR monkey* OR
‘experimental animal*’ OR ‘lab* animal*’
Toxicokinetics
Search terms perﬂuoro* OR pfos OR pfoa OR pfas OR ‘ﬂuorotelomer alcohol’ AND toxicokinetic* OR absorption
OR distribution OR metabolism OR excretion OR ADME OR biotransformation OR
pharmacokinetic* OR disposition OR fate OR transfer OR conjugat* OR hydroxylation OR ‘half-life’
OR ‘half life’ OR PBPK OR ‘physiologically based pharmacokinetic modelling*’ OR uptake OR
elimination OR urine OR bile OR faeces OR feces OR milk
Chemistry and analysis
Search terms perﬂuoro* OR pfos OR pfoa OR pfas OR ‘ﬂuorotelomer alcohol’ AND chemistry OR analysis OR
determination OR detection OR spectroscopy OR chromatography OR TLC OR GC OR GC-MS OR
HPLC OR LC-MS OR ICP-MS
Occurrence in Food
Search terms perﬂuoro* OR pfos OR pfoa OR pfas OR ‘ﬂuorotelomer alcohol’ AND occurrence* OR level* OR
concentration* OR amount*OR food OR beverage OR ‘drinking water’ OR ‘bottled water’ OR
vegetable* OR legume* OR fruit* OR grain* OR cereal* OR poultry OR chicken OR beef OR
turkey OR meat OR egg* OR milk OR seafood OR ﬁsh OR shrimp OR prawn* OR mollusc* OR
feed OR feedstuff OR beef OR pork OR livestock OR bivalve*
Food Processing
Search terms perﬂuoro* OR pfos OR pfoa OR pfas OR ‘ﬂuorotelomer alcohol’ AND process* OR cook* OR roast*
OR fry* OR boil* OR bak* OR ‘thermal processing’ OR sterilisation OR sterilization OR sterilise OR
sterilize OR freez* OR heat*
(Dietary) Exposure
Search terms perﬂuoro* OR pfos OR pfoa OR pfas OR ‘ﬂuorotelomer alcohol’ AND ‘exposure assessment*’ OR
‘dietary exposure assessment*’ OR ‘human dietary exposure assessment*’
(Non-dietary) Exposure
Search terms perﬂuoro* OR pfos OR pfoa OR pfas OR ‘ﬂuorotelomer alcohol’ AND ‘non-dietary exposure
assessment*’ OR ‘human non-dietary exposure assessment*’ OR ‘exposure pathway*’ OR ‘indoor
exposure’ OR ‘dermal exposure’ OR occupational OR dust OR air OR ‘in-utero’ OR inutero OR ‘in
utero’ OR skin
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Production/Use
Search terms perﬂuoro* OR pfos OR pfoa OR pfas OR ‘ﬂuorotelomer alcohol’ AND source* OR application OR
use* OR production OR ‘production volume’ OR application
Environmental fate
Search terms perﬂuoro* OR pfos OR pfoa OR pfas OR ‘ﬂuorotelomer alcohol’ AND ‘environmental fate’ OR
‘environmental monitoring’ OR soil OR biosolid OR manure OR sediment OR sewage OR sludge
OR water OR ‘waste water*’ OR ‘ground water*’ OR wastewater* OR groundwater* OR river OR
land OR lake OR grass OR vegetation
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Appendix E – EFSA guidance documents applied for the risk assessment
The following EFSA guidances were followed for the development of the risk assessment:
• EFSA (European Food Safety Authority), 2005. Opinion of the Scientiﬁc Committee on a
request from EFSA related to a harmonised approach for risk assessment of substances which
are both genotoxic and carcinogenic. EFSA Journal 2005;3(10):282, 31 pp. https://doi.org/10.
2903/j.efsa.2005.282
• EFSA (European Food Safety Authority), 2007. Guidance of the Scientiﬁc Committee on a
request from EFSA related to Uncertainties in Dietary Exposure Assessment. EFSA Journal
2007;4(12):438, 54 pp. https://doi.org/10.2903/j.efsa.2007.438
• EFSA (European Food Safety Authority), 2009. Guidance of the Scientiﬁc Committee on
transparency in the scientiﬁc aspects of risk assessments carried out by EFSA. Part 2: General
principles. The EFSA Journal 2009;7(5):1051, 22 pp. https://doi.org/10.2903/j.efsa.2009.1051
• EFSA (European Food Safety Authority), 2010. Standard sample description for food and feed.
EFSA Journal 2010;8(1):1457, 54 pp. https://doi.org/10.2903/j.efsa.2010.1457
• EFSA (European Food Safety Authority), 2010. Management of left-censored data in dietary
exposure assessment of chemical substances. EFSA Journal 2010;8(3):1557, 96 pp. https://doi.
org/10.2903/j.efsa.2010.1557
• EFSA (European Food Safety Authority), 2011. Use of the EFSA Comprehensive European Food
Consumption Database in Intakes Assessment. EFSA Journal 2011;9(3):2097, 34 pp. https://
doi.org/10.2903/j.efsa.2011.2097
• EFSA Scientiﬁc Committee, 2011. Scientiﬁc Opinion on genotoxicity testing strategies applicable
to food and feed safety assessment. EFSA Journal 2011;9(9):2379, 69 pp. https://doi.org/10.
2903/j.efsa.2011.2379
• EFSA Scientiﬁc Committee, 2012. Guidance on selected default values to be used by the EFSA
Scientiﬁc Committee, Scientiﬁc Panels and Units in the absence of actual measured data. EFSA
Journal 2012;10(3):2579, 32 pp. https://doi.org/10.2903/j.efsa.2012.2579
• EFSA Scientiﬁc Committee, 2012. Scientiﬁc Opinion on Risk Assessment Terminology. EFSA
Journal 2012;10(5):2664, 43 pp. https://doi.org/10.2903/j.efsa.2012.2664
• EFSA Scientiﬁc Committee, Hardy A, Benford D, Halldorsson T, Jeger MJ, Knutsen HK, More S,
Naegeli H, Noteborn H, Ockleford C, Ricci A, Rychen G, Schlatter JR, Silano V, Solecki R, Turck
D, Younes M, Bresson J-L, Grifﬁn J, Hougaard Benekou S, van Loveren H, Luttik R, Messean A,
Penninks A, Ru G, Stegeman JA, van der Werf W, Westendorf J, Woutersen RA, Barizzone F,
Bottex B, Lanzoni A, Georgiadis N and Alexander J, 2017. Guidance on the assessment of the
biological relevance of data in scientiﬁc assessments. EFSA Journal 2017;15(8):4970, 73 pp.
https://doi.org/10.2903/j.efsa.2017.4970
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